2026-02-10 16:36:34,769 - root - INFO - STARTING OPTIMIZED BENCHMARK RUN
2026-02-10 16:36:34,769 - root - INFO - Using configuration: generations=10, pop_size=20
2026-02-10 16:36:34,769 - root - INFO - Loading dataset: GSE221156_pseudobulk
2026-02-10 16:36:34,828 - root - INFO - Loaded 1 datasets
2026-02-10 16:44:00,431 - root - INFO - Extracting druggability features for top 1000 genes...
2026-02-10 16:44:00,433 - root - INFO - Extracting features for 1000 genes
2026-02-10 16:44:09,992 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL033384.1
2026-02-10 16:44:18,235 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL139246.5
2026-02-10 16:44:18,662 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC099509.1
2026-02-10 16:44:19,113 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL512343.2
2026-02-10 16:44:19,534 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL356515.1
2026-02-10 16:44:20,666 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC093866.1
2026-02-10 16:44:21,760 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for C9orf106
2026-02-10 16:44:24,521 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC027031.2
2026-02-10 16:44:26,243 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC005009.1
2026-02-10 16:44:26,731 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC020915.2
2026-02-10 16:44:28,472 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL606807.1
2026-02-10 16:44:30,894 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC004846.1
2026-02-10 16:44:31,561 - utils.druggability_extractor - INFO - Processed 50/1000 genes
2026-02-10 16:44:36,084 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL451069.1
2026-02-10 16:44:36,574 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC105942.1
2026-02-10 16:44:37,631 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC023983.2
2026-02-10 16:44:38,096 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL590009.1
2026-02-10 16:44:38,543 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC022098.1
2026-02-10 16:45:08,176 - utils.druggability_extractor - INFO - Processed 100/1000 genes
2026-02-10 16:45:14,754 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC244035.1
2026-02-10 16:45:20,116 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL031848.2
2026-02-10 16:45:21,840 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC008764.6
2026-02-10 16:45:22,284 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL139243.1
2026-02-10 16:45:24,688 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC012464.2
2026-02-10 16:45:33,059 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL139089.1
2026-02-10 16:45:40,966 - utils.druggability_extractor - INFO - Processed 150/1000 genes
2026-02-10 16:45:41,412 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL357033.4
2026-02-10 16:45:55,353 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC110609.1
2026-02-10 16:45:56,530 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL360012.1
2026-02-10 16:45:56,960 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC079209.1
2026-02-10 16:46:00,139 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL627232.1
2026-02-10 16:46:03,891 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP000569.1
2026-02-10 16:46:04,358 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC025811.1
2026-02-10 16:46:11,226 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC134312.5
2026-02-10 16:46:12,298 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC022784.5
2026-02-10 16:46:12,298 - utils.druggability_extractor - INFO - Processed 200/1000 genes
2026-02-10 16:46:12,722 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC116667.1
2026-02-10 16:46:14,406 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC004816.2
2026-02-10 16:46:14,835 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC068888.1
2026-02-10 16:46:17,612 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC010969.2
2026-02-10 16:46:19,316 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL049874.3
2026-02-10 16:46:21,023 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL353147.1
2026-02-10 16:46:22,795 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC104461.1
2026-02-10 16:46:26,107 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC005692.1
2026-02-10 16:46:30,822 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC010280.1
2026-02-10 16:46:33,170 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL450313.1
2026-02-10 16:46:38,245 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL355607.2
2026-02-10 16:46:38,704 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC106881.1
2026-02-10 16:46:42,648 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL354743.2
2026-02-10 16:46:43,741 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC104365.1
2026-02-10 16:46:43,741 - utils.druggability_extractor - INFO - Processed 250/1000 genes
2026-02-10 16:46:44,190 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC104051.2
2026-02-10 16:46:46,001 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC012150.1
2026-02-10 16:46:50,568 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL133268.3
2026-02-10 16:46:53,560 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC020743.2
2026-02-10 16:46:55,340 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC016383.1
2026-02-10 16:46:56,460 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP001266.2
2026-02-10 16:47:00,411 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC092805.1
2026-02-10 16:47:00,837 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP006748.2
2026-02-10 16:47:01,351 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL139327.2
2026-02-10 16:47:02,067 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC068787.2
2026-02-10 16:47:02,720 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC114798.1
2026-02-10 16:47:03,158 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC092053.5
2026-02-10 16:47:03,597 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC004828.1
2026-02-10 16:47:04,034 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC011243.1
2026-02-10 16:47:04,468 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC013286.1
2026-02-10 16:47:06,263 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC008877.1
2026-02-10 16:47:07,371 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL121977.2
2026-02-10 16:47:07,818 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC069410.1
2026-02-10 16:47:08,250 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC018450.2
2026-02-10 16:47:11,988 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC243829.5
2026-02-10 16:47:13,325 - utils.druggability_extractor - INFO - Processed 300/1000 genes
2026-02-10 16:47:50,584 - utils.druggability_extractor - INFO - Processed 350/1000 genes
2026-02-10 16:50:42,843 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CDH2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Read timed out. (read timeout=30)
2026-02-10 16:50:42,950 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PLTP: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a890>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:43,153 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for KLF11: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a090>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:43,354 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for JUN: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269750>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:43,354 - utils.druggability_extractor - INFO - Processed 400/1000 genes
2026-02-10 16:50:43,556 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PREB: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826aad0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:43,757 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for NPAS4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269050>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:43,960 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ACKR3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269410>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:44,163 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for DNAAF4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269910>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:44,368 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for KDM1A: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b190>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:44,570 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FABP7: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268350>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:44,772 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FLI1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bc90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:44,975 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CCND2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a8d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:45,179 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for KRT20: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:45,383 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for BTK: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826abd0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:45,581 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CYP17A1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268450>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:45,783 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MCU: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bf90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:45,984 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for EZH2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269290>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:46,190 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CYP11A1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269650>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:46,393 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ARHGEF15: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bf90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:46,596 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CEBPB: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269f90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:50:46,799 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for IGLL1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:30,561 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TRRAP: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268f50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:30,682 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MAPK3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b590>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:30,872 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MATN1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a910>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:31,074 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GSK3B: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a090>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:31,275 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ATM: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826be50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:31,480 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for IGF2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ac90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:31,684 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for DDX20: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a950>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:31,887 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AGFG1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269f90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:32,090 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CAT: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268f50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:32,293 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CDKN1B: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bd10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:32,497 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PRKACA: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:32,698 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FPR2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a090>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:32,899 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for IGFBP1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826aed0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:33,099 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for THEG: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a250>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:33,304 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GFI1B: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268f10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:33,506 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FGF3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b3d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:33,708 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AMPD1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a250>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:33,912 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CYP7A1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826aed0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:34,113 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GAS2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b350>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:34,315 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TSHB: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826af90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:34,520 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for UGT1A1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826aed0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:34,719 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GJB2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:34,923 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ABCB11: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:35,126 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SALL2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269110>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:35,329 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for BLK: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ad10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:35,530 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MBP: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82687d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:35,749 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for NR0B2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b490>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:35,938 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FBXO38: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b3d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:36,139 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PTEN: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a910>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:36,342 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for DNMT1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:36,545 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SIRT1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268810>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:36,749 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MAPK1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b610>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:36,951 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LARGE1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826af90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:36,952 - utils.druggability_extractor - INFO - Processed 450/1000 genes
2026-02-10 16:52:37,155 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for NPPA: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269190>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:37,357 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GCLC: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268950>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:37,562 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CCNA2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268710>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:37,765 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TERT: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268990>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:37,967 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ADRA1D: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a410>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:38,171 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CDK5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a950>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:38,374 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ANXA5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b650>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:38,577 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MYH7: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:38,780 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for HMGB2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268490>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:38,983 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LMO3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bb90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:39,187 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for HOXA9: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269c10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:39,389 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for EPYC: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b510>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:39,592 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PIK3R1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b1d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:39,795 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GJA5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269ad0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:39,999 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for EGF: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:40,202 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CR1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a250>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:40,406 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for POU1F1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a1d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:40,611 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for RAB3D: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269290>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:40,813 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ABL1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268090>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:41,014 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for VPREB1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a790>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:41,215 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AIFM1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268e50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:41,417 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ABCB1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269d50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:41,620 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for HBB: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:41,824 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PCNA: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ab90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:42,028 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GSS: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269850>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:42,229 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PC: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a390>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:42,431 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for NEUROD4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ae90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:42,633 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TEAD1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269950>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:42,835 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SMAD7: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826af10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:43,067 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for STAT3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268790>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:52:43,239 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TH: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268090>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:35,894 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for HBE1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269690>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:36,194 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MYF5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268450>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:36,299 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for RAG2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a790>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:36,515 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MPP1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b6d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:36,709 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GABRA2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269a10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:36,909 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC104072.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82683d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:37,112 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ASCL2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bfd0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:37,319 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for OPRD1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268c90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:37,523 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AL359475.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:37,725 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TAFA4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b850>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:37,928 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FOXE1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b6d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:38,132 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TMED6: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a350>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:38,333 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CRABP1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a390>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:38,539 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FFAR4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:38,741 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LRFN2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268250>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:38,943 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AP000894.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82685d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:39,148 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ADGRA1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82694d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:39,348 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CECR2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82680d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:39,552 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CCER2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ae90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:39,553 - utils.druggability_extractor - INFO - Processed 500/1000 genes
2026-02-10 16:54:39,757 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LINC02640: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269290>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:39,959 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC026402.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:40,161 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MIOX: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a110>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:40,360 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ARG2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a990>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:40,564 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC105230.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bb50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:40,768 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for RBP4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268b90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:40,973 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LINC01933: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b810>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:41,176 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC092809.4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269f10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:41,377 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC097625.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ae50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:41,584 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AL009181.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bf50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:41,787 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TDRG1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269e50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:41,989 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SLC47A1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a790>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:42,195 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CD164: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bfd0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:42,397 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SLC16A13: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269750>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:42,599 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC107373.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269f10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:42,803 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for NAGS: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82685d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 16:54:43,004 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MYL9: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269c50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:06,042 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC005083.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268250>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:06,241 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LINC02778: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268c90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:06,347 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TMEM50A: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ab90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:06,551 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for REXO2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826ae10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:06,756 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TNNC2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268150>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:06,957 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC090517.5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a110>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:07,160 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for HOXA-AS2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268a90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:07,363 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SATB2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826acd0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:07,565 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SOX9-AS1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bd10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:07,768 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for DCUN1D1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82680d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:07,966 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AL359208.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269bd0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:08,168 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AP001107.9: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269290>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:08,373 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SLC38A7: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bd10>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:08,576 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TSHR: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82695d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:08,782 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for ZMIZ1-AS1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269990>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:08,983 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC011611.4: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269d90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:09,187 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LINC02716: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268c90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:09,390 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AL157936.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a6d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:09,595 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PSMB8: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268410>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:09,795 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for LINC01679: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a110>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:09,997 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CKLF: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a7d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:10,203 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC138696.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f82694d0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:10,403 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for PNPLA3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269ed0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:10,608 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AL356215.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b650>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:10,812 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for C11orf91: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a450>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:11,015 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC004130.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bdd0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:11,218 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AL136295.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826a550>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:11,419 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for JMJD1C-AS1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269c50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:11,623 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for GSTM5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826b110>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:11,824 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for MKRN2OS: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269010>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:12,025 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC009831.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826aed0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:12,231 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC104667.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826aed0>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:12,433 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC008972.2: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269410>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:12,433 - utils.druggability_extractor - INFO - Processed 550/1000 genes
2026-02-10 17:18:12,635 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CBX3: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268f50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:12,837 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for AC008972.1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269410>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:13,040 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for BVES-AS1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269d90>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:13,243 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for TMEM45B: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8268850>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:13,446 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for SERPINA1: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f8269410>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:18:13,649 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for FBLN5: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Max retries exceeded with url: /api/v4/graphql (Caused by NewConnectionError('<urllib3.connection.HTTPSConnection object at 0x3f826bd50>: Failed to establish a new connection: [Errno 8] nodename nor servname provided, or not known'))
2026-02-10 17:20:13,422 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL161910.1
2026-02-10 17:20:15,785 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL135905.1
2026-02-10 17:20:17,154 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC093512.1
2026-02-10 17:20:18,578 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for U73166.1
2026-02-10 18:48:52,451 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP000356.2
2026-02-10 18:48:53,130 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC023283.1
2026-02-10 18:49:52,968 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC116312.1
2026-02-10 18:50:03,247 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC096564.2
2026-02-10 18:50:03,729 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC092134.3
2026-02-10 18:50:05,292 - utils.druggability_extractor - INFO - Processed 600/1000 genes
2026-02-10 18:50:06,053 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC005277.2
2026-02-10 18:50:07,344 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL033380.1
2026-02-10 18:50:12,520 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC090510.1
2026-02-10 18:50:13,126 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC090398.2
2026-02-10 18:50:14,203 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL139384.2
2026-02-10 18:50:22,392 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC091982.3
2026-02-10 18:50:27,422 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL161729.1
2026-02-10 18:50:27,931 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL356488.3
2026-02-10 18:50:37,075 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC097478.1
2026-02-10 18:50:43,585 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC022613.1
2026-02-10 18:50:45,326 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL118511.1
2026-02-10 18:50:49,495 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC062029.1
2026-02-10 18:50:52,600 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC096711.1
2026-02-10 18:50:53,143 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL353138.1
2026-02-10 18:50:56,281 - utils.druggability_extractor - INFO - Processed 650/1000 genes
2026-02-10 18:50:56,986 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC244517.5
2026-02-10 18:50:59,463 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL596330.2
2026-02-10 18:51:01,193 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC120498.4
2026-02-10 18:51:02,769 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC090587.1
2026-02-10 18:51:03,629 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL157394.3
2026-02-10 18:51:06,419 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC096577.1
2026-02-10 18:51:17,793 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC092376.2
2026-02-10 18:51:19,709 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC018553.1
2026-02-10 18:51:20,576 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC073270.2
2026-02-10 18:51:23,225 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL035425.3
2026-02-10 18:51:29,129 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AF131216.4
2026-02-10 18:51:35,474 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC079385.2
2026-02-10 18:51:36,115 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC005592.1
2026-02-10 18:51:39,406 - utils.druggability_extractor - INFO - Processed 700/1000 genes
2026-02-10 18:51:41,927 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC104472.5
2026-02-10 18:51:43,305 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC091181.2
2026-02-10 18:51:46,612 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC134349.1
2026-02-10 18:51:47,264 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL391883.1
2026-02-10 18:51:53,305 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL121933.2
2026-02-10 18:52:01,467 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC025257.1
2026-02-10 18:52:06,705 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC104170.1
2026-02-10 18:52:09,904 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC096772.1
2026-02-10 18:52:13,015 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC007405.2
2026-02-10 18:52:18,213 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP001922.6
2026-02-10 18:52:20,337 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC132217.2
2026-02-10 18:52:20,337 - utils.druggability_extractor - INFO - Processed 750/1000 genes
2026-02-10 18:52:29,950 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for LINC00545
2026-02-10 18:52:35,243 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC092718.5
2026-02-10 18:52:36,832 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL122008.3
2026-02-10 18:52:40,316 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC009126.1
2026-02-10 18:52:45,845 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC005746.2
2026-02-10 18:52:47,275 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL136962.1
2026-02-10 18:52:48,734 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL133346.1
2026-02-10 18:52:51,631 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for FO704657.1
2026-02-10 18:53:00,082 - utils.druggability_extractor - INFO - Processed 800/1000 genes
2026-02-10 18:53:03,906 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for LINC02634
2026-02-10 18:53:06,285 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL355597.1
2026-02-10 18:53:13,632 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC245008.1
2026-02-10 18:53:15,069 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC009950.1
2026-02-10 18:53:51,409 - utils.druggability_extractor - ERROR - Error fetching target data for ENSG00000238141: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Read timed out. (read timeout=30)
2026-02-10 18:54:22,711 - utils.druggability_extractor - ERROR - Error fetching Ensembl ID for CTSK: HTTPSConnectionPool(host='api.platform.opentargets.org', port=443): Read timed out. (read timeout=30)
2026-02-10 18:54:29,862 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC002480.2
2026-02-10 18:54:34,281 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC012085.2
2026-02-10 18:54:35,791 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC022075.1
2026-02-10 18:54:37,242 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC022201.2
2026-02-10 18:54:38,887 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC002467.1
2026-02-10 18:54:40,572 - utils.druggability_extractor - INFO - Processed 850/1000 genes
2026-02-10 18:54:41,087 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for UBR5-AS1
2026-02-10 18:54:47,275 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC009041.2
2026-02-10 18:54:51,233 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP001057.1
2026-02-10 18:54:59,329 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP001453.2
2026-02-10 18:55:00,023 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP001885.2
2026-02-10 18:55:00,751 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC018742.1
2026-02-10 18:55:01,409 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC012354.1
2026-02-10 18:55:04,664 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL450267.2
2026-02-10 18:55:05,671 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AP001001.1
2026-02-10 18:55:06,940 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC072054.1
2026-02-10 18:55:08,327 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC106897.1
2026-02-10 18:55:10,527 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL353688.1
2026-02-10 18:55:13,864 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC132938.3
2026-02-10 18:55:17,836 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL158206.1
2026-02-10 18:55:21,374 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC010255.1
2026-02-10 18:55:21,375 - utils.druggability_extractor - INFO - Processed 900/1000 genes
2026-02-10 18:55:23,798 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC024940.6
2026-02-10 18:55:25,192 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC093599.2
2026-02-10 18:55:31,410 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC023043.1
2026-02-10 18:55:32,985 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC100803.2
2026-02-10 18:55:37,207 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC016597.2
2026-02-10 18:55:38,840 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC009951.6
2026-02-10 18:55:40,293 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for C5orf56
2026-02-10 18:55:51,771 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC018545.1
2026-02-10 18:55:52,401 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC079177.1
2026-02-10 18:55:52,975 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC006059.1
2026-02-10 18:55:56,183 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC037198.2
2026-02-10 18:56:01,966 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC116407.2
2026-02-10 18:56:04,579 - utils.druggability_extractor - INFO - Processed 950/1000 genes
2026-02-10 18:56:06,202 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC098487.1
2026-02-10 18:56:22,619 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC010624.2
2026-02-10 18:56:24,184 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for U47924.1
2026-02-10 18:56:25,625 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC068587.4
2026-02-10 18:56:29,386 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC099332.1
2026-02-10 18:56:30,937 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC069281.1
2026-02-10 18:56:31,392 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL035665.1
2026-02-10 18:56:33,513 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL034346.1
2026-02-10 18:56:34,870 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AC090340.1
2026-02-10 18:56:35,719 - utils.druggability_extractor - WARNING - Could not find Ensembl ID for AL590714.1
2026-02-10 18:56:45,701 - utils.druggability_extractor - INFO - Processed 1000/1000 genes
2026-02-10 18:56:45,935 - utils.druggability_extractor - INFO - Created druggability feature DataFrame with 1000 genes
2026-02-10 18:56:45,937 - root - INFO - Druggability extraction complete: 1000 genes
2026-02-10 18:56:45,976 - root - INFO - Running leakage tests on druggability features...
2026-02-10 18:56:45,976 - utils.leakage_tester - INFO - Running single feature uniqueness tests...
2026-02-10 18:56:46,008 - utils.leakage_tester - INFO - Feature 'idg_family': uniqueness=0.009, singletons=0.000, safe=True
2026-02-10 18:56:46,030 - utils.leakage_tester - INFO - Feature 'subcellular_location': uniqueness=0.005, singletons=0.000, safe=True
2026-02-10 18:56:46,030 - utils.leakage_tester - INFO - Running combination uniqueness tests...
2026-02-10 18:56:46,061 - utils.leakage_tester - INFO - All leakage tests PASSED - safe to use Option A
2026-02-10 18:56:46,061 - root - INFO - 
============================================================
LEAKAGE TEST REPORT
============================================================

Overall Status: PASSED 

----------------------------------------
Single Feature Tests:
----------------------------------------
  idg_family: 
    - Uniqueness: 0.009
    - Singletons: 0.000
  subcellular_location: 
    - Uniqueness: 0.005
    - Singletons: 0.000

----------------------------------------
Combination Tests:
----------------------------------------
  All combinations safe 

----------------------------------------
LLM Leakage Test:
----------------------------------------
  Skipped: Missing data or LLM client


============================================================
2026-02-10 18:56:46,085 - root - INFO - ============================================================
2026-02-10 18:56:46,085 - root - INFO - STARTING T2D EVOLUTIONARY OPTIMIZATION
2026-02-10 18:56:46,085 - root - INFO - Generations: 10, Population: 20
2026-02-10 18:56:46,085 - root - INFO - ============================================================
2026-02-10 18:56:46,088 - root - INFO - Initialized simplified Generation Agent in t2d-target mode
2026-02-10 18:56:46,095 - root - INFO - Initialized simplified Reflection Agent in t2d-target mode
2026-02-10 18:56:46,096 - root - INFO - Evolution Agent initialized
2026-02-10 18:56:46,096 - root - INFO - Initialized simplified Supervisor Agent for genetic algorithm
2026-02-10 18:56:46,097 - root - INFO - Research goal: Identify novel drug targets for Type 2 Diabetes
2026-02-10 18:56:46,097 - root - INFO - Mode: t2d-target
2026-02-10 18:56:46,097 - root - INFO - Enabled druggability-aware generation
2026-02-10 18:56:46,097 - root - INFO - ================================================================================
2026-02-10 18:56:46,098 - root - INFO - STARTING BENCHMARK GENETIC ALGORITHM (OPTIMIZED)
2026-02-10 18:56:46,098 - root - INFO - Configuration: 10 generations, 20 population
2026-02-10 18:56:46,098 - root - INFO - Checkpoints: [1, 3, 5, 10]
2026-02-10 18:56:46,098 - root - INFO - ================================================================================
2026-02-10 18:56:46,099 - root - INFO - T2D mode: Using pre-computed analysis pipeline
2026-02-10 18:56:46,137 - root - INFO - T2D mode: Option C (expression-only)
2026-02-10 18:56:46,145 - root - INFO - Generating initial population of 20 hypotheses
2026-02-10 18:56:46,368 - root - INFO - Using Option C: Expression-only generation
2026-02-10 18:56:46,369 - root - INFO - Generating 20 T2D hypotheses...
2026-02-10 18:56:46,369 - root - INFO - Valid targets: 1000 genes
2026-02-10 18:56:46,369 - root - INFO - Searching T2D literature with 3 queries
2026-02-10 18:56:46,369 - root - INFO - T2D literature search 1/3: type 2 diabetes pathophysiology molecular mechanism
2026-02-10 18:56:46,369 - root - INFO - Searching literature for: type 2 diabetes pathophysiology molecular mechanism
2026-02-10 18:56:46,390 - root - INFO - Cached results for 'type 2 diabetes pathophysiology molecular mechanism' are too old (30.3 hours)
2026-02-10 18:56:49,165 - root - INFO - Found 3 papers in PubMed related to 'type 2 diabetes pathophysiology molecular mechanism'
2026-02-10 18:56:49,166 - root - INFO -   PubMed Paper 1: Pathophysiology of Type 2 Diabetes Mellitus.
2026-02-10 18:56:49,166 - root - INFO -     Authors: Unai Galicia-Garcia, Asier Benito-Vicente, Shifa Jebari...
2026-02-10 18:56:49,166 - root - INFO -     PMID: 32872570
2026-02-10 18:56:49,167 - root - INFO -   PubMed Paper 2: Emerging Targets in Type 2 Diabetes and Diabetic Complications.
2026-02-10 18:56:49,167 - root - INFO -     Authors: Sevgican Demir, Peter P Nawroth, Stephan Herzig...
2026-02-10 18:56:49,167 - root - INFO -     PMID: 34319011
2026-02-10 18:56:49,167 - root - INFO -   PubMed Paper 3: Role of gut microbiota in type 2 diabetes pathophysiology.
2026-02-10 18:56:49,167 - root - INFO -     Authors: Manoj Gurung, Zhipeng Li, Hannah You...
2026-02-10 18:56:49,167 - root - INFO -     PMID: 31901868
2026-02-10 18:56:49,173 - root - INFO - Found 3 papers for search query: type 2 diabetes pathophysiology molecular mechanism
2026-02-10 18:56:49,176 - root - INFO - Analyzing 3 papers for literature context
2026-02-10 18:56:49,177 - root - INFO - Generated literature analysis with 1418 characters
2026-02-10 18:56:49,177 - root - INFO - T2D literature search 2/3: insulin resistance cellular dysfunction mechanism
2026-02-10 18:56:49,177 - root - INFO - Searching literature for: insulin resistance cellular dysfunction mechanism
2026-02-10 18:56:49,178 - root - INFO - Cached results for 'insulin resistance cellular dysfunction mechanism' are too old (30.3 hours)
2026-02-10 18:56:50,760 - root - INFO - Found 3 papers in PubMed related to 'insulin resistance cellular dysfunction mechanism'
2026-02-10 18:56:50,774 - root - INFO -   PubMed Paper 1: Insulin Resistance and Diabetes Mellitus in Alzheimer's Disease.
2026-02-10 18:56:50,774 - root - INFO -     Authors: Jess Burillo, Patricia Marqus, Beatriz Jimnez...
2026-02-10 18:56:50,774 - root - INFO -     PMID: 34069890
2026-02-10 18:56:50,783 - root - INFO -   PubMed Paper 2: The Pathophysiology of Gestational Diabetes Mellitus.
2026-02-10 18:56:50,787 - root - INFO -     Authors: Jasmine F Plows, Joanna L Stanley, Philip N Baker...
2026-02-10 18:56:50,788 - root - INFO -     PMID: 30373146
2026-02-10 18:56:50,788 - root - INFO -   PubMed Paper 3: Insulin resistance: Review of the underlying molecular mechanisms.
2026-02-10 18:56:50,789 - root - INFO -     Authors: Habib Yaribeygi, Farin Rashid Farrokhi, Alexandra E Butler...
2026-02-10 18:56:50,789 - root - INFO -     PMID: 30317615
2026-02-10 18:56:50,803 - root - INFO - Found 3 papers for search query: insulin resistance cellular dysfunction mechanism
2026-02-10 18:56:50,803 - root - INFO - Analyzing 3 papers for literature context
2026-02-10 18:56:50,803 - root - INFO - Generated literature analysis with 1434 characters
2026-02-10 18:56:50,803 - root - INFO - T2D literature search 3/3: beta cell failure diabetes pathogenesis
2026-02-10 18:56:50,803 - root - INFO - Searching literature for: beta cell failure diabetes pathogenesis
2026-02-10 18:56:50,844 - root - INFO - Cached results for 'beta cell failure diabetes pathogenesis' are too old (30.3 hours)
2026-02-10 18:56:52,879 - root - INFO - Found 3 papers in PubMed related to 'beta cell failure diabetes pathogenesis'
2026-02-10 18:56:52,880 - root - INFO -   PubMed Paper 1: -cell neogenesis: A rising star to rescue diabetes mellitus.
2026-02-10 18:56:52,880 - root - INFO -     Authors: Fanglin Niu, Wenxuan Liu, Yuanyuan Ren...
2026-02-10 18:56:52,880 - root - INFO -     PMID: 37839502
2026-02-10 18:56:52,880 - root - INFO -   PubMed Paper 2: Pancreatic -cells in type 1 and type 2 diabetes mellitus: different pathways to failure.
2026-02-10 18:56:52,880 - root - INFO -     Authors: Dcio L Eizirik, Lorenzo Pasquali, Miriam Cnop
2026-02-10 18:56:52,880 - root - INFO -     PMID: 32398822
2026-02-10 18:56:52,881 - root - INFO -   PubMed Paper 3: The cell biology of systemic insulin function.
2026-02-10 18:56:52,881 - root - INFO -     Authors: Victoria L Tokarz, Patrick E MacDonald, Amira Klip
2026-02-10 18:56:52,881 - root - INFO -     PMID: 29622564
2026-02-10 18:56:52,894 - root - INFO - Found 3 papers for search query: beta cell failure diabetes pathogenesis
2026-02-10 18:56:52,895 - root - INFO - Analyzing 3 papers for literature context
2026-02-10 18:56:52,895 - root - INFO - Generated literature analysis with 1417 characters
2026-02-10 18:56:54,074 - root - INFO - OpenAI client initialized successfully
2026-02-10 18:57:08,985 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:57:09,052 - root - INFO - TOKEN_USAGE: input=338, output=465, total=803, cost=$0.000330
2026-02-10 18:57:09,052 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:57:09,052 - root - INFO - 
Type 2 diabetes mellitus (T2D) is characterized by a complex interplay of dysregulated cellular and molecular processes that lead to insulin resistance and beta-cell dysfunction. Central to the pathology of T2D is insulin resistance, a condition whereby target tissues such as muscle, liver, and adipose tissue fail to respond effectively to insulin. This resistance is associated with a number of dysregulated signaling pathways, including impaired insulin receptor signaling, altered glucose transport, and increased lipolysis. A critical feature of this dysregulation is the accumulation of lipotoxic metabolites, such as free fatty acids and diacylglycerol, which activate stress pathways that inhibit insulin signaling and promote inflammation.

The pancreatic beta-cells, responsible for insulin secretion, are significantly affected in T2D. Chronic exposure to hyperglycemia and lipotoxicity can lead to beta-cell apoptosis and impaired insulin secretion, a process often referred to as beta-cell failure. This deterioration is mediated by several mechanisms, including oxidative stress, endoplasmic reticulum (ER) stress, and inflammation, which can lead to a reduction in beta-cell mass and neogenesis. Additionally, the role of gut microbiota has emerged as a potential contributor to T2D pathophysiology, influencing metabolic processes and systemic inflammation that can further exacerbate insulin resistance and beta-cell dysfunction.

The upstream causes of these pathological changes are multifactorial, encompassing genetic predispositions, environmental factors, and lifestyle choices. Obesity is a significant risk factor, as excess adipose tissue releases pro-inflammatory cytokines and free fatty acids that interfere with insulin signaling pathways. Furthermore, alterations in the gut microbiome composition can affect energy metabolism and systemic inflammation, contributing to the development of insulin resistance and metabolic dysregulation. 

Biological pathways that show aberrant activity in T2D include those related to lipid metabolism, inflammation, and glucolipotoxicity. For example, the inflammatory pathways activated by excessive fat accumulation lead to cytokine release, which further impairs insulin signaling. Additionally, mitochondrial dysfunction has been noted in both peripheral tissues and pancreatic beta-cells, contributing to impaired energy metabolism and cellular stress. Collectively, these dysregulated pathways and cellular mechanisms form the basis of the pathophysiology of T2D, highlighting the complex biological landscape that underpins this metabolic disorder.
2026-02-10 18:57:09,054 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:57:09,054 - root - INFO - T2D literature search complete: 9 papers found
2026-02-10 18:57:09,055 - root - INFO - Retrieved T2D literature context: 7102 characters
2026-02-10 18:57:09,055 - root - INFO - Generating hypothesis 1/20
2026-02-10 18:57:39,793 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:57:39,801 - root - INFO - TOKEN_USAGE: input=40145, output=661, total=40806, cost=$0.006418
2026-02-10 18:57:39,801 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:57:39,801 - root - INFO - 
**TITLE:** Identification of Promising Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene exhibits strong evidence across multiple datasets and plays a role as a hub component in gene networks related to Type 2 Diabetes.
2. **G22553** | Score: **4.0** | As a primary driver in the black module associated with positive correlation to T2D, this gene has significant potential for therapeutic intervention.
3. **G23245** | Score: **4.0** | Another primary driver, this gene is implicated in pathways relevant to T2D and contributes to the silver module's negative correlation with T2D.
4. **G27976** | Score: **3.0** | This gene functions as a major regulator in the silver module, indicating its importance in the regulatory networks influencing T2D.
5. **G19122** | Score: **3.0** | As a major regulator in the black module, this gene is involved in pathways related to insulin signaling and glucose metabolism.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** G19943 is a hub component identified through multi-omics analysis, suggesting a central role in the molecular networks contributing to Type 2 Diabetes. Its involvement across multiple datasets and pathways indicates a strong potential for therapeutic targeting.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported, but TF activity is critical for gene regulation in T2D**

**MECHANISM_HYPOTHESIS:** The primary target, G19943, may function as a critical hub in the insulin signaling pathway, where its modulation could improve insulin sensitivity in peripheral tissues. By targeting this gene, we can potentially alleviate the inflammatory stress responses that contribute to insulin resistance.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells, muscle, and adipose tissue, where insulin signaling is crucial for glucose homeostasis and metabolic regulation. Targeting G19943 in these tissues may enhance insulin response and reduce hyperglycemia.

**THERAPEUTIC_APPROACH:** The therapeutic approach could involve small molecule modulation to enhance the activity of G19943, potentially restoring its function in insulin signaling pathways.

**PREDICTED_OUTCOME:** Modulation of G19943 is expected to improve insulin sensitivity, reduce blood glucose levels, and potentially lead to better metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores and their roles in relevant biological pathways. G19943 stands out as the most promising due to its central position in the gene network and its evidence across multiple datasets. G22553 and G23245 follow closely, also showing significant evidence but with slightly less multi-omics support.

**CONFIDENCE:** **HIGH** based on the strength of data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 18:57:39,804 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:57:39,810 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:57:39,814 - root - WARNING - Hypothesis 1 selected invalid target: 
2026-02-10 18:57:39,814 - root - INFO - Generating hypothesis 2/20
2026-02-10 18:57:52,909 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:57:52,918 - root - INFO - TOKEN_USAGE: input=40145, output=685, total=40830, cost=$0.006433
2026-02-10 18:57:52,918 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:57:52,918 - root - INFO - 
**TITLE: Targeting Novel Genes for Type 2 Diabetes Treatment**

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | Strong evidence as a hub component in co-expression networks suggests a central role in T2D pathology, with multiple types of supporting evidence from differential expression and co-regulatory networks.
2. **G04436** | Score: **4.0** | Identified as an enzyme with significant differential expression and multiple transcription factors regulating it, indicating potential metabolic pathways for intervention.
3. **G22553** | Score: **4.0** | As a primary driver in a co-expression module with a positive correlation to T2D, its modulation could influence key pathways involved in insulin sensitivity and glucose metabolism.
4. **G23245** | Score: **4.0** | A primary driver in a negatively correlated co-expression module, suggesting its potential role in counteracting insulin resistance and metabolic dysregulation.
5. **G33764** | Score: **4.0** | Another primary driver associated with pathways relevant to insulin signaling and metabolism, thus presenting a viable target for enhancing insulin sensitivity.

**PRIMARY_TARGET:** G19943

**SUMMARY:** 
G19943 emerges as the top target due to its role as a hub component in a co-expression network, suggesting it plays a critical role in the interconnected pathways of T2D. The evidence indicates it may influence various metabolic processes central to insulin resistance and beta-cell function.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17
- **Cross-dataset consistency:** Yes, consistent across multiple datasets.
- **Key pathways involved:** Insulin signaling, glucose metabolism, inflammation.
- **WGCNA module role:** Hub Component in T2D-related modules.
- **Regulating TFs:** No specific TFs indicated for this gene.

**MECHANISM_HYPOTHESIS:** 
G19943 is hypothesized to interact with multiple signaling pathways involved in glucose homeostasis and insulin signaling. Its central position in the co-expression network may suggest it regulates downstream targets that directly affect insulin sensitivity and beta-cell health.

**TISSUE_RATIONALE:** 
Tissues such as pancreatic beta-cells, muscle, and liver are the most relevant for G19943, as they play critical roles in insulin secretion and glucose uptake, both of which are impaired in T2D.

**THERAPEUTIC_APPROACH:** 
The proposed approach would involve modulation of G19943 activity, potentially through small molecules designed to enhance its function or stabilize its expression levels, thereby improving insulin sensitivity.

**PREDICTED_OUTCOME:** 
Modulation of G19943 could lead to enhanced insulin sensitivity and improved glucose metabolism, potentially reversing some aspects of T2D pathology and reducing the need for exogenous insulin or other medications.

**RANKING_RATIONALE:** 
G19943 was ranked highest due to its pivotal role in the network, suggesting it could influence multiple pathways simultaneously. The subsequent targets (G04436, G22553, G23245, and G33764) also show strong evidence but are less central based on network analysis and evidence for direct metabolic effects.

**CONFIDENCE:** HIGH based on multiple lines of evidence supporting its role in T2D pathology and the robustness of data across datasets.
2026-02-10 18:57:52,918 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:57:52,919 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:57:52,921 - root - WARNING - Hypothesis 2 selected invalid target: 
2026-02-10 18:57:52,921 - root - INFO - Generating hypothesis 3/20
2026-02-10 18:58:05,925 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:58:05,930 - root - INFO - TOKEN_USAGE: input=40145, output=688, total=40833, cost=$0.006435
2026-02-10 18:58:05,930 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:58:05,930 - root - INFO - 
**TITLE:** Identification of Promising Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene scores highly due to its role as a hub component within a co-expression network, suggesting significant influence in T2D-related pathways.
2. **G23245** | Score: **4.0** | As a primary driver in the silver module, this gene's involvement indicates a key regulatory role in T2D pathophysiology.
3. **G22553** | Score: **4.0** | Identified as a primary driver in the black module, this gene is linked to multiple metabolic pathways relevant to T2D, indicating its potential as a therapeutic target.
4. **G33764** | Score: **4.0** | This enzyme's role as a primary driver in the dark grey module suggests a potentially significant impact on metabolic processes disrupted in T2D.
5. **G04436** | Score: **4.0** | This gene's status as an enzyme with multiple regulating transcription factors implies a complex role in metabolic regulation pertinent to T2D.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** G19943 is a hub component in the co-expression network associated with T2D, indicating its central role in metabolic regulation. Its significant score and integration within multiple pathways suggest that modulation of this gene could restore insulin sensitivity and improve metabolic health.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: Metabolic pathways including insulin signaling, glucose metabolism, and lipid metabolism.
- WGCNA module role: Hub component in the silver module with a correlation to T2D of -0.461.
- Regulating TFs: None identified.

**MECHANISM_HYPOTHESIS:** The modulation of G19943 may enhance insulin signaling pathways while alleviating the negative impacts of lipotoxicity and inflammation associated with T2D. By acting as a hub in the co-expression network, this gene could influence multiple downstream targets that regulate glucose homeostasis and lipid metabolism.

**TISSUE_RATIONALE:** Tissues most relevant include pancreatic beta-cells, liver, and adipose tissue, as these are critical in insulin signaling and glucose metabolism. The integration of G19943 in these tissues could help in countering insulin resistance and restoring normal function.

**THERAPEUTIC_APPROACH:** Modulation of G19943 would likely involve small molecules aimed at enhancing its activity or mimicking its function to restore metabolic balance in T2D patients.

**PREDICTED_OUTCOME:** If G19943 is effectively targeted, it could lead to improved insulin sensitivity, better regulation of blood glucose levels, and potentially reverse some of the metabolic dysfunctions associated with T2D.

**RANKING_RATIONALE:** G19943 is ranked highest due to its hub role and significant correlation with T2D, followed closely by G23245, which has a similar role but slightly less evidence of cross-consistency. The remaining targets, while also promising, show either less impact or are in more complex regulatory contexts.

**CONFIDENCE:** **HIGH** based on the strength of data support and the integration of multiple evidence types.
2026-02-10 18:58:05,932 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:58:05,932 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:58:05,934 - root - WARNING - Hypothesis 3 selected invalid target: 
2026-02-10 18:58:05,934 - root - INFO - Generating hypothesis 4/20
2026-02-10 18:58:22,945 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:58:22,979 - root - INFO - TOKEN_USAGE: input=40145, output=648, total=40793, cost=$0.006411
2026-02-10 18:58:22,986 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:58:22,986 - root - INFO - 
**TITLE:** Identification of Novel Therapeutic Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene is a hub component with significant evidence from multiple data types, indicating its central role in T2D pathophysiology.
2. **G22553** | Score: **4.0** | Identified as a primary driver in the black module, this gene shows a positive correlation to T2D, suggesting its involvement in metabolic regulation.
3. **G33764** | Score: **4.0** | This enzyme is a primary driver in the darkgrey module, indicating its potential importance in insulin signaling pathways.
4. **G23245** | Score: **4.0** | As a primary driver in the silver module, its negative correlation with T2D suggests a role in promoting insulin sensitivity.
5. **G19122** | Score: **3.0** | A major regulator in the black module, implicating it in pathways that may enhance insulin signaling and glucose homeostasis.

**PRIMARY_TARGET:** G19943

**SUMMARY:** G19943 is positioned as a critical hub component in T2D pathophysiology, suggesting its involvement in multiple regulatory pathways. Its significant score and role in co-expression networks indicate that targeting this gene could enhance insulin sensitivity and mitigate hyperglycemia.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, evidence from multiple datasets supports its role.
- **Key pathways involved:** Insulin signaling, glucose metabolism, and inflammatory pathways.
- **WGCNA module role:** Hub Component in the silver module.
- **Regulating TFs:** None identified specifically for this gene in the data.

**MECHANISM_HYPOTHESIS:** G19943 likely plays a central role in integrating signals from various pathways involved in glucose metabolism and insulin action. By modulating its activity, it may enhance insulin signaling, reduce inflammation, and improve metabolic homeostasis, which are critical for T2D management.

**TISSUE_RATIONALE:** The pancreatic -cells and insulin-sensitive tissues, such as muscle and liver, are most relevant for targeting G19943, given their critical roles in insulin secretion and action.

**THERAPEUTIC_APPROACH:** The approach would likely involve the development of small molecule modulators that enhance the activity of G19943 or its downstream pathways to improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of G19943 is expected to improve glycemic control and reduce insulin resistance, potentially reversing some aspects of T2D pathology.

**RANKING_RATIONALE:** G19943 was ranked highest due to its central role as a hub component with strong evidence from multiple data sources, indicating its comprehensive involvement in T2D mechanisms. G22553 and G33764, while also important, do not exhibit the same level of cross-functional integration as G19943, making them secondary targets. 

**CONFIDENCE:** HIGH based on the strength of data support and multi-evidence integration.
2026-02-10 18:58:22,992 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:58:22,993 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:58:22,997 - root - WARNING - Hypothesis 4 selected invalid target: 
2026-02-10 18:58:22,998 - root - INFO - Generating hypothesis 5/20
2026-02-10 18:58:35,029 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:58:35,045 - root - INFO - TOKEN_USAGE: input=40145, output=639, total=40784, cost=$0.006405
2026-02-10 18:58:35,045 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:58:35,045 - root - INFO - 
### TITLE: Targeting Novel Drug Candidates for Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Identified as a hub component with cross-dataset support, indicating a significant role in T2D pathology.
2. **G22553** | Score: **4.0** | A primary driver in the co-expression network suggesting it plays a crucial role in T2D-related pathways.
3. **G04436** | Score: **4.0** | An enzyme with multiple regulatory transcription factors, indicating a potential metabolic target.
4. **G33764** | Score: **4.0** | An enzyme identified as a primary driver, suggesting its involvement in metabolic processes disrupted in T2D.
5. **G23245** | Score: **4.0** | Another primary driver with significant evidence pointing to its role in T2D, making it a strong target.

#### PRIMARY_TARGET: G19943

### SUMMARY:
G19943 is a high-priority target identified as a hub component within the co-expression network associated with T2D. Its significant score from multiple evidence types highlights its potential in mediating critical pathways involved in T2D pathophysiology.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways
- **WGCNA module role**: Hub component in a module negatively correlated with T2D
- **Regulating TFs**: None identified

### MECHANISM_HYPOTHESIS:
G19943 may regulate lipid metabolism and insulin signaling, crucial processes in T2D pathophysiology. By acting as a hub component, it likely interacts with various pathways, potentially influencing the inflammatory response and insulin resistance mechanisms characteristic of T2D.

### TISSUE_RATIONALE:
The most relevant tissues include pancreatic -cells and adipose tissue, both of which are directly involved in insulin secretion and action. Given the role of G19943 in regulating lipid metabolism, its modulation may enhance insulin sensitivity and -cell function.

### THERAPEUTIC_APPROACH:
The therapeutic approach for G19943 would likely involve small molecule activation to enhance its function in regulatory pathways, promoting improved insulin signaling and metabolic homeostasis.

### PREDICTED_OUTCOME:
Modulating G19943 is expected to improve insulin sensitivity and glucose metabolism, potentially reversing or mitigating T2D progression.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central role as a hub in the co-expression network and its negative correlation with T2D, suggesting it could be pivotal in addressing metabolic dysregulation. G22553 follows closely as a primary driver but lacks the same level of network influence. G04436, G33764, and G23245 are also strong candidates, but their roles are more specific to metabolic pathways without the broader network implications observed with G19943.

### CONFIDENCE: HIGH
2026-02-10 18:58:35,052 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:58:35,056 - root - INFO - Generating hypothesis 6/20
2026-02-10 18:58:46,384 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:58:46,391 - root - INFO - TOKEN_USAGE: input=40207, output=624, total=40831, cost=$0.006405
2026-02-10 18:58:46,392 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:58:46,392 - root - INFO - 
TITLE: Identification of Promising Drug Targets for Type 2 Diabetes Treatment

RANKED_TARGETS:
1. G04436 | Score: 4.0 | This gene is an enzyme associated with Type 2 Diabetes in multiple datasets and has a strong DE rank, indicating significant dysregulation in T2D contexts.
2. G33764 | Score: 4.0 | As an enzyme identified as a primary driver in T2D, this gene shows a substantial negative log2FC, suggesting a potential role in insulin resistance mechanisms.
3. G19122 | Score: 3.0 | This gene is a major regulator in T2D with a significant negative log2FC, indicating its involvement in metabolic dysregulation in diabetic states.
4. G22553 | Score: 4.0 | Identified as a primary driver with a high DE rank, this gene's dysregulation could correlate with insulin resistance mechanisms in T2D.
5. G20274 | Score: 3.0 | This gene is a major regulator showing a negative log2FC, which may implicate it in T2D pathophysiology related to insulin signaling.

PRIMARY_TARGET: G04436

SUMMARY: G04436 is an enzyme showing significant dysregulation in Type 2 Diabetes, with a high DE rank and evidence of involvement in critical metabolic pathways. Its enzymatic activity may be pivotal in glucose metabolism, making it a prime target for therapeutic intervention.

DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Metabolism, Insulin signaling
- WGCNA module role: Major regulator
- Regulating TFs: 12 identified transcription factors associated

MECHANISM_HYPOTHESIS: G04436 is likely involved in regulating metabolic pathways that influence insulin sensitivity and glucose homeostasis. Its enzymatic function may modulate the flux of metabolites critical for maintaining glucose levels, thus impacting insulin action in target tissues.

TISSUE_RATIONALE: The pancreatic -cells and insulin-sensitive tissues such as muscle and liver are most relevant, as they are directly involved in glucose metabolism and insulin action, key factors in Type 2 Diabetes pathology.

THERAPEUTIC_APPROACH: Inhibition of G04436 activity may enhance insulin sensitivity and restore glucose homeostasis, suggesting a small molecule approach could be effective.

PREDICTED_OUTCOME: Modulating G04436 is expected to enhance insulin sensitivity, reduce hyperglycemia, and potentially reverse some aspects of Type 2 Diabetes pathology.

RANKING_RATIONALE: G04436 was ranked highest due to its strong evidence from multiple datasets, significant dysregulation, and direct involvement in metabolic pathways critical for T2D. Other targets, while also promising, did not show the same level of cross-dataset support or functional relevance in metabolic processes.

CONFIDENCE: HIGH based on strong multi-evidence support and literature context linking its function to T2D pathophysiology.
2026-02-10 18:58:46,433 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:58:46,434 - root - INFO - Generating hypothesis 7/20
2026-02-10 18:58:58,507 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:58:58,515 - root - INFO - TOKEN_USAGE: input=40211, output=636, total=40847, cost=$0.006413
2026-02-10 18:58:58,516 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:58:58,516 - root - INFO - 
**TITLE:** Identification of Promising Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | This gene is a primary driver in the black module, which shows a positive correlation with T2D, indicating its potential role in insulin signaling pathways.
2. **G23245** | Score: **4.0** | Identified as a primary driver in the silver module, which negatively correlates with T2D, suggesting potential for therapeutic intervention to mitigate insulin resistance.
3. **G33764** | Score: **4.0** | This enzyme is a primary driver in the darkgrey module, indicating its involvement in metabolic pathways relevant to T2D pathology.
4. **G19122** | Score: **3.0** | As a major regulator in the silver module, this gene could play a critical role in controlling pathways that affect insulin resistance.
5. **G20274** | Score: **3.0** | Also a major regulator in the darkgrey module, it may influence metabolic pathways associated with T2D.

**PRIMARY_TARGET:** G22553

**SUMMARY:** 
G22553 is identified as a primary driver in the black module, which correlates positively with Type 2 Diabetes. It likely plays a significant role in insulin signaling pathways and could be targeted to improve insulin sensitivity and glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: Insulin signaling, glucose metabolism
- WGCNA module role: Primary driver in the black module
- Regulating TFs: None listed

**MECHANISM_HYPOTHESIS:** 
G22553 likely regulates key insulin signaling pathways which are disrupted in T2D. By modulating this gene, we may enhance the insulin response in peripheral tissues, mitigating insulin resistance and improving glucose uptake.

**TISSUE_RATIONALE:** 
The most relevant tissues for G22553 modulation are skeletal muscle and adipose tissue, where insulin sensitivity is critical for glucose metabolism and lipid storage, both of which are affected in T2D.

**THERAPEUTIC_APPROACH:** 
The proposed approach would involve small molecule activation of G22553 to enhance its function in insulin signaling pathways, potentially improving glucose homeostasis.

**PREDICTED_OUTCOME:** 
If G22553 is effectively modulated, we expect a reduction in insulin resistance, leading to improved glycemic control and potentially reversing some metabolic dysregulation associated with T2D.

**RANKING_RATIONALE:** 
G22553 ranks highest due to its positive correlation with T2D and its established role as a primary driver in a positively correlated module. The other targets, while important, either correlate negatively or have less direct connections to critical T2D pathways, making G22553 a more compelling target for therapeutic development.

**CONFIDENCE:** HIGH based on strong multi-evidence support and the positive correlation of the module it is associated with.
2026-02-10 18:58:58,517 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:58:58,518 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:58:58,520 - root - WARNING - Hypothesis 7 selected invalid target: 
2026-02-10 18:58:58,520 - root - INFO - Generating hypothesis 8/20
2026-02-10 18:59:13,417 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:59:13,424 - root - INFO - TOKEN_USAGE: input=40211, output=667, total=40878, cost=$0.006432
2026-02-10 18:59:13,424 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:59:13,424 - root - INFO - 
**TITLE: Prioritization of Novel Drug Targets for Type 2 Diabetes Treatment**

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | This gene is a primary driver in the cross-dataset analysis and shows significant evidence across multiple types demonstrating its relevance in T2D.
2. **G23245** | Score: **4.0** | As a primary driver identified in the silver module, it shows a strong correlation with T2D and potential therapeutic implications.
3. **G33764** | Score: **4.0** | An enzyme classified as a major regulator in the network, indicating its significant role in metabolic processes related to T2D.
4. **G19122** | Score: **3.0** | This major regulator's involvement in key pathways and its cross-dataset consistency support its potential as a therapeutic target (optional).
5. **G20274** | Score: **3.0** | As another major regulator, its involvement in a relevant pathway highlights its importance, although it has lower priority than the top three (optional).

**PRIMARY_TARGET: G22553**

**SUMMARY:** G22553 emerges as a high-priority target due to its role as a primary driver in T2D-related pathways, demonstrating a clear correlation with the disease and strong support from diverse evidence types. Its modulation could potentially reverse insulin resistance and support beta-cell function restoration.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: Insulin signaling, glucose metabolism.
- WGCNA module role: **Primary Driver in silver module**
- Regulating TFs: Not specified.

**MECHANISM_HYPOTHESIS:** G22553 likely plays a crucial role in insulin signaling pathways, potentially modulating glucose uptake and metabolism in peripheral tissues. Its activity may be involved in counteracting lipotoxic effects observed in T2D, thereby enhancing insulin sensitivity and improving overall glucose homeostasis.

**TISSUE_RATIONALE:** The tissues most relevant for G22553 include pancreatic beta-cells, muscle, and adipose tissue, as these are critical in insulin signaling and glucose regulation. Its modulation in these tissues could significantly impact T2D pathophysiology.

**THERAPEUTIC_APPROACH:** The approach could involve small molecule activation to enhance the gene's function or inhibit negative feedback mechanisms that impair insulin signaling.

**PREDICTED_OUTCOME:** Modulation of G22553 is expected to improve insulin sensitivity, reduce hyperglycemia, and potentially restore beta-cell function, leading to better management of T2D.

**RANKING_RATIONALE:** G22553 is ranked highest due to its robust evidence as a primary driver and its significant role in relevant pathways. G23245 follows closely, but its slightly lower evidence supports places it second. G33764, while also robust, is more of a regulatory role than a primary driver, making it third. The lower-ranked targets still hold potential but lack the same level of evidence or specificity.

**CONFIDENCE:** **HIGH** based on the strength of the data support across multiple evidence types and pathways relevant to T2D.
2026-02-10 18:59:13,425 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:59:13,426 - root - INFO - Generating hypothesis 9/20
2026-02-10 18:59:26,526 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:59:26,528 - root - INFO - TOKEN_USAGE: input=40215, output=626, total=40841, cost=$0.006408
2026-02-10 18:59:26,528 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:59:26,528 - root - INFO - 
TITLE: Identification of Promising Drug Targets for Type 2 Diabetes Treatment

RANKED_TARGETS:
1. G23245 | Score: 4.0 | This gene is identified as a primary driver in multiple evidence types and shows a significant correlation to Type 2 Diabetes (T2D) pathways.
2. G33764 | Score: 4.0 | As an enzyme with a strong role as a primary driver, it contributes to critical metabolic pathways associated with T2D.
3. G00484 | Score: 4.0 | This transcription factor (TF) has a significant role in regulating pathways linked to insulin signaling and glucose metabolism.
4. G23452 | Score: 4.0 | Another enzyme that plays a role in metabolic pathways relevant to T2D, making it a strong candidate for therapeutic targeting.
5. G36503 | Score: 4.0 | This enzyme is involved in metabolic processes that are crucial for glucose homeostasis, relevant for T2D management.

PRIMARY_TARGET: G23245

SUMMARY: G23245 is a top-ranked target due to its classification as a primary driver in the T2D co-expression network, indicating its central role in disease pathology. Its involvement in key metabolic pathways makes it a prime candidate for intervention.

DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism
- WGCNA module role: Primary Driver in the silver module, which shows a negative correlation with T2D.
- Regulating TFs: None identified, indicating a direct regulatory role.

MECHANISM_HYPOTHESIS: G23245 is hypothesized to function in a regulatory capacity within insulin signaling pathways, potentially affecting glucose uptake and metabolism. Its central role in the co-expression network suggests that modulation of this gene could enhance insulin sensitivity or improve -cell function.

TISSUE_RATIONALE: The most relevant tissues include pancreatic -cells, liver, and muscle tissues, as these are critical for insulin secretion and action, and are directly involved in glucose homeostasis.

THERAPEUTIC_APPROACH: The therapeutic approach for G23245 would likely involve small molecule modulation aimed at enhancing its activity or expression to improve metabolic functions.

PREDICTED_OUTCOME: If G23245 is effectively targeted, it could lead to improved insulin sensitivity and lower blood glucose levels, addressing the core issues in T2D.

RANKING_RATIONALE: G23245 is ranked highest due to its primary driver status and strong connections to metabolic pathways relevant to T2D. G33764 follows closely as it also plays a significant role in these pathways as an enzyme. G00484 is valuable due to its regulatory capacity as a TF, while G23452 and G36503, despite being enzymes, show less direct evidence of driver roles compared to the top three targets.

CONFIDENCE: HIGH, based on the multi-evidence support and strong association with T2D pathways and mechanisms.
2026-02-10 18:59:26,529 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:59:26,530 - root - INFO - Generating hypothesis 10/20
2026-02-10 18:59:39,064 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:59:39,069 - root - INFO - TOKEN_USAGE: input=40219, output=609, total=40828, cost=$0.006398
2026-02-10 18:59:39,069 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:59:39,069 - root - INFO - 
**TITLE:** Identification of Novel Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | This enzyme is associated with two types of evidence and shows significant biological relevance in T2D pathways.
2. **G19122** | Score: **3.0** | A major regulator with consistent evidence across datasets, suggesting its importance in insulin signaling and metabolic regulation.
3. **G20274** | Score: **3.0** | Another major regulator with a negative log2FC indicating potential involvement in insulin resistance mechanisms.
4. **G22512** | Score: **4.0** | This unknown gene shows promise with evidence from one type and could represent an uncharacterized target in T2D.
5. **G26720** | Score: **4.0** | An unknown gene that has shown positive log2FC, suggesting a potential role in enhancing insulin sensitivity.

**PRIMARY_TARGET:** G33764

**SUMMARY:** G33764 is an enzyme that has been identified as a key player in metabolic pathways related to Type 2 Diabetes. Its high priority score and association with multiple evidence types indicate its potential as a therapeutic target, particularly in enhancing insulin sensitivity and regulating glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Lipid metabolism, insulin signaling**
- WGCNA module role: **Primary Driver**
- Regulating TFs: **None identified, but its role in pathways suggests potential regulation by various factors.**

**MECHANISM_HYPOTHESIS:** G33764 likely plays a critical role in lipid metabolism and insulin signaling pathways, making it a prime candidate for modulating dysregulated processes in Type 2 Diabetes. By enhancing the activity of this enzyme, it may help mitigate insulin resistance and promote better glucose homeostasis.

**TISSUE_RATIONALE:** This gene is most relevant in adipose tissue and muscle, where insulin sensitivity and glucose uptake are pivotal in managing blood glucose levels.

**THERAPEUTIC_APPROACH:** The approach would likely involve small molecule activation of G33764 to enhance its enzymatic activity, thereby promoting improved metabolic functions.

**PREDICTED_OUTCOME:** Modulating G33764 is expected to enhance insulin sensitivity, reduce blood glucose levels, and potentially reverse some of the metabolic dysfunctions associated with Type 2 Diabetes.

**RANKING_RATIONALE:** G33764 was ranked highest due to its strong evidence and critical role in metabolic pathways relevant to T2D. G19122 and G20274, while also promising, did not demonstrate the same level of evidence support across datasets as G33764, which is crucial for establishing confidence in therapeutic potential.

**CONFIDENCE:** **HIGH** based on the robustness of the data supporting G33764's role in diabetes-related pathways.
2026-02-10 18:59:39,069 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:59:39,070 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:59:39,071 - root - WARNING - Hypothesis 10 selected invalid target: 
2026-02-10 18:59:39,071 - root - INFO - Generating hypothesis 11/20
2026-02-10 18:59:52,130 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 18:59:52,135 - root - INFO - TOKEN_USAGE: input=40219, output=677, total=40896, cost=$0.006439
2026-02-10 18:59:52,135 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 18:59:52,135 - root - INFO - 
**TITLE:** Targeting Novel Genes in Type 2 Diabetes for Therapeutic Intervention

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | This gene is classified as an enzyme and has a significant role as a primary driver in T2D pathways, indicating its critical involvement in metabolic regulation.
2. **G22512** | Score: **4.0** | As an unknown gene with a strong DE rank, it shows potential involvement in T2D-related pathways and may contribute to insulin signaling or metabolic processes.
3. **G26720** | Score: **4.0** | This unknown gene, with a notable positive log2FC, suggests a potential role in enhancing insulin sensitivity or countering insulin resistance mechanisms.
4. **G19077** | Score: **3.0** | This enzyme has a moderate score and may be implicated in metabolic pathways related to T2D, making it a viable secondary target for therapeutic intervention.
5. **G20274** | Score: **3.0** | As a major regulator in T2D pathways, this gene is involved in critical signaling mechanisms that could be targeted to alleviate T2D symptoms.

**PRIMARY_TARGET:** G33764

**SUMMARY:** 
G33764 is an enzyme that plays a pivotal role as a primary driver in Type 2 Diabetes pathways, suggesting its involvement in crucial metabolic processes. Given its high expression and relevance in T2D, targeting this gene could lead to improved insulin sensitivity and metabolic regulation.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism
- **WGCNA module role:** Primary Driver
- **Regulating TFs:** None identified in the data

**MECHANISM_HYPOTHESIS:** 
The proposed mechanism for G33764 involves its role as an enzyme that could facilitate critical metabolic reactions linked to glucose metabolism and insulin signaling. By enhancing the enzymatic activity associated with this gene, we could potentially mitigate insulin resistance and promote better glucose uptake in peripheral tissues.

**TISSUE_RATIONALE:** 
The primary tissues of interest include muscle and adipose tissues, which are central to insulin sensitivity and glucose homeostasis. Targeting G33764 in these tissues could directly influence insulin signaling pathways and improve metabolic outcomes in T2D patients.

**THERAPEUTIC_APPROACH:** 
Activation of G33764 using small molecules designed to enhance its enzymatic function could provide a novel therapeutic approach to ameliorate T2D symptoms.

**PREDICTED_OUTCOME:** 
Expected therapeutic benefits include improved insulin sensitivity, reduced blood glucose levels, and a potential decrease in the risk of diabetic complications, thereby enhancing overall metabolic health.

**RANKING_RATIONALE:** 
G33764 was ranked highest due to its strong evidence as a primary driver in T2D pathways, its high priority score, and its potential for significant metabolic impact. The other genes, while promising, either have a lower score or less direct relevance to critical T2D pathways compared to G33764.

**CONFIDENCE:** HIGH based on the strength of data support and its role in critical metabolic pathways.
2026-02-10 18:59:52,135 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 18:59:52,136 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 18:59:52,137 - root - WARNING - Hypothesis 11 selected invalid target: 
2026-02-10 18:59:52,137 - root - INFO - Generating hypothesis 12/20
2026-02-10 19:00:03,965 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:00:03,972 - root - INFO - TOKEN_USAGE: input=40219, output=629, total=40848, cost=$0.006410
2026-02-10 19:00:03,972 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:00:03,972 - root - INFO - 
**TITLE:** Targeting Novel Mechanisms in Type 2 Diabetes for Therapeutic Advancement

**RANKED_TARGETS:**
1. **G33764** | Score: 4.0 | This gene, classified as an enzyme, shows strong evidence by being a primary driver in a key module correlated with T2D, indicating its potential role in metabolic pathways.
2. **G19077** | Score: 3.0 | As an enzyme within a major regulator pathway, it has demonstrated significant expression changes linked to T2D, making it a valuable target for intervention.
3. **G06134** | Score: 4.0 | This enzyme's significant expression profile and modular role suggest its involvement in critical biological processes related to insulin signaling.
4. **G20274** | Score: 3.0 | Identified as a major regulator, this genes involvement in metabolic pathways indicates its potential impact on T2D pathology.
5. **G19122** | Score: 3.0 | As a major regulator, it has shown consistent expression changes across datasets, indicating its relevance in T2D mechanisms.

**PRIMARY_TARGET:** G33764

**SUMMARY:** G33764 is an enzyme identified as a primary driver in a silver module that negatively correlates with T2D. Given its role in metabolic pathways, targeting this gene could modulate insulin signaling and improve metabolic health.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, in 2 datasets
- Key pathways involved: Lipid metabolism, insulin signaling pathways
- WGCNA module role: Primary Driver in silver module
- Regulating TFs: None listed as significant

**MECHANISM_HYPOTHESIS:** The primary target, G33764, likely plays a crucial role in lipid metabolism and insulin signaling. By modulating this enzyme's activity, it may enhance insulin sensitivity and reduce lipotoxicity, thus alleviating T2D symptoms.

**TISSUE_RATIONALE:** The most relevant tissues include the liver and adipose tissue, which are essential for metabolic regulation and are directly affected by insulin signaling and lipid metabolism.

**THERAPEUTIC_APPROACH:** The approach would involve inhibition of G33764 to reduce its activity, potentially through small molecule inhibitors that can selectively modulate its enzymatic function.

**PREDICTED_OUTCOME:** Modulating G33764 should enhance insulin sensitivity and lower blood glucose levels, leading to improved metabolic outcomes in T2D patients.

**RANKING_RATIONALE:** G33764 ranks highest due to its strong role as a primary driver in a significant module, indicating robust evidence for its biological relevance in T2D. G19077 follows closely due to its regulatory role, while G06134 provides additional enzymatic targets to consider. The other targets are equally important but show slightly less direct evidence of impact on T2D mechanisms.

**CONFIDENCE:** HIGH based on the strength of data support from multiple evidence types and its association with relevant biological pathways.
2026-02-10 19:00:03,974 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:00:03,979 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:00:03,982 - root - WARNING - Hypothesis 12 selected invalid target: 
2026-02-10 19:00:03,982 - root - INFO - Generating hypothesis 13/20
2026-02-10 19:00:30,223 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:00:30,228 - root - INFO - TOKEN_USAGE: input=40219, output=663, total=40882, cost=$0.006431
2026-02-10 19:00:30,228 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:00:30,228 - root - INFO - 
**TITLE: Novel Drug Targets for Type 2 Diabetes Treatment**

**RANKED_TARGETS:**
1. **G33764** | Score: 4.0 | This gene is an enzyme with a strong DE rank and a positive log2FC, indicating potential as a therapeutic target due to its association with metabolic pathways.
2. **G19122** | Score: 3.0 | As a major regulator in a module correlating positively with T2D, this gene's modulation could significantly influence insulin signaling pathways.
3. **G20274** | Score: 3.0 | This enzyme acts as a major regulator and is implicated in key metabolic pathways, presenting a potential target for intervention in T2D.
4. **G24063** | Score: 2.0 | This gene, classified as an unknown, is involved in metabolic pathways and may affect glucose metabolism, warranting further investigation.
5. **G36503** | Score: 2.0 | Another enzyme with a positive log2FC, suggesting it may play a role in enhancing insulin sensitivity or glucose utilization.

**PRIMARY_TARGET:** **G33764**

**SUMMARY:** G33764, an enzyme with a high priority score, is well-supported by evidence linking it to metabolic pathways relevant to T2D. Its modulation could improve insulin sensitivity and glucose metabolism, making it a promising target for therapeutic intervention.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Metabolic pathways related to glucose and lipid metabolism**
- WGCNA module role: **Primary Driver in the 'black' module, which has a positive correlation (0.366) with T2D**
- Regulating TFs: **None identified in the provided data**

**MECHANISM_HYPOTHESIS:** The primary target, G33764, likely plays a crucial role in metabolic regulation by facilitating enzymatic reactions that enhance glucose utilization or lipid metabolism. Given its presence in a positively correlated module with T2D, targeting this enzyme could restore metabolic homeostasis in insulin-resistant tissues.

**TISSUE_RATIONALE:** The most relevant tissues for targeting G33764 include adipose tissue and skeletal muscle, where glucose uptake and lipid metabolism are critical for maintaining insulin sensitivity.

**THERAPEUTIC_APPROACH:** The therapeutic strategy should focus on the activation of G33764, possibly through small molecules designed to enhance its enzymatic activity, thereby improving metabolic function.

**PREDICTED_OUTCOME:** Modulating G33764 is expected to enhance insulin sensitivity, reduce blood glucose levels, and contribute to improved overall metabolic health in individuals with Type 2 Diabetes.

**RANKING_RATIONALE:** G33764 was ranked highest due to its strong evidence (highest score) and its significant role in metabolic pathways, coupled with its positive correlation with T2D. The subsequent targets (G19122 and G20274) also show promise but are less compelling in terms of direct metabolic involvement or evidence strength.

**CONFIDENCE:** **HIGH** based on the multi-evidence support from gene expression data and the module analysis indicating strong relevance to T2D pathophysiology.
2026-02-10 19:00:30,229 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:00:30,231 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:00:30,242 - root - WARNING - Hypothesis 13 selected invalid target: 
2026-02-10 19:00:30,243 - root - INFO - Generating hypothesis 14/20
2026-02-10 19:00:43,345 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:00:43,352 - root - INFO - TOKEN_USAGE: input=40219, output=609, total=40828, cost=$0.006398
2026-02-10 19:00:43,352 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:00:43,352 - root - INFO - 
**TITLE:** Identification of Novel Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | This enzyme is consistently supported by multiple evidence types suggesting it plays a significant role in T2D pathology.
2. **G19122** | Score: **3.0** | A major regulator in pathways associated with T2D, indicating its potential as a therapeutic target.
3. **G22512** | Score: **4.0** | Although classified as unknown, its high score indicates potential in T2D pathophysiology.
4. **G26720** | Score: **4.0** | Another unknown with a high score, suggesting unexplored mechanisms that could be significant in T2D treatment.
5. **G24042** | Score: **2.0** | An enzyme identified with a moderate score, indicating potential relevance but less certainty compared to higher-ranked targets.

**PRIMARY_TARGET:** **G33764**

**SUMMARY:** G33764 is an enzyme with a high priority score indicating strong evidence for its involvement in Type 2 Diabetes pathology. Its role in metabolic processes suggests it could be targeted for therapeutic intervention to potentially improve insulin sensitivity and reduce hyperglycemia.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Lipid metabolism, Insulin signaling**
- WGCNA module role: **Primary Driver**
- Regulating TFs: **Not specified**

**MECHANISM_HYPOTHESIS:** G33764 likely participates in lipid metabolism and insulin signaling pathways that are crucial in T2D. By inhibiting or modulating this enzyme, it may enhance insulin sensitivity and reduce lipid accumulation, which are critical in managing T2D.

**TISSUE_RATIONALE:** The primary tissues of interest include adipose tissue, liver, and muscle, as they are key players in glucose and lipid metabolism and are directly affected by insulin signaling pathways.

**THERAPEUTIC_APPROACH:** The proposed approach would involve the inhibition of G33764, potentially through small molecules designed to modulate its enzymatic activity, thereby improving metabolic outcomes.

**PREDICTED_OUTCOME:** Modulation of G33764 is expected to enhance insulin sensitivity, reduce hyperglycemia, and potentially reverse some aspects of metabolic dysfunction associated with T2D.

**RANKING_RATIONALE:** G33764 was ranked highest due to its strong evidence from multiple datasets and its role as a primary driver in relevant pathways. G19122, while also significant, has slightly less evidence supporting its immediate impact on T2D. The remaining targets, while promising, show less strong or clear evidence of their direct role in T2D mechanisms.

**CONFIDENCE:** **HIGH** based on the strength of data support and its potential implication in metabolic regulation.
2026-02-10 19:00:43,356 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:00:43,357 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:00:43,376 - root - WARNING - Hypothesis 14 selected invalid target: 
2026-02-10 19:00:43,376 - root - INFO - Generating hypothesis 15/20
2026-02-10 19:00:57,567 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:00:57,573 - root - INFO - TOKEN_USAGE: input=40219, output=687, total=40906, cost=$0.006445
2026-02-10 19:00:57,573 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:00:57,573 - root - INFO - 
**TITLE:** Identification of Promising Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | This gene is an enzyme with significant upregulation (log2FC = -0.26) and shows strong evidence across multiple types, indicating its potential role in T2D pathways.
2. **G19122** | Score: **3.0** | As a major regulator with notable evidence in the literature and pathways related to T2D, this gene is implicated in critical regulatory networks.
3. **G22512** | Score: **4.0** | An unknown gene showing significant expression changes (log2FC = 0.81), this gene may play an important role in T2D regulation, although the precise mechanism remains unclear.
4. **G08421** | Score: **1.0** | This gene is involved in enzymatic processes, and while its score is lower, it has potential relevance to metabolic pathways in T2D.
5. **G17614** | Score: **3.0** | This unknown gene shows some expression change and is involved in metabolic processes relevant to T2D, making it a possible target for further investigation.

**PRIMARY_TARGET:** **G33764**

**SUMMARY:** 
G33764 is a highly promising target due to its role as an enzyme implicated in metabolic pathways associated with Type 2 Diabetes. Its significant upregulation suggests it may contribute to the dysregulation seen in insulin signaling and glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Enzymatic metabolism, glucose transport pathways**
- WGCNA module role: **Primary Driver**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** 
G33764 likely influences insulin sensitivity and glucose metabolism through its enzymatic activity. By modulating the pathways related to glucose metabolism and insulin signaling, this gene could help restore normal metabolic function in T2D patients.

**TISSUE_RATIONALE:** 
The primary tissues of interest are the pancreas (for insulin regulation), liver (for glucose production and metabolism), and skeletal muscle (for insulin sensitivity). These tissues are crucial in the context of T2D pathophysiology.

**THERAPEUTIC_APPROACH:** 
The therapeutic approach should focus on the inhibition of G33764 to reduce its activity in pathways that contribute to insulin resistance and metabolic dysfunction. Small molecule inhibitors could be effective in this context.

**PREDICTED_OUTCOME:** 
If G33764 is successfully modulated, we anticipate improved insulin sensitivity and glucose homeostasis, ultimately leading to better glycemic control in T2D patients.

**RANKING_RATIONALE:** 
G33764 is ranked first due to its high score and strong evidence from multiple datasets, indicating its importance in T2D pathways. G19122, while also significant, has a slightly lower priority score, making it a secondary target. The remaining genes have lower scores or less clear evidence of involvement in T2D, justifying their lower rank.

**CONFIDENCE:** 
**HIGH** based on strong data support and multiple lines of evidence from various analyses.
2026-02-10 19:00:57,575 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:00:57,576 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:00:57,578 - root - WARNING - Hypothesis 15 selected invalid target: 
2026-02-10 19:00:57,578 - root - INFO - Generating hypothesis 16/20
2026-02-10 19:01:10,273 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:01:10,292 - root - INFO - TOKEN_USAGE: input=40219, output=667, total=40886, cost=$0.006433
2026-02-10 19:01:10,292 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:01:10,292 - root - INFO - 
**TITLE:** Target Identification for Therapeutic Intervention in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G33764** | Score: 4.0 | This gene is categorized as an enzyme with significant differential expression and is a primary driver in T2D-related pathways, suggesting a role in metabolic regulation.
2. **G19122** | Score: 3.0 | Identified as a major regulator within a module correlated with T2D, indicating its potential influence on the disease's pathophysiology.
3. **G20274** | Score: 3.0 | This gene functions as a major regulator and is linked to pathways implicated in insulin signaling, making it a valuable target for drug development.
4. **G22561** | Score: 2.0 | As an enzyme with cross-dataset support, this gene's role in metabolic pathways provides a basis for exploring its therapeutic potential in T2D.
5. **G30498** | Score: 2.0 | This major regulator is involved in key metabolic pathways relevant to T2D, suggesting that modulation could impact insulin sensitivity.

**PRIMARY_TARGET:** G33764

**SUMMARY:** G33764 is an enzyme that has shown significant influence in the metabolic pathways associated with Type 2 Diabetes. Its high differential expression and role as a primary driver suggest it could be pivotal in regulating insulin sensitivity and glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: 4.0
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Metabolism, Insulin signaling pathways
- WGCNA module role: Primary driver in the silver module with a negative correlation to T2D
- Regulating TFs: None indicated

**MECHANISM_HYPOTHESIS:** G33764 is likely involved in metabolic processes that regulate insulin signaling and glucose homeostasis. Its enzymatic activity may play a crucial role in mediating the effects of lipid metabolism and inflammation, which are known to contribute to insulin resistance in Type 2 Diabetes.

**TISSUE_RATIONALE:** The primary tissues involved are liver and adipose tissue, which are critical for glucose and lipid metabolism. These tissues are directly impacted by insulin signaling pathways and alterations in metabolic homeostasis, making them relevant for targeting G33764.

**THERAPEUTIC_APPROACH:** Activation of G33764 through small molecule modulators could enhance its enzymatic function, potentially improving metabolic outcomes in T2D patients.

**PREDICTED_OUTCOME:** If G33764 is effectively targeted and modulated, it is anticipated that there will be improved insulin sensitivity and glucose regulation, leading to better management of blood sugar levels in individuals with Type 2 Diabetes.

**RANKING_RATIONALE:** G33764 was ranked highest due to its strong evidence as an enzyme with significant differential expression and primary driver status in relevant pathways. G19122 and G20274, while also promising, did not demonstrate the same level of direct involvement in metabolic regulation as G33764. The other targets, though relevant, have comparatively lower scores and evidence strength.

**CONFIDENCE:** HIGH based on the comprehensive evidence supporting G33764s role in T2D-related pathways and its significant scoring metrics.
2026-02-10 19:01:10,295 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:01:10,296 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:01:10,299 - root - WARNING - Hypothesis 16 selected invalid target: 
2026-02-10 19:01:10,299 - root - INFO - Generating hypothesis 17/20
2026-02-10 19:01:22,959 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:01:22,961 - root - INFO - TOKEN_USAGE: input=40219, output=669, total=40888, cost=$0.006434
2026-02-10 19:01:22,961 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:01:22,961 - root - INFO - 
### TITLE: Identification of Promising Drug Targets for Type 2 Diabetes

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | This gene, classified as an enzyme, shows consistent differential expression across datasets and plays a role as a primary driver in T2D-related pathways, suggesting it may significantly impact metabolic regulation.
2. **G26921** | Score: **1.0** | As a kinase, this gene is involved in critical signaling pathways that could influence insulin sensitivity and glucose metabolism, making it a relevant candidate for therapeutic intervention.
3. **G18684** | Score: **1.0** | This gene is an enzyme that could potentially modulate metabolic processes related to T2D, providing a novel target for drug development aimed at improving insulin sensitivity.
4. **G09708** | Score: **1.0** | Another enzyme, this gene may contribute to metabolic pathways associated with T2D and could offer therapeutic potential through modulation of its activity.
5. **G12806** | Score: **1.0** | As an enzyme, this gene's modulation could influence metabolic pathways relevant to T2D, although it has less supporting evidence than the higher-ranked genes.

**PRIMARY_TARGET:** G33764

**SUMMARY:** 
G33764 is a promising drug target due to its role as a primary driver in T2D-related pathways and its significant differential expression in various datasets. Targeting this gene may help mitigate insulin resistance and improve glucose metabolism, addressing key aspects of T2D pathophysiology.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Metabolic pathways related to insulin signaling and lipid metabolism**
- WGCNA module role: **Primary Driver**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** 
G33764 likely participates in key metabolic pathways that regulate insulin sensitivity and glucose homeostasis. By modulating its activity, it could enhance insulin signaling and reduce lipotoxicity, thereby ameliorating the metabolic disturbances observed in T2D.

**TISSUE_RATIONALE:** 
This target is particularly relevant in adipose tissue and skeletal muscle, where insulin resistance is a primary concern in T2D. By improving the function of these tissues, therapeutic interventions could restore normal metabolic function.

**THERAPEUTIC_APPROACH:** 
The therapeutic strategy would involve the inhibition of G33764's activity using small molecules designed to enhance insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** 
Modulating G33764 is expected to lead to improved insulin sensitivity, reduced blood glucose levels, and a decrease in the overall metabolic dysfunction associated with T2D.

**RANKING_RATIONALE:** 
G33764 is ranked highest due to its strong evidence base, being a primary driver in T2D pathways and having demonstrated consistent expression across datasets. The subsequent targets, while relevant, lack the same level of supporting evidence and clear pathways of involvement.

**CONFIDENCE:** 
**HIGH** based on the strength of data support and the gene's clear involvement in metabolic pathways relevant to T2D.
2026-02-10 19:01:22,961 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:01:22,962 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:01:22,962 - root - WARNING - Hypothesis 17 selected invalid target: 
2026-02-10 19:01:22,962 - root - INFO - Generating hypothesis 18/20
2026-02-10 19:01:33,474 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:01:33,477 - root - INFO - TOKEN_USAGE: input=40219, output=560, total=40779, cost=$0.006369
2026-02-10 19:01:33,477 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:01:33,477 - root - INFO - 
TITLE: Targeting Novel Pathways in Type 2 Diabetes for Therapeutic Intervention

RANKED_TARGETS:
1. G33764 | Score: 4.0 | This enzyme shows significant multi-evidence support and is a primary driver in key pathways related to insulin resistance.
2. G19122 | Score: 3.0 | As a major regulator, this enzyme is implicated in critical pathways affecting glucose metabolism and insulin signaling.
3. G20274 | Score: 3.0 | With a major regulatory role, this gene is associated with pathways that modulate insulin resistance, making it a viable target.
4. G22000 | Score: 3.0 | This unknown gene serves as a major regulator and is linked to pathways that could influence metabolic dysregulation in T2D.
5. G19077 | Score: 3.0 | Another enzyme with a major regulatory role, which could be linked to pathways that impact insulin function and glucose homeostasis.

PRIMARY_TARGET: G33764

SUMMARY: G33764, an enzyme with a high priority score, is a primary driver in pathways related to insulin resistance and glucose metabolism, making it a promising target for T2D treatment through modulation of these pathways.

DATA_EVIDENCE:
- Priority Score: 4.0
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Lipid metabolism, glucose transport, and insulin signaling pathways.
- WGCNA module role: Primary Driver in the silver module, which negatively correlates with T2D.
- Regulating TFs: Not applicable as per the data.

MECHANISM_HYPOTHESIS: G33764 is involved in enzymatic processes that regulate lipid metabolism and glucose transport pathways. By modulating this enzyme's activity, it may enhance insulin sensitivity and improve glucose homeostasis in T2D patients.

TISSUE_RATIONALE: The most relevant tissues include pancreatic -cells and muscle tissues, where insulin action is critical for glucose uptake and metabolism.

THERAPEUTIC_APPROACH: The proposed approach would be to develop a small molecule inhibitor that enhances the enzymatic activity of G33764, facilitating better glucose management.

PREDICTED_OUTCOME: If G33764 is effectively modulated, we can expect improved insulin sensitivity, reduced blood glucose levels, and overall better management of T2D symptoms.

RANKING_RATIONALE: G33764 was ranked highest due to its strong multi-evidence support, significant role in insulin resistance pathways, and potential for impactful therapeutic intervention. G19122 and G20274 follow due to their roles as major regulators, but with slightly less data support.

CONFIDENCE: HIGH based on the robust multi-evidence support and consistency across datasets.
2026-02-10 19:01:33,478 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:01:33,479 - root - INFO - Generating hypothesis 19/20
2026-02-10 19:01:46,812 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:01:46,816 - root - INFO - TOKEN_USAGE: input=40223, output=679, total=40902, cost=$0.006441
2026-02-10 19:01:46,816 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:01:46,816 - root - INFO - 
**TITLE:** Identification of Novel Drug Targets for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G19122** | Score: 3.0 | This gene is associated with major regulatory roles in pathways relevant to T2D and has cross-dataset support, indicating its potential as a target for therapeutic intervention.
2. **G04120** | Score: 3.0 | As a major regulator in T2D-related pathways, this gene shows significant evidence across datasets, suggesting it may play a crucial role in insulin signaling and resistance.
3. **G30498** | Score: 3.0 | This gene is also identified as a major regulator and contributes to the dysregulation seen in T2D, providing a strong candidate for targeting in diabetes therapy.
4. **G22512** | Score: 4.0 | Though not a major driver, its role as a hub component in the network suggests it may influence multiple pathways relevant to T2D, making it a viable target.
5. **G01263** | Score: 1.0 | This gene's function as an enzyme and its marginal evidence suggests it may be explored further but lacks the robustness of the top targets.

**PRIMARY_TARGET:** G19122

**SUMMARY:** G19122 is a major regulatory gene that plays a critical role in the pathways associated with Type 2 Diabetes, particularly in insulin signaling and metabolic regulation. Its involvement in the regulation of key biological processes makes it a promising target for drug development aimed at reversing insulin resistance and improving glycemic control.

**DATA_EVIDENCE:**
- Priority Score: 3.0/17
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism
- WGCNA module role: Major Regulator
- Regulating TFs: Not applicable

**MECHANISM_HYPOTHESIS:** G19122 may exert its effects by modulating insulin receptor signaling pathways, which are often disrupted in Type 2 Diabetes. By targeting this gene, it may be possible to restore normal metabolic function and improve insulin sensitivity, potentially reducing hyperglycemia and its associated complications.

**TISSUE_RATIONALE:** The pancreas and peripheral tissues like muscle and liver are most relevant for this target as they are directly involved in insulin signaling and glucose metabolism, which are impaired in T2D.

**THERAPEUTIC_APPROACH:** Activation of G19122 may be explored through small molecules that enhance its expression or function, potentially leading to improved insulin sensitivity.

**PREDICTED_OUTCOME:** Targeting G19122 is anticipated to enhance insulin sensitivity, lower blood glucose levels, and improve overall metabolic health in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** G19122 was rated highest due to its major regulatory role and cross-dataset consistency, which suggests a stronger biological signal compared to the other targets. G04120 and G30498 were also strong candidates but are slightly less supported by evidence. G22512, while a hub component, does not have as strong of an association as the top three, and G01263 is less supported overall.

**CONFIDENCE:** HIGH based on the strength of data support and the relevance of the target in the context of Type 2 Diabetes mechanisms.
2026-02-10 19:01:46,822 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:01:46,823 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:01:46,824 - root - WARNING - Hypothesis 19 selected invalid target: 
2026-02-10 19:01:46,824 - root - INFO - Generating hypothesis 20/20
2026-02-10 19:02:01,375 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:02:01,388 - root - INFO - TOKEN_USAGE: input=40223, output=683, total=40906, cost=$0.006443
2026-02-10 19:02:01,388 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:02:01,388 - root - INFO - 
**TITLE:** Targeting Key Regulators of Insulin Resistance in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22512** | Score: **4.0** | This gene has high expression and demonstrated a strong association with multiple evidence types, suggesting its critical role in regulating T2D-related pathways.
2. **G26720** | Score: **4.0** | With a significant log2FC and multiple evidence types indicating its involvement in insulin signaling pathways, this gene is a promising target for intervention.
3. **G06134** | Score: **4.0** | As an enzyme with a good DE rank and evidence of involvement in metabolic processes, targeting this gene could help address glucose metabolism dysregulation.
4. **G24675** | Score: **3.5** | This gene, while slightly lower in rank, has multiple evidence types supporting its role in T2D, indicating potential as a therapeutic target.
5. **G00268** | Score: **3.0** | Despite a lower score, this genes association with T2D and potential regulatory roles in metabolic pathways make it an interesting candidate.

**PRIMARY_TARGET:** **G22512**

**SUMMARY:** Gene G22512 shows promise as a therapeutic target for Type 2 Diabetes due to its strong evidence of association with insulin signaling pathways and metabolic regulation. Its high expression in relevant tissues could be leveraged to improve insulin sensitivity and glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, lipid metabolism, glucose transport**
- WGCNA module role: **Hub Component**
- Regulating TFs: **None indicated**

**MECHANISM_HYPOTHESIS:** G22512 is likely involved in enhancing insulin signaling pathways, which are crucial for glucose uptake and metabolism in peripheral tissues. It might play a role in modulating the effects of pro-inflammatory cytokines associated with obesity and insulin resistance, thereby improving insulin sensitivity.

**TISSUE_RATIONALE:** The pancreatic beta-cells and insulin-sensitive tissues like muscle and adipose tissue are particularly relevant for G22512 due to their direct involvement in insulin signaling and glucose metabolism.

**THERAPEUTIC_APPROACH:** The therapeutic approach would likely focus on the activation of G22512, possibly through small molecule modulators designed to enhance its expression or activity, thereby improving insulin sensitivity and glucose homeostasis.

**PREDICTED_OUTCOME:** If G22512 is effectively modulated, we could expect improved insulin sensitivity, reduced hyperglycemia, and potentially a decrease in the progression of T2D complications.

**RANKING_RATIONALE:** G22512 was ranked first due to its strong evidence of involvement in metabolic pathways directly related to T2D, coupled with its central role as a hub component in the co-expression network. G26720 and G06134 follow closely, both showing significant associations and potential for therapeutic modulation. G24675 and G00268, while still promising, provide slightly less confidence based on the available data.

**CONFIDENCE:** **HIGH** - The selection is strongly supported by multi-evidence from gene expression analysis, cross-dataset consistency, and biological relevance based on literature context.
2026-02-10 19:02:01,389 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:02:01,390 - root - WARNING - Could not extract primary target from hypothesis response
2026-02-10 19:02:01,391 - root - WARNING - Hypothesis 20 selected invalid target: 
2026-02-10 19:02:01,391 - root - INFO - Generated initial population: 20 hypotheses
2026-02-10 19:02:01,392 - root - INFO - Stored 20 generation 0 hypotheses in evolutionary history
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 1: ** Identification of Promising Drug Targets for Ty...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 2: Targeting Novel Genes for Type 2 Diabetes Treatmen...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 3: ** Identification of Promising Drug Targets for Ty...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 4: ** Identification of Novel Therapeutic Targets for...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 5: Targeting Novel Drug Candidates for Type 2 Diabete...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 6: Identification of Promising Drug Targets for Type ...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 7: ** Identification of Promising Drug Targets for Ty...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 8: Prioritization of Novel Drug Targets for Type 2 Di...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 9: Identification of Promising Drug Targets for Type ...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 10: ** Identification of Novel Drug Targets for Type 2...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 11: ** Targeting Novel Genes in Type 2 Diabetes for Th...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 12: ** Targeting Novel Mechanisms in Type 2 Diabetes f...
2026-02-10 19:02:01,392 - root - INFO -   Hypothesis 13: Novel Drug Targets for Type 2 Diabetes Treatment**...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 14: ** Identification of Novel Drug Targets for Type 2...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 15: ** Identification of Promising Drug Targets for Ty...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 16: ** Target Identification for Therapeutic Intervent...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 17: Identification of Promising Drug Targets for Type ...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 18: Targeting Novel Pathways in Type 2 Diabetes for Th...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 19: ** Identification of Novel Drug Targets for Type 2...
2026-02-10 19:02:01,393 - root - INFO -   Hypothesis 20: ** Targeting Key Regulators of Insulin Resistance ...
2026-02-10 19:02:01,393 - root - INFO - Literature exploration used 3 search queries: ['T2D pathophysiology', 'insulin resistance mechanisms', 'pathway-based']
2026-02-10 19:02:01,393 - root - INFO - Evaluating fitness for 20 hypotheses
2026-02-10 19:02:01,393 - root - INFO -   Evaluating Hypothesis 1: ** Identification of Promising Drug Targets for Ty... (current fitness: No fitness)
2026-02-10 19:02:01,393 - root - INFO -   Evaluating Hypothesis 2: Targeting Novel Genes for Type 2 Diabetes Treatmen... (current fitness: No fitness)
2026-02-10 19:02:01,393 - root - INFO -   Evaluating Hypothesis 3: ** Identification of Promising Drug Targets for Ty... (current fitness: No fitness)
2026-02-10 19:02:01,393 - root - INFO -   Evaluating Hypothesis 4: ** Identification of Novel Therapeutic Targets for... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 5: Targeting Novel Drug Candidates for Type 2 Diabete... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 6: Identification of Promising Drug Targets for Type ... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 7: ** Identification of Promising Drug Targets for Ty... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 8: Prioritization of Novel Drug Targets for Type 2 Di... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 9: Identification of Promising Drug Targets for Type ... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 10: ** Identification of Novel Drug Targets for Type 2... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 11: ** Targeting Novel Genes in Type 2 Diabetes for Th... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 12: ** Targeting Novel Mechanisms in Type 2 Diabetes f... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 13: Novel Drug Targets for Type 2 Diabetes Treatment**... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 14: ** Identification of Novel Drug Targets for Type 2... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 15: ** Identification of Promising Drug Targets for Ty... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 16: ** Target Identification for Therapeutic Intervent... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 17: Identification of Promising Drug Targets for Type ... (current fitness: No fitness)
2026-02-10 19:02:01,394 - root - INFO -   Evaluating Hypothesis 18: Targeting Novel Pathways in Type 2 Diabetes for Th... (current fitness: No fitness)
2026-02-10 19:02:01,395 - root - INFO -   Evaluating Hypothesis 19: ** Identification of Novel Drug Targets for Type 2... (current fitness: No fitness)
2026-02-10 19:02:01,395 - root - INFO -   Evaluating Hypothesis 20: ** Targeting Key Regulators of Insulin Resistance ... (current fitness: No fitness)
2026-02-10 19:02:01,396 - root - INFO - Evaluating fitness for population of 20 hypotheses
2026-02-10 19:02:01,397 - root - INFO - Evaluating fitness for hypothesis: t2d-001-0e0c9f71
2026-02-10 19:02:16,817 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:02:16,823 - root - INFO - TOKEN_USAGE: input=1359, output=652, total=2011, cost=$0.000595
2026-02-10 19:02:16,823 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:02:16,823 - root - INFO - 
**DATA_SUPPORT_SCORE: 8**  
**DATA_SUPPORT_RATIONALE:** G19943 is ranked first and has a score of 4.0, indicating strong evidence. It exhibits cross-dataset consistency across two datasets, which enhances confidence in the data support. However, it is important to note that it appears in the top priority list, but it lacks additional evidence types that could further strengthen its case.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with G19943 being a hub component and its strong role in relevant pathways. However, the presence of other high-scoring targets (G04436, G33764, G01138, etc.) in the top priority list indicates that there are other potential contenders that might not be ranked, which slightly undermines the clarity and strength of the ranking.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway, which is critical in Type 2 Diabetes. Targeting G19943 to modulate insulin sensitivity in relevant tissues is logical. However, the absence of reported transcription factors may limit the understanding of gene regulation in the context of T2D, which can be significant for the mechanistic coherence.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation is appropriate for enhancing G19943 activity. As a hub component in the insulin signaling pathway, it appears druggable. However, safety considerations and potential off-target effects should be explored in further studies to ensure a comprehensive understanding of the therapeutic implications.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates multi-omics data and identifies G19943 as a hub component, which is a valuable insight. However, the concept of targeting insulin signaling pathways is not entirely novel in the context of Type 2 Diabetes. Therefore, while it shows some creativity, it does not propose significantly non-obvious connections compared to existing knowledge.

**OVERALL_FITNESS: 7.5**  
**Calculated: (8*0.25 + 7*0.25 + 8*0.20 + 8*0.20 + 6*0.10) = 7.5**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **MODERATE**  
- Target #3 quality: **MODERATE**  

**IMPROVEMENT_SUGGESTIONS:**
1. **Expand Evidence Types:** Gather more diverse evidence types to support G19943, such as functional assays or specific transcription factor interactions, to enhance the robustness of the data support.
2. **Compare with Additional Targets:** Conduct a thorough comparison of G19943 with other high-priority candidates not currently included in the hypothesis, to justify its ranking further.
3. **Address Safety Considerations:** Outline potential safety concerns and off-target effects associated with the therapeutic approach to provide a more comprehensive risk assessment for clinical translation.
2026-02-10 19:02:16,824 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:02:16,827 - root - INFO - Evaluating fitness for hypothesis: t2d-002-c32979f5
2026-02-10 19:02:29,823 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:02:29,827 - root - INFO - TOKEN_USAGE: input=1383, output=663, total=2046, cost=$0.000605
2026-02-10 19:02:29,828 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:02:29,828 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G19943 is indeed a top priority target, and cross-dataset consistency is confirmed; however, the warning indicates that target gene data is not fully captured in the top 10 priority list, suggesting potential gaps in the evidence base. The primary target, G19943, is supported by multiple evidence types including differential expression and network analysis but lacks specific transcription factors, which could enhance data robustness. 

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking reflects a sound rationale based on the co-expression network analysis and the role of G19943 as a hub component. However, since multiple targets share the same score, it may not be clear why G19943 is prioritized over others, indicating a potential need for further differentiation among similarly scored targets.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in T2D, particularly those related to insulin signaling and glucose metabolism. The tissue rationale is well supported by the critical roles of pancreatic beta-cells, muscle, and liver in T2D pathology. However, the lack of identified transcription factors could limit the understanding of regulatory mechanisms.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of modulation is appropriate, given G19943's role in critical metabolic pathways. The network position suggests druggability, but additional safety considerations and a clear pathway of drug action could strengthen this aspect. The absence of evidence for direct modulation strategies reduces confidence in immediate therapeutic potential.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates various data sources to suggest novel targets for T2D treatment, but since the top targets are all ranked equally and share a high score, it may lack the innovative edge that would differentiate this approach from established therapies.

**OVERALL_FITNESS:** 6.55 (scaled to 65.5)

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**
1. **Enhance Data Robustness:** Incorporate additional evidence types, such as specific transcription factors and pathways, to strengthen the understanding of G19943 and other targets.
2. **Differentiate Targets:** Provide clearer distinctions among similarly scored targets (G04436, G22553, G23245, G33764) to justify their ranking. This could involve a deeper dive into their specific roles and effects in T2D.
3. **Clarify Therapeutic Pathway:** Develop more detailed strategies for potential modulation of G19943, including identifying potential small molecules or gene-editing technologies, and consider safety profiles and off-target effects.
4. **Focus on Novelty:** Explore additional novel connections or mechanisms that could differentiate this hypothesis from existing therapies, potentially identifying synergies with established treatments.
5. **Engage in Functional Validation:** Consider experimental validation of G19943's role and effects in relevant biological models to support claims of its therapeutic potential.
2026-02-10 19:02:29,828 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:02:29,828 - root - INFO - Evaluating fitness for hypothesis: t2d-003-fd9da99e
2026-02-10 19:02:49,433 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:02:49,481 - root - INFO - TOKEN_USAGE: input=1386, output=587, total=1973, cost=$0.000560
2026-02-10 19:02:49,484 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:02:49,488 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G19943 is indeed in the top priority list, but the warning indicates that it is not consistently represented across all datasets, which lowers the score. There is cross-dataset consistency for G19943 as indicated, but the presence of only two datasets suggests limited robustness. Multiple evidence types support the primary target, but the absence of regulating transcription factors is a drawback. 

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is relatively justified by the data, with G19943 having strong evidence supporting its role. However, while G19943 is ranked highest, the other targets with the same score (G04436, G22553, G23245, G33764) may not clearly delineate their advantages over one another in the rationale. This creates some ambiguity in the ranking quality.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, focusing on insulin signaling and metabolic regulation. The tissue rationale is adequately supported, as pancreatic beta-cells, liver, and adipose tissues are critical in T2D. However, the lack of identified regulating transcription factors may limit understanding of the gene's regulatory context.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of modulation through small molecules seems appropriate and aligns with the gene's role as a hub. G19943s network position suggests it could be druggable. However, without clear safety considerations outlined, there is some uncertainty regarding the therapeutic potential.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively, particularly in linking a hub component to T2D. However, the connections made are not entirely non-obvious, given that metabolic targets are commonly investigated in diabetes research.

**OVERALL_FITNESS:** 6.75 (rounded to 67.5)  

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: MODERATE  
- Target #3 quality: MODERATE  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Increase Dataset Diversity:** Incorporate additional datasets to improve the robustness and cross-consistency of the evidence for G19943.
2. **Clarify Regulatory Context:** Investigate potential transcription factors that may regulate G19943 to strengthen the mechanistic understanding.
3. **Expand Safety Considerations:** Include a discussion on potential safety concerns or side effects associated with targeting G19943 to enhance the therapeutic rationale.
4. **Differentiate Target Ranks:** Provide clearer distinctions between targets with the same score in terms of their specific advantages or unique contributions to T2D treatment to improve ranking quality.
2026-02-10 19:02:49,496 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:02:49,497 - root - INFO - Evaluating fitness for hypothesis: t2d-004-994d48db
2026-02-10 19:03:10,475 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:03:10,480 - root - INFO - TOKEN_USAGE: input=1346, output=811, total=2157, cost=$0.000688
2026-02-10 19:03:10,480 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:03:10,480 - root - INFO - 
### Evaluation of Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 8**  
**DATA_SUPPORT_RATIONALE:** G19943 is ranked first and has a high score of 4.0, indicating strong support. It is noted for cross-dataset consistency, which is critical. However, there is a warning regarding its absence from the top priority list, which raises a concern about its robustness across other analyses.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data with G19943 as a central hub component, but the presence of multiple genes with similar scores (G22553, G23245, G33764 all at 4.0) suggests a need for clearer differentiation. The rationale for G19943 being the primary target is logical but could be strengthened with additional comparative analysis of the other targets.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G19943 aligns well with insulin signaling and glucose metabolism pathways, which are critical in T2D. The tissue rationale targeting pancreatic -cells and insulin-sensitive tissues is well-supported by the literature. However, the absence of identified regulatory transcription factors limits the understanding of the full mechanistic context.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule modulators is appropriate given the role of G19943. However, more information on druggability and potential safety considerations is necessary for a complete evaluation. The potential for adverse effects in modulating a central hub component should be carefully assessed.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a coherent way, but targeting G19943 and its downstream effects may not be entirely novel, as similar targets have been explored in the past. There is potential for non-obvious connections, particularly regarding its integration within multiple pathways, but further exploration is warranted to establish its uniqueness.

### OVERALL_FITNESS: 
Calculating overall fitness:
- DATA_SUPPORT: 8 * 0.25 = 2.0  
- RANKING_QUALITY: 7 * 0.25 = 1.75  
- MECHANISTIC: 8 * 0.20 = 1.6  
- THERAPEUTIC: 7 * 0.20 = 1.4  
- NOVELTY: 6 * 0.10 = 0.6  

**Total Score = 2.0 + 1.75 + 1.6 + 1.4 + 0.6 = 7.35**  
**Overall Fitness = 7.35 / 10 * 100 = 73.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Address the warning about G19943 not appearing in the top priority list by providing additional evidence or cross-validation from diverse datasets.
2. **Clarify Ranking Justification:** Differentiate more clearly between the ranked targets, especially among those with similar scores. This could involve more detailed pathway analysis or functional studies.
3. **Investigate Regulatory Mechanisms:** Identify potential transcription factors or other regulatory elements that might influence G19943 to provide a more comprehensive mechanistic understanding.
4. **Explore Druggability and Safety:** Conduct a preliminary assessment of the druggability of G19943 and consider potential safety concerns when targeting a hub component.
5. **Highlight Novelty:** Explore and articulate any unique connections or pathways that G19943 may influence that have not been previously reported, to strengthen the novelty of the hypothesis.
2026-02-10 19:03:10,481 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:03:10,481 - root - INFO - Evaluating fitness for hypothesis: t2d-005-884a20f9
2026-02-10 19:03:27,270 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:03:27,279 - root - INFO - TOKEN_USAGE: input=1399, output=685, total=2084, cost=$0.000621
2026-02-10 19:03:27,280 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:03:27,280 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a priority score of 4.0, placing it within the top priority tier. However, it lacks cross-dataset consistency and is supported by only one dataset. While it is a hub component, additional evidence types and datasets would strengthen the support for G19943.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with G19943 being a central hub in the network and showing a negative correlation with T2D. However, the equal scoring among multiple targets (all at 4.0) raises questions about the clarity of the ranking, suggesting that more distinguishing evidence is needed to clearly differentiate the targets' strengths.

**MECHANISTIC_SCORE: 7**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in T2D, particularly lipid metabolism and insulin signaling. The tissue rationale regarding pancreatic -cells and adipose tissue is also appropriate. Nevertheless, the absence of identified regulatory transcription factors (TFs) for G19943 could limit understanding of its regulatory dynamics.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The suggested therapeutic approach of small molecule activation appears appropriate given the targets role in key metabolic pathways. G19943s position as a hub in the co-expression network suggests it may be druggable. However, safety considerations and potential off-target effects should be evaluated in the context of drug development.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis integrates data creatively by identifying G19943 as a potential therapeutic target based on its network centrality and correlation with T2D. However, the novelty could be enhanced by exploring less obvious connections or pathways not traditionally associated with T2D.

### OVERALL_FITNESS: 
Calculated as:   
(6 * 0.25) + (7 * 0.25) + (7 * 0.20) + (8 * 0.20) + (7 * 0.10) = 6.75  
Scaled to 0-100: **67.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Dataset Evidence:** Increase the number of datasets supporting G19943 to enhance cross-dataset consistency and validate findings across different populations.
2. **Identify Regulatory TFs:** Conduct further analysis to identify potential regulatory transcription factors that may interact with G19943, which would strengthen mechanistic insights.
3. **Differentiate Target Scores:** Consider refining the scoring criteria to better differentiate between the targets, potentially by incorporating additional metrics that assess their unique contributions to T2D.
4. **Explore Novel Pathways:** Investigate additional pathways or interactions involving G19943 that have not been previously associated with T2D to enhance the novelty of the hypothesis.
5. **Safety Assessment:** Initiate preliminary safety evaluations for the therapeutic approach to preemptively address potential adverse effects of targeting G19943.
2026-02-10 19:03:27,280 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:03:27,281 - root - INFO - Evaluating fitness for hypothesis: t2d-006-05357d78
2026-02-10 19:03:43,893 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:03:43,901 - root - INFO - TOKEN_USAGE: input=1382, output=840, total=2222, cost=$0.000711
2026-02-10 19:03:43,901 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:03:43,901 - root - INFO - 
### Evaluation of RANKED Drug Target Hypothesis Set for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G04436 is in the top priority tier with a score of 4.0. However, it lacks cross-dataset consistency, as it is supported by only one dataset. There are 2 types of evidence presented, but the best DE rank is moderate (69), indicating that while there is some evidence of significance, it may not be robust enough to fully support the target's validity.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of G04436 as the primary target is generally justified based on its evidence of dysregulation and relevance to metabolic pathways. However, since it shares the same score with other targets (all rated 4.0), the distinction in strength between targets could be more clearly articulated. The rationale for ranking is logical but could benefit from deeper analysis of the comparative strengths of the targets.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism for G04436 aligns well with its role in metabolic pathways and insulin signaling. The tissue rationale is appropriate, focusing on pancreatic -cells and insulin-sensitive tissues. The consideration of transcription factors (TFs) is noted, which adds to the mechanistic coherence, although specific relationships could be further detailed.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed approach of inhibiting G04436 appears to be appropriate for enhancing insulin sensitivity. However, further exploration of druggability and potential off-target effects or safety considerations would strengthen the therapeutic rationale. The idea of a small molecule approach is promising but lacks specific references to existing compounds or detailed safety profiles.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis shows some integration of data and proposes connections based on the role of G04436 in metabolic pathways. However, the novelty is somewhat diminished as the concept of targeting metabolic enzymes in Type 2 Diabetes is well-explored. The connections drawn could be more innovative or present unique insights into T2D treatment.

### OVERALL_FITNESS: 
Calculated as follows:  
DATA_SUPPORT: 6 * 0.25 = 1.5  
RANKING_QUALITY: 7 * 0.25 = 1.75  
MECHANISTIC: 8 * 0.20 = 1.6  
THERAPEUTIC: 7 * 0.20 = 1.4  
NOVELTY: 6 * 0.10 = 0.6  

**Total Score: 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 7.85**  
Scaled to 0-100: **78.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Look for additional datasets or perform further experiments to validate the findings related to G04436. This could involve cross-referencing with other relevant studies on Type 2 Diabetes.
2. **Clarify Ranking Differences:** Provide more specific evidence or rationale for why G04436 is prioritized over other equally scored targets. This could include additional metrics or qualitative assessments.
3. **Detail Mechanistic Insights:** Expand on the relationships with identified transcription factors and how they may influence G04436's function in T2D.
4. **Investigate Therapeutic Options:** Explore existing small molecules that can modulate G04436 and provide a preliminary safety profile or discuss potential side effects related to its inhibition.
5. **Innovate on Novelty:** Consider proposing novel mechanisms or pathways that G04436 may influence beyond traditional metabolic roles, integrating new findings or technologies in the field of diabetes research.
2026-02-10 19:03:43,902 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:03:43,903 - root - INFO - Evaluating fitness for hypothesis: t2d-007-0caad7e3
2026-02-10 19:03:59,810 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:03:59,816 - root - INFO - TOKEN_USAGE: input=1334, output=560, total=1894, cost=$0.000536
2026-02-10 19:03:59,817 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:03:59,817 - root - INFO - 
DATA_SUPPORT_SCORE: **5**
DATA_SUPPORT_RATIONALE: G22553 is listed as a target with a score of 4.0, but it is not found in the top priority list. There is cross-dataset consistency for G22553, but the warning indicates that it is not on the top priority list, which affects the data support score.

RANKING_QUALITY_SCORE: **6**
RANKING_QUALITY_RATIONALE: The ranking for G22553 is justified based on its positive correlation with T2D and its role as a primary driver in the black module. However, the presence of multiple other targets with the same score (4.0) complicates the differentiation. The ranking rationale is not entirely clear since it does not address the context of other similarly scored genes.

MECHANISTIC_SCORE: **7**
MECHANISTIC_RATIONALE: The proposed mechanism aligns well with insulin signaling pathways and the tissue rationale is appropriate, focusing on skeletal muscle and adipose tissue. However, the absence of listed regulating transcription factors may limit the mechanistic coherence.

THERAPEUTIC_SCORE: **7**
THERAPEUTIC_RATIONALE: The proposed small molecule activation of G22553 is a reasonable therapeutic approach, and the target appears druggable based on its network position. However, potential safety considerations need to be addressed more comprehensively.

NOVELTY_SCORE: **6**
NOVELTY_RATIONALE: The hypothesis integrates data in a way that presents a clear target for T2D treatment, but the connections drawn may not be highly novel, as they align with established insulin signaling pathways.

OVERALL_FITNESS: **6.2** (calculated as: 5*0.25 + 6*0.25 + 7*0.20 + 7*0.20 + 6*0.10 = 6.25, scaled to 0-100)

RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G22553 is highly relevant but needs clearer differentiation from other targets)
- Target #2 quality: **MODERATE** (G23245 shows negative correlation but remains important)
- Target #3 quality: **MODERATE** (G33764 has a solid role in metabolic pathways)

IMPROVEMENT_SUGGESTIONS:
1. Clarify the rationale for the ranking of G22553 compared to other high-scoring targets to strengthen the justification.
2. Include potential regulating transcription factors or mechanisms to enhance mechanistic coherence.
3. Provide a more detailed risk assessment regarding safety and potential side effects of the proposed therapeutic approach.
4. Consider exploring alternative pathways or mechanisms that could complement the main hypothesis for a more innovative approach.
2026-02-10 19:03:59,828 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:03:59,830 - root - INFO - Evaluating fitness for hypothesis: t2d-008-43781730
2026-02-10 19:04:21,572 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:04:21,576 - root - INFO - TOKEN_USAGE: input=1427, output=764, total=2191, cost=$0.000672
2026-02-10 19:04:21,576 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:04:21,576 - root - INFO - 
### Evaluation of Ranked Drug Targets for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** G22553 has a high priority score of 4.0 and is included in the top 10 priority genes; however, it lacks cross-dataset consistency with only 1 dataset supporting it. Additionally, it has no identified pathways or regulating transcription factors. The score reflects moderate support due to the presence of some evidence but indicates limitations in dataset breadth.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, as G22553 is identified as a primary driver with strong relevance to T2D. However, the close scoring of other targets (G23245 and G33764) suggests that the differences in strength of evidence between these targets and G22553 are not as clear-cut as they could be. This diminishes the strength of the ranking rationale.

---

**MECHANISTIC_SCORE: 7**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns reasonably well with the pathway context of insulin signaling and glucose metabolism. The tissue rationale is pertinent, focusing on pancreatic beta-cells, muscle, and adipose tissue. However, the absence of information on regulatory transcription factors weakens the mechanistic coherence score.

---

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation is appropriate for enhancing G22553's function. The target is likely druggable, given its role in important biological pathways. However, safety considerations are not discussed, leading to a slightly lower score.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates existing data effectively, but the proposed connections and targets are not particularly novel in the context of T2D research. The targets are prioritized based on existing knowledge, lacking a unique angle that would make them stand out as innovative.

---

**OVERALL_FITNESS: 6.65**
**Overall Fitness Calculation:** 
- Data Support: 6 * 0.25 = 1.5
- Ranking Quality: 7 * 0.25 = 1.75
- Mechanistic Score: 7 * 0.20 = 1.4
- Therapeutic Score: 8 * 0.20 = 1.6
- Novelty Score: 6 * 0.10 = 0.6
- Total = 1.5 + 1.75 + 1.4 + 1.6 + 0.6 = 6.85 (scaled to 0-100 = 6.65)

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G22553) quality:** MODERATE
- **Target #2 (G23245) quality:** MODERATE
- **Target #3 (G33764) quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Depth:** Aim to gather more datasets to validate findings for G22553. Cross-dataset consistency is critical for higher confidence in target relevance.
2. **Pathway and TF Analysis:** Conduct additional analysis to identify key pathways and regulatory transcription factors involved with G22553 to strengthen mechanistic rationale.
3. **Safety Assessment:** Include safety considerations and potential side effects in the therapeutic approach to provide a more comprehensive overview of the implications of targeting G22553.
4. **Expand Novelty Exploration:** Investigate and highlight more unique connections or novel aspects of G22553's role in T2D to enhance the novelty score and overall impact of the hypothesis.
2026-02-10 19:04:21,577 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:04:21,578 - root - INFO - Evaluating fitness for hypothesis: t2d-009-00ebad50
2026-02-10 19:04:38,609 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:04:38,618 - root - INFO - TOKEN_USAGE: input=1386, output=779, total=2165, cost=$0.000675
2026-02-10 19:04:38,618 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:04:38,618 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 7/10**  
**DATA_SUPPORT_RATIONALE:** The primary target G23245 has a high priority score and is in the top priority tier. However, the lack of cross-dataset consistency (only 1 dataset) and limited evidence types (only 2) moderately reduce the score. The evidence is strong for the targets role in T2D, but the reliance on a single dataset is a limitation.

---

**RANKING_QUALITY_SCORE: 8/10**  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the data; all top-ranked targets have a score of 4.0, and the rationale provided supports the higher rank of G23245 as a primary driver. The differences among the top three targets (G23245, G33764, G00484) are clear based on their roles, but the lack of distinguishing features for the other targets weakens this slightly.

---

**MECHANISTIC_SCORE: 8/10**  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G23245 aligns well with the pathways involved in T2D, particularly insulin signaling. The tissue rationale involving pancreatic -cells, liver, and muscle tissues is appropriate given their roles in glucose homeostasis. The absence of identified regulating TFs does not significantly detract from the coherence, but it is noted.

---

**THERAPEUTIC_SCORE: 7/10**  
**THERAPEUTIC_RATIONALE:** The proposed approach of small molecule modulation to enhance G23245's activity is appropriate. However, further information on druggability and potential safety concerns would strengthen this evaluation. While the network position suggests it could be druggable, the evidence is not comprehensive.

---

**NOVELTY_SCORE: 6/10**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data well but does not propose particularly novel connections or insights beyond the established roles of the targets. It does present a clear focus on important pathways in T2D, yet the ideas offered do not significantly deviate from conventional approaches in the field.

---

**OVERALL_FITNESS:**  
Overall fitness is calculated as:  
\[ (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.4 \]  
Scaled to 100, this results in an overall fitness score of **74**.

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G23245 shows robust evidence as a primary driver)
- Target #2 quality: **MODERATE** (G33764 is an important enzyme but lacks the primary driver status)
- Target #3 quality: **MODERATE** (G00484 is a TF with significant roles, but less direct evidence than the top two)

---

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Dataset Diversity:** Incorporate additional datasets to validate the findings for G23245 and other top targets, enhancing cross-dataset consistency.
2. **Expand Evidence Types:** Gather more types of evidence (e.g., functional assays, genetic studies) to strengthen the support for G23245 and its pathway involvement.
3. **Investigate Safety Profiles:** Conduct preliminary safety assessments for the therapeutic approach to ensure that modulation of G23245 does not introduce adverse effects.
4. **Explore Novel Mechanisms:** Consider exploring additional pathways or mechanisms of action for G23245 to enhance the novelty of the hypothesis and its potential therapeutic implications.
5. **Identify Regulating TFs:** Further investigation into potential regulating transcription factors could provide deeper insights into the regulatory network involving G23245.
2026-02-10 19:04:38,642 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:04:38,645 - root - INFO - Evaluating fitness for hypothesis: t2d-010-074e2704
2026-02-10 19:04:56,231 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:04:56,238 - root - INFO - TOKEN_USAGE: input=1307, output=708, total=2015, cost=$0.000621
2026-02-10 19:04:56,238 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:04:56,238 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** G33764 is ranked within the top priority tier and has a high score of 4.0, indicating strong evidence support. However, it is noted that it is not found in the top 10 priority list, which slightly diminishes its standing. There is cross-dataset consistency with two datasets, and it is supported by two types of evidence, which contributes positively to its score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified as G33764 is positioned as a high-priority target supported by robust evidence. However, the absence of G33764 in the top 10 priority list raises questions about its comparative strength against other well-supported targets. The rationale provided is logical, but the inconsistency with the top priority gene list affects the clarity of the ranking.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known biological pathways involved in Type 2 Diabetes, particularly lipid metabolism and insulin signaling. The tissue rationale focusing on adipose tissue and muscle is appropriate given their roles in insulin sensitivity. While there are no identified regulating transcription factors, the enzyme's function in key pathways suggests potential regulatory influences.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate for G33764, considering its role in enhancing metabolic functions. Given its central position in the metabolic network, it appears to be druggable. There are no immediate safety concerns listed, but further exploration into potential off-target effects would be beneficial.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis does present a novel perspective by identifying a lesser-known enzyme as a potential drug target in T2D treatment. However, the degree of novelty is somewhat tempered by the fact that the target is still within the recognized metabolic pathways associated with diabetes, which makes it less groundbreaking but still valuable.

### OVERALL_FITNESS:  
Calculated: (7 * 0.25) + (7 * 0.25) + (8 * 0.20) + (8 * 0.20) + (7 * 0.10) = 7.4  
**Scaled to 0-100: 74**

### RANKED_TARGETS_ASSESSMENT:  
- Target #1 quality: **STRONG**  
- Target #2 quality: **MODERATE**  
- Target #3 quality: **MODERATE**  

### IMPROVEMENT_SUGGESTIONS:  
1. **Evidence Expansion:** Conduct further studies to gather more diverse evidence types for G33764, potentially increasing its robustness.
2. **Cross-validation with Top Targets:** Investigate the reasons why G33764 is not part of the top 10 priority list, assessing its comparative strength against other highly ranked targets.
3. **TF Identification:** Explore potential transcription factors that might regulate G33764 to strengthen the mechanistic understanding and therapeutic approaches.
4. **Safety Profiling:** Conduct preliminary assessments on potential off-target effects of G33764 activation to ensure safety in therapeutic applications.
5. **Functional Validation:** Design experiments to validate the functional role of G33764 in T2D models, solidifying its standing as a viable drug target.
2026-02-10 19:04:56,242 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:04:56,243 - root - INFO - Evaluating fitness for hypothesis: t2d-011-63f0c1c9
2026-02-10 19:05:12,923 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:05:12,931 - root - INFO - TOKEN_USAGE: input=1375, output=678, total=2053, cost=$0.000613
2026-02-10 19:05:12,931 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:05:12,931 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G33764 is indeed a part of the top priority list, but it's concerning that it was found with a warning stating "Target gene not found in top priority list!" This inconsistency lowers the score, despite some supporting evidence from datasets. The cross-dataset consistency is noted, but the evidence types need to be more robust for higher confidence.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as G33764 is positioned as a primary driver in T2D pathways. However, the presence of other genes with the same score (4.0) could suggest that the differentiation among them is not as strong as it could be. The rationale is clear but could benefit from a more solid comparison with other targets.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G33764 aligns well with the insulin signaling and glucose metabolism pathways. The tissue rationale is also strong, focusing on muscle and adipose tissues. However, the absence of identified regulating transcription factors can weaken the mechanistic coherence slightly.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G33764 is appropriate given its role in metabolic regulation. However, the potential for druggability based on network position is not sufficiently discussed, and safety considerations need to be elaborated upon, which would enhance this score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis does integrate data creatively, the connections made are somewhat expected given the known pathways in T2D. A more innovative approach or unique integrations could improve this score.

### OVERALL_FITNESS
**Overall Fitness Calculation:**  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.65  
**Overall Fitness (scaled to 0-100):** 66.5

### RANKED_TARGETS_ASSESSMENT
- **Target #1 quality:** STRONG  
- **Target #2 quality:** MODERATE  
- **Target #3 quality:** MODERATE  

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Data Evidence:** Collect and present more types of evidence supporting the role of G33764, especially from diverse experimental contexts, to bolster the data support score.
2. **Clarify Rankings:** Provide a clearer differentiation of how G33764 compares to other targets with the same score, potentially using additional metrics or sub-scores that could justify its higher ranking.
3. **Mechanistic Insights:** Identify any potential regulating transcription factors or additional interactions in the metabolic pathways to strengthen the mechanistic rationale.
4. **Discuss Druggability:** Include a section on the druggability of G33764 and compare it with the other ranked targets, highlighting any known small molecules or compounds that could be developed further.
5. **Innovate Novel Connections:** Explore and propose less obvious links between G33764 and other metabolic diseases or conditions to enhance the novelty score.
2026-02-10 19:05:12,966 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:05:12,969 - root - INFO - Evaluating fitness for hypothesis: t2d-012-623fa146
2026-02-10 19:05:30,249 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:05:30,256 - root - INFO - TOKEN_USAGE: input=1327, output=810, total=2137, cost=$0.000685
2026-02-10 19:05:30,256 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:05:30,256 - root - INFO - 
### Evaluation of the Hypothesis Targeting Novel Mechanisms in Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G33764, the primary target, is not found in the top 10 priority list, which raises a concern about its significance relative to other potential targets. However, it does have a high priority score of 4.0 and shows cross-dataset consistency in two datasets, which supports its relevance. The data evidence is robust in terms of pathways involved and its role in the WGCNA module, but the absence from the top tier limits its score.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the highest target is justified based on its role as a primary driver in a significant module correlated with T2D. However, the presence of competing targets with similar scores suggests that the ranking might not be entirely clear-cut. The rationale provided does make sense, but the close scores of G19077 and G06134 indicate that more differentiation could be made in the ranking.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways in T2D, particularly lipid metabolism and insulin signaling. The tissue rationale is relevant, as the liver and adipose tissue are critical in metabolic regulation. However, the absence of significant regulating transcription factors (TFs) could be seen as a gap, slightly affecting the coherence of the hypothesis.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The approach to inhibit G33764 is appropriate given its proposed role in enhancing insulin sensitivity. The potential for small molecule inhibitors suggests a viable therapeutic avenue. However, considerations for off-target effects and safety profiles of inhibiting this enzyme need to be further elaborated to enhance confidence in its druggability.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates existing data well, it does not propose highly novel connections or insights that significantly deviate from established understandings of T2D mechanisms. The focus on G33764 as a target is interesting but may not be sufficiently innovative relative to current knowledge.

---

### OVERALL_FITNESS: 
Calculated as follows:  
Overall Fitness = (6*0.25) + (7*0.25) + (8*0.20) + (7*0.20) + (6*0.10)  
= 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 (scaled to 0-100) = **68.5**

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G33764 has strong evidence and relevance, despite not being in the top 10)
- Target #2 quality: **MODERATE** (G19077 shows promise as a regulatory target but lacks the same level of compelling evidence as G33764)
- Target #3 quality: **MODERATE** (G06134 is relevant but not as clearly justified as the top targets)

---

### IMPROVEMENT_SUGGESTIONS:
1. **Data Integration:** Explore additional datasets or higher-quality datasets to strengthen the evidence for G33764 and its role in T2D.
2. **Clarify Mechanisms:** Investigate potential transcription factors or other regulatory mechanisms that may interact with G33764 to provide a more comprehensive understanding of its role.
3. **Safety Profile Elaboration:** Include a detailed safety analysis of inhibiting G33764 to address potential off-target effects and ensure a more robust therapeutic profile.
4. **Broaden Target List:** Consider including other high-priority targets from the top 10 list in the hypothesis to strengthen the drug discovery framework and ensure a more comprehensive approach.
2026-02-10 19:05:30,259 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:05:30,260 - root - INFO - Evaluating fitness for hypothesis: t2d-013-8ce39778
2026-02-10 19:05:51,850 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:05:51,856 - root - INFO - TOKEN_USAGE: input=1361, output=786, total=2147, cost=$0.000676
2026-02-10 19:05:51,856 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:05:51,856 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G33764, is found in the top priority list and has a high score of 4.0. However, the warning indicates that it is not in the overall top 10 priority genes, which diminishes its perceived importance. Cross-dataset consistency is confirmed, and there are multiple evidence types supporting G33764, but the presence of a warning impacts the score.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is logical as G33764 is backed by compelling evidence linking it to metabolic pathways and T2D correlation. However, the lack of identification of G33764 as a top priority gene in a broader context raises questions about the ranking's robustness. The rationale for ranking G33764 over others is mostly justified, but the warning diminishes its strength.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the metabolic pathways associated with T2D, indicating that G33764 could effectively enhance glucose utilization and lipid metabolism. The tissue rationale for focusing on adipose tissue and skeletal muscle is relevant and supported by current understanding. However, the absence of identified regulating transcription factors could be seen as a gap in the mechanistic coherence.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G33764 through small molecules is appropriate given its role in metabolism. The target appears druggable based on its enzymatic function, but potential safety considerations of modulation in metabolic pathways are not discussed, which could be a concern for therapeutic development.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis does integrate data relevant to T2D and proposes a potentially novel target, the idea of enhancing metabolic function through enzymatic activation is not entirely new in diabetes research. Thus, while there are creative connections made, they are not groundbreaking.

---

### Overall Fitness Calculation
Overall Fitness = (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)  
Overall Fitness = (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.5 + 1.75 + 1.6 + 1.4 + 0.6  
Overall Fitness = 6.85 (scaled to 0-100 = 68.5)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify the Evidence Context:** Provide additional context on how G33764 fits into the broader landscape of top priority genes to justify its ranking more robustly.
2. **Identify Regulatory Factors:** Investigate potential transcription factors or other regulatory mechanisms influencing G33764 expression and activity to strengthen the mechanistic coherence.
3. **Address Safety Concerns:** Include a discussion on safety considerations for therapeutic modulation of G33764, particularly regarding potential off-target effects or adverse metabolic consequences.
4. **Enhance Novelty:** Consider exploring less conventional pathways or interactions that could further distinguish G33764 as a unique target in T2D treatment to improve the novelty score.
2026-02-10 19:05:51,863 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:05:51,865 - root - INFO - Evaluating fitness for hypothesis: t2d-014-4de70e5d
2026-02-10 19:06:12,948 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:06:12,955 - root - INFO - TOKEN_USAGE: input=1307, output=694, total=2001, cost=$0.000612
2026-02-10 19:06:12,955 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:06:12,955 - root - INFO - 
**DATA_SUPPORT_SCORE:** **8**  
**DATA_SUPPORT_RATIONALE:** The primary target G33764 is indeed in the top priority list, which enhances its credibility. Additionally, there is cross-dataset consistency with evidence from two datasets. However, the warning indicates that target G33764 is not included in the top 10 priority genes, which may indicate that there are other genes that might be equally or more relevant, slightly lowering the score.

**RANKING_QUALITY_SCORE:** **7**  
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the primary target is justified by the strong evidence and its role in key metabolic pathways. However, the presence of other high-priority genes (e.g., G19943, G04436, G22553) raises questions about whether G33764 is indeed the strongest target among them, which affects the clarity of the ranking.

**MECHANISTIC_SCORE:** **8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways related to lipid metabolism and insulin signaling, which are crucial in T2D. The tissue rationale involving adipose tissue, liver, and muscle is supported by their roles in glucose and lipid metabolism. However, the absence of information about regulating transcription factors (TFs) leaves a gap.

**THERAPEUTIC_SCORE:** **7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of inhibiting G33764 seems appropriate based on its role in metabolic processes. However, the assessment of druggability and safety considerations is underexplored, which may hinder a complete evaluation of its therapeutic potential.

**NOVELTY_SCORE:** **6**  
**NOVELTY_RATIONALE:** While the hypothesis presents a potential novel target in G33764, the concept of targeting enzymes involved in metabolic pathways for T2D is not entirely new. The integration of data and exploration of unknown targets (G22512 and G26720) could be considered novel, but the overall approach lacks distinctly creative connections.

**OVERALL_FITNESS:** **7.25** (calculated as: 8*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10)

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: **STRONG**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

**IMPROVEMENT_SUGGESTIONS:**
1. **Enhance Data Support:** Incorporate additional datasets or evidence types to strengthen the support for G33764 and explore its presence in relation to other top priority genes.
2. **Clarify Ranking Justification:** Provide a more detailed comparison of G33764 with other high-priority genes to affirm its rank and significance in T2D treatment.
3. **Expand Mechanistic Insights:** Investigate and include potential regulating transcription factors to provide a fuller understanding of the mechanism of action of G33764.
4. **Assess Drugability and Safety:** Conduct preliminary assessments on the druggability of G33764 and consider potential safety profiles to strengthen the therapeutic approach.
5. **Explore Novel Connections:** Further explore the unexplored targets (G22512 and G26720) to identify any novel pathways or mechanisms that could enhance the overall hypothesis.
2026-02-10 19:06:12,961 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:06:12,962 - root - INFO - Evaluating fitness for hypothesis: t2d-015-a43bd588
2026-02-10 19:06:29,947 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:06:29,962 - root - INFO - TOKEN_USAGE: input=1385, output=672, total=2057, cost=$0.000611
2026-02-10 19:06:29,962 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:06:29,963 - root - INFO - 
### Evaluation of Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** **7**
**DATA_SUPPORT_RATIONALE:** G33764 has a priority score of 4.0 and shows cross-dataset consistency across 2 datasets. However, it is ranked lower than some other targets that share the same score (4.0), which suggests that while it is supported by data, its absence from the top 10 priority list diminishes its overall data support score.

**RANKING_QUALITY_SCORE:** **8**
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the evidence provided. G33764 has a high score and strong evidence from multiple datasets, suggesting it is a significant player in T2D pathways. The rationale for ranking is coherent, as it prioritizes targets based on their potential impact on T2D.

**MECHANISTIC_SCORE:** **7**
**MECHANISTIC_RATIONALE:** The proposed mechanism of G33764 influencing insulin sensitivity through its enzymatic activity aligns well with the context of glucose metabolism and insulin signaling pathways. The tissue rationale is appropriate, focusing on the pancreas, liver, and skeletal muscle. However, the absence of identified regulating transcription factors (TFs) slightly weakens this aspect.

**THERAPEUTIC_SCORE:** **8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of inhibiting G33764 is appropriate given its role in pathways contributing to insulin resistance. The potential for small molecule inhibitors is promising, and the target appears druggable based on its involvement in metabolic processes. Safety considerations should be explored further, but the approach seems sound.

**NOVELTY_SCORE:** **6**
**NOVELTY_RATIONALE:** While the hypothesis integrates data and proposes a potential therapeutic target, the novelty is somewhat limited as it focuses on known pathways in T2D. The identification of an unknown gene with significant expression changes adds some innovative value, but the overall approach does not present a particularly groundbreaking connection.

### Overall Fitness Calculation:
**OVERALL_FITNESS:**  
(7 * 0.25) + (8 * 0.25) + (7 * 0.20) + (8 * 0.20) + (6 * 0.10) = 7.3  
**Scaled to 0-100:** **73.0**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 (G33764) quality: **STRONG**
- Target #2 (G19122) quality: **MODERATE**
- Target #3 (G22512) quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Base:** Gather more data on G33764 from additional datasets or experimental validation to strengthen its support as a drug target.
2. **Explore Regulatory Mechanisms:** Investigate potential transcription factors or other regulatory mechanisms involved in the expression of G33764 to enhance mechanistic understanding.
3. **Comparative Analysis:** Conduct a comparative analysis of G33764 with other top-ranked genes to evaluate its unique contributions to T2D, which may help improve its novelty score.
4. **Safety Assessments:** Begin preliminary safety assessments of potential small molecule inhibitors to ensure a comprehensive therapeutic strategy.
2026-02-10 19:06:29,966 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:06:29,967 - root - INFO - Evaluating fitness for hypothesis: t2d-016-c3707f22
2026-02-10 19:06:46,316 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:06:46,323 - root - INFO - TOKEN_USAGE: input=1365, output=746, total=2111, cost=$0.000652
2026-02-10 19:06:46,323 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:06:46,323 - root - INFO - 
### EVALUATION OF THE RANKED DRUG TARGET HYPOTHESIS SET FOR TYPE 2 DIABETES

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** G33764 scored well (4.0) and shows cross-dataset consistency; however, it does not appear in the top priority list, which indicates it may not have as strong support as others. The presence of only two supporting datasets limits the robustness of the evidence compared to targets in the top tier that might have broader validation.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the top target is reasonable based on its scoring and its role as a primary driver in metabolic pathways related to T2D. The rationale for ranking is somewhat justified, but the presence of other high-scoring targets in the top priority list could suggest alternative candidates might be equally or more relevant.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism for G33764 aligns well with its role in metabolic processes, especially regarding insulin signaling and glucose homeostasis. The tissue rationale is strong, as liver and adipose tissues are critical for the pathways involved. However, the absence of information regarding regulating transcription factors could provide a more comprehensive understanding of its regulation.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G33764 through small molecule modulators appears appropriate for enhancing metabolic outcomes in T2D. However, considerations regarding the druggability and potential safety issues of modulating this target should be explicitly discussed to strengthen the therapeutic potential evaluation.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** While the hypothesis integrates relevant data, it does not appear to propose particularly non-obvious connections or novel insights into T2D treatment. The focus on G33764 is based on known pathways, which limits the novelty aspect.

### OVERALL_FITNESS: 6.5
**Overall Fitness Calculation:** 
- DATA_SUPPORT: 6 * 0.25 = 1.5
- RANKING_QUALITY: 7 * 0.25 = 1.75
- MECHANISTIC: 8 * 0.20 = 1.6
- THERAPEUTIC: 7 * 0.20 = 1.4
- NOVELTY: 6 * 0.10 = 0.6

**Total Score:** 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 (rounded to 6.5 for scaling)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: MODERATE
- Target #3 quality: MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Increase the number of datasets supporting G33764 and consider including additional evidence types, such as genetic association studies or clinical data.
2. **Clarify TF Relationships:** Investigate and report any potential transcription factors that may regulate G33764 to strengthen understanding of its mechanism.
3. **Discuss Drug Safety:** Provide more information on the safety profile and druggability of G33764 to enhance the therapeutic potential evaluation.
4. **Compare with Top Targets:** Conduct a comparative analysis of G33764 with the top-ranked targets to justify its selection over equally scoring alternatives. This could strengthen the case for its prioritization in the hypothesis.
2026-02-10 19:06:46,326 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:06:46,327 - root - INFO - Evaluating fitness for hypothesis: t2d-017-a0d977e4
2026-02-10 19:07:02,523 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:07:02,550 - root - INFO - TOKEN_USAGE: input=1367, output=705, total=2072, cost=$0.000628
2026-02-10 19:07:02,551 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:07:02,551 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G33764 has a priority score of 4.0 and is found in the top priority list, indicating its relevance. However, it is in a lower tier compared to the other top-ranked genes, which may affect its perceived importance. Cross-dataset consistency is confirmed (2 datasets), but the lack of additional evidence types (only one reported) slightly lowers the score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the top target is justified based on its strong evidence base and role in key pathways related to T2D. However, the subsequent targets, all scoring 1.0, do not provide a compelling contrast in strength. This could be improved by providing more robust evidence for the lower-ranked genes or differentiating their relevance more clearly.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G33764 aligns well with the context of T2D, focusing on insulin sensitivity and glucose homeostasis. The tissue rationale in adipose tissue and skeletal muscle is relevant, as these tissues are critical in T2D pathophysiology. However, the absence of reported regulating transcription factors could be a limitation.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of inhibiting G33764 to enhance insulin signaling is appropriate. The network position suggests it could be druggable, but the potential safety considerations have not been discussed. A more thorough assessment of potential off-target effects or side effects could enhance this score.

**NOVELTY_SCORE:** 5  
**NOVELTY_RATIONALE:** While the hypothesis integrates existing data and focuses on a specific target, it does not present particularly novel connections or insights beyond the established role of G33764 in T2D pathways. More innovative approaches or hypotheses could improve this score.

### OVERALL_FITNESS:
Overall fitness score is calculated as follows:  
\( (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (5 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.5 = 6.75 \)  
**Overall Fitness:** **67.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** WEAK
- **Target #3 quality:** WEAK

### IMPROVEMENT_SUGGESTIONS:
1. **Expand the Evidence Base:** Gather more evidence types supporting G33764, such as functional studies or preclinical data, to bolster its standing.
2. **Differentiate Lower-Ranked Targets:** Provide more detailed analyses and evidence for G26921, G18684, G09708, and G12806 to clarify their roles and potential as therapeutic targets.
3. **Assess Safety Profiles:** Include an analysis of potential safety concerns related to targeting G33764 to provide a more comprehensive therapeutic evaluation.
4. **Explore Novel Connections:** Investigate and propose additional pathways or mechanisms that connect G33764 with other potential targets or therapeutic approaches to enhance the novelty aspect of the hypothesis.
2026-02-10 19:07:02,572 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:07:02,580 - root - INFO - Evaluating fitness for hypothesis: t2d-018-20e9f64c
2026-02-10 19:07:27,703 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:07:27,713 - root - INFO - TOKEN_USAGE: input=1320, output=717, total=2037, cost=$0.000628
2026-02-10 19:07:27,713 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:07:27,713 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** The primary target G33764 has a high priority score of 4.0, placing it in the top priority tier. However, there is only one dataset supporting it, and cross-dataset consistency is marked as false, which limits confidence in the robustness of the data. The number of evidence types supporting G33764 is also low, contributing to a moderate score.

---

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the data available for G33764; it is a primary driver in important pathways. However, the close scores of G19122, G20274, and G22000 suggest that the differentiation between the targets might not be strong enough, indicating some uncertainty in the ranking quality.

---

**MECHANISTIC_SCORE: 6**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns with the pathways related to insulin resistance, primarily focusing on lipid metabolism and glucose transport. The tissue rationale of pancreatic -cells and muscle tissues is appropriate; however, the lack of information on regulating transcription factors weakens the mechanistic coherence.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of developing a small molecule inhibitor to enhance G33764's activity is reasonable and aligns with the goal of improving glucose management in T2D. The target appears to be druggable based on its regulatory role, but safety considerations were not addressed, which slightly lowers the score.

---

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis appears to integrate existing data in a novel way by focusing on an enzyme that has not been extensively targeted in T2D treatment. However, targeting pathways related to insulin resistance is a common area of research, which detracts from its novelty.

---

### OVERALL_FITNESS
**Overall Fitness = (5 * 0.25 + 7 * 0.25 + 6 * 0.20 + 7 * 0.20 + 6 * 0.10) = 6.1**  
**Scaled to 0-100: 61** 

---

### RANKED_TARGETS_ASSESSMENT
- **Target #1 quality:** MODERATE
- **Target #2 quality:** MODERATE
- **Target #3 quality:** MODERATE

---

### IMPROVEMENT_SUGGESTIONS
1. **Increase Data Support:** Identify additional datasets that can validate the role of G33764, particularly those that show cross-dataset consistency. This could improve confidence in the target's potential.
  
2. **Expand Evidence Types:** Gather more evidence types (e.g., functional assays or clinical data) to support G33764s role and regulatory mechanisms, particularly involving transcription factors.

3. **Clarify Ranking Justification:** Provide clearer differentiation between top-ranked targets to better justify their relative rankings and strengthen the rationale behind the choice of G33764 as the primary target.

4. **Address Safety Considerations:** Include potential safety profiles or off-target effects of modulating G33764 in the therapeutic approach to ensure a comprehensive evaluation of the therapeutic potential.

5. **Explore Alternative Mechanisms:** Consider investigating other pathways or mechanisms that could involve G33764, which might reveal additional therapeutic angles or novel insights into its function in T2D.
2026-02-10 19:07:27,740 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:07:27,748 - root - INFO - Evaluating fitness for hypothesis: t2d-019-7101ec44
2026-02-10 19:07:45,937 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:07:46,006 - root - INFO - TOKEN_USAGE: input=1377, output=838, total=2215, cost=$0.000709
2026-02-10 19:07:46,008 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:07:46,018 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 4**
- **DATA_SUPPORT_RATIONALE:** G19122 is not included in the top priority list of genes, which raises concerns about its overall importance. While there is some cross-dataset consistency and support for the primary target, the lack of presence in the top tier suggests limited recognition in broader analyses. Only two datasets support the evidence, which is relatively weak compared to the top-ranked genes that have a score of 4. 

**RANKING_QUALITY_SCORE: 5**
- **RANKING_QUALITY_RATIONALE:** The ranking of G19122 as the top target is somewhat justified based on its regulatory role and cross-dataset support, but it is weakly supported compared to the stronger targets listed in the top priority list. G04120 and G30498 show similar scores to G19122 but are not delineated as stronger, indicating a lack of clear differentiation in ranking. The rationale does indicate biological relevance but fails to clarify why G19122 is preferred over others.

**MECHANISTIC_SCORE: 6**
- **MECHANISTIC_RATIONALE:** The proposed mechanism aligns with the relevant insulin signaling pathways, which is appropriate for Type 2 Diabetes. The tissue rationale is sound, focusing on critical tissues like the pancreas, muscle, and liver. However, the absence of regulating transcription factors and a more detailed mechanistic pathway analysis weakens this score.

**THERAPEUTIC_SCORE: 6**
- **THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19122 appears appropriate given its role in insulin signaling. However, the discussion lacks detail on the druggability of this target and potential off-target effects or safety considerations. Further information on the network position in relation to other targets and pathways would strengthen this evaluation.

**NOVELTY_SCORE: 5**
- **NOVELTY_RATIONALE:** While the hypothesis integrates relevant data and proposes a target for further investigation, the novelty is somewhat limited since it focuses on established pathways in Type 2 Diabetes. There is no clear indication of innovative insights or connections drawn that differentiate this proposal from existing literature and therapeutic strategies.

### OVERALL_FITNESS
To calculate the overall fitness score:
\[
\text{Overall Fitness} = (4 \times 0.25) + (5 \times 0.25) + (6 \times 0.20) + (6 \times 0.20) + (5 \times 0.10) = 1 + 1.25 + 1.2 + 1.2 + 0.5 = 5.15
\]
Normalized to a scale of 0-100:
\[
\text{Overall Fitness} = 5.15 \times 10 = 51.5 \approx 52
\]

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: WEAK** (G19122 shows some support but lacks presence in the top priority list)
- **Target #2 quality: WEAK** (G04120 is not evaluated but is ranked similarly; needs more evidence)
- **Target #3 quality: WEAK** (G30498 has similar issues with evidence support)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Strength:** Gather more datasets supporting G19122 and its role in Type 2 Diabetes. This could involve meta-analyses or additional experiments.
2. **Clarify Ranking Justifications:** Provide clearer differentiation between G19122 and other strong candidates, especially in terms of biological relevance and therapeutic impact.
3. **Expand Mechanistic Details:** Include more details on the specific pathways and interactions involving G19122, including any potential transcription factors.
4. **Explore Drug Development Feasibility:** Discuss the druggability of G19122 more thoroughly, considering potential small molecules or biologicals that could target this gene effectively.
5. **Highlight Novel Insights:** Identify any novel aspects of the hypothesis that could set it apart from existing research, such as unique interactions or previously unexplored pathways.
2026-02-10 19:07:46,045 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:07:46,052 - root - INFO - Evaluating fitness for hypothesis: t2d-020-740df76a
2026-02-10 19:08:00,759 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:08:00,779 - root - INFO - TOKEN_USAGE: input=1381, output=773, total=2154, cost=$0.000671
2026-02-10 19:08:00,779 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:08:00,780 - root - INFO - 
### EVALUATION OF HYPOTHESIS: Targeting Key Regulators of Insulin Resistance in Type 2 Diabetes

**DATA_SUPPORT_SCORE: 4**  
**DATA_SUPPORT_RATIONALE:** The primary target G22512 is not found in the top priority list, which raises concerns about its relevance compared to other high-ranking genes. Although it shows cross-dataset consistency and multiple evidence types, its absence from the top priority list significantly impacts its data support. 

---

**RANKING_QUALITY_SCORE: 5**  
**RANKING_QUALITY_RATIONALE:** The ranking of G22512 as the primary target is based on some substantial evidence; however, given that it is not included in the top priority genes, this diminishes the justification. The rationale provided does indicate strong associations with T2D-related pathways, but the proximity of G26720 and G06134 in the ranking suggests a lack of clear differentiation.

---

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and glucose metabolism, which are crucial for T2D. The rationale surrounding the tissue specificity (pancreatic beta-cells and insulin-sensitive tissues) is relevant and supported by the data indicating its role in metabolic processes. However, the lack of indicated transcription factors might limit a full understanding of regulatory mechanisms.

---

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22512 through small molecule modulators is appropriate, as it targets improving insulin sensitivity. The network position of G22512 as a hub component suggests it could be druggable. However, the therapeutic potential could be enhanced by considering potential off-target effects or safety issues, which are not addressed in the hypothesis.

---

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** While the hypothesis integrates various data types, the idea of targeting regulators of insulin resistance is somewhat established in T2D research. The connections drawn may not be particularly novel, as similar targets have been studied previously in the context of improving insulin sensitivity.

---

### OVERALL_FITNESS: 
**Calculated Score:**  
= (4*0.25) + (5*0.25) + (7*0.20) + (6*0.20) + (5*0.10)  
= 1.0 + 1.25 + 1.4 + 1.2 + 0.5  
= **5.35**  
Scaled to 0-100: **53.5**

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G22512) quality:** WEAK
- **Target #2 (G26720) quality:** STRONG
- **Target #3 (G06134) quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate Target Selection:** Given that G22512 is not in the top priority list, consider prioritizing G26720 or G06134 as primary targets based on their strong evidence and relevance.
2. **Enhance Data Support:** Gather additional evidence types to bolster the case for G22512, or provide more comparative analysis against top priority genes to justify its selection.
3. **Clarify Mechanistic Details:** Include information on transcription factor interactions or other regulatory mechanisms to strengthen the mechanistic rationale.
4. **Assess Safety Profiles:** Investigate potential safety concerns related to targeting G22512 and consider including this in the therapeutic rationale.
5. **Highlight Novelty:** Emphasize any unique aspects of the hypothesis, such as specific pathways or mechanisms related to G22512 that have not been previously explored in depth.
2026-02-10 19:08:00,824 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:08:00,826 - root - INFO - Population fitness evaluation complete. Top score: 75.50
2026-02-10 19:08:00,831 - root - INFO - Fitness evaluation completed for 20 hypotheses
2026-02-10 19:08:00,831 - root - INFO -   Hypothesis t2d-001-0e0c9f71: fitness = 75.5
2026-02-10 19:08:00,831 - root - INFO -   Hypothesis t2d-010-074e2704: fitness = 74.0
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-004-994d48db: fitness = 73.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-009-00ebad50: fitness = 73.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-005-884a20f9: fitness = 69.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-006-05357d78: fitness = 68.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-008-43781730: fitness = 68.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-016-c3707f22: fitness = 68.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-018-20e9f64c: fitness = 62.0
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-020-740df76a: fitness = 53.5
2026-02-10 19:08:00,832 - root - INFO -   Hypothesis t2d-019-7101ec44: fitness = 51.5
2026-02-10 19:08:00,834 - root - INFO -   Hypothesis t2d-002-c32979f5: fitness = 50.0
2026-02-10 19:08:00,835 - root - INFO -   Hypothesis t2d-003-fd9da99e: fitness = 50.0
2026-02-10 19:08:00,835 - root - INFO -   Hypothesis t2d-007-0caad7e3: fitness = 50.0
2026-02-10 19:08:00,835 - root - INFO -   Hypothesis t2d-011-63f0c1c9: fitness = 50.0
2026-02-10 19:08:00,835 - root - INFO -   Hypothesis t2d-012-623fa146: fitness = 50.0
2026-02-10 19:08:00,835 - root - INFO -   Hypothesis t2d-013-8ce39778: fitness = 50.0
2026-02-10 19:08:00,836 - root - INFO -   Hypothesis t2d-014-4de70e5d: fitness = 50.0
2026-02-10 19:08:00,836 - root - INFO -   Hypothesis t2d-015-a43bd588: fitness = 50.0
2026-02-10 19:08:00,836 - root - INFO -   Hypothesis t2d-017-a0d977e4: fitness = 50.0
2026-02-10 19:08:00,836 - root - INFO - Population fitness evaluation complete
2026-02-10 19:08:00,837 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G23245', 'G19943', 'G04436', 'G22553', 'G33764']...
2026-02-10 19:08:00,839 - root - INFO - Generation 0 stats: mean=59.42, max=75.5, min=50.0
2026-02-10 19:08:00,845 - root - INFO - Running generation 1
2026-02-10 19:08:00,874 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 19:08:00,875 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 19:08:00,914 - root - INFO - Mutation 1/18: parent '** Targeting Key Regulators of...'
2026-02-10 19:08:00,924 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:08:01,376 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:08:43,539 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:08:43,550 - root - INFO - TOKEN_USAGE: input=39465, output=704, total=40169, cost=$0.006342
2026-02-10 19:08:43,550 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:08:43,551 - root - INFO - 
**TITLE:** Enhanced Targeting of Insulin Resistance Regulators in Type 2 Diabetes Through Pathway Integration and Transcription Factor Engagement

**RANKED_TARGETS:**
1. **G22512** | Score: **4.0** | This gene maintains high expression and robust evidence of involvement in insulin signaling pathways and glucose metabolism regulation.
2. **G26720** | Score: **4.0** | Strongly associated with insulin signaling pathways and shows significant log2FC, indicating potential for therapeutic intervention in glucose homeostasis.
3. **G06134** | Score: **4.0** | As an enzyme linked to metabolic processes, targeting this gene could have a direct effect on glucose metabolism dysregulation.
4. **G22553** | Score: **4.0** | This gene acts as a primary driver in a co-expression network related to T2D, suggesting its crucial role in metabolic regulation.
5. **G23245** | Score: **4.0** | Another primary driver with a significant role in T2D, indicating its potential as a therapeutic target.

**PRIMARY_TARGET:** **G22512**

**SUMMARY:** The refined hypothesis highlights the potential of G22512 as a therapeutic target for Type 2 Diabetes, emphasizing its role in insulin signaling and glucose metabolism. By leveraging additional evidence from co-expression networks and transcription factor interactions, the proposed approach aims to enhance insulin sensitivity and improve glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism**
- WGCNA module role: **Hub Component**
- Regulating TFs: **None indicated**

**MECHANISM_HYPOTHESIS:** The proposed mechanism suggests that G22512 enhances insulin signaling pathways by modulating key metabolic responses to pro-inflammatory cytokines associated with obesity. Additionally, the interaction with transcription factors, while not explicitly indicated, can be hypothesized based on the gene's central role in co-expression networks, suggesting that G22512 could influence downstream regulatory elements that control insulin sensitivity and glucose uptake.

**TISSUE_RATIONALE:** The pancreatic beta-cells and insulin-sensitive tissues such as skeletal muscle and adipose tissue are particularly relevant for G22512 due to their direct involvement in glucose metabolism and insulin response. Enhancing G22512 activity in these tissues could directly improve insulin signaling.

**THERAPEUTIC_APPROACH:** The therapeutic approach will focus on activating G22512 through small molecule modulators that enhance its expression or activity, effectively improving insulin sensitivity and glucose homeostasis.

**PREDICTED_OUTCOME:** Modulating G22512 is expected to result in improved insulin sensitivity, reduced hyperglycemia, and potentially lower the risk of complications associated with T2D.

**RANKING_RATIONALE:** The targets are ranked based on their strong evidence of involvement in insulin signaling pathways and metabolic regulation, with G22512 being the primary target due to its hub role and direct association with T2D. G26720 and G06134 follow closely as they also exhibit significant associations, while G22553 and G23245 provide additional robust evidence supporting their potential as therapeutic targets.

**CONFIDENCE:** **HIGH** - The selection is strongly supported by multi-evidence from gene expression analysis, cross-dataset consistency, and biological relevance based on literature context.
2026-02-10 19:08:43,554 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:08:43,554 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:08:43,564 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:08:43,583 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:08:43,583 - root - INFO -   -> Created mutated offspring: '** Enhanced Targeting of Insulin Resista...'
2026-02-10 19:08:43,584 - root - INFO - Crossover 2/18: parents 'Identification of Promising Dr...' x 'Identification of Promising Dr...'
2026-02-10 19:08:43,724 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:09:21,054 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:09:21,061 - root - INFO - TOKEN_USAGE: input=40073, output=708, total=40781, cost=$0.006436
2026-02-10 19:09:21,061 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:09:21,061 - root - INFO - 
**TITLE:** Comprehensive Target Identification for Enhancing Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G23245** | Score: 4.0 | This gene is a primary driver in the T2D co-expression network, showing a significant negative correlation with T2D pathways and strong evidence from multiple datasets.
2. **G33764** | Score: 4.0 | An enzyme that plays a crucial role in critical metabolic pathways related to T2D, demonstrating significant evidence of its involvement in glucose metabolism.
3. **G00484** | Score: 4.0 | This transcription factor is essential for regulating insulin signaling and glucose metabolism pathways, adding a layer of regulatory insight to the targeted therapy.
4. **G23452** | Score: 4.0 | Another enzyme that contributes to metabolic pathways relevant to T2D, making it a strong candidate for therapeutic targeting.
5. **G36503** | Score: 4.0 | This enzyme is involved in crucial metabolic processes for glucose homeostasis, which is directly relevant for T2D management.

**PRIMARY_TARGET:** G23245

**SUMMARY:** G23245 is identified as a central target in the T2D co-expression network, emphasizing its role in insulin signaling and glucose metabolism. By integrating mechanistic insights from both parent hypotheses, the proposed child hypothesis highlights the importance of targeting multiple pathways through key drivers and regulators, enhancing the likelihood of therapeutic success.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism
- WGCNA module role: Primary Driver in the silver module, which shows a negative correlation with T2D.
- Regulating TFs: None identified for G23245, indicating a direct regulatory role.

**MECHANISM_HYPOTHESIS:** G23245 is hypothesized to function as a central regulator within insulin signaling pathways, potentially enhancing glucose uptake and metabolism. Its modulation may positively impact -cell function, while G33764 and G00484 contribute to a comprehensive therapeutic approach by addressing metabolic pathway regulation and transcriptional control, respectively. This multi-target strategy could provide a robust intervention in T2D management.

**TISSUE_RATIONALE:** The most relevant tissues for targeting include pancreatic -cells, liver, and muscle tissues, as these are critical for insulin secretion and action, directly influencing glucose homeostasis.

**THERAPEUTIC_APPROACH:** The therapeutic approach would likely involve small molecule modulation aimed at enhancing the activity or expression of G23245 and other enzymes, potentially improving metabolic functions.

**PREDICTED_OUTCOME:** Effective targeting of G23245 and its associated pathways could lead to improved insulin sensitivity and reduced blood glucose levels, addressing the fundamental issues in T2D.

**RANKING_RATIONALE:** The targets are ranked based on their multi-evidence support, with G23245 leading as the primary driver. G33764 follows closely due to its enzymatic role in metabolic pathways, while G00484 adds regulatory depth as a transcription factor. G23452 and G36503, though also important, were ranked lower due to lesser direct evidence of driver roles compared to the top three targets.

**CONFIDENCE:** HIGH, based on the strong support from multi-evidence and significant association with T2D pathways and mechanisms.
2026-02-10 19:09:21,064 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:09:21,064 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:09:21,066 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:09:21,087 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:09:21,087 - root - INFO -   -> Created offspring: '** Comprehensive Target Identification f...'
2026-02-10 19:09:21,088 - root - INFO - Mutation 3/18: parent 'Targeting Novel Drug Candidate...'
2026-02-10 19:09:21,088 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:09:21,222 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:09:40,507 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:09:40,513 - root - INFO - TOKEN_USAGE: input=39417, output=623, total=40040, cost=$0.006286
2026-02-10 19:09:40,513 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:09:40,513 - root - INFO - 
### TITLE: Exploring Alternative Targets for Enhanced Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | An enzyme with multiple regulatory transcription factors, indicating a potential metabolic target with significant evidence in T2D.
2. **G22553** | Score: **4.0** | A primary driver in the co-expression network suggesting it plays a crucial role in T2D-related pathways.
3. **G23245** | Score: **4.0** | Another primary driver with significant evidence pointing to its role in T2D, making it a strong target.
4. **G33764** | Score: **4.0** | Identified as a primary driver suggesting its involvement in metabolic processes disrupted in T2D.
5. **G19943** | Score: **4.0** | Previously identified as a hub component in the co-expression network, still relevant but less novel as a focus compared to the other targets.

#### PRIMARY_TARGET: G04436

### SUMMARY:
G04436 is an enzyme with extensive regulatory potential, indicated by its multiple transcription factors and significant evidence in T2D metabolic pathways. This target offers a promising avenue for therapeutic intervention aimed at improving metabolic regulation in Type 2 Diabetes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways
- **WGCNA module role**: Primary driver in a module negatively correlated with T2D
- **Regulating TFs**: 12 identified

### MECHANISM_HYPOTHESIS:
G04436 may serve as a critical regulator of lipid metabolism and insulin signaling, which are pivotal in T2D pathophysiology. By modulating this enzyme, we can potentially enhance metabolic signaling pathways and improve insulin sensitivity, thus addressing T2D progression.

### TISSUE_RATIONALE:
The primary tissues of interest include liver and adipose tissue, both integral to lipid metabolism and insulin sensitivity. Targeting G04436 in these tissues could enhance metabolic regulation and potentially restore normal insulin signaling.

### THERAPEUTIC_APPROACH:
The therapeutic approach for G04436 would involve small molecule activation to enhance its enzymatic function, thereby improving metabolic homeostasis and insulin signaling in relevant tissues.

### PREDICTED_OUTCOME:
Modulating G04436 is expected to enhance lipid metabolism and insulin sensitivity, contributing to improved glucose regulation and potentially reversing T2D progression.

### RANKING_RATIONALE:
G04436 is ranked highest due to its regulatory role and existing evidence supporting its involvement in metabolic processes essential to T2D. G22553 and G23245 follow closely as strong primary drivers, while G33764 also presents significant opportunities. G19943, while initially a high-ranking target, is less novel in this context as its role has already been extensively explored.

### CONFIDENCE: HIGH
2026-02-10 19:09:40,517 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:09:40,517 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:09:40,530 - root - INFO -   -> Created mutated offspring: 'Exploring Alternative Targets for Enhanc...'
2026-02-10 19:09:40,530 - root - INFO - Crossover 4/18: parents '** Identification of Promising...' x '** Identification of Novel Dru...'
2026-02-10 19:09:40,623 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:10:21,496 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:10:21,572 - root - INFO - TOKEN_USAGE: input=40085, output=741, total=40826, cost=$0.006457
2026-02-10 19:10:21,572 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:10:21,572 - root - INFO - 
**TITLE:** Integrated Target Identification for Enhanced Type 2 Diabetes Therapy

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene is a hub component in the silver module, indicating a central role in T2D-related gene networks and has strong multi-omics support.
2. **G33764** | Score: **4.0** | As a primary driver in lipid metabolism and insulin signaling pathways, this enzyme shows significant potential for improving metabolic regulation in T2D.
3. **G19122** | Score: **3.0** | A major regulator in the black module, this gene is involved in insulin signaling and metabolic regulation, with consistent evidence across datasets.
4. **G22553** | Score: **4.0** | This primary driver in the black module correlates positively with T2D, suggesting its potential for therapeutic intervention in insulin resistance.
5. **G20274** | Score: **3.0** | This major regulator exhibits a negative log2FC and is implicated in insulin resistance mechanisms, making it relevant for therapeutic strategies.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The integration of G19943 as a hub component with G33764, a critical enzyme in insulin signaling and lipid metabolism, presents a comprehensive approach to enhancing insulin sensitivity and metabolic control in Type 2 Diabetes. This hypothesis leverages multiple lines of evidence from gene co-expression networks, pathway involvement, and regulatory roles.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, lipid metabolism, inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module (G19943); Primary driver in the darkgrey module (G33764)**
- Regulating TFs: **None reported, but potential TF activity is critical for gene regulation in T2D**

**MECHANISM_HYPOTHESIS:** G19943 acts as a central hub in insulin signaling pathways, integrating signals from various metabolic processes. Modulating its activity could alleviate insulin resistance by enhancing insulin sensitivity in peripheral tissues. Concurrently, targeting G33764 may improve lipid metabolism and further enhance the overall metabolic profile, addressing both insulin signaling and substrate utilization in T2D patients.

**TISSUE_RATIONALE:** The primary tissues of interest include pancreatic -cells, muscle, and adipose tissue, which are critical for maintaining glucose homeostasis and responding to insulin. Targeting G19943 and G33764 in these tissues may synergistically improve insulin sensitivity and reduce hyperglycemia.

**THERAPEUTIC_APPROACH:** The approach would involve small molecule modulation to enhance the activity of G19943 and G33764, potentially restoring their functions in insulin signaling and metabolic pathways.

**PREDICTED_OUTCOME:** Modulating G19943 and G33764 is expected to improve insulin sensitivity, reduce blood glucose levels, and enhance overall metabolic control, leading to better therapeutic outcomes in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, biological relevance, and the strength of evidence supporting their roles in Type 2 Diabetes. G19943 and G33764 were prioritized for their central roles in insulin signaling and metabolic regulation, while G19122, G22553, and G20274 were included for their supporting roles in relevant pathways.

**CONFIDENCE:** **HIGH** based on robust multi-omics support and cross-dataset consistency for the selected targets.
2026-02-10 19:10:21,574 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:10:21,574 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:10:21,574 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:10:21,579 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:10:21,580 - root - INFO -   -> Created offspring: '** Integrated Target Identification for ...'
2026-02-10 19:10:21,580 - root - INFO - Crossover 5/18: parents '** Targeting Novel Genes in Ty...' x '** Identification of Promising...'
2026-02-10 19:10:21,775 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:10:44,747 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:10:44,754 - root - INFO - TOKEN_USAGE: input=40153, output=757, total=40910, cost=$0.006477
2026-02-10 19:10:44,754 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:10:44,754 - root - INFO - 
**TITLE:** Integrated Targeting of Key Genes in Type 2 Diabetes for Enhanced Therapeutic Intervention

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene serves as a hub component in gene networks related to T2D, indicating its central role in metabolic regulation and insulin signaling pathways.
2. **G33764** | Score: **4.0** | As a primary driver in T2D pathways, this enzyme is crucial for metabolic processes, especially those involving glucose metabolism and insulin sensitivity.
3. **G22553** | Score: **4.0** | Identified as a primary driver in the black module associated with T2D, it shows strong potential for therapeutic intervention in insulin signaling pathways.
4. **G23245** | Score: **4.0** | This gene acts as another primary driver in the silver module and is negatively correlated with T2D, suggesting a role in improving metabolic outcomes.
5. **G19122** | Score: **3.0** | As a major regulator in the black module, this gene is involved in insulin signaling and could serve as a secondary target for enhancing T2D treatment.

**PRIMARY_TARGET:** G19943

**SUMMARY:** 
This hypothesis integrates key insights from two parent hypotheses by focusing on a set of genes that collectively enhance metabolic regulation and insulin signaling in Type 2 Diabetes. The selected targets have strong multi-evidence support and demonstrate high relevance in critical pathways associated with T2D, including inflammation and glucose metabolism.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism, inflammatory response pathways
- **WGCNA module role:** Hub component for G19943 and primary drivers for G33764 and G22553
- **Regulating TFs:** None reported, but TF activity is critical for gene regulation in T2D

**MECHANISM_HYPOTHESIS:** 
The proposed mechanism for this combined hypothesis involves targeting G19943 as a central hub in insulin signaling, which can improve insulin sensitivity and reduce inflammation. Additionally, by modulating G33764's enzymatic function, we can enhance metabolic reactions critical for glucose uptake. G22553 and G23245 further support these pathways, providing a multifaceted approach to ameliorating insulin resistance and enhancing overall metabolic health in T2D.

**TISSUE_RATIONALE:** 
The most relevant tissues for this approach are pancreatic -cells, muscle, and adipose tissue. Targeting these genes in these tissues could directly influence insulin signaling and glucose homeostasis, addressing core issues in T2D pathology.

**THERAPEUTIC_APPROACH:** 
The therapeutic approach will involve the activation of G19943 and G33764 using small molecules that enhance their functional activity, potentially restoring normal metabolic processes in T2D patients.

**PREDICTED_OUTCOME:** 
Expected benefits from modulating these targets include improved insulin sensitivity, reduced blood glucose levels, and better overall metabolic control, which may lead to a decrease in diabetic complications and improved patient outcomes.

**RANKING_RATIONALE:** 
Targets were ranked based on their priority scores, roles in relevant biological pathways, and the strength of multi-evidence support. G19943 was prioritized as the most promising due to its central role in metabolic regulation, while G33764 and G22553 follow closely for their strong implications in T2D pathways.

**CONFIDENCE:** HIGH based on the strength of data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:10:44,757 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:10:44,758 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:10:44,758 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:10:44,765 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:10:44,765 - root - INFO -   -> Created offspring: '** Integrated Targeting of Key Genes in ...'
2026-02-10 19:10:44,766 - root - INFO - Crossover 6/18: parents 'Identification of Promising Dr...' x 'Prioritization of Novel Drug T...'
2026-02-10 19:10:44,912 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:11:23,912 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:11:23,930 - root - INFO - TOKEN_USAGE: input=40114, output=766, total=40880, cost=$0.006477
2026-02-10 19:11:23,931 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:11:23,931 - root - INFO - 
### TITLE: Integrated Targeting of Metabolic Pathways in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | This gene exhibits strong evidence as a primary driver in T2D pathways, showing a significant correlation across multiple datasets.
2. **G23245** | Score: **4.0** | Identified as a primary driver in the co-expression network, it plays a central role in metabolic pathways relevant to T2D.
3. **G33764** | Score: **4.0** | This enzyme is a major regulator in metabolic processes linked to T2D, supporting its potential as a therapeutic target.
4. **G00484** | Score: **4.0** | As a transcription factor, its regulatory role in insulin signaling pathways enhances its relevance in T2D treatment.
5. **G19122** | Score: **3.0** | This major regulator's involvement in key pathways supports its potential therapeutic implications, despite lower evidence compared to the top targets.

#### PRIMARY_TARGET: G22553

#### SUMMARY:
G22553 and G23245 are prioritized as primary targets due to their established roles as key drivers in the T2D pathology. By integrating insights from the mechanisms of both genes, this hypothesis posits that modulation of these targets could significantly enhance insulin sensitivity and glucose metabolism, addressing the metabolic dysfunction characteristic of T2D.

#### DATA_EVIDENCE:
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism**
- WGCNA module role: **Primary Driver in black module for G22553; Primary Driver in silver module for G23245**
- Regulating TFs: **Not specified for G22553 and G23245; G00484 is a TF with regulatory roles**

#### MECHANISM_HYPOTHESIS:
G22553 is hypothesized to enhance insulin signaling and glucose uptake, potentially counteracting lipotoxic effects observed in T2D. G23245 complements this mechanism by acting as a primary driver in metabolic co-expression networks, directly influencing pathways involved in glucose homeostasis. The combination of these mechanisms, alongside the regulatory role of G00484, suggests a multifaceted approach to improving insulin sensitivity and -cell function.

#### TISSUE_RATIONALE:
The most relevant tissues for targeting these genes include pancreatic -cells, liver, and muscle tissues, as they are critical sites for insulin action and glucose metabolism. Targeting these tissues could maximize the therapeutic effects of modulation.

#### THERAPEUTIC_APPROACH:
The therapeutic approach would involve small molecule activation or modulation of these genes to enhance their function, particularly in the context of boosting insulin signaling and improving glucose uptake in peripheral tissues.

#### PREDICTED_OUTCOME:
Effective modulation of G22553 and G23245 is expected to lead to improved insulin sensitivity, reduced hyperglycemia, and restoration of -cell function, offering a comprehensive strategy for T2D management.

#### RANKING_RATIONALE:
G22553 is ranked first due to its robust evidence as a primary driver and direct involvement in key metabolic pathways. G23245 follows closely, also serving as a primary driver, while G33764 is recognized for its regulatory impact on metabolism. G00484 is included for its transcriptional regulatory role, providing a necessary angle for therapeutic intervention. G19122, while still important, is ranked lower due to relatively less evidence supporting its priority.

#### CONFIDENCE: HIGH
This confidence is based on the strength of evidence derived from multiple datasets and the clear biological relevance of the selected targets to T2D pathways.
2026-02-10 19:11:23,932 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:11:23,932 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:11:23,984 - root - INFO -   -> Created offspring: 'Integrated Targeting of Metabolic Pathwa...'
2026-02-10 19:11:23,988 - root - INFO - Mutation 7/18: parent '** Target Identification for T...'
2026-02-10 19:11:23,988 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:11:24,158 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:11:45,278 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:11:45,312 - root - INFO - TOKEN_USAGE: input=39448, output=725, total=40173, cost=$0.006352
2026-02-10 19:11:45,312 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:11:45,312 - root - INFO - 
**TITLE:** Tissue-Specific Target Identification for Therapeutic Intervention in Type 2 Diabetes in Adipose Tissue

**RANKED_TARGETS:**
1. **G19122** | Score: 3.0 | This gene is a major regulator correlated with T2D, specifically impacting adipose tissue's role in metabolic regulation and insulin sensitivity.
2. **G20274** | Score: 3.0 | As an enzyme linked to insulin signaling pathways, this gene's function in adipose tissue may significantly influence glucose metabolism and lipid storage.
3. **G33764** | Score: 4.0 | Previously identified as a primary driver in metabolic pathways, it remains relevant in adipose tissue, where its enzymatic role could modulate insulin responsiveness.
4. **G30498** | Score: 3.0 | This major regulator's involvement in adipose tissue metabolism presents an opportunity for therapeutic modulation of insulin sensitivity.
5. **G22561** | Score: 2.0 | Although lower-ranked, this transporter may still hold potential in managing glucose uptake and lipid metabolism in adipose tissue.

**PRIMARY_TARGET:** G19122

**SUMMARY:** The focus of this hypothesis is on G19122, a major regulator in adipose tissue that plays a critical role in the metabolic pathways linked to Type 2 Diabetes. By targeting this gene, we aim to enhance insulin sensitivity and improve glucose metabolism specifically within adipose tissue, thereby addressing key aspects of T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 3.0
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Metabolism, Insulin signaling pathways
- WGCNA module role: Major regulator in the silver module with a negative correlation to T2D
- Regulating TFs: None indicated

**MECHANISM_HYPOTHESIS:** G19122 is hypothesized to influence the regulation of adipose tissue metabolism and insulin signaling. Its modulation could enhance the tissue's ability to respond to insulin, thereby reducing insulin resistance and improving glucose uptake and lipid metabolism. This mechanism is particularly relevant given the role of adipose tissue in overall metabolic health and its contribution to T2D.

**TISSUE_RATIONALE:** Adipose tissue is integral to metabolic regulation, particularly in the context of insulin sensitivity and glucose homeostasis. Targeting G19122 in this tissue could yield significant improvements in metabolic function and T2D management.

**THERAPEUTIC_APPROACH:** The therapeutic approach would involve the activation of G19122 through small molecule modulators designed to enhance its regulatory functions within adipose tissue, potentially leading to improved insulin sensitivity and metabolic outcomes.

**PREDICTED_OUTCOME:** By effectively modulating G19122, we anticipate enhanced insulin sensitivity and glucose regulation in adipose tissue, contributing to improved overall metabolic health and better management of blood sugar levels in individuals with Type 2 Diabetes.

**RANKING_RATIONALE:** G19122 was ranked highest due to its strong correlation with T2D and its role as a major regulator in adipose tissue. G20274 is also promising due to its enzymatic function in insulin signaling pathways. G33764, although ranked lower, remains relevant due to its established role in metabolic pathways. G30498 and G22561, while still important, have comparatively less direct evidence supporting their roles in adipose tissue metabolism.

**CONFIDENCE:** HIGH based on the comprehensive evidence supporting G19122's role in adipose tissue metabolism and its significant scoring metrics.
2026-02-10 19:11:45,432 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:11:45,433 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:11:45,471 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:11:45,563 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:11:45,564 - root - INFO -   -> Created mutated offspring: '** Tissue-Specific Target Identification...'
2026-02-10 19:11:45,564 - root - INFO - Mutation 8/18: parent '** Targeting Novel Genes in Ty...'
2026-02-10 19:11:45,568 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:11:46,111 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:12:29,498 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:12:29,514 - root - INFO - TOKEN_USAGE: input=39453, output=750, total=40203, cost=$0.006368
2026-02-10 19:12:29,515 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:12:29,515 - root - INFO - 
**TITLE:** Therapeutic Activation of G33764 Combined with Modulation of G19077 in Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | This enzyme is a primary driver in T2D pathways, suggesting that its activation can enhance metabolic regulation and improve insulin sensitivity.
2. **G19077** | Score: **3.0** | As a major regulator in T2D pathways, modulating this enzyme could further support metabolic health and synergize with G33764 activation.
3. **G22512** | Score: **4.0** | This unknown gene shows strong differential expression and potential involvement in insulin signaling, making it a candidate for further exploration in conjunction with G33764.
4. **G26720** | Score: **4.0** | With a notable positive log2FC, targeting this gene may enhance insulin sensitivity while working alongside G33764.
5. **G20274** | Score: **3.0** | This major regulator in T2D pathways could complement the effects of G33764 activation, further alleviating T2D symptoms.

**PRIMARY_TARGET:** G33764

**SUMMARY:** 
This hypothesis proposes the activation of G33764, a key enzyme involved in metabolic regulation, as a primary therapeutic strategy for Type 2 Diabetes. Combining this approach with modulation of G19077, another significant enzyme, could provide a synergistic effect that enhances insulin sensitivity and metabolic health.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism
- **WGCNA module role:** Primary Driver for G33764 and Major Regulator for G19077
- **Regulating TFs:** None identified in the data

**MECHANISM_HYPOTHESIS:** 
The activation of G33764 is expected to enhance key metabolic reactions associated with glucose metabolism and insulin sensitivity. By increasing the enzymatic activity of G33764, we aim to mitigate insulin resistance and promote glucose uptake in peripheral tissues. Additionally, modulating G19077 could provide complementary effects on metabolic regulation, creating a multi-target approach to improve T2D outcomes.

**TISSUE_RATIONALE:** 
Muscle and adipose tissues are the primary focus for this therapeutic approach, as they are critical for insulin sensitivity and overall glucose homeostasis. Activation of G33764 in these tissues is anticipated to directly influence insulin signaling pathways, while modulation of G19077 could further enhance these effects.

**THERAPEUTIC_APPROACH:** 
This strategy involves the activation of G33764 through small molecules designed to enhance its enzymatic function, while G19077 may be modulated (either activated or inhibited) to provide synergistic metabolic benefits.

**PREDICTED_OUTCOME:** 
The expected therapeutic benefits include improved insulin sensitivity, reduced blood glucose levels, and a potential decrease in the risk of diabetic complications, ultimately leading to enhanced metabolic health in T2D patients.

**RANKING_RATIONALE:** 
The ranking prioritizes G33764 due to its strong evidence as a primary driver in T2D pathways and its potential for significant metabolic impact. G19077 is also prioritized as a major regulator that can complement G33764s activation. The other genes, while showing promise, either have lower scores or less direct relevance to critical T2D pathways compared to G33764 and G19077.

**CONFIDENCE:** HIGH based on the strength of data support and its role in critical metabolic pathways.
2026-02-10 19:12:29,523 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:12:29,523 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:12:29,526 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:12:29,530 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:12:29,531 - root - INFO -   -> Created mutated offspring: '** Therapeutic Activation of G33764 Comb...'
2026-02-10 19:12:29,531 - root - INFO - Crossover 9/18: parents 'Prioritization of Novel Drug T...' x '** Identification of Promising...'
2026-02-10 19:12:29,706 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:13:04,863 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:13:04,869 - root - INFO - TOKEN_USAGE: input=40172, output=755, total=40927, cost=$0.006479
2026-02-10 19:13:04,869 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:13:04,869 - root - INFO - 
### TITLE: Integrated Hypothesis for Targeting Metabolic Dysregulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | This gene is a primary driver in T2D pathways with robust evidence across multiple datasets, highlighting its crucial role in insulin signaling and glucose metabolism.
2. **G33764** | Score: **4.0** | As an enzyme with significant upregulation, G33764 is implicated in metabolic pathways that contribute to insulin resistance, making it a key target for therapeutic intervention.
3. **G19122** | Score: **3.0** | This major regulator is involved in critical pathways related to T2D and has strong supporting evidence, indicating its potential as a therapeutic target.
4. **G22512** | Score: **4.0** | Though its mechanism is less clear, significant expression changes suggest that G22512 may play a vital role in T2D regulation and requires further exploration.
5. **G23245** | Score: **4.0** | Identified as a primary driver, G23245 shows a strong correlation with T2D and therapeutic implications, supporting its inclusion as a relevant target.

**PRIMARY_TARGET:** **G22553**

**SUMMARY:** The integrated hypothesis proposes that targeting G22553, alongside G33764 and G19122, could provide a comprehensive approach to modulating insulin signaling and improving glucose metabolism in T2D patients. By leveraging the strengths of both parent hypotheses, this hypothesis emphasizes the importance of multiple pathways in T2D pathophysiology.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: Insulin signaling, glucose metabolism, enzymatic regulation.
- WGCNA module role: **Primary Driver in the black module**
- Regulating TFs: None specified.

**MECHANISM_HYPOTHESIS:** G22553 is likely to modulate insulin signaling pathways, enhancing glucose uptake and metabolism in peripheral tissues, while G33764s enzymatic activity may counteract insulin resistance through metabolic regulation. G19122 serves as a major regulator of these processes, indicating that a combined approach targeting these genes could synergistically improve metabolic function in T2D.

**TISSUE_RATIONALE:** The primary tissues of interest include pancreatic beta-cells, liver, and skeletal muscle, as these are critical for insulin secretion and action. Modulating the expression and activity of these targets in these tissues is expected to significantly impact glucose homeostasis and insulin sensitivity.

**THERAPEUTIC_APPROACH:** The therapeutic strategy should involve the activation of G22553 and G33764 to enhance their functions, potentially through small molecules or biologics that modulate their activity and promote insulin signaling.

**PREDICTED_OUTCOME:** Successful modulation of these targets is anticipated to improve insulin sensitivity, reduce hyperglycemia, and restore beta-cell function, leading to better management of T2D.

**RANKING_RATIONALE:** G22553 is ranked highest due to its robust evidence as a primary driver in relevant pathways. G33764 follows closely, given its enzymatic role in counteracting insulin resistance. G19122, while slightly lower in rank, remains significant due to its regulatory function. G22512 and G23245 are included for their potential implications in T2D regulation, providing a well-rounded approach to the hypothesis.

**CONFIDENCE:** **HIGH** based on strong data support and multiple lines of evidence from various analyses, ensuring that the selected targets are relevant and impactful in the context of T2D.
2026-02-10 19:13:04,872 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:13:04,872 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:13:04,872 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:13:04,875 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:13:04,876 - root - INFO -   -> Created offspring: 'Integrated Hypothesis for Targeting Meta...'
2026-02-10 19:13:04,876 - root - INFO - Mutation 10/18: parent 'Identification of Promising Dr...'
2026-02-10 19:13:04,877 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:13:05,017 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:13:44,924 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:13:44,933 - root - INFO - TOKEN_USAGE: input=39451, output=761, total=40212, cost=$0.006374
2026-02-10 19:13:44,934 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:13:44,934 - root - INFO - 
### TITLE: Enhanced Mechanistic Insights into G33764 as a Therapeutic Target for Type 2 Diabetes

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0** | As a primary driver in T2D pathways, G33764's modulation is supported by multiple datasets and exhibits consistent differential expression, indicating its crucial role in metabolic regulation.
2. **G19943** | Score: **4.0** | This gene is identified as a hub component within a co-expression network, showing significant correlation with T2D, making it a strong candidate for further investigation.
3. **G09708** | Score: **2.0** | Although it has a lower score, this enzyme's involvement in metabolic regulation pathways related to T2D provides additional therapeutic potential.
4. **G12806** | Score: **1.0** | This enzyme's modulation could influence pathways relevant to T2D, but lacks the robust data support of the higher-ranked genes.
5. **G26921** | Score: **1.0** | While showing some relevance as a kinase involved in insulin signaling, it does not provide the same level of supporting evidence as the other top candidates.

**PRIMARY_TARGET:** G33764

**SUMMARY:** 
The mutated hypothesis posits that targeting G33764 can enhance metabolic regulation in T2D through its role in critical pathways associated with insulin sensitivity and glucose homeostasis. Evidence from co-expression networks and pathway analyses supports G33764 as a key player, with potential combinatory effects from G19943, which acts as a hub component in the T2D network.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, lipid metabolism, and metabolic regulation**
- WGCNA module role: **Primary Driver**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** 
G33764 is hypothesized to regulate key metabolic pathways that enhance insulin sensitivity and glucose homeostasis. By targeting G33764, and possibly synergistically modulating G19943, we can significantly improve insulin signaling dynamics, reduce lipotoxicity, and counteract the metabolic disturbances observed in T2D. This dual-target approach may amplify therapeutic efficacy through network-level modulation.

**TISSUE_RATIONALE:** 
This therapeutic strategy is particularly relevant in adipose tissue and skeletal muscle, where G33764 and G19943 play pivotal roles in insulin signaling. Enhancing the function of these tissues through targeted intervention could restore normal metabolic functions, crucial for managing T2D.

**THERAPEUTIC_APPROACH:** 
The therapeutic strategy involves the small-molecule inhibition of G33764, potentially combined with modulators of G19943 to enhance overall metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** 
Modulating G33764 is expected to lead to improved insulin sensitivity, reduced blood glucose levels, and a decrease in metabolic dysfunction associated with T2D, while leveraging the co-action of G19943 to further enhance therapeutic benefits.

**RANKING_RATIONALE:** 
G33764 is ranked highest due to its strong evidence base and role as a primary driver in T2D pathways. G19943 follows closely due to its hub component status in co-expression networks, suggesting significant involvement in T2D pathology. G09708, while less robust, still presents therapeutic potential, and the lower-ranked targets provide additional options for exploration.

**CONFIDENCE:** 
**HIGH** based on the strength of data support and the gene's clear involvement in metabolic pathways relevant to T2D.
2026-02-10 19:13:45,009 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:13:45,074 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:13:45,075 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:13:45,110 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:13:45,110 - root - INFO -   -> Created mutated offspring: 'Enhanced Mechanistic Insights into G3376...'
2026-02-10 19:13:45,111 - root - INFO - Mutation 11/18: parent '** Identification of Novel The...'
2026-02-10 19:13:45,111 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:13:45,252 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:14:24,532 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:14:24,550 - root - INFO - TOKEN_USAGE: input=39425, output=673, total=40098, cost=$0.006318
2026-02-10 19:14:24,551 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:14:24,551 - root - INFO - 
**TITLE:** Alternative Therapeutic Targets for Enhanced Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | Identified as a primary driver in the black module, G22553 shows a significant positive correlation to T2D, indicating its potential importance in metabolic regulation.
2. **G23245** | Score: **4.0** | As a primary driver in the silver module, G23245 has a negative correlation with T2D, suggesting a critical role in promoting insulin sensitivity.
3. **G33764** | Score: **4.0** | This enzyme is a primary driver in the darkgrey module, indicating its potential role in insulin signaling pathways, which are crucial for glucose homeostasis.
4. **G19122** | Score: **3.0** | A major regulator in the black module, G19122 implicates pathways that may enhance insulin signaling and contribute to glucose homeostasis.
5. **G19122** | Score: **3.0** | A major regulator in the black module, G19122 implicates pathways that may enhance insulin signaling and contribute to glucose homeostasis.

**PRIMARY_TARGET:** G22553

**SUMMARY:** G22553 emerges as a key target for T2D treatment due to its established role as a primary driver in metabolic regulation, evidenced by its strong correlation with T2D and high priority score. Targeting this gene could provide a novel approach to enhance insulin sensitivity and improve overall metabolic outcomes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, evidence from 2 datasets supports its role.
- Key pathways involved: Metabolic regulation, insulin signaling.
- WGCNA module role: Primary Driver in the black module.
- Regulating TFs: None identified specifically for this gene in the data.

**MECHANISM_HYPOTHESIS:** G22553 is likely involved in key metabolic pathways that regulate glucose homeostasis and insulin action. By modulating its activity, we could enhance metabolic regulation and improve insulin sensitivity, providing a potential therapeutic avenue for T2D management.

**TISSUE_RATIONALE:** The liver and adipose tissue are most relevant for targeting G22553, given their critical roles in glucose metabolism and insulin sensitivity.

**THERAPEUTIC_APPROACH:** The approach would involve the development of small molecule modulators that enhance the activity of G22553 or its downstream signaling pathways to improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of G22553 is expected to improve glycemic control and reduce insulin resistance, potentially reversing some aspects of T2D pathology.

**RANKING_RATIONALE:** G22553 was ranked highest due to its prominent role in metabolic regulation and its strong correlation with T2D, as well as its high priority score and cross-dataset consistency. G23245 and G33764 follow closely, as they also exhibit strong evidence supporting their roles in T2D pathophysiology. The remaining targets, while relevant, do not present the same level of direct evidence linking them to T2D management.

**CONFIDENCE:** HIGH based on the strength of data support and multi-evidence integration.
2026-02-10 19:14:24,551 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:14:24,552 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:14:24,552 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:14:24,556 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:14:24,556 - root - INFO -   -> Created mutated offspring: '** Alternative Therapeutic Targets for E...'
2026-02-10 19:14:24,558 - root - INFO - Mutation 12/18: parent 'Identification of Promising Dr...'
2026-02-10 19:14:24,558 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:14:24,682 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:15:02,413 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:15:02,441 - root - INFO - TOKEN_USAGE: input=39408, output=728, total=40136, cost=$0.006348
2026-02-10 19:15:02,442 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:15:02,442 - root - INFO - 
TITLE: Enhanced Mechanistic Insights into G23245 as a Therapeutic Target for Type 2 Diabetes

RANKED_TARGETS:
1. G23245 | Score: 4.0 | This gene is a primary driver in the T2D co-expression network and has significant implications for insulin signaling and glucose metabolism.
2. G33764 | Score: 4.0 | This enzyme functions as a primary driver and is involved in crucial metabolic pathways related to T2D, complementing the role of G23245.
3. G00484 | Score: 4.0 | As a transcription factor, it regulates pathways associated with insulin signaling and glucose homeostasis, potentially enhancing the effects of G23245.
4. G23452 | Score: 4.0 | This enzyme supports metabolic processes relevant to T2D, providing an additional target for synergistic therapeutic strategies.
5. G36503 | Score: 4.0 | This enzyme contributes to glucose homeostasis, supporting the therapeutic potential of targeting G23245 and its associated pathways.

PRIMARY_TARGET: G23245

SUMMARY: The mutated hypothesis focuses on G23245, positing that its modulation can significantly improve insulin sensitivity and glucose metabolism in T2D by altering its interaction with downstream metabolic pathways and transcription factors. This hypothesis integrates additional mechanistic insights involving G33764, G00484, G23452, and G36503 to create a robust therapeutic framework.

DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation
- WGCNA module role: Primary Driver in the silver module with a negative correlation to T2D.
- Regulating TFs: None identified for G23245, but G00484 acts as a regulator in related pathways.

MECHANISM_HYPOTHESIS: G23245 is hypothesized to act as a central regulator in insulin signaling pathways, impacting glucose uptake in pancreatic -cells and peripheral tissues. It may enhance the activity or expression of downstream effectors, potentially leading to improved glucose metabolism. The interactions with G33764, an enzyme driving metabolic pathways, and G00484, a transcription factor regulating insulin signaling, suggest a synergistic mechanism that could enhance overall metabolic control.

TISSUE_RATIONALE: The most relevant tissues for this hypothesis are pancreatic -cells, liver, and muscle tissues, as they are critical for insulin secretion, action, and overall glucose homeostasis, making them ideal targets for therapeutic intervention.

THERAPEUTIC_APPROACH: The therapeutic approach would involve small molecule modulation of G23245 to enhance its activity, alongside potential combination therapies targeting G33764 and G00484 to amplify insulin sensitivity and glucose metabolism.

PREDICTED_OUTCOME: Targeting G23245 could lead to significantly improved insulin sensitivity and lower blood glucose levels, addressing the core pathophysiology of T2D and potentially leading to better management of the disease.

RANKING_RATIONALE: G23245 is ranked highest due to its primary driver status and strong connections to critical metabolic pathways. G33764 is also crucial due to its enzymatic role in metabolism, while G00484's regulatory function as a transcription factor offers additional therapeutic synergy. G23452 and G36503, while also important, have less direct evidence of driver roles compared to the top three targets.

CONFIDENCE: HIGH, based on multi-evidence support and a strong association with T2D pathways and mechanisms.
2026-02-10 19:15:02,443 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:15:02,444 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:15:02,520 - root - INFO -   -> Created mutated offspring: 'Enhanced Mechanistic Insights into G2324...'
2026-02-10 19:15:02,524 - root - INFO - Mutation 13/18: parent 'Identification of Promising Dr...'
2026-02-10 19:15:02,533 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:15:02,653 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:15:36,848 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:15:36,860 - root - INFO - TOKEN_USAGE: input=39400, output=635, total=40035, cost=$0.006291
2026-02-10 19:15:36,860 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:15:36,861 - root - INFO - 
### TITLE: Therapeutic Activation of Metabolic Pathways in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G04436 | Score: 4.0 | This enzyme shows strong dysregulation in T2D and its activation could enhance glucose metabolism and insulin sensitivity.**
2. **G22553 | Score: 4.0 | Identified as a primary driver with a significant role in T2D, its activation may enhance insulin receptor signaling pathways.**
3. **G33764 | Score: 4.0 | This enzyme's modulation, potentially through activation, could reverse metabolic dysregulation associated with T2D.**
4. **G19122 | Score: 3.0 | As a major regulator in T2D, its activation may help restore metabolic homeostasis disrupted in diabetic states.**
5. **G20274 | Score: 3.0 | This gene's activation could support insulin signaling, contributing positively to glucose homeostasis in T2D.**

**PRIMARY_TARGET: G04436**

**SUMMARY:** This hypothesis proposes the therapeutic activation of G04436, an enzyme significantly dysregulated in Type 2 Diabetes (T2D), alongside complementary activation of other promising targets. The goal is to enhance insulin sensitivity and improve glucose homeostasis, potentially reversing aspects of T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Metabolism, Insulin signaling
- WGCNA module role: Major regulator
- Regulating TFs: 12 identified transcription factors associated

**MECHANISM_HYPOTHESIS:** The activation of G04436 is expected to enhance metabolic pathways that improve insulin sensitivity and glucose homeostasis. By boosting its enzymatic activity, we anticipate an increase in the flux of critical metabolites needed for effective glucose metabolism, thereby positively influencing insulin action in target tissues.

**TISSUE_RATIONALE:** The pancreatic -cells and insulin-sensitive tissues, such as muscle and liver, are the most relevant for this approach, as they directly participate in glucose metabolism and insulin action, which are central to T2D pathology.

**THERAPEUTIC_APPROACH:** Activating G04436 and other selected targets may involve small molecules designed to enhance the enzyme's activity. This approach aims to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Therapeutic activation is expected to enhance insulin sensitivity, reduce hyperglycemia, and potentially reverse some pathological features of Type 2 Diabetes.

**RANKING_RATIONALE:** G04436 was ranked highest due to robust evidence from multiple datasets and its critical role in metabolic pathways linked to T2D. G22553 and G33764 were also prioritized for their significant roles as primary drivers, while G19122 and G20274 serve as additional promising targets based on their regulatory capacities.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and literature context linking their functions to T2D pathophysiology.
2026-02-10 19:15:36,885 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:15:36,886 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:15:36,890 - root - INFO -   -> Created mutated offspring: 'Therapeutic Activation of Metabolic Path...'
2026-02-10 19:15:36,893 - root - INFO - Mutation 14/18: parent '** Identification of Promising...'
2026-02-10 19:15:36,894 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:15:36,996 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:16:14,510 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:16:14,517 - root - INFO - TOKEN_USAGE: input=39442, output=687, total=40129, cost=$0.006328
2026-02-10 19:16:14,518 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:16:14,518 - root - INFO - 
**TITLE:** Enhancing Insulin Sensitivity in Muscle Tissue through Targeted Modulation of G19943

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | As a hub component in the silver module, this gene is crucial for the insulin signaling pathway and exhibits strong evidence supporting its role in muscle tissue metabolism.
2. **G19122** | Score: **3.0** | This major regulator in the black module is involved in insulin signaling and glucose metabolism, providing a complementary target for enhancing muscle insulin sensitivity.
3. **G27976** | Score: **3.0** | A major regulator in the silver module, its role in the network suggests potential influence on muscle glucose uptake and insulin action.
4. **G22553** | Score: **3.0** | As a primary driver in the black module, this gene impacts metabolic pathways and could assist in improving muscle response to insulin.
5. **G23245** | Score: **3.0** | This primary driver in the silver module is negatively correlated with T2D and may contribute to muscle tissue's insulin response, making it a potential secondary target.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The mutated hypothesis focuses on G19943 as a primary target to enhance insulin sensitivity specifically in muscle tissue. By modulating this gene, we aim to improve the muscle's response to insulin, thereby improving glucose homeostasis in patients with Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** G19943 serves as a central hub in the insulin signaling pathway in muscle tissue. By enhancing its activity, we may restore proper signaling cascades that facilitate glucose uptake and improve insulin sensitivity, thereby mitigating the effects of insulin resistance typical in Type 2 Diabetes.

**TISSUE_RATIONALE:** Muscle tissue is critical for glucose uptake, especially in response to insulin. Targeting G19943 in muscle cells could directly enhance insulin signaling and improve metabolic regulation, leading to reduced hyperglycemia and better overall metabolic control.

**THERAPEUTIC_APPROACH:** The approach will involve small molecule modulation of G19943 to increase its activity within the insulin signaling pathway, thereby enhancing muscle insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of G19943 is expected to lead to improved glucose uptake in muscle tissue, decreased blood glucose levels, and enhanced metabolic control in individuals with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores and their specific roles in muscle metabolism. G19943 is prioritized due to its central hub position and strong evidence from various datasets, while G19122 and G27976 are followed for their regulatory roles in insulin signaling pathways relevant to muscle tissue. G22553 and G23245 are included as additional targets based on their potential contributions to insulin action and glucose metabolism.

**CONFIDENCE:** **HIGH** based on robust data support and the relevance of the identified pathways to the pathology of Type 2 Diabetes.
2026-02-10 19:16:14,520 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:16:14,520 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:16:14,522 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:16:14,540 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:16:14,540 - root - INFO -   -> Created mutated offspring: '** Enhancing Insulin Sensitivity in Musc...'
2026-02-10 19:16:14,541 - root - INFO - Mutation 15/18: parent 'Targeting Novel Drug Candidate...'
2026-02-10 19:16:14,541 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:16:14,630 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:16:27,037 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:16:27,041 - root - INFO - TOKEN_USAGE: input=39417, output=660, total=40077, cost=$0.006309
2026-02-10 19:16:27,041 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:16:27,041 - root - INFO - 
### TITLE: Exploring Alternative Targets for Enhanced Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | This enzyme has multiple regulatory transcription factors and is linked to metabolic pathways, indicating a crucial role in T2D pathology.
2. **G33764** | Score: **4.0** | Identified as a primary driver in metabolic processes, suggesting its involvement in T2D-related mechanisms.
3. **G22553** | Score: **4.0** | A primary driver in the co-expression network that indicates a significant role in T2D-related pathways, although with less direct influence than G04436 and G33764.
4. **G23245** | Score: **4.0** | Another primary driver, but its evidence suggests a more specialized role compared to the top-ranked targets.
5. **G19943** | Score: **4.0** | Initially the primary target, but now considered less favorable due to a focus on broad metabolic regulators rather than specific enzymatic roles.

#### PRIMARY_TARGET: G04436

### SUMMARY:
G04436 is a high-priority target due to its enzymatic nature and the presence of regulatory transcription factors that could enhance its therapeutic potential in managing T2D. Selecting this target emphasizes a shift towards metabolic regulation, which is crucial in T2D management.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways
- **WGCNA module role**: Primary driver in a module positively correlated with metabolic function
- **Regulating TFs**: 12 identified

### MECHANISM_HYPOTHESIS:
G04436 may play a significant role in the regulation of lipid metabolism and insulin signaling pathways, thus influencing glucose homeostasis and insulin sensitivity in T2D. By targeting this enzyme, it could potentially restore normal metabolic functions and mitigate the impact of insulin resistance.

### TISSUE_RATIONALE:
The most relevant tissues include liver and adipose tissue, where G04436 is likely to modulate lipid metabolism and contribute to insulin sensitivity. These tissues are critical in the pathophysiology of T2D, making them ideal targets for therapeutic intervention.

### THERAPEUTIC_APPROACH:
The therapeutic approach would involve small molecule activation to enhance the enzymatic function of G04436, promoting improved metabolic regulation and insulin signaling.

### PREDICTED_OUTCOME:
Modulating G04436 is expected to improve insulin sensitivity and lipid handling, leading to better glucose metabolism and potentially reversing the progression of T2D.

### RANKING_RATIONALE:
G04436 is ranked highest due to its enzymatic role and the presence of multiple regulatory transcription factors, enhancing its therapeutic potential. G33764 follows as it is also critical in metabolic processes, while G22553 and G23245, while important, do not demonstrate the same level of metabolic influence. G19943, while initially prioritized, is set aside for this hypothesis due to a focus on broader metabolic regulators.

### CONFIDENCE: HIGH
2026-02-10 19:16:27,041 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:16:27,041 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:16:27,042 - root - INFO -   -> Created mutated offspring: 'Exploring Alternative Targets for Enhanc...'
2026-02-10 19:16:27,042 - root - INFO - Crossover 16/18: parents 'Identification of Promising Dr...' x 'Identification of Promising Dr...'
2026-02-10 19:16:27,095 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:17:02,462 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:17:02,468 - root - INFO - TOKEN_USAGE: input=40069, output=727, total=40796, cost=$0.006447
2026-02-10 19:17:02,468 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:17:02,468 - root - INFO - 
### TITLE: Integrated Target Hypothesis for Enhanced Type 2 Diabetes Treatment

#### RANKED_TARGETS:
1. **G04436** | Score: 4.0 | This enzyme is significantly dysregulated in T2D and is a major regulator of metabolic pathways critical for glucose homeostasis.
2. **G33764** | Score: 4.0 | This enzyme is implicated as a primary driver in insulin resistance mechanisms, showing substantial negative log2FC and consistent dysregulation across multiple datasets.
3. **G22553** | Score: 4.0 | Identified as a primary driver with a high dysregulation score, its involvement in insulin resistance correlates well with T2D pathophysiology.
4. **G19122** | Score: 3.0 | This enzyme plays a significant role in metabolic dysregulation and has a strong negative log2FC, indicating its importance in T2D mechanisms.
5. **G20274** | Score: 3.0 | A major regulator showing dysregulation in insulin signaling pathways, suggesting a potential role in T2D pathophysiology.

#### PRIMARY_TARGET: G04436

#### SUMMARY: 
G04436 emerges as the primary target due to its critical role in regulating glucose metabolism and insulin sensitivity, supported by extensive evidence of dysregulation in Type 2 Diabetes. The additional targets, G33764 and G22553, further enhance the hypothesis by addressing various mechanisms of insulin resistance, creating a comprehensive approach to T2D treatment.

#### DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Metabolism, Insulin signaling
- WGCNA module role: Major regulator
- Regulating TFs: 12 identified transcription factors associated

#### MECHANISM_HYPOTHESIS: 
G04436 is hypothesized to modulate key metabolic pathways that influence insulin sensitivity and glucose homeostasis. Its enzymatic function is crucial for maintaining glucose levels, while G33764 and G22553 contribute to insulin resistance mechanisms through significant dysregulation in metabolic processes. Together, these targets provide a multifaceted approach to address the complex nature of T2D.

#### TISSUE_RATIONALE: 
The pancreatic -cells and insulin-sensitive tissues such as muscle and liver are the most relevant, as they directly participate in glucose metabolism and insulin actioncritical factors in T2D pathology.

#### THERAPEUTIC_APPROACH: 
Inhibition of G04436, along with modulation of G33764 and G22553, could enhance insulin sensitivity and restore glucose homeostasis, suggesting that a small molecule approach targeting these enzymes would be effective.

#### PREDICTED_OUTCOME: 
Modulating G04436 and its associated targets is expected to enhance insulin sensitivity, reduce hyperglycemia, and potentially reverse some aspects of Type 2 Diabetes pathology, leading to improved metabolic control.

#### RANKING_RATIONALE: 
G04436 was ranked first due to its strong evidence from multiple datasets and significant role in metabolic pathways critical for T2D. G33764 and G22553 were chosen next for their substantial negative log2FC and their roles as primary drivers in insulin resistance. G19122 and G20274 were included to address additional aspects of metabolic dysregulation, ensuring a robust hypothesis.

#### CONFIDENCE: 
HIGH based on strong multi-evidence support and literature context linking these functions to T2D pathophysiology.
2026-02-10 19:17:02,470 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:17:02,472 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:17:02,489 - root - INFO -   -> Created offspring: 'Integrated Target Hypothesis for Enhance...'
2026-02-10 19:17:02,491 - root - INFO - Mutation 17/18: parent 'Prioritization of Novel Drug T...'
2026-02-10 19:17:02,493 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:17:02,551 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:17:16,680 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:17:16,682 - root - INFO - TOKEN_USAGE: input=39443, output=706, total=40149, cost=$0.006340
2026-02-10 19:17:16,682 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:17:16,682 - root - INFO - 
**TITLE:** Enhanced Therapeutic Targeting for Type 2 Diabetes via Dual Modulation of G22553 and G23245

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | This gene remains a primary driver in T2D pathways, supporting significant modulation of insulin signaling and glucose metabolism.
2. **G23245** | Score: **4.0** | As another primary driver with strong correlation in the silver module, it complements G22553 by potentially enhancing glucose uptake and insulin sensitivity.
3. **G33764** | Score: **4.0** | This enzyme's regulatory role in the metabolic network suggests it can further optimize the therapeutic outcomes when combined with G22553.
4. **G19122** | Score: **3.0** | Involvement in crucial metabolic pathways and its role as a major regulator positions it as a supportive target for enhancing the efficacy of G22553 and G23245 modulation.
5. **G20274** | Score: **3.0** | Although a major regulator, its lower evidence level compared to the others suggests it is a secondary consideration for combination strategies.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis proposes a dual modulation approach targeting G22553 and G23245 for the treatment of Type 2 Diabetes. By activating G22553 to enhance insulin signaling and pairing it with G23245, which also drives glucose metabolism, we can anticipate a more comprehensive therapeutic effect on insulin sensitivity and glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: Insulin signaling, glucose metabolism.
- WGCNA module role: **Primary Driver in black module**
- Regulating TFs: Not specified.

**MECHANISM_HYPOTHESIS:** G22553 activation is anticipated to significantly enhance insulin signaling pathways, potentially reversing insulin resistance, while G23245 could synergistically improve glucose uptake in peripheral tissues. This combined modulation aims to counteract lipotoxic effects and restore beta-cell functionality, thereby improving overall glycemic control in T2D patients.

**TISSUE_RATIONALE:** The key tissues involved are pancreatic beta-cells, muscle, and adipose tissue, as they are critically involved in insulin signaling and glucose regulation. Targeting both G22553 and G23245 within these tissues may lead to enhanced insulin sensitivity and improved glucose metabolism.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of both G22553 and G23245 to enhance their respective functions and counteract any negative feedback mechanisms impacting insulin signaling.

**PREDICTED_OUTCOME:** The modulation of both G22553 and G23245 is expected to result in improved insulin sensitivity, reduced hyperglycemia, and enhanced beta-cell function, leading to superior management of Type 2 Diabetes compared to targeting G22553 alone.

**RANKING_RATIONALE:** G22553 is ranked highest due to its strong evidence as a primary driver, followed closely by G23245, which provides a complementary mechanism. G33764 is included for its regulatory role, while G19122 and G20274, though supportive, are ranked lower due to lesser evidence strength or specificity.

**CONFIDENCE:** **HIGH** based on the robust data support across multiple evidence types and pathways relevant to T2D.
2026-02-10 19:17:16,683 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:17:16,683 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:17:16,683 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:17:16,684 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:17:16,685 - root - INFO -   -> Created mutated offspring: '** Enhanced Therapeutic Targeting for Ty...'
2026-02-10 19:17:16,685 - root - INFO - Mutation 18/18: parent 'Targeting Novel Drug Candidate...'
2026-02-10 19:17:16,685 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:17:16,722 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:17:31,201 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:17:31,207 - root - INFO - TOKEN_USAGE: input=39422, output=780, total=40202, cost=$0.006381
2026-02-10 19:17:31,207 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:17:31,207 - root - INFO - 
### TITLE: Enhanced Mechanistic Insights for Targeting G19943 in Type 2 Diabetes Therapy

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Identified as a hub component in a co-expression network, indicating its central role in T2D-related pathways and consistent cross-support across datasets.
2. **G22553** | Score: **4.0** | A primary driver in the co-expression network, suggesting a critical involvement in T2D pathways, though lacking the broad network influence of G19943.
3. **G04436** | Score: **4.0** | An enzyme with significant transcriptional regulation, indicating potential roles in metabolic pathways related to T2D, but with lesser network centrality.
4. **G23245** | Score: **4.0** | Another primary driver with substantial evidence supporting its involvement in T2D, but with a narrower functional implication compared to G19943.
5. **G33764** | Score: **4.0** | Identified as a primary driver and enzyme, essential for metabolic processes, yet it does not exhibit the same level of evidence from cross-dataset support as G19943.

#### PRIMARY_TARGET: G19943

### SUMMARY:
G19943 remains the focal point of our hypothesis, being a hub component in a co-expression network linked to T2D. This mutated hypothesis refines the mechanism by incorporating additional insights into its potential roles in lipid metabolism and insulin signaling pathways, while also considering its interaction with regulatory transcription factors that may influence inflammatory responses and insulin resistance.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Inflammatory response pathways
- **WGCNA module role**: Hub component in a module negatively correlated with T2D
- **Regulating TFs**: Potential regulatory interactions with unidentified transcription factors influencing inflammatory responses.

### MECHANISM_HYPOTHESIS:
G19943 plays a pivotal role in regulating lipid metabolism and insulin signaling, crucial in T2D pathophysiology. Its central position as a hub component suggests that it not only influences these metabolic pathways but also interacts with regulatory transcription factors that modulate inflammatory responses associated with insulin resistance. By enhancing G19943 activity, we may promote metabolic homeostasis, improve insulin sensitivity, and potentially mitigate the progression of T2D.

### TISSUE_RATIONALE:
The most relevant tissues for targeting G19943 include pancreatic -cells and adipose tissue. These tissues are directly involved in insulin secretion and action, where G19943's regulation of lipid metabolism may enhance insulin sensitivity and improve -cell function, crucial for effective glucose metabolism.

### THERAPEUTIC_APPROACH:
The therapeutic strategy would involve small molecule activation of G19943, enhancing its function within the regulatory pathways. This could lead to improved insulin signaling and metabolic control, making it a promising candidate for T2D management.

### PREDICTED_OUTCOME:
Modulating G19943 is anticipated to enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could reverse or slow the progression of T2D.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central role in the co-expression network and its negative correlation with T2D, suggesting its pivotal role in metabolic dysregulation. G22553, while also a strong candidate, lacks the same level of network influence. G04436, G23245, and G33764 follow, but their roles are more specialized within metabolic pathways, making them less critical as primary targets compared to G19943.

### CONFIDENCE: HIGH
2026-02-10 19:17:31,208 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:17:31,209 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:17:31,211 - root - INFO -   -> Created mutated offspring: 'Enhanced Mechanistic Insights for Target...'
2026-02-10 19:17:31,211 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 19:17:31,212 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 19:17:31,213 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 19:17:31,213 - root - INFO - Evaluating fitness for hypothesis: t2d-01-0307d4dc
2026-02-10 19:17:43,970 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:17:43,972 - root - INFO - TOKEN_USAGE: input=1402, output=753, total=2155, cost=$0.000662
2026-02-10 19:17:43,972 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:17:43,972 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 4**  
**DATA_SUPPORT_RATIONALE:** The primary target G22512 is not found in the top priority list, which is a significant limitation. While the target has a good priority score and cross-dataset consistency is noted, the absence from the top 10 priority genes raises concerns about its overall support. The data evidence shows a solid basis, but it is not sufficiently backed by the highest-ranking targets.

---

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is based on their potential involvement in insulin signaling pathways and metabolic regulation. However, the justification for ranking G22512 as the primary target is weakened by its exclusion from the top priority list. While the rationale for ranking the other targets seems coherent, the absence of G22512 in the top tier diminishes the overall strength of the rankings.

---

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and glucose metabolism. The rationale provided for tissue specificity is relevant, focusing on pancreatic beta-cells and insulin-sensitive tissues. However, the lack of explicit transcription factor relationships is a gap that could strengthen the mechanistic argument.

---

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The approach of activating G22512 through small molecule modulators is appropriate, and the target's position in a co-expression network suggests it could be druggable. However, without clear evidence of safety considerations or established pathways for small molecule intervention, the therapeutic potential is somewhat uncertain.

---

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** The hypothesis does integrate various data types and suggests a potentially innovative therapeutic approach. However, the connections made are not particularly non-obvious in the context of Type 2 Diabetes research, which limits the novelty score.

---

### OVERALL_FITNESS: 
Calculating overall fitness:  
(4 * 0.25) + (6 * 0.25) + (7 * 0.20) + (6 * 0.20) + (5 * 0.10) = 1 + 1.5 + 1.4 + 1.2 + 0.5 = 5.6  
**Overall Fitness Score: 56** (scaled to 0-100)

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 (G22512) quality: **WEAK** - Excluded from top priority list, diminishing support.
- Target #2 (G26720) quality: **MODERATE** - Strong association with insulin signaling, but needs more evidence for top tier.
- Target #3 (G06134) quality: **MODERATE** - Relevant as an enzyme, but also not in top priority list.

---

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate Target Inclusion:** Consider re-evaluating G22512's position in the context of the top priority list, or provide a strong justification for its inclusion as the primary target despite this absence.
2. **Enhance Mechanistic Details:** Include more explicit connections to transcription factors and regulatory pathways to strengthen the mechanistic rationale.
3. **Provide Safety Considerations:** Discuss potential safety considerations associated with targeting G22512 and the small molecule modulators to enhance therapeutic potential.
4. **Broaden Data Evidence:** Explore additional datasets or evidence types that could support the case for G22512 as a priority target, reinforcing its significance in the context of T2D therapy.
2026-02-10 19:17:43,973 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:17:43,973 - root - INFO - Evaluating fitness for hypothesis: t2d-01-9ef573b6
2026-02-10 19:17:57,864 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:17:57,870 - root - INFO - TOKEN_USAGE: input=1406, output=663, total=2069, cost=$0.000609
2026-02-10 19:17:57,870 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:17:57,870 - root - INFO - 
**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target G23245 is indeed found in the top priority list, ranked as the 4th gene, with a score of 4.0. There is cross-dataset consistency as evidence supports its role from at least two datasets. However, while the primary target has strong evidence, there is a warning indicating that it is not in the top priority list when considering other contexts which slightly reduces the score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified by the data, with higher-ranked targets (G23245, G33764, G00484) showing strong involvement in insulin signaling and glucose metabolism pathways. However, the slight ambiguity introduced by the warning about the target's priority may indicate potential issues in the robustness of the ranking.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and glucose metabolism, emphasizing the role of G23245 as a central regulator. The tissue rationale (pancreatic -cells, liver, and muscle) is well-supported, as these are indeed critical for the observed effects on glucose homeostasis. However, the absence of identified regulating transcription factors for G23245 could be a point of weakness.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule modulation to enhance the activity of G23245 seems appropriate given its central role in the metabolic pathways of T2D. The selected targets appear druggable based on their network positions, and the suggested interventions focus on improving metabolic functions, which is directly relevant to T2D management. Safety considerations, while not explicitly discussed, should be monitored given the complexity of metabolic pathways.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a way that reflects a comprehensive understanding of T2D management. By focusing on a multi-target approach that includes both metabolic enzymes and transcription factors, it proposes connections that are not entirely obvious but still build upon established knowledge in diabetes research.

**OVERALL_FITNESS:** 7.5 (rounded to 75)  
**Calculation:** (8*0.25 + 7*0.25 + 8*0.20 + 8*0.20 + 7*0.10) = 7.5

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Clarify Data Support:** Address the warning regarding G23245 not being in the top priority list by providing additional evidence or context to solidify its importance.
2. **Investigate Transcriptional Regulation:** Explore potential transcription factors or regulatory mechanisms that could be linked to G23245 to strengthen the mechanistic understanding.
3. **Expand on Safety Considerations:** Include a discussion on potential off-target effects or safety profiles for the proposed therapeutic approaches to enhance the confidence in the clinical applicability of the targets.
2026-02-10 19:17:57,872 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:17:57,873 - root - INFO - Evaluating fitness for hypothesis: t2d-01-68968a97
2026-02-10 19:18:09,838 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:18:09,847 - root - INFO - TOKEN_USAGE: input=1382, output=713, total=2095, cost=$0.000635
2026-02-10 19:18:09,848 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:18:09,848 - root - INFO - 
### Evaluation of Ranked Drug Target Hypothesis for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** G04436 has a Priority Score of 4/17, which places it in the top priority tier. However, while it has some cross-dataset consistency (supported by 2 datasets), the evidence types are limited (only 2 types). There is a lack of pathways directly associated with G04436, which lowers the score.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking is primarily justified by the regulatory role of G04436 in metabolic pathways relevant to T2D. The other targets also show strong evidence, but G04436's comprehensive regulatory potential makes it a compelling choice. The rationale provided is logical, emphasizing the importance of metabolic regulation in T2D management.

#### MECHANISTIC_SCORE: 7
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with metabolic pathways, particularly lipid metabolism and insulin signaling, which are critical in T2D. The tissue rationale (liver and adipose tissue) is supported by existing knowledge of metabolic processes. However, while the involvement of transcription factors is acknowledged, further detail on how these factors interact with G04436 could strengthen the coherence.

#### THERAPEUTIC_SCORE: 8
**THERAPEUTIC_RATIONALE:** The approach of small molecule activation to enhance G04436's function is appropriate and aligns with its role as a metabolic regulator. The target's position in the network suggests druggability, and the potential for improving metabolic homeostasis and insulin sensitivity is promising. Safety considerations were not discussed in detail, which is a slight gap.

#### NOVELTY_SCORE: 5
**NOVELTY_RATIONALE:** While the hypothesis integrates relevant biological data, the approach of targeting metabolic regulators in T2D is well-explored. G04436's role is compelling, but the novelty of targeting this specific enzyme is moderate given existing knowledge in the field. More innovative connections or unexpected insights would enhance this score.

### OVERALL_FITNESS: 6.7
**Calculated: (6*0.25 + 8*0.25 + 7*0.20 + 8*0.20 + 5*0.10) = 6.7**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G04436 shows promising regulatory potential and some evidence.)
- Target #2 quality: **STRONG** (G22553 is a primary driver, indicating robust relevance.)
- Target #3 quality: **STRONG** (G23245 also shows strong evidence and is a key driver.)

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base**: Gather more evidence types and datasets for G04436 to strengthen its support.
2. **Pathway Analysis**: Incorporate pathway analysis to provide a clearer picture of G04436s involvement in T2D.
3. **Detail Mechanism**: Elaborate on the role of transcription factors and how they influence G04436 function to enhance mechanistic coherence.
4. **Safety Considerations**: Include safety profiles and potential off-target effects of small molecule activators in the therapeutic approach. 
5. **Explore Novelty**: Consider integrating more innovative strategies or lesser-known pathways that could provide a fresh perspective on T2D management.
2026-02-10 19:18:09,849 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:18:09,849 - root - INFO - Evaluating fitness for hypothesis: t2d-01-79a406f1
2026-02-10 19:18:22,157 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:18:22,230 - root - INFO - TOKEN_USAGE: input=1439, output=653, total=2092, cost=$0.000608
2026-02-10 19:18:22,231 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:18:22,231 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** While G19943 and G33764 are supported by multi-omics data and show cross-dataset consistency, they are not present in the top priority list. The evidence types supporting the primary target include pathway involvement and WGCNA module roles, but the absence of regulatory transcription factors is a limitation.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is based on their scores and biological relevance, with G19943 and G33764 being central to insulin signaling and metabolic regulation. However, the justification could be stronger if more emphasis were placed on the unique contributions of each target relative to the others, particularly since some of the lower-ranked targets (like G22553) also show strong potential.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling context, and the tissue rationale involving pancreatic -cells, muscle, and adipose tissue is sound. However, the lack of reported regulatory transcription factors could be a concern, as these factors often play crucial roles in gene expression regulation in metabolic pathways.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation appears appropriate for enhancing the activity of G19943 and G33764. However, the assessment of druggability should consider both network position and the specific biological roles of these targets in T2D. Safety considerations should also be more explicitly addressed, particularly regarding potential off-target effects.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple data types to identify targets for T2D therapy, which is valuable. However, the connections made do not seem particularly non-obvious, given the existing knowledge about insulin signaling and metabolic regulation in T2D.

**OVERALL_FITNESS:** 6.55 (calculated as 6 * 0.25 + 7 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10, scaled to 0-100)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: MODERATE  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Address Target Inclusion:** Re-evaluate the relevance of G19122, G22553, and G20274 concerning the proposed mechanism and consider their potential implications in the therapeutic context.
2. **Enhance Transcription Factor Analysis:** Include an investigation into potential regulatory transcription factors that might interact with the key targets, as this could strengthen the mechanistic understanding.
3. **Safety Considerations:** Clearly outline potential safety concerns and off-target effects related to the modulation of G19943 and G33764, providing a comprehensive risk assessment for therapeutic strategies.
4. **Expand Novelty Aspects:** Explore innovative connections or mechanisms that may not have been previously identified in the literature, perhaps by integrating more diverse data sources or novel methodologies.
2026-02-10 19:18:22,262 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:18:22,263 - root - INFO - Evaluating fitness for hypothesis: t2d-01-10c7384e
2026-02-10 19:18:36,401 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:18:36,407 - root - INFO - TOKEN_USAGE: input=1455, output=800, total=2255, cost=$0.000698
2026-02-10 19:18:36,407 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:18:36,407 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is in the top priority list; however, some other ranked targets, such as G33764, are not, which reduces the overall score. There is cross-dataset consistency for the primary target and strong evidence supporting its significance in T2D pathways. However, the evidence types supporting G19943 are not comprehensive, affecting the score.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data presented, particularly for the top three targets. G19943 is appropriately prioritized as a central hub in metabolic regulation, while G33764 and G22553 follow closely due to their roles in T2D pathways. The rationale provided aligns with their priority scores, although there is some overlap in scoring that could be better clarified.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways, and the tissue rationale is supported by the roles of pancreatic -cells, muscle, and adipose tissue in T2D. However, the lack of reported transcription factors (TFs) does raise some concerns regarding regulatory aspects, which slightly detracts from the coherence of the mechanism.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G33764 appears appropriate given their roles in metabolic regulation. The potential for druggability is suggested by their network positions, but there may be safety considerations depending on the specific small molecules used, which are not addressed in the hypothesis.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates insights from previously established research, but the connections made are somewhat conventional in the context of T2D research. While the combination of targets is useful, the approach does not propose significantly novel mechanisms or targets that have not been explored previously.

---

### OVERALL_FITNESS
Overall fitness score is calculated as follows:  
Overall fitness = (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)

= (7 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
= 1.75 + 2.00 + 1.60 + 1.40 + 0.60  
= 7.35 (on a scale of 0-10)  

Scaled to a 0-100 scale:  
Overall fitness = 73.5

### RANKED_TARGETS_ASSESSMENT
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Evidence Types:** Include more diverse types of evidence for the primary target G19943 and other prioritized targets to strengthen the data support.
2. **Clarify Ranking Justification:** Provide clearer differentiation in priority scores between closely ranked targets to improve transparency in the ranking quality.
3. **Investigate TF Relationships:** Explore potential transcription factors that may regulate the proposed target genes to enhance the mechanistic coherence.
4. **Safety Considerations:** Discuss potential safety issues regarding the activation of these targets with small molecules to address potential adverse effects associated with the therapeutic approach.
5. **Explore Novel Connections:** Consider presenting innovative insights or novel connections between the targets to enhance the overall novelty of the hypothesis.
2026-02-10 19:18:36,407 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:18:36,408 - root - INFO - Evaluating fitness for hypothesis: t2d-01-e87f8bbb
2026-02-10 19:18:52,574 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:18:52,614 - root - INFO - TOKEN_USAGE: input=1526, output=764, total=2290, cost=$0.000687
2026-02-10 19:18:52,614 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:18:52,614 - root - INFO - 
### EVALUATION OF HYPOTHESIS: Integrated Targeting of Metabolic Pathways in Type 2 Diabetes Management

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The ranked targets (G22553, G23245, and others) are indeed in the top priority tier, and they are associated with a high score of 4.0. However, there is a lack of cross-dataset consistency for the primary target G22553, as it is only supported by one dataset. Furthermore, it has only one type of evidence, which limits its robustness. The integration of evidence from multiple datasets would strengthen support for the primary target.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of targets is generally justified by the data provided, particularly for G22553 and G23245, which are recognized as primary drivers in T2D pathways. However, the evidence for G22553 shows a Best DE Rank of 1803, which could indicate a need for stronger supporting data compared to other high-ranking targets, potentially affecting the perceived strength of the overall ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanisms for G22553 and G23245 align well with the pathways involved in glucose metabolism and insulin signaling. The tissue rationale is solid, focusing on pancreatic -cells, liver, and muscle tissues, which are critical for insulin action. However, the lack of specified regulating transcription factors for G22553 and G23245 could be a gap in understanding the full regulatory landscape.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule modulation is appropriate for enhancing insulin signaling and glucose uptake. The targets are likely druggable given their roles in metabolic pathways, although safety considerations are not explicitly mentioned. Addressing potential off-target effects and long-term safety profiles would strengthen this aspect.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** While the hypothesis integrates existing knowledge effectively, it does not appear to propose particularly novel connections or mechanisms that have not been explored in prior research. The integration of G22553 and G23245 is valuable, but similar approaches have been seen in the literature regarding insulin sensitivity and glucose metabolism.

### OVERALL_FITNESS: 69
Calculated as: \( 6 \times 0.25 + 7 \times 0.25 + 8 \times 0.20 + 7 \times 0.20 + 6 \times 0.10 = 69 \)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG** (G22553 shows robust evidence as a primary driver)
- **Target #2 quality: STRONG** (G23245 has a similar profile, supporting its role)
- **Target #3 quality: MODERATE** (G33764, while relevant, has less evidence compared to the top two)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Robustness**: Aim to gather additional datasets to support G22553 and improve cross-dataset consistency.
2. **Expand Mechanistic Insights**: Identify and integrate potential regulating transcription factors for G22553 and G23245 to provide a more comprehensive understanding of their regulation.
3. **Address Safety Concerns**: Include a detailed safety assessment plan for the proposed therapeutic approach, including potential off-target effects and long-term implications of targeting these genes.
4. **Explore Novel Mechanisms**: Investigate and highlight any novel connections or mechanisms that could differentiate this hypothesis from existing literature, potentially increasing its impact and novelty.
2026-02-10 19:18:52,614 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:18:52,615 - root - INFO - Evaluating fitness for hypothesis: t2d-01-2baea794
2026-02-10 19:19:07,219 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:19:07,224 - root - INFO - TOKEN_USAGE: input=1423, output=772, total=2195, cost=$0.000677
2026-02-10 19:19:07,224 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:19:07,224 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 4**  
**DATA_SUPPORT_RATIONALE:** The primary target G19122 is not found in the top priority list, which raises concerns about its overall significance relative to other targets. However, it has a solid score of 3.0 and shows cross-dataset consistency with evidence from two datasets. The evidence types supporting G19122 include its correlation with T2D, involvement in key metabolic pathways, and its role in WGCNA, which provides a moderate level of support.

**RANKING_QUALITY_SCORE: 5**  
**RANKING_QUALITY_RATIONALE:** While G19122 has a strong rationale for its ranking, the fact that it is not included in the top priority list weakens the justification for its position as the primary target. The ranking does differentiate between targets well, with G33764 also showing strong relevance, but without inclusion in the top tier, the justification is less compelling. 

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G19122 aligns well with the pathways involved in T2D, particularly metabolic regulation and insulin signaling. The tissue rationale is sound, as adipose tissue is critical in glucose homeostasis. However, the lack of indicated regulatory transcription factors detracts slightly from the mechanistic coherence.

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19122 using small molecule modulators appears appropriate and promising for enhancing insulin sensitivity. However, the extent to which G19122 can be targeted effectively and safely in a therapeutic setting remains uncertain, especially since there are no indicated safety considerations or evidence of druggability.

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** The hypothesis presents a reasonable integration of existing data and explores the role of a specific gene in adipose tissue concerning T2D. However, the connections made, while relevant, are not particularly novel in the context of existing research on T2D and adipose tissue metabolism.

### OVERALL_FITNESS
**Overall Fitness Calculation:**  
(4 * 0.25) + (5 * 0.25) + (7 * 0.20) + (6 * 0.20) + (5 * 0.10) = 5.3  
**Scaled to 0-100:** 53

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **WEAK** (due to absence from top priority list and lower data support)
- Target #2 quality: **MODERATE** (G20274 has potential but ranks lower)
- Target #3 quality: **STRONG** (G33764 has a high score and established relevance)

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Selection:** Consider re-evaluating G19122's position against the top priority genes. Investigate if it can be repositioned or if additional data can enhance its support.
2. **Expand Evidence Base:** Gather more evidence types supporting G19122's role in T2D, such as functional studies or clinical data, to strengthen its standing as a primary target.
3. **Investigate Transcription Factors:** Identify any potential regulatory transcription factors associated with G19122 to enhance mechanistic understanding and therapeutic strategy.
4. **Druggability Assessment:** Conduct a more thorough investigation into the druggability of G19122 and the feasibility of the proposed therapeutic approach, including safety profiles.
5. **Novelty Enhancement:** Explore unique aspects of G19122's role in T2D that could be emphasized to highlight novel therapeutic avenues or connections.
2026-02-10 19:19:07,225 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:19:07,226 - root - INFO - Evaluating fitness for hypothesis: t2d-01-b3112ea6
2026-02-10 19:19:22,873 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:19:22,879 - root - INFO - TOKEN_USAGE: input=1448, output=743, total=2191, cost=$0.000663
2026-02-10 19:19:22,879 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:19:22,879 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target G33764 has a high priority score and is included in the top priority list. Its activation is supported by data from two datasets, which provides strong cross-dataset consistency. However, the lack of identified regulating transcription factors may limit the depth of evidence.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as G33764 is prioritized due to its strong evidence as a primary driver in T2D pathways. G19077, while also ranked highly, may not have as robust support compared to G33764. The rationale is sound, but the presence of additional promising candidates (G22512, G26720) could warrant reevaluation of their positions.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways related to glucose metabolism and insulin sensitivity, particularly in muscle and adipose tissues. However, the absence of identified transcription factors may suggest a gap in understanding the regulatory network, which slightly detracts from the overall coherence.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach focuses on the activation of G33764 and modulation of G19077, which is appropriate given their roles in metabolic pathways. The targets appear to be druggable based on their network positions, and the predicted outcomes align well with the therapeutic goals for T2D. Safety considerations are not explicitly addressed, which could be a concern in drug development.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a meaningful way, particularly by proposing a combinatorial approach to target activation and modulation. However, the connections between the targets and their roles in T2D, while relevant, are somewhat conventional in the context of metabolic disease research.

---

### OVERALL_FITNESS: 
**Calculated Score:**  
(8 * 0.25) + (7 * 0.25) + (8 * 0.20) + (8 * 0.20) + (6 * 0.10) = 7.5  
**Scaled to 0-100:** 75

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** MODERATE

---

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Data Evidence:** Seek additional datasets or evidence types to further support the roles of G19077 and other ranked targets. Identifying potential regulating transcription factors would strengthen the data support.
  
2. **Address Safety Considerations:** Include a discussion of potential safety concerns associated with the activation of G33764 and modulation of G19077, as well as any known side effects or interactions.

3. **Reevaluate Target Rankings:** Consider the potential of G22512 and G26720, which show strong differential expression and may provide complementary benefits. Reassessing their roles could lead to a more comprehensive approach.

4. **Transcription Factor Identification:** Investigate potential transcription factors that may regulate G33764 and G19077, using computational predictions or experimental validations to fill this gap in mechanistic understanding.

5. **Novelty Enhancement:** Explore less conventional pathways or novel combinations of targets that could enhance the therapeutic approach, ensuring that the hypothesis remains innovative in the field of T2D research.
2026-02-10 19:19:22,881 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:19:22,882 - root - INFO - Evaluating fitness for hypothesis: t2d-01-ae1cd7e4
2026-02-10 19:19:34,357 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:19:34,363 - root - INFO - TOKEN_USAGE: input=1453, output=728, total=2181, cost=$0.000655
2026-02-10 19:19:34,363 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:19:34,363 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is indeed in the top priority list, but G33764, G19122, G22512, and G23245 are not. This affects the overall data support somewhat negatively. However, the hypothesis is backed by two datasets showing cross-dataset consistency, which is a strong point. Multiple evidence types support G22553, enhancing confidence in its role.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, especially highlighting G22553 as a primary driver in relevant pathways. However, the lack of inclusion of G33764 in the top 10 priority genes raises questions regarding its ranking relative to other targets. The rationale for ranking is coherent, but the absence of some targets in the priority list slightly weakens the strength of the overall ranking.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and glucose metabolism. The tissue rationale is solid, focusing on pancreatic beta-cells, liver, and skeletal muscle, which are indeed critical for T2D management. However, the absence of specified regulatory TFs could be a point of improvement.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and G33764 is appropriate given their roles in enhancing insulin functions. The potential of these targets to be druggable based on their network position is promising. However, safety considerations for the activation of these targets should be more explicitly addressed to bolster the therapeutic potential.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data effectively, the connections made among the targets are somewhat expected given their established roles in T2D. The approach is systematic, but it lacks highly innovative or unconventional connections that would elevate its novelty.

### OVERALL_FITNESS
**OVERALL_FITNESS:** (7*0.25 + 7*0.25 + 8*0.20 + 8*0.20 + 6*0.10) = 7.3 (scaled to 73)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G22553 is well-supported as a primary driver)
- Target #2 quality: **MODERATE** (G33764 has strong implications, but absent from top priority list)
- Target #3 quality: **MODERATE** (G19122 is significant but also absent from the top list)

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate Target Inclusion:** Consider reviewing the reasoning behind the exclusion of G33764 and G19122 from the top priority list. If they are indeed critical, their re-evaluation could strengthen the hypothesis.
2. **Expand on Mechanistic Details:** Include details on potential regulatory transcription factors (TFs) that may influence the targets to provide a more comprehensive understanding of the mechanisms at play.
3. **Address Safety Considerations:** Explicitly discuss any potential safety concerns or adverse effects associated with the proposed therapeutic approach, especially regarding the activation of targets.
4. **Enhance Novelty:** Explore additional connections or lesser-known interactions among the targets to elevate the novelty of the hypothesis. This could involve investigating non-canonical roles or novel pathways involved in T2D.
2026-02-10 19:19:34,363 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:19:34,364 - root - INFO - Evaluating fitness for hypothesis: t2d-01-cd4f49dc
2026-02-10 19:19:46,943 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:19:46,946 - root - INFO - TOKEN_USAGE: input=1459, output=745, total=2204, cost=$0.000666
2026-02-10 19:19:46,947 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:19:46,947 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** G33764, while having a high score in the hypothesis, is found not in the top priority list. The presence of cross-dataset consistency supports it, but the absence from the top-tier list significantly impacts its data support score. The evidence types supporting G33764 are limited, impacting its overall support.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 is somewhat justified given its role as a primary driver in T2D pathways. However, the presence of stronger candidates like G19943 in the top priority list raises questions. The rationale for placing G33764 highest needs to be revisited in light of the top priority genes.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in T2D, particularly concerning insulin sensitivity and glucose homeostasis. The rationale of targeting adipose tissue and skeletal muscle is logical, supported by the roles of G33764 and G19943. However, the lack of reported regulating transcription factors is a minor gap.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of inhibiting G33764, potentially in combination with G19943, is appropriate given their roles in metabolic regulation. Both targets appear druggable based on their network positions. However, further exploration of safety considerations is warranted, particularly for combination therapies.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** While the hypothesis integrates existing data effectively, the connections made are somewhat expected in the context of T2D research. The idea of dual-targeting is not novel in itself, but the specific focus on G33764 and G19943 presents a thoughtful approach. More unique aspects could strengthen this score.

**OVERALL_FITNESS: 6.8**  
*(Calculated as: 6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 6.8)*

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: MODERATE** (G33764 has high potential but lacks placement in the top priority list.)
- **Target #2 quality: STRONG** (G19943 is a top candidate with robust evidence supporting its role.)
- **Target #3 quality: WEAK** (G09708, G12806, and G26921 are not well-supported and do not present significant therapeutic potential.)

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess the Priority of G33764:** Conduct additional analyses to confirm G33764s relevance in the context of updated top priority lists, or justify its placement with stronger supporting data.
2. **Expand Data Evidence:** Increase the variety of evidence supporting G33764, particularly focusing on functional studies or clinical correlations that connect it to T2D.
3. **Explore Transcription Factors:** Investigate potential regulating transcription factors that may influence G33764, as this could provide deeper mechanistic insights and enhance the hypothesis.
4. **Consider Safety Profiles:** Include a discussion of potential safety concerns regarding the inhibition of G33764 and the combined approach with G19943, ensuring thorough risk assessment.
5. **Enhance Novelty Aspects:** Integrate more innovative approaches or hypotheses around the dual-targeting strategy that could differentiate this research from existing studies in T2D.
2026-02-10 19:19:46,948 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:19:46,949 - root - INFO - Evaluating fitness for hypothesis: t2d-01-0bd88fe2
2026-02-10 19:20:06,508 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:20:06,512 - root - INFO - TOKEN_USAGE: input=1371, output=717, total=2088, cost=$0.000636
2026-02-10 19:20:06,512 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:20:06,512 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** G22553 is indeed in the top priority list, indicating its importance. However, the evidence supporting it is limited to two datasets, which, while consistent, does not provide extensive multi-source validation. The identification of no regulating transcription factors also weakens the overall data support.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified, as G22553, G23245, and G33764 all have high scores and significant roles in T2D. However, the mention of G19122 twice (as targets 4 and 5) suggests a potential oversight in target differentiation, which might affect the clarity of the ranking.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism of G22553 aligning with metabolic pathways is reasonable, and the focus on liver and adipose tissues is supported by its role in glucose metabolism. However, the lack of identified regulating transcription factors raises questions about the completeness of the mechanistic understanding.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of developing small molecule modulators is sensible and appropriate for enhancing G22553 activity. However, there is a need for further exploration of potential safety concerns associated with modulation of this target.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis presents a valuable exploration of alternative targets for T2D management. However, the connections made are not particularly groundbreaking, as the targets identified have been previously associated with metabolic regulation.

### OVERALL_FITNESS: 
Calculated as follows:  
- DATA_SUPPORT: 7 * 0.25 = 1.75  
- RANKING_QUALITY: 8 * 0.25 = 2.00  
- MECHANISTIC: 7 * 0.20 = 1.40  
- THERAPEUTIC: 8 * 0.20 = 1.60  
- NOVELTY: 6 * 0.10 = 0.60  
**Overall Fitness = 1.75 + 2.00 + 1.40 + 1.60 + 0.60 = 7.35**  
**Scaled to 0-100: 73.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Sources:** Enhance the robustness of the data support by integrating more datasets or experimental evidence to confirm the role of G22553 and its mechanism in T2D management.
2. **Clarify Target Differentiation:** Address the redundancy in the listing of G19122 to avoid confusion and ensure clarity in the target assessment.
3. **Explore TF Relationships:** Investigate potential transcription factors that may regulate G22553 to provide a more comprehensive mechanistic understanding.
4. **Safety Assessments:** Conduct preliminary safety assessments for the proposed therapeutic approach to anticipate potential side effects of modulating G22553.
5. **Expand Novelty Discussion:** Highlight unique aspects of the hypothesis more clearly to strengthen the argument for its novelty in T2D therapeutic strategies.
2026-02-10 19:20:06,512 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:20:06,513 - root - INFO - Evaluating fitness for hypothesis: t2d-01-180e17a8
2026-02-10 19:20:19,819 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:20:19,822 - root - INFO - TOKEN_USAGE: input=1488, output=825, total=2313, cost=$0.000718
2026-02-10 19:20:19,823 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:20:19,823 - root - INFO - 
### Evaluation of the Hypothesis on G23245 as a Therapeutic Target for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G23245 is in the top priority tier with a score of 4.0, which is consistent with several other high-priority genes. However, there is a lack of cross-dataset consistency, as only one dataset supports the evidence. Additionally, the mean log2 fold change is negative (-0.425), which suggests that the target's expression may not align positively with T2D pathophysiology. The priority score of 4/17 indicates moderate support but is not particularly strong given the limited evidence types.

---

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking of G23245 is justified based on its primary driver status and its connections to significant metabolic pathways. The rationale provided for the ranking is reasonable, with G33764 and G00484 also being strong candidates that complement G23245s role. The clear distinction between the top-ranked targets and those ranked lower is evident, as the top three targets suggest a synergistic therapeutic approach to T2D management.

---

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with established insulin signaling pathways, which are crucial for glucose metabolism. The involvement of G00484 as a transcription factor regulating these pathways adds depth to the mechanistic understanding. However, the absence of identified regulating transcription factors for G23245 could weaken the overall coherence. The tissue rationale is well-supported, focusing on pancreatic -cells, liver, and muscle tissues, which are indeed critical for insulin action and glucose homeostasis.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule modulation to enhance G23245 activity is appropriate, considering its role in insulin signaling. The potential for combination therapies with G33764 and G00484 is a strong point, indicating a thoughtful strategy to improve insulin sensitivity. However, further exploration of the druggability of these targets and possible safety considerations is necessary to bolster this score.

---

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** While the hypothesis integrates data effectively, the connections made between G23245 and its associated pathways are not particularly groundbreaking in the context of T2D research. The hypothesis could benefit from more innovative or less-explored connections to enhance its novelty. The integration of multiple targets does provide a creative framework, but the overall concept remains within established paradigms of T2D therapy.

---

**OVERALL_FITNESS:**  
(6 * 0.25) + (8 * 0.25) + (7 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.6 (rounded to 67)  
**Overall Fitness: 67/100**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Increase Data Evidence:** Aim to gather more datasets that support the role of G23245 in T2D to strengthen the evidence base and improve cross-dataset consistency.
2. **Identify Transcription Factors:** Investigate potential regulatory transcription factors for G23245 to enhance mechanistic coherence and provide a clearer understanding of its role within the insulin signaling pathways.
3. **Expand Safety Considerations:** Conduct preliminary assessments of potential safety issues associated with modulating G23245 and its interactions with G33764 and G00484 to inform the therapeutic approach.
4. **Explore Novel Mechanisms:** Look for less conventional connections or pathways involving G23245 that could add novelty to the therapeutic strategy and differentiate it from existing T2D treatments.
2026-02-10 19:20:19,823 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:20:19,824 - root - INFO - Evaluating fitness for hypothesis: t2d-01-3e3c0cd2
2026-02-10 19:20:32,825 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:20:32,830 - root - INFO - TOKEN_USAGE: input=1393, output=741, total=2134, cost=$0.000654
2026-02-10 19:20:32,830 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:20:32,830 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G04436, has a Priority Score of 4.0, placing it in the top priority tier along with other ranked targets. However, there is a lack of cross-dataset consistency for G04436, which slightly diminishes its robustness. While 2 datasets are mentioned in the summary, the evidence from only 1 dataset for the primary target limits the strength of the support.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of G04436 as the top target is justified based on its significance in T2D and the high score. The rationale provided indicates a clear understanding of its role in metabolic pathways. However, the similarity in scores among several targets (G22553, G33764) suggests that the distinctions between their relevance may not be well-defined, which slightly weakens the ranking's clarity.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism of activating G04436 to enhance glucose metabolism and insulin sensitivity aligns well with known metabolic pathways. The rationale for targeting pancreatic -cells and insulin-sensitive tissues is consistent with T2D pathology. Additionally, consideration of 12 transcription factors that regulate G04436 adds to the mechanistic coherence.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G04436 and other targets through small molecules is appropriate, given the context of T2D treatment. The targets appear to have a relevant metabolic role which suggests they could be druggable. However, specific safety considerations and potential side effects of activating these targets are not discussed, which is an important factor in evaluating therapeutic potential.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a way that emphasizes the therapeutic potential of G04436, but it does not propose particularly novel connections or insights beyond the known roles of these targets in T2D. The approach is somewhat conventional in the context of metabolic disease research, which may limit its novelty score.

---

**OVERALL_FITNESS:** 
\[
\text{Overall Fitness} = (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 6.7 \approx 67
\]

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG  
- **Target #2 quality:** STRONG  
- **Target #3 quality:** STRONG  

---

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Cross-Dataset Validation:** Aim to gather more datasets for G04436 to enhance the robustness of the evidence supporting its dysregulation in T2D and to establish cross-dataset consistency.
  
2. **Clarify Ranking Distinctions:** Provide more detailed rationale for the ranking differences among similarly scored targets. This can include additional data or insights into why some targets may have more therapeutic promise than others.

3. **Safety Considerations:** Include a section addressing potential safety concerns and side effects associated with the activation of G04436 and other targets to strengthen the therapeutic potential evaluation.

4. **Explore Novel Mechanisms:** Investigate and highlight any less explored interactions or pathways involving G04436 and other targets that could showcase novel therapeutic avenues for T2D treatment.
2026-02-10 19:20:32,834 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:20:32,837 - root - INFO - Evaluating fitness for hypothesis: t2d-01-f3a26fde
2026-02-10 19:20:43,758 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:20:43,769 - root - INFO - TOKEN_USAGE: input=1385, output=666, total=2051, cost=$0.000607
2026-02-10 19:20:43,770 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:20:43,771 - root - INFO - 
**DATA_SUPPORT_SCORE: 8**  
**DATA_SUPPORT_RATIONALE:** G19943 has a high priority score of 4.0 and is supported by cross-dataset consistency from two datasets. However, the warning indicates that it is not found in the top priority list, which reduces confidence somewhat. There is strong evidence for its role in the insulin signaling pathway and muscle metabolism, but the number of evidence types specific to G19943 could be further strengthened.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking of G19943 is justified by its high score and central role as a hub component in the silver module. The next targets (G19122, G27976) are lower-scoring but still relevant to insulin signaling. However, the presence of other high-scoring genes in the top priority list raises questions about the distinctiveness of the ranking, implying that some lower-ranked targets may also warrant consideration.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context. The tissue rationale for focusing on muscle tissue is solid, given its critical role in glucose uptake. However, the absence of reported regulating transcription factors could be noted as a gap that might limit understanding of the mechanisms involved.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation targeting G19943 appears appropriate and aligns with the goal of enhancing insulin sensitivity. G19943's position as a hub suggests it could be druggable. However, there may be safety considerations or off-target effects that need to be addressed further, given its central role in signaling pathways.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a logical way but does not present particularly novel connections or insights beyond established roles of insulin signaling in glucose metabolism. There's potential for increased novelty if non-obvious connections or novel mechanisms were proposed.

**OVERALL_FITNESS: 7.3**  
(Score Calculation: 8*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 7.25, scaled to 100 gives 7.3)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **MODERATE**  
- Target #3 quality: **MODERATE**  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Increase Evidence Base:** Gather more diverse evidence types for G19943, including functional studies or clinical correlations to strengthen the hypothesis.
2. **Explore TF Relationships:** Investigate potential transcription factors that may regulate G19943 to provide a more comprehensive understanding of its mechanistic role.
3. **Broaden Target Assessment:** Consider evaluating other high-ranking genes from the top priority list to see if they might complement or enhance the therapeutic approach focused on G19943.
4. **Safety Assessment:** Conduct preliminary assessments on the safety and potential off-target effects of modulating G19943 to better inform therapeutic feasibility.
2026-02-10 19:20:43,772 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:20:43,772 - root - INFO - Evaluating fitness for hypothesis: t2d-01-f98f612c
2026-02-10 19:20:53,441 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:20:53,447 - root - INFO - TOKEN_USAGE: input=1419, output=741, total=2160, cost=$0.000657
2026-02-10 19:20:53,447 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:20:53,448 - root - INFO - 
### Evaluation of the Drug Target Hypothesis for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G04436 has a Priority Score of 4.0, and while it is in the top priority tier, there is only cross-dataset consistency for 2 of the other targets. The support from evidence types for G04436 is somewhat limited given that it only has 2 datasets. The lack of multiple evidence types and pathways for G04436 reduces the overall score.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of G04436 as the highest target is justified based on its enzymatic nature and importance in metabolic pathways. However, the distinction between G04436 and the other targets is not as strong as it could beespecially since G33764 also has significant metabolic implications. The rationale provided for the ranking does make sense, but the close scores among the top targets suggest that the differentiation could be improved.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism of action for G04436 aligns well with the lipid metabolism and insulin signaling pathways. The tissue rationale is also strong, as liver and adipose tissues are critical in T2D pathology. The identification of 12 regulatory transcription factors further supports the mechanistic coherence, indicating a clear relationship between G04436 and the physiological processes involved in T2D.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate for enhancing the function of G04436. Given its role in metabolic regulation, the target appears druggable based on network position. However, the evaluation does not mention potential safety considerations, which is important for a comprehensive therapeutic assessment.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis does integrate data in a creative way by emphasizing alternative targets in T2D management, shifting focus toward metabolic regulation. However, the connections made are not entirely non-obvious, as metabolic pathways are a known area of interest in T2D research. More innovative insights into the specific roles of the targets could enhance this aspect.

### OVERALL_FITNESS: 6.75
**Calculated:** (6*0.25) + (7*0.25) + (8*0.20) + (7*0.20) + (6*0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.75

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** MODERATE
- **Target #3 quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Types:** Gather more diverse evidence types for G04436 and the ranked targets to strengthen the data support. This could include genetic, proteomic, and metabolomic data.
2. **Enhance Distinction Among Targets:** Provide additional mechanistic insights or comparative data to clearly differentiate G04436 from G33764 and the other targets, illustrating why it ranks highest.
3. **Address Safety Considerations:** Include a discussion of potential safety issues or side effects associated with targeting G04436 to provide a more comprehensive therapeutic assessment.
4. **Explore Novel Connections:** Investigate and present non-obvious connections or novel insights that could enhance the novelty score and overall argument for the chosen targets.
2026-02-10 19:20:53,449 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:20:53,450 - root - INFO - Evaluating fitness for hypothesis: t2d-01-43ace99b
2026-02-10 19:21:04,166 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:21:04,171 - root - INFO - TOKEN_USAGE: input=1485, output=632, total=2117, cost=$0.000602
2026-02-10 19:21:04,171 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:21:04,171 - root - INFO - 
### EVALUATION OF RANKED DRUG TARGET HYPOTHESIS FOR TYPE 2 DIABETES

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** 
While G04436 and other ranked targets have high scores, the evidence for the primary target is limited, showing only 1 dataset with no cross-dataset consistency. The priority score, although decent (4.0), does not carry substantial multi-evidence support (only 2 evidence types). This weakens the overall data support.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** 
The ranking is logical, with higher-ranked targets showing strong negative log2FC and consistency with T2D pathology. However, the lack of cross-dataset validation reduces the robustness of the ranking, making it less compelling than it could be.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** 
The proposed mechanism aligns well with known pathways involved in insulin sensitivity and glucose homeostasis. The rationale for targeting pancreatic -cells and insulin-sensitive tissues is sound, and the involvement of identified transcription factors adds depth to the mechanistic understanding.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** 
The therapeutic approach of inhibiting G04436 and modulating the other targets is appropriate given their roles in insulin resistance. However, a more detailed exploration of druggability and potential off-target effects could strengthen this score.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** 
While the integration of multiple targets is commendable, the connections drawn are somewhat expected in the context of T2D research. More innovative hypotheses regarding target interactions or novel pathways would enhance the originality of the proposal.

### OVERALL_FITNESS: 6.75
**Calculated:**
(6 * 0.25 + 7 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.75

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Dataset Evidence:** Aim to validate findings across additional datasets to enhance cross-dataset consistency for G04436 and its associated targets.
2. **Expand Evidence Types:** Include more types of evidence (e.g., functional assays, genetic studies) to solidify the support for the primary target.
3. **Explore Druggability:** Provide a more in-depth analysis of the druggability of G04436 and its partners, including potential safety profiles and off-target effects.
4. **Novel Mechanisms:** Consider investigating additional novel pathways or interactions that could further elucidate the roles of the ranked targets in T2D.
2026-02-10 19:21:04,171 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:21:04,171 - root - INFO - Evaluating fitness for hypothesis: t2d-01-06dfdad0
2026-02-10 19:21:16,900 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:21:16,907 - root - INFO - TOKEN_USAGE: input=1404, output=682, total=2086, cost=$0.000620
2026-02-10 19:21:16,907 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:21:16,907 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
DATA_SUPPORT_RATIONALE: The primary target G22553 is indeed in the top priority list, which strengthens the proposal. However, G23245, while ranked second, is also found in the top priority list. The cross-dataset consistency is confirmed for the top-ranked targets. The evidence types supporting the primary target are strong, but the overall data support could be enhanced by including additional evidence types for G23245 and other targets.

**RANKING_QUALITY_SCORE: 7**  
RANKING_QUALITY_RATIONALE: The ranking is mostly justified by the data, particularly as G22553 and G23245 are both high-scoring targets. However, since G33764, G19122, and G20274 are ranked lower despite their regulatory roles, the rationale could be clearer. The differentiation between the strengths of the ranks could be improved by providing more context for the effectiveness of each target.

**MECHANISTIC_SCORE: 8**  
MECHANISTIC_RATIONALE: The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways. The tissue rationale is clearly supported, particularly with the focus on pancreatic beta-cells, muscle, and adipose tissue. However, the lack of specification regarding regulating transcription factors (TFs) could be seen as a gap in the mechanistic coherence.

**THERAPEUTIC_SCORE: 7**  
THERAPEUTIC_RATIONALE: The proposed approach of small molecule activation is appropriate for the targets identified, and both G22553 and G23245 appear druggable based on their network positions. While safety considerations are not mentioned, it's critical to assess potential off-target effects in the context of dual modulation strategies. 

**NOVELTY_SCORE: 5**  
NOVELTY_RATIONALE: While the hypothesis integrates existing data and proposes a dual modulation strategy, the approach is somewhat conventional in the context of T2D research. The connections made between the targets are valuable but not particularly novel, as dual targeting in metabolic diseases has been explored previously.

**OVERALL_FITNESS: 6.6**  
(6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 5*0.10 = 6.6)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: MODERATE  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Enhance Evidence Types:** Increase the variety of evidence types for G23245 and other lower-ranked targets to strengthen the overall data support.
2. **Clarify Ranking Rationale:** Provide more detailed justification for the ranking, particularly for why targets like G19122 and G20274 are ranked lower despite their regulatory roles.
3. **Include TF Analysis:** Consider including potential regulating transcription factors that may influence the modulation of the proposed targets to bolster mechanistic coherence.
4. **Discuss Safety Considerations:** Elaborate on safety and potential side effects of the proposed therapeutic approach, especially in the context of dual modulation.
5. **Explore Novel Mechanisms:** Investigate and propose any unique aspects or innovative mechanisms that could enhance the novelty of the hypothesis, potentially differentiating it from existing research.
2026-02-10 19:21:16,909 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:21:16,909 - root - INFO - Evaluating fitness for hypothesis: t2d-01-2f4105f2
2026-02-10 19:21:28,732 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:21:28,735 - root - INFO - TOKEN_USAGE: input=1540, output=793, total=2333, cost=$0.000707
2026-02-10 19:21:28,735 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:21:28,735 - root - INFO - 
### EVALUATION OF HYPOTHESIS ON G19943 AS A TARGET FOR TYPE 2 DIABETES THERAPY

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a high priority score (4.0), but there is only one dataset providing evidence, which limits the robustness of the data support. Although G19943 is identified as a hub component in a co-expression network and has cross-dataset consistency in the original hypothesis, the evaluation context indicates inconsistency in dataset support. Additionally, the lack of diverse evidence types (only 2) diminishes the overall score.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of G19943 is justified based on its central role in the co-expression network and its negative correlation with T2D. However, the evaluation context reveals that other ranked targets (like G04436, G22553, etc.) also have the same score, suggesting that the distinction among them isn't clearly defined. The rationale provided does explain why G19943 is prioritized, but the lack of stronger differentiation between the top targets slightly lowers the score.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the identified pathways, particularly in lipid metabolism and insulin signaling. The rationale for targeting pancreatic -cells and adipose tissue is relevant, given their roles in insulin secretion and action. However, the absence of detailed evidence regarding regulatory transcription factors (TFs) could have strengthened the coherence of the mechanism hypothesis, leading to a slightly lower score.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The approach of small molecule activation of G19943 is appropriate given its role in metabolic pathways. The evaluation suggests G19943's centrality in the network may enhance druggability. However, without specific data on safety considerations or potential side effects, the score is moderate rather than high.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** While the hypothesis integrates insights into G19943s role in T2D therapy effectively, the connections made are somewhat expected given current understanding of metabolic dysregulation in T2D. There are no particularly non-obvious connections or innovative angles presented in the hypothesis that would elevate the novelty score further.

### OVERALL_FITNESS: 6.65
**Calculation:** 
- DATA_SUPPORT_SCORE: 6 * 0.25 = 1.5
- RANKING_QUALITY_SCORE: 7 * 0.25 = 1.75
- MECHANISTIC_SCORE: 8 * 0.20 = 1.6
- THERAPEUTIC_SCORE: 7 * 0.20 = 1.4
- NOVELTY_SCORE: 6 * 0.10 = 0.6
- Total = 6.65 (scaled to 0-100 = 66.5)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Seek additional datasets to validate G19943s role further and ensure cross-dataset consistency.
2. **Enhance Mechanistic Insights:** Explore specific regulatory transcription factors and their interactions with G19943 to clarify the mechanistic hypothesis.
3. **Define Safety Profiles:** Investigate potential safety issues and side effects related to G19943 modulation to strengthen the therapeutic approach.
4. **Distinguish Rankings:** Provide clearer differentiators among similarly scored targets to refine the ranking rationale and strengthen the case for G19943 as the primary target.
2026-02-10 19:21:28,735 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:21:28,736 - root - INFO - Population fitness evaluation complete. Top score: 73.50
2026-02-10 19:21:28,737 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 19:21:28,738 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G04436', 'G23245', 'G22553', 'G04436', 'G04436']...
2026-02-10 19:21:28,738 - root - INFO - Generation 1 stats: mean=62.75, max=75.5, min=50.0
2026-02-10 19:21:28,738 - root - INFO - Generation 1 complete
2026-02-10 19:21:28,738 - root - INFO - --- CAPTURING CHECKPOINT GEN 1 ---
2026-02-10 19:21:28,739 - root - INFO - Running generation 2
2026-02-10 19:21:28,739 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 19:21:28,739 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 19:21:28,739 - root - INFO - Mutation 1/18: parent '** Alternative Therapeutic Tar...'
2026-02-10 19:21:28,740 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:21:28,784 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:21:45,568 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:21:45,584 - root - INFO - TOKEN_USAGE: input=39455, output=721, total=40176, cost=$0.006351
2026-02-10 19:21:45,585 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:21:45,585 - root - INFO - 
**TITLE:** Enhanced Mechanistic Insights for Targeting G22553 in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | G22553 is a primary driver in the black module, showing a strong positive correlation with T2D and implicating critical metabolic pathways.
2. **G23245** | Score: **4.0** | As a primary driver in the silver module, G23245 has a significant negative correlation to T2D, suggesting it promotes insulin sensitivity and may complement G22553's function.
3. **G33764** | Score: **4.0** | This enzyme is a primary driver in the darkgrey module, indicating its role in insulin signaling pathways, which are crucial for maintaining glucose homeostasis.
4. **G19122** | Score: **3.0** | A major regulator in the black module, G19122 is involved in insulin signaling pathways, potentially enhancing the effects of G22553.
5. **G19943** | Score: **4.0** | As a hub component, G19943 shows a strong correlation with T2D, suggesting it may interact with multiple pathways affecting metabolic regulation.

**PRIMARY_TARGET:** G22553

**SUMMARY:** The refined hypothesis emphasizes G22553 as a pivotal target for T2D treatment, supported by its role in metabolic regulation and strong correlation with T2D. Enhanced understanding of its interaction with other regulatory genes such as G23245 and G19122 could lead to synergistic therapeutic strategies.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, evidence from 2 datasets supports its role.
- Key pathways involved: Metabolic regulation, insulin signaling, glucose homeostasis.
- WGCNA module role: Primary Driver in the black module.
- Regulating TFs: None identified specifically for this gene in the data.

**MECHANISM_HYPOTHESIS:** G22553 likely functions within a network of metabolic pathways that regulate glucose homeostasis and insulin action. Its modulation may enhance not only its own activity but also the activity of G23245 and G19122, which provide complementary mechanisms for improving insulin sensitivity. The interaction with these genes suggests a multi-faceted approach to enhancing metabolic outcomes in T2D, providing a robust therapeutic target.

**TISSUE_RATIONALE:** The liver and adipose tissues remain the most relevant targets for G22553, as they are central to glucose metabolism and insulin sensitivity, which are crucial in the context of T2D.

**THERAPEUTIC_APPROACH:** The therapeutic approach would involve the development of small molecule activators targeting G22553, potentially in combination with modulators of G23245 and G19122 to maximize therapeutic efficacy.

**PREDICTED_OUTCOME:** Modulating G22553 alongside its regulatory partners is expected to significantly improve glycemic control, reduce insulin resistance, and enhance overall metabolic health in T2D patients.

**RANKING_RATIONALE:** G22553 is ranked highest due to its pivotal role in metabolic regulation and strong correlation with T2D. G23245 and G33764 follow closely due to their complementary functions in promoting insulin sensitivity and supporting insulin signaling, respectively. G19122 and G19943 are included for their potential roles in enhancing the overall therapeutic strategy.

**CONFIDENCE:** HIGH based on the strength of data support and integration across multiple evidence types.
2026-02-10 19:21:45,585 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:21:45,586 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:21:45,590 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:21:45,600 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:21:45,608 - root - INFO -   -> Created mutated offspring: '** Enhanced Mechanistic Insights for Tar...'
2026-02-10 19:21:45,610 - root - INFO - Crossover 2/18: parents 'Enhanced Mechanistic Insights ...' x '** Identification of Novel Dru...'
2026-02-10 19:21:45,692 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:22:24,437 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:22:24,443 - root - INFO - TOKEN_USAGE: input=40155, output=760, total=40915, cost=$0.006479
2026-02-10 19:22:24,443 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:22:24,444 - root - INFO - 
**TITLE:** Comprehensive Targeting of Metabolic Regulation Pathways in Type 2 Diabetes  

**RANKED_TARGETS:**  
1. **G33764** | Score: **4.0** | This enzyme is a primary driver in metabolic pathways and has significant implications for enhancing insulin sensitivity and glucose metabolism.  
2. **G23245** | Score: **4.0** | As a primary driver in the T2D co-expression network, it is essential for insulin signaling and glucose homeostasis, making it a critical therapeutic target.  
3. **G00484** | Score: **4.0** | This transcription factor is known to regulate pathways associated with insulin signaling, potentially enhancing the therapeutic effects of G33764 and G23245.  
4. **G19122** | Score: **3.0** | A major regulator with consistent evidence across datasets, suggesting its importance in insulin signaling and metabolic regulation, complementing the effects of the top targets.  
5. **G20274** | Score: **3.0** | With a negative log2FC and involvement in insulin resistance mechanisms, this enzyme represents an additional target for therapeutic intervention in the context of T2D.

**PRIMARY_TARGET:** **G33764**  

**SUMMARY:** This hypothesis posits that targeting G33764 can significantly enhance insulin sensitivity and glucose metabolism in Type 2 Diabetes (T2D). The combination of G33764 with G23245 and G00484 provides a robust therapeutic strategy that integrates enzymatic action, metabolic regulation, and transcriptional control, addressing the multifaceted nature of T2D.

**DATA_EVIDENCE:**  
- Priority Score: **4.0/17 for primary target**  
- Cross-dataset consistency: **Yes, 2 datasets**  
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism**  
- WGCNA module role: **Primary Driver in the dark grey module**  
- Regulating TFs: **G00484 acts as a regulator in related pathways.**

**MECHANISM_HYPOTHESIS:** G33764 is hypothesized to play a critical role in enhancing insulin sensitivity through its enzymatic activity in lipid metabolism, while G23245 acts as a central regulator in glucose homeostasis. The interaction with G00484, a transcription factor, suggests a synergistic mechanism that could enhance insulin signaling pathways. This combined approach addresses insulin resistance and metabolic dysregulation prevalent in T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this hypothesis are adipose tissue, pancreatic -cells, and muscle tissues, as they are crucial for insulin secretion, action, and overall glucose regulation, making them ideal targets for therapeutic intervention.

**THERAPEUTIC_APPROACH:** The therapeutic approach will involve small molecule activation of G33764 to enhance its enzymatic activity, alongside modulation of G23245 and G00484 to amplify insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Modulating G33764, along with synergistic targeting of G23245 and G00484, is expected to enhance insulin sensitivity, reduce blood glucose levels, and potentially reverse some metabolic dysfunctions associated with Type 2 Diabetes.

**RANKING_RATIONALE:** G33764 is ranked highest due to its strong evidence and critical role in metabolic pathways relevant to T2D, followed closely by G23245 which has robust connections to insulin signaling. G00484 is ranked next for its regulatory role, while G19122 and G20274 provide additional support and insights into managing insulin resistance and metabolic dysfunction.

**CONFIDENCE:** **HIGH** based on the robustness of the data supporting the roles of these targets in diabetes-related pathways.
2026-02-10 19:22:24,446 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:22:24,446 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:22:24,446 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:22:24,449 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:22:24,450 - root - INFO -   -> Created offspring: '** Comprehensive Targeting of Metabolic ...'
2026-02-10 19:22:24,450 - root - INFO - Crossover 3/18: parents 'Integrated Target Hypothesis f...' x 'Exploring Alternative Targets ...'
2026-02-10 19:22:24,499 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:23:05,996 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:23:06,006 - root - INFO - TOKEN_USAGE: input=40209, output=773, total=40982, cost=$0.006495
2026-02-10 19:23:06,006 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:23:06,007 - root - INFO - 
### TITLE: Comprehensive Target Hypothesis for Optimized Type 2 Diabetes Treatment

#### RANKED_TARGETS:
1. **G04436** | Score: 4.0 | This enzyme is a major regulator of metabolic pathways related to glucose homeostasis and is supported by multiple lines of evidence indicating its critical role in T2D.
2. **G33764** | Score: 4.0 | As a primary driver in insulin resistance mechanisms, its significant dysregulation across datasets highlights its importance in T2D pathology.
3. **G22553** | Score: 4.0 | Identified as a primary driver in co-expression networks, it plays a key role in T2D-related pathways, complementing the roles of G04436 and G33764.
4. **G19122** | Score: 3.0 | This enzyme is implicated in metabolic dysregulation and has a strong negative log2FC, indicating a relevant role in T2D mechanisms.
5. **G20274** | Score: 3.0 | As a major regulator in insulin signaling pathways, its dysregulation suggests a significant contribution to T2D pathophysiology.

#### PRIMARY_TARGET: G04436

### SUMMARY:
The hypothesis integrates key insights from both parent hypotheses by prioritizing G04436 as the central target due to its critical role in glucose metabolism and insulin sensitivity. The inclusion of G33764 and G22553 addresses various mechanisms of insulin resistance, while G19122 and G20274 provide further support for the metabolic dysregulation observed in T2D.

### DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Metabolism, Insulin signaling, Lipid metabolism
- WGCNA module role: G04436 and G33764 are primary drivers in relevant modules
- Regulating TFs: 12 identified transcription factors associated with G04436

### MECHANISM_HYPOTHESIS:
G04436 is hypothesized to modulate essential metabolic pathways that influence insulin sensitivity and glucose homeostasis. It interacts with G33764 and G22553 to address the multifaceted nature of insulin resistance, while G19122 and G20274 further enhance the understanding of metabolic dysregulation in T2D. This comprehensive approach aims to address both the direct and indirect effects of T2D pathophysiology.

### TISSUE_RATIONALE:
The most relevant tissues include pancreatic -cells, liver, and adipose tissue, as they are directly involved in glucose metabolism and insulin signaling, which are critical factors in T2D pathology.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the inhibition of G04436 and modulation of G33764 and G22553, combined with the consideration of G19122 and G20274, to enhance insulin sensitivity and restore glucose homeostasis. A small molecule approach targeting these enzymes is expected to be effective.

### PREDICTED_OUTCOME:
Modulating these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and potentially reverse aspects of Type 2 Diabetes pathology, leading to improved metabolic control and patient outcomes.

### RANKING_RATIONALE:
G04436 was ranked first due to its robust evidence from multiple datasets and its pivotal role in metabolic pathways critical for T2D. G33764 and G22553 followed as they are also key drivers in insulin resistance mechanisms, while G19122 and G20274 were included to provide additional context for metabolic dysregulation and enhance the overall strength of the hypothesis.

### CONFIDENCE: HIGH based on strong multi-evidence support and literature context linking these functions to T2D pathophysiology.
2026-02-10 19:23:06,008 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:23:06,009 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:23:06,023 - root - INFO -   -> Created offspring: 'Comprehensive Target Hypothesis for Opti...'
2026-02-10 19:23:06,025 - root - INFO - Crossover 4/18: parents 'Exploring Alternative Targets ...' x '** Identification of Novel Dru...'
2026-02-10 19:23:06,133 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:23:42,502 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:23:42,542 - root - INFO - TOKEN_USAGE: input=40051, output=747, total=40798, cost=$0.006456
2026-02-10 19:23:42,543 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:23:42,543 - root - INFO - 
### TITLE: Integrative Targeting of Lipid Metabolism and Insulin Signaling for Enhanced Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | This enzyme plays a critical regulatory role in lipid metabolism and insulin signaling, supported by strong evidence across multiple datasets.
2. **G33764** | Score: **4.0** | Another key enzyme that directly influences insulin sensitivity and glucose metabolism, validated through diverse evidence types.
3. **G22553** | Score: **4.0** | A primary driver in metabolic pathways, indicating its essential role in T2D mechanisms and potential therapeutic targeting.
4. **G19122** | Score: **3.0** | A major regulator that has shown consistent evidence in insulin signaling pathways, providing a complementary approach to the primary targets.
5. **G20274** | Score: **3.0** | This target has a negative log2FC suggesting its involvement in insulin resistance mechanisms, making it relevant for addressing T2D.

#### PRIMARY_TARGET: G04436

### SUMMARY:
The proposed hypothesis integrates the mechanistic insights from both parent hypotheses, focusing on G04436 and G33764 as primary therapeutic targets. By targeting these enzymes, which are crucial for lipid metabolism and insulin signaling, we can address multiple pathways involved in Type 2 Diabetes, enhancing therapeutic potential and improving patient outcomes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways
- **WGCNA module role**: G04436 and G33764 are primary drivers in modules negatively correlated with T2D.
- **Regulating TFs**: G04436 is regulated by 12 transcription factors, enhancing its potential as a therapeutic target.

### MECHANISM_HYPOTHESIS:
G04436 and G33764 are both critical regulators of lipid metabolism and insulin signaling, which are disrupted in Type 2 Diabetes. By enhancing the enzymatic activity of G04436, we can improve lipid profiles and insulin sensitivity, while modulating G33764 can further amplify these effects, leading to better glucose homeostasis and reduced insulin resistance. This integrative approach addresses the multifactorial nature of T2D pathophysiology.

### TISSUE_RATIONALE:
The most relevant tissues for targeting G04436 and G33764 include the liver and adipose tissue, where they play pivotal roles in lipid metabolism and insulin responsiveness. Focusing interventions in these tissues is crucial for enhancing metabolic regulation and improving overall insulin signaling.

### THERAPEUTIC_APPROACH:
The therapeutic strategy would involve the small molecule activation of both G04436 and G33764, aiming to enhance their enzymatic functions and improve metabolic homeostasis in patients with Type 2 Diabetes.

### PREDICTED_OUTCOME:
Modulating G04436 and G33764 is expected to significantly enhance insulin sensitivity, improve lipid metabolism, and contribute to better glucose regulation, potentially reversing T2D progression and alleviating associated metabolic dysfunctions.

### RANKING_RATIONALE:
G04436 and G33764 rank highest due to their extensive evidence supporting their roles in T2D pathways and their potential for therapeutic modulation. G22553 follows as it provides additional support in metabolic pathways, while G19122 and G20274 add depth by targeting related mechanisms in insulin signaling and resistance.

### CONFIDENCE: HIGH based on the robustness of the data supporting the selected targets and their roles in diabetes-related pathways.
2026-02-10 19:23:42,543 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:23:42,544 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:23:42,548 - root - INFO -   -> Created offspring: 'Integrative Targeting of Lipid Metabolis...'
2026-02-10 19:23:42,548 - root - INFO - Mutation 5/18: parent '** Enhancing Insulin Sensitivi...'
2026-02-10 19:23:42,549 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:23:42,656 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:24:13,806 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:24:13,813 - root - INFO - TOKEN_USAGE: input=39468, output=747, total=40215, cost=$0.006368
2026-02-10 19:24:13,813 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:24:13,813 - root - INFO - 
**TITLE:** Enhancing Insulin Sensitivity in Muscle Tissue through Targeted Modulation of G19943 and G22553

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0/17** | As a hub component in the silver module, G19943 plays a crucial role in the insulin signaling pathway, making it fundamental for muscle tissue metabolism.
2. **G22553** | Score: **4.0/17** | This primary driver in the black module is highly correlated with insulin regulation and metabolic pathways, complementing G19943 in enhancing muscle insulin sensitivity.
3. **G23245** | Score: **4.0/17** | As a primary driver in the silver module, it exhibits a negative correlation with T2D, suggesting it may significantly influence muscle insulin action.
4. **G27976** | Score: **3.0/17** | A major regulator in the silver module that influences muscle glucose uptake, providing additional support for insulin signaling mechanisms.
5. **G19122** | Score: **3.0/17** | This major regulator in the black module is involved in insulin signaling and glucose metabolism, offering a supportive role in enhancing insulin sensitivity.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The mutated hypothesis retains G19943 as the primary target to enhance insulin sensitivity in muscle tissue while integrating G22553 as a complementary target. Together, these genes may synergistically restore insulin signaling pathways and improve glucose homeostasis in Type 2 Diabetes patients.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for G19943**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism**
- WGCNA module role: **Hub component in silver module (G19943), Primary driver in black module (G22553)**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** G19943 serves as a central hub in the insulin signaling pathway, while G22553, as a primary driver, enhances this effect by modulating additional insulin regulatory mechanisms in muscle tissue. By targeting both genes, we could optimize the restoration of insulin signaling cascades, promoting glucose uptake and improving insulin sensitivity.

**TISSUE_RATIONALE:** Muscle tissue is essential for glucose uptake, especially in response to insulin. Targeting G19943 and G22553 in muscle cells could significantly improve insulin signaling and metabolic control, leading to reduced hyperglycemia and enhanced metabolic stability in Type 2 Diabetes patients.

**THERAPEUTIC_APPROACH:** The approach will involve small molecule modulation of G19943 and G22553 to increase their activity within the insulin signaling pathways, thereby enhancing muscle insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of G19943 and G22553 is expected to lead to improved glucose uptake in muscle tissue, decreased blood glucose levels, and enhanced metabolic regulation in individuals with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores and their specific roles in muscle metabolism. G19943 is prioritized due to its central hub position in insulin signaling, while G22553 is included for its complementary role as a primary driver that can enhance metabolic pathways. G23245 is also highlighted for its negative correlation with T2D, followed by G27976 and G19122 for their regulatory influences on glucose metabolism and insulin action.

**CONFIDENCE:** **HIGH** based on robust data support and the relevance of the identified pathways to the pathology of Type 2 Diabetes.
2026-02-10 19:24:13,816 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:24:13,816 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:24:13,817 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:24:13,821 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:24:13,821 - root - INFO -   -> Created mutated offspring: '** Enhancing Insulin Sensitivity in Musc...'
2026-02-10 19:24:13,822 - root - INFO - Crossover 6/18: parents 'Exploring Alternative Targets ...' x '** Enhanced Therapeutic Target...'
2026-02-10 19:24:14,061 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:24:51,947 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:24:51,953 - root - INFO - TOKEN_USAGE: input=40148, output=769, total=40917, cost=$0.006484
2026-02-10 19:24:51,953 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:24:51,953 - root - INFO - 
### TITLE: Comprehensive Modulation of Key Drivers in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | This gene is a primary driver in T2D pathways, significantly modulating insulin signaling and glucose metabolism.
2. **G23245** | Score: **4.0** | As a primary driver, it complements G22553 by enhancing glucose uptake and insulin sensitivity, making it essential for a dual-target approach.
3. **G04436** | Score: **4.0** | This enzyme has multiple regulatory transcription factors and plays a crucial role in lipid metabolism and insulin signaling, reinforcing metabolic control.
4. **G33764** | Score: **4.0** | Identified as a primary driver, it has a notable regulatory role in metabolic pathways, providing additional support in optimizing therapeutic outcomes.
5. **G19122** | Score: **3.0** | This major regulator is involved in critical metabolic pathways and can enhance the efficacy of G22553 and G23245 modulation.

#### PRIMARY_TARGET: G22553

### SUMMARY:
This hypothesis proposes a comprehensive therapeutic strategy by simultaneously targeting G22553 and G23245, both of which are primary drivers in T2D-related pathways, while also incorporating G04436, a critical regulator of lipid metabolism and insulin signaling. By leveraging the strengths of these targets, we aim to enhance glucose homeostasis and insulin sensitivity, addressing the multifaceted nature of Type 2 Diabetes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism
- **WGCNA module role**: Primary driver in relevant modules for G22553, G23245, and G33764
- **Regulating TFs**: Multiple transcription factors identified for G04436

### MECHANISM_HYPOTHESIS:
The activation of G22553 is expected to enhance insulin signaling pathways, potentially reversing insulin resistance, while G23245 will synergistically improve glucose uptake in peripheral tissues. Additionally, modulating G04436 will facilitate improved lipid metabolism and restore insulin signaling, addressing both insulin sensitivity and glucose regulation. This comprehensive approach aims to counteract the metabolic dysregulation observed in T2D.

### TISSUE_RATIONALE:
The primary tissues of interest include pancreatic beta-cells, muscle, liver, and adipose tissue. These tissues are integral to insulin sensitivity, glucose uptake, and lipid metabolism, making them critical targets for therapeutic interventions aimed at reversing T2D.

### THERAPEUTIC_APPROACH:
The proposed approach involves small molecule activation of G22553 and G23245 to enhance their respective functions, alongside modulation of G04436 to counteract negative feedback mechanisms impacting metabolic pathways.

### PREDICTED_OUTCOME:
The combined modulation of G22553, G23245, and G04436 is anticipated to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control, leading to superior management of Type 2 Diabetes compared to targeting individual pathways.

### RANKING_RATIONALE:
The targets are ranked based on their roles as primary drivers in T2D pathways and their evidence strength across multiple datasets. G22553 leads due to its well-established role in insulin signaling, followed by G23245 which complements its function. G04436 is included for its regulatory significance, while G33764 and G19122 provide additional support without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 19:24:51,954 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:24:51,954 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:24:51,957 - root - INFO -   -> Created offspring: 'Comprehensive Modulation of Key Drivers ...'
2026-02-10 19:24:51,958 - root - INFO - Mutation 7/18: parent '** Identification of Novel Dru...'
2026-02-10 19:24:51,958 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:24:51,993 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:25:22,889 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:25:22,892 - root - INFO - TOKEN_USAGE: input=39390, output=674, total=40064, cost=$0.006313
2026-02-10 19:25:22,892 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:25:22,892 - root - INFO - 
**TITLE:** Targeting G33764 in Muscle Tissue for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G33764** | Score: **4.0/17** | This enzyme is a primary driver in T2D pathways and shows significant biological relevance in muscle tissue, crucial for glucose metabolism.
2. **G19122** | Score: **3.0/17** | A major regulator involved in insulin signaling, with consistent evidence across datasets highlighting its importance in muscle insulin responsiveness.
3. **G20274** | Score: **3.0/17** | An enzyme with evidence suggesting its negative log2FC indicates potential contribution to insulin resistance mechanisms specifically in muscle tissue.
4. **G22512** | Score: **4.0/17** | An unknown gene with promising evidence that could represent an uncharacterized target in muscle-related T2D pathways.
5. **G26720** | Score: **4.0/17** | An unknown gene that has shown positive log2FC, indicating a potential role in enhancing muscle insulin sensitivity.

**PRIMARY_TARGET:** G33764

**SUMMARY:** The hypothesis posits that targeting G33764 in muscle tissue could significantly enhance insulin sensitivity and glucose uptake in individuals with Type 2 Diabetes. The enzyme's role as a primary driver in relevant metabolic pathways makes it a prime candidate for therapeutic modulation.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism**
- WGCNA module role: **Primary Driver**
- Regulating TFs: **None identified**

**MECHANISM_HYPOTHESIS:** G33764 is hypothesized to play a pivotal role in facilitating glucose uptake in muscle tissues by modulating insulin signaling pathways. By enhancing the activity of G33764, we may improve insulin sensitivity and counteract the mechanisms of insulin resistance that are prevalent in Type 2 Diabetes.

**TISSUE_RATIONALE:** Muscle tissue is crucial for glucose homeostasis, as it accounts for a significant portion of glucose disposal in response to insulin. Enhancing the function of G33764 could directly improve glucose uptake and utilization in this tissue, thus addressing one of the key defects in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The proposed approach would involve small molecule activation of G33764 to enhance its enzymatic activity in muscle tissue, thereby promoting improved glucose metabolism and insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating G33764 is expected to significantly enhance insulin sensitivity in muscle tissue, leading to reduced blood glucose levels and improvement in the metabolic dysfunctions associated with Type 2 Diabetes.

**RANKING_RATIONALE:** G33764 was ranked highest due to its strong evidence and critical role in pathways relevant to T2D, particularly within muscle tissue. G19122 and G20274 were also included due to their roles as regulators in insulin signaling, while G22512 and G26720 present uncharacterized potential that warrants further investigation.

**CONFIDENCE:** **HIGH** based on the robustness of the data supporting G33764's role in diabetes-related pathways and its significance in muscle tissue.
2026-02-10 19:25:22,892 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:25:22,892 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:25:22,893 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:25:22,894 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:25:22,894 - root - INFO -   -> Created mutated offspring: '** Targeting G33764 in Muscle Tissue for...'
2026-02-10 19:25:22,894 - root - INFO - Crossover 8/18: parents 'Enhanced Mechanistic Insights ...' x '** Identification of Novel Dru...'
2026-02-10 19:25:22,931 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:25:38,310 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:25:38,315 - root - INFO - TOKEN_USAGE: input=40208, output=750, total=40958, cost=$0.006481
2026-02-10 19:25:38,316 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:25:38,316 - root - INFO - 
**TITLE:** Integrated Target Hypothesis for Enhancing Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | Identified as a hub component in co-expression networks with a strong correlation to T2D pathways, suggesting a pivotal role in metabolic regulation.
2. **G33764** | Score: **4.0** | An enzyme central to lipid metabolism and insulin signaling, with significant evidence supporting its therapeutic potential for improving insulin sensitivity.
3. **G19122** | Score: **3.0** | A major regulator with consistent evidence indicating its importance in insulin signaling, making it a valuable complementary target.
4. **G22553** | Score: **4.0** | A primary driver in the co-expression network, contributing to the regulation of key metabolic pathways related to T2D.
5. **G04436** | Score: **4.0** | An enzyme with significant transcriptional regulation roles, indicating potential involvement in metabolic pathways relevant to T2D.

**PRIMARY_TARGET:** G19943

**SUMMARY:** The integration of G19943, G33764, and G19122 as primary targets leverages their distinct yet complementary roles in lipid metabolism and insulin signaling pathways, addressing both the central regulatory mechanisms and peripheral metabolic responses in Type 2 Diabetes. Enhanced modulation of these targets is anticipated to yield significant therapeutic benefits.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Lipid metabolism, Insulin signaling pathways, Metabolic regulation pathways**
- WGCNA module role: **Hub component in a module negatively correlated with T2D**
- Regulating TFs: **Potential interactions with regulatory transcription factors not yet identified.**

**MECHANISM_HYPOTHESIS:** G19943, as a hub component, regulates lipid metabolism and insulin signaling, while G33764 enhances enzymatic functions that promote insulin sensitivity. G19122 contributes to the modulation of insulin signaling pathways, creating a comprehensive framework for addressing the metabolic dysregulation seen in T2D. By targeting these genes, we can potentially enhance metabolic control, reduce insulin resistance, and mitigate the progression of T2D.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include pancreatic -cells, where insulin secretion occurs, and adipose tissue, which is crucial for insulin action and lipid metabolism. Targeting these areas can improve glucose homeostasis and overall metabolic health.

**THERAPEUTIC_APPROACH:** The strategy would involve the small molecule activation of G19943 and G33764, aiming to enhance their functions within their respective pathways, while potentially modulating G19122 for improved insulin signaling.

**PREDICTED_OUTCOME:** Enhancing the activity of the proposed targets is expected to significantly improve insulin sensitivity, optimize glucose metabolism, and provide a therapeutic benefit that could reverse or slow the progression of Type 2 Diabetes.

**RANKING_RATIONALE:** G19943 was ranked highest due to its central role in the co-expression network and its negative correlation with T2D, followed by G33764, which also plays a critical role in metabolic pathways. G19122 was included as a complementary target due to its consistent evidence in insulin signaling, while G22553 and G04436, despite being strong candidates, are positioned lower due to their more specialized roles compared to the top three.

**CONFIDENCE:** **HIGH** based on the robustness of data supporting the roles of G19943 and G33764 in diabetes-related pathways.
2026-02-10 19:25:38,317 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:25:38,317 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:25:38,317 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:25:38,320 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:25:38,320 - root - INFO -   -> Created offspring: '** Integrated Target Hypothesis for Enha...'
2026-02-10 19:25:38,320 - root - INFO - Crossover 9/18: parents '** Enhanced Targeting of Insul...' x '** Identification of Promising...'
2026-02-10 19:25:38,385 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:25:58,982 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:25:58,987 - root - INFO - TOKEN_USAGE: input=40180, output=793, total=40973, cost=$0.006503
2026-02-10 19:25:58,987 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:25:58,987 - root - INFO - 
### TITLE: Integrated Approach for Targeting Insulin Resistance in Type 2 Diabetes via Multi-Omics Validation and Pathway Modulation

---

### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | This gene is a hub component in the gene network related to T2D, showing strong evidence across multiple datasets, indicating its central role in insulin signaling pathways.
2. **G22553** | Score: **4.0** | A primary driver in the co-expression network, its significant correlation with T2D highlights its potential as a therapeutic target in insulin resistance.
3. **G23245** | Score: **4.0** | Another primary driver implicated in pathways relevant to T2D, suggesting its critical role in metabolic dysregulation and potential for therapeutic intervention.
4. **G22512** | Score: **4.0** | This gene maintains high expression in insulin-sensitive tissues, indicating its potential to enhance insulin signaling and improve glucose metabolism.
5. **G19122** | Score: **3.0** | As a major regulator in the insulin signaling pathway, targeting this gene could complement the modulation of the other primary targets to enhance overall metabolic regulation.

---

### PRIMARY_TARGET: **G19943**

### SUMMARY: 
The proposed hypothesis integrates insights from both parent hypotheses, emphasizing the role of G19943 as a central hub in the insulin signaling network. By prioritizing G19943 and other key drivers such as G22553 and G23245, this hypothesis aims to address insulin resistance in T2D through a comprehensive approach that combines multi-omics data validation and pathway modulation.

### DATA_EVIDENCE:
- Priority Score: **4.0/17** for primary target
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, inflammatory response pathways, glucose metabolism**
- WGCNA module role: **Hub Component in the silver module**
- Regulating TFs: **None reported, but TF activity is critical for gene regulation in T2D**

### MECHANISM_HYPOTHESIS:
The mechanism suggests that G19943 functions as a critical hub in the insulin signaling pathway, where its modulation could improve insulin sensitivity in peripheral tissues. Combining insights from parent hypotheses, the hypothesis posits that targeting G19943 alongside other primary drivers like G22553 and G23245 could mitigate inflammatory stress responses and enhance metabolic function. This integrated approach leverages the co-expression networks and transcription factor interactions around these genes to optimize therapeutic outcomes.

### TISSUE_RATIONALE:
The relevant tissues for this hypothesis include pancreatic -cells, skeletal muscle, and adipose tissue, where insulin signaling is crucial for glucose homeostasis and metabolic regulation. Targeting these genes in these tissues may lead to enhanced insulin response and reduction in hyperglycemia.

### THERAPEUTIC_APPROACH:
The therapeutic approach will focus on small molecule modulation to enhance the activity of G19943 and its co-targets, effectively restoring and improving insulin signaling pathways disrupted in T2D.

### PREDICTED_OUTCOME:
Modulation of the primary target, G19943, along with the co-targets, is expected to lead to improved insulin sensitivity, reduced blood glucose levels, and better overall metabolic control in patients with Type 2 Diabetes.

### RANKING_RATIONALE:
The targets were ranked based on their strong evidence of involvement in insulin signaling and metabolic regulation, with G19943 leading due to its central role in the gene network. G22553 and G23245 were included for their significant contributions to co-expression networks, while G22512 and G19122 complete the ranking as they support the mechanistic insights in enhancing insulin sensitivity.

### CONFIDENCE: **HIGH** based on the strength of data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:25:58,989 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:25:58,990 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:25:58,992 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:25:58,998 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:25:58,999 - root - INFO -   -> Created offspring: 'Integrated Approach for Targeting Insuli...'
2026-02-10 19:25:58,999 - root - INFO - Mutation 10/18: parent 'Enhanced Mechanistic Insights ...'
2026-02-10 19:25:58,999 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:25:59,057 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:26:29,555 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:26:29,562 - root - INFO - TOKEN_USAGE: input=39557, output=769, total=40326, cost=$0.006395
2026-02-10 19:26:29,562 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:26:29,562 - root - INFO - 
### TITLE: Therapeutic Activation of G19943 and Synergistic Modulation with G04436 in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | As a hub component in the co-expression network, G19943 serves a central role in metabolic pathways related to T2D, making it a prime target for activation to enhance insulin sensitivity.
2. **G04436** | Score: **4.0** | This enzyme, while less central than G19943, shows significant transcriptional regulation and potential for metabolic pathway modulation, complementing the effects of G19943 activation.
3. **G22553** | Score: **4.0** | Though a primary driver in T2D pathways, it lacks the broad network influence of G19943, positioning it as a secondary target for therapeutic synergy.
4. **G23245** | Score: **4.0** | Another primary driver with substantial involvement in T2D, but with a narrower functional implication compared to G19943, making it a less favorable primary target.
5. **G33764** | Score: **4.0** | This enzyme is essential for metabolic processes but lacks the same level of evidence as G19943 and G04436, making it a lower priority in this therapeutic context.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This mutated hypothesis proposes the therapeutic activation of G19943 to enhance its role in lipid metabolism and insulin signaling in T2D. Additionally, we explore a combination approach with G04436 to further strengthen metabolic regulation and improve insulin sensitivity, leveraging their respective roles in key pathways.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways
- **WGCNA module role**: Hub component in a module negatively correlated with T2D
- **Regulating TFs**: Potential interactions with transcription factors that may influence metabolic regulation.

### MECHANISM_HYPOTHESIS:
The proposed mechanism involves the activation of G19943 to enhance its function within insulin signaling and lipid metabolism pathways, addressing the metabolic dysfunction characteristic of T2D. This activation is expected to improve insulin sensitivity and glucose homeostasis. Concurrently, modulating G04436 can complement this effect by further enhancing metabolic regulation through its enzymatic activity, thus offering a synergistic therapeutic approach.

### TISSUE_RATIONALE:
The most relevant tissues for targeting G19943 and G04436 include pancreatic -cells and adipose tissue, where they can directly influence insulin secretion and action. Enhancing G19943 activity may improve -cell function and insulin sensitivity, while G04436 can support overall metabolic homeostasis.

### THERAPEUTIC_APPROACH:
The therapeutic strategy will involve small molecule activation of G19943, potentially combined with modulation of G04436. This dual approach aims to restore metabolic balance and improve insulin sensitivity, making it a promising candidate for T2D management.

### PREDICTED_OUTCOME:
Activating G19943 and synergistically modulating G04436 is anticipated to enhance insulin sensitivity, improve glucose metabolism, and provide significant therapeutic benefits that may reverse or slow the progression of T2D.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central network role and direct correlation with T2D pathways. G04436 follows as a strong candidate for synergistic modulation, while G22553 and G23245 are less central but still relevant. G33764 ranks lower due to its more specialized role in metabolic pathways.

### CONFIDENCE: HIGH
2026-02-10 19:26:29,563 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:26:29,563 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:26:29,567 - root - INFO -   -> Created mutated offspring: 'Therapeutic Activation of G19943 and Syn...'
2026-02-10 19:26:29,567 - root - INFO - Crossover 11/18: parents 'Enhanced Mechanistic Insights ...' x '** Tissue-Specific Target Iden...'
2026-02-10 19:26:29,638 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:27:09,838 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:27:09,845 - root - INFO - TOKEN_USAGE: input=40324, output=863, total=41187, cost=$0.006566
2026-02-10 19:27:09,845 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:27:09,845 - root - INFO - 
### TITLE: Integrative Targeting of G19943 and G19122 for Enhanced Therapeutic Strategies in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Recognized as a hub component in the co-expression network, it plays a central role in T2D pathways, linking lipid metabolism and insulin signaling.
2. **G19122** | Score: **3.0** | Identified as a major regulator in adipose tissue, it significantly influences insulin sensitivity and glucose metabolism, complementing G19943's centrality in metabolic regulation.
3. **G33764** | Score: **4.0** | This enzyme is crucial in metabolic pathways related to T2D, with implications in both lipid metabolism and insulin signaling, making it a valuable secondary target.
4. **G22553** | Score: **4.0** | As a primary driver in the co-expression network, it supports T2D-related pathways, although its influence is not as extensive as G19943.
5. **G20274** | Score: **3.0** | An enzyme linked to insulin signaling pathways, it has significant potential for modulating glucose metabolism in adipose tissue, thus enhancing the overall therapeutic strategy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis proposes a multi-targeted approach to Type 2 Diabetes therapy by focusing on G19943 as the primary target due to its central role in metabolic regulation and complementing it with G19122, which is critical for insulin sensitivity in adipose tissue. Additional targets such as G33764 and G20274 are included to further enhance the therapeutic strategy, addressing weaknesses in both parent hypotheses by providing a comprehensive network of pathways involved in T2D.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Inflammatory response pathways, Metabolic regulation in adipose tissue
- **WGCNA module role**: Hub component and major regulator in pathways negatively correlated with T2D
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic and inflammatory pathways.

### MECHANISM_HYPOTHESIS:
G19943 is hypothesized to function as a master regulator of lipid metabolism and insulin signaling, thereby influencing T2D pathophysiology significantly. Its interaction with G19122 enhances insulin sensitivity specifically in adipose tissue, addressing a critical aspect of metabolic regulation. Additionally, G33764 and G20274 support the modulation of insulin responsiveness and glucose uptake, reinforcing the overall effectiveness of the therapeutic approach. This integrated mechanism ensures a multifaceted attack on the various aspects of Type 2 Diabetes.

### TISSUE_RATIONALE:
The primary tissues of interest include pancreatic -cells and adipose tissue. G19943's regulation of metabolic pathways in the pancreas promotes insulin secretion and sensitivity, while G19122's role in adipose tissue directly affects insulin action and lipid storage, crucial for maintaining glucose homeostasis.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the activation of G19943 and G19122 using small molecule modulators that enhance their regulatory functions, leading to improved insulin signaling and metabolic outcomes in T2D management.

### PREDICTED_OUTCOME:
Modulating G19943 and G19122 is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could reverse or slow the progression of Type 2 Diabetes.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central role in the co-expression network and its comprehensive metabolic influence. G19122 follows closely, addressing insulin sensitivity in adipose tissue. G33764 and G22553 provide additional metabolic support, while G20274 rounds out the strategy as a relevant target linked to insulin signaling pathways. This ranking reflects a strategic combination of targets that maximizes therapeutic potential.

### CONFIDENCE: HIGH based on the comprehensive evidence supporting G19943's and G19122's roles in metabolic regulation and the additional support from other targets.
2026-02-10 19:27:09,849 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:27:09,850 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:27:09,865 - root - INFO -   -> Created offspring: 'Integrative Targeting of G19943 and G191...'
2026-02-10 19:27:09,866 - root - INFO - Crossover 12/18: parents 'Exploring Alternative Targets ...' x 'Enhanced Mechanistic Insights ...'
2026-02-10 19:27:09,917 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:27:48,449 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:27:48,457 - root - INFO - TOKEN_USAGE: input=40203, output=780, total=40983, cost=$0.006498
2026-02-10 19:27:48,457 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:27:48,457 - root - INFO - 
### TITLE: Synergistic Targeting of Metabolic Pathways for Enhanced Management of Type 2 Diabetes

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | An enzyme with significant regulatory capabilities in lipid metabolism and insulin signaling, supported by multiple transcription factors.
2. **G33764** | Score: **4.0** | Identified as a primary driver in T2D pathways, exhibiting consistent differential expression and crucial metabolic regulation.
3. **G19943** | Score: **4.0** | A hub component in co-expression networks with strong ties to T2D pathology, enhancing the regulatory network when combined with G04436 and G33764.
4. **G22553** | Score: **4.0** | Acts as a primary driver in the co-expression network, providing additional support for metabolic processes related to T2D.
5. **G23245** | Score: **4.0** | Another primary driver showing significant evidence for its role in T2D, contributing to the overall network robustness.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This hypothesis posits that targeting G04436, in conjunction with G33764 and G19943, can synergistically enhance metabolic regulation in Type 2 Diabetes. By leveraging their roles in lipid metabolism and insulin signaling, this multi-target approach aims to create a more comprehensive therapeutic strategy compared to targeting individual pathways.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 (for G04436)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Metabolic regulation
- **WGCNA module role**: G04436 and G33764 both act as primary drivers in negatively correlated modules with T2D.
- **Regulating TFs**: G04436 is regulated by 12 transcription factors, enhancing its therapeutic potential.

### MECHANISM_HYPOTHESIS:
The combined modulation of G04436 and G33764 is hypothesized to enhance lipid metabolism and insulin signaling, addressing key metabolic disruptions in T2D. G19943 serves as a critical hub, integrating signals from both G04436 and G33764, thereby improving the efficacy of therapeutic interventions. This multifaceted approach targets essential metabolic pathways collaboratively, potentially leading to improved insulin sensitivity and glucose homeostasis.

### TISSUE_RATIONALE:
The tissues of primary interest include the liver and adipose tissue, where G04436 and G33764 are crucial for lipid metabolism and insulin sensitivity. By focusing on these tissues, the therapeutic strategy aims to restore normal metabolic functions that are often disrupted in T2D patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic approach involves the activation of G04436 and G33764 through small molecule modulators, potentially combined with strategies to enhance G19943 activity. This dual-target modulation aims to restore metabolic homeostasis and improve insulin sensitivity.

### PREDICTED_OUTCOME:
Modulation of G04436 and G33764 is expected to lead to significant improvements in lipid metabolism and insulin sensitivity, ultimately resulting in better glucose regulation and a reduction in T2D progression.

### RANKING_RATIONALE:
The targets were ranked based on their strong evidence support, their roles as primary drivers or hubs in metabolic pathways, and their potential to work synergistically when combined. G04436 is prioritized for its comprehensive regulatory role, followed closely by G33764 and G19943 for their significant contributions to T2D pathology and network interactions.

### CONFIDENCE: HIGH
The confidence in this hypothesis is based on the robust data support across multiple datasets and the clear involvement of the selected genes in critical metabolic pathways relevant to Type 2 Diabetes.
2026-02-10 19:27:48,459 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:27:48,459 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:27:48,462 - root - INFO -   -> Created offspring: 'Synergistic Targeting of Metabolic Pathw...'
2026-02-10 19:27:48,463 - root - INFO - Crossover 13/18: parents 'Therapeutic Activation of Meta...' x '** Identification of Promising...'
2026-02-10 19:27:48,508 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:28:21,673 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:28:21,679 - root - INFO - TOKEN_USAGE: input=40114, output=689, total=40803, cost=$0.006430
2026-02-10 19:28:21,679 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:28:21,680 - root - INFO - 
**TITLE:** Integrated Activation of Metabolic Pathways for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene serves as a hub component in gene networks related to T2D, indicating its central role in metabolic regulation and insulin signaling.**
2. **G04436 | Score: 4.0 | This enzyme's activation has been shown to enhance glucose metabolism and improve insulin sensitivity, making it crucial for metabolic homeostasis in T2D.**
3. **G22553 | Score: 4.0 | As a primary driver in T2D, its modulation supports insulin receptor signaling pathways, which are essential for glucose uptake.**
4. **G19122 | Score: 3.0 | This major regulator in insulin signaling pathways can help restore metabolic balance disrupted in diabetes.**
5. **G33764 | Score: 4.0 | Its modulation can positively impact metabolic dysregulation associated with T2D, enhancing overall metabolic function.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the activation of key metabolic pathways through the modulation of G19943, G04436, and G22553, which are vital for improving insulin sensitivity and glucose metabolism in Type 2 Diabetes. By targeting these crucial genes, we aim to provide a comprehensive therapeutic approach that addresses multiple aspects of T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, metabolism, inflammatory response
- WGCNA module role: Hub component in the silver module
- Regulating TFs: 0 reported, but the roles of transcription factors in T2D are critical

**MECHANISM_HYPOTHESIS:** The activation of G19943 is anticipated to enhance insulin signaling pathways, thereby improving insulin sensitivity in peripheral tissues. Coupled with the activation of G04436 and G22553, which modulate glucose metabolism and support insulin receptor signaling, this integrated approach is expected to reverse metabolic dysregulation and improve glucose homeostasis in T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells, muscle, and liver, as they are directly involved in glucose metabolism and insulin action, which are central to T2D pathophysiology.

**THERAPEUTIC_APPROACH:** This hypothesis focuses on the activation of the selected targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** The modulation of these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their roles in key biological pathways, and the robustness of the supporting evidence. G19943 was selected as the primary target due to its central role as a hub component in the gene network, while G04436 and G22553 were prioritized for their significant contributions to metabolic regulation and insulin signaling.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:28:21,681 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:28:21,682 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:28:21,682 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:28:21,685 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:28:21,685 - root - INFO -   -> Created offspring: '** Integrated Activation of Metabolic Pa...'
2026-02-10 19:28:21,686 - root - INFO - Crossover 14/18: parents '** Comprehensive Target Identi...' x 'Enhanced Mechanistic Insights ...'
2026-02-10 19:28:21,758 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:28:58,266 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:28:58,273 - root - INFO - TOKEN_USAGE: input=40254, output=734, total=40988, cost=$0.006478
2026-02-10 19:28:58,273 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:28:58,273 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhancing Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G23245** | Score: 4.0 | Central driver in insulin signaling pathways with strong evidence supporting its role in glucose metabolism.
2. **G33764** | Score: 4.0 | Key enzyme in metabolic pathways linked to T2D, complementing the role of G23245 and enhancing metabolic control.
3. **G00484** | Score: 4.0 | This transcription factor is crucial in regulating insulin signaling and glucose homeostasis, providing a regulatory layer to the therapeutic strategy.
4. **G23452** | Score: 4.0 | Enzyme that supports metabolic processes relevant to T2D, adding depth to the multi-target approach.
5. **G36503** | Score: 4.0 | Contributes to glucose homeostasis, further reinforcing the therapeutic potential of combined targeting.

**PRIMARY_TARGET:** G23245

**SUMMARY:** This hypothesis integrates insights from both parent hypotheses, emphasizing the central role of G23245 in insulin sensitivity and glucose metabolism while also addressing the contributions of G33764 and G00484. By targeting multiple interconnected pathways, this approach aims to enhance therapeutic effectiveness for managing Type 2 Diabetes (T2D).

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: Primary Driver in the silver module, negatively correlated with T2D.
- Regulating TFs: None identified for G23245, but G00484 acts as a regulator in related pathways.

**MECHANISM_HYPOTHESIS:** G23245 is hypothesized to act as a pivotal regulator within insulin signaling pathways, potentially enhancing glucose uptake in both pancreatic -cells and peripheral tissues. By modulating G23245, we expect to positively influence downstream metabolic processes. The synergistic roles of G33764, as an enzyme driving critical metabolic pathways, and G00484, as a transcription factor regulating insulin signaling, provide a comprehensive mechanism that can enhance overall metabolic control in T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this hypothesis include pancreatic -cells, liver, and muscle. These tissues are essential for insulin secretion and action, directly influencing glucose homeostasis and providing optimal targets for therapeutic intervention.

**THERAPEUTIC_APPROACH:** The proposed therapeutic approach involves small molecule modulation aimed at enhancing the activity of G23245, alongside potential combination therapies targeting G33764 and G00484 to further amplify insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Effective modulation of G23245 and its associated pathways is expected to lead to significantly improved insulin sensitivity and reduced blood glucose levels, directly addressing the underlying pathophysiology of T2D and enhancing overall disease management.

**RANKING_RATIONALE:** G23245 is ranked highest due to its central regulatory role and strong evidence supporting its involvement in critical metabolic pathways. G33764 follows closely because of its enzymatic role in metabolism, while G00484 adds necessary regulatory depth to the approach. G23452 and G36503 provide additional support and robustness, though they are ranked lower due to less evidence of primary driver roles compared to the top three targets.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 19:28:58,274 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:28:58,274 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:28:58,275 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:28:58,277 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:28:58,277 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 19:28:58,277 - root - INFO - Mutation 15/18: parent '** Identification of Promising...'
2026-02-10 19:28:58,277 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:28:58,310 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:29:33,213 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:29:33,220 - root - INFO - TOKEN_USAGE: input=39443, output=727, total=40170, cost=$0.006353
2026-02-10 19:29:33,221 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:29:33,221 - root - INFO - 
**TITLE:** Enhanced Drug Target Hypothesis for Type 2 Diabetes through Mechanistic Refinement of G19943

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene maintains its strong position as a hub component across multiple datasets, strongly correlating with insulin signaling and inflammatory pathways in Type 2 Diabetes.
2. **G22553** | Score: **4.0** | A primary driver in the black module, this gene shows significant evidence in pathways relevant to T2D, particularly in insulin sensitivity.
3. **G23245** | Score: **4.0** | As another primary driver, this gene is implicated in pathways that negatively correlate with T2D, suggesting its potential for therapeutic intervention.
4. **G27976** | Score: **3.0** | Serving as a major regulator in the silver module, this gene's role reinforces its importance in the regulatory networks impacting T2D.
5. **G19122** | Score: **3.0** | This gene is involved in insulin signaling pathways, supporting its role in the modulation of glucose metabolism.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The refined hypothesis focuses on G19943 as a central hub in the insulin signaling pathway, highlighting its potential to modulate inflammatory responses involved in Type 2 Diabetes. By targeting this gene, we aim to enhance insulin sensitivity and metabolic control.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported, but could be influenced by stress-responsive TFs**

**MECHANISM_HYPOTHESIS:** The primary target, G19943, may act as a pivotal hub in the insulin signaling cascade, where its modulation could improve insulin sensitivity in peripheral tissues, particularly under conditions of metabolic stress. This gene's interaction with inflammatory mediators may also suggest a dual role in reducing the chronic inflammation associated with insulin resistance. Furthermore, exploring potential transcription factors that may indirectly influence G19943's expression could enhance our understanding and targeting strategy.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells, muscle, and adipose tissue, where insulin signaling is crucial for glucose homeostasis. Targeting G19943 specifically in these tissues could lead to enhanced insulin response and a reduction in hyperglycemia, addressing the core metabolic dysfunctions seen in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic approach could involve small molecule modulation to enhance the activity of G19943, potentially restoring its function in insulin signaling pathways and reducing inflammatory responses.

**PREDICTED_OUTCOME:** Modulating G19943 is expected to improve insulin sensitivity, reduce blood glucose levels, and lead to better metabolic control in patients with Type 2 Diabetes, thereby addressing both insulin resistance and inflammation.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores and their roles in relevant biological pathways. G19943 remains the most promising due to its central position in the gene network, supported by its evidence across multiple datasets. G22553 and G23245 follow closely, also showing significant evidence but with slightly less multi-omics support.

**CONFIDENCE:** **HIGH** based on the strength of data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:29:33,225 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:29:33,231 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:29:33,237 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:29:33,248 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:29:33,249 - root - INFO -   -> Created mutated offspring: '** Enhanced Drug Target Hypothesis for T...'
2026-02-10 19:29:33,249 - root - INFO - Mutation 16/18: parent 'Enhanced Mechanistic Insights ...'
2026-02-10 19:29:33,250 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:29:33,369 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:29:46,184 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:29:46,187 - root - INFO - TOKEN_USAGE: input=39557, output=734, total=40291, cost=$0.006374
2026-02-10 19:29:46,187 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:29:46,187 - root - INFO - 
### TITLE: Dual Modulation of G19943 and G22553 for Enhanced Type 2 Diabetes Therapy

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Remains a central hub component in the co-expression network, pivotal in T2D pathways.
2. **G22553** | Score: **4.0** | Acts as a primary driver in T2D-associated metabolic pathways, showing potential synergies with G19943.
3. **G04436** | Score: **4.0** | An enzyme indicating substantial involvement in metabolic regulation, complementing the effects of G19943.
4. **G23245** | Score: **4.0** | A primary driver with strong evidence supporting its role in T2D, though less central than G19943.
5. **G33764** | Score: **4.0** | A primary driver and enzyme relevant for metabolic processes, but with less cross-dataset support than G19943 and G22553.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This mutated hypothesis proposes a dual modulation strategy targeting both G19943 and G22553 to enhance metabolic control in T2D. By activating G19943 while also targeting G22553, we aim to leverage their synergistic potential in regulating insulin signaling and lipid metabolism pathways, ultimately improving insulin sensitivity and mitigating T2D progression.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 (for G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Inflammatory response pathways
- **WGCNA module role**: G19943 is a hub component in a module negatively correlated with T2D.
- **Regulating TFs**: Potential regulatory interactions with unidentified transcription factors influencing inflammatory responses.

### MECHANISM_HYPOTHESIS:
G19943 plays a critical role in insulin signaling and lipid metabolism, and activating this target could restore metabolic homeostasis. Simultaneously, targeting G22553, a primary driver in T2D pathways, can enhance the effects of G19943, resulting in a more robust response in improving insulin sensitivity. The combination of these actions may also address associated inflammatory pathways, providing a more comprehensive approach to combat T2D.

### TISSUE_RATIONALE:
The most relevant tissues include pancreatic -cells and adipose tissue, where G19943 and G22553's roles in insulin secretion and action are critical. Targeting these tissues could enhance insulin sensitivity and -cell function, facilitating effective glucose metabolism.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves the development of small molecule activators for both G19943 and G22553. This dual approach aims to enhance their functions within regulatory pathways associated with glucose and lipid metabolism.

### PREDICTED_OUTCOME:
Modulating G19943 and G22553 is anticipated to synergistically enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could reverse or slow the progression of T2D.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central role in the T2D-related co-expression network. G22553 follows closely as it complements G19943's function, making them suitable for a combination approach. G04436, G23245, and G33764 are included for their established roles in metabolic regulation but offer less network influence than the top two targets.

### CONFIDENCE: HIGH
2026-02-10 19:29:46,188 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:29:46,188 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:29:46,189 - root - INFO -   -> Created mutated offspring: 'Dual Modulation of G19943 and G22553 for...'
2026-02-10 19:29:46,189 - root - INFO - Crossover 17/18: parents 'Exploring Alternative Targets ...' x '** Alternative Therapeutic Tar...'
2026-02-10 19:29:46,249 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:30:21,822 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:30:21,829 - root - INFO - TOKEN_USAGE: input=40152, output=759, total=40911, cost=$0.006478
2026-02-10 19:30:21,829 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:30:21,829 - root - INFO - 
### TITLE: Integrated Targeting of Metabolic Pathways for Enhanced Management of Type 2 Diabetes

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | This enzyme is a primary driver in metabolic regulation with strong evidence linking it to insulin signaling and lipid metabolism in T2D.
2. **G22553** | Score: **4.0** | A significant primary driver in the black module, indicating a strong positive correlation with metabolic regulation and T2D.
3. **G33764** | Score: **4.0** | This enzyme is also a primary driver in the darkgrey module, contributing to insulin signaling pathways crucial for glucose homeostasis.
4. **G23245** | Score: **4.0** | As a primary driver in the silver module, it has a negative correlation with T2D, suggesting its role in promoting insulin sensitivity.
5. **G19122** | Score: **3.0** | A major regulator associated with enhancing insulin signaling, making it an important target, albeit with less evidence than the top three.

#### PRIMARY_TARGET: G04436

### SUMMARY:
The integration of G04436, G22553, and G33764 as primary targets presents a multifaceted approach to T2D management, focusing on enhancing both insulin sensitivity and metabolic regulation. By leveraging the strengths of these targets, the hypothesis aims to address the complex pathology of T2D through combined modulation of lipid metabolism and insulin signaling pathways.

### DATA_EVIDENCE:
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, lipid metabolism, metabolic regulation
- **WGCNA module role:** G04436 as a primary driver in a module positively correlated with metabolic function; G22553 in the black module and G33764 in the darkgrey module suggest strong connections to T2D pathophysiology.
- **Regulating TFs:** G04436 has 12 identified regulatory transcription factors.

### MECHANISM_HYPOTHESIS:
G04436 plays a pivotal role in the regulation of lipid metabolism and insulin signaling pathways. By enhancing its activity, alongside targeting G22553 and G33764, we could significantly improve glucose homeostasis and insulin sensitivity, addressing not only the metabolic dysfunctions seen in T2D but also contributing to the restoration of normal metabolic functions.

### TISSUE_RATIONALE:
The liver and adipose tissue are the most relevant tissues for targeting this hypothesis, as they are critical in glucose metabolism, insulin sensitivity, and lipid regulation. These tissues are often dysregulated in T2D, making them ideal candidates for therapeutic intervention.

### THERAPEUTIC_APPROACH:
The therapeutic strategy would involve the development of small molecule activators to enhance the function of G04436 and potentially modulate the pathways influenced by G22553 and G33764, leading to improved metabolic regulation and insulin sensitivity.

### PREDICTED_OUTCOME:
Modulating these targets is expected to lead to better glycemic control, enhanced insulin sensitivity, and improved lipid handling, ultimately mitigating the progression of T2D and potentially reversing some of its pathological effects.

### RANKING_RATIONALE:
G04436 is ranked highest due to its critical role in metabolic regulation and the presence of multiple regulatory transcription factors, followed closely by G22553 and G33764, which together provide robust support for insulin signaling. G23245 and G19122, while important, provide supplementary support and insights into insulin sensitivity and regulation.

### CONFIDENCE: HIGH based on the strength of data support and integration across multiple evidence types.
2026-02-10 19:30:21,831 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:30:21,831 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:30:21,835 - root - INFO -   -> Created offspring: 'Integrated Targeting of Metabolic Pathwa...'
2026-02-10 19:30:21,835 - root - INFO - Mutation 18/18: parent '** Identification of Novel Dru...'
2026-02-10 19:30:21,836 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:30:21,892 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:30:36,065 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:30:36,068 - root - INFO - TOKEN_USAGE: input=39386, output=623, total=40009, cost=$0.006282
2026-02-10 19:30:36,068 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:30:36,068 - root - INFO - 
**TITLE:** Alternative Drug Target Hypothesis for Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This unknown gene shows strong evidence across multiple datasets and has been identified as a hub component, indicating a pivotal role in T2D pathways.
2. **G22553** | Score: **4.0** | Another unknown gene with strong evidence from two types indicates its potential as a primary driver in T2D-related metabolic processes.
3. **G19122** | Score: **3.0** | A major regulator with consistent evidence across datasets, suggesting its critical involvement in insulin signaling and metabolic regulation.
4. **G20274** | Score: **3.0** | This enzyme has a negative log2FC and is implicated in insulin resistance, indicating its potential role in T2D mechanisms.
5. **G22512** | Score: **4.0** | This unknown gene is promising with evidence from one type, possibly representing an uncharacterized target in T2D.

**PRIMARY_TARGET:** G19943

**SUMMARY:** The alternative hypothesis focuses on G19943, which has emerged as a key hub component in T2D pathways with strong evidence supporting its involvement in metabolic regulation. This gene's multiple evidence types suggest it may play a crucial role in modulating insulin sensitivity and glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Lipid metabolism, insulin signaling**
- WGCNA module role: **Hub Component**
- Regulating TFs: **None identified**

**MECHANISM_HYPOTHESIS:** G19943 likely acts as a central hub in metabolic pathways related to Type 2 Diabetes, influencing both lipid metabolism and insulin signaling. By targeting this gene, we can potentially enhance its activity, thereby improving insulin sensitivity and glucose homeostasis in affected individuals.

**TISSUE_RATIONALE:** This gene is most relevant in adipose tissue and muscle, where its modulation could directly impact insulin sensitivity and glucose uptake, both critical factors in managing blood glucose levels.

**THERAPEUTIC_APPROACH:** The therapeutic strategy would involve the development of small molecules aimed at enhancing the activity of G19943, thereby promoting improved metabolic functions.

**PREDICTED_OUTCOME:** Targeting G19943 is expected to enhance insulin sensitivity, reduce blood glucose levels, and potentially reverse some of the metabolic dysfunctions associated with Type 2 Diabetes.

**RANKING_RATIONALE:** G19943 was ranked highest due to its strong multi-evidence support and its role as a hub component, indicating a critical involvement in T2D pathways. G22553 also ranks highly, but G19943's established role as a hub component gives it a slight edge in potential therapeutic relevance.

**CONFIDENCE:** **HIGH** based on the robustness of the data supporting G19943's role in diabetes-related pathways.
2026-02-10 19:30:36,068 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:30:36,068 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:30:36,068 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:30:36,069 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:30:36,070 - root - INFO -   -> Created mutated offspring: '** Alternative Drug Target Hypothesis fo...'
2026-02-10 19:30:36,070 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 19:30:36,070 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 19:30:36,070 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 19:30:36,070 - root - INFO - Evaluating fitness for hypothesis: t2d-02-f6892a63
2026-02-10 19:30:51,723 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:30:51,730 - root - INFO - TOKEN_USAGE: input=1419, output=615, total=2034, cost=$0.000582
2026-02-10 19:30:51,730 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:30:51,731 - root - INFO - 
DATA_SUPPORT_SCORE: 6  
DATA_SUPPORT_RATIONALE: The primary target G22553 is included in the top priority list, but it is ranked third in the top 10, which diminishes the strength of its support. There is cross-dataset consistency for the target, and evidence from two datasets supports its role. However, the presence of other targets like G19943 and G23245 in the top priority list without being highlighted as primary drivers reduces the overall support.

RANKING_QUALITY_SCORE: 7  
RANKING_QUALITY_RATIONALE: The ranking of G22553 as the primary target is justified by its strong correlation with T2D and its role in metabolic pathways. However, there is a lack of clarity in differentiating the higher-ranked targets, as several have the same score, which could lead to ambiguity in the ranking. The rationale for the ranking is sound but could benefit from clearer distinctions between the targets.

MECHANISTIC_SCORE: 8  
MECHANISTIC_RATIONALE: The proposed mechanism aligns well with the metabolic pathways involved in T2D. The tissue rationale focuses on the liver and adipose tissues, which are indeed central to glucose metabolism and insulin sensitivity. However, the lack of identified regulatory transcription factors for G22553 is a notable gap in the mechanistic understanding.

THERAPEUTIC_SCORE: 7  
THERAPEUTIC_RATIONALE: The proposed therapeutic approach of developing small molecule activators for G22553 is appropriate, considering its role in metabolic regulation. The potential for druggable targets exists, but safety considerations regarding the modulation of multiple targets simultaneously need to be addressed to ensure a holistic therapeutic strategy.

NOVELTY_SCORE: 6  
NOVELTY_RATIONALE: The hypothesis presents a reasonable integration of existing data but does not significantly diverge from established knowledge regarding the role of metabolic pathways in T2D. The connections made between G22553 and its regulatory partners are insightful but not particularly groundbreaking, which lowers the novelty score.

OVERALL_FITNESS: 6.7  
(Calculated as: 6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 6.7)

RANKED_TARGETS_ASSESSMENT:  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

IMPROVEMENT_SUGGESTIONS:  
1. Enhance the clarity of the ranking system by providing more differentiated scores or criteria for distinguishing between targets with the same score.
2. Investigate and identify potential regulatory transcription factors for G22553 to strengthen the mechanistic understanding and improve the data support.
3. Consider providing additional safety data or mechanisms of action for the proposed therapeutic strategy to address potential risks associated with polypharmacy.
4. Explore and highlight novel pathways or interactions that may not be widely recognized in the current literature to strengthen the novelty aspect of the hypothesis.
2026-02-10 19:30:51,732 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:30:51,733 - root - INFO - Evaluating fitness for hypothesis: t2d-02-af99c15a
2026-02-10 19:31:06,362 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:31:06,365 - root - INFO - TOKEN_USAGE: input=1458, output=722, total=2180, cost=$0.000652
2026-02-10 19:31:06,365 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:31:06,365 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G33764, while not listed in the top priority gene list, has a significant score of 4.0 and shows cross-dataset consistency (2 datasets). However, the absence of G33764 in the top priority genes reduces confidence in the overall ranking. There are multiple evidence types supporting the primary target, but the lack of inclusion in the top tier slightly undermines the strength of the data.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the primary target is justified based on its strong role in metabolic pathways relevant to insulin sensitivity. However, the presence of G23245 and G00484both ranked equallycreates ambiguity in how the targets are prioritized. The rationale aligns well with the data, but the absence of G33764 in the top priority list is a notable flaw.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with the known pathways involved in insulin signaling and glucose metabolism, supported by the tissue rationale involving adipose, pancreatic -cells, and muscle tissues. The relationship with G00484 as a transcription factor enhances the mechanistic understanding. However, explicit details on how G33764 interacts with these pathways could strengthen the score.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach proposed (small molecule activation of G33764 and modulation of G23245 and G00484) appears appropriate for enhancing insulin sensitivity. The targets are likely druggable based on their network positions, although potential safety considerations related to off-target effects should be evaluated. More detail on safety and potential interactions would improve the score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates metabolic regulation pathways in a comprehensive manner but does not propose particularly non-obvious connections among the targets. The focus on combination therapy is valuable, but similar strategies have been explored in the literature, so the novelty is moderate.

### OVERALL_FITNESS: 
**Calculated Score:** 
\[ 
(6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 6.75 
\]  
**Scaled to 0-100:** **68** (rounded to nearest whole number)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Incorporate Additional Evidence:** Include more robust data supporting the role of G33764, ideally positioning it within the top priority tier for stronger validation.
2. **Clarify Mechanistic Details:** Provide a more detailed explanation of how G33764 interacts with other targets and pathways to reinforce the mechanistic hypothesis.
3. **Expand on Therapeutic Considerations:** Discuss potential safety concerns and off-target effects related to the small molecule activation of G33764 to ensure a comprehensive therapeutic strategy.
4. **Highlight Novelty More Clearly:** Emphasize any unique aspects of the approach or connections that differentiate this hypothesis from existing literature to enhance its perceived novelty.
2026-02-10 19:31:06,366 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:31:06,366 - root - INFO - Evaluating fitness for hypothesis: t2d-02-2be5b78a
2026-02-10 19:31:18,295 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:31:18,299 - root - INFO - TOKEN_USAGE: input=1531, output=727, total=2258, cost=$0.000666
2026-02-10 19:31:18,299 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:31:18,299 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G04436 has a good priority score of 4.0 but is only supported by one dataset with no cross-dataset consistency, which limits the strength of the evidence. Additionally, while other targets have the same score, the lack of evidence types for the primary target reduces the overall score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking of G04436 as the top target is justified based on its central role in glucose metabolism and insulin sensitivity. However, the evidence is not robust, as the primary target does not demonstrate cross-dataset consistency. G33764 and G22553 are also appropriately ranked, but overall, the evidence does not firmly establish a clear hierarchy among the targets.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns reasonably well with the pathways involved in T2D, particularly glucose metabolism and insulin signaling. The rationale for focusing on pancreatic -cells, liver, and adipose tissue is appropriate given their roles in T2D. However, a clearer connection between the proposed transcription factors and the mechanism could strengthen this aspect.

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of inhibiting G04436 and modulating the other targets seems appropriate, but the potential druggability of these targets is not sufficiently addressed. The safety considerations are not elaborated on, which is critical for evaluating the therapeutic strategy's viability.

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** While the hypothesis integrates several important targets, the connections made are somewhat conventional in the context of T2D research. The proposal does not present particularly novel insights or innovative therapeutic angles that differ significantly from existing approaches.

### OVERALL_FITNESS: 6.1  
Calculated as follows:  
(6 * 0.25) + (7 * 0.25) + (7 * 0.20) + (6 * 0.20) + (5 * 0.10) = 1.5 + 1.75 + 1.4 + 1.2 + 0.5 = 6.35 (rounded to 6.1 for scaling)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (G04436 shows potential but lacks strong evidence across datasets)
- Target #2 quality: **STRONG** (G33764 is well-supported and plays a key role in insulin resistance)
- Target #3 quality: **STRONG** (G22553 is also well-positioned in networks related to T2D)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Base:** Gather additional datasets to support the findings for G04436 and ensure cross-dataset consistency to strengthen the hypothesis.
2. **Highlight Mechanistic Details:** Provide a more detailed discussion on how the identified transcription factors regulate G04436 and other targets, enhancing the mechanistic coherence.
3. **Evaluate Drugability More Thoroughly:** Conduct a more detailed assessment of the druggability of the targets, including potential safety profiles and any existing compounds that may affect their activity.
4. **Explore Novel Approaches:** Consider integrating novel therapeutic angles or innovative methodologies that could differentiate this hypothesis from existing research in T2D treatment.
2026-02-10 19:31:18,299 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:31:18,300 - root - INFO - Evaluating fitness for hypothesis: t2d-02-916751b7
2026-02-10 19:31:31,754 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:31:31,764 - root - INFO - TOKEN_USAGE: input=1505, output=746, total=2251, cost=$0.000673
2026-02-10 19:31:31,764 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:31:31,764 - root - INFO - 
### Evaluation of the RANKED Drug Target Hypothesis Set for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 7
**DATA_SUPPORT_RATIONALE:** 
The primary target G04436 has a priority score of 4, indicating it is in the top priority tier. However, there is only 1 dataset supporting this target without cross-dataset consistency. The other primary target G33764, while also scoring 4, is not evaluated in this context, which would have benefited the overall score. The evidence types supporting G04436 (2) are decent but could be improved with more diverse sources.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** 
The ranking is largely justified as G04436 and G33764 are both ranked highest due to their established roles in lipid metabolism and insulin signaling. The rationale for their ranking is clear, with G22553 providing additional support as a metabolic driver. However, the justification for the ranking could be slightly strengthened by more comparative data on lower-ranked targets.

#### MECHANISTIC_SCORE: 9
**MECHANISTIC_RATIONALE:** 
The proposed mechanism of enhancing enzymatic activity in G04436 and G33764 aligns well with the dysregulation observed in lipid metabolism and insulin signaling in Type 2 Diabetes. The tissue rationale focusing on liver and adipose tissue is appropriate given their roles in metabolism. The consideration of TF relationships further supports the proposed mechanisms.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** 
The therapeutic approach of small molecule activation for both targets is appropriate and aligns with the goal of improving metabolic homeostasis. However, the druggability of G04436 and G33764 could be elaborated upon, as well as any potential safety considerations that could arise from modulating these targets.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** 
While the hypothesis integrates mechanisms of lipid metabolism and insulin signaling, which are well-established in diabetes research, the proposal does not present highly novel connections or creative integrations of data. It builds on existing knowledge but does not introduce significantly new concepts or approaches.

### OVERALL_FITNESS: 7.3
**Calculation:**  
(7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.75 + 2 + 1.8 + 1.4 + 0.6 = 7.3

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G04436 is well-supported and critical)
- Target #2 quality: **STRONG** (G33764 is equally important and validated)
- Target #3 quality: **MODERATE** (G22553 adds value but less robustly supported)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Diversity:** Explore additional datasets to support G04436 and G33764, enhancing cross-dataset consistency.
2. **Enhance Drugability Analysis:** Provide more detailed insights into the druggability of the targets, including any known small molecules or compounds that could modulate their activity.
3. **Address Safety Considerations:** Discuss potential safety risks associated with targeting these enzymes, including off-target effects or adverse reactions.
4. **Incorporate Novel Mechanistic Insights:** Explore and integrate any emerging literature that provides new insights into the mechanisms of G04436 and G33764 to enhance the novelty of the hypothesis.
2026-02-10 19:31:31,765 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:31:31,766 - root - INFO - Evaluating fitness for hypothesis: t2d-02-fea653b3
2026-02-10 19:31:45,570 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:31:45,574 - root - INFO - TOKEN_USAGE: input=1445, output=746, total=2191, cost=$0.000664
2026-02-10 19:31:45,575 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:31:45,575 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G19943 is ranked in the top priority gene list with a score of 4.0, but G22553, while also having a score of 4.0, is not in the top priority list. Additionally, there is cross-dataset consistency for G19943, which strengthens its support. However, the number of evidence types supporting the primary target is limited, resulting in a score of 6.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of G19943 as the primary target is justified due to its central role in the insulin signaling pathway. However, the presence of other targets with equivalent scores in the top tier suggests that the distinction between G19943 and G22553 might not be as clear-cut. The ranking rationale is coherent, but the lack of distinction in priority scores among the top targets slightly undermines its strength.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known roles of G19943 and G22553 in insulin signaling and metabolism in muscle tissue. Muscle tissue is indeed critical for glucose uptake, and the rationale for targeting these genes is supported by existing research. However, the lack of reported regulating transcription factors leaves some aspect of the mechanistic understanding incomplete.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation seems appropriate for enhancing insulin sensitivity. Both targets are positioned within significant signaling pathways, making them likely druggable. However, potential safety considerations related to modulating these targets in a therapeutic context were not addressed, which could impact the overall therapeutic viability.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the integration of G19943 and G22553 as complementary targets is a thoughtful approach, the connections drawn are somewhat conventional given the known roles of these genes in insulin signaling. The hypothesis does not present particularly non-obvious connections or innovative strategies, limiting its novelty.

---

**OVERALL_FITNESS:** 6.75  
(Weighted scores: 6 * 0.25 + 7 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10 = 6.75)

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: **STRONG** (G19943 is a central hub in the insulin signaling pathway)
- Target #2 quality: **MODERATE** (G22553 is important but not prioritized in the top 10)
- Target #3 quality: **MODERATE** (G23245 is significant, but its role is less clear compared to G19943 and G22553)

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Increase Evidence Types:** Gather more diverse evidence to support the roles of G19943 and G22553, such as functional assays or in vivo studies that demonstrate their modulation effects on insulin sensitivity.
2. **Clarify Ranking Justification:** Consider refining the ranking of targets based on functional data or pathway involvement to provide clearer distinctions among targets with similar scores.
3. **Address Safety Considerations:** Include a discussion on potential side effects or safety profiles related to the modulation of these targets to enhance the therapeutic rationale.
4. **Incorporate TF Data:** Investigate and include any potential transcription factors that may regulate the expression of G19943 and G22553 to strengthen the mechanistic hypothesis.
2026-02-10 19:31:45,577 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:31:45,577 - root - INFO - Evaluating fitness for hypothesis: t2d-02-423c0d56
2026-02-10 19:32:00,754 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:32:00,760 - root - INFO - TOKEN_USAGE: input=1529, output=731, total=2260, cost=$0.000668
2026-02-10 19:32:00,760 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:32:00,760 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a high priority score of 4.0, but it lacks cross-dataset consistency, which limits the robustness of the evidence. While it is ranked highly among priority genes, the evidence types (only 2) are insufficient to fully support the claim of strong data backing across multiple datasets, which is essential for validation.

---

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified, with the primary targets G22553 and G23245 both rated at 4.0 and identified as primary drivers of T2D pathways. The rationale for their ranking is logical, focusing on their significant roles in insulin signaling and glucose metabolism. However, the lack of supporting evidence for G22553 reduces confidence in its ranking.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the roles of the selected targets in insulin signaling and glucose metabolism. The tissue rationale focusing on pancreatic beta-cells, muscle, liver, and adipose tissue is consistent and relevant. However, the absence of regulating transcription factors for G22553 slightly weakens the mechanistic coherence.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation for the primary targets is appropriate and aligns with their known functions. However, there are no specific safety considerations mentioned, and the druggability of the targets is not clearly addressed, which could impact potential therapeutic outcomes.

---

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates known pathways and targets in a comprehensive manner, which is beneficial. However, the connections made are fairly conventional in the context of Type 2 Diabetes management, lacking truly innovative or non-obvious elements that would elevate the novelty score.

---

**OVERALL_FITNESS: 7.4**  
(Score Calculation: (7 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 7.4)

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG  
- **Target #2 quality:** STRONG  
- **Target #3 quality:** STRONG  

---

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Support:** Aim to gather additional datasets to validate the role of G22553, potentially enhancing its credibility. Cross-validation with more robust evidence types (like RNA-Seq or proteomics) would strengthen the data support.
   
2. **Address Safety Considerations:** Include detailed assessments of potential side effects or safety profiles associated with the modulation of the proposed targets, particularly G22553 and G23245.

3. **Explore Regulatory Transcription Factors:** Investigate and identify specific transcription factors that regulate G22553 to enhance the mechanistic understanding and provide more comprehensive insight into its role within T2D pathways.

4. **Novelty Enhancement:** Consider exploring less conventional pathways or targets that might interact with the proposed targets, potentially leading to novel therapeutic strategies that are not currently being investigated. 

5. **Detailed Drugability Assessment:** Include a discussion on the druggability of each target, considering their structural characteristics and the availability of small molecules or compounds that can effectively modulate their activity.
2026-02-10 19:32:00,761 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:32:00,762 - root - INFO - Evaluating fitness for hypothesis: t2d-01-6b29cc26
2026-02-10 19:32:14,252 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:32:14,257 - root - INFO - TOKEN_USAGE: input=1372, output=741, total=2113, cost=$0.000650
2026-02-10 19:32:14,257 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:32:14,257 - root - INFO - 
### Evaluation of the Hypothesis on Targeting G33764 in Muscle Tissue for Enhanced Insulin Sensitivity in Type 2 Diabetes

**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** G33764 is indeed in the top priority list, but it is ranked fifth among others with the same score. The evidence from two datasets provides a solid foundation, but the warning about its absence in the highest priority tier indicates some concerns about its relative importance. The primary target has cross-dataset consistency, which is a positive factor.

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking is partially justified; G33764 is positioned as a primary driver, but the presence of similarly scored genes raises questions about the clarity of the distinctions between them. The rationale does provide a logical framework for its selection, but the ranking could benefit from further differentiation between the targets to strengthen the argument.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways, which are critical in T2D. The focus on muscle tissue is appropriate, given its role in glucose homeostasis. However, the lack of identified regulatory transcription factors (TFs) may limit the mechanistic depth of the hypothesis, indicating an area for improvement.

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The proposed small molecule activation of G33764 is a reasonable therapeutic approach. However, without detailed insights into the druggability of G33764 and potential safety concerns, the score reflects a moderate level of confidence in its therapeutic potential. The evaluation could benefit from additional data regarding the network position of the target.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis offers a fresh perspective by targeting a less characterized gene like G33764, suggesting avenues that are not immediately obvious. However, there may be other known mechanisms or pathways involved in muscle insulin sensitivity that could dilate the novelty of the approach.

### OVERALL_FITNESS: 
\[ (5*0.25) + (6*0.25) + (7*0.20) + (6*0.20) + (6*0.10) = 1.25 + 1.5 + 1.4 + 1.2 + 0.6 = 5.95 \]
\[ \text{Overall Fitness (scaled to 0-100): } 59.5 \]

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G33764) quality:** MODERATE
- **Target #2 (G19122) quality:** STRONG
- **Target #3 (G20274) quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify Target Ranking:** Provide a more detailed comparison of G33764 with similarly scored targets to clarify its relative importance and to strengthen the justification for its top ranking.
2. **Expand on Mechanistic Insights:** Identify potential regulatory TFs or other molecular interactions that could further elucidate G33764s role in insulin signaling pathways.
3. **Evaluate Druggability and Safety:** Conduct preliminary assessments of G33764's druggability and potential safety concerns associated with its activation to enhance therapeutic potential.
4. **Broaden the Novelty Assessment:** Investigate existing literature for other pathways or mechanisms that could further validate the novelty of targeting G33764, potentially leading to stronger connections with known diabetes treatments.
2026-02-10 19:32:14,258 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:32:14,258 - root - INFO - Evaluating fitness for hypothesis: t2d-02-44641350
2026-02-10 19:32:28,076 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:32:28,081 - root - INFO - TOKEN_USAGE: input=1448, output=734, total=2182, cost=$0.000658
2026-02-10 19:32:28,081 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:32:28,081 - root - INFO - 
### EVALUATION OF THE RANKED DRUG TARGET HYPOTHESIS SET FOR TYPE 2 DIABETES

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, and there is cross-dataset consistency for top-ranked targets. However, the warning about G19122 not being in the top priority list diminishes the score slightly, as it is a key component of the proposed mechanism. Multiple evidence types support G19943, contributing positively to the score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data, particularly for G19943 and G33764, which have strong evidence supporting their roles in T2D pathways. The rationale provided for the ranking makes logical sense but could benefit from a clearer distinction between the strengths of G19122 compared to the top two targets.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the stated pathways of insulin signaling and lipid metabolism. The tissue rationale is also solid, as pancreatic -cells and adipose tissue are indeed relevant for T2D. However, the potential interactions with regulatory transcription factors need more exploration, which slightly lessens the score.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G33764 seems appropriate and well-founded, as it targets key metabolic pathways. While the potential for safety considerations is acknowledged, further details on druggability and specific safety profiles for these targets would enhance the score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis does integrate data creatively, particularly in combining the roles of the targets in T2D. However, the connections made are somewhat conventional in the context of diabetes research, leading to a moderate score in this dimension.

### OVERALL_FITNESS: 
Calculated as follows:  
(7 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.75 + 2 + 1.6 + 1.4 + 0.6 = **7.45**, scaled to 0-100 yields **74.5**.

### RANKED_TARGETS_ASSESSMENT: 
- Target #1 quality: **STRONG** (G19943 is central to the hypothesis and has robust backing)
- Target #2 quality: **STRONG** (G33764 plays a critical role in the mechanisms described)
- Target #3 quality: **MODERATE** (G19122 is important but its absence from the top priority list affects its perceived strength)

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Include more evidence types for G19122 and explore its role in greater detail to strengthen its justification as a target.
2. **Clarify Mechanistic Insights:** Elaborate on potential regulatory transcription factors and their interactions with the proposed targets to solidify the mechanistic framework.
3. **Detail Therapeutic Modalities:** Provide specific examples of small molecules or activation strategies for G19943 and G33764, including preliminary data on their safety profiles and druggability.
4. **Highlight Novelty:** Emphasize novel aspects of the hypothesis, particularly any unique pathways or regulatory mechanisms that may not be well covered in existing literature.
2026-02-10 19:32:28,083 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:32:28,083 - root - INFO - Evaluating fitness for hypothesis: t2d-02-f4bae3a3
2026-02-10 19:32:44,428 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:32:44,431 - root - INFO - TOKEN_USAGE: input=1491, output=704, total=2195, cost=$0.000646
2026-02-10 19:32:44,431 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:32:44,431 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is indeed in the top priority list, which confirms its relevance. However, there is a warning indicating that the target gene is not found in the top priority list, which affects the score. There is cross-dataset consistency for some targets, but the overall evidence types supporting the primary target could be better defined. 

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified based on the scores provided, with G19943 leading due to its centrality in the insulin signaling network. The other targets also have strong evidence supporting their roles. However, the presence of other high-scoring genes (like G04436, G33764, and G01138) not included in the evaluation suggests that there may be stronger candidates not considered in this hypothesis.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context and highlights the importance of the targeted tissues (pancreatic -cells, skeletal muscle, and adipose tissue) in glucose metabolism. Although the rationale for transcription factor (TF) relationships is noted as lacking, the overall coherence of the mechanism is strong.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of using small molecules to modulate G19943 and its co-targets is appropriate and feasible. However, the evaluation lacks specific safety considerations and details on druggability based on network positioning, leading to a slightly lower score.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates multi-omics approaches and highlights key interactions effectively, but it does not present particularly novel insights or connections that would set it apart from existing knowledge in the field of Type 2 Diabetes research.

### OVERALL_FITNESS:  
Calculated score:  
(5 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.5  
Scaled to 0-100: **65**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Incorporate additional evidence types to support the primary target G19943, including specific studies or data points that show its role in insulin resistance.
2. **Clarify TF Relationships:** Investigate and report any transcription factors that may interact with G19943 and the other targets, enhancing the mechanistic understanding of the hypothesis.
3. **Address Top Priority Candidates:** Consider including or discussing the implications of other high-ranking genes (e.g., G04436, G33764) that may serve as additional or alternative targets for therapeutic intervention.
4. **Detail Safety Considerations:** Provide safety profiles or potential off-target effects of the proposed small molecule therapies to strengthen the therapeutic rationale.
5. **Highlight Novel Insights:** Emphasize unique aspects of the integration of data and proposed mechanisms that could provide new avenues for research or therapy in Type 2 Diabetes.
2026-02-10 19:32:44,431 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:32:44,432 - root - INFO - Evaluating fitness for hypothesis: t2d-02-2ebf8f12
2026-02-10 19:32:57,582 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:32:57,588 - root - INFO - TOKEN_USAGE: input=1529, output=720, total=2249, cost=$0.000661
2026-02-10 19:32:57,589 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:32:57,589 - root - INFO - 
### Evaluation of the Hypothesis

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a strong priority score and is listed as a hub component in the co-expression network, indicating its importance in T2D pathways. However, it lacks cross-dataset consistency, which weakens the overall support. The evidence type is limited to only two, which is relatively low for a robust hypothesis.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of G19943 as the primary target is justified due to its central role in metabolic pathways related to T2D. The rationale for the other targets being secondary based on their network influence is logical; however, the equal scoring among multiple targets (all 4.0) creates ambiguity regarding their relative strengths.

#### MECHANISTIC_SCORE: 7
**MECHANISTIC_RATIONALE:** The proposed mechanism of activating G19943 to enhance insulin signaling and lipid metabolism is coherent with the context of T2D. The tissue rationale (pancreatic -cells and adipose tissue) aligns well with the targets' roles. However, the lack of information on transcription factor interactions limits the depth of the mechanistic coherence.

#### THERAPEUTIC_SCORE: 6
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G19943 and modulating G04436 appears appropriate and strategic, given their roles in insulin sensitivity. However, the potential druggability of these targets and safety considerations are not discussed in detail, which is crucial for assessing the viability of the therapeutic strategy.

#### NOVELTY_SCORE: 5
**NOVELTY_RATIONALE:** The hypothesis integrates known data about G19943 and G04436 in a promising way, but the connections drawn are not particularly novel. The idea of targeting metabolic pathways in T2D is well-established, which makes this hypothesis less innovative.

### OVERALL_FITNESS: 6.1
- **Calculated:** (6*0.25 + 7*0.25 + 7*0.20 + 6*0.20 + 5*0.10) = 6.1

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** MODERATE
- **Target #3 quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Variety:** Aim to gather more evidence types (e.g., functional studies, human clinical data) to support G19943 and G04436. This might include additional datasets to enhance cross-dataset consistency.
2. **Clarify Target Ranking:** Consider re-evaluating the scoring system to distinguish more clearly between the targets, ensuring that the ranking reflects their relative strengths and weaknesses more precisely.
3. **Expand Mechanistic Insights:** Include more details about potential transcription factor interactions with G19943 and G04436, as well as any known signaling pathways that could be impacted by their activation.
4. **Discuss Druggability and Safety:** Provide information about the druggability of G19943 and G04436, including any known inhibitors or activators, and discuss safety profiles or side effects that may arise from therapeutic modulation.
5. **Highlight Novelty:** Emphasize aspects of the hypothesis that may offer new insights or applications in T2D management, potentially integrating recent findings or innovative approaches to target engagement.
2026-02-10 19:32:57,590 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:32:57,591 - root - INFO - Novelty bonus applied: 0.3% -> fitness 63.50 -> 63.71
2026-02-10 19:32:57,591 - root - INFO - Evaluating fitness for hypothesis: t2d-02-f2ccbff7
2026-02-10 19:33:15,489 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:33:15,491 - root - INFO - TOKEN_USAGE: input=1622, output=748, total=2370, cost=$0.000692
2026-02-10 19:33:15,491 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:33:15,491 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** G19943 has a high priority score of 4.0, placing it in the top priority tier. However, it lacks cross-dataset consistency (only 1 dataset reported), which limits the robustness of the evidence. Additionally, while G19943 is a hub component, the lack of multiple evidence types (only 2 types) and pathways further impacts the score.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is generally justified, with G19943 positioned as the primary target due to its pivotal role in metabolic regulation. The rationale for the ranking is logical, with G19122 serving as a complement to G19943s function. However, the lack of substantial differentiation in scores among the top-ranked targets suggests that the relative strength of evidence could be better clarified.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanisms of action for G19943 and G19122 align well with the known pathways involved in T2D, particularly lipid metabolism and insulin signaling. The tissue rationale is solid, focusing on pancreatic -cells and adipose tissue. However, the absence of specific regulating transcription factors in the evidence reported may limit the mechanistic coherence score.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic strategy of activating G19943 and G19122 with small molecule modulators appears appropriate given their roles in metabolism and insulin signaling. However, while the targets seem druggable based on their network position, potential safety considerations and specific drug development pathways were not discussed, which slightly lowers the score.

**NOVELTY_SCORE: 8**  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative manner, focusing on a multi-targeted approach that is not common in the current T2D therapeutic landscape. The connection between targets and the proposed mechanism offers a fresh perspective on tackling the disease.

### OVERALL_FITNESS: 7.1  
(Calculated as: 6*0.25 + 8*0.25 + 7*0.20 + 7*0.20 + 8*0.10 = 7.1)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG** - G19943 shows robust data support and a clear mechanistic rationale.
- **Target #2 quality: STRONG** - G19122 provides a complementary mechanism and aligns well with the proposal.
- **Target #3 quality: MODERATE** - G33764, while valuable, lacks the strong evidence and centrality seen in the top two targets.

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Cross-Dataset Evidence:** Aim to gather data from additional datasets to enhance the robustness of the evidence supporting G19943 and G19122.
2. **Expand Evidence Types:** Incorporate diverse types of evidence (e.g., genetic, proteomic, and functional assays) to strengthen the support for the primary target.
3. **Clarify Mechanistic Details:** Provide more information on the interactions with transcription factors and how these may influence the proposed pathways.
4. **Address Safety Concerns:** Include a discussion on potential safety and side effects of targeting G19943 and G19122 to strengthen the therapeutic rationale.
5. **Differentiation Among Targets:** Ensure that the ranking reflects clear differences in strength and support among the targets to enhance clarity in the proposal.
2026-02-10 19:33:15,491 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:33:15,492 - root - INFO - Novelty bonus applied: 0.3% -> fitness 71.00 -> 71.24
2026-02-10 19:33:15,492 - root - INFO - Evaluating fitness for hypothesis: t2d-02-71199dfc
2026-02-10 19:33:29,314 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:33:29,321 - root - INFO - TOKEN_USAGE: input=1538, output=756, total=2294, cost=$0.000684
2026-02-10 19:33:29,321 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:33:29,321 - root - INFO - 
### EVALUATION SCORES

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G04436 has a reasonable priority score (4/17) and is ranked well. However, it lacks cross-dataset consistency, which is a significant limitation. The fact that there is only one dataset supporting G04436 and no pathways reported weakens the overall data support. The presence of 12 regulating transcription factors is a positive aspect, suggesting potential for regulatory interactions.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the scores and roles of the targets in T2D pathways. All targets have a score of 4.0, indicating they share a similar level of evidence. However, the absence of strong differentiation between these targets could make the ranking less impactful. The rationale for ranking G04436 first is reasonable given its regulatory role, but the lack of a clear distinction among the others could be improved.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the metabolic pathways involved in T2D, particularly lipid metabolism and insulin signaling. The focus on liver and adipose tissues is appropriate given their roles in these pathways. The consideration of transcription factors is also a strong point, as it acknowledges potential regulatory layers that could impact the effectiveness of the approach.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of targeting G04436 and G33764 through small molecule modulators is appropriate and aligns with current strategies in metabolic diseases. However, the evaluation of druggability and safety considerations could be further detailed. The targets' network positions suggest that they could be viable, but more evidence on their druggability would strengthen this score.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates targets in a way that emphasizes their synergistic potential, which is valuable. However, the concept of multi-target approaches in T2D is not entirely novel in the current landscape of diabetes research. While it does propose connections between key metabolic regulators, these connections may not be sufficiently innovative to warrant a higher score.

---

### OVERALL_FITNESS: 
Calculated as follows:  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.75  
**Overall Fitness:** 68%

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Evidence:** Seek additional datasets to validate the findings for G04436 and improve cross-dataset consistency. This can bolster confidence in the selected targets and their roles.
   
2. **Differentiate Rankings:** Provide more detailed comparisons among the ranked targets to clarify why some are prioritized over others. Consider additional functional assays or network analyses to uncover unique contributions of each target.

3. **Therapeutic Feasibility:** Investigate the druggability of the targets more thoroughly, including potential small molecule libraries or existing drugs that might interact with these targets. Include safety profiles or previous studies showing the therapeutic effects of targeting these genes.

4. **Novelty Exploration:** Explore unconventional pathways or new combinations of existing treatments that incorporate the ranked targets to enhance the novelty of the hypothesis. Highlighting innovative therapeutic strategies could strengthen the overall hypothesis.
2026-02-10 19:33:29,322 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:33:29,323 - root - INFO - Evaluating fitness for hypothesis: t2d-02-46eb5158
2026-02-10 19:33:43,241 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:33:43,244 - root - INFO - TOKEN_USAGE: input=1387, output=688, total=2075, cost=$0.000621
2026-02-10 19:33:43,245 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:33:43,245 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed in the top priority list with a score of 4.0, and there is cross-dataset consistency supporting it. However, the evidence types supporting G19943 are not as robust as desired, with no reported regulating transcription factors, which is critical in metabolic pathways. 

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking appears justified as all top-ranked targets (G19943, G04436, G22553) have matching scores and are positioned as crucial components of metabolic regulation and insulin signaling. However, the lack of additional metrics for the lower-ranked targets (G19122, G33764) may suggest room for improvement in distinguishing between them.

**MECHANISTIC_SCORE: 7**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and metabolic context. The tissue rationale focuses on relevant tissues (pancreatic -cells, muscle, liver), which is appropriate for T2D. However, the absence of reported transcription factors in the analysis does weaken the mechanistic coherence, as TFs are integral to the regulation of these pathways.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets through small molecules is appropriate and promising for enhancing insulin sensitivity. The targets are likely druggable due to their central roles in metabolic networks. Potential safety considerations need further exploration, particularly regarding the effects of long-term modulation of these pathways.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The integration of these targets does present a creative approach, addressing multiple aspects of T2D pathology. However, the connections made between the targets and the proposed mechanisms, while valuable, are not highly novel in the context of existing diabetes research.

### OVERALL_FITNESS
Overall fitness is calculated as follows:
\[ \text{Overall Fitness} = 7 \times 0.25 + 8 \times 0.25 + 7 \times 0.20 + 8 \times 0.20 + 6 \times 0.10 = 7.55 \]
Scaled to 0-100:
\[ \text{Overall Fitness} = 75.5 \]

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Evidence Collection:** Seek additional data types that can further support the role of G19943 and its regulatory mechanisms, particularly focusing on transcription factors or downstream signaling effects.
   
2. **Clarify Target Distinctions:** Provide clearer differentiation between lower-ranked targets (G19122, G33764) to justify their ranking and potential contributions to T2D treatment.

3. **Explore Safety Profiles:** Include a more thorough analysis of the safety profiles associated with the modulation of these targets, considering potential off-target effects or long-term implications of activation.

4. **Expand on Novel Mechanisms:** Investigate and integrate novel interactions or pathways that could strengthen the hypothesis and enhance its innovative aspects.
2026-02-10 19:33:43,245 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:33:43,245 - root - INFO - Evaluating fitness for hypothesis: t2d-02-5a3943f7
2026-02-10 19:33:58,288 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:33:58,292 - root - INFO - TOKEN_USAGE: input=1432, output=807, total=2239, cost=$0.000699
2026-02-10 19:33:58,292 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:33:58,292 - root - INFO - 
### Evaluation of Integrated Multi-Target Approach for Enhancing Insulin Sensitivity in Type 2 Diabetes Management

**DATA_SUPPORT_SCORE: 8**
**DATA_SUPPORT_RATIONALE:** The primary target G23245 is indeed in the top priority list, and it has a priority score of 4.0. Additionally, the cross-dataset consistency is confirmed with two datasets supporting the role of G23245. However, while the evidence for the primary target is strong, there is a lack of evidence types specifically mentioned for G23245, which prevents a perfect score. 

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, as the targets are ranked by their relevance to insulin signaling and glucose metabolism. However, the rationale could be strengthened by providing more detailed evidence that differentiates the strength of G33764, G00484, and the lower-ranked targets. While the top three targets are well justified, the distinctions among the lower-ranked ones could be clearer.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, focusing on insulin signaling and glucose metabolism. The tissue rationale is also appropriate, as pancreatic -cells, liver, and muscle are critical to the disease's pathology. However, the mention of transcription factors could be expanded to explain how they influence the overall regulatory mechanisms in greater detail.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation is appropriate and aligns well with the targets' roles. The combination therapies targeting G33764 and G00484 could further enhance insulin sensitivity, indicating a well-thought-out strategy. However, there could be additional considerations regarding potential off-target effects or safety issues that are not addressed.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis does integrate data in a creative way by considering a multi-target approach, which is not very common in T2D management. The connections made among the targets are solid, but the novelty could be further enhanced by discussing how this integrated approach compares to existing therapies or by exploring less obvious targets that could complement this strategy.

### OVERALL_FITNESS: 
Calculated as follows: 
- DATA_SUPPORT: 8 * 0.25 = 2.0
- RANKING_QUALITY: 7 * 0.25 = 1.75
- MECHANISTIC: 8 * 0.20 = 1.6
- THERAPEUTIC: 8 * 0.20 = 1.6
- NOVELTY: 7 * 0.10 = 0.7

**Total Score: 2.0 + 1.75 + 1.6 + 1.6 + 0.7 = 7.85**
**Scaled to 0-100:** 78.5

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Collection:** Strengthen the data support by including more diverse types of evidence for G23245 and its associated pathways, such as clinical data or additional functional studies.
2. **Clarify Target Distinctions:** Improve clarity in the ranking rationale by providing specific data points that differentiate the strength and impact of each target, particularly for G33764 and G00484 relative to G23245.
3. **Address Safety Considerations:** Include a discussion around potential safety concerns or side effects associated with targeting these pathways, especially in the context of combination therapies.
4. **Explore Additional Targets:** Consider investigating less obvious targets that may synergistically enhance the proposed therapeutic approach, potentially increasing the hypothesis's novelty and impact.
2026-02-10 19:33:58,292 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:33:58,293 - root - INFO - Evaluating fitness for hypothesis: t2d-01-67143470
2026-02-10 19:34:09,865 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:34:09,869 - root - INFO - TOKEN_USAGE: input=1425, output=643, total=2068, cost=$0.000600
2026-02-10 19:34:09,869 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:34:09,869 - root - INFO - 
### EVALUATION

#### DATA_SUPPORT_SCORE: **8**
**DATA_SUPPORT_RATIONALE:** G19943 is listed as the top-ranked target with a score of 4.0, indicating strong support. It is consistent across two datasets, reinforcing its reliability as a target. However, the warning about not being found in the top priority list raises some concerns about its broader relevance compared to other targets that also scored 4.0.

#### RANKING_QUALITY_SCORE: **8**
**RANKING_QUALITY_RATIONALE:** The ranking appears justified as G19943 is a hub component in the insulin signaling pathway, and its relationships with inflammatory pathways are well-supported. However, the close scores of G22553 and G23245 suggest that the distinctions between them and G19943 could be made clearer to strengthen the ranking rationale.

#### MECHANISTIC_SCORE: **8**
**MECHANISTIC_RATIONALE:** The mechanism proposed aligns well with the insulin signaling context, and the focus on G19943's dual role in inflammation and insulin sensitivity is coherent. The rationale for targeting specific tissues is appropriate, but without reported transcription factors, there's an opportunity for further mechanistic exploration.

#### THERAPEUTIC_SCORE: **7**
**THERAPEUTIC_RATIONALE:** The proposed small molecule modulation of G19943 is a logical approach to enhance its function in insulin signaling. However, potential safety considerations need to be addressed, particularly regarding the modulation of inflammatory responses, which could have unintended consequences.

#### NOVELTY_SCORE: **6**
**NOVELTY_RATIONALE:** While the hypothesis integrates important data on G19943's roles, it does not propose significantly novel connections or mechanisms beyond what is already established in the literature. A more creative exploration of G19943's interactions could enhance this score.

### OVERALL_FITNESS: 
(8 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = **7.6** (scaled to 0-100: **76**)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Address the Warning:** Investigate the discrepancy regarding G19943 not being found in the top priority list, and clarify its relevance in comparison to other high-scoring genes.
2. **Enhance Ranking Justification:** Provide more detailed comparisons between G19943 and other top-ranked targets (G22553 and G23245) to clarify their relative strengths and weaknesses.
3. **Explore Transcription Factors:** Investigate potential transcription factors that may regulate G19943 to strengthen the mechanistic rationale and expand the therapeutic targeting strategies.
4. **Consider Safety Profiles:** Discuss potential safety concerns regarding the modulation of G19943 and how they might be mitigated in a therapeutic context. This could involve preclinical studies to assess the effects of modulation on inflammation.
2026-02-10 19:34:09,870 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:34:09,870 - root - INFO - Evaluating fitness for hypothesis: t2d-02-988ad127
2026-02-10 19:34:18,557 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:34:18,560 - root - INFO - TOKEN_USAGE: input=1494, output=615, total=2109, cost=$0.000593
2026-02-10 19:34:18,560 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:34:18,560 - root - INFO - 
### EVALUATION OF THE HYPOTHESIS

#### DATA_SUPPORT_SCORE: 7
**DATA_SUPPORT_RATIONALE:** The ranked targets (G19943 and G22553) are in the top priority tier, both scoring 4.0. However, the cross-dataset consistency is limited as G19943 shows only one dataset with a non-consistent rank. The evidence supports G19943 as a hub component, but overall, the evidence types are fewer than ideal for strong support.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, particularly for G19943, which is a central hub in the co-expression network. The rationale for ranking G22553 closely follows as it complements G19943. The lower-ranked targets may have similar scores but lack the same network influence, making the rationale sound.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in T2D, particularly in insulin signaling and lipid metabolism. The tissue rationale is appropriate, focusing on pancreatic -cells and adipose tissue, which are critical for glucose metabolism. However, the lack of specified regulating transcription factors (TFs) in the evaluation context could be considered a minor gap.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators for both G19943 and G22553 is appropriate given their roles in regulatory pathways. Both targets are likely druggable based on their network positions, although safety considerations are not explicitly addressed in the hypothesis.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The integration of dual modulation of G19943 and G22553 shows creativity and potential for synergy, which is a non-obvious connection. However, the hypothesis could benefit from more innovative approaches or novel mechanisms that have not been previously explored.

### OVERALL_FITNESS: 7.25 (rounded to 73)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Dataset Evidence:** Increase the number of datasets supporting G19943 and G22553 to enhance cross-dataset consistency and validate the findings more robustly.
2. **Identify Regulating Transcription Factors:** Investigate and include potential transcription factors that could regulate the pathways involving G19943 and G22553, which would strengthen the mechanistic rationale.
3. **Address Safety Concerns:** Explicitly outline potential safety considerations in the therapeutic approach to provide a more comprehensive evaluation of the proposed drug targets.
4. **Innovate Further:** Explore additional, less conventional pathways or mechanisms that could be synergistically modulated alongside G19943 and G22553 to increase the novelty of the approach.
2026-02-10 19:34:18,561 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:34:18,561 - root - INFO - Novelty bonus applied: 0.5% -> fitness 73.50 -> 73.87
2026-02-10 19:34:18,561 - root - INFO - Evaluating fitness for hypothesis: t2d-02-1a2f3ce3
2026-02-10 19:34:33,722 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:34:33,729 - root - INFO - TOKEN_USAGE: input=1517, output=706, total=2223, cost=$0.000651
2026-02-10 19:34:33,729 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:34:33,729 - root - INFO - 
### EVALUATION OF TARGET HYPOTHESIS

#### DATA_SUPPORT_SCORE: **7**
**DATA_SUPPORT_RATIONALE:** The primary target G04436 has a high score of 4.0, indicating it is in the top priority tier. However, there is a lack of cross-dataset consistency since the evidence is derived from only one dataset. Furthermore, while the primary target has 12 regulatory transcription factors identified, overall evidence types supporting G04436 are limited, affecting the robustness of this score.

#### RANKING_QUALITY_SCORE: **8**
**RANKING_QUALITY_RATIONALE:** The ranking of the targets is largely justified, as all top-ranked targets (G04436, G22553, G33764) share similar scores and are associated with critical pathways in T2D management. The rationale explaining why G04436 is prioritized over others is clear, given its strong evidence in metabolic regulation. However, further differentiation among targets in terms of their specific contributions could strengthen the ranking.

#### MECHANISTIC_SCORE: **9**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways related to insulin signaling and lipid metabolism. The tissue rationale focusing on the liver and adipose tissue is strongly supported by their roles in T2D. Additionally, the recognition of regulatory transcription factors adds depth to the mechanistic understanding, allowing for a more coherent hypothesis.

#### THERAPEUTIC_SCORE: **8**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of developing small molecule activators for G04436 and others is appropriate, as enhancing function is a common strategy in metabolic diseases. The targets appear to be druggable due to their significant roles in metabolic networks. However, there may be safety considerations around modulating these pathways that should be further explored.

#### NOVELTY_SCORE: **7**
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets and pathways in a comprehensive manner, which is somewhat creative. However, targeting metabolic pathways in T2D is not a new concept, and while the integration is solid, the connections drawn may not be entirely non-obvious to the field.

### OVERALL_FITNESS: **7.75**
**Calculated: (7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 7*0.10) = 7.75**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G04436 has robust support for its role in metabolic regulation)
- Target #2 quality: **STRONG** (G22553 shows significant correlation with metabolic regulation)
- Target #3 quality: **STRONG** (G33764 is crucial for insulin signaling pathways)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Cross-Dataset Validation:** To enhance the confidence in the findings, additional datasets should be utilized to verify the roles of the primary target and other ranked targets.
2. **Clarify Mechanistic Differences:** Provide clearer distinctions among the ranked targets concerning their specific mechanisms of action and contributions to T2D pathology.
3. **Explore Safety Profiles:** Conduct preliminary assessments of potential safety issues related to modulating these targets to anticipate challenges in therapeutic applications.
4. **Expand Novelty Aspects:** Investigate and highlight any unique interactions or lesser-known effects of the targets that could provide a more novel angle to the hypothesis.
2026-02-10 19:34:33,730 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:34:33,731 - root - INFO - Evaluating fitness for hypothesis: t2d-01-77bc8678
2026-02-10 19:34:47,748 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:34:47,752 - root - INFO - TOKEN_USAGE: input=1321, output=757, total=2078, cost=$0.000652
2026-02-10 19:34:47,752 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:34:47,752 - root - INFO - 
### EVALUATION OF DRUG TARGET HYPOTHESIS FOR TYPE 2 DIABETES

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** G19943 is ranked 1st with a score of 4.0 and is indeed in the top priority list. However, the warning indicates that while it is a priority target, it is not in the top 10 priority genes, which slightly diminishes confidence in its overall data support. Cross-dataset consistency is confirmed, supporting its relevance. Multiple evidence types are lacking, as only one type of evidence is noted for G19943.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the data available. G19943 is a strong candidate as a hub component, which is significant in T2D pathways. However, G22553, which is ranked equally high, may also have similar potential, suggesting that the differences in their significance could have been more clearly articulated in the rationale.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G19943 aligns well with its role in lipid metabolism and insulin signaling. The tissue rationale supporting its relevance in adipose tissue and muscle is well-founded, as these tissues are critical for insulin sensitivity. However, the absence of identified regulating transcription factors may weaken the mechanistic explanation slightly.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach involving small molecules to enhance G19943's activity is appropriate, given its role as a hub gene. The hypothesis suggests that enhancing its activity could yield positive outcomes, aligning well with the goals of increasing insulin sensitivity. However, the potential druggability based on network position isn't fully addressed, and more consideration of safety concerns would strengthen this score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates the data creatively by focusing on a lesser-characterized gene as a potential target. Yet, the novelty is somewhat limited as it does not significantly challenge existing paradigms or offer groundbreaking insights beyond existing knowledge of insulin signaling pathways.

### OVERALL_FITNESS:
Calculating the overall fitness:  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85  
**Overall Fitness (scaled to 0-100):** **68.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G19943):** STRONG
- **Target #2 quality (G22553):** STRONG
- **Target #3 quality (G19122):** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Types:** Expand the types of evidence supporting G19943, including functional studies or additional validation in relevant models to strengthen its position.
2. **Clarify Ranking Rationale:** Provide a clearer distinction between G19943 and G22553 to justify G19943 as the primary target over others with similar scores.
3. **Address Transcription Factor Relationships:** Investigate potential transcription factors that may regulate G19943 to enhance mechanistic understanding and support the therapeutic approach.
4. **Explore Druggability and Safety Considerations:** Include a discussion on the druggability of G19943 in terms of its structure and potential off-target effects to better outline the therapeutic potential.
2026-02-10 19:34:47,752 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:34:47,753 - root - INFO - Population fitness evaluation complete. Top score: 76.50
2026-02-10 19:34:47,753 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 19:34:47,754 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G04436', 'G19943', 'G22553', 'G19943']...
2026-02-10 19:34:47,754 - root - INFO - Generation 2 stats: mean=63.24, max=76.5, min=50.0
2026-02-10 19:34:47,754 - root - INFO - Generation 2 complete
2026-02-10 19:34:47,754 - root - INFO - Running generation 3
2026-02-10 19:34:47,754 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 19:34:47,754 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 19:34:47,755 - root - INFO - Mutation 1/18: parent '** Enhanced Mechanistic Insigh...'
2026-02-10 19:34:47,755 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:34:47,795 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:35:26,661 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:35:26,665 - root - INFO - TOKEN_USAGE: input=39502, output=772, total=40274, cost=$0.006389
2026-02-10 19:35:26,666 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:35:26,666 - root - INFO - 
### TITLE: Tissue-Specific Hypothesis for Targeting G22553 in Adipose Tissue for Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | G22553 is a primary driver in the black module, showing a strong positive correlation with T2D, indicating its critical role in adipose tissue metabolism.
2. **G23245** | Score: **4.0** | As a primary driver in the silver module, G23245 negatively correlates with T2D and suggests a role in enhancing insulin sensitivity in adipocytes.
3. **G33764** | Score: **4.0** | This enzyme, as a primary driver in the darkgrey module, is crucial for insulin signaling pathways, particularly in adipose tissue where insulin action is vital for glucose homeostasis.
4. **G19122** | Score: **3.0** | A major regulator in the black module, G19122s involvement in insulin signaling could complement G22553s function in adipose tissue.
5. **G19943** | Score: **4.0** | As a hub component, G19943 is critical in various metabolic pathways and may interact with G22553 to enhance metabolic regulation in adipose tissue.

**PRIMARY_TARGET:** G22553

**SUMMARY:** The mutated hypothesis focuses on G22553 as a central target for T2D management specifically within adipose tissue. By enhancing our understanding of its interactions with key regulatory genes like G23245 and G19122, we aim to develop synergistic therapeutic strategies that improve insulin sensitivity and overall metabolic health in T2D patients.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, evidence from 2 datasets supports its role.
- Key pathways involved: Metabolic regulation, insulin signaling, glucose homeostasis, adipocyte function.
- WGCNA module role: Primary Driver in the black module.
- Regulating TFs: None identified specifically for this gene in the data.

**MECHANISM_HYPOTHESIS:** G22553 is proposed to function within the adipose tissue's metabolic network, regulating glucose homeostasis and insulin action. Its modulation may enhance not only its own activity but also the activity of G23245 and G19122, leading to improved insulin sensitivity and metabolic outcomes in T2D patients. The interaction between these genes provides a multifaceted approach to enhancing metabolic regulation, especially in adipose tissue.

**TISSUE_RATIONALE:** Adipose tissue is critical for regulating glucose metabolism and insulin sensitivity in T2D. Targeting G22553 within this tissue can lead to significant improvements in metabolic health, as adipocytes play a central role in energy storage and insulin action.

**THERAPEUTIC_APPROACH:** The therapeutic approach will involve the development of small molecule activators targeting G22553, potentially combined with modulators of G23245 and G19122 to maximize therapeutic efficacy in enhancing insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating G22553 alongside its regulatory partners in adipose tissue is expected to significantly improve glycemic control, reduce insulin resistance, and enhance overall metabolic health in T2D patients.

**RANKING_RATIONALE:** G22553 is ranked highest for its pivotal role in metabolic regulation within adipose tissue and its strong correlation with T2D. G23245 and G33764 follow closely due to their complementary functions in promoting insulin sensitivity and supporting insulin signaling, respectively. G19122 and G19943 are included for their potential roles in enhancing the overall therapeutic strategy.

**CONFIDENCE:** HIGH based on the strength of data support and integration across multiple evidence types.
2026-02-10 19:35:26,666 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:35:26,666 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:35:26,667 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:35:26,668 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:35:26,669 - root - INFO -   -> Created mutated offspring: 'Tissue-Specific Hypothesis for Targeting...'
2026-02-10 19:35:26,669 - root - INFO - Mutation 2/18: parent 'Integrative Targeting of G1994...'
2026-02-10 19:35:26,669 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:35:26,706 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:36:06,474 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:36:06,480 - root - INFO - TOKEN_USAGE: input=39640, output=773, total=40413, cost=$0.006410
2026-02-10 19:36:06,480 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:36:06,480 - root - INFO - 
### TITLE: Enhanced Therapeutic Strategies in Type 2 Diabetes through Targeting G33764 and G19122

#### RANKED_TARGETS:
1. **G33764** | Score: **4.0** | This enzyme plays a crucial role in metabolic pathways related to T2D, with implications in lipid metabolism and insulin signaling, making it a valuable primary target.
2. **G19122** | Score: **3.0** | Identified as a major regulator in adipose tissue, it significantly influences insulin sensitivity and glucose metabolism, complementing G33764's metabolic regulation.
3. **G22553** | Score: **4.0** | As a primary driver in the co-expression network, it supports T2D-related pathways, enhancing overall metabolic regulation alongside G33764.
4. **G20274** | Score: **3.0** | An enzyme linked to insulin signaling pathways, it has significant potential for modulating glucose metabolism, thereby supporting the therapeutic strategy focused on G33764.
5. **G19943** | Score: **4.0** | Although ranked lower, it remains relevant as a hub component in the co-expression network, providing a supportive role in metabolic pathways influenced by G33764.

#### PRIMARY_TARGET: G33764

### SUMMARY:
This mutated hypothesis proposes targeting G33764 as the primary focus for Type 2 Diabetes therapy due to its pivotal role in metabolic pathways related to insulin signaling and lipid metabolism. G19122 is included as a crucial secondary target that enhances insulin sensitivity in adipose tissue, while G22553 and G20274 provide additional metabolic support, addressing various aspects of T2D.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 (G33764)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Metabolic regulation in adipose tissue
- **WGCNA module role**: Primary driver in metabolic pathways
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
G33764 is hypothesized to act as a master regulator within metabolic pathways directly influencing insulin signaling and lipid metabolism, making it a central player in T2D pathophysiology. Its interaction with G19122 enhances insulin sensitivity in adipose tissue, crucial for effective glucose homeostasis. Furthermore, the inclusion of G22553 and G20274 fortifies the therapeutic approach by addressing additional mechanisms involved in glucose uptake and metabolic regulation.

### TISSUE_RATIONALE:
The primary tissues of interest include adipose tissue and liver, where G33764's role in lipid metabolism and insulin signaling is critical for maintaining glucose homeostasis and preventing insulin resistance.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the activation of G33764 and G19122 using small molecule modulators designed to enhance their regulatory functions, ultimately leading to improved insulin sensitivity and metabolic outcomes in T2D management.

### PREDICTED_OUTCOME:
Modulating G33764 and G19122 is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could reverse or slow the progression of Type 2 Diabetes.

### RANKING_RATIONALE:
G33764 is ranked highest due to its central role in metabolic pathways relevant to T2D, followed by G19122, which directly influences insulin sensitivity. G22553 and G20274 provide additional metabolic support, while G19943 remains a relevant target but is less central in this specific hypothesis.

### CONFIDENCE: HIGH based on the comprehensive evidence supporting G33764's and G19122's roles in metabolic regulation and the additional support from other targets.
2026-02-10 19:36:06,482 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:36:06,482 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:36:06,486 - root - INFO -   -> Created mutated offspring: 'Enhanced Therapeutic Strategies in Type ...'
2026-02-10 19:36:06,487 - root - INFO - Crossover 3/18: parents '** Comprehensive Targeting of ...' x 'Integrated Approach for Target...'
2026-02-10 19:36:06,530 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:37:00,356 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:37:00,363 - root - INFO - TOKEN_USAGE: input=40368, output=773, total=41141, cost=$0.006519
2026-02-10 19:37:00,363 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:37:00,363 - root - INFO - 
**TITLE:** Integrated Multi-Omics Targeting for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene acts as a central hub in the insulin signaling pathway, with robust support across multiple datasets indicating its crucial role in T2D.
2. **G23245** | Score: **4.0** | As a primary driver implicated in metabolic dysregulation, its modulation is expected to synergistically enhance insulin sensitivity when combined with G19943.
3. **G33764** | Score: **4.0** | This enzyme's activity is essential for metabolism and directly influences insulin sensitivity, making it a strong candidate for therapeutic intervention.
4. **G22553** | Score: **4.0** | Serving as a primary driver in the co-expression network, its targeting can significantly impact insulin resistance mechanisms.
5. **G19122** | Score: **3.0** | Its role as a major regulator in insulin signaling supports and complements the modulation of the other primary targets.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:**  
This hypothesis proposes a comprehensive approach to target insulin resistance in Type 2 Diabetes (T2D) by integrating key drivers from both parent hypotheses. By focusing on G19943, G23245, and G33764, we aim to enhance insulin sensitivity and glucose metabolism through a synergistic modulation of critical pathways involved in T2D, leveraging robust multi-omics data.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, inflammatory response**
- WGCNA module role: **Hub Component in the silver module**
- Regulating TFs: **None reported, but interaction with potential regulatory networks is acknowledged.**

**MECHANISM_HYPOTHESIS:**  
The combined mechanistic hypothesis suggests that G19943, as a central hub in insulin signaling, enhances the overall insulin response in peripheral tissues. Targeting G23245 alongside G33764, which plays a significant role in glucose and lipid metabolism, creates a synergistic effect that can mitigate insulin resistance. The integration of these targets addresses multifaceted aspects of T2D, including inflammatory responses that may further exacerbate metabolic dysfunction.

**TISSUE_RATIONALE:**  
The most relevant tissues for this hypothesis include pancreatic -cells, skeletal muscle, and adipose tissue, as they are critical for effective insulin action and glucose homeostasis. Targeting these genes in these tissues is expected to enhance the insulin response and improve metabolic control.

**THERAPEUTIC_APPROACH:**  
The therapeutic strategy will involve small molecule modulation to enhance the activity of G19943 and its co-targets, effectively restoring and improving insulin signaling pathways disrupted in T2D.

**PREDICTED_OUTCOME:**  
Modulation of the primary target, G19943, in conjunction with G23245 and G33764, is anticipated to lead to significant improvements in insulin sensitivity, reduction of blood glucose levels, and better overall metabolic regulation in patients with Type 2 Diabetes.

**RANKING_RATIONALE:**  
The targets were ranked based on the strength of evidence supporting their roles in insulin signaling and metabolic regulation, with G19943 being the leading target due to its central role. G23245 and G33764 follow closely for their significant contributions to insulin sensitivity and metabolic pathways, while G22553 and G19122 provide complementary support for the overall mechanistic approach.

**CONFIDENCE:** **HIGH** based on the robustness of data supporting the roles of these targets in diabetes-related pathways.
2026-02-10 19:37:00,364 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:37:00,364 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:37:00,365 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:37:00,368 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:37:00,368 - root - INFO -   -> Created offspring: '** Integrated Multi-Omics Targeting for ...'
2026-02-10 19:37:00,369 - root - INFO - Crossover 4/18: parents '** Identification of Promising...' x 'Therapeutic Activation of G199...'
2026-02-10 19:37:00,426 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:37:39,284 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:37:39,291 - root - INFO - TOKEN_USAGE: input=40249, output=791, total=41040, cost=$0.006512
2026-02-10 19:37:39,291 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:37:39,291 - root - INFO - 
**TITLE:** Synergistic Modulation of G19943 and G04436 to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | As a hub component in gene networks related to T2D, G19943 plays a critical role in insulin signaling and metabolism, making it the top therapeutic target.
2. **G04436** | Score: **4.0** | This enzyme complements G19943 by providing additional metabolic regulation, enhancing the overall therapeutic effect when activated alongside G19943.
3. **G22553** | Score: **4.0** | A primary driver in T2D pathways, G22553 supports insulin signaling and can provide synergistic effects when combined with G19943 and G04436.
4. **G27976** | Score: **3.0** | A major regulator in the silver module, G27976 contributes to the regulatory networks influencing T2D and can help solidify the insulin sensitivity achieved through the primary targets.
5. **G23245** | Score: **3.0** | While less central than the top targets, G23245 is a primary driver involved in relevant pathways and serves as a secondary support target.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The new hypothesis proposes a comprehensive therapeutic strategy that focuses on the activation of G19943 to enhance insulin sensitivity while simultaneously modulating G04436 to fortify metabolic regulation. Additionally, G22553, G27976, and G23245 serve as supportive targets to further enhance the efficacy of this combined approach.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, lipid metabolism, and inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported, but TF activity is critical for gene regulation in T2D**

**MECHANISM_HYPOTHESIS:** The activation of G19943 is hypothesized to enhance its function within insulin signaling and lipid metabolism pathways, directly addressing the metabolic dysregulation characteristic of T2D. Concurrently, G04436 modulation is expected to provide a synergistic effect by enhancing metabolic regulation through its enzymatic activity. This combined approach is anticipated to decrease insulin resistance and improve glucose homeostasis in T2D patients.

**TISSUE_RATIONALE:** The most relevant tissues for targeting G19943 and G04436 include pancreatic -cells, muscle, and adipose tissue, where they can directly influence insulin secretion and action. Enhancing G19943 activity is expected to improve -cell function and insulin sensitivity, while G04436 can support overall metabolic homeostasis.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule activation of G19943, potentially combined with modulation of G04436, aiming to restore metabolic balance and improve insulin sensitivity for T2D management.

**PREDICTED_OUTCOME:** The synergistic modulation of G19943 and G04436 is expected to significantly enhance insulin sensitivity and improve glucose metabolism, providing therapeutic benefits that may reverse or slow the progression of T2D.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their roles in relevant biological pathways, and their potential for synergistic effects. G19943 stands out as the most promising due to its central position in the gene network and its strong evidence across multiple datasets. G04436 follows as a critical complementary target, while G22553 and G27976 provide additional support in enhancing insulin signaling pathways.

**CONFIDENCE:** **HIGH** based on the strength of data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:37:39,293 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:37:39,293 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:37:39,294 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:37:39,296 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:37:39,297 - root - INFO -   -> Created offspring: '** Synergistic Modulation of G19943 and ...'
2026-02-10 19:37:39,297 - root - INFO - Crossover 5/18: parents 'Integrative Targeting of Lipid...' x '** Integrated Target Hypothesi...'
2026-02-10 19:37:39,360 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:38:20,101 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:38:20,108 - root - INFO - TOKEN_USAGE: input=40315, output=770, total=41085, cost=$0.006509
2026-02-10 19:38:20,108 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:38:20,108 - root - INFO - 
### TITLE: Targeting a Multi-Pathway Approach in Type 2 Diabetes Management through Integrated Lipid Metabolism and Insulin Signaling Modulation

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Identified as a hub component linked to T2D pathways, indicating a pivotal role in metabolic regulation.
2. **G33764** | Score: **4.0** | A key enzyme central to lipid metabolism and insulin signaling, supported by extensive evidence of its therapeutic potential in enhancing insulin sensitivity.
3. **G04436** | Score: **4.0** | An enzyme that plays a crucial role in metabolic regulation and is supported by significant transcriptional regulation data, enhancing its therapeutic potential.
4. **G22553** | Score: **4.0** | A primary driver in key metabolic pathways, making it a valuable target for enhancing metabolic control in T2D.
5. **G19122** | Score: **3.0** | A major regulator in insulin signaling with consistent evidence supporting its role in T2D pathways, providing additional therapeutic targets.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis integrates multiple mechanistic insights from both parent hypotheses, focusing on G19943, G33764, and G04436 as primary therapeutic targets. By targeting these genes, which are essential for both lipid metabolism and insulin signaling, we aim to improve insulin sensitivity and overall metabolic control in Type 2 Diabetes patients.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Metabolic regulation pathways
- **WGCNA module role**: G19943 is a hub component in a module negatively correlated with T2D.
- **Regulating TFs**: G33764 and G04436 show interactions with regulatory transcription factors, enhancing their potential as therapeutic targets.

### MECHANISM_HYPOTHESIS:
The integrated approach focuses on G19943 as a hub regulating lipid metabolism and insulin signaling, while G33764 enhances enzymatic functions that promote insulin sensitivity. G04436 contributes to metabolic regulation through its transcriptional activities, collectively creating a comprehensive framework to target dysregulated pathways in Type 2 Diabetes. This multi-target strategy addresses the complexity of T2D by modulating several interconnected pathways, improving overall metabolic health.

### TISSUE_RATIONALE:
The most relevant tissues for targeting these genes include the liver and adipose tissue, where they play pivotal roles in lipid metabolism, insulin action, and glucose homeostasis. Focusing interventions in these tissues is essential for enhancing metabolic regulation and improving insulin sensitivity.

### THERAPEUTIC_APPROACH:
The strategy would involve the small molecule activation of G19943, G33764, and G04436, aiming to enhance their functions within their respective pathways to improve metabolic homeostasis and insulin sensitivity.

### PREDICTED_OUTCOME:
Modulating these targets is expected to significantly enhance insulin sensitivity, optimize lipid metabolism, and provide a therapeutic benefit that could reverse or slow the progression of Type 2 Diabetes, leading to improved patient outcomes.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central role in metabolic regulation and strong evidence supporting its therapeutic potential, followed by G33764 and G04436 for their crucial roles in lipid metabolism and insulin signaling. G22553 is included for its primary driver status in metabolic pathways, while G19122 provides additional support in insulin signaling, rounding out a comprehensive therapeutic approach.

### CONFIDENCE: HIGH based on the robustness of data supporting the selected targets and their roles in diabetes-related pathways.
2026-02-10 19:38:20,110 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:38:20,110 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:38:20,113 - root - INFO -   -> Created offspring: 'Targeting a Multi-Pathway Approach in Ty...'
2026-02-10 19:38:20,114 - root - INFO - Crossover 6/18: parents '** Identification of Promising...' x '** Identification of Promising...'
2026-02-10 19:38:20,175 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:38:54,566 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:38:54,573 - root - INFO - TOKEN_USAGE: input=40137, output=762, total=40899, cost=$0.006478
2026-02-10 19:38:54,574 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:38:54,574 - root - INFO - 
**TITLE:** Integrative Approach to Targeting Gene Networks in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene is a hub component in T2D-related networks, supported by multiple datasets indicating its critical role in insulin signaling and metabolic homeostasis.
2. **G22553** | Score: **4.0** | As a primary driver in the black module, this gene shows a strong positive correlation with T2D and has significant potential for therapeutic intervention.
3. **G23245** | Score: **4.0** | This gene is a primary driver in the silver module and is implicated in pathways associated with T2D, providing a negative correlation which highlights its role in metabolic regulation.
4. **G27976** | Score: **3.0** | A major regulator in the silver module, this gene's role in T2D regulation emphasizes its importance in maintaining metabolic balance.
5. **G19122** | Score: **3.0** | As a major regulator involved in insulin signaling, this gene provides additional support for targeting pathways related to glucose metabolism.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The proposed hypothesis emphasizes the central role of G19943 as a hub in T2D-related gene networks, while also integrating the contributions of G22553 and G23245 as primary drivers of metabolic pathways. By targeting these interconnected genes, the hypothesis aims to address the multifaceted nature of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported, but TF activity is critical for gene regulation in T2D**

**MECHANISM_HYPOTHESIS:** The primary target, G19943, is hypothesized to function as a critical hub in insulin signaling pathways. Its modulation is expected to enhance insulin sensitivity in peripheral tissues while potentially alleviating inflammatory stress responses linked to insulin resistance. This is complemented by the roles of G22553 and G23245, which drive pathways that either promote or inhibit T2D pathology, thereby providing a comprehensive therapeutic framework.

**TISSUE_RATIONALE:** Targeting these genes in pancreatic -cells, muscle, and adipose tissue is critical, as these tissues are central to glucose homeostasis and insulin response. The involvement of G19943 in insulin signaling pathways suggests that enhancing its activity could have a direct beneficial effect on glucose metabolism in these tissues.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will involve small molecule modulation to enhance the activity of G19943 and potentially other targets, with the goal of restoring their function in insulin signaling and metabolic pathways.

**PREDICTED_OUTCOME:** Modulation of G19943 is expected to improve insulin sensitivity, reduce blood glucose levels, and enhance overall metabolic control in patients with Type 2 Diabetes, potentially leading to a reduction in the incidence of diabetes-related complications.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, roles in relevant biological pathways, and evidence of involvement in T2D pathology. G19943 is highlighted as the most promising due to its central position in the gene network, while G22553 and G23245 are equally vital due to their primary driver roles in T2D-related modules.

**CONFIDENCE:** **HIGH** based on the strong support from multi-omics data and the interconnectivity of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:38:54,575 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:38:54,576 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:38:54,576 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:38:54,579 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:38:54,579 - root - INFO -   -> Created offspring: '** Integrative Approach to Targeting Gen...'
2026-02-10 19:38:54,579 - root - INFO - Crossover 7/18: parents 'Comprehensive Modulation of Ke...' x 'Dual Modulation of G19943 and ...'
2026-02-10 19:38:54,619 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:39:31,589 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:39:31,596 - root - INFO - TOKEN_USAGE: input=40325, output=769, total=41094, cost=$0.006510
2026-02-10 19:39:31,596 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:39:31,596 - root - INFO - 
### TITLE: Integrated Modulation of G19943, G22553, and G04436 for Comprehensive Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Central hub in T2D pathways, facilitating insulin signaling and metabolic regulation.
2. **G22553** | Score: **4.0** | A primary driver in insulin signaling pathways, complementing G19943's function to improve glucose metabolism.
3. **G04436** | Score: **4.0** | Critical enzyme involved in metabolic regulation, enhancing the effects of both G19943 and G22553.
4. **G23245** | Score: **4.0** | Primary driver that supports glucose uptake and insulin sensitivity, adding synergistic benefits to the combined approach.
5. **G33764** | Score: **4.0** | Provides additional regulatory support within metabolic pathways, enhancing overall therapeutic efficacy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis proposes a robust therapeutic strategy targeting G19943, G22553, and G04436 to address the multifaceted nature of Type 2 Diabetes (T2D). By integrating insights from both parent hypotheses, we aim to leverage the synergistic interactions between these key drivers and regulators to enhance insulin sensitivity and metabolic control, ultimately improving patient outcomes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- **WGCNA module role**: G19943 is identified as a hub component in relevant modules negatively correlated with T2D.
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
G19943 plays a critical role in coordinating insulin signaling and lipid metabolism, effectively restoring metabolic homeostasis. By targeting G22553 in conjunction with G19943, we enhance the modulation of insulin signaling pathways, which is crucial for reversing insulin resistance. Additionally, by including G04436, we can further optimize lipid metabolism, thereby addressing both glucose regulation and lipid dysregulation, which are central to T2D pathology. The integration of G23245 and G33764 provides additional support, ensuring a comprehensive approach to T2D management.

### TISSUE_RATIONALE:
Key tissues include pancreatic beta-cells, muscle, liver, and adipose tissue. These tissues are essential for insulin action, glucose uptake, and lipid metabolism, making them critical targets for therapeutic interventions aimed at reversing T2D.

### THERAPEUTIC_APPROACH:
The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G04436 to mitigate negative feedback mechanisms affecting metabolic pathways.

### PREDICTED_OUTCOME:
The combined modulation of G19943, G22553, and G04436 is anticipated to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergy. G19943 is prioritized for its central role, followed closely by G22553, which complements its function. G04436 is included for its regulatory significance, while G23245 and G33764 provide additional support without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 19:39:31,598 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:39:31,598 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:39:31,612 - root - INFO -   -> Created offspring: 'Integrated Modulation of G19943, G22553,...'
2026-02-10 19:39:31,613 - root - INFO - Mutation 8/18: parent '** Integrated Activation of Me...'
2026-02-10 19:39:31,614 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:39:31,673 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:39:50,446 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:39:50,451 - root - INFO - TOKEN_USAGE: input=39466, output=663, total=40129, cost=$0.006318
2026-02-10 19:39:50,452 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:39:50,452 - root - INFO - 
**TITLE:** Targeting G22553 for Enhanced Insulin Sensitivity in Type 2 Diabetes through Multi-Pathway Modulation

**RANKED_TARGETS:**
1. **G22553 | Score: 4.0 | This gene plays a primary role in insulin receptor signaling pathways, which are critical for glucose uptake and metabolism in T2D.**
2. **G19122 | Score: 3.0 | As a major regulator in insulin signaling pathways, its modulation can help restore metabolic balance disrupted in diabetes.**
3. **G33764 | Score: 4.0 | This enzymes modulation positively impacts metabolic dysregulation associated with T2D, enhancing overall metabolic function.**
4. **G23245 | Score: 4.0 | This gene acts as a primary driver in T2D, contributing to metabolic regulation and has potential as a therapeutic target.**
5. **G04436 | Score: 4.0 | This enzyme's activation enhances glucose metabolism and insulin sensitivity, making it crucial for metabolic homeostasis in T2D.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes targeting G22553, which is essential in insulin receptor signaling, to enhance insulin sensitivity and improve glucose metabolism in Type 2 Diabetes. The modulation of G19122 and G33764 will complement this approach by restoring metabolic balance and addressing dysregulation, providing a multi-faceted therapeutic strategy.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: Primary driver in the black module
- Regulating TFs: 0 reported but crucial for T2D

**MECHANISM_HYPOTHESIS:** The activation of G22553 is anticipated to enhance insulin receptor signaling, leading to improved glucose uptake and metabolism in peripheral tissues. Coupled with the modulation of G19122, which restores insulin signaling balance, and G33764, which addresses metabolic dysregulation, this integrated approach is expected to yield significant improvements in insulin sensitivity and overall metabolic control in T2D patients.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells, muscle, and liver, as they are directly involved in glucose metabolism and insulin action, which are central to the pathophysiology of T2D.

**THERAPEUTIC_APPROACH:** This hypothesis focuses on the activation of the selected targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** The modulation of these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their critical roles in insulin signaling and glucose metabolism, and the robustness of the supporting evidence. G22553 was selected as the primary target due to its central role in insulin receptor signaling, while G19122 and G33764 were prioritized for their significant contributions to metabolic regulation and insulin signaling.
2026-02-10 19:39:50,453 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:39:50,453 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:39:50,454 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:39:50,457 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:39:50,457 - root - INFO -   -> Created mutated offspring: '** Targeting G22553 for Enhanced Insulin...'
2026-02-10 19:39:50,457 - root - INFO - Mutation 9/18: parent 'Integrated Multi-Target Approa...'
2026-02-10 19:39:50,458 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:39:50,513 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:40:30,850 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:40:30,853 - root - INFO - TOKEN_USAGE: input=39516, output=762, total=40278, cost=$0.006385
2026-02-10 19:40:30,853 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:40:30,853 - root - INFO - 
### TITLE: Enhanced Modulation of G23245 with Integrated Pathway Insights for Optimizing Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G23245** | Score: 4.0 | Central to insulin signaling and primary driver in glucose metabolism, reinforcing its role in therapeutic enhancement.
2. **G33764** | Score: 4.0 | Functions as a key enzyme in metabolic pathways, supporting G23245 through synergistic effects on glucose homeostasis.
3. **G00484** | Score: 4.0 | This transcription factor regulates insulin signaling, providing a necessary regulatory layer to enhance the effects of G23245 and G33764.
4. **G19943** | Score: 4.0 | Functions as a hub component in the silver module, indicating its importance in T2D-related pathways and complementing the primary targets.
5. **G22553** | Score: 4.0 | Acts as a primary driver in the black module, reinforcing metabolic regulation and presenting a supportive mechanism to the top targets.

**PRIMARY_TARGET:** G23245

**SUMMARY:** This refined hypothesis focuses on leveraging the central role of G23245 in insulin sensitivity while integrating the contributions of G33764 and G00484 to enhance metabolic regulation. Additionally, the inclusion of G19943 and G22553 provides additional layers of support and robustness to the therapeutic strategy, aiming for a comprehensive approach to managing Type 2 Diabetes (T2D).

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: G23245 is a primary driver in the silver module, which is negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in related pathways, enhancing the understanding of transcriptional control in insulin sensitivity.

**MECHANISM_HYPOTHESIS:** G23245 is hypothesized to be a pivotal regulator within insulin signaling pathways, enhancing glucose uptake in pancreatic -cells and peripheral tissues. By activating G23245, we anticipate a positive influence on downstream metabolic processes, supported by G33764, which enhances metabolic pathways, and G00484, which regulates insulin signaling. The addition of G19943 and G22553 further enriches this mechanism, emphasizing a multi-faceted approach to improving insulin sensitivity.

**TISSUE_RATIONALE:** The most relevant tissues for this hypothesis include pancreatic -cells, liver, and muscle, as these are critical for insulin secretion and action, directly impacting glucose homeostasis and providing optimal targets for therapeutic intervention.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves the development of small molecule activators targeting G23245, coupled with combination therapies aimed at modulating G33764 and G00484 for enhanced effects on insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Effective modulation of G23245 and its associated pathways is expected to significantly improve insulin sensitivity and reduce blood glucose levels, directly addressing the underlying pathophysiology of T2D and optimizing overall disease management.

**RANKING_RATIONALE:** G23245 is ranked highest due to its central role in insulin signaling and strong evidence supporting its involvement in critical metabolic pathways. G33764 follows closely for its enzymatic role in metabolism, while G00484 adds necessary regulatory depth. G19943 and G22553 provide additional support, reinforcing the robustness of the therapeutic approach.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 19:40:30,853 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:40:30,854 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:40:30,854 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:40:30,855 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:40:30,856 - root - INFO -   -> Created mutated offspring: 'Enhanced Modulation of G23245 with Integ...'
2026-02-10 19:40:30,856 - root - INFO - Mutation 10/18: parent '** Integrated Target Hypothesi...'
2026-02-10 19:40:30,857 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:40:30,896 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:41:14,112 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:41:14,121 - root - INFO - TOKEN_USAGE: input=39531, output=787, total=40318, cost=$0.006402
2026-02-10 19:41:14,121 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:41:14,121 - root - INFO - 
**TITLE:** Tissue-Specific Target Hypothesis for Enhancing Insulin Sensitivity in Adipose Tissue in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | As a hub component in the co-expression network, G19943 demonstrates a strong negative correlation with T2D, indicating its critical role in metabolic regulation within adipose tissue.
2. **G33764** | Score: **4.0** | This enzyme's central role in lipid metabolism and insulin signaling is crucial for enhancing insulin sensitivity, particularly in adipocytes where lipid storage and mobilization occur.
3. **G19122** | Score: **3.0** | Identified as a major regulator in insulin signaling, G19122 supports the modulation of metabolic pathways essential for maintaining glucose homeostasis in adipose tissue.
4. **G22553** | Score: **4.0** | As a primary driver within a co-expression network correlated with T2D, G22553 may play a significant role in the regulation of fat storage and insulin signaling in adipose tissue.
5. **G04436** | Score: **4.0** | An enzyme with transcriptional regulation roles, G04436 indicates potential involvement in lipid metabolism pathways relevant to T2D and could enhance adaptive responses in adipose tissue.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis focuses on the pivotal role of G19943 as the primary target in enhancing insulin sensitivity in adipose tissue, leveraging its status as a hub component in the co-expression network linked to T2D. The complementary roles of G33764 and G19122 in lipid metabolism and insulin signaling pathways further strengthen the approach to tackle metabolic dysregulation in Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Lipid metabolism, Insulin signaling pathways, Metabolic regulation pathways**
- WGCNA module role: **Hub component in a module negatively correlated with T2D**
- Regulating TFs: **Potential interactions with regulatory transcription factors not yet identified.**

**MECHANISM_HYPOTHESIS:** The modulation of G19943 is expected to enhance the regulatory mechanisms governing lipid metabolism and insulin signaling in adipose tissue. G33764's role as an enzyme will further support increased insulin sensitivity, while G19122's influence on insulin signaling pathways will synergize these effects, collectively improving metabolic control in Type 2 Diabetes.

**TISSUE_RATIONALE:** Adipose tissue is essential for insulin action and lipid homeostasis, making it a critical target for enhancing glucose metabolism and overall metabolic health in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy will involve small molecule activation of G19943 and G33764 to boost their functional roles in lipid metabolism and insulin sensitivity, with a potential modulatory approach for G19122 to optimize insulin signaling.

**PREDICTED_OUTCOME:** Targeting these genes is expected to enhance insulin sensitivity, optimize glucose metabolism, and provide significant therapeutic benefits in managing Type 2 Diabetes, particularly by improving the function of adipose tissue.

**RANKING_RATIONALE:** G19943 is ranked highest due to its central role in the co-expression network and its negative correlation with T2D. G33764 is positioned next for its critical involvement in insulin signaling and lipid metabolism. G19122, while slightly lower, supports the insulin signaling framework. G22553 and G04436 are also strong candidates but are ranked lower due to their more specialized roles compared to the top three.

**CONFIDENCE:** **HIGH** based on the robustness of data supporting the roles of G19943 and G33764 in diabetes-related pathways.
2026-02-10 19:41:14,124 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:41:14,125 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:41:14,127 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:41:14,141 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:41:14,142 - root - INFO -   -> Created mutated offspring: '** Tissue-Specific Target Hypothesis for...'
2026-02-10 19:41:14,142 - root - INFO - Mutation 11/18: parent 'Comprehensive Target Hypothesi...'
2026-02-10 19:41:14,142 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:41:14,204 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:41:49,222 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:41:49,227 - root - INFO - TOKEN_USAGE: input=39554, output=762, total=40316, cost=$0.006390
2026-02-10 19:41:49,227 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:41:49,227 - root - INFO - 
### TITLE: Tissue-Specific Target Hypothesis for Enhanced Type 2 Diabetes Treatment in Adipose Tissue

#### RANKED_TARGETS:
1. **G33764** | Score: 4.0 | This gene exhibits significant dysregulation in insulin resistance mechanisms, particularly in adipose tissue, indicating its critical role in T2D pathology.
2. **G20274** | Score: 3.0 | As a major regulator in insulin signaling pathways, its dysregulation in adipose tissue further supports its importance in the pathophysiology of T2D.
3. **G19122** | Score: 3.0 | Implicated in metabolic dysregulation, this gene has shown a strong negative log2FC in adipose tissue, suggesting its relevance in T2D mechanisms.
4. **G22553** | Score: 4.0 | Identified as a primary driver in co-expression networks, highlighting its significant role in T2D pathways, especially within adipose tissue.
5. **G04436** | Score: 4.0 | While critical in glucose metabolism and insulin sensitivity, the focus on adipose tissue underscores the need to investigate its interaction with other prioritized genes.

#### PRIMARY_TARGET: G33764

### SUMMARY:
This mutated hypothesis emphasizes G33764 as the primary target, focusing on its role in adipose tissue, where insulin resistance is particularly pronounced in T2D. The inclusion of G20274 and G19122, along with G22553 and G04436, reinforces the multi-faceted approach to understanding insulin signaling and metabolic dysregulation in this tissue.

### DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, Lipid metabolism, Energy homeostasis
- WGCNA module role: G33764 is a primary driver in relevant modules related to T2D.
- Regulating TFs: 10 identified transcription factors associated with G33764.

### MECHANISM_HYPOTHESIS:
G33764 is hypothesized to disrupt insulin signaling in adipose tissue, leading to insulin resistance and impaired glucose homeostasis. Its interaction with G20274 and G19122 elucidates the complex regulatory network impacting lipid metabolism, while G22553 and G04436 further enhance our understanding of these dysregulated pathways in T2D.

### TISSUE_RATIONALE:
Adipose tissue is critical in glucose metabolism and insulin sensitivity, making it the most relevant tissue for this hypothesis. The dysfunction of adipose tissue contributes significantly to the overall metabolic disturbances observed in T2D, emphasizing the need for targeted therapies.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the inhibition of G33764 to enhance insulin sensitivity in adipose tissue, potentially combined with modulation of G20274 and G19122 to restore glucose homeostasis. A small molecule approach targeting these pathways is expected to be effective.

### PREDICTED_OUTCOME:
Targeting G33764 in adipose tissue is anticipated to improve insulin sensitivity, reduce hyperglycemia, and address the underlying metabolic dysfunction associated with Type 2 Diabetes, leading to better overall metabolic control and patient outcomes.

### RANKING_RATIONALE:
G33764 is ranked first due to its strong evidence linking it to insulin resistance mechanisms in adipose tissue. G20274 and G19122 follow for their roles in insulin signaling and metabolic dysregulation, while G22553 and G04436 provide additional context and support for the hypothesis.

### CONFIDENCE: HIGH based on strong multi-evidence support and the relevance of the chosen tissue in T2D pathophysiology.
2026-02-10 19:41:49,228 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:41:49,228 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:41:49,231 - root - INFO -   -> Created mutated offspring: 'Tissue-Specific Target Hypothesis for En...'
2026-02-10 19:41:49,231 - root - INFO - Crossover 12/18: parents '** Integrated Activation of Me...' x 'Comprehensive Target Hypothesi...'
2026-02-10 19:41:49,279 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:42:23,388 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:42:23,396 - root - INFO - TOKEN_USAGE: input=40280, output=739, total=41019, cost=$0.006485
2026-02-10 19:42:23,396 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:42:23,396 - root - INFO - 
**TITLE:** Synergistic Modulation of Insulin Sensitivity and Glucose Homeostasis in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G04436 | Score: 4.0 | This enzyme is a major regulator of metabolic pathways related to glucose homeostasis and is supported by multiple lines of evidence indicating its critical role in T2D.**
2. **G19943 | Score: 4.0 | As a hub component in gene networks, this gene integrates signaling pathways crucial for insulin sensitivity and glucose metabolism.**
3. **G22553 | Score: 4.0 | This gene is a primary driver in T2D-related pathways, enhancing insulin receptor signaling and glucose uptake.**
4. **G33764 | Score: 4.0 | This enzyme plays a significant role in insulin resistance mechanisms, with robust evidence supporting its dysregulation in T2D.**
5. **G19122 | Score: 3.0 | A major regulator in insulin signaling pathways that can help restore metabolic balance disrupted in diabetes.**

**PRIMARY_TARGET:** G04436

**SUMMARY:** This hypothesis posits that a synergistic approach targeting G04436, G19943, G22553, G33764, and G19122 will provide a comprehensive strategy for enhancing insulin sensitivity and restoring glucose homeostasis in Type 2 Diabetes. By integrating insights from both parent hypotheses, this approach aims to address multiple metabolic pathways involved in T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: G04436 and G33764 identified as primary drivers in relevant modules
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The modulation of G04436 is expected to enhance crucial metabolic pathways that influence insulin sensitivity and glucose homeostasis. Coupled with the activation of G19943, which serves as a hub for insulin signaling, and G22553, which facilitates glucose uptake, this approach aims to reverse the metabolic dysregulation observed in T2D. Additionally, targeting G33764 and G19122 will address insulin resistance mechanisms and support robust insulin signaling.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, muscle, and liver, as they are directly involved in glucose metabolism and insulin action, which are critical factors in T2D pathophysiology.

**THERAPEUTIC_APPROACH:** This hypothesis focuses on the activation of the selected targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** The modulation of these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their roles in key biological pathways, and the robustness of the supporting evidence. G04436 was selected as the primary target due to its central role in glucose homeostasis, while G19943 and G22553 were prioritized for their significant contributions to insulin signaling and metabolic regulation. G33764 and G19122 were included to further enhance the understanding and treatment of metabolic dysregulation in T2D.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:42:23,401 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:42:23,401 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:42:23,402 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:42:23,405 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:42:23,405 - root - INFO -   -> Created offspring: '** Synergistic Modulation of Insulin Sen...'
2026-02-10 19:42:23,405 - root - INFO - Crossover 13/18: parents '** Targeting G33764 in Muscle ...' x '** Identification of Promising...'
2026-02-10 19:42:23,585 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:42:59,189 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:42:59,197 - root - INFO - TOKEN_USAGE: input=40150, output=636, total=40786, cost=$0.006404
2026-02-10 19:42:59,197 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:42:59,198 - root - INFO - 
**TITLE:** Integrated Targeting of G19943, G33764, and G19122 for Enhanced Insulin Sensitivity and Glucose Homeostasis in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | Serves as a hub component in T2D gene networks, indicating its central role in regulating insulin signaling.
2. **G33764** | Score: **4.0** | A primary driver in metabolic pathways relevant to T2D; enhances glucose metabolism and insulin sensitivity in muscle tissue.
3. **G19122** | Score: **3.0** | A major regulator in insulin signaling pathways, crucial for muscle insulin responsiveness and glucose uptake.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes that targeting G19943, in conjunction with G33764 and G19122, will synergistically enhance insulin sensitivity and improve glucose metabolism in individuals with Type 2 Diabetes. G19943's role as a hub in regulatory networks allows it to influence multiple pathways, while G33764 and G19122 provide critical support in muscle tissues response to insulin.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17** (for G19943)
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported but relevant for regulation of insulin signaling**

**MECHANISM_HYPOTHESIS:** The integrated targeting strategy focuses on G19943 as a central hub, which can modulate the activity of G33764 and G19122 to enhance insulin signaling and glucose uptake. By improving the functional connectivity between these genes, we expect to mitigate insulin resistance and promote glucose homeostasis.

**TISSUE_RATIONALE:** Key tissues for this hypothesis include muscle and adipose tissues, as they play essential roles in glucose uptake and insulin sensitivity. Targeting these pathways in the relevant tissues will enhance their metabolic functions and improve glucose handling.

**THERAPEUTIC_APPROACH:** The approach would involve small molecule activation of G19943 to restore its function in insulin signaling, along with modulation of G33764 and G19122 to ensure coordinated enhancement of glucose metabolism.

**PREDICTED_OUTCOME:** Modulating G19943, along with G33764 and G19122, is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and overall better metabolic control in Type 2 Diabetes patients.

**RANKING_RATIONALE:** G19943 was ranked highest due to its central role in T2D gene networks and its strong evidence across datasets. G33764 follows as it enhances muscle insulin sensitivity, while G19122 is included for its significant regulatory role in insulin signaling pathways.

**CONFIDENCE:** **HIGH** based on the robustness of data supporting the roles of G19943, G33764, and G19122 in T2D-related pathways.
2026-02-10 19:42:59,213 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:42:59,214 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:42:59,214 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:42:59,219 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:42:59,220 - root - INFO -   -> Created offspring: '** Integrated Targeting of G19943, G3376...'
2026-02-10 19:42:59,221 - root - INFO - Mutation 14/18: parent 'Integrative Targeting of G1994...'
2026-02-10 19:42:59,221 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 19:42:59,411 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:43:36,565 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:43:36,572 - root - INFO - TOKEN_USAGE: input=39640, output=764, total=40404, cost=$0.006404
2026-02-10 19:43:36,572 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:43:36,572 - root - INFO - 
### TITLE: Targeting G22553 and G19122 for Enhanced Metabolic Regulation in Type 2 Diabetes Therapy

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | As a primary driver in the co-expression network, G22553 plays a significant role in T2D-related pathways, particularly in metabolic regulation.
2. **G19122** | Score: **3.0** | G19122 is identified as a major regulator of insulin sensitivity in adipose tissue, complementing G22553's role in metabolic pathways.
3. **G33764** | Score: **4.0** | This enzyme is integral to lipid metabolism and insulin signaling, making it a valuable secondary target in T2D management.
4. **G20274** | Score: **3.0** | Linked to insulin signaling pathways, G20274 supports glucose metabolism and further enhances the therapeutic strategy.
5. **G00484** | Score: **4.0** | As a transcription factor, G00484 may regulate pathways involved in metabolic processes, providing an additional layer of therapeutic potential.

#### PRIMARY_TARGET: G22553

### SUMMARY:
The mutated hypothesis proposes to focus on G22553 as the primary target due to its pivotal role in T2D-related metabolic pathways, while G19122 is included for its significant influence on insulin sensitivity in adipose tissue. The combination of these targets aims to create a robust therapeutic strategy that addresses multiple aspects of Type 2 Diabetes, leveraging the strengths of G33764 and G20274 to further enhance metabolic regulation.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Metabolic regulation, Adipose tissue function
- **WGCNA module role**: Primary driver in pathways negatively correlated with T2D
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
G22553 is hypothesized to act as a primary regulator of metabolic pathways, significantly impacting lipid metabolism and insulin signaling in T2D. Its interaction with G19122 will enhance insulin sensitivity in adipose tissue, addressing critical aspects of metabolic dysfunction. Additionally, G33764 and G20274 will provide supplementary modulation of glucose uptake and insulin responsiveness, creating a comprehensive approach to T2D therapy.

### TISSUE_RATIONALE:
The primary tissues of interest include adipose tissue and liver, where G22553's regulation can enhance metabolic processes and improve insulin action, crucial for maintaining glucose homeostasis.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the activation of G22553 and G19122 using small molecule modulators to enhance their regulatory functions, which is expected to lead to improved insulin signaling and metabolic outcomes in T2D management.

### PREDICTED_OUTCOME:
Modulating G22553 and G19122 is anticipated to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could alleviate the progression of Type 2 Diabetes.

### RANKING_RATIONALE:
G22553 is ranked highest due to its central role in metabolic regulation and its comprehensive metabolic influence. G19122 follows closely for its critical role in insulin sensitivity. G33764 and G20274 provide additional metabolic support, while G00484 rounds out the strategy as a relevant target linked to transcriptional regulation of metabolic pathways.

### CONFIDENCE: HIGH based on the comprehensive evidence supporting G22553's and G19122's roles in metabolic regulation and the additional support from other targets.
2026-02-10 19:43:36,573 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:43:36,573 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:43:36,576 - root - INFO -   -> Created mutated offspring: 'Targeting G22553 and G19122 for Enhanced...'
2026-02-10 19:43:36,577 - root - INFO - Mutation 15/18: parent 'Comprehensive Modulation of Ke...'
2026-02-10 19:43:36,577 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:43:36,642 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:44:10,229 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:44:10,237 - root - INFO - TOKEN_USAGE: input=39545, output=768, total=40313, cost=$0.006393
2026-02-10 19:44:10,237 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:44:10,237 - root - INFO - 
### TITLE: Enhanced Therapeutic Modulation in Type 2 Diabetes Management via Combined Activation Strategies

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | This enzyme is crucial in lipid metabolism and insulin signaling, and its activation can improve metabolic control.
2. **G22553** | Score: **4.0** | As a primary driver in insulin signaling, its activation is expected to reverse insulin resistance effectively.
3. **G33764** | Score: **4.0** | This gene has significant regulatory roles in metabolic pathways; activating it could synergistically enhance metabolic flexibility.
4. **G23245** | Score: **4.0** | Activation of this gene can further enhance glucose uptake and insulin sensitivity, supporting the overall therapeutic strategy.
5. **G19122** | Score: **3.0** | This major regulator's activation can enhance the efficacy of the overall therapeutic approach by targeting critical metabolic pathways.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This mutated hypothesis proposes a novel therapeutic strategy that focuses on the activation of G04436 as the primary target, complemented by the activation of G22553, G33764, and G23245. By enhancing the functions of these key drivers in lipid and glucose metabolism, we aim to achieve superior metabolic control and improved insulin sensitivity in Type 2 Diabetes management.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G04436)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism
- **WGCNA module role**: Primary driver in relevant modules for G22553 and G33764
- **Regulating TFs**: Multiple transcription factors identified for G04436

### MECHANISM_HYPOTHESIS:
The activation of G04436 is expected to enhance lipid metabolism and improve insulin sensitivity, effectively addressing one of the critical aspects of Type 2 Diabetes pathology. Additionally, the activation of G22553 will further strengthen insulin signaling pathways, while G33764 and G23245 will collaboratively enhance glucose uptake and metabolic flexibility. This combined activation approach aims to create a robust therapeutic effect by targeting multiple facets of metabolic dysregulation in T2D.

### TISSUE_RATIONALE:
The primary tissues of interest include the liver, muscle, and adipose tissue. These tissues are pivotal in managing insulin sensitivity, glucose uptake, and lipid metabolism, making them critical targets for therapeutic interventions aimed at reversing Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The proposed approach involves small molecule activation of G04436, G22553, G33764, and G23245 to enhance their respective functions, promoting a multifaceted improvement in metabolic control and insulin sensitivity.

### PREDICTED_OUTCOME:
The combined activation of G04436, G22553, G33764, and G23245 is anticipated to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control, leading to more effective management of Type 2 Diabetes compared to conventional approaches targeting single pathways.

### RANKING_RATIONALE:
The targets are ranked based on their roles as primary drivers in T2D pathways and their evidence strength across multiple datasets. G04436 leads due to its critical role in lipid metabolism and regulatory significance, followed by G22553 for its established role in insulin signaling. G33764 and G23245 are included for their potential synergistic effects on glucose metabolism, while G19122 provides additional support without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 19:44:10,239 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:44:10,239 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:44:10,243 - root - INFO -   -> Created mutated offspring: 'Enhanced Therapeutic Modulation in Type ...'
2026-02-10 19:44:10,243 - root - INFO - Crossover 16/18: parents '** Integrated Activation of Me...' x '** Identification of Novel Dru...'
2026-02-10 19:44:10,327 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:44:50,265 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:44:50,273 - root - INFO - TOKEN_USAGE: input=40113, output=771, total=40884, cost=$0.006480
2026-02-10 19:44:50,273 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:44:50,273 - root - INFO - 
**TITLE:** Comprehensive Modulation of Metabolic Pathways to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene is a hub component in T2D-related gene networks, crucial for metabolic regulation and insulin signaling, making it a prime candidate for therapeutic targeting.**
2. **G33764 | Score: 4.0 | As a primary driver in metabolic pathways, its modulation is essential for regulating insulin sensitivity and glucose metabolism, complementing the effects of G19943.**
3. **G04436 | Score: 4.0 | This enzyme enhances glucose metabolism and has demonstrated significant evidence of improving insulin sensitivity, thus supporting the mechanisms initiated by G19943 and G33764.**
4. **G22553 | Score: 4.0 | Its role as a primary driver in insulin receptor signaling pathways makes it vital for facilitating glucose uptake and enhancing the overall efficacy of the therapeutic strategy.**
5. **G19122 | Score: 3.0 | This major regulator in insulin signaling pathways can help restore metabolic balance, further augmenting the effects of the primary targets in improving insulin sensitivity.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the activation of critical metabolic pathways through the modulation of G19943, G33764, G04436, and G22553, focusing on enhancing insulin sensitivity and glucose metabolism in Type 2 Diabetes. By simultaneously targeting these genes, we aim to provide a robust therapeutic approach that addresses multiple facets of T2D pathology while overcoming limitations identified in previous hypotheses.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, metabolism, inflammatory response, lipid metabolism
- WGCNA module role: Hub component (G19943), Primary Driver (G33764, G22553)
- Regulating TFs: None identified, but potential for regulatory interactions exists

**MECHANISM_HYPOTHESIS:** The activation of G19943 is expected to enhance insulin signaling pathways, promoting improved insulin sensitivity in peripheral tissues. G33764's modulation is projected to regulate lipid metabolism, while G04436 and G22553 will facilitate glucose uptake and receptor signaling, respectively. This comprehensive approach aims to address the dysregulation seen in T2D through synergistic action on multiple targets, potentially leading to enhanced metabolic control.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells, muscle, and liver, as they play crucial roles in glucose metabolism and insulin action, directly impacting the pathophysiology of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their roles in key biological pathways, and the robustness of the supporting evidence. G19943 was selected as the primary target due to its central role as a hub component in the gene network, while G33764 and G04436 were prioritized for their significant contributions to metabolic regulation and insulin signaling. G22553 and G19122 were included for their essential roles in supporting the overall therapeutic strategy. 

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:44:50,275 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:44:50,276 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:44:50,281 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:44:50,289 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:44:50,289 - root - INFO -   -> Created offspring: '** Comprehensive Modulation of Metabolic...'
2026-02-10 19:44:50,290 - root - INFO - Mutation 17/18: parent 'Integrative Targeting of G1994...'
2026-02-10 19:44:50,290 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:44:50,332 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:45:35,432 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:45:35,437 - root - INFO - TOKEN_USAGE: input=39639, output=835, total=40474, cost=$0.006447
2026-02-10 19:45:35,437 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:45:35,437 - root - INFO - 
### TITLE: Dual Activation of G19943 and G19122 for Enhanced Therapeutic Modulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Maintains its position as a hub component in the co-expression network, crucial for lipid metabolism and insulin signaling related to T2D, and is targeted for activation to enhance its regulatory role.
2. **G19122** | Score: **3.0** | Continues to play a significant role in adipose tissue metabolism and insulin sensitivity; proposed for activation to synergize with G19943 in improving glucose metabolism.
3. **G22553** | Score: **4.0** | Serves as a primary driver in T2D-related pathways and supports metabolic processes, making it a strong candidate for additional modulation.
4. **G33764** | Score: **4.0** | Important enzyme in metabolic regulation, its activation could further augment the effects of G19943 and G19122 in lipid and glucose metabolism.
5. **G20274** | Score: **3.0** | While still relevant in insulin signaling pathways, its role is less central compared to the primary targets, but could provide supportive modulation.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This mutated hypothesis proposes a dual activation strategy targeting G19943 and G19122 to enhance their roles in glucose and lipid metabolism in Type 2 Diabetes. Activation of these targets is expected to synergistically improve insulin sensitivity and metabolic regulation, while additional modulation of G22553 and G33764 may provide further therapeutic benefits.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, Insulin signaling pathways, Metabolic regulation in adipose tissue
- **WGCNA module role**: G19943 remains a hub component, with G19122 as a major regulator in the silver module negatively correlated with T2D.
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
The mechanism posits that activating G19943 will enhance its role as a master regulator of lipid metabolism and insulin signaling, thereby significantly improving T2D pathophysiology. Complementary activation of G19122 is expected to boost insulin sensitivity specifically in adipose tissue, addressing critical metabolic aspects. Additionally, the modulation of G22553 and G33764, both of which play supportive roles in metabolic pathways, will fortify the therapeutic approach, ensuring a multifaceted strategy against T2D.

### TISSUE_RATIONALE:
The primary tissues of focus include pancreatic -cells and adipose tissue. Activation of G19943 will enhance insulin secretion and sensitivity in the pancreas, while activation of G19122 will directly improve insulin action and lipid storage in adipose tissue, vital for maintaining glucose homeostasis.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the activation of G19943 and G19122 using small molecule modulators designed to enhance their regulatory functions, leading to improved insulin signaling and metabolic outcomes in the management of Type 2 Diabetes.

### PREDICTED_OUTCOME:
Activating G19943 and G19122 is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and yield a therapeutic benefit that could reverse or slow the progression of Type 2 Diabetes.

### RANKING_RATIONALE:
G19943 is ranked highest due to its central role and activation potential to address multiple metabolic pathways. G19122 follows as it directly complements the primary target in adipose tissue. G22553 and G33764 provide additional metabolic support through their roles in T2D-related pathways, while G20274, although important, is less central in this therapeutic strategy.

### CONFIDENCE: HIGH based on robust evidence supporting the roles of G19943 and G19122 in metabolic regulation and the synergistic potential of this dual activation strategy.
2026-02-10 19:45:35,437 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:45:35,438 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:45:35,440 - root - INFO -   -> Created mutated offspring: 'Dual Activation of G19943 and G19122 for...'
2026-02-10 19:45:35,441 - root - INFO - Crossover 18/18: parents '** Enhanced Mechanistic Insigh...' x 'Comprehensive Modulation of Ke...'
2026-02-10 19:45:35,478 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:45:54,406 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:45:54,412 - root - INFO - TOKEN_USAGE: input=40308, output=741, total=41049, cost=$0.006491
2026-02-10 19:45:54,412 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:45:54,412 - root - INFO - 
**TITLE:** Integrated Multi-Target Approach for Enhanced Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | G22553 is a primary driver in T2D pathways, significantly modulating insulin signaling and glucose metabolism, making it essential for targeted therapies.
2. **G23245** | Score: **4.0** | As a complementary driver, G23245 enhances glucose uptake and insulin sensitivity, making it a crucial partner to G22553 in improving metabolic outcomes.
3. **G04436** | Score: **4.0** | This enzyme plays a critical role in lipid metabolism and insulin signaling, supporting the therapeutic strategy by addressing dyslipidemia often associated with T2D.
4. **G33764** | Score: **4.0** | Identified as a primary driver in insulin signaling pathways, G33764 provides additional regulatory support for improving glucose homeostasis.
5. **G19122** | Score: **3.0** | A major regulator in metabolic pathways, G19122 can enhance the efficacy of G22553 and G23245, bridging insulin signaling and glucose metabolism.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a multi-target therapeutic strategy that emphasizes G22553 as the primary target while leveraging the complementary roles of G23245 and G04436 to enhance glucose metabolism and insulin sensitivity. The inclusion of G33764 and G19122 further strengthens the approach by supporting insulin signaling and metabolic regulation, addressing the complexities of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, evidence from 2 datasets supports its role.
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism.
- WGCNA module role: Primary driver in the black and silver modules.
- Regulating TFs: None identified specifically for this gene in the data.

**MECHANISM_HYPOTHESIS:** G22553 is expected to enhance insulin signaling pathways, potentially reversing insulin resistance while G23245 will synergistically improve glucose uptake in peripheral tissues. G04436 will facilitate improved lipid metabolism, addressing dyslipidemia, while G33764 and G19122 reinforce metabolic pathways crucial for maintaining glucose homeostasis. This comprehensive approach aims to restore metabolic balance and improve overall health outcomes in T2D patients.

**TISSUE_RATIONALE:** The primary tissues of interest include the liver, adipose, and skeletal muscle, as they are integral to insulin sensitivity, glucose uptake, and lipid metabolismessential for effective management of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy involves the development of small molecule activators targeting G22553 and G23245, alongside modulators of G04436, to optimize their functions and enhance metabolic regulation.

**PREDICTED_OUTCOME:** The combined modulation of G22553, G23245, and G04436 is anticipated to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control, leading to superior management of Type 2 Diabetes compared to targeting individual pathways.

**RANKING_RATIONALE:** G22553 is ranked highest due to its pivotal role in insulin signaling and metabolic regulation, followed by G23245 for its complementary function. G04436, G33764, and G19122 provide additional support in regulating lipid metabolism and enhancing the overall therapeutic strategy, ensuring a robust multi-target approach.

**CONFIDENCE:** HIGH based on the strength of data support and integration across multiple evidence types.
2026-02-10 19:45:54,414 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:45:54,414 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:45:54,415 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:45:54,417 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:45:54,417 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Approach for ...'
2026-02-10 19:45:54,417 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 19:45:54,417 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 19:45:54,418 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 19:45:54,419 - root - INFO - Evaluating fitness for hypothesis: t2d-03-e3575a7c
2026-02-10 19:46:10,644 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:46:10,648 - root - INFO - TOKEN_USAGE: input=1470, output=782, total=2252, cost=$0.000690
2026-02-10 19:46:10,649 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:46:10,649 - root - INFO - 
### EVALUATION OF THE HYPOTHESIS

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a priority score of 4.0, and although it is included in the top priority list, it is not the highest-ranked target. There is cross-dataset consistency supporting its role, with evidence from two datasets. However, the lack of identified regulatory transcription factors for this gene may limit confidence in its functional implications.

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, with G22553 being a primary driver in the black module with a strong correlation to T2D. However, the close scores among multiple targets (all ranked at 4.0) make it challenging to clearly distinguish the stronger targets from the lower ones. The rationale for ranking is somewhat valid but could benefit from clearer distinctions between target strength.

**MECHANISTIC_SCORE:** 7  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns with the pathway context of metabolic regulation and insulin signaling, and the rationale for focusing on adipose tissue is well-supported by its role in T2D. However, the absence of specific regulatory transcription factors for G22553 limits the depth of understanding of its regulatory network.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators for G22553, along with potential modulators for G23245 and G19122, is appropriate given their proposed roles in enhancing insulin sensitivity. The network position of G22553 as a hub component suggests a promising therapeutic target, although safety considerations should be assessed in further studies.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by focusing on a tissue-specific approach for T2D management. However, the connections made among the targets are somewhat conventional, as they align with known metabolic pathways, which may limit the novelty of the approach.

### OVERALL FITNESS CALCULATION:
Overall Fitness = (DATA_SUPPORT * 0.25) + (RANKING_QUALITY * 0.25) + (MECHANISTIC * 0.20) + (THERAPEUTIC * 0.20) + (NOVELTY * 0.10)  
Overall Fitness = (7 * 0.25) + (6 * 0.25) + (7 * 0.20) + (8 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.75 + 1.5 + 1.4 + 1.6 + 0.6 = **6.85**  
Scaled to 0-100: **68.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G22553):** STRONG
- **Target #2 quality (G23245):** STRONG
- **Target #3 quality (G33764):** STRONG

### IMPROVEMENT SUGGESTIONS:
1. **Enhance Data Support:** Investigate additional datasets or biological contexts that could provide further evidence for G22553 and its regulatory mechanisms.
2. **Clarify Ranking Distinctions:** Consider refining the scoring system to more clearly differentiate between targets with similar scores, perhaps by evaluating their functional roles in greater detail.
3. **Identify Regulatory TFs:** Conduct additional studies to identify potential transcription factors that regulate G22553, enhancing the mechanistic understanding of its role in T2D.
4. **Perform Safety Assessments:** Early safety profiling of potential small molecule activators should be integrated into the therapeutic strategy development to preemptively address any adverse effects.
2026-02-10 19:46:10,649 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:46:10,649 - root - INFO - Evaluating fitness for hypothesis: t2d-03-d83f4585
2026-02-10 19:46:25,691 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:46:25,694 - root - INFO - TOKEN_USAGE: input=1533, output=827, total=2360, cost=$0.000726
2026-02-10 19:46:25,694 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:46:25,694 - root - INFO - 
### Evaluation of Hypothesis: Enhanced Therapeutic Strategies in Type 2 Diabetes through Targeting G33764 and G19122

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G33764 has a high priority score of 4.0 but lacks cross-dataset consistency, which is critical for validating its role in Type 2 Diabetes. There are only two evidence types supporting it, which is relatively low compared to the number of datasets typically expected in robust hypotheses. The evidence is decent but not strong enough for a higher score.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the highest target is supported by its role as a primary driver in metabolic pathways. However, the distinction between the top targets could be clearer, especially since G22553 and G19943 also received a score of 4.0. The rationale for the ranking does make sense but could benefit from further clarification on how G19122 and the others distinctly contribute to the therapeutic strategy.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways involved in insulin signaling and lipid metabolism. The tissue rationale focusing on adipose tissue and liver is appropriate, given their roles in glucose homeostasis. However, the lack of detail regarding the involvement of transcription factors (TFs) in the regulation of G33764 and its interaction with the other targets could be improved.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G33764 and G19122 using small molecule modulators is appropriate and aligns with the goal of enhancing insulin sensitivity. However, the assessment of druggability could be more robust. Safety considerations are not addressed, which is important when evaluating potential therapeutic strategies for a chronic condition like Type 2 Diabetes.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** While the hypothesis integrates existing knowledge creatively by focusing on G33764 and its interaction with G19122, the connections made are somewhat conventional in the context of metabolic regulation in T2D. There is potential for novel insights, but the idea of targeting these pathways is not entirely groundbreaking.

### OVERALL_FITNESS: 
Calculated as follows:
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 (scaled to 0-100 = 68.5)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (G33764 has substantial potential but lacks strong cross-dataset support)
- Target #2 quality: **MODERATE** (G19122 is relevant and supports insulin sensitivity, but evidence is not robust)
- Target #3 quality: **STRONG** (G22553 is a primary driver, providing a valuable support mechanism for the hypothesis)

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Seek additional datasets to validate the role of G33764, especially those demonstrating cross-dataset consistency.
2. **Clarify Ranking Justification:** Provide a more detailed comparison of the mechanisms and roles of G19122 and other targets relative to G33764 to strengthen the rationale for their ranking.
3. **Expand on TF Relationships:** Include specific transcription factors that might interact with G33764 and the other targets to enhance mechanistic understanding.
4. **Address Safety Considerations:** Discuss potential safety profiles and adverse effects associated with the modulation of these targets to provide a more comprehensive therapeutic strategy.
5. **Explore Novelty Further:** Investigate additional novel connections or mechanisms in metabolic regulation that could differentiate this hypothesis from existing literature to enhance its innovative aspect.
2026-02-10 19:46:25,694 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:46:25,695 - root - INFO - Novelty bonus applied: 0.3% -> fitness 68.50 -> 68.73
2026-02-10 19:46:25,695 - root - INFO - Evaluating fitness for hypothesis: t2d-03-1baf28f9
2026-02-10 19:46:42,882 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:46:42,897 - root - INFO - TOKEN_USAGE: input=1471, output=665, total=2136, cost=$0.000620
2026-02-10 19:46:42,899 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:46:42,899 - root - INFO - 
DATA_SUPPORT_SCORE: **5**
DATA_SUPPORT_RATIONALE: The primary target G19943 is indeed in the top priority list, which supports its relevance. However, G23245 and G33764 are also present in the ranking but are not top-ranked, indicating that while there is some data support, the overall support for the ranked targets is not as robust as it could be. The cross-dataset consistency for the primary target is good, with two datasets supporting it.

RANKING_QUALITY_SCORE: **7**
RANKING_QUALITY_RATIONALE: The ranking is justified by the data, especially for the primary target G19943, which is a key hub in insulin signaling. However, the presence of other equally scored targets in the top 10 list (like G22553 and G04436) creates ambiguity in the ranking. The rationale provided for the ranking is coherent, focusing on the roles of the targets in insulin sensitivity and metabolic regulation.

MECHANISTIC_SCORE: **6**
MECHANISTIC_RATIONALE: The proposed mechanism aligns well with the context of insulin signaling and metabolic pathways. The tissue rationale is supported, as the targeted tissues are indeed critical for insulin action. However, no regulatory transcription factors are reported, which could enhance the mechanistic understanding.

THERAPEUTIC_SCORE: **8**
THERAPEUTIC_RATIONALE: The therapeutic approach is appropriate, as small molecule modulation is a common strategy for enhancing activity in metabolic pathways. The selected targets are likely druggable given their roles in significant metabolic processes, but potential safety considerations associated with modulation of these pathways should be investigated further.

NOVELTY_SCORE: **6**
NOVELTY_RATIONALE: The hypothesis integrates various targets and highlights their synergistic effect, which is a creative approach. However, the connections between some targets are somewhat conventional in the context of T2D, which may limit the novelty.

OVERALL_FITNESS: **6.55** (5*0.25 + 7*0.25 + 6*0.20 + 8*0.20 + 6*0.10 = 6.55)

RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G19943 is a central hub in the insulin signaling pathway)
- Target #2 quality: **MODERATE** (G23245 shows promise but is not as prominent in the top priority list)
- Target #3 quality: **MODERATE** (G33764 has good evidence but is also not in the top priority tier)

IMPROVEMENT_SUGGESTIONS:
1. **Strengthen Cross-Dataset Support**: Gather more evidence across additional datasets for G23245 and G33764 to enhance their credibility as top targets.
2. **Explore Regulatory Networks**: Identify and report any potential regulatory transcription factors that might interact with the proposed targets; this could provide additional mechanistic insights.
3. **Clarify Target Selection**: Consider revisiting the rationale for excluding other high-scoring targets from the ranked list to ensure comprehensive coverage of potential candidates.
4. **Investigate Safety Profiles**: Conduct preliminary assessments of the safety profiles of the proposed therapeutic approaches to anticipate any adverse effects associated with modulation of these targets.
2026-02-10 19:46:42,899 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:46:42,903 - root - INFO - Evaluating fitness for hypothesis: t2d-03-39765494
2026-02-10 19:46:59,382 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:46:59,387 - root - INFO - TOKEN_USAGE: input=1489, output=707, total=2196, cost=$0.000648
2026-02-10 19:46:59,387 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:46:59,387 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 and the complementary target G04436 are both present in the top priority list, which indicates strong support. Additionally, there is cross-dataset consistency noted for these targets, enhancing their credibility. However, the total number of evidence types supporting the primary target is not specified, which slightly reduces the score.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their scores and their roles in T2D pathways. G19943 and G04436 are ranked highest due to their critical functions, and the rationale provided for their ranking is logical. However, there are other high-scoring targets (like G22553) that could also be considered for a higher position, which could indicate a slight lack of clarity in distinguishing between top targets.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and lipid metabolism pathways, which are central to T2D. The tissue rationale is also strong, focusing on pancreatic -cells, muscle, and adipose tissue, where these targets are expected to have significant effects. However, the absence of reported transcription factors (TFs) weakens the rationale slightly, as TFs play a crucial role in gene regulation related to T2D.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 alongside modulating G04436 is appropriate given their roles in insulin sensitivity. Both targets are likely druggable based on their central positions in relevant pathways. However, safety considerations are not addressed, which could affect the therapeutic potential of the proposed strategy.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by proposing a synergistic approach to enhance insulin sensitivity through well-characterized targets. However, while it does connect known pathways, the novelty of the specific combinations and mechanisms could be more pronounced to warrant a higher score.

---

**OVERALL_FITNESS:** 7.6 (scaled to 76)  
**Calculated: (7*0.25 + 8*0.25 + 8*0.20 + 8*0.20 + 7*0.10 = 1.75 + 2 + 1.6 + 1.6 + 0.7 = 7.6)**

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: **STRONG** (G19943 is well-supported and central)
- Target #2 quality: **STRONG** (G04436 complements G19943 effectively)
- Target #3 quality: **MODERATE** (G22553 is relevant but not as central as the top two)

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Evidence Types:** Include more evidence types to support the primary target and clarify the mechanisms of action.
2. **Address Safety Considerations:** Provide insights into potential safety concerns regarding the proposed therapeutic approach.
3. **Clarify TF Relationships:** Investigate and report any relevant transcription factors that may influence the targets, enhancing the mechanistic rationale.
4. **Consider Additional Data:** Evaluate whether additional datasets or experimental validation could provide more robust support for the hypothesis.
2026-02-10 19:46:59,388 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:46:59,389 - root - INFO - Evaluating fitness for hypothesis: t2d-03-3a195dc8
2026-02-10 19:47:14,251 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:47:14,255 - root - INFO - TOKEN_USAGE: input=1529, output=696, total=2225, cost=$0.000647
2026-02-10 19:47:14,255 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:47:14,255 - root - INFO - 
### EVALUATION OF HYPOTHESIS

#### DATA_SUPPORT_SCORE: **6**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a good priority score and is ranked in the top priority tier. However, cross-dataset consistency for G19943 is not established, which limits confidence in the robustness of the data. The number of evidence types supporting the primary target is also low (only 1 dataset), which affects the overall score.

#### RANKING_QUALITY_SCORE: **7**
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data available, with top-ranked targets demonstrating a central role in metabolic pathways. However, G19943's lower dataset support compared to other targets in the top gene list raises some concerns about its relative strength compared to others. The rationale is logical, but the support for G19943 is weaker than expected for a top-tier target.

#### MECHANISTIC_SCORE: **8**
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the pathways involved in T2D, with a clear focus on lipid metabolism and insulin signaling. The tissue rationale concerning the liver and adipose tissue is well-supported, reflecting their critical roles in metabolic regulation. However, the lack of regulatory transcription factors for G19943 slightly detracts from this score.

#### THERAPEUTIC_SCORE: **7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the primary targets seems appropriate given their roles in enhancing insulin sensitivity and metabolic control. The potential druggability of the targets is plausible based on their network position, but specific safety considerations weren't addressed, which could impact therapeutic outcomes.

#### NOVELTY_SCORE: **8**
**NOVELTY_RATIONALE:** The hypothesis demonstrates creative integration of mechanistic insights and proposes a multi-target strategy that is not commonly addressed in standard T2D research. The connections drawn between lipid metabolism and insulin signaling are insightful, adding value to the hypothesis.

### OVERALL_FITNESS: **7.25**
**Calculated as:** \( (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (8 * 0.10) = 7.25 \)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (G19943 has some support but lacks cross-dataset consistency)
- Target #2 quality: **STRONG** (G33764 is well-supported in lipid metabolism and insulin signaling)
- Target #3 quality: **STRONG** (G04436 plays a crucial regulatory role and has significant evidence)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Consistency:** Aim to gather more datasets that support the role of G19943 in T2D to enhance confidence in its prioritization.
2. **Expand Evidence Types:** Incorporate additional evidence types (e.g., functional studies, clinical data) to support the role of G19943 and improve its ranking.
3. **Address Safety Considerations:** Discuss potential safety issues related to the activation of these targets and outline any preliminary safety data if available.
4. **Explore Regulatory Relationships:** Investigate potential transcription factors or regulatory mechanisms for G19943 to strengthen its mechanistic rationale and support its role as a hub in metabolic regulation.
2026-02-10 19:47:14,255 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:47:14,256 - root - INFO - Evaluating fitness for hypothesis: t2d-01-abcef22c
2026-02-10 19:47:28,863 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:47:28,865 - root - INFO - TOKEN_USAGE: input=1460, output=740, total=2200, cost=$0.000663
2026-02-10 19:47:28,865 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:47:28,865 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is indeed in the top priority list with a score of 4.0. However, the warning indicates that while it is a top-ranked target, there are other genes, like G04436, G33764, and G01138, that are equally prioritized. There is cross-dataset consistency for the top-ranked targets (including G19943), and the evidence type supporting the primary target is strong but could be enhanced if more datasets corroborated its central role.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified by their scores and roles in T2D-related pathways. G19943 is positioned as the most promising target due to its hub role in insulin signaling, while G22553 and G23245 also contribute significantly to the metabolic network. The rationale provided aligns well with the data presented, although a more detailed explanation of the differences between similarly scored targets could further substantiate the ranking.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, particularly in insulin signaling and inflammation, which are pivotal in T2D. The tissue rationale is strong, focusing on pancreatic -cells, muscle, and adipose tissue, which are critical for glucose homeostasis. However, the absence of reported transcription factors (TFs) could be a limitation in fully understanding gene regulation.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation to enhance G19943 activity is appropriate given its role in insulin signaling. The potential for druggability is supported by its network position, but safety considerations are not elaborated upon, which is critical for evaluating overall therapeutic potential.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates multi-omics data to identify interconnected gene networks, which is a valuable approach. However, the connections drawn between these genes and T2D pathology, while important, do not appear to present particularly novel insights compared to existing literature in this field.

---

**OVERALL_FITNESS:** 7.4  
**(Calculated: 7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 1.75 + 2 + 1.6 + 1.4 + 0.6 = 7.4)**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **STRONG**  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Enhance Data Evidence:** Incorporate additional datasets or evidence types that support G19943 and other ranked targets to strengthen the data support score.
   
2. **Clarify TF Relationships:** Investigate and report any relevant transcription factors that may regulate the target genes or their pathways, enhancing mechanistic coherence.

3. **Safety Considerations:** Provide a detailed assessment of potential safety concerns related to the therapeutic approach to strengthen the therapeutic potential score. This could include discussing potential side effects or off-target effects of small molecule modulators based on existing literature.

4. **Differentiate Similar Targets:** Add a more detailed analysis or rationale for distinguishing between targets with similar scores to improve the ranking quality and clarity of target selection.
2026-02-10 19:47:28,865 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:47:28,865 - root - INFO - Evaluating fitness for hypothesis: t2d-03-859cee21
2026-02-10 19:47:37,782 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:47:37,787 - root - INFO - TOKEN_USAGE: input=1528, output=570, total=2098, cost=$0.000571
2026-02-10 19:47:37,787 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:47:37,788 - root - INFO - 
### EVALUATION RESULTS

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a priority score of 4.0 but lacks cross-dataset consistency, as it is only supported by one dataset. The two evidence types provide some data support, but the limited number of datasets and lack of consistency reduces the overall score.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the roles of the targets within T2D pathways and their synergistic potential. However, all targets share the same score, which slightly diminishes clarity in ranking strength. The rationale effectively explains the prioritization based on their functions.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context and tissue rationale, emphasizing insulin signaling and metabolic regulation. However, the lack of specific transcription factor interactions weakens the score slightly.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate and targets are likely druggable. However, the proposal could benefit from more specific safety considerations and a clearer outline of potential adverse effects, affecting the overall score.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative way, proposing a comprehensive strategy; however, the connections made are somewhat expected within the context of T2D management. This reduces the score for novelty, as similar approaches are prevalent in current research.

**OVERALL_FITNESS: 7.4**  
**Calculated:** (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.4

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Cross-Dataset Validation:** Aim to validate findings across additional datasets to enhance the robustness of the evidence for G19943 and strengthen the data support score.
2. **Explore Transcription Factor Interactions:** Investigate specific transcription factors that may regulate G19943 and its associated pathways to enhance mechanistic coherence.
3. **Detail Safety Profiles:** Provide a more comprehensive overview of potential safety concerns and side effects related to the therapeutic approach to address the therapeutic score.
4. **Clarify Unique Contributions:** Highlight unique contributions of lower-ranked targets (G23245 and G33764) to demonstrate their non-obvious connections and bolster the novelty score.
2026-02-10 19:47:37,789 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:47:37,790 - root - INFO - Evaluating fitness for hypothesis: t2d-03-a10a0594
2026-02-10 19:47:49,792 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:47:49,809 - root - INFO - TOKEN_USAGE: input=1361, output=662, total=2023, cost=$0.000601
2026-02-10 19:47:49,809 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:47:49,809 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target, G22553, is found in the top priority list (ranked 3rd with a score of 4.0). However, the warning indicates that there is a lack of strong evidence supporting this target beyond its inclusion in the priority tier. While cross-dataset consistency is confirmed, the evidence types supporting the primary target are limited, which affects the score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified as G22553 is a central player in insulin receptor signaling, supported by its high score. The other targets also have high scores, indicating their relevance to T2D. However, there is a lack of clear distinctions between the higher-ranked and lower-ranked targets, which slightly diminishes the strength of the ranking rationale.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway and the tissues involved (pancreatic -cells, muscle, liver) are appropriate for the context of T2D. However, the absence of reported regulating transcription factors (TFs) could limit the understanding of the regulatory network, which could enhance the mechanism's coherence.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets is appropriate for enhancing insulin sensitivity. The targets are likely druggable based on their network positions, and the proposal to use small molecules is a viable strategy. Safety considerations are not explicitly addressed in the hypothesis, which could raise concerns about potential side effects.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates multi-pathway modulation in a creative way, targeting multiple genes to enhance insulin sensitivity. However, the connections proposed are somewhat conventional for T2D research, and there are no particularly non-obvious connections highlighted that would elevate the novelty score.

**OVERALL_FITNESS: 6.5**  
(Calculated as follows: 6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 6.5)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: MODERATE  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Enhance Evidence Base:** Increase the variety and robustness of data supporting G22553 and its interactions by including additional evidence types, such as functional assays or clinical data.
2. **Clarify TF Relationships:** Investigate and report any potential transcription factors that may regulate the targets, as this can strengthen the mechanistic understanding and provide insights into regulatory networks.
3. **Address Safety Concerns:** Include a discussion on potential side effects or safety issues associated with targeting these genes, which can provide a more comprehensive view of the therapeutic potential.
4. **Differentiate Target Rankings:** More clearly delineate the differences in function and impact between the ranked targets to strengthen the rationale for their ordering.
2026-02-10 19:47:49,810 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:47:49,810 - root - INFO - Evaluating fitness for hypothesis: t2d-03-2ce5501d
2026-02-10 19:48:03,413 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:48:03,416 - root - INFO - TOKEN_USAGE: input=1460, output=628, total=2088, cost=$0.000596
2026-02-10 19:48:03,416 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:48:03,416 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G23245 is indeed found in the top priority list, along with several other ranked targets. There is cross-dataset consistency supporting the primary target, which adds weight to the evidence. However, the warning about the target gene not being found in the top priority list is slightly concerning, as it suggests a potential oversight in the data reporting.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified by the data presented, with G23245 being central to insulin signaling and supported by other targets that are ranked closely. Each target has a defined role that complements the others, contributing to a coherent therapeutic strategy. However, some minor ambiguity exists regarding the scoring of targets and their relative strengths.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways of insulin signaling and glucose metabolism. The rationale for focusing on pancreatic -cells, liver, and muscle tissues is well-supported by existing literature, and the interactions with transcription factors like G00484 are appropriately acknowledged.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic strategy of developing small molecule activators for G23245, along with combination therapies for G33764 and G00484, is appropriate and aligns with current drug development practices in diabetes management. The network position of these targets suggests they are likely druggable. However, specifics about safety considerations and potential side effects could have been elaborated further.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data effectively, the connections made among the targets are somewhat conventional in the context of T2D research. There is room for more innovative or less obvious connections that could enhance the novelty of the proposed approach.

### Overall Fitness Calculation
- Overall Fitness = (7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (8 * 0.20) + (6 * 0.10) = 7.65 (scaled to 0-100: 76.5)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify Target Gene Lists:** Ensure that all target genes are consistently represented in both the hypothesis and the top priority lists to avoid confusion and misinterpretation.
2. **Expand on Safety Considerations:** Provide a more detailed discussion on potential safety issues that could arise from the proposed therapeutic approaches, including off-target effects and how they will be mitigated.
3. **Enhance Novelty Aspects:** Explore and articulate more unconventional connections or innovative strategies that could differentiate this hypothesis from existing research, potentially by incorporating emerging technologies or novel combinatorial approaches.
2026-02-10 19:48:03,416 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:48:03,416 - root - INFO - Evaluating fitness for hypothesis: t2d-03-9050c464
2026-02-10 19:48:23,376 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:48:23,378 - root - INFO - TOKEN_USAGE: input=1485, output=688, total=2173, cost=$0.000636
2026-02-10 19:48:23,379 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:48:23,379 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, but there is a warning indicating G33764 is not found in the top priority list, which detracts from overall data support. There is cross-dataset consistency for G19943 and G33764. However, the overall support for the primary target is somewhat diminished due to the exclusion of G33764 from the top 10 priority genes.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, particularly with G19943 and G33764 both having high scores and supporting roles in metabolic pathways. However, the rankings of G22553 and G04436, which also share the same score, could be seen as less definitive. The rationale for the ranking is coherent, but the inclusion of G33764 in the primary list could enhance the clarity of the distinctions between targets.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in lipid metabolism and insulin signaling. The tissue rationale for focusing on adipose tissue is well-founded, as it directly relates to insulin sensitivity and glucose metabolism. The note on potential regulatory transcription factors adds depth but could benefit from further exploration of their specific roles.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G19943 and G33764 appears appropriate given their roles. However, the druggability of these targets could be better supported with evidence from existing literature or drug development pathways. Safety considerations are not discussed, which is important for a comprehensive therapeutic evaluation.

---

**NOVELTY_SCORE:** 5  
**NOVELTY_RATIONALE:** While the hypothesis integrates existing data and highlights important regulatory pathways, it does not significantly propose novel connections or highly innovative approaches. The targets are relevant but not particularly groundbreaking in the context of Type 2 Diabetes research.

---

**OVERALL_FITNESS:** 6.4  
**Calculated Score:** (6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 5*0.10) = 6.4

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: MODERATE  
- Target #3 quality: MODERATE  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Re-evaluate Target Inclusion:** Assess the rationale for excluding G33764 from the top priority list and consider including it to enhance overall data support.
2. **Expand on Safety Considerations:** Include a discussion on potential safety concerns related to the proposed therapeutic approach to provide a more comprehensive evaluation.
3. **Explore Regulatory Transcription Factors:** Identify potential transcription factors related to G19943, G33764, and other ranked targets to strengthen the mechanistic hypothesis.
4. **Consider Broader Pathway Implications:** Discuss how modulation of these targets may interact with other metabolic pathways beyond lipid metabolism and insulin signaling to enhance novelty.
5. **Investigate Druggability:** Provide evidence or references supporting the druggability of the targets outlined, which could improve therapeutic potential evaluation.
2026-02-10 19:48:23,379 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:48:23,379 - root - INFO - Evaluating fitness for hypothesis: t2d-03-c9dfae61
2026-02-10 19:48:37,738 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:48:37,744 - root - INFO - TOKEN_USAGE: input=1522, output=736, total=2258, cost=$0.000670
2026-02-10 19:48:37,744 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:48:37,744 - root - INFO - 
### Evaluation of the Hypothesis on Tissue-Specific Target for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G33764 has a priority score of 4, placing it in the top tier of targets; however, it has only one supporting dataset and lacks cross-dataset consistency, which diminishes its overall robustness. The evidence types are limited, which affects the strength of the data support.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the evidence presented, particularly the significant dysregulation of G33764 in insulin resistance mechanisms in adipose tissue. However, the lack of strong differentiation between the scores of the other targets (G20274, G19122, G22553, and G04436) could imply that the distinctions may not be as clear-cut as presented, affecting the overall clarity of the ranking.

#### MECHANISTIC_SCORE: 7
**MECHANISTIC_RATIONALE:** The proposed mechanism that highlights G33764's role in disrupting insulin signaling aligns well with the known pathways related to adipose tissue and T2D. However, the absence of data on regulating transcription factors and the lack of detailed pathway involvement for G33764 slightly weaken the coherence of the mechanism hypothesis.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** Targeting G33764 for inhibition to enhance insulin sensitivity is a reasonable approach, given its hypothesized role in insulin signaling. Further, the potential to combine this with modulation of other targets (G20274 and G19122) is well thought out. However, without more evidence on druggability and safety considerations, the score is moderated.

#### NOVELTY_SCORE: 8
**NOVELTY_RATIONALE:** The hypothesis integrates information regarding tissue specificity and highlights a multi-target approach, which is a novel angle in the context of T2D treatment. However, the connections drawn could be seen as somewhat conventional, as adipose tissue's role in T2D is widely acknowledged.

### OVERALL_FITNESS: 6.75
**Calculated Score:** (6*0.25 + 7*0.25 + 7*0.20 + 7*0.20 + 8*0.10) = 6.75

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (Good evidence but lacks cross-dataset support)
- Target #2 quality: **MODERATE** (Relevant but not distinguished enough from others)
- Target #3 quality: **MODERATE** (Supports the hypothesis but lacks strong evidence)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Evidence:** Incorporate additional datasets to strengthen the evidence supporting G33764 and its role in T2D. Aim for cross-dataset consistency to enhance confidence in the findings.
2. **Expand Mechanistic Insights:** Provide more detailed information on the pathways involved and the role of transcription factors. Understanding how G33764 interacts with these factors could clarify its mechanism.
3. **Drugability Assessment:** Conduct a preliminary assessment of the druggability of G33764 and associated targets, including potential safety profiles, to solidify the therapeutic approach.
4. **Clarify Ranking Distinctions:** Justify the rank order with more robust comparisons between the targets. Highlight specific experimental evidence that differentiates G33764 from G20274, G19122, G22553, and G04436.
2026-02-10 19:48:37,746 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:48:37,747 - root - INFO - Novelty bonus applied: 0.3% -> fitness 68.50 -> 68.73
2026-02-10 19:48:37,747 - root - INFO - Evaluating fitness for hypothesis: t2d-03-9beddb36
2026-02-10 19:48:54,057 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:48:54,062 - root - INFO - TOKEN_USAGE: input=1437, output=803, total=2240, cost=$0.000697
2026-02-10 19:48:54,062 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:48:54,062 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G04436 is not found in the top priority list, which raises concerns about its overall relevance. However, there is cross-dataset consistency for the primary target and the other ranked targets (G19943, G22553, G33764) are also in the top priority tier. The evidence types supporting the primary target is limited, which affects the score.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as the targets have high scores and are relevant to T2D. However, the absence of G04436 in the top priority list diminishes the strength of the ranking. The rationale for ranking appears logical, but the ranking may need adjustment to reflect the most current understanding of target significance.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the described pathways, particularly in relation to insulin signaling and glucose metabolism. The tissue rationale involving pancreatic -cells, muscle, and liver is well-supported. Additionally, the identified transcription factors associated with G04436 enhance the mechanistic understanding, strengthening this aspect of the hypothesis.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets is appropriate, aiming to restore metabolic function. The targets appear to be druggable based on their network positions. Nevertheless, safety considerations were not explicitly discussed, which could be important in evaluating the overall therapeutic potential.

---

**NOVELTY_SCORE:** 5  
**NOVELTY_RATIONALE:** While the hypothesis proposes a potentially synergistic approach, the integration of the data seems somewhat conventional in the context of T2D research. The connections made are relevant, but they do not present significantly novel insights, which restricts the novelty score.

---

### OVERALL_FITNESS
Overall fitness calculation:  
= (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)  
= (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (5 * 0.10)  
= 1.5 + 1.75 + 1.6 + 1.4 + 0.5  
= 6.75  
**Scaled to 0-100:** 67.5

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**
- Target #4 quality: **STRONG**
- Target #5 quality: **MODERATE**

---

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Inclusion:** Re-evaluate the relevance of G04436 in relation to the top priority genes and consider whether additional evidence could elevate its standing. 
2. **Expand Evidence Base:** Gather more comprehensive data supporting the primary target and its role in T2D to strengthen the hypothesis.
3. **Discuss Safety Considerations:** Include potential safety concerns regarding the therapeutic approach to provide a more balanced evaluation of the targets.
4. **Enhance Novelty Aspects:** Explore and highlight any innovative connections or mechanisms that could set this hypothesis apart from existing research in T2D.
5. **Strengthen Cross-Validation:** Utilize additional datasets to corroborate findings related to the ranked targets and enhance overall confidence in the hypothesis.
2026-02-10 19:48:54,062 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:48:54,063 - root - INFO - Evaluating fitness for hypothesis: t2d-03-8f02aa3e
2026-02-10 19:49:07,920 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:49:07,926 - root - INFO - TOKEN_USAGE: input=1334, output=622, total=1956, cost=$0.000573
2026-02-10 19:49:07,926 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:49:07,927 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, has high evidence support with a score of 4.0 and is confirmed as a hub in T2D gene networks with consistency across two datasets. However, G33764 and G19122, while ranked, are not in the top priority list, which somewhat weakens the overall data support for the hypothesis.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is primarily justified for G19943 and G33764, both scoring 4.0 and indicating strong roles in T2D pathways. However, G19122, with a score of 3.0, is less robust in comparison to the top-ranked targets. The rationale is clear, but the inclusion of lower-ranked targets with less supporting evidence slightly undermines the ranking's strength.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with established insulin signaling pathways, and the rationale for focusing on muscle and adipose tissues is appropriate since these tissues are crucial for glucose homeostasis. The absence of reported regulating transcription factors is a minor gap, but the mechanism is generally sound.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The strategy of small molecule activation is appropriate for restoring function in insulin signaling. G19943's central role suggests it is likely druggable, and the overall approach seems to consider safety and efficacy in enhancing insulin sensitivity. Additional details on safety considerations would strengthen this evaluation.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates existing data creatively, targeting G19943 as a hub component is not entirely novel in the context of T2D research. However, the combined targeting of the three genes does propose a unique approach which adds some novelty to the hypothesis.

**OVERALL_FITNESS:** 6.7 (rounded to 67)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **MODERATE**  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Target Validation:** Include additional data or experiments to support the inclusion of G19122, as its lower score in the priority list may impact the overall strength of the hypothesis.
2. **Enhance Mechanistic Details:** Provide more insights into potential transcription factors and regulatory mechanisms associated with G19943, G33764, and G19122 to bolster the mechanistic rationale.
3. **Address Safety Considerations:** Include a discussion on potential safety and off-target effects of the proposed small molecule activators to ensure comprehensive therapeutic evaluation.
4. **Diversify Evidence Sources:** Consider additional datasets or validation studies that might further confirm the roles of G33764 and G19122 in T2D, enhancing the overall data support for the hypothesis.
2026-02-10 19:49:07,928 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:49:07,928 - root - INFO - Evaluating fitness for hypothesis: t2d-03-ee922daf
2026-02-10 19:49:22,226 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:49:22,229 - root - INFO - TOKEN_USAGE: input=1524, output=788, total=2312, cost=$0.000701
2026-02-10 19:49:22,229 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:49:22,229 - root - INFO - 
### EVALUATION

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a high priority score of 4.0, placing it in the top priority tier. However, it lacks cross-dataset consistency, as it is only supported by one dataset. While there are two evidence types mentioned, the lack of pathway involvement and the low ranking (1803) in differentially expressed genes (DE) limit the overall data support.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, particularly for G22553 and G19122, which are highlighted for their critical roles in metabolic regulation and insulin sensitivity. However, the presence of multiple targets with the same score (4.0) in the top tier raises questions about the clear differentiation between their strengths. The rationale provided is logical, but the lack of additional evidence types for some targets could weaken the ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism for G22553 as a primary regulator of lipid metabolism and insulin signaling aligns well with the identified pathways. The tissue rationale of focusing on adipose tissue and liver is appropriate, as these are critical for metabolic function. However, the absence of specific transcription factors in the evidence could be seen as a gap in the analysis of TF relationships.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G22553 and G19122 using small molecule modulators seems appropriate, given their roles in metabolic regulation. However, the assessment of druggability based on network position is not explicitly addressed, and potential safety considerations are not discussed. This limits confidence in the therapeutic assessment.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates data in a reasonable manner, focusing on the interplay between regulation of metabolic pathways and insulin sensitivity. However, the connections made are somewhat conventional in the context of T2D research, lacking truly innovative insights or unique angles that would elevate the novelty score.

### OVERALL_FITNESS: 67.5
**Calculation:** (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.75 + 7 + 1.6 + 1.4 + 0.6 = 17.35 out of 25, scaled to 0-100 = 69.4

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Cross-Dataset Validation:** Seek additional datasets to validate the roles of G22553 and G19122 to strengthen the confidence in their therapeutic potential and support cross-dataset consistency.
   
2. **Expand Evidence Types:** Include more evidence types for G22553, such as pathway analysis or additional functional assays, to provide a more robust basis for its ranking and therapeutic relevance.

3. **Explore Transcription Factor Relationships:** Investigate specific transcription factors that might be regulating G22553 and G19122, providing a more detailed understanding of the regulatory networks involved.

4. **Assess Druggability and Safety:** Conduct preliminary assessments of the druggability of the proposed targets and consider potential side effects or safety concerns related to their modulation.

5. **Highlight Novel Mechanisms:** Emphasize any unique mechanisms of action or innovative connections to existing therapies that G22553 and G19122 may provide, enhancing the novelty and appeal of the hypothesis.
2026-02-10 19:49:22,230 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:49:22,230 - root - INFO - Evaluating fitness for hypothesis: t2d-03-ba3d6736
2026-02-10 19:49:37,008 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:49:37,015 - root - INFO - TOKEN_USAGE: input=1526, output=774, total=2300, cost=$0.000693
2026-02-10 19:49:37,015 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:49:37,015 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G04436 has a priority score of 4.0, which is commendable, but it falls into a competitive tier with several other targets scoring the same. There is only one dataset supporting G04436, which limits the strength of the evidence. Additionally, there is no cross-dataset consistency for G04436, which weakens the overall score. The presence of 12 regulating transcription factors is a positive aspect but does not strongly compensate for the lack of diversity in evidence types.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of the targets appears reasonable with respect to their roles in T2D pathways, particularly with G04436 being a primary driver in lipid metabolism. However, the justification could be strengthened by showing how the evidence from multiple datasets distinctly supports the ranking of these targets, as most have similar scores. The rationale provided makes sense, but the lack of data diversity for G04436 reduces confidence in the ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in T2D, particularly in lipid and glucose metabolism. The tissue rationale focusing on liver, muscle, and adipose tissue is well-supported, as these are critical in managing insulin sensitivity. The consideration of transcription factors regulating G04436 adds depth to the hypothesis, contributing to a coherent mechanistic framework.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the identified targets is appropriate given their roles in metabolic regulation. The expectation that combined activation will lead to improved insulin sensitivity is reasonable, and the targets do appear to be druggable based on their network positions. However, potential safety concerns regarding the simultaneous activation of multiple targets could be further addressed to bolster the therapeutic score.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis presents an innovative integration of multiple targets for a multifaceted approach to T2D management. However, the connections made between the targets could be considered somewhat conventional in the context of existing research. There might be more creative ways to express the interactions or mechanisms that could enhance the perceived novelty of the approach.

### OVERALL_FITNESS: 6.75 (rounded to 68)
**Overall Fitness Calculation:** 
(6 * 0.25 + 7 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10) * 100 = 67.5, rounded to 68.

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G04436):** MODERATE
- **Target #2 quality (G22553):** STRONG (based on its established role in insulin signaling)
- **Target #3 quality (G33764):** MODERATE (potentially synergistic effects, but less clear data support)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Diversity:** Seek additional datasets to validate the findings for G04436, ideally with cross-dataset consistency to strengthen the evidence base.
2. **Clarify Safety Considerations:** Address potential safety concerns for combined activation of these targets, possibly including preclinical data or literature on similar approaches.
3. **Explore Novel Mechanisms:** Investigate and articulate more innovative connections or mechanisms among the targets that could enhance the hypothesis's novelty.
4. **Broaden the Scope of Analysis:** Consider additional targets for evaluation that may provide complementary effects or have existing evidence of synergistic interactions.
2026-02-10 19:49:37,016 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:49:37,017 - root - INFO - Evaluating fitness for hypothesis: t2d-03-680a0d5f
2026-02-10 19:49:51,985 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:49:51,993 - root - INFO - TOKEN_USAGE: input=1469, output=778, total=2247, cost=$0.000687
2026-02-10 19:49:51,994 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:49:51,994 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is listed in the top priority list, which is a positive indication. However, targets G33764 and G19122 are not in the top priority list, which raises concerns about the overall support for the ranked targets. The cross-dataset consistency adds credibility, as does the multi-evidence support, though the key pathways identified are relevant to T2D. Overall, while there is some solid data support, the presence of non-listed targets limits the score.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data provided. G19943 is rightly prioritized as the hub component, and the others are ranked based on their roles in metabolic regulation. However, some targets lack sufficient evidence to strongly differentiate their importance, which slightly reduces the clarity of the ranking. The rationale for ranking is logical, but the inclusion of targets not in the top 10 detracts from its robustness.

---

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the identified pathways, particularly insulin signaling, which is critical for T2D. The tissue rationale is also strong, focusing on pancreatic -cells, muscle, and liver, which are directly involved in glucose metabolism. The lack of identified regulatory transcription factors is a minor gap, but overall, the coherence of the mechanism is solid.

---

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of targeting these genes with small molecules to enhance activity is appropriate, given their roles in metabolic pathways. The targets are likely druggable due to their significance in T2D pathology. However, a more detailed assessment of potential safety issues is necessary, especially given the complexity of metabolic pathways and potential off-target effects.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a valuable way, focusing on multiple targets to enhance insulin sensitivity. However, the connections and interactions proposed are somewhat conventional in T2D research, which limits the novelty. Non-obvious connections among targets could be better defined to enhance the creativity of the approach.

---

### OVERALL_FITNESS
**Overall Fitness Calculation:**  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85  
**Overall Fitness (scaled to 100):** 68.5

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** WEAK (not in top priority)
- **Target #3 quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Target Validation:** Consider validating the roles of G33764 and G19122 in existing datasets to justify their inclusion or re-evaluate the selection of targets.
2. **Expand Evidence Base:** Identify and present additional supporting evidence for all ranked targets to strengthen their justification and bolster data support.
3. **Mechanistic Insights:** Explore potential regulatory transcription factors that could play a role in the proposed mechanisms to enhance understanding and coherence.
4. **Safety Evaluation:** Conduct a preliminary safety assessment of the therapeutic approach, addressing potential off-target effects and metabolic interactions.
5. **Novelty Enhancement:** Consider proposing innovative combinations of existing drugs or new target interactions that may not have been previously explored to enhance the novelty of the hypothesis.
2026-02-10 19:49:51,996 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:49:51,997 - root - INFO - Evaluating fitness for hypothesis: t2d-03-7399f879
2026-02-10 19:50:09,772 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:50:09,774 - root - INFO - TOKEN_USAGE: input=1594, output=815, total=2409, cost=$0.000728
2026-02-10 19:50:09,775 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:50:09,775 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** G19943 has a high priority score of 4.0 and is a hub component in the co-expression network, indicating its importance in metabolism and signaling pathways related to Type 2 Diabetes (T2D). However, there is only one dataset supporting G19943, which limits the cross-dataset consistency. The evidence types are limited, and while G19122 has a reasonable score and relevance, it lacks the robust cross-dataset support seen with G19943.

---

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking provided is justified based on the evidence for G19943 as a hub component and its role in lipid metabolism and insulin signaling. G19122 is appropriately ranked second due to its complementary role in adipose tissue metabolism. The rationale for the ranking aligns well with the data presented, especially considering the potential synergy between G19943 and G19122.

---

**MECHANISTIC_SCORE: 7**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the described pathways of lipid metabolism and insulin signaling. The tissue rationale is strong, focusing on pancreatic -cells and adipose tissue, which are critical for glucose homeostasis. However, while the role of transcription factors is mentioned, there is a lack of specific details on how they interact with these targets, which could strengthen the rationale further.

---

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G19122 appears appropriate given their roles in metabolic regulation. The potential for druggable targets is supported by their network positions as hub components. However, safety considerations regarding the activation of these targets were not discussed in detail, which is crucial for any therapeutic hypothesis.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis proposes a dual activation strategy, which is somewhat innovative in its approach to target two key components in T2D simultaneously. However, the idea of enhancing insulin sensitivity and metabolism through dual activation is a well-explored area in diabetes research, which slightly reduces the novelty score.

---

### OVERALL_FITNESS
**Overall Fitness Calculation:**
- DATA_SUPPORT: 7 * 0.25 = 1.75
- RANKING_QUALITY: 8 * 0.25 = 2.00
- MECHANISTIC: 7 * 0.20 = 1.40
- THERAPEUTIC: 8 * 0.20 = 1.60
- NOVELTY: 6 * 0.10 = 0.60

**Total Score: 1.75 + 2.00 + 1.40 + 1.60 + 0.60 = 7.35**

**Scaled to 0-100: 7.35 * 10 = 73.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** MODERATE
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Dataset Support:** Attempt to gather more datasets that validate the role of G19943 and G19122, particularly focusing on their expression in various contexts of T2D.
2. **Expand on Mechanistic Details:** Provide additional insights into how transcription factors interact with G19943 and G19122, and how these interactions influence metabolic pathways.
3. **Discuss Safety Considerations:** Address potential adverse effects of activating these targets, including off-target effects or potential dysregulation of metabolic pathways.
4. **Explore Novel Targets:** Consider integrating additional targets like G22553 and G33764 into the initial activation phase to enhance the therapeutic strategy and provide a more comprehensive approach to treatment.
2026-02-10 19:50:09,775 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:50:09,775 - root - INFO - Evaluating fitness for hypothesis: t2d-03-4ccc84dd
2026-02-10 19:50:24,207 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:50:24,210 - root - INFO - TOKEN_USAGE: input=1439, output=695, total=2134, cost=$0.000633
2026-02-10 19:50:24,211 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:50:24,211 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is found in the top priority list but is accompanied by other targets (G23245, G04436) that are also highly scored (4.0). There is cross-dataset consistency for G22553, and it has strong support from two datasets. However, the lack of additional evidence types for G19122 and the absence of specific regulating transcription factors somewhat limits the score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified as G22553 is supported by substantial evidence and is placed appropriately as the highest-ranked target due to its pivotal role in insulin signaling. G23245, G04436, and G33764 follow logically, enhancing the therapeutic strategy. The rationale for ranking is clear and aligns well with the evidence provided.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism effectively aligns with known pathways involved in Type 2 Diabetes, including insulin signaling and glucose metabolism. The tissue rationale focuses on relevant tissues (liver, adipose, skeletal muscle), which are essential for insulin sensitivity and metabolic regulation. However, the absence of identified transcription factors for G22553 is a slight gap.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators is appropriate given the targets' roles; however, the druggability of G19122 remains uncertain, which may pose safety considerations. Overall, the targets are well-positioned within the metabolic network, but further exploration of safety profiles would strengthen this score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates multiple targets creatively, the connections made are not entirely novel in the context of Type 2 Diabetes management. The integration of data is solid, but it does not present a groundbreaking perspective or innovative approach that significantly diverges from existing strategies.

### OVERALL FITNESS
**OVERALL_FITNESS:** (7 * 0.25 + 8 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10) = 7.4  
**Scaled to 0-100:** 74.0

### RANKED_TARGETS_ASSESSMENT
- **Target #1 quality:** STRONG  
- **Target #2 quality:** STRONG  
- **Target #3 quality:** STRONG  

### IMPROVEMENT_SUGGESTIONS
1. **Expand Evidence Base:** Increase the number of evidence types supporting G19122, including data on gene expression regulation and functional studies to bolster its significance.
2. **Investigate Transcription Factors:** Further investigate potential transcription factors that may regulate G22553 and other targets, as understanding these relationships may enhance the mechanistic rationale.
3. **Safety and Druggability Studies:** Conduct preliminary studies on the safety and druggability of G19122 to ensure that all proposed targets can be effectively translated into therapeutic agents.
4. **Novel Mechanistic Insights:** Explore novel mechanisms or pathways involving G22553, G23245, and G04436 that may yield new therapeutic insights or lead to unexpected benefits in treating Type 2 Diabetes.
2026-02-10 19:50:24,211 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:50:24,212 - root - INFO - Population fitness evaluation complete. Top score: 73.50
2026-02-10 19:50:24,212 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 19:50:24,212 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G19943', 'G19943', 'G33764', 'G33764', 'G22553']...
2026-02-10 19:50:24,212 - root - INFO - Generation 3 stats: mean=60.52, max=76.5, min=50.0
2026-02-10 19:50:24,212 - root - INFO - Generation 3 complete
2026-02-10 19:50:24,212 - root - INFO - --- CAPTURING CHECKPOINT GEN 3 ---
2026-02-10 19:50:24,212 - root - INFO - Running generation 4
2026-02-10 19:50:24,213 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 19:50:24,213 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 19:50:24,213 - root - INFO - Crossover 1/18: parents 'Dual Activation of G19943 and ...' x '** Integrated Multi-Target App...'
2026-02-10 19:50:24,275 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:51:00,463 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:51:00,469 - root - INFO - TOKEN_USAGE: input=40394, output=817, total=41211, cost=$0.006549
2026-02-10 19:51:00,469 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:51:00,469 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Strategy for Enhanced Management of Type 2 Diabetes via Synergistic Modulation of Key Metabolic Regulators

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | Central hub in metabolic pathways, crucial for lipid metabolism and insulin signaling, with strong evidence supporting its regulatory role in T2D.
2. **G22553** | Score: **4.0** | A primary driver in insulin signaling pathways, essential for glucose metabolism, with comprehensive data support across multiple datasets.
3. **G33764** | Score: **4.0** | An important enzyme in metabolic regulation that can enhance the effects of G19943 and G22553 in glucose homeostasis.
4. **G19122** | Score: **3.0** | A major regulator in adipose tissue metabolism, complementing the effects of G19943 and G22553 by improving insulin sensitivity.
5. **G04436** | Score: **4.0** | Plays a critical role in lipid metabolism and insulin signaling, providing additional support for the therapeutic strategy targeting dyslipidemia in T2D.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy that synergistically activates G19943, G22553, and G33764 to enhance insulin sensitivity and metabolic regulation in Type 2 Diabetes. The inclusion of G19122 and G04436 provides additional layers of support, addressing lipid metabolism and insulin signaling complexities, and ensuring a robust therapeutic approach.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Lipid metabolism, insulin signaling, glucose metabolism
- WGCNA module role: G19943 is a hub component in the silver module, while G22553 is a primary driver in the black module.
- Regulating TFs: None identified specifically for these genes in the data.

**MECHANISM_HYPOTHESIS:** The mechanism hypothesizes that activating G19943 will enhance its role as a master regulator of lipid metabolism and insulin signaling, significantly improving the pathophysiology of T2D. Complementary activation of G22553 is expected to reinforce insulin signaling and glucose uptake in peripheral tissues, while G33764 will support overall metabolic regulation. G19122 will further enhance insulin sensitivity in adipose tissue, and the modulation of G04436 will address dyslipidemia, creating a multifaceted strategy against T2D.

**TISSUE_RATIONALE:** The primary tissues of focus include adipose tissue, liver, and skeletal muscle, as these are integral to insulin sensitivity, glucose uptake, and lipid metabolism. Activation of G19943 will enhance insulin secretion in pancreatic -cells, while G22553 and G33764 will improve insulin action and metabolic regulation in the liver and skeletal muscle, respectively.

**THERAPEUTIC_APPROACH:** The therapeutic approach involves the development of small molecule activators targeting G19943, G22553, and G33764, alongside modulators for G19122 and G04436 to optimize their functions and enhance metabolic regulation.

**PREDICTED_OUTCOME:** The combined modulation of G19943, G22553, and G33764 is anticipated to significantly improve insulin sensitivity, enhance glucose metabolism, and yield a therapeutic benefit that could lead to better management and potential reversal of Type 2 Diabetes.

**RANKING_RATIONALE:** G19943 is ranked highest due to its central role in multiple metabolic pathways. G22553 follows closely for its complementary function in insulin signaling. G33764 is included for its supporting role in metabolic regulation, while G19122 and G04436 provide additional metabolic support, ensuring a robust multi-target approach.

**CONFIDENCE:** HIGH based on the strength of data support, multi-evidence types, and the synergistic potential of the proposed therapeutic strategy.
2026-02-10 19:51:00,471 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:51:00,471 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:51:00,472 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:51:00,475 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:51:00,475 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Strategy f...'
2026-02-10 19:51:00,475 - root - INFO - Crossover 2/18: parents '** Synergistic Modulation of I...' x '** Synergistic Modulation of G...'
2026-02-10 19:51:00,561 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:51:37,413 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:51:37,416 - root - INFO - TOKEN_USAGE: input=40345, output=774, total=41119, cost=$0.006516
2026-02-10 19:51:37,416 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:51:37,416 - root - INFO - 
**TITLE:** Comprehensive Modulation of Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes through Multi-Targeted Approach

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene serves as a hub component in the gene network, playing a critical role in insulin signaling and metabolic regulation, making it essential for enhancing insulin sensitivity.**
2. **G04436 | Score: 4.0 | This enzyme is a significant regulator of glucose homeostasis and complements G19943 by enhancing overall metabolic regulation when co-targeted.**
3. **G22553 | Score: 4.0 | As a primary driver in T2D pathways, it supports insulin receptor signaling and glucose uptake, providing a synergistic effect alongside G19943 and G04436.**
4. **G33764 | Score: 4.0 | This enzyme is involved in insulin resistance mechanisms and its modulation is essential for addressing the metabolic dysregulation seen in T2D.**
5. **G19122 | Score: 3.0 | A major regulator in insulin signaling pathways, it can help restore metabolic balance by further enhancing the effects of the primary targets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a multi-targeted therapeutic strategy that focuses on the synergistic modulation of G19943, G04436, G22553, G33764, and G19122. By integrating insights from the parent hypotheses, this approach aims to comprehensively enhance insulin sensitivity and restore glucose homeostasis in Type 2 Diabetes by addressing multiple metabolic pathways involved in T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation
- WGCNA module role: G19943 and G33764 identified as hub components in relevant modules
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The activation of G19943 is anticipated to enhance its function within insulin signaling pathways, directly addressing insulin resistance and improving glucose metabolism. Concurrently, modulating G04436 is expected to provide metabolic regulation through its enzymatic activity, while G22553 enhances glucose uptake. Targeting G33764 will further address mechanisms of insulin resistance, and G19122 will support insulin signaling pathways, creating a robust therapeutic strategy for T2D.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include pancreatic -cells, muscle, and liver. These tissues are critical for glucose metabolism and insulin action, thus making them ideal candidates for therapeutic intervention in T2D management.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The coordinated modulation of these targets is expected to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their strong roles in key biological pathways, and the robustness of the supporting evidence. G19943 was selected as the primary target due to its central role in insulin signaling, while G04436 and G22553 were prioritized for their significant contributions to metabolic regulation. G33764 and G19122 were included to further enhance the understanding and treatment of metabolic dysregulation in T2D.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:51:37,417 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:51:37,417 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:51:37,417 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:51:37,418 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:51:37,419 - root - INFO -   -> Created offspring: '** Comprehensive Modulation of Insulin S...'
2026-02-10 19:51:37,420 - root - INFO - Crossover 3/18: parents 'Enhanced Therapeutic Strategie...' x '** Comprehensive Modulation of...'
2026-02-10 19:51:37,465 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:52:02,720 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:52:02,725 - root - INFO - TOKEN_USAGE: input=40362, output=720, total=41082, cost=$0.006486
2026-02-10 19:52:02,725 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:52:02,725 - root - INFO - 
**TITLE:** Integrated Targeting of Metabolic Pathways for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene acts as a hub component in T2D-related gene networks, crucial for metabolic regulation and insulin signaling.
2. **G33764** | Score: **4.0** | A primary driver in metabolic pathways, its modulation is essential for regulating lipid metabolism and glucose homeostasis.
3. **G22553** | Score: **4.0** | Its role as a primary driver in insulin receptor signaling pathways makes it vital for facilitating glucose uptake.
4. **G19122** | Score: **3.0** | This major regulator significantly influences insulin sensitivity and glucose metabolism, enhancing the effects of primary targets.
5. **G04436** | Score: **4.0** | This enzyme enhances glucose metabolism and has demonstrated efficacy in improving insulin sensitivity, supporting the other targets.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis focuses on a synergistic approach to enhance insulin sensitivity in Type 2 Diabetes by integrating the modulation of key metabolic regulators, particularly G19943, G33764, and G22553. By leveraging their interconnected roles in metabolic pathways, we aim to improve glucose metabolism and address insulin resistance more effectively than previous hypotheses.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 (G19943)
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, metabolism, lipid metabolism, and glucose uptake.
- WGCNA module role: Hub component (G19943), Primary Driver (G33764, G22553)
- Regulating TFs: None identified, but potential for regulatory interactions exists.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves activating G19943 to enhance insulin signaling pathways, which is expected to promote improved insulin sensitivity in peripheral tissues. G33764's role in regulating lipid metabolism complements this effect, while G22553 facilitates glucose uptake through insulin receptor signaling. The addition of G19122 and G04436 provides further support, targeting adipose tissue and enhancing glucose metabolism, respectively, thus creating a multi-faceted approach to combat T2D.

**TISSUE_RATIONALE:** The primary tissues of interest include adipose tissue, liver, and skeletal muscle, as they play crucial roles in glucose metabolism and insulin action, directly impacting the pathophysiology of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets using small molecule modulators designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores and their roles in key biological pathways, with G19943 selected as the primary target due to its central role as a hub component in the gene network. G33764 and G22553 were prioritized for their significant contributions to metabolic regulation and insulin signaling, while G19122 and G04436 were included for their essential roles in supporting the overall therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:52:02,726 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:52:02,726 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:52:02,727 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:52:02,730 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:52:02,731 - root - INFO -   -> Created offspring: '** Integrated Targeting of Metabolic Pat...'
2026-02-10 19:52:02,732 - root - INFO - Crossover 4/18: parents '** Comprehensive Modulation of...' x '** Identification of Promising...'
2026-02-10 19:52:02,793 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:52:45,013 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:52:45,019 - root - INFO - TOKEN_USAGE: input=40247, output=820, total=41067, cost=$0.006529
2026-02-10 19:52:45,020 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:52:45,020 - root - INFO - 
**TITLE:** Integrated Modulation of Key Metabolic and Insulin Signaling Pathways for Enhanced Treatment of Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene serves as a crucial hub component in T2D-related gene networks, demonstrating strong evidence across multiple datasets and playing a central role in insulin signaling.**
2. **G22553 | Score: 4.0 | Identified as a primary driver in the black module associated with T2D, it significantly influences insulin receptor signaling and glucose uptake mechanisms.**
3. **G33764 | Score: 4.0 | As a primary driver in metabolic regulation, its modulation is essential for improving insulin sensitivity and managing lipid metabolism, complementing the actions of G19943 and G22553.**
4. **G04436 | Score: 4.0 | This enzyme enhances glucose metabolism and has shown potential in improving insulin sensitivity, thus supporting the overall therapeutic strategy aimed at metabolic control.**
5. **G19122 | Score: 3.0 | A major regulator in insulin signaling pathways, it aids in restoring metabolic balance, further augmenting the effects of the primary targets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive strategy to enhance insulin sensitivity and metabolic function in Type 2 Diabetes by targeting key genes involved in insulin signaling and metabolic pathways. By focusing on G19943, G22553, and G33764, alongside G04436 and G19122, we aim to address the multifaceted nature of T2D pathology through synergistic modulation of these critical targets.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: Hub component (G19943), Primary Driver (G22553), Primary Driver (G33764), Major Regulator (G19122)
- Regulating TFs: None identified, but potential for regulatory interactions exists

**MECHANISM_HYPOTHESIS:** The activation of G19943 is anticipated to enhance insulin signaling pathways, leading to improved insulin sensitivity in peripheral tissues such as muscle, liver, and adipose tissue. G22553 will facilitate glucose uptake and improve insulin receptor signaling, while G33764 will regulate lipid metabolism, thus addressing the dysregulation of metabolic pathways in T2D. Additionally, G04436 will support glucose metabolism, and G19122 will help restore metabolic balance, creating a comprehensive therapeutic approach targeting multiple aspects of T2D pathology.

**TISSUE_RATIONALE:** The most relevant tissues for this approach include pancreatic -cells, muscle, liver, and adipose tissue, all of which are integral to glucose homeostasis and insulin action. Targeting these tissues will directly impact the pathophysiology of Type 2 Diabetes and improve metabolic health.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, ultimately leading to better clinical outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, robust evidence from multiple datasets, and crucial roles in key biological pathways. G19943 was selected as the primary target due to its central importance in the gene network, while G22553 and G33764 were prioritized for their significant contributions to insulin receptor signaling and metabolic regulation. G04436 and G19122 were included for their essential roles in supporting the overall therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:52:45,021 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:52:45,021 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:52:45,022 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:52:45,024 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:52:45,024 - root - INFO -   -> Created offspring: '** Integrated Modulation of Key Metaboli...'
2026-02-10 19:52:45,024 - root - INFO - Crossover 5/18: parents 'Tissue-Specific Target Hypothe...' x 'Enhanced Therapeutic Strategie...'
2026-02-10 19:52:45,068 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:53:23,373 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:53:23,381 - root - INFO - TOKEN_USAGE: input=40356, output=802, total=41158, cost=$0.006535
2026-02-10 19:53:23,381 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:53:23,381 - root - INFO - 
### TITLE: Integrated Adipose Tissue and Metabolic Regulation Hypothesis for Type 2 Diabetes Treatment Targeting G33764, G19122, and G20274

#### RANKED_TARGETS:
1. **G33764** | Score: 4.0 | This gene is a primary driver in insulin signaling and metabolic pathways, with established dysregulation in T2D, making it a crucial target.
2. **G19122** | Score: 3.0 | This gene plays a significant role in enhancing insulin sensitivity in adipose tissue, complementing G33764's effects on metabolic regulation.
3. **G20274** | Score: 3.0 | As a major regulator of insulin signaling, its modulation can synergistically enhance the therapeutic effects of targeting G33764 and G19122 in T2D.
4. **G22553** | Score: 4.0 | Serving as a primary driver in co-expression networks that correlate with T2D, it supports the overall metabolic context of the hypothesis.
5. **G04436** | Score: 4.0 | This gene is critical in glucose metabolism and its interactions with the prioritized targets can further elucidate dysregulated pathways in T2D.

#### PRIMARY_TARGET: G33764

### SUMMARY:
This hypothesis emphasizes the critical role of G33764 as a primary target for improving insulin sensitivity and metabolic control in type 2 diabetes, alongside G19122 and G20274 to enhance the therapeutic strategy. The integration of G22553 and G04436 adds robustness to the understanding of metabolic dysregulation in adipose tissue, addressing the multi-faceted nature of T2D.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, Lipid metabolism, Energy homeostasis
- **WGCNA module role**: G33764 is a primary driver in relevant modules related to T2D.
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
G33764 is hypothesized to act as a master regulator of insulin signaling and lipid metabolism, contributing significantly to the pathophysiology of T2D. Its interaction with G19122 enhances insulin sensitivity specifically in adipose tissue, which is critical for effective glucose homeostasis. Furthermore, targeting G20274 can reinforce the insulin signaling pathway and improve glucose metabolism, while G22553 and G04436 provide additional context for the dysregulation observed in metabolic pathways.

### TISSUE_RATIONALE:
The primary focus is on adipose tissue, where the interplay of insulin signaling and metabolic regulation is most pronounced in T2D. Dysfunctions in this tissue contribute significantly to the overall metabolic disturbances, making it essential for targeted therapies.

### THERAPEUTIC_APPROACH:
The therapeutic approach involves the modulation of G33764, G19122, and G20274 using small molecule activators to enhance their regulatory functions, leading to improved insulin sensitivity and metabolic outcomes in T2D management.

### PREDICTED_OUTCOME:
Modulating G33764 in conjunction with G19122 and G20274 is anticipated to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could reverse or slow the progression of type 2 diabetes.

### RANKING_RATIONALE:
I ranked G33764 first due to its central role in insulin signaling and metabolic regulation, followed by G19122 for its direct influence on insulin sensitivity. G20274 is ranked third for its synergistic potential in the therapeutic strategy, while G22553 and G04436 provide additional metabolic support and context.

### CONFIDENCE: HIGH based on strong multi-evidence support and the relevance of the chosen tissue in T2D pathophysiology.
2026-02-10 19:53:23,383 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:53:23,383 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:53:23,386 - root - INFO -   -> Created offspring: 'Integrated Adipose Tissue and Metabolic ...'
2026-02-10 19:53:23,387 - root - INFO - Mutation 6/18: parent 'Integrated Modulation of G1994...'
2026-02-10 19:53:23,387 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:53:23,431 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:54:02,056 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:54:02,063 - root - INFO - TOKEN_USAGE: input=39551, output=770, total=40321, cost=$0.006395
2026-02-10 19:54:02,063 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:54:02,063 - root - INFO - 
### TITLE: Enhanced Multi-Target Strategy for Type 2 Diabetes Management with Focus on G19943 and Synergistic Modulators

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Serves as a central hub in insulin signaling and metabolic pathways, demonstrating cross-dataset consistency.
2. **G22553** | Score: **4.0** | Functions as a primary driver in insulin signaling, enhancing glucose metabolism alongside G19943.
3. **G04436** | Score: **4.0** | Critical enzyme involved in metabolic regulation, supporting the synergistic effects of G19943 and G22553.
4. **G23245** | Score: **4.0** | Acts as a primary driver for glucose uptake and insulin sensitivity, providing valuable support to the primary targets.
5. **G33764** | Score: **4.0** | Offers additional regulatory support within metabolic pathways, enhancing overall therapeutic efficacy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis refines the original strategy by emphasizing the central role of G19943 in insulin signaling while integrating G22553 and G04436 as synergistic modulators. By leveraging the co-expression networks and transcription factor activity data, we aim to enhance the metabolic effects of these targets, improving insulin sensitivity and offering a comprehensive approach to Type 2 Diabetes management.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- **WGCNA module role**: G19943 is a hub component in modules negatively correlated with T2D, along with G22553 and G23245 in their respective modules.
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism suggests that G19943 is pivotal in orchestrating insulin signaling and lipid metabolism, while G22553 enhances this effect by increasing glucose uptake and improving insulin sensitivity. G04436 is included for its role in regulating metabolic enzymes that directly influence lipid profiles, thus addressing the dual challenges of glucose and lipid metabolism in Type 2 Diabetes. The model also considers the transcription factor interactions that may amplify the transcriptional activation of these targets, leading to a more robust metabolic response.

### TISSUE_RATIONALE:
Key tissues include pancreatic beta-cells, muscle, liver, and adipose tissue. These tissues are integral to insulin action, glucose uptake, and lipid metabolism, making them critical for the therapeutic interventions aimed at reversing Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The strategy involves small molecule activation of G19943 and G22553 to enhance their functions, combined with modulation of G04436 to optimize lipid metabolism and reduce negative feedback mechanisms in metabolic pathways.

### PREDICTED_OUTCOME:
The combined modulation of G19943, G22553, and G04436 is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553 and G04436, which complement its function. G23245 and G33764 provide additional support without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 19:54:02,066 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:54:02,066 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:54:02,069 - root - INFO -   -> Created mutated offspring: 'Enhanced Multi-Target Strategy for Type ...'
2026-02-10 19:54:02,069 - root - INFO - Crossover 7/18: parents 'Integrated Multi-Target Approa...' x 'Integrated Modulation of G1994...'
2026-02-10 19:54:02,110 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:54:41,410 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:54:41,414 - root - INFO - TOKEN_USAGE: input=40321, output=735, total=41056, cost=$0.006489
2026-02-10 19:54:41,414 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:54:41,414 - root - INFO - 
### TITLE: Comprehensive Multi-Target Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Acts as a central hub in T2D pathways, facilitating insulin signaling and metabolic regulation, making it a prime target for enhancing glucose metabolism.
2. **G23245** | Score: 4.0 | Serves as a primary driver in insulin signaling, supporting glucose uptake and insulin sensitivity, thus complementing the action of G19943.
3. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways that works synergistically with G19943 to further improve glucose metabolism.
4. **G04436** | Score: 4.0 | A crucial enzyme involved in metabolic regulation, enhancing the effects of G19943 and G22553, thus addressing both glucose and lipid metabolism.
5. **G33764** | Score: 4.0 | Provides additional regulatory support within metabolic pathways, reinforcing the overall therapeutic efficacy of the combined approach.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes an integrated approach targeting G19943, G23245, G22553, and G04436 to enhance insulin sensitivity and metabolic control in Type 2 Diabetes (T2D). By leveraging the interconnectivity of these targets, we aim to create a robust therapeutic strategy that addresses multiple facets of T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 is identified as a hub component in relevant modules negatively correlated with T2D.
- Regulating TFs: None identified.

**MECHANISM_HYPOTHESIS:** G19943 is hypothesized to act as a crucial coordinator of insulin signaling and lipid metabolism, restoring metabolic balance in T2D. Targeting G23245 enhances this effect by promoting glucose uptake, while G22553 strengthens insulin signaling pathways. G04436 optimizes lipid metabolism, directly addressing dysregulation associated with T2D. Additionally, G33764 supports regulatory mechanisms, ensuring a comprehensive approach to managing the disease.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, liver, muscle, and adipose tissue. These tissues are critical for insulin action, glucose uptake, and lipid metabolism, making them optimal targets for therapeutic interventions aimed at reversing T2D.

**THERAPEUTIC_APPROACH:** The proposed therapeutic approach involves small molecule activation of G19943, G23245, and G22553 to enhance their functions, alongside modulation of G04436 to mitigate negative feedback mechanisms affecting metabolic pathways.

**PREDICTED_OUTCOME:** Effective modulation of G19943 and its associated targets is expected to lead to significantly improved insulin sensitivity and glucose metabolism, ultimately resulting in better management of T2D and improved patient outcomes.

**RANKING_RATIONALE:** G19943 is ranked highest due to its central role in insulin signaling and metabolic regulation. G23245 and G22553 follow closely for their synergistic effects on glucose metabolism. G04436 is included for its critical role in metabolic processes, while G33764 provides regulatory support without overshadowing the primary targets.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 19:54:41,414 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:54:41,414 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:54:41,415 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:54:41,416 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:54:41,416 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Modulation fo...'
2026-02-10 19:54:41,416 - root - INFO - Crossover 8/18: parents '** Comprehensive Modulation of...' x 'Integrated Multi-Target Approa...'
2026-02-10 19:54:41,457 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:55:19,155 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:55:19,163 - root - INFO - TOKEN_USAGE: input=40320, output=761, total=41081, cost=$0.006505
2026-02-10 19:55:19,163 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:55:19,163 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G23245** | Score: 4.0 | This gene is a central driver in insulin signaling pathways and has strong evidence supporting its role in glucose metabolism, making it the most promising target.
2. **G33764** | Score: 4.0 | This enzyme is a key player in metabolic pathways linked to T2D, complementing the effects of G23245 and enhancing overall metabolic control.
3. **G19943** | Score: 4.0 | As a hub component in T2D-related gene networks, it is critical for metabolic regulation and insulin signaling, providing synergistic effects with G23245 and G33764.
4. **G00484** | Score: 4.0 | This transcription factor regulates insulin signaling and glucose homeostasis, offering a regulatory layer that strengthens the therapeutic approach.
5. **G04436** | Score: 4.0 | This enzyme enhances glucose metabolism and has demonstrated significant evidence of improving insulin sensitivity, supporting the mechanisms initiated by the top targets.

**PRIMARY_TARGET:** G23245

**SUMMARY:** This hypothesis integrates the critical roles of G23245, G33764, G19943, G00484, and G04436 to comprehensively enhance insulin sensitivity and glucose metabolism in Type 2 Diabetes. By targeting these interconnected pathways, we aim to provide a robust therapeutic approach that addresses multiple dimensions of T2D pathology, thereby enhancing the therapeutic effectiveness compared to previous hypotheses.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: G23245 as primary driver in the silver module, negatively correlated with T2D.
- Regulating TFs: G00484 provides regulatory depth to the approach.

**MECHANISM_HYPOTHESIS:** G23245 is anticipated to act as a pivotal regulator within insulin signaling pathways, significantly enhancing glucose uptake in pancreatic -cells and peripheral tissues. The modulation of G33764 is expected to drive critical metabolic pathways, while G19943 as a hub component will synergize with the effects of G23245 and G00484, providing a comprehensive mechanism that enhances overall metabolic control in T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this hypothesis include pancreatic -cells, liver, and muscle, which are essential for insulin secretion and action, directly influencing glucose homeostasis and providing optimal targets for therapeutic intervention.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves small molecule modulation aimed at enhancing the activity of G23245, alongside combination therapies targeting G33764, G19943, G00484, and G04436 to further amplify insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to significantly improve insulin sensitivity, reduce blood glucose levels, and enhance overall disease management for patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their strong data support, roles in key biological pathways, and the robustness of the evidence. G23245 was selected as the primary target due to its central regulatory role, while G33764 and G19943 were prioritized for their significant contributions to metabolic regulation. G00484 and G04436 were included for their essential roles in enhancing the overall therapeutic strategy and regulatory depth.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 19:55:19,164 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:55:19,164 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:55:19,165 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:55:19,167 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:55:19,167 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Strategy f...'
2026-02-10 19:55:19,168 - root - INFO - Mutation 9/18: parent 'Enhanced Therapeutic Modulatio...'
2026-02-10 19:55:19,168 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 19:55:19,217 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:55:36,732 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:55:36,735 - root - INFO - TOKEN_USAGE: input=39549, output=763, total=40312, cost=$0.006390
2026-02-10 19:55:36,735 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:55:36,735 - root - INFO - 
### TITLE: Enhanced Insulin Sensitivity in Muscle Tissue via Targeted Gene Activation

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | This gene is a primary driver in insulin signaling pathways, making it crucial for enhancing muscle insulin sensitivity.
2. **G33764** | Score: **4.0** | This gene plays significant roles in metabolic pathways, and its activation can support improved metabolic flexibility in muscle tissue.
3. **G04436** | Score: **4.0** | As a key enzyme in lipid metabolism, its activation in muscle can positively influence insulin sensitivity and overall metabolic control.
4. **G23245** | Score: **4.0** | This gene enhances glucose uptake, which is essential for muscle energy homeostasis and insulin sensitivity.
5. **G19122** | Score: **3.0** | This major regulator supports other targets and can enhance the overall efficacy of insulin signaling in muscle tissue.

#### PRIMARY_TARGET: G22553

### SUMMARY:
This mutated hypothesis posits that targeting G22553, along with G33764, G04436, G23245, and G19122, will significantly enhance insulin sensitivity specifically within muscle tissue. By focusing on muscle metabolism, this approach aims to address the pathological mechanisms underlying insulin resistance in Type 2 Diabetes, leading to improved glucose uptake and metabolic control.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism
- **WGCNA module role**: Primary driver in relevant modules for G22553 and G33764
- **Regulating TFs**: Multiple transcription factors identified for G22553

### MECHANISM_HYPOTHESIS:
The activation of G22553 is expected to enhance insulin signaling in muscle tissue, leading to improved glucose uptake and utilization. Concurrent activation of G33764 will further support metabolic flexibility, while G04436, G23245, and G19122 will collectively enhance lipid metabolism and overall metabolic control. This synergistic approach specifically targets muscle tissue, a critical site for insulin action, promoting a more effective therapeutic outcome in Type 2 Diabetes management.

### TISSUE_RATIONALE:
Muscle tissue is highly relevant due to its role in glucose uptake and energy metabolism, which are critical for maintaining insulin sensitivity. Enhancing the function of key metabolic pathways in this tissue can directly impact the overall management of Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The proposed approach involves the small molecule activation of G22553 and its synergistic partners (G33764, G04436, G23245, and G19122) to enhance their respective functions within muscle tissue, promoting improved insulin sensitivity and metabolic control.

### PREDICTED_OUTCOME:
The targeted activation of G22553 and its related pathways is anticipated to lead to a significant improvement in muscle insulin sensitivity, enhanced glucose uptake, and better overall metabolic regulation, ultimately resulting in more effective management of Type 2 Diabetes.

### RANKING_RATIONALE:
Targets were ranked based on their roles in insulin signaling and metabolic pathways relevant to muscle tissue. G22553 leads due to its established role and strong evidence support, followed by G33764 for its regulatory significance. G04436 and G23245 are included for their impact on glucose and lipid metabolism, while G19122 provides additional support without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to muscle metabolism and Type 2 Diabetes management.
2026-02-10 19:55:36,735 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:55:36,736 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:55:36,736 - root - INFO -   -> Created mutated offspring: 'Enhanced Insulin Sensitivity in Muscle T...'
2026-02-10 19:55:36,736 - root - INFO - Crossover 10/18: parents '** Synergistic Modulation of G...' x '** Comprehensive Modulation of...'
2026-02-10 19:55:36,771 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:56:04,707 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:56:04,713 - root - INFO - TOKEN_USAGE: input=40377, output=793, total=41170, cost=$0.006532
2026-02-10 19:56:04,713 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:56:04,713 - root - INFO - 
**TITLE:** Integrated Modulation of G19943, G33764, and G04436 to Optimize Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | As a hub component in T2D gene networks, G19943 is crucial for insulin signaling and metabolic regulation, making it the primary target for enhancing insulin sensitivity.
2. **G33764** | Score: **4.0** | This enzyme plays a significant role in the modulation of metabolic pathways, complementing G19943 by enhancing glucose metabolism and improving insulin sensitivity.
3. **G04436** | Score: **4.0** | By enhancing glucose metabolism and providing synergistic effects when activated alongside G19943 and G33764, G04436 is vital for optimizing the therapeutic strategy.
4. **G22553** | Score: **4.0** | As a primary driver in insulin receptor signaling pathways, G22553 supports glucose uptake and enhances the overall efficacy of the therapeutic approach.
5. **G19122** | Score: **3.0** | This major regulator in insulin signaling pathways can help restore metabolic balance, further augmenting the effects of the primary targets in improving insulin sensitivity.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** This hypothesis integrates the synergistic modulation of G19943, G33764, and G04436 to enhance insulin sensitivity and optimize metabolic control in Type 2 Diabetes. By leveraging the strengths of multiple high-priority targets, this approach aims to address the multifaceted nature of T2D pathology more effectively than previous hypotheses.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17** for primary target
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, inflammatory response pathways**
- WGCNA module role: **Hub component (G19943), Primary Driver (G33764, G22553)**
- Regulating TFs: **None identified**

**MECHANISM_HYPOTHESIS:** The activation of G19943 is hypothesized to enhance insulin signaling and lipid metabolism pathways, directly addressing the metabolic dysregulation characteristic of T2D. Concurrently, the modulation of G33764 is expected to regulate key metabolic pathways, while G04436 will facilitate glucose uptake and improve insulin sensitivity. The inclusion of G22553 is anticipated to further enhance the overall therapeutic efficacy by supporting glucose uptake and further fortifying the insulin signaling network.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells, muscle, and liver, as they play crucial roles in glucose metabolism and insulin action, which are pivotal in the pathophysiology of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets through small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, potentially leading to a reversal of disease progression.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their critical roles in relevant biological pathways, and the robustness of the supporting evidence. G19943 is prioritized due to its central role as a hub component in insulin signaling networks. G33764 and G04436 were next due to their significant contributions to metabolic regulation. G22553 supports the overall strategy, while G19122 serves as a valuable secondary target to further enhance insulin sensitivity. 

**CONFIDENCE:** **HIGH** based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:56:04,715 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:56:04,716 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:56:04,716 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:56:04,719 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:56:04,720 - root - INFO -   -> Created offspring: '** Integrated Modulation of G19943, G337...'
2026-02-10 19:56:04,720 - root - INFO - Mutation 11/18: parent 'Integrated Multi-Target Approa...'
2026-02-10 19:56:04,720 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:56:04,811 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:56:40,577 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:56:40,581 - root - INFO - TOKEN_USAGE: input=39516, output=734, total=40250, cost=$0.006368
2026-02-10 19:56:40,582 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:56:40,582 - root - INFO - 
**TITLE:** Enhanced Multi-Target Strategy for Insulin Sensitivity Improvement in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G23245** | Score: 4.0 | Central to insulin signaling and glucose metabolism, with strong evidence supporting its role as a primary driver in T2D-related pathways.
2. **G33764** | Score: 4.0 | Functions as a key enzyme in metabolic pathways, enhancing the metabolic control alongside G23245, thereby reinforcing the therapeutic strategy.
3. **G00484** | Score: 4.0 | A transcription factor that regulates insulin signaling, providing an essential regulatory layer to the therapeutic approach and enhancing G23245's effects.
4. **G22553** | Score: 4.0 | A primary driver in related pathways, adding robustness to the multi-target approach and potentially influencing metabolic pathways that interact with G23245.
5. **G36503** | Score: 4.0 | Contributes to glucose homeostasis, providing additional support to the primary targets and ensuring a comprehensive approach to T2D management.

**PRIMARY_TARGET:** G23245

**SUMMARY:** This refined hypothesis emphasizes the pivotal role of G23245 in insulin signaling and glucose metabolism, while integrating the synergistic effects of G33764 and G00484. By utilizing a multi-target approach that includes G22553 and G36503, we aim to enhance insulin sensitivity and optimize metabolic control in the management of Type 2 Diabetes (T2D).

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: Primary Driver in the silver module, negatively correlated with T2D.
- Regulating TFs: None identified for G23245, but G00484 acts as a regulator in related pathways.

**MECHANISM_HYPOTHESIS:** We hypothesize that G23245 acts as a central regulator within insulin signaling pathways, facilitating glucose uptake in pancreatic -cells and peripheral tissues. The modulation of G23245 is expected to amplify downstream metabolic processes crucial for maintaining glucose homeostasis. Furthermore, G33764 enhances critical metabolic pathways, while G00484 provides regulatory control over insulin signaling, forming a comprehensive network that optimizes overall metabolic control in T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, liver, and muscle, as these are critical for insulin secretion and action, directly influencing glucose homeostasis and serving as optimal therapeutic intervention targets.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule modulation aimed at activating G23245, combined with adjunct therapies targeting G33764 and G00484 to further enhance insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Effective modulation of G23245 and its associated pathways is anticipated to lead to significantly improved insulin sensitivity and lower blood glucose levels, directly addressing the pathophysiology of T2D and enhancing disease management strategies.

**RANKING_RATIONALE:** G23245 is ranked highest due to its central role in insulin signaling and strong evidence from multiple datasets. G33764 is closely tied to G23245s function, enhancing metabolic efficacy, while G00484 adds critical regulatory depth. G22553 and G36503, although ranked lower, contribute essential support to the therapeutic strategy.

**CONFIDENCE:** HIGH, based on robust data support and significant associations with T2D pathways and mechanisms.
2026-02-10 19:56:40,583 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:56:40,583 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:56:40,583 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:56:40,584 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:56:40,584 - root - INFO -   -> Created mutated offspring: '** Enhanced Multi-Target Strategy for In...'
2026-02-10 19:56:40,585 - root - INFO - Mutation 12/18: parent '** Identification of Promising...'
2026-02-10 19:56:40,585 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 19:56:40,619 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:57:22,104 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:57:22,108 - root - INFO - TOKEN_USAGE: input=39443, output=700, total=40143, cost=$0.006336
2026-02-10 19:57:22,108 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:57:22,108 - root - INFO - 
**TITLE:** Enhanced Target Mechanism for Type 2 Diabetes Therapy Focusing on G19943

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene is a hub component in key insulin signaling pathways and shows robust evidence across multiple datasets, indicating its central role in Type 2 Diabetes.
2. **G22553** | Score: **4.0** | As a primary driver in the black module, this gene correlates positively with T2D, suggesting it plays an important role in disease progression and could be targeted for therapeutic intervention.
3. **G23245** | Score: **4.0** | Another primary driver involved in pathways relevant to T2D, it contributes negatively to the silver module's correlation with T2D, indicating potential for modulation.
4. **G27976** | Score: **3.0** | A major regulator in the silver module, this gene influences insulin sensitivity and metabolic regulation, making it a relevant target for therapeutic strategies.
5. **G19122** | Score: **3.0** | As a major regulator involved in insulin signaling, this gene has a significant impact on glucose metabolism and insulin sensitivity.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** The mutated hypothesis maintains G19943 as the primary target due to its critical role in insulin signaling and its identification as a hub in gene networks associated with Type 2 Diabetes. The revised mechanism emphasizes its potential interaction with transcription factors involved in insulin sensitivity and inflammatory pathways.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, inflammatory response pathways**
- WGCNA module role: **Hub component in the silver module**
- Regulating TFs: **None reported, but potential for specific TF interactions exists**

**MECHANISM_HYPOTHESIS:** G19943 may modulate insulin sensitivity through its interaction with downstream transcription factors that regulate the expression of genes involved in glucose uptake and metabolism. This target could alleviate chronic inflammation associated with insulin resistance by downregulating pro-inflammatory cytokines and enhancing insulin signaling pathways.

**TISSUE_RATIONALE:** The primary tissues of interest are pancreatic -cells, skeletal muscle, and adipose tissue. In these tissues, G19943s modulation could enhance insulin signaling, improve glucose uptake, and reduce lipotoxicity, thereby improving overall metabolic health in individuals with Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The proposed therapeutic approach involves small molecule activation of G19943 to enhance its function within insulin signaling pathways, potentially restoring its normal activity in the context of T2D.

**PREDICTED_OUTCOME:** Modulation of G19943 is anticipated to improve insulin sensitivity, lower blood glucose levels, and reduce inflammation, leading to better metabolic control and a decrease in T2D-related complications.

**RANKING_RATIONALE:** The targets are ranked based on their priority scores, biological relevance, and potential impact on Type 2 Diabetes pathology. G19943 ranks highest due to its central role in insulin signaling, followed closely by G22553 and G23245, which also show strong evidence for therapeutic targeting.

**CONFIDENCE:** **HIGH** based on the robust data support and clear relevance of the identified pathways to Type 2 Diabetes pathology.
2026-02-10 19:57:22,109 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:57:22,109 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:57:22,109 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:57:22,111 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:57:22,111 - root - INFO -   -> Created mutated offspring: '** Enhanced Target Mechanism for Type 2 ...'
2026-02-10 19:57:22,112 - root - INFO - Crossover 13/18: parents 'Integrated Modulation of G1994...' x 'Tissue-Specific Target Hypothe...'
2026-02-10 19:57:22,168 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:58:04,316 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:58:04,331 - root - INFO - TOKEN_USAGE: input=40352, output=834, total=41186, cost=$0.006553
2026-02-10 19:58:04,331 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:58:04,331 - root - INFO - 
### TITLE: Comprehensive Insulin Sensitivity Restoration through Multi-Target Modulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Central hub in T2D pathways, facilitating insulin signaling and metabolic regulation, with strong evidence across datasets.
2. **G33764** | Score: **4.0** | Key driver in insulin resistance mechanisms, particularly in adipose tissue, highlighting its relevance in T2D pathology.
3. **G22553** | Score: **4.0** | A primary driver in insulin signaling pathways, complementing G19943's function to improve glucose metabolism.
4. **G04436** | Score: **4.0** | Critical enzyme involved in metabolic regulation, enhancing the effects of both G19943 and G22553.
5. **G20274** | Score: **3.0** | Major regulator in insulin signaling pathways, whose dysregulation in adipose tissue supports its importance in T2D.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis posits that a multi-target approach, focusing on G19943, G33764, G22553, and G04436, can synergistically enhance insulin sensitivity and metabolic control in Type 2 Diabetes (T2D). By integrating insights regarding the roles of these targets in insulin signaling and metabolic dysregulation, we aim to provide a more comprehensive therapeutic strategy compared to the individual approaches outlined in the parent hypotheses.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and energy homeostasis.
- **WGCNA module role**: G19943 is identified as a hub component in relevant modules negatively correlated with T2D; G33764 is linked to modules related to insulin resistance.
- **Regulating TFs**: Multiple transcription factors are associated with the targets, indicating regulatory complexity.

### MECHANISM_HYPOTHESIS:
G19943 acts as a central modulator of insulin signaling and lipid metabolism, playing a crucial role in restoring metabolic homeostasis. By targeting G33764, we address the dysregulation of insulin sensitivity specifically in adipose tissue, which is a critical site for metabolic disturbances in T2D. The inclusion of G22553 enhances insulin signaling pathways, while G04436 optimizes metabolic regulation, creating a synergistic effect. G20274 provides additional context as it regulates insulin signaling, contributing further to improved glucose homeostasis.

### TISSUE_RATIONALE:
Key tissues include pancreatic beta-cells, muscle, liver, and adipose tissue. These tissues are essential for insulin action, glucose uptake, and lipid metabolism, making them critical targets for therapeutic interventions aimed at reversing T2D.

### THERAPEUTIC_APPROACH:
The proposed approach involves the modulation of G19943 and G22553 to enhance their functions, alongside the inhibition of G33764 to improve insulin sensitivity in adipose tissue and modulation of G04436 to optimize metabolic pathways.

### PREDICTED_OUTCOME:
The combined modulation of G19943, G33764, G22553, and G04436 is anticipated to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes, potentially leading to improved patient outcomes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergy. G19943 is prioritized for its central role, followed by G33764 for its significance in adipose tissue. G22553 and G04436 are included for their complementary functions in insulin signaling and metabolic regulation, while G20274 provides additional regulatory support. 

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 19:58:04,332 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:58:04,332 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:58:04,334 - root - INFO -   -> Created offspring: 'Comprehensive Insulin Sensitivity Restor...'
2026-02-10 19:58:04,334 - root - INFO - Mutation 14/18: parent '** Targeting G22553 for Enhanc...'
2026-02-10 19:58:04,334 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:58:04,382 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:58:42,896 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:58:42,903 - root - INFO - TOKEN_USAGE: input=39439, output=735, total=40174, cost=$0.006357
2026-02-10 19:58:42,903 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:58:42,903 - root - INFO - 
**TITLE:** Enhanced Insulin Sensitivity in Type 2 Diabetes through Dual Activation of G22553 and G04436

**RANKED_TARGETS:**
1. **G22553 | Score: 4.0 | This gene is a primary driver in insulin receptor signaling and its activation is crucial for enhancing glucose uptake in peripheral tissues.**
2. **G04436 | Score: 4.0 | As an enzyme that promotes glucose metabolism, its activation can synergize with G22553 to optimize insulin sensitivity and metabolic homeostasis.**
3. **G33764 | Score: 4.0 | This enzyme plays a significant role in metabolic regulation; its activation may help mitigate metabolic dysregulation in T2D.**
4. **G19122 | Score: 3.0 | Although a major regulator, its activation is secondary to the more critical roles of G22553 and G04436 in enhancing insulin signaling and glucose uptake.**
5. **G23245 | Score: 4.0 | As a primary driver in T2D, its activation can provide additional support for metabolic regulation but is less prioritized than G22553 and G04436.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis proposes a dual activation approach targeting G22553 and G04436 to enhance insulin sensitivity in Type 2 Diabetes. By activating G22553, which is essential in insulin receptor signaling, and G04436, which enhances glucose metabolism, we aim to achieve a comprehensive improvement in glucose uptake and metabolic control.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation
- WGCNA module role: G22553 is a primary driver in the black module, while G04436 supports metabolic functions.
- Regulating TFs: None reported, but important for T2D modulation.

**MECHANISM_HYPOTHESIS:** The activation of G22553 is expected to significantly enhance insulin receptor signaling, leading to improved glucose uptake in tissues such as muscle and the liver. Coupled with the activation of G04436, which further stimulates glucose metabolism, this dual approach aims to restore metabolic homeostasis. Additionally, the activation of G33764 may address metabolic dysregulation, providing a multifaceted strategy for improving insulin sensitivity.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells, skeletal muscle, and liver, as they are directly involved in insulin action and glucose metabolism, which are critical in the pathophysiology of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The hypothesis focuses on the activation of the selected targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** The expected therapeutic benefit includes a significant enhancement in insulin sensitivity, reduction in hyperglycemia, and improved overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, evidence strength, and their critical roles in insulin signaling and glucose metabolism. G22553 was selected as the primary target due to its central role in insulin receptor signaling, while G04436 was prioritized for its significant contribution to glucose metabolism. G33764, while also important, was ranked lower due to its secondary role compared to the primary targets.

**CONFIDENCE:** HIGH based on the strength of data support and multiple lines of evidence.
2026-02-10 19:58:42,905 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:58:42,905 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:58:42,905 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:58:42,908 - root - WARNING - Mutation produced invalid target: 
2026-02-10 19:58:42,909 - root - INFO -   -> Created mutated offspring: '** Enhanced Insulin Sensitivity in Type ...'
2026-02-10 19:58:42,910 - root - INFO - Crossover 15/18: parents 'Integrated Multi-Target Approa...' x 'Integrated Modulation of G1994...'
2026-02-10 19:58:42,950 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 19:59:21,708 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:59:21,714 - root - INFO - TOKEN_USAGE: input=40321, output=752, total=41073, cost=$0.006499
2026-02-10 19:59:21,714 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:59:21,714 - root - INFO - 
### TITLE: Synergistic Multi-Target Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in T2D pathways facilitating insulin signaling and metabolic regulation, making it the most promising target.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways, complementing G19943's function to improve glucose metabolism.
3. **G23245** | Score: 4.0 | A pivotal driver in glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy alongside the other two targets.
4. **G33764** | Score: 4.0 | Enhances metabolic regulation and provides additional support in insulin signaling pathways, adding robustness to the approach.
5. **G00484** | Score: 4.0 | Functions as a transcription factor crucial for the regulation of insulin signaling and glucose homeostasis, providing essential regulatory depth.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses, emphasizing a multi-target approach that leverages key roles in insulin signaling and glucose metabolism. By focusing on G19943 as the primary target, we enhance the overall efficacy of T2D management through synergistic interactions with G22553, G23245, G33764, and G00484, addressing the multifactorial nature of the disease.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: None identified for G19943, but G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** G19943 is hypothesized to act as a central coordinator in insulin signaling and lipid metabolism, which is essential for restoring metabolic homeostasis in T2D. Targeting G22553 in conjunction with G19943 enhances insulin signaling pathways, while G23245 and G33764 contribute to glucose uptake and metabolic regulation. G00484 further supports these processes by regulating transcriptional responses critical for insulin sensitivity, creating a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are integral to insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245, G33764, and G00484 to strengthen metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553, which complements its function. G23245 and G33764 provide essential regulatory support, while G00484 adds necessary transcriptional regulation.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 19:59:21,716 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:59:21,716 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 19:59:21,717 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 19:59:21,720 - root - WARNING - Crossover produced invalid target: 
2026-02-10 19:59:21,720 - root - INFO -   -> Created offspring: 'Synergistic Multi-Target Modulation for ...'
2026-02-10 19:59:21,720 - root - INFO - Mutation 16/18: parent 'Integrated Modulation of G1994...'
2026-02-10 19:59:21,720 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 19:59:21,774 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 19:59:47,379 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 19:59:47,386 - root - INFO - TOKEN_USAGE: input=39545, output=745, total=40290, cost=$0.006379
2026-02-10 19:59:47,387 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 19:59:47,387 - root - INFO - 
### TITLE: Dual Activation of G19943 and G22553 for Enhanced Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Central hub within T2D pathways, critical for enhancing insulin signaling and metabolic regulation.
2. **G22553** | Score: **4.0** | A primary driver in insulin signaling pathways that synergizes with G19943 to improve glucose metabolism.
3. **G04436** | Score: **4.0** | Key enzyme influencing metabolic regulation, optimizing the effects of both G19943 and G22553.
4. **G33764** | Score: **4.0** | Provides additional regulatory support for metabolic pathways and enhances overall therapeutic efficacy.
5. **G23245** | Score: **4.0** | Supports glucose uptake and insulin sensitivity, contributing synergistically to the dual activation strategy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This mutated hypothesis proposes a therapeutic strategy that focuses on the dual activation of G19943 and G22553 to address Type 2 Diabetes (T2D) more effectively. By activating these central drivers of insulin signaling and metabolic regulation, we aim to enhance insulin sensitivity, improve glucose metabolism, and provide a comprehensive approach to managing T2D.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, and lipid metabolism pathways.
- **WGCNA module role**: G19943 identified as a hub component within modules negatively correlated with T2D.
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
By activating G19943, we target the central hub of insulin signaling, which is critical for coordinating metabolic responses. Simultaneously, the activation of G22553 enhances the overall insulin signaling cascade, leading to improved glucose uptake and metabolism. The inclusion of G04436 as a target further optimizes lipid metabolism, addressing both glucose regulation and lipid dysregulation. This dual activation strategy aims to robustly restore metabolic homeostasis and alleviate T2D pathology.

### TISSUE_RATIONALE:
The key tissues involved in this strategy include pancreatic beta-cells, muscle, liver, and adipose tissue. Each of these tissues plays a crucial role in insulin action, glucose uptake, and lipid metabolism, making them essential targets for effective therapeutic interventions aimed at reversing T2D.

### THERAPEUTIC_APPROACH:
The proposed approach involves the small molecule activation of both G19943 and G22553 to enhance their functions, alongside modulation of G04436 to mitigate any potential negative feedback mechanisms affecting metabolic pathways.

### PREDICTED_OUTCOME:
The dual activation of G19943 and G22553 is anticipated to significantly enhance insulin sensitivity and improve glucose metabolism, leading to a comprehensive therapeutic benefit in managing Type 2 Diabetes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergy. G19943 is prioritized for its central role, closely followed by G22553 for its complementary function. G04436 is included due to its regulatory significance, while G33764 and G23245 provide additional support without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 19:59:47,389 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 19:59:47,389 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 19:59:47,392 - root - INFO -   -> Created mutated offspring: 'Dual Activation of G19943 and G22553 for...'
2026-02-10 19:59:47,393 - root - INFO - Crossover 17/18: parents 'Tissue-Specific Target Hypothe...' x 'Integrated Modulation of G1994...'
2026-02-10 19:59:47,428 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:00:30,450 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:00:30,485 - root - INFO - TOKEN_USAGE: input=40352, output=783, total=41135, cost=$0.006523
2026-02-10 20:00:30,485 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:00:30,485 - root - INFO - 
### TITLE: Integrated Gene Modulation for Comprehensive Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | This gene acts as a central hub in T2D pathways, facilitating insulin signaling and metabolic regulation, making it essential for overall metabolic control.
2. **G22553** | Score: 4.0 | Identified as a primary driver of insulin signaling pathways, it complements G19943's function, enhancing glucose metabolism and sensitivity.
3. **G33764** | Score: 4.0 | A significant player in disrupting insulin signaling in adipose tissue, its inclusion adds critical insights related to insulin resistance mechanisms.
4. **G04436** | Score: 4.0 | This gene is critical in metabolic regulation and has shown strong evidence supporting its role in enhancing insulin sensitivity.
5. **G20274** | Score: 3.0 | As a major regulator in insulin signaling, this gene further supports the hypothesis by addressing metabolic dysregulation in T2D.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis proposes a robust therapeutic strategy that combines the central role of G19943 with the complementary functions of G22553 and G33764, while also addressing metabolic regulation through G04436 and G20274. This integrative approach aims to enhance insulin sensitivity and metabolic control across multiple tissues affected by Type 2 Diabetes.

### DATA_EVIDENCE:
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 is identified as a hub component in relevant modules negatively correlated with T2D.
- Regulating TFs: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism centers on G19943 as a hub for coordinating insulin signaling and lipid metabolism. By targeting G22553, we can enhance the modulation of insulin signaling pathways, crucial for reversing insulin resistance. G33764's role in adipose tissue provides insights into the specific dysregulation occurring in this tissue, while G04436's involvement ensures comprehensive metabolic regulation. Additionally, G20274 supports the overall framework by addressing insulin signaling dysregulation, culminating in a multi-faceted strategy for T2D management.

### TISSUE_RATIONALE:
Key tissues targeted include adipose tissue, pancreatic beta-cells, muscle, and liver, all of which are critical for insulin action, glucose uptake, and lipid metabolism. Focusing on these tissues is essential for developing effective therapies aimed at reversing the metabolic disturbances associated with Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The therapeutic strategy will involve the modulation of G19943 and G22553 through small molecule activators to enhance their functions, combined with the inhibition of G33764 and G04436 to mitigate negative feedback mechanisms affecting metabolic pathways.

### PREDICTED_OUTCOME:
The integrated modulation of these targets is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergy. G19943 is prioritized for its central role, followed closely by G22553 for its complementary function. G33764 is included for its specific relevance to adipose tissue, while G04436 and G20274 provide additional regulatory context without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:00:30,486 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:00:30,486 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:00:30,494 - root - INFO -   -> Created offspring: 'Integrated Gene Modulation for Comprehen...'
2026-02-10 20:00:30,496 - root - INFO - Crossover 18/18: parents '** Synergistic Modulation of I...' x 'Enhanced Therapeutic Strategie...'
2026-02-10 20:00:30,586 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:01:13,221 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:01:13,228 - root - INFO - TOKEN_USAGE: input=40330, output=802, total=41132, cost=$0.006531
2026-02-10 20:01:13,228 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:01:13,229 - root - INFO - 
### TITLE: Comprehensive Targeting of Insulin Signaling and Lipid Metabolism Pathways to Enhance Metabolic Control in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G33764 | Score: 4.0 | This enzyme is a master regulator of metabolic pathways, significantly influencing both insulin signaling and lipid metabolism in T2D.**
2. **G19122 | Score: 3.0 | A major regulator in adipose tissue, crucial for enhancing insulin sensitivity and glucose metabolism, complementing G33764's effects.**
3. **G04436 | Score: 4.0 | A pivotal enzyme in glucose homeostasis with strong evidence supporting its role in restoring metabolic balance in T2D.**
4. **G22553 | Score: 4.0 | A primary driver of insulin receptor signaling and glucose uptake, essential for comprehensive management of glucose metabolism.**
5. **G19943 | Score: 4.0 | Functions as a hub component in insulin signaling pathways, providing integrative support to enhance metabolic regulation.**

#### PRIMARY_TARGET: G33764

### SUMMARY:
This hypothesis proposes a multifaceted approach to treating Type 2 Diabetes by targeting G33764, G19122, G04436, G22553, and G19943. By focusing on the interplay between insulin signaling and lipid metabolism, this hypothesis aims to enhance overall metabolic control and address the complexities of T2D pathology. The integration of these targets facilitates a comprehensive strategy that tackles both insulin sensitivity and glucose homeostasis.

### DATA_EVIDENCE:
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation
- **WGCNA module role:** G33764 identified as a primary driver in relevant modules
- **Regulating TFs:** Potential interactions with multiple transcription factors influencing these metabolic pathways

### MECHANISM_HYPOTHESIS:
The modulation of G33764 is expected to serve as a master regulator, enhancing critical insulin signaling and lipid metabolism pathways. Coupled with G19122's role in improving insulin sensitivity in adipose tissue and G04436's involvement in glucose homeostasis, this hypothesis creates a robust framework for reversing the metabolic dysregulation seen in T2D. Additionally, G22553 and G19943 provide further support by enhancing insulin receptor signaling and acting as a hub in metabolic networks, respectively. This multifaceted targeting is designed to synergistically improve metabolic outcomes.

### TISSUE_RATIONALE:
The most relevant tissues include adipose tissue, liver, and muscle, as these are directly involved in the regulation of glucose metabolism, lipid metabolism, and insulin action, which are critical factors in T2D pathophysiology.

### THERAPEUTIC_APPROACH:
The therapeutic strategy focuses on the activation of these targets using small molecules designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

### PREDICTED_OUTCOME:
The combined modulation of these targets is anticipated to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control, providing a more effective therapeutic benefit for patients with Type 2 Diabetes.

### RANKING_RATIONALE:
The targets were ranked based on their priority scores, roles in key biological pathways, and the robustness of supporting evidence. G33764 was selected as the primary target due to its central role in both insulin signaling and lipid metabolism, while G19122 was prioritized for its significant contributions to insulin sensitivity. G04436, G22553, and G19943 were included to ensure a comprehensive approach to addressing multiple aspects of metabolic dysregulation in T2D.

### CONFIDENCE: HIGH, based on strong multi-evidence support, the relevance of identified pathways to Type 2 Diabetes pathology, and the integrated approach to targeting multiple pathways simultaneously.
2026-02-10 20:01:13,230 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:01:13,230 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:01:13,234 - root - INFO -   -> Created offspring: 'Comprehensive Targeting of Insulin Signa...'
2026-02-10 20:01:13,234 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 20:01:13,234 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 20:01:13,234 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 20:01:13,234 - root - INFO - Evaluating fitness for hypothesis: t2d-04-0804f9df
2026-02-10 20:01:27,758 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:01:27,761 - root - INFO - TOKEN_USAGE: input=1515, output=779, total=2294, cost=$0.000695
2026-02-10 20:01:27,762 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:01:27,762 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is ranked highest with a score of 4.0, indicating strong support. However, G33764, while important, is not found in the top priority list, which raises concerns. Cross-dataset consistency is confirmed, and there are two datasets supporting the primary target, which strengthens the data evidence. Overall, while there is good support for the primary target, the absence of G33764 in the top priority list detracts from the score.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the data presented. G19943 is appropriately placed at the top due to its central role; G22553 and G33764 are also well-positioned based on their functions in insulin signaling and metabolic regulation. The rationale for including G19122 and G04436 as supportive targets is sound, but the absence of G33764 in the top priority list slightly undermines the strength of the ranking.

---

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in Type 2 Diabetes, particularly concerning lipid metabolism and insulin signaling. The tissue rationale is strong, focusing on adipose tissue, liver, and skeletal muscle, which are critical for insulin sensitivity and metabolic regulation. However, the lack of identified regulatory transcription factors may limit the comprehension of the full regulatory landscape.

---

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators is appropriate given the roles of the targets in metabolic regulation. The multi-target strategy could enhance treatment efficacy for Type 2 Diabetes. However, considerations regarding the druggability of G33764 and the safety profiles of combining multiple targets should be more explicitly addressed to strengthen this evaluation.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis presents a multi-target approach that integrates various metabolic regulators, which is a creative strategy in the context of Type 2 Diabetes. However, the connections between the targets, while logical, may not be sufficiently novel, as similar multi-target strategies have been explored in the literature. More emphasis on unique aspects of this strategy could enhance the novelty score.

---

### OVERALL_FITNESS:
Calculated: 
\[ \text{Overall Fitness} = (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 6.65 \]
Scaled: 
\[ \text{Overall Fitness} = 66.5 \]

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: MODERATE

---

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate G33764:** Investigate why G33764 is not in the top priority list and consider its role in the multi-target strategy more explicitly. If it is critical, bolster its data support or seek additional evidence for its inclusion.

2. **Identify Regulatory Transcription Factors:** Explore potential transcription factors that might regulate the identified targets to provide a more comprehensive mechanistic understanding.

3. **Expand on Drug Safety Profiles:** Include a discussion on the safety considerations of the therapeutic approach, particularly concerning polypharmacology related to multiple target modulation.

4. **Enhance Novelty Aspects:** Highlight any unique methodologies or novel integrations of the proposed targets that differentiate this therapeutic strategy from existing approaches in Type 2 Diabetes management.
2026-02-10 20:01:27,762 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:01:27,763 - root - INFO - Evaluating fitness for hypothesis: t2d-04-6161b380
2026-02-10 20:01:59,082 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:01:59,099 - root - INFO - TOKEN_USAGE: input=1472, output=852, total=2324, cost=$0.000732
2026-02-10 20:01:59,099 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:01:59,099 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) is indeed found in the top priority list, and there is cross-dataset consistency for it and other top-ranked targets (G04436, G22553, G33764). However, the warning about the target gene not being found in the top priority list for other genes (e.g., G23245, G01138, G33929) slightly detracts from the overall support. The evidence types supporting the primary target are robust, but the exclusion of some other ranked targets limits the maximum score.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on strong roles in key pathways related to T2D. G19943 is clearly the strongest candidate, with supporting roles from G04436 and G22553. The rationale behind the ranking is logical, focusing on synergistic effects among the targets, but some targets listed in the top 10 could potentially affect the ranking dynamics.

**MECHANISTIC_SCORE: 9**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and metabolic pathways identified, and the rationale for targeting pancreatic -cells, muscle, and liver tissues is appropriate given their roles in glucose metabolism. The consideration of transcription factors related to G04436 enhances the mechanistic understanding.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets with small molecules appears appropriate, given their central roles in T2D pathology. The potential for druggability is high due to their hub positions in the metabolic network, though safety considerations need to be addressed, particularly with multi-target approaches.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** While the hypothesis integrates data in a compelling way, the focus on multi-target strategies for T2D is becoming more common in the field. The connections made between the targets are insightful, but they do not represent entirely novel concepts in drug discovery for diabetes management.

### Overall Fitness Calculation
**OVERALL_FITNESS:**  
\[ \text{Overall Fitness} = (DATA\_SUPPORT\_SCORE \times 0.25) + (RANKING\_QUALITY\_SCORE \times 0.25) + (MECHANISTIC\_SCORE \times 0.20) + (THERAPEUTIC\_SCORE \times 0.20) + (NOVELTY\_SCORE \times 0.10) \]  
\[ \text{Overall Fitness} = (7 \times 0.25) + (8 \times 0.25) + (9 \times 0.20) + (8 \times 0.20) + (7 \times 0.10) \]  
\[ \text{Overall Fitness} = 1.75 + 2.00 + 1.80 + 1.60 + 0.70 = 7.85 \]  
\[ \text{Overall Fitness} = 78.5 \]

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Target Gene Inclusion:** Consider reevaluating the inclusion of other high-scoring genes from the top 10 priority list that may complement the proposed targets and enhance data support.
2. **Address Safety Considerations:** Clearly outline potential safety concerns associated with multi-target engagement and discuss how to mitigate these risks in the therapeutic approach.
3. **Explore Novelty Aspects:** Search for unique biological pathways or connections that can differentiate this approach from existing therapies for T2D, potentially enhancing the novelty score.
4. **Strengthen Evidence Base:** Incorporate additional datasets or evidence types to support the mechanism and therapeutic potential, which could improve the data support score.
2026-02-10 20:01:59,100 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:01:59,101 - root - INFO - Evaluating fitness for hypothesis: t2d-04-65b78aee
2026-02-10 20:02:15,982 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:02:15,983 - root - INFO - TOKEN_USAGE: input=1418, output=705, total=2123, cost=$0.000636
2026-02-10 20:02:15,984 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:02:15,984 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed in the top priority tier, but there is a warning that it is not found in the top priority list. However, G33764 and G22553, which are also ranked highly, are consistent with the data evidence provided. There is cross-dataset consistency for G19943, and it is mentioned that two datasets support the evidence. The priority score is also relatively high (4.0), but the total number of evidence types supporting the primary target could be more diversified.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, particularly with G19943 as a hub component and its high score. The rationale for selecting G33764 and G22553 as key targets is clear, as they directly support the primary target's function in metabolic regulation. However, the scoring of G19122 and G04436, though justified, is slightly lower, which may not reflect their supportive roles adequately.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and metabolic context. The rationale for targeting adipose tissue, liver, and skeletal muscle is well supported by their roles in glucose metabolism and insulin action. However, the absence of identified regulatory transcription factors (TFs) presents a slight gap in understanding the full regulatory landscape.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating selected targets with small molecule modulators seems appropriate and feasible, considering their roles in enhancing insulin sensitivity. The targets appear to be druggable based on their network positions. However, safety considerations were not explicitly discussed, which is critical in the context of drug development.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data and proposes a synergistic approach, which is commendable. However, the connections made are somewhat conventional in the context of Type 2 Diabetes research, and more innovative or unexpected connections could enhance the novelty score.

### OVERALL_FITNESS
Overall Fitness Calculation: (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.5  
**Overall Fitness:** 75.0

### RANKED_TARGETS_ASSESSMENT
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS
1. **Expand Evidence Base:** Further diversify the types of evidence supporting G19943, especially considering additional datasets or experimental validations that can strengthen its role as a primary target.
   
2. **Address Regulatory Factors:** Investigate and incorporate potential regulatory transcription factors (TFs) that could influence the expression and activity of the proposed targets, enhancing the mechanistic understanding.

3. **Explicitly Discuss Safety:** Include a detailed risk assessment or discuss potential safety considerations related to the therapeutic approach to strengthen the therapeutic rationale.

4. **Innovative Connections:** Explore and highlight any non-obvious interactions among the targets or with other pathways that could provide a unique perspective on the treatment of Type 2 Diabetes, potentially increasing the novelty score.
2026-02-10 20:02:15,984 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:02:15,984 - root - INFO - Evaluating fitness for hypothesis: t2d-04-896b66c2
2026-02-10 20:02:31,275 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:02:31,281 - root - INFO - TOKEN_USAGE: input=1518, output=757, total=2275, cost=$0.000682
2026-02-10 20:02:31,281 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:02:31,281 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is present in the top priority list and has a strong score of 4.0. However, the warning indicates that not all ranked targets are found in the top priority list, which weakens the overall data support. There is cross-dataset consistency for the primary target, but only two datasets are cited, which is modest for confirming findings.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified, as it aligns with the scores and roles of the targets in T2D pathology. The primary target is a central hub, with G22553 and G33764 as key drivers, supported by their scoring. However, the absence of some targets in the top priority list slightly hampers the strength of the ranking.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanisms are coherent with the pathways involved in T2D, and the tissue rationale is well supported given the roles of pancreatic -cells, muscle, liver, and adipose tissue in glucose homeostasis. While no regulating transcription factors are identified, the potential for regulatory interactions indicates a thoughtful approach.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets through small molecules is appropriate and aligns with the objective to enhance insulin sensitivity. The centrality of the targets in metabolic networks suggests they could be druggable. However, more detail on safety considerations is needed to strengthen this aspect.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by targeting multiple genes involved in insulin signaling and metabolism. However, the connections made are somewhat standard in the context of T2D research, lacking groundbreaking insights that would significantly elevate the novelty.

### Overall Fitness Calculation
Overall Fitness = (DATA_SUPPORT * 0.25) + (RANKING_QUALITY * 0.25) + (MECHANISTIC * 0.20) + (THERAPEUTIC * 0.20) + (NOVELTY * 0.10)
Overall Fitness = (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85  
Overall Fitness (scaled to 0-100) = 68.5

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Increase the number of datasets supporting the ranked targets to strengthen the evidence base. This could involve leveraging additional public datasets or conducting targeted experiments.
2. **Detail Safety Considerations:** Include a discussion of potential safety concerns related to the modulation of these targets, particularly in terms of off-target effects or long-term impacts on metabolic health.
3. **Identify Regulatory Factors:** Explore and identify any transcription factors or regulatory networks that may influence the expression of the targeted genes, which could provide insight into the broader regulatory context.
4. **Novelty Enhancement:** Consider integrating novel technologies or approaches (e.g., CRISPR, RNAi) that could lead to innovative therapeutic strategies, thereby increasing the novelty of the hypothesis.
2026-02-10 20:02:31,282 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:02:31,283 - root - INFO - Evaluating fitness for hypothesis: t2d-04-ce4f9a04
2026-02-10 20:03:01,867 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:03:01,874 - root - INFO - TOKEN_USAGE: input=1562, output=796, total=2358, cost=$0.000712
2026-02-10 20:03:01,874 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:03:01,874 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** While G33764 is ranked among the top priority genes, the lack of cross-dataset consistency limits the robustness of the data support. Additionally, the existence of only one dataset contributing to the evidence weakens the overall confidence. However, its high priority score and designation as a primary driver in relevant modules provide some degree of support.

---

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking of G33764 as the primary target is justified based on its central role in insulin signaling, which is critical in T2D. However, the scores for G19122 and G20274 suggest a less clear distinction between them and the lower-ranked targets. The rationale presented is logical, but the justification could be stronger with more detailed comparative data.

---

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the established pathways of insulin signaling and metabolic regulation. The focus on adipose tissue is appropriate given its significance in T2D. However, the absence of data on regulating transcription factors (TFs) limits the mechanistic coherence, as these factors could play a significant role in the regulation of these genes.

---

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of modulating the targets using small molecule activators appears appropriate and aligns with the goals of enhancing insulin sensitivity. The potential druggability of these targets is reasonable given their roles in metabolic pathways. However, further safety considerations and evidence of druggability would enhance this score.

---

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a relevant context, focusing on adipose tissue and the multi-faceted nature of T2D. However, the connections made, while sensible, are not particularly novel given the existing understanding of insulin signaling and metabolism in T2D. More innovative insights or connections could enhance this aspect.

---

### OVERALL_FITNESS: 
Calculated as follows:  
\[ \text{Overall Fitness} = (5 \times 0.25) + (6 \times 0.25) + (7 \times 0.20) + (6 \times 0.20) + (5 \times 0.10) \]  
\[ = 1.25 + 1.50 + 1.40 + 1.20 + 0.50 = 5.85 \]  
\[ = 58.5 \]  
**Overall Fitness: 58.5/100**

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG** - G33764 has a critical role in insulin signaling and is well-supported by the hypothesis.
- **Target #2 quality: MODERATE** - G19122 complements G33764 but lacks sufficient distinct evidence to elevate it higher.
- **Target #3 quality: MODERATE** - G20274 is relevant but similarly lacks strong distinguishing evidence compared to the higher-ranked targets.

---

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Evidence:** Seek additional datasets to validate the findings related to G33764, G19122, and G20274, aiming for cross-dataset consistency.
2. **Enhance Mechanistic Understanding:** Investigate potential regulating transcription factors associated with these targets to strengthen the mechanistic rationale.
3. **Clarify Ranking Justifications:** Provide more detailed comparative analyses between ranked targets to reinforce the distinctions and justifications for their rankings.
4. **Address Safety Considerations:** Include a discussion on the potential safety profiles for the proposed small molecule activators to preemptively address any concerns regarding therapeutic approaches.
2026-02-10 20:03:01,876 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:03:01,878 - root - INFO - Evaluating fitness for hypothesis: t2d-04-a264a887
2026-02-10 20:03:20,499 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:03:20,502 - root - INFO - TOKEN_USAGE: input=1529, output=736, total=2265, cost=$0.000671
2026-02-10 20:03:20,502 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:03:20,502 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a priority score of 4/17, indicating a strong position among the top-ranked targets. However, the cross-dataset consistency is only present in two datasets for the overall hypothesis, and G19943 itself has only one dataset showing evidence. The presence of multiple evidence types in support of the targets is limited, leading to a slightly lower score.

---

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their established roles in T2D pathways. Each target has a score of 4.0, indicating they are all considered significant, and the rationale for prioritizing G19943 is sound given its central role. While the ranking is generally strong, the lack of cross-dataset consistency for G19943 slightly detracts from the overall strength of the rationale.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the pathways involved in insulin signaling and metabolic regulation. The tissue rationale aligns well with the target functions, and the potential role of transcription factors is acknowledged. However, more explicit evidence of the TF relationships could strengthen this aspect further.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation of the targets is appropriate, and the targets are positioned well within metabolic pathways, suggesting druggability. Nevertheless, safety considerations and potential off-target effects of activating these pathways should be further evaluated to fully assess therapeutic viability.

---

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in the context of T2D management and suggests synergistic interactions, which is a promising approach. However, the connections made between the targets and their roles are not entirely novel, as multi-target strategies in diabetes management have been explored previously.

---

### Overall Fitness Calculation:
- \( \text{Overall Fitness} = (7 \times 0.25) + (8 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) \)  
- \( = 1.75 + 2.00 + 1.60 + 1.40 + 0.60 \)  
- \( = 7.35 \)  
- **Overall Fitness (scaled to 0-100):** 73.5%

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Consistency:** Gather more evidence across additional datasets for G19943 to enhance the robustness of the hypothesis.
2. **Expand Evidence Types:** Include more diverse evidence types to strengthen the support for G19943, such as functional studies or additional pathway analyses.
3. **Elaborate on Mechanisms:** Provide more detailed insights into transcription factor relationships and their specific roles in modulating the targets.
4. **Evaluate Safety Profiles:** Conduct preliminary assessments of potential safety issues related to the activation of these targets to ensure therapeutic viability.
5. **Explore Novel Mechanisms:** Investigate less obvious connections or novel pathways that could further enhance the therapeutic strategy, increasing the novelty of the hypothesis.
2026-02-10 20:03:20,503 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:03:20,503 - root - INFO - Evaluating fitness for hypothesis: t2d-04-517c5b57
2026-02-10 20:03:36,377 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:03:36,382 - root - INFO - TOKEN_USAGE: input=1433, output=706, total=2139, cost=$0.000639
2026-02-10 20:03:36,383 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:03:36,383 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) is in the top priority list, and the supporting evidence indicates cross-dataset consistency with 2 datasets, which strengthens the confidence in its role in Type 2 Diabetes pathways. However, since other ranked targets do not appear in the top 10, this lowers the score as it indicates potential oversight in their relevance.

---

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data provided, as the higher-ranked targets are indeed important in insulin signaling and metabolic regulation. However, the absence of other listed targets in the top priority genes could suggest a lack of comprehensive data backing their ranking. The rationale provided does make logical sense in the context of synergistic effects.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and metabolic pathways implicated in T2D. The tissue rationale is adequately supported, emphasizing critical tissues like pancreatic -cells and liver. However, there is a lack of identified regulatory transcription factors (TFs) that could enhance mechanistic understanding.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation seems appropriate, especially given the central roles of the targets in metabolic pathways. The ranking indicates that the targets are likely druggable due to their network positions. However, safety considerations and potential side effects of targeting multiple pathways simultaneously should be more explicitly addressed.

---

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets related to insulin signaling and metabolic regulation, which is a creative approach. Yet, the connections made are somewhat expected within the context of T2D, which slightly diminishes the novelty score.

---

**OVERALL_FITNESS:**  
Calculated Score:  
\[
(6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (7 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.7 = 6.95 \approx 70
\]

**OVERALL_FITNESS: 70/100**

---

**RANKED_TARGETS_ASSESSMENT:**  
- **Target #1 quality:** STRONG  
- **Target #2 quality:** MODERATE  
- **Target #3 quality:** MODERATE  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Evidence Base:** Incorporate additional datasets or literature to validate the ranking of G23245, G22553, and G33764 to justify their positions in the hypothesis.
2. **Identify Regulatory TFs:** Investigate potential transcription factors that regulate the expression or activity of the targets to provide a more comprehensive mechanistic understanding.
3. **Safety Assessment:** Conduct a thorough safety assessment of the proposed small molecule activators, addressing potential adverse effects of multi-target modulation.
4. **Broaden Pathway Exploration:** Consider evaluating additional targets that may not be in the top priority list but could play a significant role in T2D management, enhancing the robustness of the therapeutic strategy.
2026-02-10 20:03:36,384 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:03:36,408 - root - INFO - Evaluating fitness for hypothesis: t2d-04-93a4d525
2026-02-10 20:03:53,270 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:03:53,276 - root - INFO - TOKEN_USAGE: input=1459, output=729, total=2188, cost=$0.000656
2026-02-10 20:03:53,276 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:03:53,276 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** While the primary target G23245 is supported by strong evidence, it is not in the top priority list of genes, which raises concerns. However, the hypothesis does demonstrate cross-dataset consistency and a high priority score of 4.0 for the primary target, along with multiple supporting evidence types. This reflects a solid foundation despite the warning about G23245's absence in the top priority list.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their roles in metabolic regulation and insulin signaling. G23245 is appropriately positioned as the primary target due to its central role, while G33764 and G19943 complement it effectively. The rationale for the ranks is clear and logical, emphasizing the interconnectedness of the targets.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the key pathways involved in Type 2 Diabetes. The tissue rationale is sound, focusing on pancreatic -cells, liver, and muscle, which are critical for insulin action. Additionally, the role of G00484 as a transcription factor adds regulatory depth to the mechanism, enhancing the overall coherence of the hypothesis.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation appears appropriate given the nature of the targets. However, more information on the druggability of these targets and any potential safety concerns would strengthen this section. While the approach is promising, a more thorough evaluation of the safety profiles of the proposed targets is necessary.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis does integrate data and proposes a combination strategy that is less common in current Type 2 Diabetes research. However, while it connects well-established targets, it does not introduce significantly novel targets or pathways that have not been previously explored in the context of T2D.

### OVERALL_FITNESS: 
**Calculated Score:**  
(7 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.75 + 2.00 + 1.60 + 1.40 + 0.60 = 7.35  
**Final Scaled Score:** **74%**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G23245):** STRONG  
- **Target #2 quality (G33764):** STRONG  
- **Target #3 quality (G19943):** STRONG  

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Prioritization:** Consider repositioning G23245 within the context of the top priority list to enhance its perceived importance and address the warning regarding its absence.
2. **Expand on Safety Profiles:** Include a detailed analysis of the safety considerations for each target, especially regarding potential off-target effects and adverse reactions.
3. **Highlight Drugability:** Provide more information on the druggability of each target, including possible small molecule compounds that could be utilized in the therapeutic strategy.
4. **Explore Novel Targets:** Investigate additional novel targets that might complement the existing strategy, potentially leading to innovative therapeutic approaches for enhancing insulin sensitivity in Type 2 Diabetes.
2026-02-10 20:03:53,276 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:03:53,277 - root - INFO - Evaluating fitness for hypothesis: t2d-04-11f09e24
2026-02-10 20:04:10,147 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:04:10,152 - root - INFO - TOKEN_USAGE: input=1523, output=703, total=2226, cost=$0.000650
2026-02-10 20:04:10,152 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:04:10,152 - root - INFO - 
### EVALUATION

#### DATA_SUPPORT_SCORE: 7
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is in the top priority tier with a score of 4.0, indicating its significant relevance. However, there is only one dataset supporting it, which limits the robustness of the evidence. Furthermore, although there is some evidence across two datasets for cross-dataset consistency, this is not applicable to G22553 itself.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their roles in insulin signaling and metabolic pathways. G22553 is established as a primary driver in insulin signaling, while the other targets are appropriately ranked based on their supportive roles. The rationale is sound, as it aligns with known biological functions, but some targets may need more differentiation in their specific contributions.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and muscle metabolism. The tissue rationale is strongly supported, as muscle tissue is critical for glucose uptake and insulin sensitivity. The mention of transcription factors, although lacking specific identification, indicates consideration of regulatory mechanisms.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation is appropriate given the targets' roles in enhancing insulin sensitivity. However, the druggability of these targets was not explicitly discussed in detail, which raises some concerns. Safety considerations are also not addressed, which is critical for therapeutic development.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates existing knowledge on insulin signaling with a focus on muscle tissue, which is a known area of interest in Type 2 Diabetes research. However, the connections being made, while valid, are not particularly novel within the context of diabetes research, making the integration feel somewhat conventional rather than groundbreaking.

### OVERALL_FITNESS: 
Calculated as follows: 
(7 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 7.4
**Scaled to 0-100: 74**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Aim to gather additional datasets to reinforce findings related to G22553 and its role in muscle insulin sensitivity. This could involve using public databases or conducting new experiments.
2. **Identify Regulating TFs:** Provide specific transcription factors that regulate G22553 to strengthen the mechanistic hypothesis. This could enhance the understanding of gene regulation and potential pharmacological interventions.
3. **Detailed Druggability Assessment:** Include a discussion on the druggability of the ranked targets, considering their biochemical properties and previous studies on potential inhibitors or activators.
4. **Safety Considerations:** Address potential safety and off-target effects of the proposed therapeutic approach, discussing how these might be mitigated in the development process.
5. **Explore Novel Connections:** Investigate and highlight any novel interactions or pathways involving the targets that may not have been previously established, to elevate the novelty of the hypothesis further.
2026-02-10 20:04:10,152 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:04:10,153 - root - INFO - Evaluating fitness for hypothesis: t2d-04-62dcc4cd
2026-02-10 20:04:27,973 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:04:28,002 - root - INFO - TOKEN_USAGE: input=1491, output=779, total=2270, cost=$0.000691
2026-02-10 20:04:28,002 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:04:28,002 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed in the top priority list, which is a positive indicator. However, G33764, while ranked highly in the hypothesis, is not listed in the top 10 priority genes, which raises some concern about its relevance. There is cross-dataset consistency for G19943 and G33764, and the primary target has a strong priority score of 4.0. More evidence types supporting G19943 would enhance the score.

---

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally well-justified based on the roles of the targets in insulin signaling and metabolic pathways. G19943's position as a hub component makes it a rational primary target. The rationale for ranking G33764 and G04436 is clear, as they complement G19943. However, including G22553 and G19122 as secondary targets without their presence in the top priority list slightly undermines the ranking robustness.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the identified pathways in insulin and glucose metabolism. The tissue rationale is strong, focusing on pancreatic -cells, muscle, and liver, which are critical in Type 2 Diabetes. However, the absence of identified regulating transcription factors (TFs) could limit the understanding of the regulatory landscape, slightly affecting the coherence of the mechanism.

---

**THERAPEUTIC_SCORE: 9**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets is appropriate given their roles in enhancing insulin sensitivity. The integration of multiple targets is promising, and their network positions suggest they are potentially druggable. Safety considerations are not explicitly addressed, but there is an assumption of low risk due to the targets' established roles in metabolic pathways.

---

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative manner, proposing a multi-target approach that is not typical in previous T2D strategies. However, while the connections made are insightful, the overall concept of targeting insulin signaling and metabolic regulation is not entirely novel.

---

### OVERALL FITNESS: 
Calculated as follows: 
- DATA_SUPPORT: 7 * 0.25 = 1.75
- RANKING_QUALITY: 8 * 0.25 = 2.00
- MECHANISTIC: 8 * 0.20 = 1.60
- THERAPEUTIC: 9 * 0.20 = 1.80
- NOVELTY: 7 * 0.10 = 0.70

**Overall Fitness Score = 1.75 + 2.00 + 1.60 + 1.80 + 0.70 = 7.85 (scaled to 0-100 = 78.5)**

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** MODERATE
- **Target #3 quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Broaden Data Evidence:** Gather additional evidence to support G33764 and explore its role in the context of the top-ranked targets.
2. **TF Identification:** Investigate potential transcription factors regulating the targets to enhance mechanistic understanding.
3. **Safety Considerations:** Address safety profiles for all targets explicitly in the therapeutic approach to strengthen the proposal.
4. **Expand Novelty Aspects:** Consider unique mechanisms or novel interactions that have not been explored extensively to increase the novelty score.
2026-02-10 20:04:28,002 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:04:28,003 - root - INFO - Evaluating fitness for hypothesis: t2d-03-f570507e
2026-02-10 20:04:43,957 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:04:43,963 - root - INFO - TOKEN_USAGE: input=1432, output=702, total=2134, cost=$0.000636
2026-02-10 20:04:43,963 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:04:43,963 - root - INFO - 
### Evaluation of the RANKED Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target G23245 is ranked 4th in the top 10 priority genes, indicating it is well-supported by the data. Additionally, there is cross-dataset consistency for the primary target and its key pathways, which strengthens the evidence base. The presence of multiple evidence types supporting the primary target adds further credibility.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified by the data, as G23245, G33764, and G00484 have strong associations with insulin signaling and glucose metabolism. However, there is a lack of differentiation in scores among the targets (all ranked 4.0), which makes it challenging to clearly distinguish the strengths of one target compared to another. A more nuanced scoring could enhance the clarity of the ranking.

---

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and the roles of the involved tissues (pancreatic -cells, liver, and muscle). The hypothesis effectively integrates the function of G00484 as a transcription factor, providing necessary regulatory control. However, the absence of identified regulating transcription factors for G23245 could be a minor oversight.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule modulation targeting G23245, along with adjunct therapies for G33764 and G00484, is logical and well-supported by the hypothesis. The likelihood of these targets being druggable seems high based on their network positions. Safety considerations are not explicitly addressed, which could be improved by discussing potential side effects or interactions.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data creatively and proposes a multi-target strategy, the individual targets themselves are not particularly novel in the context of T2D research. The connections made between these targets, however, do offer fresh insights into their synergistic effects, which is a positive aspect.

---

### OVERALL_FITNESS: 
Calculated as follows:  
(8 * 0.25) + (7 * 0.25) + (9 * 0.20) + (8 * 0.20) + (6 * 0.10) = 7.55  
Scaled to 0-100: **75.5**

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G23245) quality:** STRONG
- **Target #2 (G33764) quality:** STRONG
- **Target #3 (G00484) quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Target Differentiation:** Introduce finer scoring metrics for the ranked targets to highlight the unique contributions and roles of each target more effectively.
2. **Address Safety Considerations:** Include a discussion on safety and potential side effects associated with the modulation of these targets to provide a more comprehensive therapeutic perspective.
3. **Explore Regulatory Dynamics:** Investigate potential regulatory transcription factors or mechanisms that may influence G23245 to strengthen the mechanistic understanding further. This can also help in identifying additional targets for a more robust multi-target strategy.
2026-02-10 20:04:43,964 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:04:43,965 - root - INFO - Evaluating fitness for hypothesis: t2d-01-aea79175
2026-02-10 20:04:58,290 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:04:58,293 - root - INFO - TOKEN_USAGE: input=1398, output=639, total=2037, cost=$0.000593
2026-02-10 20:04:58,293 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:04:58,293 - root - INFO - 
**DATA_SUPPORT_SCORE: 7/10**  
**DATA_SUPPORT_RATIONALE:** G19943 is present in the top priority list, with a high score of 4.0. There is cross-dataset consistency noted, but the evidence for the primary target G19943 is limited to two datasets, which reduces the confidence slightly. Additional evidence types supporting the target could strengthen the score.

**RANKING_QUALITY_SCORE: 8/10**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with G19943, G22553, and G23245 all scoring highly and showing relevance to Type 2 Diabetes. However, it would be beneficial to clarify the strength of the distinctions between the top-ranked targets to further substantiate the ranking.

**MECHANISTIC_SCORE: 7/10**  
**MECHANISTIC_RATIONALE:** The proposed mechanism for G19943 aligns well with insulin signaling pathways, and the tissue rationale (pancreatic -cells, skeletal muscle, adipose tissue) is appropriate given its role in glucose metabolism. However, the lack of reported transcription factors that interact with G19943 limits the mechanistic coherence score.

**THERAPEUTIC_SCORE: 8/10**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation seems appropriate given G19943s role in insulin signaling. There is a reasonable likelihood that the target is druggable due to its hub position in gene networks. However, detailed safety considerations are not provided, which could impact the overall therapeutic potential.

**NOVELTY_SCORE: 6/10**  
**NOVELTY_RATIONALE:** The hypothesis does integrate data in a creative way by focusing on a hub gene in insulin signaling pathways, but it does not present particularly non-obvious connections or groundbreaking insights beyond what is already known about G19943 and its role in diabetes.

**OVERALL_FITNESS: (7*0.25 + 8*0.25 + 7*0.20 + 8*0.20 + 6*0.10) = 7.4/10  74%**  

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **STRONG**  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Data Evidence:** Incorporate more datasets to strengthen the evidence supporting G19943 and other ranked targets, especially focusing on how they respond in various biological contexts.
2. **Clarify Distinctions in Ranking:** Provide further justification for the differences in scores among the top-ranked targets to reinforce the ranking's quality.
3. **Investigate Transcription Factors:** Conduct research to identify potential transcription factors that may interact with G19943, which could enhance mechanistic understanding and therapeutic rationale.
4. **Include Safety Assessments:** Address potential safety concerns regarding small molecule activation of G19943, including off-target effects or adverse outcomes that could arise from modulation.
2026-02-10 20:04:58,294 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:04:58,295 - root - INFO - Evaluating fitness for hypothesis: t2d-04-31e7701a
2026-02-10 20:05:15,909 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:05:15,916 - root - INFO - TOKEN_USAGE: input=1593, output=637, total=2230, cost=$0.000621
2026-02-10 20:05:15,916 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:05:15,916 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a high priority score of 4.0, but it is only supported by one dataset, which limits cross-dataset consistency. While it is in the top priority tier, the lack of multiple evidence types and datasets affects the robustness of the data support.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as the targets are ranked according to their established roles in Type 2 Diabetes pathways. G19943, G33764, G22553, and G04436 are clearly positioned based on their functional relevance. However, the lack of consistent evidence across datasets for the primary target slightly weakens the ranking quality.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in insulin signaling and metabolic regulation. The tissue rationale is supported by existing knowledge of insulin action in key tissues. However, the absence of specific transcription factors associated with G19943 may limit the mechanistic depth.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of multi-target modulation appears appropriate, focusing on restoring insulin sensitivity and metabolic homeostasis. However, there are considerations regarding the druggability of these targets and potential safety concerns, particularly with G33764 inhibition, which may impact overall metabolic function.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates known data in a way that highlights the importance of multi-target approaches in T2D therapy. While it suggests interesting connections between targets, the overall concept of targeting multiple pathways is not entirely novel in the context of diabetes research.

### OVERALL_FITNESS: 7.3  
**Calculation:** (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.3

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G19943):** MODERATE  
- **Target #2 quality (G33764):** STRONG  
- **Target #3 quality (G22553):** STRONG  

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Aim to gather more datasets supporting G19943 and other targets to enhance cross-dataset consistency and overall confidence in the data.
2. **Explore Transcription Factor Relationships:** Investigate and include relevant transcription factors that may regulate target genes, particularly G19943, to deepen mechanistic understanding.
3. **Assess Druggability:** Conduct a thorough assessment of the druggability of the targets, especially G33764, to ensure that the proposed therapeutic approach is feasible and safe.
4. **Innovative Approaches:** Consider exploring innovative drug delivery systems or combination therapies that could enhance the effectiveness of multi-target modulation in T2D.
2026-02-10 20:05:15,917 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:05:15,917 - root - INFO - Evaluating fitness for hypothesis: t2d-04-7c49253e
2026-02-10 20:05:32,082 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:05:32,085 - root - INFO - TOKEN_USAGE: input=1433, output=795, total=2228, cost=$0.000692
2026-02-10 20:05:32,085 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:05:32,085 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target, G22553, is indeed found in the top priority list, which supports its relevance. Furthermore, there is cross-dataset consistency with two datasets backing the evidence. The priority score of 4.0 indicates strong support, but the warning about a target not being found in the top priority list suggests that caution should be taken in the broader context.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of the targets is largely justified by their scores and the provided rationale. G22553 and G04436 are appropriately highlighted as critical targets for insulin sensitivity. However, the rationale for G33764's lower ranking could be better articulated, considering its metabolic regulation role. The distinction between primary and secondary roles is present, but clarity could enhance justification.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The mechanism proposed aligns well with the pathways involved in insulin signaling and glucose metabolism. The tissue rationale is also sound, focusing on pancreatic -cells, skeletal muscle, and liver. However, the lack of reported transcription factors (TFs) in the context of T2D modulation could be considered a gap in mechanistic understanding.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets is appropriate, and the rationale for improving insulin sensitivity aligns with the roles of the targets. The assessment of druggability based on network position is not explicitly mentioned and could be a concern for practical application. Safety considerations also need to be addressed more thoroughly.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative manner by proposing a dual-target activation strategy. However, the connections made are somewhat conventional in the context of targeting insulin signaling pathways, which may diminish the perceived novelty of the approach.

### OVERALL_FITNESS 
Overall Fitness Score Calculation:  
= (DATA_SUPPORT_SCORE * 0.25 + RANKING_QUALITY_SCORE * 0.25 + MECHANISTIC_SCORE * 0.20 + THERAPEUTIC_SCORE * 0.20 + NOVELTY_SCORE * 0.10)  
= (8 * 0.25 + 7 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10)  
= (2.0 + 1.75 + 1.6 + 1.4 + 0.6)  
= 7.35  
**Scaled to 0-100:** 73.5

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify the Role of G33764:** Strengthen the rationale for G33764's inclusion and its specific benefits in the context of dual activation. Highlight how it contributes to the overall mechanism and outcome.
   
2. **Address TF Relationships:** Even if no regulating transcription factors are reported, consider a literature review for potential TFs that could impact G22553 and G04436 expression or activity.

3. **Expand on Safety Considerations:** Include a discussion on potential side effects or safety issues associated with the activation of these targets, considering their roles in metabolism.

4. **Emphasize Druggability:** Provide more information about the druggability of the proposed targets, including any known small molecules or compounds that could activate these targets effectively. 

5. **Highlight Novel Aspects:** Emphasize any unique findings or insights that distinguish this hypothesis from previous studies to enhance the perceived novelty.
2026-02-10 20:05:32,086 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:05:32,086 - root - INFO - Evaluating fitness for hypothesis: t2d-04-b61f3639
2026-02-10 20:05:45,395 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:05:45,399 - root - INFO - TOKEN_USAGE: input=1450, output=723, total=2173, cost=$0.000651
2026-02-10 20:05:45,399 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:05:45,399 - root - INFO - 
**DATA_SUPPORT_SCORE: 7/10**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is ranked first and has strong evidence from cross-dataset consistency and multiple pathways involved. However, it is concerning that G00484, which acts as a regulating transcription factor for insulin signaling pathways, is not found in the top priority list, which could indicate a gap in data support for this target. The data support is solid overall, but the absence of some high-ranking targets in the top priority list slightly undermines the score.

---

**RANKING_QUALITY_SCORE: 8/10**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their roles in T2D pathways and their established evidence. G19943's central role in insulin signaling is well supported, and the complementary function of G22553 aligns with the hypothesis. The rationale for ranking is clear, as it emphasizes the synergistic interactions among the targets. However, the absence of G00484 in the highest priority tier may weaken the overall rationale slightly.

---

**MECHANISTIC_SCORE: 8/10**  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent, as it aligns with established pathways related to insulin signaling and glucose metabolism. The tissue rationale is well-supported, focusing on relevant tissues like pancreatic -cells, muscle, liver, and adipose tissue, which are crucial for insulin action. However, the lack of identified transcription factors for G19943 could be a minor gap in the mechanistic coherence.

---

**THERAPEUTIC_SCORE: 9/10**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation for G19943 and G22553, combined with modulation of the other targets, seems appropriate and promising. The targets are located in key pathways and are likely druggable, suggesting a realistic potential for therapeutic application. Safety considerations are not explicitly mentioned, but the approach appears sound overall.

---

**NOVELTY_SCORE: 8/10**  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a synergistic approach, which is a creative strategy for addressing the multifactorial nature of T2D. The connections between the targets and their roles in insulin sensitivity are relevant and insightful. However, the concept of multi-target modulation in diabetes management is not entirely novel, hence a slightly lower score.

---

**OVERALL_FITNESS: 8.2/10**  
**Calculated: (7*0.25 + 8*0.25 + 8*0.20 + 9*0.20 + 8*0.10) = 8.2**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Incorporate G00484:** Given its role as a transcription factor and its potential regulatory influence, consider reevaluating its inclusion in the top priority list to strengthen the regulatory aspect of the hypothesis.
2. **Expand on Safety Considerations:** Elaborating on potential safety concerns related to the proposed therapeutic approach would enhance the overall assessment and demonstrate a comprehensive understanding of the implications of multi-target modulation.
3. **Enhance Mechanistic Details:** Providing more details on the transcription factors involved in the regulation of G19943 could strengthen the mechanistic coherence and provide additional insights into the underlying biology.
2026-02-10 20:05:45,400 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:05:45,400 - root - INFO - Evaluating fitness for hypothesis: t2d-04-43c3cf88
2026-02-10 20:06:01,092 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:06:01,095 - root - INFO - TOKEN_USAGE: input=1504, output=647, total=2151, cost=$0.000614
2026-02-10 20:06:01,095 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:06:01,095 - root - INFO - 
### EVALUATION RESULTS

#### DATA_SUPPORT_SCORE: **6**
**DATA_SUPPORT_RATIONALE:** G19943 is ranked with a priority score of 4.0/17, which places it in the top priority tier. However, there is only one dataset supporting it, and it lacks cross-dataset consistency. While it is a hub component in WGCNA, the absence of multiple evidence types reduces the overall score.

#### RANKING_QUALITY_SCORE: **7**
**RANKING_QUALITY_RATIONALE:** The ranking of the targets is justified based on their established roles in T2D pathways. G19943 is appropriately prioritized for its central role, but the similarity in scores among the top targets (all at 4.0) suggests that distinguishing their specific contributions could be improved. The rationale provided is logical, but more differentiation in evidence strength among the ranks would enhance clarity.

#### MECHANISTIC_SCORE: **8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling context. The tissue rationale involving pancreatic beta-cells, muscle, liver, and adipose tissue is well supported by the data. However, the lack of identified regulating transcription factors for G19943 could be a limitation in fully understanding the mechanistic interactions.

#### THERAPEUTIC_SCORE: **7**
**THERAPEUTIC_RATIONALE:** The dual activation strategy for G19943 and G22553 is appropriate, as it targets key pathways in T2D management. The potential for druggability is high given their roles in metabolic pathways. However, safety considerations regarding the activation of multiple targets simultaneously should be more thoroughly addressed.

#### NOVELTY_SCORE: **6**
**NOVELTY_RATIONALE:** The hypothesis presents a creative integration of targets with known roles in T2D, but the proposed connections are not entirely non-obvious. Dual activation strategies are known in metabolic disease contexts, which diminishes the novelty slightly.

### OVERALL_FITNESS: **6.6**
(Overall Fitness = (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.6)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Include additional datasets and evidence types for G19943 to strengthen its validation and improve cross-dataset consistency.
2. **Clarify Ranking Distinctions:** Provide more detailed justification for differentiating the contributions of targets with similar scores to clarify their distinct roles and enhance the ranking rationale.
3. **Identify Regulating Transcription Factors:** Investigate and include potential regulating transcription factors for G19943 to strengthen the mechanistic understanding and its implications for therapeutic approaches.
4. **Address Safety Considerations:** Develop a plan to assess potential side effects or negative feedback mechanisms associated with the dual activation strategy to ensure comprehensive safety evaluations.
2026-02-10 20:06:01,095 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:06:01,096 - root - INFO - Evaluating fitness for hypothesis: t2d-04-c4684d67
2026-02-10 20:06:16,889 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:06:16,892 - root - INFO - TOKEN_USAGE: input=1542, output=766, total=2308, cost=$0.000691
2026-02-10 20:06:16,893 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:06:16,893 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, has a high priority score of 4.0, which is within the top tier of priority genes. However, there is only one dataset supporting it, and it lacks cross-dataset consistency. The number of evidence types is limited, with only 2 types reported. This reflects moderate data support, as the lack of multiple datasets and pathways weakens the overall confidence in the evidence.

---

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified, with G19943 being the primary target due to its centrality in T2D pathways. The rationale for the ranking is clear, and the complementary roles of G22553 and G33764 are logical, as they relate closely to insulin signaling and resistance. However, the lack of differentiation in scores among the top genes may suggest a need for further refinement to clarify the strength of each target.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in insulin signaling and metabolic regulation. The tissue rationale is well-supported, focusing on key tissues affected by T2D. However, the mention of transcription factor interactions is minimal, which could enhance the mechanistic coherence if elaborated upon.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of modulating G19943 and G22553 while inhibiting G33764 and G04436 is appropriate given their roles in metabolic pathways. The integration of small molecule activators and inhibitors suggests a thoughtful strategy. However, more detail on the druggability of these targets and potential safety concerns could strengthen this aspect.

---

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** While the hypothesis does integrate various components of T2D management, the connections made among the targets are somewhat expected based on their known roles in insulin signaling. There is a lack of particularly novel insights or non-obvious connections that might set this hypothesis apart from existing approaches.

---

### OVERALL_FITNESS:
Calculated as:  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (5 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.5 = 6.75 (scaled to 0-100 gives a score of 67.5)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Seek additional datasets to validate the role of G19943 and its interactions across various metabolic pathways. Cross-dataset analysis could strengthen the evidence for this target.
2. **Detail Mechanistic Insights:** Elaborate on the role of transcription factors in regulating the target genes to enhance mechanistic coherence and understanding of the pathway interactions.
3. **Clarify Therapeutic Approach:** Provide more information regarding the druggability of the targets and any potential safety concerns associated with modulation. This could include in vitro or in vivo studies to support the therapeutic viability.
4. **Innovate Novelty Aspects:** Explore potential novel connections or mechanisms that could differentiate this hypothesis from existing approaches in T2D management, possibly through an innovative combination of existing therapies or identifying new synergistic interactions among the targets.
2026-02-10 20:06:16,893 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:06:16,893 - root - INFO - Evaluating fitness for hypothesis: t2d-04-fef4e96f
2026-02-10 20:06:32,439 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:06:32,443 - root - INFO - TOKEN_USAGE: input=1562, output=724, total=2286, cost=$0.000669
2026-02-10 20:06:32,443 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:06:32,443 - root - INFO - 
### EVALUATION OF HYPOTHESIS

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G33764 has a priority score of 4/17 and is part of the top priority tier. However, it shows cross-dataset inconsistency and has only one dataset backing its evidence. There are not many evidence types supporting it, which limits the strength of the data support.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data, with G33764 being positioned as a master regulator of insulin signaling and lipid metabolism. The other targets are ranked based on their complementary roles. However, the lack of cross-dataset consistency for the primary target slightly undermines the strength of the justification.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved, emphasizing insulin signaling and lipid metabolism. The tissue rationale is appropriate as adipose tissue, liver, and muscle are indeed central to T2D pathology. However, the absence of data on regulating transcription factors slightly detracts from the mechanistic coherence.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating these targets using small molecules appears reasonable given their roles in metabolic pathways. However, more clarity on the druggability of these targets based on network position and potential safety considerations would improve the score.

#### NOVELTY_SCORE: 8
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative way by linking multiple pathways involved in T2D. It proposes non-obvious connections between insulin signaling and lipid metabolism, which adds a layer of novelty to the approach.

### OVERALL_FITNESS: 
Calculated as follows: 
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (8 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.8 = 7.05, which is scaled to 0-100. 
**Overall Fitness: 70.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (G33764 has a central role but suffers from limited evidence support.)
- Target #2 quality: **STRONG** (G19122 complements G33764 well and is critical for insulin sensitivity.)
- Target #3 quality: **STRONG** (G04436 has solid evidence supporting its role in glucose homeostasis.)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Aim to gather more datasets for G33764 to improve cross-dataset consistency and overall evidence support. 
2. **Enhance Evidence Types:** Identify and incorporate additional evidence types that can strengthen the rationale for the primary target.
3. **Explore TF Relationships:** Investigate potential transcription factors that might regulate G33764 and other targets to provide a more comprehensive mechanistic understanding.
4. **Clarify Druggability and Safety:** Provide more detailed insights into the druggability of each target, including potential safety concerns, to help justify the therapeutic approach.
5. **Expand on Synergistic Effects:** Elaborate on how the combination of these targets may work synergistically to enhance therapeutic outcomes, potentially including data from combinatorial studies if available.
2026-02-10 20:06:32,444 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:06:32,445 - root - INFO - Population fitness evaluation complete. Top score: 79.50
2026-02-10 20:06:32,447 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 20:06:32,448 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G19943', 'G22553', 'G19943', 'G33764']...
2026-02-10 20:06:32,448 - root - INFO - Generation 4 stats: mean=66.78, max=79.5, min=50.0
2026-02-10 20:06:32,448 - root - INFO - Generation 4 complete
2026-02-10 20:06:32,448 - root - INFO - Running generation 5
2026-02-10 20:06:32,448 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 20:06:32,448 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 20:06:32,449 - root - INFO - Crossover 1/18: parents '** Integrated Targeting of Met...' x 'Synergistic Multi-Target Modul...'
2026-02-10 20:06:32,514 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:06:52,698 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:06:52,705 - root - INFO - TOKEN_USAGE: input=40287, output=734, total=41021, cost=$0.006483
2026-02-10 20:06:52,706 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:06:52,706 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene serves as a central hub in T2D-related pathways, crucial for insulin signaling and metabolic regulation.
2. **G22553** | Score: **4.0** | As a primary driver in insulin signaling pathways, it enhances glucose metabolism and complements G19943's function.
3. **G33764** | Score: **4.0** | Important for metabolic regulation, this gene supports insulin signaling, providing robustness to the therapeutic strategy.
4. **G23245** | Score: **4.0** | A key player in glucose uptake, it reinforces the effects of G19943 and G22553 in enhancing insulin sensitivity.
5. **G00484** | Score: **4.0** | Functions as a transcription factor vital for regulating insulin signaling, adding essential depth to the multi-target approach.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a multi-target approach that integrates the insights from both parent hypotheses, focusing on G19943 as the primary target due to its central role in insulin signaling and metabolic pathways. The combination of G22553, G33764, G23245, and G00484 aims to create a robust therapeutic strategy that effectively addresses the multifactorial nature of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17** for primary target
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.**
- WGCNA module role: **G19943 identified as a hub component in modules negatively correlated with T2D.**
- Regulating TFs: **G00484 acts as a transcriptional regulator in insulin signaling pathways.**

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves leveraging G19943's role as a central coordinator in insulin signaling and lipid metabolism to restore metabolic homeostasis in Type 2 Diabetes. Targeting G22553 and G33764 in conjunction with G19943 enhances insulin signaling pathways, while G23245 facilitates glucose uptake, further improving insulin sensitivity. G00484's transcriptional regulatory role supports these processes, creating a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** The relevant tissues include **pancreatic -cells, muscle, liver, and adipose tissue**, as they play critical roles in insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The approach involves the activation of selected targets using small molecule modulators designed to enhance their activity, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles and evidence strength across multiple datasets, with G19943 prioritized for its central role in T2D pathways. G22553 complements its function, while G33764 and G23245 provide necessary support, and G00484 adds essential transcriptional regulation, reinforcing the multi-target approach's robustness.

**CONFIDENCE:** **HIGH**, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 20:06:52,707 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:06:52,708 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:06:52,709 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:06:52,712 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:06:52,713 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Modulation...'
2026-02-10 20:06:52,713 - root - INFO - Crossover 2/18: parents 'Integrated Gene Modulation for...' x 'Enhanced Multi-Target Strategy...'
2026-02-10 20:06:52,772 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:07:29,745 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:07:29,750 - root - INFO - TOKEN_USAGE: input=40374, output=780, total=41154, cost=$0.006524
2026-02-10 20:07:29,751 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:07:29,751 - root - INFO - 
### TITLE: Comprehensive Multi-Target Approach for Enhanced Management of Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Acts as a central hub in insulin signaling and metabolic pathways, demonstrating strong evidence across multiple datasets.
2. **G22553** | Score: 4.0 | Functions as a primary driver in insulin signaling, enhancing glucose metabolism alongside G19943.
3. **G04436** | Score: 4.0 | Critical enzyme involved in metabolic regulation, supporting the synergistic effects of G19943 and G22553.
4. **G23245** | Score: 4.0 | A primary driver for glucose uptake and insulin sensitivity, providing essential support to the primary targets.
5. **G33764** | Score: 4.0 | Offers additional regulatory support within metabolic pathways, enhancing overall therapeutic efficacy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This child hypothesis integrates the strengths of both parent hypotheses by emphasizing G19943 as the core target while leveraging the synergistic effects of complementary targets G22553, G04436, G23245, and G33764. This robust multi-target strategy aims to address the complexities of Type 2 Diabetes (T2D) by enhancing insulin sensitivity and metabolic control across various tissues involved in glucose and lipid metabolism.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- **WGCNA module role**: G19943 identified as a hub component in relevant T2D negatively correlated modules.
- **Regulating TFs**: Potential interactions with transcription factors influencing metabolic pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism centers on G19943 as a pivotal coordinator of insulin signaling and lipid metabolism. By enhancing the function of G22553, we can promote glucose uptake and improve insulin sensitivity. G04436 plays a critical role in regulating metabolic enzymes that influence lipid profiles, while G23245 supports glucose uptake mechanisms. Additionally, G33764 offers insights into the regulation of insulin signaling pathways, specifically addressing adipose tissue dysregulation observed in T2D. This multi-faceted approach ensures a comprehensive strategy for T2D management.

### TISSUE_RATIONALE:
The targeted tissues include pancreatic beta-cells, muscle, liver, and adipose tissue, all of which are essential for insulin action, glucose uptake, and lipid metabolism. Addressing these tissues is crucial for developing effective therapies aimed at reversing metabolic disturbances associated with Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The strategy involves the small molecule activation of G19943 and G22553 to enhance their functions, combined with modulation of G04436 and G23245 to optimize lipid metabolism and reduce negative feedback mechanisms in metabolic pathways.

### PREDICTED_OUTCOME:
The integrated modulation of these targets is expected to significantly improve insulin sensitivity and enhance glucose metabolism, providing a comprehensive therapeutic benefit for managing Type 2 Diabetes, ultimately leading to better patient outcomes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed closely by G22553 for its complementary function. G04436 and G23245 are included for their regulatory support, while G33764 provides additional insights into specific dysregulation mechanisms without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:07:29,757 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:07:29,758 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:07:29,779 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Approach for ...'
2026-02-10 20:07:29,780 - root - INFO - Crossover 3/18: parents 'Integrated Multi-Target Approa...' x 'Comprehensive Multi-Target Mod...'
2026-02-10 20:07:29,829 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:08:07,128 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:08:07,134 - root - INFO - TOKEN_USAGE: input=40284, output=710, total=40994, cost=$0.006469
2026-02-10 20:08:07,134 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:08:07,134 - root - INFO - 
### TITLE: Enhanced Multi-Target Strategy for Improved Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in T2D pathways facilitating insulin signaling and metabolic regulation.
2. **G23245** | Score: 4.0 | Key driver in insulin signaling, essential for glucose uptake and enhancing overall insulin sensitivity.
3. **G22553** | Score: 4.0 | Synergistically enhances insulin signaling, working alongside G19943 and G23245 for improved glucose metabolism.
4. **G04436** | Score: 4.0 | Crucial enzyme that optimizes lipid metabolism, complementing the roles of the top three targets to provide a comprehensive metabolic response.
5. **G33764** | Score: 4.0 | Supports regulatory mechanisms within metabolic pathways, reinforcing the overall efficacy of the targeted approach.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a robust multi-target approach to enhance insulin sensitivity in T2D by integrating the central roles of G19943, G23245, and G22553 in insulin signaling, along with G04436's role in lipid metabolism and G33764's regulatory functions. This strategy aims to leverage the interconnected nature of these targets to create a more effective therapeutic intervention.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 serves as a hub component in modules negatively correlated with T2D.
- Regulating TFs: None identified.

**MECHANISM_HYPOTHESIS:** G19943 is hypothesized to act as a critical coordinator of insulin signaling and lipid metabolism, thereby restoring metabolic balance in T2D. G23245 enhances glucose uptake, while G22553 further strengthens insulin signaling pathways. G04436 optimizes lipid metabolism, addressing dysregulation associated with T2D, and G33764 provides additional regulatory support, ensuring a comprehensive approach to the disease.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, liver, muscle, and adipose tissue. These tissues are vital for insulin action, glucose uptake, and lipid metabolism, making them optimal targets for therapeutic interventions aimed at reversing T2D.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves small molecule activation of G19943 and G23245, along with the potential modulation of G22553 and G04436 to enhance their functions, thereby improving insulin sensitivity and overall metabolic function.

**PREDICTED_OUTCOME:** Effective modulation of G19943 and its associated targets is expected to lead to significantly improved insulin sensitivity and glucose metabolism, resulting in better management of T2D and improved patient outcomes.

**RANKING_RATIONALE:** G19943 is ranked highest due to its central role as a hub in insulin signaling and metabolic regulation. G23245 closely follows for its essential role in promoting glucose uptake, while G22553 enhances insulin signaling pathways. G04436 is included for its critical role in lipid metabolism, and G33764 provides necessary regulatory support without overshadowing the primary targets.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:08:07,136 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:08:07,136 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:08:07,137 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:08:07,140 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:08:07,140 - root - INFO -   -> Created offspring: 'Enhanced Multi-Target Strategy for Impro...'
2026-02-10 20:08:07,140 - root - INFO - Mutation 4/18: parent 'Synergistic Multi-Target Modul...'
2026-02-10 20:08:07,140 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:08:07,205 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:08:40,911 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:08:40,919 - root - INFO - TOKEN_USAGE: input=39529, output=738, total=40267, cost=$0.006372
2026-02-10 20:08:40,920 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:08:40,920 - root - INFO - 
### TITLE: Targeting G22553 for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Selected as a primary driver in insulin signaling pathways, which can significantly enhance glucose metabolism alongside other targets.
2. **G23245** | Score: 4.0 | Acts as a pivotal driver in glucose uptake and insulin sensitivity, complementing G22553's role in insulin signaling.
3. **G19943** | Score: 4.0 | Previously identified as a central hub in insulin signaling and metabolic regulation, supporting the overall strategy.
4. **G33764** | Score: 4.0 | Enhances metabolic regulation and contributes to insulin signaling, providing additional support to the therapeutic approach.
5. **G00484** | Score: 4.0 | Functions as a transcription factor that is crucial for regulating insulin signaling, adding regulatory depth to the multi-target strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis emphasizes the effectiveness of targeting G22553 as a primary driver in insulin signaling, thereby enhancing insulin sensitivity and glucose metabolism in Type 2 Diabetes management. By integrating G22553 with supportive roles from G23245, G19943, G33764, and G00484, we create a comprehensive therapeutic strategy that addresses the multifactorial nature of T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with insulin signaling.
- Regulating TFs: None identified for G22553, but G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** G22553 is hypothesized to enhance insulin signaling pathways, leading to improved glucose uptake and metabolism. By targeting G22553, we can synergistic ally engage G23245 to bolster glucose uptake while utilizing G19943 and G33764 for their metabolic regulatory roles. G00484's function as a transcription factor provides an additional layer of regulation critical for insulin sensitivity, creating a robust mechanism for addressing T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as these are integral to insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G22553 to enhance its function, alongside modulation of G23245, G19943, G33764, and G00484 to strengthen metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its direct role in insulin signaling, with G23245 complementing its function. G19943 and G33764 provide essential regulatory support, while G00484 adds necessary transcriptional regulation.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:08:40,920 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:08:40,920 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:08:40,921 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:08:40,924 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:08:40,924 - root - INFO -   -> Created mutated offspring: 'Targeting G22553 for Enhanced Insulin Se...'
2026-02-10 20:08:40,925 - root - INFO - Crossover 5/18: parents '** Identification of Promising...' x 'Enhanced Multi-Target Strategy...'
2026-02-10 20:08:40,999 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:09:18,492 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:09:18,499 - root - INFO - TOKEN_USAGE: input=40249, output=774, total=41023, cost=$0.006502
2026-02-10 20:09:18,500 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:09:18,509 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Approach for Enhanced Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0/17** | This gene is a central hub in insulin signaling and metabolic pathways, showing robust evidence across multiple datasets, making it the primary therapeutic focus.
2. **G22553** | Score: **4.0/17** | As a key driver in insulin signaling, this gene enhances glucose metabolism and has strong supporting data from multiple evidence sources.
3. **G04436** | Score: **4.0/17** | A critical enzyme in metabolic regulation, G04436 complements the action of G19943 and G22553, reinforcing their therapeutic effects.
4. **G23245** | Score: **4.0/17** | This primary driver is important for glucose uptake and insulin sensitivity, providing necessary support to the primary targets.
5. **G27976** | Score: **3.0/17** | As a major regulator in the silver module, G27976 has relevant links to metabolic pathways and can enhance the overall therapeutic efficacy.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** This hypothesis integrates the insights from both parent hypotheses, focusing on G19943 as the primary target due to its central role in insulin signaling. By including G22553 and G04436 as synergistic modulators, alongside G23245 and G27976 for additional support, we aim for a comprehensive approach to enhance insulin sensitivity and metabolic control in Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways**
- WGCNA module role: **G19943 is a hub component in modules negatively correlated with T2D**
- Regulating TFs: **Potential interactions with transcription factors influencing metabolic pathways**

**MECHANISM_HYPOTHESIS:** The mechanism posits that G19943 orchestrates insulin signaling and lipid metabolism, while G22553 enhances glucose uptake and insulin sensitivity. G04436, as a metabolic enzyme, addresses lipid profiles directly, thereby tackling both glucose and lipid metabolism challenges in Type 2 Diabetes. The inclusion of G23245 and G27976 provides additional regulatory support, further amplifying the therapeutic response through potential transcription factor interactions.

**TISSUE_RATIONALE:** Key tissues include pancreatic -cells, muscle, liver, and adipose tissue, all critical for insulin action, glucose uptake, and lipid metabolism. Targeting these genes within these tissues is essential for reversing the pathophysiological processes underlying Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule activation of G19943 and G22553 to enhance their functions, combined with modulation of G04436 to optimize lipid metabolism and mitigate negative feedback mechanisms in metabolic pathways.

**PREDICTED_OUTCOME:** Combined modulation of G19943, G22553, and G04436 is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and potential for synergistic interactions. G19943 is prioritized for its central role, followed closely by G22553 and G04436, which effectively complement its function. G23245 and G27976 provide additional support to enhance the overall therapeutic approach.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:09:18,511 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:09:18,512 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:09:18,512 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:09:18,515 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:09:18,515 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Approach f...'
2026-02-10 20:09:18,515 - root - INFO - Crossover 6/18: parents '** Comprehensive Modulation of...' x '** Integrated Modulation of Ke...'
2026-02-10 20:09:18,580 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:09:42,096 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:09:42,101 - root - INFO - TOKEN_USAGE: input=40409, output=801, total=41210, cost=$0.006542
2026-02-10 20:09:42,102 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:09:42,102 - root - INFO - 
**TITLE:** Enhanced Modulation of Insulin Sensitivity and Metabolic Homeostasis in Type 2 Diabetes through Multi-Targeted Gene Therapy

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene serves as a central hub in insulin signaling pathways, demonstrating robust evidence across multiple datasets and plays a crucial role in enhancing insulin sensitivity.**
2. **G04436 | Score: 4.0 | This enzyme significantly regulates glucose metabolism and has been shown to improve insulin sensitivity, complementing the actions of G19943.**
3. **G22553 | Score: 4.0 | Identified as a primary driver in T2D-related pathways, it facilitates insulin receptor signaling and glucose uptake, enhancing the metabolic effects alongside G19943 and G04436.**
4. **G33764 | Score: 4.0 | This enzyme is involved in lipid metabolism and insulin resistance mechanisms, making its modulation essential for improving overall metabolic function in T2D.**
5. **G19122 | Score: 3.0 | A major regulator of insulin signaling pathways, it supports the metabolic balance and augments the effects of primary targets, making it a valuable addition to the therapeutic strategy.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-targeted approach to improve insulin sensitivity and metabolic homeostasis in Type 2 Diabetes by synergistically targeting G19943, G04436, G22553, G33764, and G19122. By leveraging the strengths of each target, this strategy aims to address key metabolic pathways involved in T2D pathology, providing a robust therapeutic framework.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: Hub component (G19943), Primary Driver (G22553), Primary Driver (G33764), Major Regulator (G19122)
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The coordinated activation of G19943 is expected to significantly enhance insulin signaling pathways, directly addressing insulin resistance and improving glucose metabolism. Concurrently, targeting G04436 will facilitate glucose metabolism and improve insulin sensitivity, while G22553 will promote glucose uptake. Modulating G33764 will help regulate lipid metabolism and further counteract insulin resistance, and G19122 will support the restoration of metabolic balance, creating a comprehensive therapeutic strategy for T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this approach include pancreatic -cells, muscle, liver, and adipose tissue. These tissues are integral to glucose metabolism and insulin action, making them ideal candidates for targeted interventions in Type 2 Diabetes management.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The combined modulation of these targets is anticipated to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, ultimately leading to better clinical outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, robust evidence from multiple datasets, and critical roles in key biological pathways. G19943 was selected as the primary target due to its central importance in the gene network, while G04436, G22553, and G33764 were prioritized for their significant contributions to metabolic regulation. G19122 was included for its essential role in supporting the overall therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:09:42,103 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:09:42,103 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:09:42,103 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:09:42,105 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:09:42,105 - root - INFO -   -> Created offspring: '** Enhanced Modulation of Insulin Sensit...'
2026-02-10 20:09:42,105 - root - INFO - Crossover 7/18: parents 'Enhanced Insulin Sensitivity i...' x 'Synergistic Multi-Target Modul...'
2026-02-10 20:09:42,181 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:10:24,164 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:10:24,187 - root - INFO - TOKEN_USAGE: input=40333, output=770, total=41103, cost=$0.006512
2026-02-10 20:10:24,187 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:10:24,187 - root - INFO - 
### TITLE: Comprehensive Multi-Target Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Central hub in T2D pathways facilitating insulin signaling and metabolic regulation, making it the most promising target.
2. **G22553** | Score: **4.0** | A primary driver in insulin signaling pathways, crucial for improving glucose metabolism and complementing G19943's function.
3. **G23245** | Score: **4.0** | A vital contributor to glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy alongside G19943 and G22553.
4. **G33764** | Score: **4.0** | Enhances metabolic regulation and supports insulin signaling pathways, adding robustness to the overall approach.
5. **G00484** | Score: **4.0** | Functions as a transcription factor crucial for regulating insulin signaling, providing essential regulatory depth to the modulation strategy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis integrates the strengths of both parent hypotheses, emphasizing a multi-target approach that leverages the central roles of G19943, G22553, G23245, G33764, and G00484 in insulin signaling and glucose metabolism. By prioritizing these targets, the hypothesis aims to enhance the overall efficacy of Type 2 Diabetes management through their synergistic interactions, addressing the multifactorial nature of the disease.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- **WGCNA module role**: G19943 identified as a hub component in modules negatively correlated with T2D.
- **Regulating TFs**: G00484 acts as a regulator in insulin signaling pathways.

### MECHANISM_HYPOTHESIS:
The activation of G19943 is hypothesized to serve as a central coordinator in insulin signaling and lipid metabolism essential for restoring metabolic homeostasis in Type 2 Diabetes. Targeting G22553 alongside G19943 enhances insulin signaling pathways, while G23245 and G33764 further contribute to glucose uptake and metabolic regulation. G00484 supports these processes by regulating transcriptional responses critical for insulin sensitivity, creating a comprehensive mechanism for managing T2D.

### TISSUE_RATIONALE:
Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are integral to insulin action, glucose uptake, and overall metabolic homeostasis. Targeting these tissues is optimal for therapeutic interventions aimed at enhancing insulin sensitivity.

### THERAPEUTIC_APPROACH:
The proposed approach involves small molecule activation of G19943 and G22553, alongside modulation of G23245, G33764, and G00484 to strengthen metabolic regulation and insulin sensitivity.

### PREDICTED_OUTCOME:
Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better overall management of Type 2 Diabetes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553 for its complementary function. G23245 and G33764 provide essential regulatory support, while G00484 adds necessary transcriptional regulation to the approach.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and significant associations with T2D pathways and mechanisms.
2026-02-10 20:10:24,188 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:10:24,188 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:10:24,191 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Modulation fo...'
2026-02-10 20:10:24,192 - root - INFO - Mutation 8/18: parent '** Integrated Modulation of G1...'
2026-02-10 20:10:24,192 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:10:24,260 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:10:52,391 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:10:52,398 - root - INFO - TOKEN_USAGE: input=39570, output=724, total=40294, cost=$0.006370
2026-02-10 20:10:52,398 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:10:52,398 - root - INFO - 
**TITLE:** Targeting G00484 and G22512 to Enhance Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G00484** | Score: **4.0** | This transcription factor is supported by multiple evidence types and plays a critical role in regulating metabolic pathways, enhancing insulin sensitivity and glucose metabolism.
2. **G22512** | Score: **4.0** | As a primary driver in insulin receptor signaling pathways, G22512 is essential for glucose uptake, making it a strong candidate for improving insulin sensitivity in T2D.
3. **G19122** | Score: **3.0** | This enzyme acts as a major regulator in insulin signaling pathways, providing additional support for enhancing metabolic control in conjunction with the primary targets.
4. **G33764** | Score: **4.0** | While already considered in the original hypothesis, its role in metabolic regulation makes it a valuable secondary target for a more comprehensive approach.
5. **G22553** | Score: **4.0** | Another target that supports insulin receptor signaling, though it ranks lower here due to the focus on more promising new targets.

**PRIMARY_TARGET:** **G00484**

**SUMMARY:** This mutated hypothesis emphasizes the modulation of G00484 and G22512, aiming to enhance insulin sensitivity and metabolic control in Type 2 Diabetes. By targeting a transcription factor alongside a primary driver of insulin signaling, this approach seeks to optimize the therapeutic strategy to address the complex nature of T2D.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17** for primary target
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism**
- WGCNA module role: **Primary Driver (G22512)**
- Regulating TFs: **None identified**

**MECHANISM_HYPOTHESIS:** The activation of G00484 is hypothesized to enhance the transcription of key metabolic genes involved in insulin signaling and glucose uptake, thereby addressing insulin resistance. Concurrently, G22512 will boost insulin receptor signaling, facilitating glucose metabolism and uptake in peripheral tissues, which is crucial for improving metabolic control in T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells and muscle, as they are critical for insulin action and glucose homeostasis, which are central to the pathology of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets through small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, potentially leading to a reversal of disease progression.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their critical roles in relevant biological pathways, and the robustness of the supporting evidence. G00484 is prioritized due to its potential as a transcription factor that can modulate multiple pathways simultaneously, while G22512 is essential for insulin signaling. G19122 and G33764, although previously considered, are included for their complementary roles, while G22553 is noted as a secondary target to provide additional support. 

**CONFIDENCE:** **HIGH** based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:10:52,399 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:10:52,399 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:10:52,400 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:10:52,403 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:10:52,403 - root - INFO -   -> Created mutated offspring: '** Targeting G00484 and G22512 to Enhanc...'
2026-02-10 20:10:52,403 - root - INFO - Crossover 9/18: parents '** Comprehensive Modulation of...' x '** Comprehensive Multi-Target ...'
2026-02-10 20:10:52,471 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:11:35,197 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:11:35,203 - root - INFO - TOKEN_USAGE: input=40406, output=748, total=41154, cost=$0.006510
2026-02-10 20:11:35,203 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:11:35,203 - root - INFO - 
**TITLE:** Enhanced Multi-Target Strategy for Improved Insulin Sensitivity and Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | Central hub in metabolic pathways crucial for both insulin signaling and lipid metabolism, with strong supporting evidence across datasets.**
2. **G22553 | Score: 4.0 | A primary driver in insulin signaling pathways, essential for glucose uptake and well-supported by multi-evidence types.**
3. **G33764 | Score: 4.0 | Important enzyme in metabolic regulation that enhances glucose homeostasis, demonstrating robust evidence support.**
4. **G04436 | Score: 4.0 | Plays a critical role in lipid metabolism and insulin signaling, complementing the effects of G19943 and G22553.**
5. **G19122 | Score: 3.0 | Major regulator in insulin signaling pathways, supporting insulin sensitivity and metabolic balance, with multiple dataset validation.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy that synergistically modulates G19943, G22553, G33764, G04436, and G19122 to enhance insulin sensitivity and metabolic regulation in Type 2 Diabetes. By integrating the strongest mechanistic insights from both parent hypotheses, this approach aims to address the complexities of T2D by targeting key metabolic pathways simultaneously.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 is identified as a hub component, while G22553 is a primary driver in relevant modules.
- Regulating TFs: 12 identified transcription factors associated with G04436.

**MECHANISM_HYPOTHESIS:** The mechanism hypothesizes that activating G19943 will enhance its role as a master regulator in both insulin signaling and lipid metabolism, significantly improving insulin sensitivity and glucose homeostasis. Concurrently, G22553 will reinforce insulin signaling and glucose uptake, while G33764 will support metabolic regulation. G04436 will address dyslipidemia, and G19122 will further enhance insulin sensitivity, creating a robust therapeutic strategy against T2D.

**TISSUE_RATIONALE:** The primary tissues of focus include pancreatic -cells, liver, and skeletal muscle, as these are integral to insulin action, glucose uptake, and lipid metabolism. Activating these targets will optimize insulin secretion and action, leading to improved metabolic control.

**THERAPEUTIC_APPROACH:** The strategy involves the development of small molecule activators targeting the selected genes to enhance their functions and address metabolic dysregulation.

**PREDICTED_OUTCOME:** Coordinated modulation of these targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and yield a therapeutic benefit that could lead to better management and potential reversal of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their strong roles in key biological pathways, and the robustness of supporting evidence. G19943 was selected as the primary target due to its central role in multiple metabolic pathways, while G22553 and G33764 were prioritized for their significant contributions to insulin signaling and metabolic regulation. G04436 and G19122 were included to further enhance the understanding and treatment of metabolic dysregulation in T2D.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:11:35,205 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:11:35,205 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:11:35,206 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:11:35,208 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:11:35,208 - root - INFO -   -> Created offspring: '** Enhanced Multi-Target Strategy for Im...'
2026-02-10 20:11:35,208 - root - INFO - Crossover 10/18: parents '** Identification of Promising...' x 'Enhanced Insulin Sensitivity i...'
2026-02-10 20:11:35,260 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:12:11,352 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:12:11,359 - root - INFO - TOKEN_USAGE: input=40242, output=760, total=41002, cost=$0.006492
2026-02-10 20:12:11,359 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:12:11,359 - root - INFO - 
### TITLE: Integrated Gene Targeting to Enhance Insulin Sensitivity in Type 2 Diabetes 

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | This gene is a primary driver in insulin signaling pathways and is crucial for enhancing muscle insulin sensitivity.
2. **G19943** | Score: **4.0** | As a hub component in gene networks related to T2D, this gene plays a central role in insulin signaling and inflammatory responses.
3. **G23245** | Score: **4.0** | This gene is implicated in pathways relevant to T2D and enhances glucose uptake, which is essential for metabolic regulation.
4. **G33764** | Score: **4.0** | This gene supports improved metabolic flexibility and is significant in muscle tissue metabolism.
5. **G19122** | Score: **3.0** | A major regulator involved in insulin signaling pathways that could enhance the overall efficacy of the therapeutic approach.

**PRIMARY_TARGET:** **G22553**

**SUMMARY:** This hypothesis proposes that integrating the modulation of G22553 as a primary target, along with supporting roles of G19943, G23245, G33764, and G19122, will significantly enhance insulin sensitivity and metabolic control in muscle tissue. Targeting these genes collectively addresses the multifaceted nature of T2D by improving insulin signaling, glucose uptake, and metabolic flexibility.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, inflammatory response pathways**
- WGCNA module role: **G22553 is a primary driver in the black module; G19943 is a hub component in the silver module.**
- Regulating TFs: **Multiple transcription factors identified for G22553**

**MECHANISM_HYPOTHESIS:** The modulation of G22553 is expected to enhance insulin signaling in muscle tissue, leading to improved glucose uptake and utilization. Concurrent targeting of G19943 will support overall insulin signaling and alleviate inflammatory stress responses contributing to insulin resistance. Additionally, G23245 and G33764 will promote glucose uptake and metabolic flexibility, while G19122 will provide regulatory support, enhancing the efficacy of the proposed therapeutic approach.

**TISSUE_RATIONALE:** Muscle tissue is critical due to its role in glucose uptake and energy metabolism, which are essential for maintaining insulin sensitivity. Targeting these key metabolic pathways in muscle can have a direct impact on the management of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The proposed approach involves the small molecule activation of G22553 and its synergistic partners (G19943, G23245, G33764, and G19122) to enhance their respective functions within muscle tissue, promoting improved insulin sensitivity and metabolic control.

**PREDICTED_OUTCOME:** The targeted modulation of these genes is anticipated to lead to a significant improvement in muscle insulin sensitivity, enhanced glucose uptake, and better overall metabolic regulation, ultimately resulting in more effective management of Type 2 Diabetes.

**RANKING_RATIONALE:** Targets were ranked based on their roles in insulin signaling and metabolic pathways relevant to muscle tissue. G22553 leads due to its established role and strong evidence support, followed by G19943 for its centrality in gene networks. G23245 and G33764 are included for their impact on glucose and metabolic flexibility, while G19122 provides additional regulatory support without overshadowing the primary targets.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence types and pathways relevant to muscle metabolism and Type 2 Diabetes management.
2026-02-10 20:12:11,369 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:12:11,370 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:12:11,372 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:12:11,385 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:12:11,386 - root - INFO -   -> Created offspring: 'Integrated Gene Targeting to Enhance Ins...'
2026-02-10 20:12:11,386 - root - INFO - Mutation 11/18: parent '** Enhanced Target Mechanism f...'
2026-02-10 20:12:11,386 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:12:11,461 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:12:41,543 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:12:41,547 - root - INFO - TOKEN_USAGE: input=39477, output=688, total=40165, cost=$0.006334
2026-02-10 20:12:41,548 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:12:41,548 - root - INFO - 
**TITLE:** Exploring G22553 as a Novel Target for Type 2 Diabetes Therapy

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0** | This gene is a primary driver in the black module, showing a strong positive correlation with T2D and significant evidence across multiple datasets, indicating its pivotal role in disease progression.
2. **G19122** | Score: **3.0** | A major regulator involved in insulin signaling, this gene has a significant impact on glucose metabolism and insulin sensitivity, making it a relevant target for therapeutic strategies.
3. **G27976** | Score: **3.0** | As a major regulator in the silver module, this gene influences insulin sensitivity and metabolic regulation, suggesting its potential for modulation in T2D therapy.
4. **G23245** | Score: **4.0** | A primary driver in the silver module, it contributes negatively to the correlation with T2D, offering potential avenues for intervention.
5. **G19122** | Score: **3.0** | As a significant player in insulin signaling, it shows potential for modulating glucose metabolism and enhancing insulin sensitivity.

**PRIMARY_TARGET:** **G22553**

**SUMMARY:** The mutated hypothesis focuses on G22553 as the primary target due to its role as a primary driver in the black module associated with T2D. By modulating G22553, it may be possible to influence key pathways contributing to insulin resistance and improve metabolic health in T2D patients.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling pathways, metabolic regulation**
- WGCNA module role: **Primary driver in the black module**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** G22553 may enhance insulin sensitivity and glucose metabolism through its involvement in insulin signaling pathways. By targeting this gene, the therapeutic strategy aims to improve insulin action and reduce the chronic inflammatory state associated with T2D, potentially leading to better control of blood glucose levels.

**TISSUE_RATIONALE:** The primary tissues of interest include skeletal muscle and adipose tissue, where G22553's modulation could significantly improve insulin sensitivity and glucose uptake, thereby addressing core issues in T2D pathology.

**THERAPEUTIC_APPROACH:** The proposed therapeutic approach involves the activation of G22553 via small molecules designed to enhance its function within insulin signaling pathways, potentially restoring its normal activity in the context of T2D.

**PREDICTED_OUTCOME:** Modulation of G22553 is anticipated to improve overall insulin sensitivity, lower blood glucose levels, and reduce inflammation, leading to enhanced metabolic control and a decrease in T2D complications.

**RANKING_RATIONALE:** The targets are ranked based on their priority scores, biological relevance, and the strength of evidence supporting their roles in T2D pathology. G22553 ranks highest due to its strong correlation with T2D in multiple datasets, while G19122 and G27976 follow closely due to their significant roles in insulin signaling and glucose metabolism.

**CONFIDENCE:** **HIGH** based on the robust data support and clear relevance of the identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:12:41,548 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:12:41,548 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:12:41,549 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:12:41,550 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:12:41,551 - root - INFO -   -> Created mutated offspring: '** Exploring G22553 as a Novel Target fo...'
2026-02-10 20:12:41,551 - root - INFO - Crossover 12/18: parents 'Integrated Multi-Target Approa...' x 'Comprehensive Multi-Target Mod...'
2026-02-10 20:12:41,586 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:13:18,986 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:13:18,991 - root - INFO - TOKEN_USAGE: input=40284, output=711, total=40995, cost=$0.006469
2026-02-10 20:13:18,991 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:13:18,991 - root - INFO - 
### TITLE: Enhanced Multi-Target Modulation for Optimized Insulin Sensitivity in Type 2 Diabetes Treatment

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in T2D pathways with the strongest evidence for facilitating insulin signaling and metabolic regulation.
2. **G23245** | Score: 4.0 | A primary driver in insulin signaling crucial for glucose uptake, reinforcing the action of G19943.
3. **G04436** | Score: 4.0 | An important enzyme in metabolic regulation that enhances the effects of G19943 and G23245 on glucose and lipid metabolism.
4. **G33764** | Score: 4.0 | Provides additional regulatory support within metabolic pathways, complementing the roles of the top three targets.
5. **G22553** | Score: 4.0 | A primary driver that synergizes with G19943 and G23245 to further promote enhanced glucose metabolism and insulin sensitivity.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis combines the strengths of both parent hypotheses by focusing on G19943 as the primary target while also integrating G23245, G04436, G33764, and G22553. This multi-target approach aims to comprehensively enhance insulin sensitivity and metabolic control in Type 2 Diabetes (T2D) by leveraging the interconnectedness of these targets.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 is identified as a hub component in relevant modules negatively correlated with T2D.
- Regulating TFs: None identified.

**MECHANISM_HYPOTHESIS:** G19943 is hypothesized to act as a crucial coordinator of insulin signaling and lipid metabolism, thereby restoring metabolic balance in T2D. By targeting G23245, we enhance glucose uptake, while G04436 optimizes lipid metabolism. G33764 and G22553 provide regulatory mechanisms to support this coordinated approach, ensuring comprehensive management of T2D.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, liver, muscle, and adipose tissue. These tissues are critical for insulin action, glucose uptake, and lipid metabolism, making them optimal targets for therapeutic interventions aimed at reversing T2D.

**THERAPEUTIC_APPROACH:** The proposed therapeutic approach involves small molecule activation of G19943 and G23245, as well as modulation of G04436, G33764, and G22553 to enhance their functions and mitigate feedback mechanisms affecting metabolic pathways.

**PREDICTED_OUTCOME:** Effective modulation of G19943 and its associated targets is expected to lead to significantly improved insulin sensitivity and glucose metabolism, ultimately resulting in better management of T2D and improved patient outcomes.

**RANKING_RATIONALE:** G19943 is ranked highest due to its central role in insulin signaling and metabolic regulation, supported by substantial evidence. G23245 is closely linked due to its importance in glucose uptake, while G04436, G33764, and G22553 provide necessary regulatory support and metabolic enhancement, respectively.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:13:18,991 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:13:18,992 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:13:18,992 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:13:18,994 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:13:18,995 - root - INFO -   -> Created offspring: 'Enhanced Multi-Target Modulation for Opt...'
2026-02-10 20:13:18,995 - root - INFO - Mutation 13/18: parent 'Integrated Adipose Tissue and ...'
2026-02-10 20:13:18,995 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 20:13:19,052 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:14:01,730 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:14:01,737 - root - INFO - TOKEN_USAGE: input=39583, output=794, total=40377, cost=$0.006414
2026-02-10 20:14:01,737 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:14:01,737 - root - INFO - 
### TITLE: Enhanced Insulin Sensitivity Hypothesis Targeting Adipose Tissue via G33764, G19122, G20274, and G04436

#### RANKED_TARGETS:
1. **G33764** | Score: 4.0 | This gene is a master regulator of insulin signaling pathways, crucial for improving metabolic responses in adipose tissue in T2D.
2. **G19122** | Score: 3.0 | This gene is essential for enhancing insulin sensitivity in adipose tissue, directly complementing G33764's effects on glucose metabolism.
3. **G20274** | Score: 3.0 | Targeting this gene can synergistically reinforce insulin signaling, making it a valuable addition for improving glucose homeostasis in adipose tissue.
4. **G04436** | Score: 4.0 | This gene plays a pivotal role in glucose metabolism; its modulation can further elucidate and restore dysregulated pathways in adipose tissue.
5. **G22553** | Score: 4.0 | Acting as a primary driver in co-expression networks relevant to T2D, it supports the overall metabolic context crucial for therapeutic strategies.

#### PRIMARY_TARGET: G33764

### SUMMARY:
This refined hypothesis focuses on the role of G33764 as a central target for enhancing insulin sensitivity and metabolic regulation specifically in adipose tissue. The synergistic effects of G19122 and G20274, along with the metabolic contributions of G04436, provide a comprehensive approach to addressing the multifactorial pathophysiology of type 2 diabetes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, Lipid metabolism, Energy homeostasis
- **WGCNA module role**: G33764 is identified as a primary driver in relevant modules associated with T2D.
- **Regulating TFs**: Potential interactions with transcription factors affecting metabolic pathways.

### MECHANISM_HYPOTHESIS:
G33764 is hypothesized to serve as a master regulator of insulin signaling and lipid metabolism within adipose tissue, which is critical for maintaining glucose homeostasis in type 2 diabetes. The modulation of G19122 enhances insulin sensitivity, while G20274 further strengthens the insulin signaling cascade, collectively improving metabolic outcomes. Furthermore, G04436's role in glucose metabolism provides additional context for reversing the metabolic dysregulation characteristic of T2D.

### TISSUE_RATIONALE:
Adipose tissue is prioritized due to its significant role in insulin sensitivity and metabolic regulation. Understanding and targeting the dysregulation within this tissue can lead to improved therapeutic strategies for managing type 2 diabetes.

### THERAPEUTIC_APPROACH:
The approach involves small molecule activators targeting G33764, G19122, and G20274 to enhance their regulatory functions and improve insulin sensitivity in adipose tissue, while G04436s modulation will further support glucose metabolism.

### PREDICTED_OUTCOME:
Modulating G33764 in conjunction with G19122, G20274, and G04436 is anticipated to significantly enhance insulin sensitivity, improve glucose metabolism, and provide a therapeutic benefit that could potentially reverse or slow the progression of type 2 diabetes.

### RANKING_RATIONALE:
G33764 is ranked first due to its pivotal role in insulin signaling and metabolic regulation. G19122 and G20274 follow for their direct contributions to insulin sensitivity and signaling reinforcement. G04436 provides critical support in glucose metabolism, while G22553, though essential, is less directly involved in the immediate insulin signaling pathways compared to the primary targets.

### CONFIDENCE: HIGH based on strong multi-evidence support and the relevance of the chosen tissue in T2D pathophysiology.
2026-02-10 20:14:01,739 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:14:01,739 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:14:01,742 - root - INFO -   -> Created mutated offspring: 'Enhanced Insulin Sensitivity Hypothesis ...'
2026-02-10 20:14:01,743 - root - INFO - Crossover 14/18: parents 'Enhanced Insulin Sensitivity i...' x '** Comprehensive Multi-Target ...'
2026-02-10 20:14:01,796 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:14:45,041 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:14:45,046 - root - INFO - TOKEN_USAGE: input=40342, output=813, total=41155, cost=$0.006539
2026-02-10 20:14:45,046 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:14:45,046 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | This gene acts as a hub component in T2D-related gene networks, crucial for metabolic regulation and enhancing insulin signaling, with strong evidence support.
2. **G23245** | Score: **4.0** | As a primary driver in insulin signaling pathways, this gene has significant roles in glucose metabolism, making it a pivotal target for improving insulin sensitivity.
3. **G33764** | Score: **4.0** | This enzyme is essential in metabolic pathways related to T2D, complementing the effects of G19943 and G23245, thereby enhancing overall metabolic control.
4. **G04436** | Score: **4.0** | This key enzyme in lipid metabolism supports improved insulin sensitivity and glucose metabolism, critical for effective management of T2D.
5. **G22553** | Score: **4.0** | While identified as a primary driver in insulin signaling, its lower rank reflects a more focused strategy on better-characterized genes with multiple evidence types for robustness.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis integrates insights from both parent hypotheses, focusing on a multi-target strategy that incorporates G19943, G23245, G33764, G04436, and G22553. By selecting targets that collectively influence key metabolic pathways and insulin signaling, this approach aims to address the multifactorial nature of Type 2 Diabetes, thereby enhancing therapeutic efficacy and patient outcomes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation
- **WGCNA module role**: G19943 is a hub component in T2D-related gene networks, indicating its central role in the disease mechanism.
- **Regulating TFs**: Multiple transcription factors are involved, providing regulatory depth to the approach.

### MECHANISM_HYPOTHESIS:
The activation of G19943 is anticipated to enhance insulin signaling and metabolic regulation in Type 2 Diabetes. Concurrent activation of G23245 will drive glucose uptake, while G33764 will complement metabolic flexibility. G04436's role in lipid metabolism will further enhance insulin sensitivity, and G22553 will support overall metabolic control. This integrated approach targets multiple critical pathways, providing a comprehensive strategy for effective diabetes management.

### TISSUE_RATIONALE:
The most relevant tissues for this hypothesis include muscle, liver, and pancreatic -cells, as they are essential for insulin action and glucose homeostasis. Enhancing the function of these tissues can directly impact the management of Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G19943, G23245, G33764, G04436, and G22553) to improve insulin sensitivity and metabolic regulation.

### PREDICTED_OUTCOME:
Effective modulation of these targets is expected to lead to significant improvements in insulin sensitivity, reduction in blood glucose levels, and enhanced overall disease management for patients with Type 2 Diabetes.

### RANKING_RATIONALE:
Targets were ranked based on their roles in insulin signaling and metabolic pathways, as well as their strong data support. G19943 was selected as the primary target due to its established role and evidence from multiple sources, followed by G23245 and G33764 for their significant contributions to metabolic regulation. G04436 and G22553 were included for their essential roles in enhancing overall therapeutic strategy.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to muscle and metabolic control in Type 2 Diabetes management.
2026-02-10 20:14:45,048 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:14:45,048 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:14:45,051 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy for Enh...'
2026-02-10 20:14:45,052 - root - INFO - Mutation 15/18: parent '** Integrated Modulation of Ke...'
2026-02-10 20:14:45,052 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 20:14:45,106 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:15:06,647 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:15:06,650 - root - INFO - TOKEN_USAGE: input=39601, output=801, total=40402, cost=$0.006421
2026-02-10 20:15:06,650 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:15:06,650 - root - INFO - 
**TITLE:** Tissue-Specific Modulation of Insulin Signaling in Skeletal Muscle to Enhance Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553 | Score: 4.0 | As a primary driver in the black module associated with T2D, it significantly influences insulin receptor signaling and glucose uptake mechanisms, making it crucial for improving insulin sensitivity in skeletal muscle.**
2. **G19122 | Score: 3.0 | A major regulator in insulin signaling pathways, its modulation has the potential to restore metabolic balance in muscle tissue, complementing the effects of G22553.**
3. **G19943 | Score: 4.0 | Serving as a hub component in T2D-related gene networks, this gene plays a central role in insulin signaling, particularly in skeletal muscle, thus enhancing overall metabolic function.**
4. **G33764 | Score: 4.0 | As a primary driver in metabolic regulation, its role in lipid metabolism is relevant for muscle tissue, supporting improved insulin sensitivity and metabolic control.**
5. **G04436 | Score: 4.0 | This enzyme enhances glucose metabolism in muscle, potentially improving insulin sensitivity, thus supporting the overall therapeutic strategy aimed at metabolic control.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis focuses on the specific modulation of insulin signaling pathways in skeletal muscle to enhance treatment efficacy for Type 2 Diabetes. By targeting G22553 as the primary focus, alongside G19122, G19943, G33764, and G04436, we aim to improve insulin sensitivity and metabolic function directly within muscle tissue, which is integral to glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism
- WGCNA module role: Primary Driver (G22553), Major Regulator (G19122), Hub Component (G19943), Primary Driver (G33764)
- Regulating TFs: None identified, but potential for regulatory interactions exists

**MECHANISM_HYPOTHESIS:** The activation of G22553 is anticipated to significantly enhance insulin receptor signaling and glucose uptake in skeletal muscle, directly addressing the impaired insulin sensitivity characteristic of Type 2 Diabetes. G19122 will aid in restoring metabolic balance in muscle tissue, while G19943 will further enhance insulin signaling pathways. Additionally, G33764 will regulate lipid metabolism, and G04436 will support glucose metabolism, ensuring a comprehensive approach focused on muscle tissue.

**TISSUE_RATIONALE:** Skeletal muscle is a primary site for glucose disposal and plays a crucial role in maintaining glucose homeostasis. Targeting this tissue will directly influence insulin sensitivity and overall metabolic health in individuals with Type 2 Diabetes, offering a focused approach to therapy.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets using small molecules designed to enhance their activity in skeletal muscle, thereby restoring normal metabolic function and improving insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is expected to significantly enhance insulin sensitivity in skeletal muscle, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, ultimately leading to better clinical outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, strong evidence from multiple datasets, and their critical roles in insulin signaling and glucose metabolism specifically within skeletal muscle. G22553 was selected as the primary target due to its central role in enhancing insulin receptor signaling, while G19122, G19943, G33764, and G04436 were included for their complementary effects on metabolic regulation in the same tissue.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:15:06,650 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:15:06,650 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:15:06,650 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:15:06,651 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:15:06,651 - root - INFO -   -> Created mutated offspring: '** Tissue-Specific Modulation of Insulin...'
2026-02-10 20:15:06,651 - root - INFO - Crossover 16/18: parents '** Comprehensive Modulation of...' x '** Comprehensive Modulation of...'
2026-02-10 20:15:06,683 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:15:38,182 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:15:38,184 - root - INFO - TOKEN_USAGE: input=40363, output=763, total=41126, cost=$0.006512
2026-02-10 20:15:38,184 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:15:38,184 - root - INFO - 
**TITLE:** Enhanced Multi-Targeted Strategy for Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene serves as a hub component in insulin signaling networks and is pivotal for enhancing insulin sensitivity, making it a top priority target.**
2. **G04436 | Score: 4.0 | As a significant regulator of glucose homeostasis, this enzyme complements G19943 and supports metabolic regulation, crucial for effective T2D management.**
3. **G22553 | Score: 4.0 | This primary driver in T2D pathways enhances insulin receptor signaling and glucose uptake, providing a synergistic effect with G19943 and G04436.**
4. **G33764 | Score: 4.0 | Involved in insulin resistance mechanisms, its modulation is essential to address metabolic dysregulation in T2D, supporting the overall therapeutic strategy.**
5. **G19122 | Score: 3.0 | A major regulator in insulin signaling pathways, its inclusion can further enhance metabolic balance and support the action of primary targets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a robust multi-targeted therapeutic approach that synergistically modulates G19943, G04436, G22553, G33764, and G19122 to enhance insulin sensitivity and restore glucose homeostasis in Type 2 Diabetes. By leveraging the strengths of the parent hypotheses and addressing potential weaknesses, this strategy aims to provide a comprehensive solution to T2D management.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation
- WGCNA module role: G19943 and G33764 identified as hub components in relevant modules
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The activation of G19943 is expected to enhance its function within insulin signaling pathways, leading to improved insulin sensitivity and glucose metabolism. Concurrently, modulating G04436 will regulate metabolic pathways through its enzymatic activity, while G22553 will facilitate glucose uptake. Targeting G33764 will further mitigate insulin resistance, and G19122 will strengthen insulin signaling pathways, promoting a coordinated therapeutic effect for T2D.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include pancreatic -cells, muscle, and liver, as they are critical for glucose metabolism and insulin action, making them optimal candidates for intervention in T2D management.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The coordinated modulation of these targets is anticipated to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The selected targets were ranked based on their high priority scores, strong roles in key biological pathways, and the robustness of the supporting evidence. G19943 was chosen as the primary target due to its central role in insulin signaling, with G04436 and G22553 following for their significant contributions to metabolic regulation. G33764 and G19122 were included to further address insulin resistance and support insulin signaling pathways, enhancing the efficacy of the therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:15:38,188 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:15:38,188 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:15:38,188 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:15:38,189 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:15:38,189 - root - INFO -   -> Created offspring: '** Enhanced Multi-Targeted Strategy for ...'
2026-02-10 20:15:38,190 - root - INFO - Crossover 17/18: parents 'Integrated Multi-Target Approa...' x 'Enhanced Multi-Target Strategy...'
2026-02-10 20:15:38,234 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:16:15,261 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:16:15,267 - root - INFO - TOKEN_USAGE: input=40322, output=683, total=41005, cost=$0.006458
2026-02-10 20:16:15,268 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:16:15,268 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity and Metabolic Control in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Central hub in insulin signaling; supports multiple pathways relevant to glucose and lipid metabolism.
2. **G23245** | Score: 4.0 | Primary driver for glucose uptake and insulin sensitivity, complementing G19943 in metabolic regulation.
3. **G22553** | Score: 4.0 | Enhances glucose metabolism and synergizes with G19943, providing additional metabolic control.
4. **G33764** | Score: 4.0 | Critical enzyme involved in metabolic regulation, supporting the overall therapeutic efficacy of the combination.
5. **G04436** | Score: 4.0 | Enzyme that enhances metabolic regulation, adding depth to the multi-target strategy.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis combines insights from both parent hypotheses, emphasizing G19943 as a central hub in insulin signaling and metabolic pathways, while integrating G23245, G22553, and G33764 to create a robust multi-target strategy. This approach aims to enhance insulin sensitivity and metabolic control, addressing the complexities of Type 2 Diabetes management.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation.
- WGCNA module role: G19943 is a hub component in modules negatively correlated with T2D.
- Regulating TFs: None identified, but targets have synergistic interactions.

**MECHANISM_HYPOTHESIS:** The proposed mechanism suggests that G19943 acts as a pivotal regulator, orchestrating insulin signaling and lipid metabolism. G23245 enhances glucose uptake, while G22553 improves insulin sensitivity through its enzymatic action. G33764 supports the regulation of key metabolic pathways, providing a comprehensive therapeutic strategy that addresses both glucose and lipid homeostasis in Type 2 Diabetes.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, liver, muscle, and adipose tissue, all of which are critical for insulin action, glucose uptake, and lipid metabolism. Targeting these tissues is essential for effective therapeutic interventions in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy involves the small molecule activation of G19943 and G22553 to enhance their functions, complemented by modulation of G23245 and G33764 for improved metabolic outcomes.

**PREDICTED_OUTCOME:** Effective modulation of the primary target and its associated pathways is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, providing a comprehensive therapeutic benefit for managing Type 2 Diabetes.

**RANKING_RATIONALE:** G19943 is ranked highest due to its central role in insulin signaling and its strong support across datasets. G23245 follows as it provides essential support for glucose uptake, while G22553 adds crucial metabolic enhancement. G33764 contributes additional regulatory depth, ensuring a robust multi-target strategy.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:16:15,269 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:16:15,270 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:16:15,270 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:16:15,272 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:16:15,273 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy for ...'
2026-02-10 20:16:15,273 - root - INFO - Crossover 18/18: parents '** Comprehensive Modulation of...' x '** Integrated Modulation of G1...'
2026-02-10 20:16:15,306 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:16:58,529 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:16:58,535 - root - INFO - TOKEN_USAGE: input=40382, output=773, total=41155, cost=$0.006521
2026-02-10 20:16:58,535 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:16:58,535 - root - INFO - 
**TITLE:** Synergistic Modulation of Insulin Signaling and Metabolic Pathways in Type 2 Diabetes through Multi-Targeted Gene Therapy

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene is a central hub in insulin signaling networks, making it crucial for enhancing insulin sensitivity and overall metabolic regulation.**
2. **G33764 | Score: 4.0 | This enzyme plays a significant role in modulating metabolic pathways, complementing G19943 by enhancing glucose metabolism and improving insulin sensitivity.**
3. **G04436 | Score: 4.0 | As an important enzyme in glucose homeostasis, G04436 works synergistically with G19943 and G33764 to optimize metabolic control and address insulin resistance.**
4. **G22553 | Score: 4.0 | This gene is a primary driver in insulin receptor signaling pathways, facilitating glucose uptake and enhancing the effectiveness of the therapeutic strategy.**
5. **G19122 | Score: 3.0 | A major regulator in insulin signaling pathways, G19122 can further restore metabolic balance by enhancing the effects of the primary targets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-targeted strategy to enhance insulin sensitivity and metabolic regulation in Type 2 Diabetes by synergistically modulating G19943, G33764, G04436, G22553, and G19122. By leveraging the strengths of these high-priority targets, the approach aims to more effectively address the multifaceted nature of T2D pathology than previous hypotheses.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation
- WGCNA module role: G19943 identified as a hub component in relevant modules
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The activation of G19943 is hypothesized to enhance its function within insulin signaling pathways, directly addressing insulin resistance and improving glucose metabolism. Modulating G33764 will regulate key metabolic pathways, while G04436 will facilitate glucose uptake and further improve insulin sensitivity. Targeting G22553 will support insulin receptor signaling, and G19122 will reinforce insulin signaling pathways, creating a robust therapeutic strategy for T2D management.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include pancreatic -cells, muscle, and liver, as they are critical for glucose metabolism and insulin action, making them ideal candidates for therapeutic intervention in T2D management.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The coordinated modulation of these targets is expected to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control in patients with Type 2 Diabetes, potentially leading to a reversal of disease progression.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, critical roles in relevant biological pathways, and the robustness of the supporting evidence. G19943 was prioritized as the primary target due to its central role in insulin signaling. G33764 and G04436 were included next for their significant contributions to metabolic regulation, while G22553 and G19122 were included to further enhance the understanding and treatment of metabolic dysregulation in T2D.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:16:58,537 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:16:58,537 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:16:58,537 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:16:58,540 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:16:58,540 - root - INFO -   -> Created offspring: '** Synergistic Modulation of Insulin Sig...'
2026-02-10 20:16:58,541 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 20:16:58,541 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 20:16:58,541 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 20:16:58,541 - root - INFO - Evaluating fitness for hypothesis: t2d-05-a66047a3
2026-02-10 20:17:09,126 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:17:09,129 - root - INFO - TOKEN_USAGE: input=1432, output=617, total=2049, cost=$0.000585
2026-02-10 20:17:09,129 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:17:09,129 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is present in the top priority list, along with other ranked targets including G22553, G33764, G23245, and G00484, all of which have a score of 4.0. There is cross-dataset consistency as evidenced by the data supporting G19943's role as a hub in T2D pathways, and multiple evidence types support its involvement in insulin signaling.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, as all targets have equal scores and are backed by their established roles in insulin signaling and metabolic pathways. The rationale clearly outlines the complementary nature of the targets, though the absence of a clear distinction between the strength of higher-ranked and lower-ranked targets slightly affects the score.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with the pathways involved in Type 2 Diabetes. The role of G19943 as a central coordinator in insulin signaling is well-supported, and the tissue rationale involving pancreatic -cells, muscle, liver, and adipose tissue is substantiated by their known functions in diabetes. The inclusion of transcription factors adds depth to the mechanism.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets is appropriate given their roles in enhancing insulin sensitivity. The targets are indeed likely druggable based on their network positions. However, while the safety considerations are not explicitly mentioned, potential off-target effects in a multi-target strategy should be noted, which slightly lowers the score.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative manner by proposing a multi-target strategy that combines insights from multiple pathways. However, the connections made, while valuable, do not appear entirely non-obvious within the context of existing diabetes research.

**OVERALL_FITNESS:** 7.6 (76.0)  

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Clarify Drug Safety Profile:** Expand on safety considerations for the multi-target approach, including potential off-target effects and strategies for mitigating risks.
2. **Differentiate Target Strengths:** Provide additional data or rationale to differentiate the relative strengths of ranked targets, particularly for those with the same score.
3. **Address Novelty:** Consider integrating a discussion on existing therapies and how this multi-target approach might provide advantages, enhancing the novelty aspect of the hypothesis.
4. **Explore Alternative Pathways:** Investigate and discuss additional pathways that could be targeted in conjunction with the proposed targets to enhance therapeutic outcomes, which could further strengthen the rationale for the multi-target strategy.
2026-02-10 20:17:09,130 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:17:09,130 - root - INFO - Evaluating fitness for hypothesis: t2d-05-b2b75cf6
2026-02-10 20:17:26,328 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:17:26,329 - root - INFO - TOKEN_USAGE: input=1539, output=810, total=2349, cost=$0.000717
2026-02-10 20:17:26,329 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:17:26,329 - root - INFO - 
### EVALUATION OF HYPOTHESIS: Comprehensive Multi-Target Approach for Enhanced Management of Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a Priority Score of 4/17, indicating it is within a high-priority range. However, there is only one dataset supporting this target, and it lacks cross-dataset consistency, which reduces its robustness. While the other targets also scored high, the lack of diverse evidence for G19943 affects the overall data support.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the established roles of the targets in insulin signaling and metabolic pathways. G19943 is appropriately prioritized as the core target due to its central hub role. However, all targets are ranked equally, which may not reflect the nuanced differences in their evidence strength and functional roles, suggesting a need for clearer distinctions in ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the identified pathways and tissues relevant to T2D, emphasizing the roles of G19943 and its complementary targets in insulin signaling and metabolic regulation. The tissue rationale is well-supported, and while the relationships with transcription factors were mentioned, further exploration of these interactions would strengthen the mechanistic coherence.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553, along with modulating G04436 and G23245, is appropriate and aligns with the goals of enhancing insulin sensitivity and metabolic control. The potential for druggability is implied, but the absence of specific safety considerations and the need for further validation in clinical contexts could be better addressed.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a way that addresses the complexity of T2D management, which is commendable. However, the connections made between targets are somewhat conventional in the context of T2D therapies, lacking truly novel insights or unexpected connections that would elevate the novelty score.

### OVERALL_FITNESS: 
**Calculation:** 
Overall Fitness = (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)  
Overall Fitness = (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85  
**Scaled to 0-100: Overall Fitness = 68.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Seek additional datasets to validate the role of G19943 and other targets to improve cross-dataset consistency.
2. **Refine Ranking Criteria:** Differentiate targets based on evidence strength and functional roles rather than assigning equal scores, which would provide a clearer hierarchy.
3. **Expand Mechanistic Insights:** Include more detailed exploration of transcription factor interactions and their roles in the proposed mechanisms for better mechanistic understanding.
4. **Address Safety Considerations:** Detail potential side effects or safety issues associated with the proposed therapeutic approach to strengthen the therapeutic rationale.
5. **Innovative Connections:** Highlight any non-obvious connections or novel insights in the multi-target approach to increase the novelty score.
2026-02-10 20:17:26,330 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:17:26,330 - root - INFO - Evaluating fitness for hypothesis: t2d-05-4052b7eb
2026-02-10 20:17:44,458 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:17:44,464 - root - INFO - TOKEN_USAGE: input=1408, output=823, total=2231, cost=$0.000705
2026-02-10 20:17:44,464 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:17:44,465 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is ranked highest with a score of 4.0, and there is cross-dataset consistency evident in two datasets. However, there is a warning that the target gene is not found in the top priority list, which affects the overall robustness of the data support. The evidence types supporting the primary target are limited; thus, the score reflects a moderate level of data support.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their roles in insulin signaling and metabolic regulation. However, the similarity in scores (4.0) among the top five targets creates ambiguity regarding the clear strength of each target compared to the others. While G19943 is identified as a hub, the rationale for the specific ranking of the other targets could be more clearly articulated to distinguish their relative importance.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the established pathway context of insulin signaling and lipid metabolism. The tissue rationale is sound, focusing on pancreatic -cells, liver, muscle, and adipose tissue, as these are critical for managing T2D. However, the absence of identified regulatory transcription factors (TFs) may limit the mechanistic understanding slightly.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach involving small molecule activation appears appropriate for enhancing insulin sensitivity and metabolic function. The identification of the targets as likely druggable based on their network positions is a positive aspect. Safety considerations could be further elaborated, particularly concerning potential off-target effects or interactions among the multiple targets.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets in a multi-target strategy, which is a creative approach to addressing T2D. It proposes connections between insulin signaling and lipid metabolism that are relevant but could benefit from a more thorough exploration of how these connections are novel compared to existing treatments.

### Overall Fitness Calculation
Overall Fitness = (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)  
= (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (7 * 0.10)  
= 1.5 + 1.75 + 1.6 + 1.4 + 0.7  
= 6.95 (scaled to 0-100 is approximately 69.5)

### Final Assessment
**OVERALL_FITNESS: 69.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **MODERATE**
- Target #3 quality: **MODERATE**

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Increase the number and types of evidence supporting the primary target and associated targets. This could include additional datasets or experimental validation.
2. **Clarify Ranking Justification:** Provide more detailed explanations on why certain targets are prioritized over others, particularly for those with equal scores.
3. **Explore Regulatory TFs:** Investigate potential regulatory transcription factors that may interact with the targets to strengthen mechanistic insights.
4. **Expand on Safety Considerations:** Provide a more comprehensive analysis of safety profiles for proposed therapeutic approaches, including potential side effects or drug interactions.
5. **Highlight Novelty:** Emphasize the unique aspects of the proposed connections and multi-target strategy compared to existing therapies. Consider including literature comparisons to strengthen the novelty claim.
2026-02-10 20:17:44,466 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:17:44,467 - root - INFO - Evaluating fitness for hypothesis: t2d-05-fd5d26e7
2026-02-10 20:17:59,810 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:17:59,813 - root - INFO - TOKEN_USAGE: input=1436, output=812, total=2248, cost=$0.000703
2026-02-10 20:17:59,813 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:17:59,813 - root - INFO - 
### Evaluation of the Hypothesis: Targeting G22553 for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### DATA_SUPPORT_SCORE: 8
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is ranked highly (3rd) in the provided top priority list, indicating it is recognized as a significant target for Type 2 Diabetes management. Cross-dataset consistency is confirmed, with support from two datasets. However, the warning about G22553 not being found in the top priority list could indicate a lack of robust support across other evaluations.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of the targets appears justified based on their roles in insulin signaling and metabolic regulation. However, all ranked targets share the same score (4.0), which may limit clarity in distinguishing their relative strengths. The rationale for prioritizing G22553 is sound, but the lack of differentiation among the other targets weakens the overall ranking quality.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism for G22553 enhancing insulin signaling aligns well with the known pathways of insulin action. The tissue rationale is supported by the involvement of pancreatic -cells, muscle, liver, and adipose tissue in glucose metabolism and insulin sensitivity. The lack of identified transcription factors for G22553 is a slight gap, but the inclusion of G00484 as a regulator mitigates this concern.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and modulating other targets is appropriate considering their roles in insulin signaling and metabolism. However, the evaluation should also consider possible druggability and safety of modulating these targets, which is less clearly addressed. Further exploration into the druggability of G22553 and its interactions with the other targets is needed for a comprehensive evaluation.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis does integrate data in a creative way by proposing a multi-target strategy that addresses the multifactorial nature of Type 2 Diabetes. However, targeting G22553 itself may not represent a particularly novel approach, as it is already recognized in the literature. The connections made between the various targets are logical but might not be groundbreaking.

#### OVERALL_FITNESS: 7.2
**Calculated Score:** (8*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.2

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G22553 is well-supported and a primary driver)
- Target #2 quality: **STRONG** (G23245 complements G22553s role effectively)
- Target #3 quality: **STRONG** (G19943 is a central hub in insulin signaling)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Distinction in Rankings**: Consider using additional criteria to distinguish between targets with the same score. This could involve deeper analysis of their unique contributions or secondary effects in insulin signaling pathways.
   
2. **Clarify Druggability and Safety**: Provide more detailed assessments of the druggability of G22553 and the other targets, along with potential safety concerns related to the therapeutic approach proposed.

3. **Expand on Transcription Factor Interactions**: Investigate additional transcription factors that may interact with G22553 and its associated pathways to strengthen the mechanistic hypothesis.

4. **Validate with More Datasets**: Seek additional datasets to further validate the roles of G22553 and the other ranked targets, enhancing the robustness of the hypothesis. 

5. **Explore Novel Mechanisms**: Consider proposing or investigating more innovative mechanisms that may arise from the interaction of the targets, to enhance the novelty of the overall hypothesis.
2026-02-10 20:17:59,814 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:17:59,814 - root - INFO - Evaluating fitness for hypothesis: t2d-05-d7bae3d4
2026-02-10 20:18:16,095 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:18:16,102 - root - INFO - TOKEN_USAGE: input=1472, output=710, total=2182, cost=$0.000647
2026-02-10 20:18:16,102 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:18:16,102 - root - INFO - 
**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is found in the top priority list, along with G04436 and G22553, which also have high scores. There is cross-dataset consistency for the primary target, supported by two datasets. However, the overall score is limited by the absence of G23245 and G27976 in the top 10 priority genes. 

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, with G19943, G22553, and G04436 all being key players in insulin signaling and metabolic pathways. However, the absence of information on the relative strength of G23245 and G27976 compared to other potential targets detracts from the clarity of the ranking.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and metabolic pathways relevant to T2D. The tissue rationale is strong, focusing on critical tissues for insulin action. Furthermore, potential interactions with transcription factors that regulate these pathways are considered, enhancing the overall coherence of the mechanism.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553, along with modulating G04436, is appropriate. These targets are positioned well within metabolic networks for drug development. However, details regarding the safety of targeting these genes are not elaborated on, which could impact the overall therapeutic potential.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a meaningful way, proposing a multi-target approach that is somewhat creative. However, the connections made to lesser-known targets (G23245 and G27976) may not be entirely novel, as these targets have not been highlighted extensively in the context of T2D management in prior research.

**OVERALL_FITNESS: 6.6**  
**Calculated: (5*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 6.6**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG** (G19943 is well-supported and central to insulin signaling)  
- Target #2 quality: **STRONG** (G22553 complements G19943s function effectively)  
- Target #3 quality: **MODERATE** (G04436 is important but needs further justification for its role compared to others in the top tier)

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Data Evidence:** Include more comprehensive evidence for G23245 and G27976 to strengthen their justification and potentially elevate their ranking.  
2. **Clarify Safety Considerations:** Elaborate on safety and potential side effects of targeting the proposed genes to enhance the therapeutic potential section.  
3. **Strengthen Rationale for Lower-ranked Targets:** Provide more data or rationale for the selection of G23245 and G27976, perhaps through literature support or additional experimental data to solidify their roles in T2D management.  
4. **Explore Additional Pathways:** Consider investigating other metabolic pathways that could be impacted by these targets to broaden the understanding of their roles in T2D.
2026-02-10 20:18:16,103 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:18:16,103 - root - INFO - Evaluating fitness for hypothesis: t2d-05-01f0da6f
2026-02-10 20:18:32,682 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:18:32,685 - root - INFO - TOKEN_USAGE: input=1499, output=637, total=2136, cost=$0.000607
2026-02-10 20:18:32,685 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:18:32,685 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is present in the top priority list, but evidence indicates that some ranked targets are not. While there is cross-dataset consistency for the primary target, the overall support for the ranked targets is diminished due to the absence of some in the top 10 priority genes. In total, there is robust evidence supporting the primary target but limited evidence for the other targets as they are not all recognized as top-tier.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is somewhat justified based on high priority scores, but it lacks complete consistency since not all ranked targets are in the top priority tier. The rationale provided shows that the targets have critical roles in pathways relevant to T2D, but the lack of some targets in the top list weakens the overall justification.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the insulin signaling and metabolic pathways associated with the identified targets. The tissue rationale is well-supported, focusing on key tissues involved in glucose metabolism. The mention of transcription factors adds depth to the mechanistic understanding, enhancing the overall coherence.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets is appropriate given their roles in improving insulin sensitivity and metabolic function. However, the potential druggability of all targets is not explicitly discussed, and safety considerations could be elaborated further to strengthen this aspect of the hypothesis.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** While the hypothesis integrates various targets in a creative way, the connections made are somewhat conventional in the context of diabetes research. The idea of utilizing multi-targeted gene therapy is not entirely novel, although the specific combination of targets may offer some innovative perspectives.

**OVERALL_FITNESS: 6.75**  
(Calculated as: 6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.75)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: WEAK  
- Target #3 quality: WEAK  

**IMPROVEMENT_SUGGESTIONS:**  
1. Ensure that all targets included in the hypothesis are present in the top priority gene list to enhance data support. Consider revising the target selection or providing more evidence for the inclusion of G22553 and G33764.
2. Elaborate on the druggability and safety considerations of each target, potentially providing examples of small molecules or therapeutic strategies that could be utilized.
3. Include more innovative angles or novel connections within the hypothesis to enhance its novelty score, potentially exploring less conventional pathways or mechanisms in T2D therapy.
2026-02-10 20:18:32,685 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:18:32,686 - root - INFO - Evaluating fitness for hypothesis: t2d-05-cceb9e7a
2026-02-10 20:18:49,173 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:18:49,179 - root - INFO - TOKEN_USAGE: input=1529, output=832, total=2361, cost=$0.000729
2026-02-10 20:18:49,180 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:18:49,180 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: **6**
**DATA_SUPPORT_RATIONALE:** 
The primary target (G19943) has a priority score of 4.0/17, which is competitive but not at the very top of the priority list. There is cross-dataset consistency noted in the overall hypothesis, but not specifically for G19943, which has only 1 dataset supporting it. The limited number of pathways associated with G19943 also detracts from its data support. Thus, while the data backing the multi-target approach is reasonable, the individual support for G19943 is weaker.

#### RANKING_QUALITY_SCORE: **7**
**RANKING_QUALITY_RATIONALE:** 
The ranking is generally justified as all targets are equally scored at 4.0, indicating a strong importance in T2D pathways. Higher-ranked targets are defined in relation to their roles in insulin signaling and metabolic regulation, but the lack of distinct differentiation between the scores suggests that the ranks may not reflect a clear hierarchy in strength. However, the rationale for prioritizing G19943 as a central hub is sound.

#### MECHANISTIC_SCORE: **8**
**MECHANISTIC_RATIONALE:** 
The proposed mechanism is coherent with the insulin signaling pathways and metabolic context. The tissue rationale aligns well with the known roles of pancreatic -cells, muscle, liver, and adipose tissue in T2D. The inclusion of G00484 as a transcription factor regulating insulin signaling is a valuable addition that supports the overall mechanism, contributing to a strong mechanistic coherence.

#### THERAPEUTIC_SCORE: **7**
**THERAPEUTIC_RATIONALE:** 
The proposed therapeutic approach of small molecule activation for G19943 and G22553 is appropriate given their roles in insulin sensitivity. However, the overall druggability of these targets has not been thoroughly assessed, which is a critical consideration for potential therapeutic interventions. While the targets are positioned well within the network, safety considerations and potential off-target effects should be evaluated in further studies.

#### NOVELTY_SCORE: **6**
**NOVELTY_RATIONALE:** 
The hypothesis integrates multiple targets in a systematic manner, which is relatively novel in the context of T2D therapy. However, the connections proposed among the targets are not entirely non-obvious, as the roles of insulin signaling and glucose metabolism are well-established. Hence, while there is creativity in the multi-target approach, it lacks a groundbreaking element that would elevate its novelty score.

### OVERALL_FITNESS: **6.5**
**Calculated Score:** 
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.5

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support for G19943:** Seek additional datasets to validate the role of G19943 as a central hub in T2D pathways. Cross-dataset validation would enhance confidence in its therapeutic potential.
   
2. **Differentiate Target Rankings:** Further refine the ranking system to establish clearer distinctions between targets, potentially based on additional evidence types or functional assays to determine which targets have the most robust effects.

3. **Evaluate Druggability and Safety:** Conduct a thorough assessment of the druggability of the targets and potential safety profiles to ensure that the proposed therapeutic approach is viable in practical applications.

4. **Expand Pathway Analysis:** Investigate additional pathways that may involve the ranked targets to strengthen the mechanistic rationale and provide insight into potential off-target effects and interactions.

5. **Explore Novel Mechanisms:** Consider integrating emerging data or novel findings about the roles of these targets in T2D that could enhance the creativity and originality of the hypothesis.
2026-02-10 20:18:49,181 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:18:49,182 - root - INFO - Evaluating fitness for hypothesis: t2d-05-085271b0
2026-02-10 20:19:06,985 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:19:06,987 - root - INFO - TOKEN_USAGE: input=1422, output=733, total=2155, cost=$0.000653
2026-02-10 20:19:06,987 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:19:06,987 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G00484 is in the top priority list, which is a strong point. Additionally, there is consistency across two datasets for the primary target. However, the warning regarding the absence of G22512 from the top priority list raises some concerns, as it is crucial to the hypothesis. The number of evidence types supporting the primary target is adequate, but the exclusion of G22512 from the top tier affects the overall confidence.

---

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the evidence presented, particularly for G00484 and G22512. However, the rationale for G22512's placement is weakened by its absence in the top priority genes, which could indicate potential oversight in evaluating its significance compared to other targets. The differentiation between the ranks of G19122, G33764, and G22553 is somewhat less clear, suggesting that there may be a lack of strong justification for their specific placements.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways, which are highly relevant to Type 2 Diabetes. The tissue rationale focusing on pancreatic -cells and muscle is well-supported, as these are critical for insulin action. However, the mention that no regulating transcription factors were identified could be seen as a gap in understanding the broader regulatory network.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets with small molecules is appropriate for enhancing metabolic function and improving insulin sensitivity in T2D. The expected outcomes align well with the pathophysiology of the disease. However, potential safety considerations surrounding the modulation of these targets should be more explicitly addressed, which could enhance the therapeutic score.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by targeting both a transcription factor and a key signaling pathway component. However, the connections made could be seen as somewhat conventional given that both G00484 and G22512 are already known in the context of metabolic control, hence the score reflects a moderate level of novelty rather than high.

---

**OVERALL_FITNESS:** 6.85 (rounded to 69)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG** (G00484 is well-supported and critical)
- **Target #2 quality: MODERATE** (G22512 is essential, but its absence from top priority affects its quality)
- **Target #3 quality: MODERATE** (G19122 has supporting evidence but is less compelling than the top two)

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess G22512:** Investigate the reasons for G22512s absence from the top priority list and consider its inclusion based on its critical role in insulin signaling.
2. **Expand Evidence:** Enhance the evidence base for G00484 and G22512 by exploring additional datasets or biological contexts that support their roles in metabolic pathways.
3. **Clarify Mechanistic Insights:** Identify and include any regulating transcription factors that may interact with G00484 to provide a more comprehensive understanding of the regulatory network.
4. **Address Safety Considerations:** Explicitly outline potential safety issues related to targeting these pathways and how they might be mitigated in the therapeutic development process.
2026-02-10 20:19:06,987 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:19:06,987 - root - INFO - Evaluating fitness for hypothesis: t2d-05-da6eaab5
2026-02-10 20:19:21,722 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:19:21,728 - root - INFO - TOKEN_USAGE: input=1446, output=698, total=2144, cost=$0.000636
2026-02-10 20:19:21,728 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:19:21,729 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, has a high priority score but is not found in the top 10 priority genes, which raises concerns about its relevance. However, there is cross-dataset consistency for top-ranked targets and strong evidence for the primary target from multiple datasets. The score reflects the strong evidence for the other ranked targets but is lowered due to the absence of G19943 in the top priority list.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the scores and the roles of the targets in key biological pathways. However, the presence of G19943 in the primary target position without being in the top 10 priority list creates a discrepancy. The rationale for the ranking is mostly sound, with higher-ranked targets showing strong evidence, but the inconsistency affects the overall judgment.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the involvement of the targets in insulin signaling, glucose metabolism, and lipid metabolism. The tissue rationale is supported by evidence of these tissues being critical for insulin action. The identification of transcription factors related to G04436 strengthens the mechanistic coherence.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators appears appropriate, as the targets are central to metabolic regulation. The interconnected nature of the targets suggests that they are likely druggable. However, safety considerations should be evaluated rigorously due to the complexity of metabolic pathways.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a creative way and proposes a multi-target strategy to address T2D. This is a non-obvious connection as it considers the synergistic effects of targeting multiple pathways rather than focusing on a singular approach.

**OVERALL_FITNESS: 7.3**
**Calculated:** (6 * 0.25 + 7 * 0.25 + 8 * 0.20 + 8 * 0.20 + 7 * 0.10) = 7.3

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: **MODERATE** (G19943 is a central hub but is not found in the top priority list)
- Target #2 quality: **STRONG** (G22553 is well-supported and critical for insulin signaling)
- Target #3 quality: **STRONG** (G33764 shows robust evidence for its role in metabolic regulation)

**IMPROVEMENT_SUGGESTIONS:**
1. **Re-evaluate G19943's Priority:** Investigate the reasons for G19943's absence from the top priority gene list and consider re-evaluating its role based on additional evidence or data integration.
2. **Expand Data Sources:** Consider incorporating more datasets or evidence types to strengthen the overall support for G19943 and the other targets.
3. **Clarify Safety Profiles:** Provide more detail on the safety considerations of the therapeutic approach, including potential side effects of modulating these pathways.
4. **Enhance Mechanistic Insights:** Explore additional mechanistic insights regarding the interactions among the targets, particularly how they might influence each other's functions in the context of insulin sensitivity and metabolic control.
2026-02-10 20:19:21,730 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:19:21,731 - root - INFO - Evaluating fitness for hypothesis: t2d-05-22e5f6e9
2026-02-10 20:19:32,972 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:19:32,979 - root - INFO - TOKEN_USAGE: input=1458, output=637, total=2095, cost=$0.000601
2026-02-10 20:19:32,980 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:19:32,980 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G22553, is present in the top priority list and has a strong score of 4.0. However, it is noted that the warning indicates that G22553 was not found in the top priority list, which impacts the overall data support. There is cross-dataset consistency noted for the targets, and multiple evidence types support G22553, but the overall inconsistency lowers the score.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as G22553 is a primary driver in insulin signaling. The rationale behind the ranking of G19943 as a hub component is also strong. The distinctions between the targets are clear, with higher-ranked targets having well-supported roles. However, the warning about G22553 not being in the top priority list creates some concern about the overall ranking validity.

---

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context. The role of muscle tissue in glucose uptake and energy metabolism is well-supported. The hypothesized interactions between the targets and the involvement of transcription factors are clearly articulated, enhancing the coherence of the mechanism.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation seems appropriate, and the proposed targets are likely druggable based on their network positions. However, safety considerations are not explicitly addressed, potentially limiting the score.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a creative manner, focusing on a synergistic approach to enhance insulin sensitivity. The connections made between the targets are logical, but they do not seem to represent particularly non-obvious innovations in the context of Type 2 Diabetes treatment.

---

**OVERALL_FITNESS:** 7.1  
**Calculated:** (6 * 0.25 + 8 * 0.25 + 9 * 0.20 + 7 * 0.20 + 7 * 0.10) = 7.1

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **STRONG**  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Clarify Data Validity:** Address the inconsistency noted regarding G22553's presence in the top priority list to strengthen the data support section. 
2. **Detail Safety Considerations:** Include an explicit discussion of potential safety issues and side effects related to the activation of the targets, which could impact therapeutic potential.
3. **Expand on Novelty:** Highlight any unique aspects of the approach or any unconventional relationships between the targets that may not be immediately apparent to strengthen the novelty score. 

These improvements could enhance the overall evaluation and robustness of the hypothesis.
2026-02-10 20:19:32,981 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:19:32,982 - root - INFO - Evaluating fitness for hypothesis: t2d-05-a2440411
2026-02-10 20:19:44,466 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:19:44,470 - root - INFO - TOKEN_USAGE: input=1386, output=709, total=2095, cost=$0.000633
2026-02-10 20:19:44,470 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:19:44,470 - root - INFO - 
### Evaluation of the Hypothesis: Exploring G22553 as a Novel Target for Type 2 Diabetes Therapy

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** G22553 is indeed in the top priority list, scoring a 4.0, and demonstrating strong evidence across two datasets, which supports its relevance. However, it is noted that while G22553 is important, there is a lack of clarity on the number of evidence types supporting it beyond dataset correlations, leading to a slightly lower score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the strength of the correlation with T2D and the rationale provided. G22553 ranks highest due to its prominent role in the black module, with G19122 and G27976 following as they also have significant relevance in insulin signaling. The rationale for ranking is clear, with distinctions made based on biological significance and evidence strength.

**MECHANISTIC_SCORE: 7**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known insulin signaling pathways, which is essential for T2D. The tissue rationale is appropriately focused on skeletal muscle and adipose tissue, where insulin sensitivity is critical. However, the lack of reported regulating transcription factors (TFs) may limit the understanding of the regulatory landscape surrounding G22553, which affects the score.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 via small molecules is appropriate, aiming to enhance its function in insulin signaling. The assessment of druggability based on the gene's network position is reasonable; however, safety considerations are not explicitly addressed in the hypothesis, which is a crucial aspect for evaluating therapeutic potential.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis presents a novel approach by focusing on G22553, but it does not significantly deviate from established paradigms of targeting insulin signaling for T2D therapy. While it suggests potential pathways for intervention, the connections made are somewhat conventional, leading to a moderate score.

### Overall Fitness Calculation:
Overall Fitness = (7 * 0.25) + (8 * 0.25) + (7 * 0.20) + (8 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.75 + 2 + 1.4 + 1.6 + 0.6 = 7.35  
Scaled to 0-100: **73.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G22553):** STRONG
- **Target #2 quality (G19122):** STRONG
- **Target #3 quality (G27976):** MODERATE (due to slightly less evidence compared to the top two)

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Evidence:** Include additional types of evidence to support G22553 beyond dataset correlations, such as expression data, functional assays, or genetic studies.
2. **Address TF Relationships:** Investigate and report on potential transcription factors that may regulate G22553 to provide a clearer understanding of its regulatory mechanisms.
3. **Safety Considerations:** Include a discussion on the safety profile of activating G22553 and any potential off-target effects or adverse reactions associated with modulation.
2026-02-10 20:19:44,471 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:19:44,472 - root - INFO - Evaluating fitness for hypothesis: t2d-05-fe3c7f63
2026-02-10 20:20:04,015 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:20:04,020 - root - INFO - TOKEN_USAGE: input=1409, output=836, total=2245, cost=$0.000713
2026-02-10 20:20:04,021 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:20:04,021 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 5**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed ranked highest in the top priority list with a score of 4.0, along with several other targets like G04436 and G22553. However, the warning indicates that one target (G23245) is not found in the top priority list; hence some inconsistency is noted. There is cross-dataset consistency for the primary target, and it is supported by evidence from two datasets. Overall, while the primary target is strong, the absence of G23245 in the top list reduces the score.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data presented. G19943 is appropriately ranked highest based on its central role in insulin signaling and metabolic regulation. However, the rationale does not clearly delineate why G23245, which is crucial for glucose uptake, is missing from the top priority list despite its importance. The overall ranking logic is plausible, but the absence of G23245 in the top list raises questions about the ranking of the surrounding targets.

---

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The mechanism proposed aligns well with the known roles of the targets in insulin signaling and metabolic pathways. The tissue rationale is strong, focusing on pancreatic -cells, liver, muscle, and adipose tissue, which are indeed critical in T2D. However, the lack of identified regulating transcription factors (TFs) could be a limitation, as understanding TFs could enhance mechanistic clarity. Overall, the coherence is high, but the absence of TF considerations slightly detracts from the score.

---

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation and modulation appears appropriate, given the biological roles of the targets. The interconnectedness of the targets suggests a promising multi-target strategy. However, druggability is not explicitly discussed, and potential safety considerations are not mentioned, which could complicate the therapeutic potential. Thus, while the approach is sound, a more detailed exploration of these aspects is needed.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a multi-target approach to enhance insulin sensitivity and metabolic regulation, which is a creative strategy in T2D treatment. However, the connections between G23245 and the other targets are not thoroughly explored due to its absence from the top priority list, which could limit its novelty. While the hypothesis is innovative, it lacks some of the depth that could enhance its overall creative integration of data.

---

### OVERALL_FITNESS: 
Calculated as follows:
\[ 
\text{Overall Fitness} = (5 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 6.65 
\]
Scaled to 0-100 gives: 
\[ 
\text{Overall Fitness} = 66.5 
\]

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG**
- **Target #2 quality: WEAK** (due to absence in top priority list)
- **Target #3 quality: STRONG**

---

### IMPROVEMENT_SUGGESTIONS:
1. **Address Target Absence:** Ensure that all key targets, especially G23245, are included in the top priority list to avoid discrepancies and improve data consistency.
2. **Expand on TF Relationships:** Investigate and include potential transcription factors that may regulate the primary and secondary targets, as this could enhance the mechanistic understanding of the hypothesis.
3. **Detail Drugability and Safety:** Provide more comprehensive analysis on the druggability of the targets and potential safety concerns related to the proposed therapeutic approach to strengthen the therapeutic potential section.
2026-02-10 20:20:04,024 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:20:04,027 - root - INFO - Evaluating fitness for hypothesis: t2d-05-4630ca95
2026-02-10 20:20:19,485 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:20:19,488 - root - INFO - TOKEN_USAGE: input=1554, output=664, total=2218, cost=$0.000632
2026-02-10 20:20:19,488 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:20:19,488 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 5  
**DATA_SUPPORT_RATIONALE:** The primary target G33764 has a priority score of 4.0, placing it in the top tier of priority genes. However, it lacks cross-dataset consistency, indicating that data support might be limited. The evidence types are minimal (only 2), which dampens the overall strength of data support.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their roles in insulin signaling and metabolic regulation. G33764 is correctly identified as the primary target due to its master regulatory role, while G19122 and G20274 logically follow given their complementary functions. However, the lack of cross-dataset consistency slightly detracts from the strength of the ranking.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known roles of the targets in insulin signaling and lipid metabolism, and the rationale for focusing on adipose tissue is well-supported by its importance in T2D. However, the absence of detailed interactions with transcription factors limits the completeness of the analysis.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of using small molecule activators is appropriate, targeting the identified pathways to enhance insulin sensitivity. However, considerations about druggability and potential safety concerns need to be elaborated further to strengthen this evaluation.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates known targets in a relevant context for T2D, but the connections drawn may not be particularly novel given existing knowledge in the field. There is potential for creativity in the specific interactions and pathways proposed, but these are not fully explored.

### OVERALL_FITNESS: 
Calculated as follows:  
(5 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.25 + 1.75 + 1.6 + 1.4 + 0.6 = 6.0  
**Scaled to 0-100:** 60

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Aim to gather more datasets to validate the findings related to G33764 and its role in T2D. Cross-validation across multiple datasets will strengthen the hypothesis.
2. **Clarify Mechanistic Interactions:** Provide more detailed information on the interactions of G33764 with transcription factors and other signaling pathways to enhance the mechanistic coherence.
3. **Expand Safety Considerations:** Include a discussion on the potential side effects and safety profiles of the proposed small molecule activators to ensure a comprehensive therapeutic evaluation.
4. **Explore Novelty Further:** Investigate and highlight unique aspects of the proposed connections or any novel insights that emerge from the analysis to elevate the novelty of the hypothesis.
2026-02-10 20:20:19,489 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:20:19,489 - root - INFO - Evaluating fitness for hypothesis: t2d-05-97741e2a
2026-02-10 20:20:35,256 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:20:35,257 - root - INFO - TOKEN_USAGE: input=1572, output=703, total=2275, cost=$0.000658
2026-02-10 20:20:35,257 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:20:35,257 - root - INFO - 
### Evaluation

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a Priority Score of 4.0, which places it within the top priority tier; however, there is only one dataset supporting this target, and it lacks cross-dataset consistency. While there are two evidence types overall, the limited dataset support diminishes the robustness of the findings.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified as G19943 is highlighted as a hub component in T2D-related gene networks, making it a strong candidate. However, the similarity in scores (all at 4.0) suggests that distinguishing factors between targets could be better articulated. The rationale behind the ranking could be strengthened by providing more detailed evidence for why some targets are prioritized over others.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in insulin signaling and metabolic regulation. The tissue rationale is appropriate, focusing on muscle, liver, and pancreatic -cells, which are critical for glucose homeostasis. However, the absence of details about regulating transcription factors may limit the full understanding of the regulatory network involved.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule modulation for enhancing target activity is appropriate given the context of insulin sensitivity improvement. However, the assessment of druggability based on network position and potential safety considerations needs to be more thoroughly evaluated to strengthen this aspect.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis presents an integrated multi-target strategy, which is valuable; however, the connections between the targets are somewhat standard in the context of diabetes research. While it creatively combines insights, the uniqueness of the approach could be enhanced by introducing more novel connections or mechanisms.

### Overall Fitness Calculation
**OVERALL_FITNESS:**  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.65  
**Overall Fitness Score (scaled to 0-100):** 67  

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG** (G19943 is a hub component with significant evidence)
- **Target #2 quality: STRONG** (G23245 is a primary driver in insulin signaling)
- **Target #3 quality: STRONG** (G33764 complements metabolic pathways effectively)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Dataset Support:** Aim to gather additional datasets supporting G19943 to enhance its reliability and cross-dataset consistency.
2. **Clarify Ranking Rationale:** Provide a more detailed justification for the ranking of each target, especially for those with similar scores.
3. **Expand on Mechanism Details:** Include information regarding the transcription factors that regulate the target genes to improve understanding of the regulatory networks involved.
4. **Assess Drugability Thoroughly:** Conduct a comprehensive analysis of the druggability of each target based on their network positions and potential safety profiles.
5. **Highlight Novel Connections:** Explore and articulate more unique connections or mechanisms that differentiate this multi-target strategy from existing approaches.
2026-02-10 20:20:35,258 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:20:35,258 - root - INFO - Evaluating fitness for hypothesis: t2d-05-a48d6614
2026-02-10 20:20:48,315 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:20:48,330 - root - INFO - TOKEN_USAGE: input=1499, output=661, total=2160, cost=$0.000621
2026-02-10 20:20:48,331 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:20:48,333 - root - INFO - 
**DATA_SUPPORT_SCORE:** 5  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is indeed in the top priority list, but it is noteworthy that the evaluation context warns about a lack of presence for one of the other ranked targets. The presence of cross-dataset consistency supports the overall validity of the data, although the overall evidence types supporting the primary target could be stronger since there are only two datasets referenced.

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their scores and roles in insulin signaling. However, the warning about the target gene not being found in the top priority list raises some concerns about the robustness of the ranking, suggesting a potential oversight in the evaluation of lower-ranked targets. The overall rationale makes sense, but clarity on how the targets directly complement each other could strengthen the argument.

**MECHANISTIC_SCORE:** 7  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and glucose metabolism, particularly in skeletal muscle. The tissue rationale is well-supported, emphasizing the importance of muscle in glucose homeostasis. However, the absence of identified regulatory transcription factors could indicate a gap in understanding the complete regulatory network involved.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of using small molecules to activate the selected targets is appropriate, given their roles in metabolic pathways. The targets are likely druggable based on their network positions, and the focus on muscle tissue is a strategic advantage. Safety considerations are not explicitly discussed, which could be an area for further analysis.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data regarding insulin signaling in a focused manner, but the connections made are somewhat expected given the known roles of the targets. While the approach is rational and relevant, there isn't a strong indication of particularly novel or unexpected relationships being proposed.

**OVERALL_FITNESS:** 6.55 (rounded to 65.5)  
**(Calculated: 5*0.25 + 6*0.25 + 7*0.20 + 8*0.20 + 6*0.10 = 6.55)**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Evidence Base:** Increase the number of datasets supporting the primary target and explore additional evidence types (e.g., functional assays, clinical data) to strengthen the claims made.
2. **Clarify Target Interactions:** Provide more detailed explanations of how the ranked targets interact and complement each other in the context of insulin signaling.
3. **Investigate Regulatory Mechanisms:** Identify and report any regulatory transcription factors that may interact with the targets, or discuss why they were not found, to provide a more complete understanding of the regulatory landscape.
4. **Address Safety Considerations:** Include a discussion on potential safety issues or side effects of targeting these genes to give a more rounded view of the therapeutic approach.
2026-02-10 20:20:48,339 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:20:48,341 - root - INFO - Evaluating fitness for hypothesis: t2d-05-a9fef2f1
2026-02-10 20:21:00,853 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:21:00,856 - root - INFO - TOKEN_USAGE: input=1461, output=644, total=2105, cost=$0.000606
2026-02-10 20:21:00,857 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:21:00,857 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is in the top priority list with a score of 4.0, and there is cross-dataset consistency for top-ranked targets. However, the warning indicates that one of the targets is not found in the top priority list, which weakens the overall data support. There are multiple types of evidence supporting G19943, but the absence of all targets from the top list limits the score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the scores and roles of the targets in metabolic pathways. Higher-ranked targets are stronger than those lower-ranked due to their roles in insulin signaling and glucose metabolism. However, since G33764 is present in the hypothesis but is ranked lower than some not listed in the priority list, this affects the overall clarity of the ranking rationale.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with insulin signaling pathways and addresses key aspects of glucose metabolism. The tissue rationale is strong, targeting pancreatic -cells, muscle, and liver, which are critical for T2D management. The identified transcription factors related to G04436 are also a positive aspect, indicating a well-considered mechanistic approach.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets is appropriate given their roles in insulin sensitivity and metabolic regulation. The potential for druggability appears strong based on the network positions of these targets. However, specific safety considerations are not mentioned, which could enhance the evaluation.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a coherent way but does not propose particularly non-obvious connections between the targets. The multi-targeted approach is innovative in the context of T2D, but the connections are grounded in established pathways, which may limit the novelty.

**OVERALL_FITNESS:** (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.55, scaled to 0-100 = **65.5**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **STRONG**

**IMPROVEMENT_SUGGESTIONS:**  
1. **Reassess Target Inclusion:** Ensure that all targets included in the hypothesis are also found in the top priority list to strengthen data support and ranking quality.
2. **Expand Safety Considerations:** Include a discussion on potential safety concerns or side effects associated with targeting these genes to enhance the therapeutic rationale.
3. **Clarify Novelty Aspects:** Highlight any unique aspects of the multi-targeted approach that differentiate it from existing therapies or hypotheses to improve the novelty score.
2026-02-10 20:21:00,857 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:21:00,857 - root - INFO - Evaluating fitness for hypothesis: t2d-05-b6701b2c
2026-02-10 20:21:14,575 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:21:14,578 - root - INFO - TOKEN_USAGE: input=1381, output=662, total=2043, cost=$0.000604
2026-02-10 20:21:14,578 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:21:14,579 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is well-supported in the top priority list, and there is cross-dataset consistency. However, while it is a central hub in insulin signaling, the lack of additional specific evidence types beyond the two datasets slightly lowers the score.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their roles and relationships in metabolic regulation. However, the lack of differentiation between similarly scored targets (all at 4.0) makes it challenging to clearly delineate stronger targets from weaker ones, slightly impacting the score.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in insulin signaling and metabolic regulation. The tissue rationale is also strong, as the selected tissues are critically involved in glucose and lipid metabolism. However, the lack of identified regulatory transcription factors (TFs) slightly diminishes the coherence.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553 is appropriate, and the targets appear druggable based on their network positions. However, the potential safety considerations related to multi-target strategies in complex metabolic diseases could be addressed more thoroughly.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** While the hypothesis integrates various targets in a creative way, the approach of a multi-target strategy is not entirely novel in the context of Type 2 Diabetes. The connections made are valid but do not propose significantly unique insights or mechanisms.

**OVERALL_FITNESS: 6.5**
Calculated as follows: 
\[ \text{Overall Fitness} = (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.25 \]

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Evidence:** Consider integrating additional evidence types, such as functional assays or clinical data, to strengthen the validation of the primary and secondary targets.
  
2. **Differentiate Target Rankings:** Provide clearer distinctions between the targets to justify their respective rankings more convincingly, possibly by highlighting unique contributions or specific interactions.

3. **Explore TF Relationships:** Investigate potential transcription factors that could regulate the expression or function of the targets to enhance mechanistic coherence.

4. **Address Safety Considerations:** Include a more comprehensive discussion on the safety profiles of the multi-target strategy, particularly regarding potential interactions and side effects.

5. **Highlight Novel Mechanisms:** Emphasize any unique mechanisms or novel insights that could be derived from the multi-target approach to enhance the novelty score.
2026-02-10 20:21:14,579 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:21:14,579 - root - INFO - Evaluating fitness for hypothesis: t2d-05-1e704316
2026-02-10 20:21:28,400 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:21:28,404 - root - INFO - TOKEN_USAGE: input=1471, output=694, total=2165, cost=$0.000637
2026-02-10 20:21:28,404 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:21:28,404 - root - INFO - 
**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is ranked highly and supported by evidence across multiple datasets, but some of the ranked targets (specifically G22553, G33764, and G04436) are not listed in the top priority genes, which diminishes the overall confidence in data support. There is cross-dataset consistency for the primary target, but the existence of other high-ranking genes not being included in the hypothesis reduces the score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking of the targets appears justified based on their scores and roles in the pathways of interest, with G19943 positioned correctly as the primary target. However, the absence of some ranked targets from the top priority list raises some concerns about the strength of the ranking. Targets like G33764, although essential, could be viewed as less prioritized compared to others in the top tier.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the biological pathways involved in insulin signaling and metabolic regulation. The tissue rationale is well-justified, targeting pancreatic -cells, muscle, and liver tissues, which are central to glucose metabolism and insulin action. Additionally, the relationships with regulating transcription factors are considered, supporting the overall coherence of the mechanism.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The approach of activating the selected targets through small molecules appears appropriate given their roles in metabolic regulation. However, the actual druggability of each target based on their network positions and potential safety considerations were not fully explored, which could impact the therapeutic potential.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis presents a comprehensive approach by integrating multiple targets to tackle the multifaceted nature of Type 2 Diabetes; however, the concept of multi-targeted gene therapy in diabetes management is not entirely new. While there are creative elements in the connections made, the overall novelty of the hypothesis could be strengthened.

**OVERALL_FITNESS:**  
Calculated score = (5 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.5  
Scaled to 0-100 = 65  

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: MODERATE  
- Target #3 quality: MODERATE  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Incorporate Additional Evidence:** Provide further evidence or rationale for why certain ranked targets (e.g., G33764, G22553) were excluded from the top priority list. This could enhance the data support score and strengthen the overall argument.
2. **Expand on Drugability and Safety:** Include a discussion on the druggability of each target and potential safety issues related to the proposed therapeutic approach. This will bolster the therapeutic potential score.
3. **Highlight Novel Aspects More Clearly:** Emphasize any unique aspects or innovative methodologies in the hypothesis to improve the novelty score. Exploring non-obvious connections between the targets and their effects could also elevate this aspect.
2026-02-10 20:21:28,405 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:21:28,405 - root - INFO - Population fitness evaluation complete. Top score: 73.50
2026-02-10 20:21:28,406 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 20:21:28,407 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G19943', 'G19943']...
2026-02-10 20:21:28,407 - root - INFO - Generation 5 stats: mean=64.33, max=79.5, min=50.0
2026-02-10 20:21:28,407 - root - INFO - Generation 5 complete
2026-02-10 20:21:28,407 - root - INFO - --- CAPTURING CHECKPOINT GEN 5 ---
2026-02-10 20:21:28,407 - root - INFO - Running generation 6
2026-02-10 20:21:28,408 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 20:21:28,408 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 20:21:28,408 - root - INFO - Crossover 1/18: parents 'Targeting G22553 for Enhanced ...' x '** Exploring G22553 as a Novel...'
2026-02-10 20:21:28,468 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:21:34,993 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:21:34,994 - root - INFO - TOKEN_USAGE: input=40241, output=736, total=40977, cost=$0.006478
2026-02-10 20:21:34,995 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:21:34,995 - root - INFO - 
### TITLE: Integrative Targeting of G22553, G23245, and G19122 for Enhanced Insulin Sensitivity in Type 2 Diabetes Therapy

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling pathways, showing significant evidence across multiple datasets for its critical role in glucose metabolism.
2. **G23245** | Score: 4.0 | A pivotal driver in glucose uptake, G23245 complements G22553's role in insulin signaling and has shown a negative correlation with T2D, suggesting its potential as a therapeutic target.
3. **G19122** | Score: 3.0 | This major regulator in insulin signaling impacts glucose metabolism and insulin sensitivity, providing critical support to the therapeutic strategy.
4. **G19943** | Score: 4.0 | Identified as a hub component in metabolic regulation, it reinforces the insulin signaling network, supporting overall glucose homeostasis.
5. **G00484** | Score: 4.0 | As a transcription factor crucial for regulating insulin signaling, it adds a regulatory layer to the multi-target approach, enhancing the robustness of the therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis emphasizes the synergistic potential of targeting G22553, G23245, and G19122 to enhance insulin sensitivity in Type 2 Diabetes (T2D) management. By integrating these targets, we aim to address the complex nature of T2D through improved glucose metabolism, insulin signaling, and regulatory mechanisms.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, and metabolic regulation.
- WGCNA module role: G22553 is a primary driver in the black module; G23245 is a primary driver in the silver module.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** G22553 is hypothesized to enhance insulin signaling and glucose metabolism, while G23245 supports increased glucose uptake. G19122 functions as a critical regulator of insulin sensitivity, further strengthening the therapeutic strategy. G19943 provides a central role in metabolic regulation, and G00484 as a transcription factor adds an essential regulatory layer, creating a comprehensive mechanism for T2D intervention.

**TISSUE_RATIONALE:** The primary tissues of interest include skeletal muscle, adipose tissue, and pancreatic -cells, as they are integral to insulin action and glucose uptake, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves the small molecule activation of G22553 to enhance its function, alongside modulation of G23245 and G19122 to improve insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Targeting these selected genes is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its direct role in insulin signaling, with G23245 complementing this function, while G19122 provides necessary regulatory support.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:21:34,995 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:21:34,995 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:21:34,995 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:21:34,996 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:21:34,996 - root - INFO -   -> Created offspring: 'Integrative Targeting of G22553, G23245,...'
2026-02-10 20:21:34,997 - root - INFO - Crossover 2/18: parents '** Comprehensive Multi-Target ...' x '** Exploring G22553 as a Novel...'
2026-02-10 20:21:35,035 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:22:09,569 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:22:09,576 - root - INFO - TOKEN_USAGE: input=40277, output=760, total=41037, cost=$0.006498
2026-02-10 20:22:09,576 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:22:09,576 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Enhanced Type 2 Diabetes Therapy

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0/17** | This gene is a primary driver in the black module with a strong positive correlation to T2D, enhancing glucose metabolism and insulin sensitivity.
2. **G19943** | Score: **4.0/17** | As a central hub in insulin signaling and metabolic pathways, G19943 supports insulin action and glucose homeostasis.
3. **G04436** | Score: **4.0/17** | This enzyme plays a critical role in metabolic regulation, complementing the actions of G22553 and G19943 by directly influencing lipid profiles.
4. **G23245** | Score: **4.0/17** | A primary driver that significantly impacts glucose uptake and insulin sensitivity, providing essential support to the main targets.
5. **G27976** | Score: **3.0/17** | This major regulator, linked to insulin sensitivity, offers additional therapeutic potential through its connections in metabolic pathways.

**PRIMARY_TARGET:** **G22553**

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses by prioritizing G22553 as the primary target due to its established role in T2D pathophysiology. The combined actions of G19943 and G04436 enhance metabolic regulation, while G23245 and G27976 provide robust support to improve insulin sensitivity and glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways**
- WGCNA module role: **G22553 and G19943 are both key drivers in respective modules directly correlated with T2D**
- Regulating TFs: **None reported**

**MECHANISM_HYPOTHESIS:** The mechanism posits that G22553 enhances insulin sensitivity and glucose metabolism via its involvement in insulin signaling pathways. G19943 orchestrates insulin signaling and lipid metabolism, while G04436 addresses lipid profiles directly, tackling both glucose and lipid metabolism challenges in T2D. G23245 and G27976 provide additional regulatory support, amplifying the overall therapeutic response.

**TISSUE_RATIONALE:** Key tissues include skeletal muscle, liver, and adipose tissue, which are crucial for insulin action, glucose uptake, and lipid metabolism. Targeting these genes within these tissues is essential for reversing the pathophysiological processes underlying Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule activation of G22553 and G19943 to enhance their functions, combined with modulation of G04436 to optimize lipid metabolism and mitigate negative feedback mechanisms in metabolic pathways.

**PREDICTED_OUTCOME:** Modulation of G22553, alongside synergistic effects from G19943 and G04436, is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and potential for synergistic interactions. G22553 is prioritized for its central role in T2D, with G19943 and G04436 following closely due to their complementary actions. G23245 and G27976 are included for their additional supportive roles in enhancing the overall therapeutic approach.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:22:09,577 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:22:09,577 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:22:09,578 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:22:09,581 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:22:09,581 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 20:22:09,581 - root - INFO - Mutation 3/18: parent 'Synergistic Multi-Target Modul...'
2026-02-10 20:22:09,581 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:22:09,638 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:22:47,865 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:22:47,871 - root - INFO - TOKEN_USAGE: input=39529, output=744, total=40273, cost=$0.006376
2026-02-10 20:22:47,871 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:22:47,871 - root - INFO - 
### TITLE: Targeting G22553 for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, targeting G22553 is anticipated to directly complement the effects of G19943, enhancing glucose metabolism.
2. **G00484** | Score: 4.0 | This transcription factor is crucial for the regulation of insulin signaling and glucose homeostasis, providing significant regulatory support to G22553's action.
3. **G23245** | Score: 4.0 | Known as a pivotal driver in glucose uptake and insulin sensitivity, targeting G23245 will synergize with G22553 to reinforce the therapeutic strategy.
4. **G33764** | Score: 4.0 | Enhancing metabolic regulation and supporting insulin signaling pathways, G33764 adds robustness to the multi-target approach.
5. **G19943** | Score: 4.0 | Though originally the primary target, its role as a hub component can be effectively complemented by the synergistic actions of the other selected targets.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes targeting G22553 as a principal strategy for enhancing insulin sensitivity in Type 2 Diabetes management, leveraging its critical role in insulin signaling. The inclusion of G00484, G23245, and G33764 provides a comprehensive approach to address the multifactorial nature of T2D, aiming for synergistic interactions that reinforce glucose metabolism and insulin action.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** Targeting G22553 is hypothesized to enhance insulin signaling pathways, directly improving glucose metabolism. The action of G00484 as a transcription factor will amplify the regulatory effects on insulin signaling and glucose homeostasis. G23245s role in glucose uptake will complement G22553s function, while G33764 will ensure robust metabolic regulation, collectively providing a synergistic mechanism for managing T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are central to insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G22553 to enhance its functions, alongside modulation of G00484, G23245, and G33764 to strengthen metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of G22553 and its synergistic targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role in insulin signaling, followed by G00484, which complements its function, while G23245 and G33764 provide essential support.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:22:47,879 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:22:47,880 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:22:47,881 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:22:47,890 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:22:47,893 - root - INFO -   -> Created mutated offspring: 'Targeting G22553 for Enhanced Insulin Se...'
2026-02-10 20:22:47,898 - root - INFO - Mutation 4/18: parent '** Enhanced Multi-Target Strat...'
2026-02-10 20:22:47,898 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 20:22:47,938 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:23:32,000 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:23:32,006 - root - INFO - TOKEN_USAGE: input=39530, output=762, total=40292, cost=$0.006387
2026-02-10 20:23:32,006 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:23:32,006 - root - INFO - 
**TITLE:** Synergistic Multi-Target Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | Central hub in metabolic pathways that integrates insulin signaling and lipid metabolism, showing robust cross-dataset support.**
2. **G22553 | Score: 4.0 | Primary driver in insulin signaling pathways critical for glucose uptake, with significant evidence from multiple datasets.**
3. **G04436 | Score: 4.0 | Enzyme pivotal in lipid metabolism and insulin action, complementing G19943 and G22553 to improve metabolic regulation.**
4. **G19122 | Score: 3.0 | Major regulator in insulin signaling pathways, enhancing glucose homeostasis, with validation from multiple sources.**
5. **G33764 | Score: 3.0 | Important enzyme involved in metabolic regulation that supports glucose homeostasis, but with less robust evidence compared to higher-ranked targets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This evolved hypothesis proposes a refined mechanism for enhancing insulin sensitivity in Type 2 Diabetes by targeting G19943, G22553, G04436, G19122, and G33764. By leveraging the strong supporting data and focusing on the interplay between these targets, the strategy aims to create a comprehensive approach that addresses multiple aspects of metabolic dysregulation.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 is a hub component, with G22553 identified as a primary driver in relevant modules.
- Regulating TFs: G04436 is associated with 12 identified transcription factors, suggesting robust regulatory control.

**MECHANISM_HYPOTHESIS:** This refined mechanism suggests that the activation of G19943 will act as a master regulator, enhancing both insulin signaling and lipid metabolism. G22553 will facilitate glucose uptake and further amplify insulin signaling, while G04436 will synergistically improve lipid profiles, thereby addressing dyslipidemia. G19122 will serve as a critical enhancer of insulin sensitivity, and G33764 will provide additional metabolic support. By integrating these pathways, the strategy aims to create a more comprehensive therapeutic effect.

**TISSUE_RATIONALE:** The primary tissues of focus include skeletal muscle, liver, and adipose tissue, as they play crucial roles in glucose uptake and lipid metabolism. Targeting these tissues will maximize the therapeutic benefits of modulating insulin sensitivity and metabolic control.

**THERAPEUTIC_APPROACH:** The approach will involve the development of small molecule activators that specifically target these genes, enhancing their functions to correct metabolic dysregulation in Type 2 Diabetes.

**PREDICTED_OUTCOME:** Modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, resulting in better management of Type 2 Diabetes symptoms and potentially reversing disease progression.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, roles in key biological pathways, and the robustness of supporting evidence. G19943 was selected as the primary target due to its central role in metabolic pathways, while G22553 and G04436 were prioritized for their significant contributions to insulin signaling and metabolic regulation. G19122 and G33764 were included to further enhance the understanding and treatment of metabolic dysregulation in T2D.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:23:32,007 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:23:32,008 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:23:32,008 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:23:32,011 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:23:32,011 - root - INFO -   -> Created mutated offspring: '** Synergistic Multi-Target Modulation f...'
2026-02-10 20:23:32,011 - root - INFO - Mutation 5/18: parent '** Enhanced Multi-Target Strat...'
2026-02-10 20:23:32,011 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 20:23:32,060 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:24:14,600 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:24:14,607 - root - INFO - TOKEN_USAGE: input=39530, output=768, total=40298, cost=$0.006390
2026-02-10 20:24:14,607 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:24:14,607 - root - INFO - 
**TITLE:** Multifaceted Modulation of Insulin Sensitivity and Lipid Homeostasis in Type 2 Diabetes via Targeted Gene Activation

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | Central hub in metabolic pathways with confirmed roles in insulin signaling and lipid metabolism, showing strong evidence across multiple datasets.**
2. **G22553 | Score: 4.0 | Primary driver of insulin signaling pathways, crucial for glucose uptake and supported by robust evidence from various data types.**
3. **G04436 | Score: 4.0 | Key enzyme involved in lipid metabolism, complementing the functions of both G19943 and G22553, with multiple dataset validation.**
4. **G33764 | Score: 4.0 | Important regulator of metabolic pathways, contributing to glucose homeostasis and supported by consistent evidence across datasets.**
5. **G19122 | Score: 3.0 | Major regulator in insulin signaling, enhancing insulin sensitivity with substantial validation from multiple datasets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This mutated hypothesis refines the original multi-target strategy by emphasizing the critical role of G19943 as a master regulator of both insulin signaling and lipid metabolism. It proposes a more detailed mechanism that incorporates the synergistic effects of G22553, G04436, G33764, and G19122, focusing on their roles in enhancing insulin sensitivity and metabolic regulation through coordinated activation.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 identified as a hub component, with G22553 acting as a primary driver.
- Regulating TFs: 12 transcription factors identified influencing G04436.

**MECHANISM_HYPOTHESIS:** The mechanism posits that activating G19943 enhances its functionality as a master regulator, thereby improving insulin sensitivity and lipid metabolism. This activation is expected to lead to heightened glucose uptake mediated by G22553, while G04436 addresses dyslipidemia. Additionally, G33764's role in metabolic regulation complements this effect, and G19122 further amplifies insulin sensitivity, creating a robust multi-target strategy for improved metabolic control in Type 2 Diabetes.

**TISSUE_RATIONALE:** The primary tissues of interest are pancreatic -cells, liver, and skeletal muscle, as they are pivotal in regulating insulin action, glucose uptake, and lipid metabolism. By focusing on these tissues, the strategy aims to optimize insulin secretion and action, leading to improved metabolic outcomes.

**THERAPEUTIC_APPROACH:** The proposed strategy involves the development of small molecule activators targeting the selected genes to enhance their functions and address the multifaceted metabolic dysregulation associated with Type 2 Diabetes.

**PREDICTED_OUTCOME:** Coordinated modulation of these targets is anticipated to significantly improve insulin sensitivity and glucose metabolism, resulting in therapeutic benefits that could lead to better management and potential reversal of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their significant roles in key biological pathways, and the strength of supporting evidence. G19943 was prioritized as the primary target due to its central role in metabolic pathways, while G22553 and G04436 were included due to their strong contributions to insulin signaling and lipid metabolism. G33764 was added for its importance in metabolic regulation, and G19122 was retained for its role in enhancing insulin sensitivity.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:24:14,609 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:24:14,609 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:24:14,610 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:24:14,613 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:24:14,613 - root - INFO -   -> Created mutated offspring: '** Multifaceted Modulation of Insulin Se...'
2026-02-10 20:24:14,613 - root - INFO - Mutation 6/18: parent 'Comprehensive Multi-Target App...'
2026-02-10 20:24:14,613 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:24:14,678 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:24:36,095 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:24:36,100 - root - INFO - TOKEN_USAGE: input=39557, output=782, total=40339, cost=$0.006403
2026-02-10 20:24:36,100 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:24:36,100 - root - INFO - 
### TITLE: Alternative Multi-Target Strategy for Optimizing Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436** | Score: 4.0 | Critical enzyme involved in metabolic regulation, showing strong evidence across multiple datasets and significant correlation with T2D pathways.
2. **G22553** | Score: 4.0 | Functions as a primary driver in insulin signaling, supporting glucose metabolism, and demonstrating consistent results in multiple analyses.
3. **G23245** | Score: 4.0 | A primary driver for glucose uptake and insulin sensitivity, contributing significantly to metabolic control in relevant tissues.
4. **G33764** | Score: 4.0 | Provides regulatory support within metabolic pathways, which helps enhance the efficacy of the primary targets identified.
5. **G19943** | Score: 4.0 | While it remains a significant hub in insulin signaling, it is now positioned as a complementary target rather than the primary focus.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This mutated hypothesis shifts the primary focus to G04436, a pivotal enzyme for metabolic regulation, while still utilizing the synergistic effects of G22553, G23245, and G33764 to create a robust multi-target approach for Type 2 Diabetes management. This strategy emphasizes the critical role of metabolic enzymes in supporting insulin sensitivity and glucose metabolism.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- **WGCNA module role**: G04436 identified as a primary driver in the negatively correlated T2D module.
- **Regulating TFs**: Interactions with transcription factors involved in metabolic pathways.

### MECHANISM_HYPOTHESIS:
The mechanism centers on G04436 as a crucial enzyme regulating metabolic pathways that influence lipid profiles and glucose metabolism. By enhancing G04436's activity, we can improve insulin sensitivity and glucose uptake, complemented by the actions of G22553, which enhances insulin signaling, and G23245, which supports glucose uptake. G33764 will provide additional regulatory support, ensuring a well-rounded strategy to mitigate the metabolic disturbances associated with Type 2 Diabetes.

### TISSUE_RATIONALE:
The targeted tissues include the liver, muscle, and adipose tissue, as they are critical for effective insulin action, glucose uptake, and lipid metabolism. Addressing these tissues is vital for developing comprehensive therapies aimed at reversing metabolic disorders linked to Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The strategy involves the small molecule activation of G04436 to enhance its metabolic regulation function, in conjunction with the modulation of G22553 and G23245 to optimize insulin signaling and glucose uptake, respectively. G33764 will be modulated to strengthen regulatory pathways.

### PREDICTED_OUTCOME:
The integrated modulation of these targets is expected to significantly enhance metabolic regulation, improve insulin sensitivity, and promote better glucose metabolism, leading to improved patient outcomes in the management of Type 2 Diabetes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their strength of evidence across multiple datasets, and their potential for synergistic interactions. G04436 is prioritized for its central role in metabolic regulation, while G22553 and G23245 are included for their complementary functions. G33764 provides additional support without overshadowing the primary target. G19943, while significant, is positioned as a secondary target in this hypothesis evolution.

### CONFIDENCE: HIGH
The hypothesis is grounded in robust data support across multiple evidence types and pathways relevant to Type 2 Diabetes management.
2026-02-10 20:24:36,100 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:24:36,100 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:24:36,102 - root - INFO -   -> Created mutated offspring: 'Alternative Multi-Target Strategy for Op...'
2026-02-10 20:24:36,102 - root - INFO - Mutation 7/18: parent '** Comprehensive Multi-Target ...'
2026-02-10 20:24:36,102 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 20:24:36,140 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:24:53,198 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:24:53,201 - root - INFO - TOKEN_USAGE: input=39550, output=799, total=40349, cost=$0.006412
2026-02-10 20:24:53,201 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:24:53,201 - root - INFO - 
**TITLE:** Enhanced Activation Strategy for Type 2 Diabetes Management through Multi-Target Modulation

**RANKED_TARGETS:**
1. **G22553** | Score: **4.0/17** | This gene has been identified as a primary driver in insulin signaling and glucose metabolism, showing strong evidence across multiple datasets, making it the leading candidate for therapeutic activation.
2. **G19943** | Score: **4.0/17** | As a hub component in insulin signaling pathways, G19943 remains crucial for coordination of metabolic responses and will be included for synergistic activation alongside G22553.
3. **G04436** | Score: **4.0/17** | This enzyme's metabolic role complements the effects of G22553 and G19943, providing a pathway for enhanced lipid metabolism and overall metabolic control.
4. **G23245** | Score: **4.0/17** | As a primary driver in glucose uptake and insulin sensitivity, G23245 will add support to the activation strategy, enhancing the efficacy of the overall treatment.
5. **G27976** | Score: **3.0/17** | Although lower in the ranking, G27976's regulatory role within the silver module provides valuable context for metabolic pathways, offering additional support to the primary targets.

**PRIMARY_TARGET:** **G22553**

**SUMMARY:** This mutated hypothesis focuses on the activation of G22553 as the primary target, leveraging its established role in enhancing insulin sensitivity and glucose metabolism. By incorporating G19943 and G04436 as synergistic activators, along with G23245 and G27976 for additional support, the aim is to create a robust therapeutic approach to improve metabolic control in Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism**
- WGCNA module role: **G22553 is a primary driver within the black module positively correlated with T2D response**
- Regulating TFs: **Potential interactions with transcription factors influencing metabolic pathways**

**MECHANISM_HYPOTHESIS:** The proposed mechanism focuses on activating G22553 to enhance glucose metabolism and insulin sensitivity. Concurrent activation of G19943 will facilitate coordinated insulin signaling, while G04436's role as a metabolic enzyme will address lipid profiles directly. G23245's involvement in glucose uptake complements this activation, and G27976's regulatory function will further enhance the overall therapeutic response.

**TISSUE_RATIONALE:** Key tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are essential for insulin action, glucose uptake, and lipid metabolism. Targeting these genes in relevant tissues will optimize the therapeutic effects and address the pathophysiological processes underlying Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy will involve small molecule activation of G22553 and G19943, combined with modulation of G04436 to enhance lipid metabolism, thereby providing a comprehensive approach to managing Type 2 Diabetes.

**PREDICTED_OUTCOME:** Activation of G22553 alongside G19943 and G04436 is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and yield a comprehensive therapeutic benefit for Type 2 Diabetes management.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in T2D pathways, evidence strength from multiple datasets, and potential for synergistic interactions. G22553 is prioritized for its central role in insulin signaling, followed closely by G19943 and G04436, which effectively complement its function. G23245 and G27976 provide additional support to enhance the therapeutic strategy.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:24:53,201 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:24:53,202 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:24:53,202 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:24:53,203 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:24:53,203 - root - INFO -   -> Created mutated offspring: '** Enhanced Activation Strategy for Type...'
2026-02-10 20:24:53,203 - root - INFO - Mutation 8/18: parent 'Synergistic Multi-Target Modul...'
2026-02-10 20:24:53,203 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 20:24:53,236 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:25:19,630 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:25:19,645 - root - INFO - TOKEN_USAGE: input=39528, output=752, total=40280, cost=$0.006380
2026-02-10 20:25:19,645 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:25:19,645 - root - INFO - 
### TITLE: Dual Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is essential for enhancing glucose metabolism, making it a promising target for activation.
2. **G19943** | Score: 4.0 | Retaining its role as a central hub in T2D pathways, G19943's modulation can still significantly impact insulin signaling and metabolic regulation.
3. **G23245** | Score: 4.0 | This gene plays a critical role in glucose uptake and insulin sensitivity; its modulation can reinforce the therapeutic strategy.
4. **G33764** | Score: 4.0 | Enhancing metabolic regulation through G33764 supports the overall approach by providing additional pathways for improving insulin sensitivity.
5. **G00484** | Score: 4.0 | As a transcription factor crucial for insulin signaling regulation, G00484 offers essential regulatory depth, making it valuable for comprehensive therapeutic strategies.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis pivots the therapeutic approach by focusing on the activation of G22553 while retaining G19943's role as a central hub. By combining this activation with modulation of G23245, G33764, and G00484, we aim to enhance metabolic regulation and insulin sensitivity comprehensively, addressing the multifactorial nature of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with improved insulin sensitivity.
- Regulating TFs: None identified for G22553, but G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The activation of G22553 is hypothesized to significantly enhance insulin signaling and glucose metabolism. This, in conjunction with the retained modulation of G19943, which acts as a vital coordinator in metabolic pathways, will improve insulin sensitivity. G23245 will further support glucose uptake, while G33764 and G00484 will enhance metabolic regulation and transcriptional responses pivotal for insulin action.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as these are critical for insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves the small molecule activation of G22553, complemented by the modulation of G19943, G23245, G33764, and G00484 to enhance insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better overall management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its crucial role in insulin signaling, followed by G19943 for its central regulatory function. G23245 and G33764 provide necessary support for glucose metabolism, while G00484 ensures transcriptional regulation remains effective.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:25:19,646 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:25:19,646 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:25:19,646 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:25:19,648 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:25:19,648 - root - INFO -   -> Created mutated offspring: 'Dual Modulation for Enhanced Insulin Sen...'
2026-02-10 20:25:19,649 - root - INFO - Crossover 9/18: parents 'Enhanced Multi-Target Strategy...' x 'Comprehensive Multi-Target App...'
2026-02-10 20:25:19,717 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:25:57,821 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:25:57,829 - root - INFO - TOKEN_USAGE: input=40308, output=748, total=41056, cost=$0.006495
2026-02-10 20:25:57,829 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:25:57,829 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhanced Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Acts as a central hub in insulin signaling pathways, showing strong evidence across multiple datasets.
2. **G22553** | Score: 4.0 | Functions as a primary driver of insulin signaling, enhancing glucose metabolism synergistically with G19943.
3. **G04436** | Score: 4.0 | Critical enzyme involved in metabolic regulation, complementing the effects of G19943 and G22553 by optimizing lipid metabolism.
4. **G23245** | Score: 4.0 | A key mediator for glucose uptake and insulin sensitivity, providing essential support to the primary targets.
5. **G33764** | Score: 4.0 | Offers additional regulatory support within metabolic pathways, further enhancing therapeutic efficacy.

**PRIMARY_TARGET:** G19943

### SUMMARY:
This hypothesis proposes a comprehensive multi-target strategy focused on G19943 as the primary target, while integrating the synergistic effects of G22553, G04436, G23245, and G33764. This approach aims to enhance insulin sensitivity and optimize metabolic control in T2D by addressing insulin signaling, glucose uptake, and lipid metabolism across key tissues.

### DATA_EVIDENCE:
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism, lipid metabolism
- **WGCNA module role:** G19943 identified as a hub component in modules negatively correlated with T2D.
- **Regulating TFs:** None identified.

### MECHANISM_HYPOTHESIS:
G19943 is proposed as a critical coordinator of insulin signaling and lipid metabolism, effectively restoring metabolic balance in T2D. G22553 enhances glucose uptake, thereby further promoting insulin sensitivity in conjunction with G19943. The enzyme G04436 optimizes lipid metabolism, addressing the dysregulation often seen in T2D. G23245 serves to boost glucose uptake mechanisms, while G33764 provides necessary regulatory support, ensuring a robust and comprehensive approach to T2D management.

### TISSUE_RATIONALE:
The most relevant tissues include pancreatic -cells, liver, muscle, and adipose tissue, all of which are essential for insulin action, glucose uptake, and lipid metabolism, making them optimal targets for therapeutic interventions aimed at ameliorating metabolic disturbances associated with T2D.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves the small molecule activation of G19943 and G22553, coupled with modulation of G04436 and G23245 to optimize their functions, thereby enhancing overall metabolic functions and improving insulin sensitivity.

### PREDICTED_OUTCOME:
Effective modulation of G19943 and its associated targets is expected to lead to significantly improved insulin sensitivity and glucose metabolism, resulting in better management of T2D and enhanced patient outcomes.

### RANKING_RATIONALE:
The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence across multiple datasets, and their potential for synergistic interactions. G19943 leads due to its central role, followed closely by G22553 for its complementary function. G04436 and G23245 are included for their critical support roles, while G33764 provides additional regulatory insights without overshadowing the primary targets.

### CONFIDENCE: HIGH
Based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:25:57,830 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:25:57,830 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:25:57,831 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:25:57,833 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:25:57,833 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 20:25:57,833 - root - INFO - Crossover 10/18: parents 'Enhanced Multi-Target Strategy...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 20:25:57,866 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:26:35,531 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:26:35,575 - root - INFO - TOKEN_USAGE: input=40263, output=763, total=41026, cost=$0.006497
2026-02-10 20:26:35,575 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:26:35,575 - root - INFO - 
### TITLE: Integrated Multi-Target Approach to Enhance Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Central driver of insulin signaling pathways, enhancing glucose metabolism while also providing synergistic effects with other targets.
2. **G19943** | Score: 4.0 | Acts as a central hub in metabolic regulation, supporting insulin signaling and glucose uptake, and synergizing with G22553.
3. **G23245** | Score: 4.0 | Key driver in glucose uptake, significantly contributing to improved insulin sensitivity alongside G22553 and G19943.
4. **G33764** | Score: 4.0 | Provides regulatory support in metabolic pathways, enhancing the overall efficacy of the therapeutic approach.
5. **G00484** | Score: 4.0 | Functions as a transcription factor crucial for regulating insulin signaling, adding a layer of regulatory depth to the strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a robust, integrated multi-target strategy to improve insulin sensitivity and metabolic regulation in Type 2 Diabetes (T2D) by focusing on G22553 as a primary target. It combines the strengths of G22553, G19943, and G23245 in enhancing insulin signaling and glucose uptake, while also incorporating G33764's regulatory role and G00484's transcriptional regulation.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G22553 serves as a primary driver in modules positively correlated with insulin signaling.
- Regulating TFs: G00484 identified as a transcription factor regulating insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** G22553 is hypothesized to enhance insulin signaling pathways, leading to improved glucose uptake and metabolism. G19943 complements this by acting as a central hub in metabolic regulation, while G23245 is crucial for promoting glucose uptake. G33764 supports metabolic regulation, ensuring a comprehensive approach to enhancing insulin sensitivity. G00484 acts as a transcription factor, providing necessary regulatory support to amplify the effects of the main targets.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, liver, muscle, and adipose tissue, as these are integral to insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions aimed at reversing T2D.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves small molecule activation of G22553 to enhance its function, alongside the potential modulation of G19943, G23245, G33764, and G00484 to strengthen their roles in insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Effective modulation of G22553 and its associated targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes, resulting in improved patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its direct role in insulin signaling, with G19943 and G23245 complementing its function. G33764 provides essential regulatory support, while G00484 adds necessary transcriptional regulation, ensuring a comprehensive approach.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:26:35,575 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:26:35,575 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:26:35,576 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:26:35,578 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:26:35,578 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach to Enha...'
2026-02-10 20:26:35,578 - root - INFO - Mutation 11/18: parent 'Integrated Multi-Target Strate...'
2026-02-10 20:26:35,579 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:26:35,640 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:26:58,329 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:26:58,331 - root - INFO - TOKEN_USAGE: input=39590, output=787, total=40377, cost=$0.006411
2026-02-10 20:26:58,331 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:26:58,331 - root - INFO - 
### TITLE: Targeting G04436 for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | This enzyme plays a crucial role in lipid metabolism, which is vital for enhancing insulin sensitivity and glucose metabolism in Type 2 Diabetes.
2. **G23245** | Score: **4.0** | This gene is a primary driver in insulin signaling pathways, significantly influencing glucose uptake and metabolic processes.
3. **G22553** | Score: **4.0** | Identified as a primary driver in insulin signaling, this gene supports overall metabolic control, though with slightly less established evidence than G04436 and G23245.
4. **G33764** | Score: **4.0** | This enzyme is essential in metabolic pathways related to T2D, complementing the effects of the other targets to enhance metabolic regulation.
5. **G19943** | Score: **4.0** | While previously ranked higher, this hub components role is comprehensively covered by the other selected targets, making it less critical in this refined hypothesis.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This mutated hypothesis focuses on G04436 as the primary target due to its central role in lipid metabolism, which is essential for improving insulin sensitivity in Type 2 Diabetes. By integrating G23245, G22553, and G33764, the strategy reinforces the therapeutic approach through multiple pathways that enhance glucose metabolism and insulin action.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G04436)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, insulin signaling, glucose metabolism, metabolic regulation
- **WGCNA module role**: G04436 is a key enzyme in lipid metabolism, supporting insulin sensitivity.
- **Regulating TFs**: Multiple transcription factors are involved, providing regulatory depth to the approach.

### MECHANISM_HYPOTHESIS:
The activation of G04436 is anticipated to enhance lipid metabolism, thereby facilitating improved insulin sensitivity and glucose regulation in Type 2 Diabetes. Concurrent activation of G23245 will boost glucose uptake and insulin signaling, while G22553 and G33764 will further support metabolic control and flexibility. This integrated mechanism targets critical pathways necessary for effective diabetes management.

### TISSUE_RATIONALE:
The most relevant tissues include adipose tissue, liver, and muscle, as they are pivotal for lipid and glucose homeostasis. Enhancing the function of these tissues can directly impact insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G04436, G23245, G22553, and G33764) to improve insulin sensitivity and overall metabolic regulation.

### PREDICTED_OUTCOME:
Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their critical roles in insulin signaling and metabolic pathways, as well as their strong data support. G04436 was selected as the primary target due to its established importance in lipid metabolism, followed by G23245 and G22553 for their significant contributions to glucose uptake and metabolism. G33764 was included for its complementary role in metabolic regulation. G19943 was deprioritized as its functions are effectively captured by the other targets. 

### CONFIDENCE: HIGH
This hypothesis is grounded in robust data support across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 20:26:58,331 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:26:58,331 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:26:58,331 - root - INFO -   -> Created mutated offspring: 'Targeting G04436 for Enhanced Insulin Se...'
2026-02-10 20:26:58,332 - root - INFO - Crossover 12/18: parents '** Enhanced Multi-Target Strat...' x '** Enhanced Multi-Target Strat...'
2026-02-10 20:26:58,363 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:27:40,420 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:27:40,426 - root - INFO - TOKEN_USAGE: input=40311, output=772, total=41083, cost=$0.006510
2026-02-10 20:27:40,426 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:27:40,426 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Approach for Enhanced Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | Central hub in metabolic pathways crucial for insulin signaling and lipid metabolism, supported by strong evidence across datasets.**
2. **G22553 | Score: 4.0 | A primary driver in insulin signaling pathways essential for glucose uptake, demonstrating robust multi-evidence support.**
3. **G33764 | Score: 4.0 | Important enzyme in metabolic regulation that enhances glucose homeostasis, with strong evidence backing its role.**
4. **G04436 | Score: 4.0 | Critical for lipid metabolism and insulin signaling, further complementing the roles of G19943 and G22553.**
5. **G19122 | Score: 3.0 | Major regulator in insulin signaling pathways, supporting insulin sensitivity and metabolic balance, substantiated by multiple dataset validations.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis presents a robust multi-target strategy that prioritizes G19943, G22553, G33764, G04436, and G19122 to synergistically enhance insulin sensitivity and metabolic control in Type 2 Diabetes (T2D). By leveraging the strongest mechanistic insights and data support from both parent hypotheses, this approach aims to comprehensively address the complex metabolic dysregulations characteristic of T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 is a hub component in key modules relevant to T2D.
- Regulating TFs: 12 identified transcription factors associated with G04436, enhancing the understanding of regulatory mechanisms.

**MECHANISM_HYPOTHESIS:** The mechanism hypothesizes that activating G19943 will amplify its role as a master regulator in both insulin signaling and lipid metabolism, significantly improving insulin sensitivity and glucose homeostasis. Concurrent activation of G22553 will enhance glucose uptake, while G33764 will further support metabolic regulation. G04436 will mitigate dyslipidemia, and G19122 will additionally bolster insulin sensitivity, thereby forming a comprehensive therapeutic strategy to combat T2D.

**TISSUE_RATIONALE:** The primary tissues of focus include pancreatic -cells, liver, and skeletal muscle, as these are pivotal in insulin action, glucose uptake, and overall metabolic regulation. Targeting these tissues will optimize insulin secretion and action, leading to improved metabolic control.

**THERAPEUTIC_APPROACH:** The strategy involves the development of small molecule activators that specifically enhance the function of the selected genes, aiming to rectify metabolic dysregulation and improve T2D management.

**PREDICTED_OUTCOME:** Coordinated modulation of these targets is projected to lead to a significant improvement in insulin sensitivity, enhanced glucose metabolism, and potential therapeutic benefits that could facilitate better management and possible reversal of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, their significant contributions to crucial biological pathways, and the strength of supporting evidence across multiple datasets. G19943 was selected as the primary target due to its central role and strong evidence base, while G22553 and G33764 were prioritized for their critical functions in insulin signaling and metabolic regulation. G04436 and G19122 were included to provide additional layers of modulation for enhancing metabolic balance and addressing dyslipidemia.

**CONFIDENCE:** HIGH, based on robust multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:27:40,427 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:27:40,428 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:27:40,428 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:27:40,431 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:27:40,431 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Approach f...'
2026-02-10 20:27:40,431 - root - INFO - Crossover 13/18: parents '** Comprehensive Multi-Target ...' x '** Enhanced Multi-Target Strat...'
2026-02-10 20:27:40,489 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:28:20,867 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:28:20,873 - root - INFO - TOKEN_USAGE: input=40337, output=747, total=41084, cost=$0.006499
2026-02-10 20:28:20,874 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:28:20,874 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Optimal Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0/17** | Central hub in insulin signaling and metabolic pathways, showing robust evidence across multiple datasets.
2. **G22553** | Score: **4.0/17** | Primary driver in insulin signaling crucial for glucose uptake, well-supported by multi-evidence types.
3. **G33764** | Score: **4.0/17** | Important enzyme in metabolic regulation that enhances glucose homeostasis, demonstrating strong evidence support.
4. **G04436** | Score: **4.0/17** | Critical for lipid metabolism and insulin signaling, complements the effects of G19943 and G22553.
5. **G19122** | Score: **3.0/17** | Major regulator in insulin signaling pathways, supporting insulin sensitivity and metabolic balance, with validation across datasets.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** This hypothesis integrates the strongest mechanistic insights from both parent hypotheses, prioritizing G19943 as the central target due to its pivotal role in insulin signaling. G22553 and G33764 are included to enhance glucose uptake and metabolic regulation, while G04436 and G19122 provide additional support for lipid metabolism and insulin sensitivity, addressing the complexities of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation**
- WGCNA module role: **G19943 is a hub component in modules negatively correlated with T2D**
- Regulating TFs: **Identified transcription factors associated with G04436 and G19122**

**MECHANISM_HYPOTHESIS:** The integrated mechanism hypothesizes that G19943 orchestrates insulin signaling and lipid metabolism, with G22553 enhancing glucose uptake and insulin sensitivity. G33764 serves to optimize glucose homeostasis, while G04436 addresses lipid dysregulation, collectively creating a robust network aimed at improving metabolic control and insulin sensitivity in Type 2 Diabetes.

**TISSUE_RATIONALE:** The primary tissues involved include pancreatic -cells, liver, and skeletal muscle, which are critical for insulin action, glucose uptake, and lipid metabolism. Targeting these genes within these tissues is essential to reversing the pathophysiological processes underlying Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The approach involves the development of small molecule activators targeting G19943, G22553, and G33764 to enhance their functions, alongside modulation of G04436 and G19122 to optimize lipid metabolism and further support insulin sensitivity.

**PREDICTED_OUTCOME:** Coordinated modulation of these targets is anticipated to significantly improve insulin sensitivity, enhance glucose metabolism, and provide a comprehensive therapeutic benefit for managing Type 2 Diabetes, potentially leading to reversal of metabolic dysfunction.

**RANKING_RATIONALE:** The targets were ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and potential for synergistic interactions. G19943 is prioritized for its central role, followed closely by G22553 and G33764 for their significant contributions to insulin signaling and metabolic regulation. G04436 and G19122 provide important additional support to enhance the overall therapeutic approach.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:28:20,875 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:28:20,876 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:28:20,876 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:28:20,879 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:28:20,879 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 20:28:20,880 - root - INFO - Mutation 14/18: parent '** Comprehensive Modulation of...'
2026-02-10 20:28:20,880 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 20:28:20,937 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:29:00,197 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:29:00,204 - root - INFO - TOKEN_USAGE: input=39556, output=758, total=40314, cost=$0.006388
2026-02-10 20:29:00,204 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:29:00,204 - root - INFO - 
**TITLE:** Enhanced Modulation of Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes via Integrated Multi-Pathway Targeting

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | Serves as a crucial hub in insulin signaling pathways, with significant cross-dataset consistency reinforcing its role in improving insulin sensitivity.**
2. **G22553 | Score: 4.0 | Functions as a primary driver in glucose uptake mechanisms, strongly correlating with T2D pathology and supporting G19943 in enhancing metabolic regulation.**
3. **G33764 | Score: 4.0 | A key player in insulin resistance mechanisms, its modulation can synergistically amplify the effects of G19943 and G22553 on metabolic balance.**
4. **G04436 | Score: 4.0 | As an enzyme that regulates glucose homeostasis, its activity complements the actions of the top-ranked targets, enhancing overall metabolic control.**
5. **G19122 | Score: 3.0 | A major regulator in insulin signaling, it is positioned to further support the effects of the primary targets, though less central than the top three.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This refined hypothesis proposes a multi-targeted therapeutic strategy focusing on G19943, G22553, G33764, and G04436 to enhance insulin sensitivity and restore glucose homeostasis in Type 2 Diabetes. By integrating insights from multi-omics data and emphasizing the synergistic interactions among these targets, this approach aims to provide a more comprehensive modulation of metabolic pathways involved in T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation
- WGCNA module role: G19943 is a hub component, while G33764 is a primary driver in relevant modules.
- Regulating TFs: 12 transcription factors identified for G04436.

**MECHANISM_HYPOTHESIS:** The activation of G19943 is expected to enhance its role in insulin signaling pathways, effectively addressing insulin resistance and facilitating glucose metabolism. Concurrently, targeting G22553 is anticipated to significantly enhance glucose uptake, while G33764 will address insulin resistance mechanisms. The modulation of G04436 will further support metabolic regulation through its enzymatic activity, creating a robust therapeutic strategy for T2D.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include pancreatic -cells, skeletal muscle, and liver, as they are critical for insulin action and glucose homeostasis, making them ideal candidates for therapeutic intervention.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The coordinated modulation of these targets is expected to significantly improve insulin sensitivity, reduce hyperglycemia, and enhance overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, the robustness of the supporting evidence, and their critical roles in key biological pathways relevant to T2D. G19943 was selected as the primary target due to its central role in insulin signaling, while G22553 and G33764 were prioritized for their significant contributions to glucose uptake and insulin resistance. G04436 was included to further enhance metabolic regulation.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:29:00,205 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:29:00,205 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:29:00,206 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:29:00,208 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:29:00,209 - root - INFO -   -> Created mutated offspring: '** Enhanced Modulation of Insulin Sensit...'
2026-02-10 20:29:00,209 - root - INFO - Mutation 15/18: parent '** Comprehensive Multi-Target ...'
2026-02-10 20:29:00,209 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 20:29:00,244 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:29:16,406 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:29:16,410 - root - INFO - TOKEN_USAGE: input=39550, output=759, total=40309, cost=$0.006388
2026-02-10 20:29:16,410 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:29:16,410 - root - INFO - 
**TITLE:** Innovative Activation Strategy for Multi-Target Therapy in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0/17** | A central hub in insulin signaling, ensuring robust modulation of metabolic pathways pivotal for T2D management.
2. **G04436** | Score: **4.0/17** | As a key enzyme, activating G04436 can enhance lipid metabolism, complementing the insulin signaling improvements provided by G19943.
3. **G22553** | Score: **4.0/17** | Activation of this driver can further enhance glucose uptake, synergizing effectively with G19943's effects on insulin signaling.
4. **G23245** | Score: **4.0/17** | Supporting glucose uptake and insulin sensitivity, G23245's activation can provide additional regulatory support to enhance therapeutic outcomes.
5. **G27976** | Score: **3.0/17** | As a major regulator, G27976's role in metabolic pathways remains crucial, but its modulation will focus on enhancing stability rather than direct activation.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** This mutated hypothesis adopts a strategy of activating key targets involved in insulin signaling and metabolic regulation. By focusing on G19943 as the primary target while activating G04436, G22553, and G23245, this approach aims to enhance insulin sensitivity and glucose metabolism comprehensively, offering a multi-target therapy for Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism**
- WGCNA module role: **G19943 is a hub component in modules negatively correlated with T2D**
- Regulating TFs: **Notable interactions with transcription factors that modulate metabolic pathways**

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves activating G19943 to enhance insulin signaling and metabolic regulation, leading to improved glucose and lipid metabolism. G04436's activation will directly influence lipid profiles, while the stimulation of G22553 and G23245 will facilitate glucose uptake and insulin sensitivity, creating a synergistic effect across the primary therapeutic axis.

**TISSUE_RATIONALE:** Key tissues targeted will include pancreatic -cells, liver, muscle, and adipose tissue, which are critical for effective insulin action and glucose uptake, thus essential for reversing T2D pathophysiology.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will focus on small molecule activators for G19943, G04436, and G22553, aiming to enhance their functions and optimize metabolic pathways, while a supportive modulation of G23245 will ensure systemic balance.

**PREDICTED_OUTCOME:** The combined activation of G19943, G04436, and G22553 is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and achieve comprehensive therapeutic benefits in managing Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling and metabolic pathways, their high scores across multiple data sources, and their potential for synergistic interactions. G19943 is prioritized as the central target due to its pivotal role, supported closely by G04436 and G22553, which enhance glucose and lipid metabolism, respectively. G23245 and G27976 provide additional support but are ranked lower due to their complementary roles rather than primary actions.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence sources and pathways relevant to T2D management.
2026-02-10 20:29:16,410 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:29:16,410 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:29:16,411 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:29:16,412 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:29:16,412 - root - INFO -   -> Created mutated offspring: '** Innovative Activation Strategy for Mu...'
2026-02-10 20:29:16,412 - root - INFO - Crossover 16/18: parents 'Targeting G22553 for Enhanced ...' x 'Synergistic Multi-Target Modul...'
2026-02-10 20:29:16,454 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:30:04,089 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:30:04,098 - root - INFO - TOKEN_USAGE: input=40305, output=753, total=41058, cost=$0.006498
2026-02-10 20:30:04,101 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:30:04,101 - root - INFO - 
### TITLE: Enhanced Multi-Target Modulation for Improved Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in insulin signaling pathways, providing robust coordination for metabolic regulation essential for T2D management.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling, complementing G19943's central role to enhance glucose metabolism effectively.
3. **G23245** | Score: 4.0 | Pivotal in glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy alongside G19943 and G22553.
4. **G33764** | Score: 4.0 | Supports metabolic regulation and insulin signaling, adding depth and robustness to the multi-target approach.
5. **G00484** | Score: 4.0 | Functions as a transcription factor crucial for regulating insulin signaling and glucose homeostasis, providing essential regulatory support.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses by emphasizing a multi-target approach that leverages the central role of G19943 in insulin signaling and glucose metabolism. By focusing on G19943 as the primary target, we enhance the efficacy of T2D management through synergistic interactions with G22553, G23245, G33764, and G00484, addressing the multifactorial nature of the disease.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways, enhancing the regulatory framework.

**MECHANISM_HYPOTHESIS:** G19943 is hypothesized to function as a central coordinator in insulin signaling and lipid metabolism, which is essential for restoring metabolic homeostasis in T2D. Targeting G22553 alongside G19943 enhances insulin signaling pathways, while G23245 and G33764 contribute to glucose uptake and metabolic regulation. G00484's role as a transcription factor further supports these processes by regulating transcriptional responses critical for insulin sensitivity, creating a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are integral to insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245, G33764, and G00484 to strengthen metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553, which complements its function. G23245 and G33764 provide essential regulatory support, while G00484 adds necessary transcriptional regulation.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:30:04,102 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:30:04,103 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:30:04,106 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:30:04,117 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:30:04,117 - root - INFO -   -> Created offspring: 'Enhanced Multi-Target Modulation for Imp...'
2026-02-10 20:30:04,118 - root - INFO - Crossover 17/18: parents '** Targeting G00484 and G22512...' x '** Comprehensive Modulation of...'
2026-02-10 20:30:04,155 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:30:23,189 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:30:23,192 - root - INFO - TOKEN_USAGE: input=40313, output=727, total=41040, cost=$0.006483
2026-02-10 20:30:23,193 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:30:23,193 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: **4.0** | This gene serves as a hub component in insulin signaling, making it critical for improving insulin sensitivity and metabolic regulation.
2. **G00484** | Score: **4.0** | A transcription factor that modulates key metabolic genes, enhancing insulin sensitivity and glucose metabolism through multiple pathways.
3. **G22553** | Score: **4.0** | A primary driver involved in insulin receptor signaling, crucial for glucose uptake and enhancing therapeutic synergy with G19943.
4. **G33764** | Score: **4.0** | This enzyme plays a significant role in addressing insulin resistance, supporting the overall metabolic dysregulation seen in T2D.
5. **G04436** | Score: **4.0** | A significant regulator of glucose homeostasis that complements the other targets by enhancing metabolic regulation.

**PRIMARY_TARGET:** **G19943**

**SUMMARY:** This hypothesis proposes a comprehensive multi-targeted approach to enhance insulin sensitivity and metabolic control in Type 2 Diabetes by targeting key regulatory genes. By integrating the mechanistic insights of hub components and transcription factors, the strategy seeks to create a robust therapeutic framework addressing multiple pathways involved in T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17** for primary target
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, metabolic regulation**
- WGCNA module role: **G19943 identified as a hub component**
- Regulating TFs: **None identified**

**MECHANISM_HYPOTHESIS:** The activation of G19943 is expected to enhance insulin signaling pathways, directly targeting insulin resistance and improving glucose metabolism. Concurrently, G00484's modulation will upregulate key metabolic genes, thereby addressing insulin sensitivity through transcriptional regulation. G22553 will facilitate glucose uptake, while G33764 will mitigate insulin resistance mechanisms, and G04436 will ensure optimal glucose homeostasis, creating a synergistic and comprehensive therapeutic strategy.

**TISSUE_RATIONALE:** The most relevant tissues for this therapeutic approach include pancreatic -cells for insulin production, muscle for glucose uptake, and liver for glucose metabolism, all of which are pivotal in maintaining glucose homeostasis and combating T2D.

**THERAPEUTIC_APPROACH:** The strategy will focus on the activation of the selected targets through small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, potentially leading to a reversal of disease progression.

**RANKING_RATIONALE:** The targets were ranked based on their priority scores, their critical roles in relevant biological pathways, and the robustness of the supporting evidence. G19943 was prioritized due to its central role in insulin signaling, while G00484 was included for its broad regulatory potential. G22553 and G33764 were selected for their roles in glucose uptake and insulin resistance, respectively, and G04436 was added for its importance in metabolic regulation, creating a holistic treatment approach.

**CONFIDENCE:** **HIGH** based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:30:23,194 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:30:23,194 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:30:23,194 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:30:23,195 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:30:23,195 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 20:30:23,195 - root - INFO - Mutation 18/18: parent '** Enhanced Modulation of Insu...'
2026-02-10 20:30:23,195 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 20:30:23,230 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:31:03,378 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:31:03,385 - root - INFO - TOKEN_USAGE: input=39577, output=786, total=40363, cost=$0.006408
2026-02-10 20:31:03,385 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:31:03,385 - root - INFO - 
**TITLE:** Combination Approach to Enhance Insulin Sensitivity in Type 2 Diabetes through Multi-Targeted Gene Therapy with Opposite Modulation

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | This gene remains a central hub in insulin signaling pathways, and activating its function may enhance insulin sensitivity further.**
2. **G04436 | Score: 4.0 | This enzyme's activation is expected to accelerate glucose metabolism, complementing the activation of G19943 and improving insulin sensitivity.**
3. **G22553 | Score: 4.0 | As a primary driver in T2D-related pathways, its activation will facilitate glucose uptake, synergizing with G19943 and G04436 for improved metabolic effects.**
4. **G33764 | Score: 4.0 | Modulating this enzyme to enhance lipid metabolism could counteract insulin resistance, providing a balanced metabolic response alongside other activated targets.**
5. **G19122 | Score: 3.0 | Activating this major regulator of insulin signaling enhances metabolic balance, supporting the synergistic effects of the primary targets.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This mutated hypothesis proposes a synergistic approach to improve insulin sensitivity and metabolic homeostasis in Type 2 Diabetes through the activation of G19943, G04436, G22553, G33764, and G19122. By activating these targets, the strategy aims to enhance insulin signaling pathways and metabolic regulation simultaneously, addressing the key mechanisms involved in T2D pathology.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: Hub component (G19943), Primary Driver (G22553), Primary Driver (G33764), Major Regulator (G19122)
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G19943 to intensify insulin signaling, thereby addressing insulin resistance and enhancing glucose metabolism. Concurrent activation of G04436 will boost glucose metabolism efficiency, while G22553 will facilitate improved glucose uptake. Enhancing the function of G33764 will regulate lipid metabolism, thus further alleviating insulin resistance. Additionally, activating G19122 will support the restoration of metabolic balance, creating a comprehensive and synergistic therapeutic strategy for T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this approach include pancreatic -cells, muscle, liver, and adipose tissue, all of which play vital roles in glucose metabolism and insulin action, making them ideal candidates for targeted interventions in Type 2 Diabetes management.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The combined activation of these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, ultimately leading to better clinical outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, robust evidence from multiple datasets, and critical roles in key biological pathways. G19943 is retained as the primary target due to its central importance in the gene network, while G04436, G22553, and G33764 were prioritized for their significant contributions to metabolic regulation. G19122 was included as an essential support mechanism to enhance overall therapeutic effectiveness.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:31:03,387 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:31:03,388 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:31:03,388 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:31:03,391 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:31:03,391 - root - INFO -   -> Created mutated offspring: '** Combination Approach to Enhance Insul...'
2026-02-10 20:31:03,391 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 20:31:03,392 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 20:31:03,392 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 20:31:03,392 - root - INFO - Evaluating fitness for hypothesis: t2d-06-6cfdc10e
2026-02-10 20:31:15,458 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:31:15,460 - root - INFO - TOKEN_USAGE: input=1434, output=650, total=2084, cost=$0.000605
2026-02-10 20:31:15,461 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:31:15,461 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is found in the top priority list, but G23245 and G19122 are not, which lowers the score. There is cross-dataset consistency for G22553, but only two datasets support the primary target, which is limited. The overall evidence supporting G22553 is strong, but the absence of the other two ranked targets in the top list impacts the data support score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data available for G22553, G23245, and G19122, as they are all implicated in insulin signaling and glucose metabolism. The rationale for their ranking is logical, especially with G22553 as the primary target, but the lack of higher-ranked targets for G23245 and G19122 diminishes the strength of the overall ranking.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context. The rationale for focusing on skeletal muscle, adipose tissue, and pancreatic -cells is well-supported by existing knowledge in diabetes research. The relationship with G00484 as a transcription factor also adds depth to the mechanistic coherence.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The approach of small molecule activation of G22553, along with modulation of G23245 and G19122, is appropriate and highlights a multi-target strategy. However, the druggability of targets, especially G19122 and G23245, is uncertain, and potential safety considerations are not clearly addressed in the hypothesis.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** While the integration of multiple targets is a common strategy, the specific combination of G22553, G23245, and G19122 presents a creative approach that could offer novel therapeutic pathways. However, the novelty is somewhat diminished by the reliance on established pathways without proposing significantly new mechanisms or connections.

### OVERALL_FITNESS: 6.9 (rounded to 69)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: MODERATE
- Target #3 quality: MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Include additional datasets or evidence types that directly support G23245 and G19122 to strengthen their justification as therapeutic targets.
2. **Address Drugability:** Provide insights into the druggability of G23245 and G19122, potentially by discussing existing compounds or biological mechanisms that could be leveraged.
3. **Safety Considerations:** Incorporate a section discussing potential safety concerns or side effects associated with targeting these genes, which would enhance the therapeutic rationale.
4. **Highlight Novel Mechanisms:** Consider exploring and articulating unique mechanisms or pathways that could emerge from targeting G22553, G23245, and G19122 together, to enhance the novelty of the hypothesis.
2026-02-10 20:31:15,461 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:31:15,461 - root - INFO - Evaluating fitness for hypothesis: t2d-06-fb5e4ae9
2026-02-10 20:31:27,746 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:31:27,749 - root - INFO - TOKEN_USAGE: input=1458, output=741, total=2199, cost=$0.000663
2026-02-10 20:31:27,749 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:31:27,750 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** While G22553 is prioritized as the primary target, it is noted that it is not in the top priority list when compared to other targets such as G19943 and G04436, which might indicate a discrepancy in the overall ranking. However, the proposal does have cross-dataset consistency and evidence from two datasets supports the primary target. The evidence types supporting the primary target are robust, but the lack of presence in the top priority list diminishes this score slightly.

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The rationale for ranking is based on the roles of each target in T2D pathways. However, the fact that G22553 is not listed among the top priority genes raises questions about the validity of the ranking. The scores for all targets are equal, making it difficult to differentiate their strengths, which could lead to ambiguity in prioritization.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with the pathways involved in T2D, including insulin signaling and glucose metabolism. The tissue rationale focusing on skeletal muscle, liver, and adipose tissue is also well-supported by existing data. However, the absence of reported regulating transcription factors weakens this aspect slightly.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and G19943 is appropriate for enhancing their functions, and the strategy accounts for optimization of lipid metabolism through modulation of G04436. The potential for druggability seems reasonable given their roles; however, safety considerations and potential off-target effects should be thoroughly evaluated.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates multiple targets and pathways, it does not present particularly non-obvious connections or insights that significantly extend current understanding or therapeutic strategies for T2D. The integration of existing knowledge is important, but a more innovative approach could enhance this score.

**OVERALL_FITNESS:** 6.4 (rounded to 64)  
(Score Calculation: (7*0.25 + 6*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 6.4)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **MODERATE** (G22553 is ranked highest but not found in the top priority list)  
- Target #2 quality: **STRONG** (G19943 has strong support and is in the top priority list)  
- Target #3 quality: **STRONG** (G04436 is also in the top priority list and has a critical metabolic role)  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Reassess Target Ranking:** Re-evaluate the prioritization of G22553 in light of its absence from the top priority list and consider whether it should be adjusted based on its evidence score relative to G19943 and G04436.
2. **Expand Mechanistic Insights:** Investigate the potential regulatory transcription factors associated with the primary and secondary targets to enhance the mechanistic understanding and overall robustness of the hypothesis.
3. **Safety Considerations:** Include a more detailed analysis of potential safety concerns associated with the proposed therapeutic approaches to ensure a comprehensive evaluation of the treatment strategy.
4. **Innovative Connections:** Explore additional novel interactions or pathways that could enhance the therapeutic potential of the proposed strategy, thereby increasing the novelty score.
2026-02-10 20:31:27,753 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:31:27,753 - root - INFO - Evaluating fitness for hypothesis: t2d-05-4a3761bd
2026-02-10 20:31:37,477 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:31:37,484 - root - INFO - TOKEN_USAGE: input=1442, output=580, total=2022, cost=$0.000564
2026-02-10 20:31:37,484 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:31:37,484 - root - INFO - 
**DATA_SUPPORT_SCORE: 8**  
**DATA_SUPPORT_RATIONALE:** G22553 is present in the top priority list, and there is cross-dataset consistency established across two datasets. The proposal references multiple types of evidence supporting the role of G22553 in insulin signaling pathways, which enhances its credibility.

---

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is largely justified by their established roles in Type 2 Diabetes pathways. The rationale recognizes the complementary functions of the targets. However, while most targets are equally scored, the justification could be stronger by highlighting the distinctive contributions of each target more clearly.

---

**MECHANISTIC_SCORE: 9**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways, and the tissue rationale is robust, focusing on key tissues involved in glucose homeostasis. The role of G00484 as a transcription factor regulating insulin signaling is well considered.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation of G22553 and modulation of the other targets appears appropriate. However, further detail on druggability and potential safety concerns would strengthen this aspect. The consideration of safety and feasibility in a therapeutic context is crucial but lacks elaboration.

---

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis does integrate data creatively by proposing a multi-target approach to enhance insulin sensitivity. However, the connections made are within established pathways, and while this is beneficial, it may not be entirely novel as similar approaches are common in diabetes research.

---

**OVERALL_FITNESS:** 
**Calculated:**  
(8 * 0.25) + (8 * 0.25) + (9 * 0.20) + (7 * 0.20) + (7 * 0.10) = 8.1  
**Overall Fitness:** 81

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **STRONG**  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Enhance Safety Considerations:** Provide more details on safety profiles and potential side effects associated with the modulation of G22553 and its synergistic targets.
2. **Clarify Target Contributions:** Distinguish the specific contributions of each target more clearly in the context of their roles and relationships to each other to reinforce the ranking rationale.
3. **Expand on Druggability:** Include discussions on the druggability of the proposed targets, potentially citing examples of existing compounds or classes that could interact with them.
2026-02-10 20:31:37,485 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:31:37,486 - root - INFO - Evaluating fitness for hypothesis: t2d-06-92855e55
2026-02-10 20:31:52,452 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:31:52,455 - root - INFO - TOKEN_USAGE: input=1460, output=763, total=2223, cost=$0.000677
2026-02-10 20:31:52,455 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:31:52,456 - root - INFO - 
**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is well-supported with a high priority score of 4.0, and there is cross-dataset consistency from two datasets. However, while G19943 and the other targets are prominent, the warning indicates that the target gene does not appear in the identified top priority list, which slightly impacts the overall data support. The existence of multiple evidence types supporting the primary target strengthens this score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their scores and the rationale provided. The higher-ranked targets (G19943, G22553, G04436) display clear strengths in supporting insulin signaling and metabolic regulation, whereas lower-ranked targets (G19122 and G33764) have less robust supporting evidence. The rationale for the ranking is coherent, emphasizing the roles these targets play in metabolic pathways.

**MECHANISTIC_SCORE:** 7  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, focusing on insulin signaling and lipid metabolism. The tissue rationale is strong, as skeletal muscle, liver, and adipose tissue are indeed crucial for these processes. Additionally, the association with transcription factors (TFs) is acknowledged, showing awareness of regulatory networks. However, a deeper exploration of the interactions and potential feedback mechanisms could enhance the coherence.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of developing small molecule activators for the targets is appropriate given their roles in metabolic regulation. The network positions of G19943, G22553, and G04436 suggest they are likely druggable. However, safety considerations and potential off-target effects are not discussed, which could be a concern in developing these therapeutics.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by proposing a multi-target modulation approach, which is relatively innovative. However, the connections between the targets, while valid, are somewhat conventional in the context of diabetes research. More unique insights or novel mechanisms could enhance the perceived novelty of the hypothesis.

**OVERALL_FITNESS:** 7.5  
**Calculation:**  
(8 * 0.25) + (8 * 0.25) + (7 * 0.20) + (7 * 0.20) + (6 * 0.10) = 2 + 2 + 1.4 + 1.4 + 0.6 = 7.4  
Rounded to one decimal place gives an overall fitness of **75.0**.

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **STRONG**  
- Target #3 quality: **STRONG**  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand the Evidence Base:** Include additional datasets or types of evidence to further validate the targets, particularly addressing the warning about the target gene not being in the top priority list.
2. **Enhance Safety Considerations:** Discuss potential safety concerns related to the therapeutic approach, including off-target effects and long-term impacts of multi-target modulation.
3. **Explore Unique Mechanisms:** Investigate and highlight more novel interactions or mechanisms that could set this hypothesis apart from existing research in Type 2 Diabetes. This could involve deeper exploration into the transcription factor relationships and their downstream effects.
4. **Address Feedback Mechanisms:** Consider a more detailed analysis of feedback loops and interactions between targets to better understand the complexity of metabolic regulation in Type 2 Diabetes.
2026-02-10 20:31:52,456 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:31:52,456 - root - INFO - Evaluating fitness for hypothesis: t2d-06-377e5f22
2026-02-10 20:32:02,049 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:32:02,052 - root - INFO - TOKEN_USAGE: input=1466, output=628, total=2094, cost=$0.000597
2026-02-10 20:32:02,053 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:32:02,053 - root - INFO - 
### Evaluation Output

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is ranked highly and has cross-dataset consistency with strong support across multiple data types. However, the warning about the target gene not being found in the top priority list indicates some concern regarding the overall data support for the ranking, which slightly lowers the score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, with clear distinctions made between the strengths of the targets based on their evidence scores. However, the presence of some targets in the top 10 priority list that were not included in the ranked hypothesis suggests a slight inconsistency in the ranking rationale.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the biochemical pathways involved in insulin sensitivity and lipid metabolism. The tissue rationale aligns with the identified roles of the targets, and the inclusion of transcription factors influencing G04436 is a positive aspect of the mechanism.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators targeting the described genes is appropriate, focusing on enhancing their functions. Given the central network position of G19943 and its associated targets, they are likely druggable. Safety considerations are not explicitly addressed, but the targets are well-established in metabolic pathways.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a creative manner, emphasizing the synergistic effects of the ranked targets. However, the connections, while relevant, may not be entirely non-obvious given the existing literature on insulin signaling and lipid metabolism.

### Overall Fitness Calculation
Overall Fitness = (6*0.25) + (7*0.25) + (8*0.20) + (8*0.20) + (7*0.10)  
Overall Fitness = 1.5 + 1.75 + 1.6 + 1.6 + 0.7 = **7.15** (scaled to 100: **71.5**)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Address the Warning:** Clarify why the target gene is not found in the top priority list and consider revising the ranked targets based on the latest data.
2. **Enhance Safety Considerations:** Include a discussion on safety profiles and potential off-target effects for the proposed small molecule activators.
3. **Strengthen Evidence Base:** Incorporate additional evidence types or datasets to further support the primary target's role and validate all the ranked targets more robustly.
4. **Expand on Novelty:** Highlight specific novel aspects of the proposed mechanism that differentiate it from existing therapeutic approaches to enhance the novelty score.
2026-02-10 20:32:02,054 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:32:02,054 - root - INFO - Evaluating fitness for hypothesis: t2d-06-75f231b2
2026-02-10 20:32:15,258 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:32:15,260 - root - INFO - TOKEN_USAGE: input=1540, output=787, total=2327, cost=$0.000703
2026-02-10 20:32:15,261 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:32:15,261 - root - INFO - 
### EVALUATION OF HYPOTHESIS ON TYPE 2 DIABETES MANAGEMENT

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** 
The primary target G04436 has a priority score of 4/17, indicating that it is in the top tier of priority genes. However, the evidence for G04436 is from only one dataset and lacks cross-dataset consistency. The presence of only two evidence types limits the robustness of the support for this target compared to others, despite the general high scores for the ranked targets.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** 
The ranking is justified as all targets share the same score of 4.0, indicating strong relevance to T2D pathways. However, the differentiation between the targets is not clearly defined, especially as G19943 is still considered significant despite being ranked lower in this hypothesis. The rationale for prioritizing G04436 is reasonable due to its role as a critical enzyme, but the lack of clear strength differentiation among the top ranks limits the overall clarity of the ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** 
The mechanism proposed aligns well with the metabolic pathways involved in T2D. The focus on G04436 as a central regulator of metabolic pathways is coherent with the tissue rationale, targeting liver, muscle, and adipose tissues critical for insulin action. Additionally, the consideration of transcription factor interactions further strengthens the mechanistic hypothesis. However, more explicit connections between the targets and their pathways could enhance this score.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** 
The therapeutic approach of activating G04436 and modulating the other targets is appropriate for addressing T2D. There is a reasonable assumption regarding the druggability of these targets, as they play significant roles in metabolic regulation. However, the hypothesis could benefit from a more detailed discussion of potential safety considerations and the practicality of targeting these enzymes within the metabolic network.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** 
The hypothesis does integrate data creatively by focusing on a multi-target approach for T2D management. However, the connections made among the targets are somewhat typical in metabolic research, which may detract from the overall novelty. A more innovative angle or the introduction of less commonly considered pathways or mechanisms could improve this score.

### OVERALL_FITNESS: 69
**Calculated:** (6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 6.75, scaled to 0-100 gives approximately 69.

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Aim to gather additional datasets that provide cross-validation for G04436 and its interactions with the other targets to strengthen the evidence base.
2. **Clarify Ranking Justification:** Provide a more detailed differentiation of the targets based on specific experimental data or biological mechanisms to enhance clarity in ranking.
3. **Expand Mechanistic Insights:** Incorporate more explicit connections between the targets and their respective pathways, including potential downstream effects of modulating these targets.
4. **Address Safety Considerations:** Discuss potential off-target effects or safety profiles associated with the activation of G04436 and modulation of the other targets to build confidence in the therapeutic strategy.
5. **Explore Novel Pathways:** Consider integrating less conventional pathways or exploring the role of additional targets that may have emerged from recent research in T2D to enhance the novelty of the hypothesis.
2026-02-10 20:32:15,261 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:32:15,261 - root - INFO - Novelty bonus applied: 0.3% -> fitness 68.50 -> 68.73
2026-02-10 20:32:15,261 - root - INFO - Evaluating fitness for hypothesis: t2d-06-df8f1424
2026-02-10 20:32:28,877 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:32:28,881 - root - INFO - TOKEN_USAGE: input=1497, output=743, total=2240, cost=$0.000670
2026-02-10 20:32:28,881 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:32:28,882 - root - INFO - 
### Evaluation of the RANKED Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** The primary target, G22553, is not found in the top priority list, which diminishes its relevance in the context of the highest-ranked genes. However, there is cross-dataset consistency for G22553, and it is supported by two datasets. The evidence for the primary target is solid, but the absence in the top priority list reduces the overall score.

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking is based on the roles of the targets in T2D pathways, with G22553 being a central player. However, given that it is not in the top priority list, there could be stronger candidates available. Nonetheless, the justification for the ranking is relatively clear, maintaining a solid rationale for the inclusion of G19943, G04436, and G23245 as synergistic targets.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways involved in glucose metabolism and insulin signaling. The tissue rationale, focusing on pancreatic -cells, muscle, liver, and adipose tissues, is appropriate and supported by existing data. However, the relationships with transcription factors could be elaborated further.

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The activation strategy for G22553 and G19943 appears well-founded, and the inclusion of G04436 for lipid metabolism is relevant. Nevertheless, the druggability of these targets should be more explicitly addressed, as well as potential safety considerations in the therapeutic approach.

**NOVELTY_SCORE: 5**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data effectively, but the connections made are somewhat conventional within the field of diabetes research. While there are some interesting combinations of targets, the overall approach does not present significant novel insights or strategies.

**OVERALL_FITNESS:**  
Calculated:  
(5 * 0.25) + (6 * 0.25) + (7 * 0.20) + (6 * 0.20) + (5 * 0.10) = 1.25 + 1.5 + 1.4 + 1.2 + 0.5 = 5.85  
Overall Fitness (scaled to 0-100): **58.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (G22553 is central but not in the top priority list)
- Target #2 quality: **STRONG** (G19943 is a key hub in insulin signaling)
- Target #3 quality: **STRONG** (G04436 has a significant metabolic role)

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Selection:** Consider including higher-ranked targets from the top priority list to strengthen the hypothesis, especially those that are involved in similar pathways as G22553.
2. **Expand on Mechanisms:** Provide more details on the potential transcription factors interacting with the targets and how they influence metabolic pathways, enhancing the mechanistic coherence.
3. **Address Druggability and Safety:** Clarify the druggability of the selected targets and potential safety profiles, which are crucial for therapeutic development.
4. **Novelty Enhancement:** Explore non-obvious connections between the targets and novel therapeutic strategies that could differentiate this approach from existing treatments for Type 2 Diabetes.
2026-02-10 20:32:28,884 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:32:28,884 - root - INFO - Evaluating fitness for hypothesis: t2d-05-9f28baf9
2026-02-10 20:32:41,400 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:32:41,404 - root - INFO - TOKEN_USAGE: input=1450, output=719, total=2169, cost=$0.000649
2026-02-10 20:32:41,404 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:32:41,404 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** While the primary target G22553 is included in the overall priority list, the warning indicates that it is not among the top 10 priority genes, which diminishes its perceived importance. However, there is cross-dataset consistency, as noted with two datasets supporting the findings. The data evidence suggests a robust role in insulin signaling, but the lack of a clear identification of G22553 in the top tier lowers the score.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is somewhat justified by the data; however, the absence of G22553 in the top priority list raises questions about the strength of its ranking compared to other targets. The rationale for ranking is coherent, as targets are selected based on their roles in T2D pathways, but the distinction between the scores is not as pronounced as it could be, leading to a moderate score.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways, and the tissue rationale is well-supported. The consideration of G00484 as a transcription factor in insulin signaling add depth to the hypothesis. Overall, the mechanistic coherence is strong, reflecting a solid understanding of the biological context.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553, combined with the modulation of other targets, appears appropriate based on the roles of these genes in insulin sensitivity. However, the druggability of G22553 and the potential safety considerations are not fully addressed, which slightly weakens the therapeutic potential score.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis presents an innovative dual modulation approach for Type 2 Diabetes, integrating multiple targets in a comprehensive strategy. However, the connections made are somewhat expected given the established roles of these genes in the relevant pathways, thus limiting the score for novelty.

### OVERALL_FITNESS
**OVERALL_FITNESS: 6.6**  
(6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 6.6)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG (G22553 has strong data support and mechanistic rationale)
- **Target #2 quality:** STRONG (G19943 is central to T2D pathways and well-justified)
- **Target #3 quality:** STRONG (G23245 supports glucose uptake and insulin sensitivity)

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify the Position of G22553:** Address the warning regarding G22553 not being in the top priority list by providing additional evidence or rationale for its inclusion as a primary target.
2. **Expand on Druggability and Safety:** Include more detailed exploration of the druggability of G22553 and potential safety considerations associated with activating this target.
3. **Enhance Distinction Among Targets:** Consider providing further differentiation among the ranked targets to strengthen the justification for their ranking, potentially through additional data on their comparative importance in T2D pathways.
4. **Explore Additional Mechanistic Details:** More detail on how the modulation of each target will interact within the proposed therapeutic strategy could enhance the mechanistic rationale.
2026-02-10 20:32:41,405 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:32:41,405 - root - INFO - Evaluating fitness for hypothesis: t2d-06-9be0570f
2026-02-10 20:32:53,761 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:32:53,764 - root - INFO - TOKEN_USAGE: input=1446, output=734, total=2180, cost=$0.000657
2026-02-10 20:32:53,765 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:32:53,765 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) and other ranked targets (G22553, G04436, G23245, G33764) all have strong evidence scores (4.0) but are not found in the top priority list, which raises concerns about their overall prioritization in the field. The existence of cross-dataset consistency is a positive aspect, as is the identification of G19943 as a hub component in WGCNA modules related to T2D. However, the lack of strong evidence types supporting G19943 limits the score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their established roles in T2D pathways and the proposed synergistic interactions. Each target has a score of 4.0, indicating equal importance, but the rationale could benefit from further differentiation among the targets to clarify why some are prioritized over others. The ranking rationale is logical but could be strengthened by more specific evidence for the complementary effects.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in insulin signaling and metabolic regulation. The tissue rationale includes relevant tissues (pancreatic -cells, liver, muscle, adipose), which is appropriate for the targets identified. However, the absence of identified regulating transcription factors (TFs) could limit the understanding of the regulatory mechanisms in play.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic strategy of activating G19943 and G22553 while modulating G04436 and G23245 is reasonable given their roles in enhancing insulin sensitivity and optimizing metabolic functions. However, the druggability of these targets should be more thoroughly evaluated, particularly considering any potential safety concerns with modulation. The targets are all linked to critical metabolic processes, suggesting a reasonable expectation for therapeutic potential.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates various targets in a multi-target approach, the connections drawn between them are relatively conventional in the context of T2D research. There is potential for more innovative connections or novel angles to be explored that could enhance the uniqueness of the approach.

**OVERALL_FITNESS:** 6.75 (calculated as: 6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG  
- **Target #2 quality:** STRONG  
- **Target #3 quality:** STRONG  

### IMPROVEMENT_SUGGESTIONS:
1. **Target Validation:** Enhance the validation of targets by including additional evidence types that support their roles in T2D beyond the current datasets.
2. **Differentiation of Ranks:** Provide more specific evidence for the synergistic interactions between targets to strengthen the justification for the ranking.
3. **Explore TF Relationships:** Investigate potential transcription factors that may regulate these targets to better understand the networks involved in T2D.
4. **Safety Profile Evaluation:** Conduct a preliminary safety profile analysis for the proposed therapeutic interventions to identify any potential risks associated with the modulation of these targets.
5. **Innovative Connections:** Explore novel mechanisms or pathways that might not be immediately obvious but could provide additional therapeutic insights or strategies for T2D management.
2026-02-10 20:32:53,765 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:32:53,766 - root - INFO - Evaluating fitness for hypothesis: t2d-06-5aa5ca1d
2026-02-10 20:33:07,790 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:33:07,794 - root - INFO - TOKEN_USAGE: input=1461, output=743, total=2204, cost=$0.000665
2026-02-10 20:33:07,795 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:33:07,795 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is in the top priority list, and it has a high priority score of 4.0. The evidence for cross-dataset consistency is strong, with support from 2 datasets. However, the warning about G22553 not being in the top priority list is misleading, as it is indeed part of the top targets with a score of 4.0. The evidence types supporting G22553 are sufficient for a strong argument but could be improved by including more diverse data types.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, as all targets are closely related to insulin signaling and metabolic regulation. Higher-ranked targets (G22553, G19943, G23245) have clear roles that complement each other, making the ranking coherent. However, the rationale could be more explicit regarding how the synergy between the targets has been validated through experimental evidence.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways of insulin signaling and glucose metabolism. The tissue rationale is supported by the inclusion of pancreatic -cells, liver, muscle, and adipose tissue, which are crucial for T2D management. The involvement of G00484 as a transcription factor is considered, but a more detailed explanation of its regulatory role would strengthen the argument.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and modulating the other targets is appropriate, given their roles in insulin signaling. The network position of these targets suggests they are likely druggable. Safety considerations are not mentioned, which is a critical aspect, but the overall approach seems well-founded in targeting metabolic pathways associated with T2D.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a creative manner, proposing a multi-target therapeutic strategy for T2D. However, the connections drawn between the targets, while logical, are not particularly novel in the context of existing literature on T2D therapies, which often explore multi-target strategies.

---

**OVERALL_FITNESS:** 7.6  
**Calculated:** (7*0.25 + 8*0.25 + 8*0.20 + 8*0.20 + 7*0.10) = 1.75 + 2 + 1.6 + 1.6 + 0.7 = 7.65

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

---

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Types:** Include additional types of evidence (e.g., clinical study data, experimental validation) to strengthen the support for G22553 and its synergistic interactions with the other targets.
2. **Clarify Ranking Justification:** Provide clearer descriptions of how the rankings were determined, especially regarding the synergistic effects and experimental validation of each target's role.
3. **Address Safety Considerations:** Include a section discussing potential safety concerns related to the therapeutic approach, especially in the context of drug interactions and patient populations.
4. **Enhance Mechanistic Insights:** Offer more detailed insights into how G00484 and other regulatory factors influence the insulin signaling pathway and the overall metabolic context.
2026-02-10 20:33:07,796 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:33:07,797 - root - INFO - Evaluating fitness for hypothesis: t2d-06-d642bff5
2026-02-10 20:33:21,202 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:33:21,206 - root - INFO - TOKEN_USAGE: input=1545, output=730, total=2275, cost=$0.000670
2026-02-10 20:33:21,206 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:33:21,206 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 5  
**DATA_SUPPORT_RATIONALE:** The primary target (G04436) has a priority score of 4/17, which signifies a solid position within the top priority tier. However, there is no cross-dataset consistency for G04436, which slightly diminishes its data support. The evidence type count is limited, with only 2 types supporting the primary target. Overall, while the score reflects some support, the lack of cross-dataset consistency and limited evidence types holds it back.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as all targets are scored equally and have significant roles in insulin signaling and metabolism. However, the rationale could be improved by providing clearer distinctions in strength among targets, particularly for G22553 and G33764, which were ranked slightly lower despite their similar scores.

**MECHANISTIC_SCORE:** 6  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the lipid metabolism and insulin sensitivity context. The tissue rationale is appropriate as adipose tissue, liver, and muscle are central to glucose homeostasis. However, the WGCNA role for G04436 indicates it has no established connections in the module, which could be a concern for mechanistic coherence. The TF relationships are mentioned but could be explored deeper to enhance the hypothesis.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation is suitable for the targets identified. The targets are likely druggable based on their roles in metabolic pathways. However, the safety considerations could be mentioned in more detail, particularly regarding the potential off-target effects of modulating these metabolic pathways.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates data to propose a multi-target approach that enhances insulin sensitivity, which is a creative strategy. However, the connections made between the targets and their roles could be further elaborated to underscore the novelty of the approach compared to existing therapies.

**OVERALL_FITNESS:** 6.2  
(5*0.25 + 7*0.25 + 6*0.20 + 7*0.20 + 6*0.10 = 6.2)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Aim to gather more evidence types and improve cross-dataset consistency for G04436 and other targets to strengthen the overall data support.
2. **Clarify Ranking Justification:** Provide additional distinctions in the ranking of G22553 and G33764 based on more specific data or evidence to solidify their positions relative to G04436 and G23245.
3. **Deepen Mechanistic Insights:** Explore the WGCNA roles and transcription factor interactions in more detail to better understand how these targets function within their respective pathways and their regulatory networks.
4. **Detail Safety Considerations:** Include more information on potential safety issues associated with modulating these targets, particularly in terms of side effects and off-target interactions to ensure a comprehensive therapeutic evaluation.
5. **Highlight Novel Connections:** Emphasize any novel findings or insights gained from the data integration that may not be obvious or already known, to showcase the uniqueness of the hypothesis further.
2026-02-10 20:33:21,206 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:33:21,207 - root - INFO - Novelty bonus applied: 0.2% -> fitness 50.00 -> 50.08
2026-02-10 20:33:21,207 - root - INFO - Evaluating fitness for hypothesis: t2d-06-62e8a613
2026-02-10 20:33:35,333 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:33:35,336 - root - INFO - TOKEN_USAGE: input=1470, output=735, total=2205, cost=$0.000661
2026-02-10 20:33:35,336 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:33:35,337 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a strong score of 4.0 and is well-supported by data from two datasets. However, the warning about the target gene not being found in the top priority list raises concerns about the robustness of the support for this multi-target approach. The presence of cross-dataset consistency is a positive factor, but the fact that other targets may not be as well-supported detracts from the score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data, as all targets have high scores and significant contributions to insulin signaling and metabolic regulation. The rationale for selecting G19943 as the primary target due to its central role is sensible. However, the absence of some high-ranking targets in the hypothesis raises the question of whether the best possible targets were considered.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in T2D, particularly insulin signaling and lipid metabolism. The tissue rationale focusing on pancreatic -cells, liver, and skeletal muscle is also well-supported. The identification of transcription factors associated with G04436 enhances the understanding of regulatory mechanisms. Overall, there is coherence in the proposed mechanism.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed approach of developing small molecule activators for the selected genes is appropriate and could yield significant therapeutic benefits. However, the assessment of druggability based on network position is vague, and potential safety considerations are not addressed in detail. These factors prevent a higher score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates data from multiple sources and proposes a multi-target approach, which is a valuable strategy. However, the connections made between the targets and their roles in T2D are somewhat expected in the field, and there isn't a strong emphasis on non-obvious connections that would elevate the novelty.

### OVERALL_FITNESS: 
Calculated score:  
(7 * 0.25) + (8 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.75 + 2.00 + 1.60 + 1.40 + 0.60 = 7.35  
Scaled to 0-100: **73.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G19943 is well-supported and central to the hypothesis)
- Target #2 quality: **STRONG** (G22553's role in insulin signaling is critical)
- Target #3 quality: **STRONG** (G33764 supports metabolic regulation effectively)

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Data Evidence:** Incorporate additional datasets or evidence types to bolster the support for the targets, particularly for those not in the top priority list.
  
2. **Address Safety Considerations:** Include a discussion on potential safety issues related to the therapeutic approach to enhance the credibility of the proposal.

3. **Explore Additional Targets:** Consider evaluating other high-priority targets that may have been overlooked, especially given the warning about target gene presence.

4. **Enhance Novelty Aspect:** Emphasize unique connections or innovative strategies that could differentiate this approach from existing therapies in Type 2 Diabetes management.
2026-02-10 20:33:35,337 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:33:35,337 - root - INFO - Evaluating fitness for hypothesis: t2d-06-822750b2
2026-02-10 20:33:50,287 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:33:50,295 - root - INFO - TOKEN_USAGE: input=1445, output=754, total=2199, cost=$0.000669
2026-02-10 20:33:50,295 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:33:50,295 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE:** 5  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, has robust support with a score of 4.0/17 and cross-dataset consistency across 2 datasets. However, the warning indicates that not all ranked targets are in the top priority list, which slightly diminishes the overall score. Multiple evidence types support the primary target, justifying a higher score.

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as G19943 is recognized as a central hub in insulin signaling, and the other targets have strong supporting evidence. The rationale for ranking is clear, though G04436's presence in the top priority list indicates a need for further analysis to ensure all relevant targets are appropriately valued.

**MECHANISTIC_SCORE:** 7  
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the pathways involved in Type 2 Diabetes, integrating insulin signaling, glucose metabolism, and lipid metabolism. The tissue rationale is strong, focused on pancreatic -cells, liver, and skeletal muscle, which are critical for insulin action. The consideration of transcription factor relationships strengthens the coherence of the proposed mechanism.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators for G19943, G22553, and G33764 is appropriate given their roles in enhancing insulin sensitivity and glucose uptake. The potential for these targets to be druggable based on their network positions is high. Safety considerations are not addressed in detail, but the approach seems promising based on the mechanistic insights provided.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a creative manner, proposing a multi-target strategy that is not immediately obvious. However, the targets themselves may not be entirely novel in the context of Type 2 Diabetes research, which could limit the score.

### Overall Fitness Calculation
**Overall Fitness:**  
= DATA_SUPPORT_SCORE * 0.25 + RANKING_QUALITY_SCORE * 0.25 + MECHANISTIC_SCORE * 0.20 + THERAPEUTIC_SCORE * 0.20 + NOVELTY_SCORE * 0.10  
= 5 * 0.25 + 6 * 0.25 + 7 * 0.20 + 8 * 0.20 + 6 * 0.10  
= 1.25 + 1.5 + 1.4 + 1.6 + 0.6  
= **6.35/10**  
= **63.5/100** 

### RANKED_TARGETS_ASSESSMENT
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS
1. **Address Target Inclusion:** Re-evaluate the ranking criteria to ensure all relevant targets are considered in the priority list to prevent oversights that could impact therapeutic strategies.
2. **Enhance Safety Considerations:** Provide more comprehensive safety assessments for the proposed therapeutic approach, including potential off-target effects and toxicity profiles.
3. **Expand Novelty Discussion:** Highlight unique aspects of the integrated approach more clearly to strengthen the novelty score, perhaps by discussing less common connections or mechanisms that have not been extensively explored in previous research.
4. **Clarify Data Sources:** Clearly outline the datasets used and their specific contributions to the evidence supporting the primary and ranked targets to improve the data support score.
2026-02-10 20:33:50,296 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:33:50,296 - root - INFO - Evaluating fitness for hypothesis: t2d-05-a0b219fc
2026-02-10 20:34:08,614 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:34:08,618 - root - INFO - TOKEN_USAGE: input=1456, output=808, total=2264, cost=$0.000703
2026-02-10 20:34:08,619 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:34:08,619 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) is supported by cross-dataset consistency and a high priority score. However, G33764, which plays a significant role in the hypothesis, does not appear in the top priority list, which detracts from the overall data support. The evidence provided for the primary target is strong, but the absence of some ranked targets in the top genes limits the score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is based on the priority scores and the biological relevance of each target. However, the presence of G33764 in the hypothesis yet not in the top-10 priority list raises concerns about the justification of its rank. While G19943 is clearly positioned as a primary target based on its central role in insulin signaling, the rationale could be clearer about why targets like G33764 warrant their positions over others in the top tier.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and metabolic pathways involved in T2D. The tissue rationale (pancreatic -cells, skeletal muscle, and liver) is appropriate, as these are critical for insulin action. The identification of transcription factors for G04436 adds a layer of complexity to the mechanism, indicating thoughtful consideration of regulatory relationships, though more detail on how these TFs interact could strengthen this aspect.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating the selected targets seems appropriate given their roles in metabolic regulation. The network position of G19943 and the others suggests they could be druggable. However, more information on safety considerations and potential side effects of targeting these pathways would enhance confidence in the therapeutic potential.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates multi-pathway targeting, which is a compelling approach for T2D, but it does not introduce significantly novel connections between targets outside the established roles of insulin signaling and glucose metabolism. The integration of multi-omics data adds a layer of sophistication but remains within conventional frameworks for diabetes research.

### OVERALL_FITNESS: 
Calculated Score:  
\[ (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 \]  
Scaled to 0-100: **68.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Justify G33764's Role:** Provide additional data or rationale for G33764's inclusion in the hypothesis, especially why it deserves a spot in the therapeutic strategy despite not being in the top priority list.
2. **Expand Safety Considerations:** Include a discussion about the potential side effects or safety concerns associated with the proposed therapeutic approach to enhance the therapeutic score.
3. **Detail Transcription Factor Interactions:** Elaborate on how the identified transcription factors influence G04436 and the other targets, which could strengthen the mechanistic coherence.
4. **Broaden Novelty Aspects:** Explore potential novel interactions or mechanisms that have not been extensively studied and could enhance the novelty score.
5. **Integrate More Evidence Types:** Consider using additional evidence types, such as clinical data or patient-derived samples, to further support the hypothesis and improve the data support score.
2026-02-10 20:34:08,620 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:34:08,621 - root - INFO - Evaluating fitness for hypothesis: t2d-06-f88e2474
2026-02-10 20:34:22,541 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:34:22,544 - root - INFO - TOKEN_USAGE: input=1457, output=649, total=2106, cost=$0.000608
2026-02-10 20:34:22,544 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:34:22,545 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** While the primary target G19943 is present and supported by robust cross-dataset consistency, several ranked targets (G27976) do not appear in the top priority list, which diminishes the overall strength of data support. There is evidence from two datasets regarding the primary target, but the absence of all ranked targets from the top tier reduces the score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the established roles of the targets in insulin signaling and metabolic pathways. However, the presence of G27976, which has a lower score, raises questions about the relative strength of the lower-ranked targets. The rationale for prioritizing G19943 is strong, but the distinction between higher and lower-ranked targets could be clearer.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in Type 2 Diabetes. The activation of G19943 for enhancing insulin signaling is supported by the data, and the rationale for targeting specific tissues is reasonable. The consideration of transcription factors involved in modulation adds depth to the mechanism, supporting its coherence.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The approach of using small molecule activators is appropriate, as it targets well-established pathways in diabetes management. The targets selected appear druggable based on their network positions. However, further exploration of safety considerations for the multi-target activation strategy would strengthen this aspect.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data effectively but does not propose significantly novel connections or mechanisms beyond the known roles of its targets. While the strategy of multi-target activation is promising, it's a more common approach in therapeutic development, which limits the novelty score.

**OVERALL_FITNESS:** 6.75  
(Weighted calculation: (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.75)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Re-evaluate Target Inclusion:** Consider revising the ranked targets to ensure they align with the top priority list, especially focusing on targets that have demonstrated clear relevance and consistency across datasets.
2. **Clarify Distinction in Ranking:** Strengthen the rationale for ranking distinctions among G04436, G22553, and G23245 to ensure the differences in their contributions are clear and compelling.
3. **Explore Safety Profiles:** Conduct a preliminary assessment of safety profiles for the proposed small molecule activators to address potential adverse effects, especially when targeting multiple pathways simultaneously.
4. **Highlight Novel Mechanisms:** Consider incorporating novel biochemical pathways or mechanisms that may not be widely recognized to enhance the novelty of the hypothesis.
2026-02-10 20:34:22,545 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:34:22,545 - root - INFO - Evaluating fitness for hypothesis: t2d-06-a1f0f2bf
2026-02-10 20:34:36,570 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:34:36,574 - root - INFO - TOKEN_USAGE: input=1451, output=809, total=2260, cost=$0.000703
2026-02-10 20:34:36,574 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:34:36,574 - root - INFO - 
### Evaluation of the Hypothesis: Enhanced Multi-Target Modulation for Improved Insulin Sensitivity in Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is indeed in the top priority list, which enhances the credibility of the hypothesis. However, there is a warning about a target gene not found in the top priority list, which raises some concerns about the completeness of the evidence. There is cross-dataset consistency for the primary target, and there are multiple types of evidence supporting G19943, which contributes positively to the score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking of targets is generally justified, as G19943 is supported by strong evidence and is central to the hypothesis. The other targets are ranked in a manner that reflects their roles in the insulin signaling pathway, aligning with the expected outcomes. However, the absence of some lower-ranked targets in the top priority list could create ambiguity regarding their relative strength in comparison to others.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with the pathways involved in T2D. The rationale for targeting pancreatic -cells, muscle, liver, and adipose tissue is sound, as these tissues are critical for insulin action. The role of G00484 as a transcription factor is appropriately considered in supporting insulin signaling. Overall, the mechanism presented is logical and well-supported by the data.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation appears appropriate, given the roles of the targets in insulin signaling and glucose metabolism. However, the evaluation of druggability based on network position and safety considerations could be elaborated further. While the targets seem promising, more detailed information on potential safety concerns and specific activation strategies would strengthen this aspect.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a way that emphasizes a multi-target approach, which is relatively novel in the context of T2D management. However, the connections proposed among the targets, while sound, may not be particularly unexpected, which slightly limits the novelty score. More innovative insights or unexpected relationships could enhance this dimension.

### OVERALL_FITNESS: 
Calculated as follows: 
- DATA_SUPPORT: 7 * 0.25 = 1.75
- RANKING_QUALITY: 8 * 0.25 = 2.00
- MECHANISTIC: 8 * 0.20 = 1.60
- THERAPEUTIC: 7 * 0.20 = 1.40
- NOVELTY: 6 * 0.10 = 0.60 

Total fitness score: 1.75 + 2.00 + 1.60 + 1.40 + 0.60 = **7.35** (scaled to 0-100: **73.5**)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G19943 is a central hub with robust evidence)
- Target #2 quality: **STRONG** (G22553 complements G19943 effectively)
- Target #3 quality: **STRONG** (G23245 is pivotal for glucose uptake)

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Include additional evidence types or datasets to strengthen support for the targets, particularly those not found in the top priority list.
2. **Clarify Drug Development:** Provide more detailed strategies for the therapeutic approach, including specifics on potential druggability and safety considerations.
3. **Enhance Novelty:** Explore and highlight more innovative connections or insights that could differentiate this hypothesis from existing literature, potentially focusing on unexpected interactions or novel regulatory mechanisms.
2026-02-10 20:34:36,575 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:34:36,575 - root - INFO - Evaluating fitness for hypothesis: t2d-06-82c28f1c
2026-02-10 20:34:48,652 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:34:48,690 - root - INFO - TOKEN_USAGE: input=1425, output=785, total=2210, cost=$0.000685
2026-02-10 20:34:48,690 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:34:48,690 - root - INFO - 
### Evaluation of the RANKED Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) is ranked number one, and there is cross-dataset consistency for this target, which is a positive indicator. However, the warning states that the target gene is not found in the top priority list, which raises concerns about its relevance despite the support from two datasets. The priority score of 4.0 is decent, but the overall evidence types supporting the primary target could be stronger, considering there are no identified regulating transcription factors.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as all targets have a score of 4.0, indicating similar importance. However, the lack of distinguishing factors among the targets could be a concern. The rationale for prioritizing G19943 is based on its role as a hub component in insulin signaling, which makes sense given its biological importance. Nonetheless, the absence of substantial differentiation in scores among the targets complicates the ranking's clarity.

---

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways involved in insulin signaling and glucose metabolism, particularly in the context of Type 2 Diabetes. The rationale for focusing on pancreatic -cells, muscle, and liver tissues is well-supported by the roles these tissues play in glucose homeostasis. However, the absence of identified regulating transcription factors may limit the mechanistic depth.

---

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The proposed approach of activating targets through small molecules is appropriate given their roles in insulin sensitivity and metabolic regulation. The strategy appears druggable based on the network positions of the targets, and the focus on enhancing metabolic function is well-aligned with therapeutic needs in Type 2 Diabetes. However, safety considerations and potential off-target effects were not addressed, which could impact the overall therapeutic potential.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** While the hypothesis integrates data across multiple targets, it does not propose particularly innovative connections or insights that are not already established in the field. The multi-target approach is becoming more common, which diminishes the novelty of the strategy. However, the focus on a synergistic effect of targeting multiple pathways is a valuable aspect.

---

### OVERALL_FITNESS: 6.7
**Calculated as:** (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.7 (scaled to 0-100)

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G19943) quality:** STRONG
- **Target #2 (G00484) quality:** MODERATE
- **Target #3 (G22553) quality:** MODERATE
- **Target #4 (G33764) quality:** MODERATE
- **Target #5 (G04436) quality:** MODERATE

---

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Gather more supporting evidence types for the primary target, particularly identifying regulating transcription factors.
2. **Clarify Ranking Justification:** Differentiate the targets more clearly in terms of their unique roles and contributions to the pathways involved.
3. **Address Safety Considerations:** Include a discussion of potential safety concerns and off-target effects related to the proposed therapeutic approach.
4. **Enhance Novelty:** Investigate and highlight any novel or less-explored connections among the targets to strengthen the hypothesis's uniqueness.
2026-02-10 20:34:48,691 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:34:48,691 - root - INFO - Evaluating fitness for hypothesis: t2d-06-df3eb9f5
2026-02-10 20:35:02,219 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:35:02,222 - root - INFO - TOKEN_USAGE: input=1484, output=677, total=2161, cost=$0.000629
2026-02-10 20:35:02,222 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:35:02,222 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) is ranked highly, but there are concerns since other targets (G33764, G22553, G04436) are not present in the top 10 priority genes list. There is cross-dataset consistency for the primary target, and the evidence includes a strong role in insulin signaling and metabolic regulation. However, the absence of certain ranked targets in the top priority list moderately lowers the score.

---

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data availability and the roles of the targets in metabolic processes related to T2D. The rationale behind prioritizing the targets based on their scores and roles in pathways is sound. However, the missing top-ranked genes from the primary comparison list raises questions about the robustness of the rankings.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with known insulin signaling pathways and addresses critical aspects of glucose and lipid metabolism. The tissue rationale aligns well with the targets, indicating that the approach considers physiological contexts. The role of transcription factors associated with G04436 demonstrates an understanding of regulatory networks, enhancing the mechanistic coherence.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating the targets seems appropriate given their roles in enhancing insulin sensitivity. Furthermore, the targets' network positions suggest they may be druggable. However, considerations regarding potential safety and off-target effects should be more explicitly addressed to fully support the therapeutic potential.

---

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates multi-targeted approaches to enhance insulin sensitivity, which is an evolving concept in diabetes treatment. However, while the connections made are relevant, they are not particularly novel in the context of existing therapeutic strategies aimed at T2D.

---

**OVERALL_FITNESS:**  
Calculated as follows:  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.65  
Scaled to 0-100: **Overall Fitness: 66.5**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **STRONG**  
- Target #2 quality: **MODERATE**  
- Target #3 quality: **MODERATE**  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Target Validation:** Ensure that all ranked targets are present in the top priority gene list or provide additional evidence to justify their inclusion.
2. **Safety Considerations:** Include a section that discusses potential safety issues related to the activation of these targets, as this is crucial for clinical applicability.
3. **Novelty Enhancement:** Explore more innovative combinations or lesser-known pathways that could be integrated into the hypothesis to strengthen its novelty.
4. **Further Mechanistic Insights:** Provide a deeper understanding of how the activation of each target will specifically interact with the others in the context of insulin signaling, possibly through detailed modeling or preliminary experimental data.
2026-02-10 20:35:02,222 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:35:02,223 - root - INFO - Population fitness evaluation complete. Top score: 79.00
2026-02-10 20:35:02,223 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 20:35:02,224 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G04436']...
2026-02-10 20:35:02,224 - root - INFO - Generation 6 stats: mean=60.59, max=79.5, min=50.0
2026-02-10 20:35:02,224 - root - INFO - Generation 6 complete
2026-02-10 20:35:02,224 - root - INFO - Running generation 7
2026-02-10 20:35:02,224 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 20:35:02,224 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 20:35:02,224 - root - INFO - Crossover 1/18: parents 'Targeting G22553 for Enhanced ...' x 'Enhanced Multi-Target Modulati...'
2026-02-10 20:35:02,259 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:35:41,187 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:35:41,192 - root - INFO - TOKEN_USAGE: input=40312, output=750, total=41062, cost=$0.006497
2026-02-10 20:35:41,192 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:35:41,193 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 coordinates metabolic regulation, making it essential for improving insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling, G22553s modulation complements G19943, enhancing glucose metabolism and insulin action.
3. **G23245** | Score: 4.0 | Critical for glucose uptake and insulin sensitivity, G23245 reinforces the therapeutic strategy by working synergistically with G19943 and G22553.
4. **G00484** | Score: 4.0 | This transcription factor is a key regulator of insulin signaling, providing necessary regulatory support to the actions of G19943 and G22553.
5. **G33764** | Score: 4.0 | Supporting metabolic regulation, G33764 adds depth to the multi-target approach, ensuring robust interaction within insulin signaling pathways.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a multi-target approach focusing on G19943 as the primary target due to its central role in insulin signaling and metabolic regulation. By incorporating G22553, G23245, G00484, and G33764, we aim to address the multifactorial nature of Type 2 Diabetes (T2D) with robust synergistic interactions that enhance insulin sensitivity and glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways, enhancing the regulatory framework.

**MECHANISM_HYPOTHESIS:** The combination of G19943 as the central coordinator and G22553 as a primary driver is hypothesized to significantly enhance insulin signaling and glucose metabolism in T2D. G23245 will facilitate glucose uptake, while G00484 will regulate transcriptional responses critical for insulin sensitivity. G33764 will ensure overall metabolic regulation, creating a comprehensive mechanism for managing T2D through synergistic interactions among the targets.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are integral to insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245 and G00484 to strengthen metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553, which complements its function. G23245 and G00484 provide essential regulatory support, while G33764 adds necessary metabolic regulation.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:35:41,194 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:35:41,194 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:35:41,194 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:35:41,196 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:35:41,196 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy for ...'
2026-02-10 20:35:41,197 - root - INFO - Crossover 2/18: parents 'Enhanced Multi-Target Modulati...' x 'Dual Modulation for Enhanced I...'
2026-02-10 20:35:41,234 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:36:19,383 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:36:19,391 - root - INFO - TOKEN_USAGE: input=40320, output=748, total=41068, cost=$0.006497
2026-02-10 20:36:19,391 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:36:19,391 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in insulin signaling pathways, essential for coordinating metabolic regulation and enhancing overall insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver of insulin signaling, crucial for improving glucose metabolism and amplifying the effects of G19943.
3. **G23245** | Score: 4.0 | Plays a critical role in glucose uptake and insulin sensitivity, providing necessary support to the insulin signaling cascade.
4. **G33764** | Score: 4.0 | Functions as a primary driver in metabolic regulation, enhancing insulin action and supporting the overall therapeutic strategy.
5. **G00484** | Score: 4.0 | Acts as a key transcription factor in insulin signaling pathways, ensuring effective transcriptional regulation of genes involved in glucose homeostasis.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses by leveraging G19943s role as a central coordinator in insulin signaling while emphasizing the complementary actions of G22553 and G23245 to enhance glucose metabolism and insulin sensitivity. Additionally, G33764 and G00484 provide critical regulatory support, creating a comprehensive approach to address the multifactorial nature of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 serves as a transcriptional regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that G19943 operates as a central hub in insulin signaling, while G22553 enhances this pathway's activity, leading to improved glucose metabolism. G23245 facilitates glucose uptake and further amplifies insulin sensitivity. G33764 contributes to metabolic regulation, and G00484's role as a transcription factor ensures robust gene expression necessary for metabolic homeostasis. This multi-target strategy aims to create synergistic effects that restore insulin sensitivity and improve overall metabolic function in T2D.

**TISSUE_RATIONALE:** Target tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are critical for mediating insulin action, glucose uptake, and overall metabolic regulation. These tissues are pivotal in developing effective therapeutic interventions for T2D.

**THERAPEUTIC_APPROACH:** The approach involves the small molecule activation of G19943 and G22553, complemented by the modulation of G23245, G33764, and G00484 to enhance insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to result in significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed closely by G22553, which complements its function. G23245 and G33764 provide essential support for glucose metabolism, while G00484 ensures effective transcriptional regulation.

**CONFIDENCE:** HIGH, based on robust data support and significant associations with T2D mechanisms.
2026-02-10 20:36:19,392 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:36:19,392 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:36:19,393 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:36:19,395 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:36:19,396 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy to E...'
2026-02-10 20:36:19,396 - root - INFO - Crossover 3/18: parents 'Synergistic Multi-Target Modul...' x '** Comprehensive Modulation of...'
2026-02-10 20:36:19,450 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:36:59,723 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:36:59,730 - root - INFO - TOKEN_USAGE: input=40341, output=724, total=41065, cost=$0.006486
2026-02-10 20:36:59,730 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:36:59,730 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity and Metabolic Homeostasis in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Serves as a central hub in T2D pathways with strong evidence of involvement in insulin signaling and metabolic regulation.
2. **G04436** | Score: 4.0 | Functions as a key regulator of glucose homeostasis, enhancing the effects of G19943 and providing robust metabolic regulation.
3. **G22553** | Score: 4.0 | A primary driver in insulin receptor signaling, synergistically supporting G19943 and G04436 in improving glucose uptake.
4. **G33764** | Score: 4.0 | Addresses mechanisms of insulin resistance, complementing the effects of G19943 and enhancing overall metabolic control.
5. **G19122** | Score: 3.0 | Major regulator that supports insulin signaling pathways, reinforcing the therapeutic strategy by further improving metabolic balance.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis posits a comprehensive multi-target approach that integrates key findings from both parent hypotheses. By prioritizing G19943 as the central target, and supporting it with G04436, G22553, G33764, and G19122, the strategy aims to enhance insulin sensitivity while simultaneously addressing multiple pathways involved in Type 2 Diabetes management.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation.
- WGCNA module role: G19943 and G33764 identified as hub components in relevant modules.
- Regulating TFs: 12 transcription factors identified for G04436.

**MECHANISM_HYPOTHESIS:** The activation of G19943 is hypothesized to enhance insulin signaling and metabolic homeostasis, directly addressing insulin resistance in T2D. Concurrent modulation of G04436 is expected to improve glucose homeostasis through enzymatic regulation, while G22553 enhances glucose uptake. G33764 directly targets insulin resistance mechanisms, and G19122 further supports overall insulin signaling, creating a robust therapeutic framework for managing T2D.

**TISSUE_RATIONALE:** The primary tissues involved include pancreatic -cells, muscle, liver, and adipose tissue, as these are crucial for insulin action, glucose uptake, and overall metabolic regulation, making them prime targets for therapeutic intervention in T2D.

**THERAPEUTIC_APPROACH:** The proposed strategy involves small molecule activation of G19943, G04436, and G22553 to enhance their functions, alongside modulation of G33764 and G19122 to strengthen metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of these interconnected targets is anticipated to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better overall management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence backing, and their potential for synergistic interactions. G19943 is prioritized for its central role, while G04436 and G22553 are crucial for enhancing metabolic regulation. G33764 addresses insulin resistance, and G19122 supports overall insulin signaling pathways.

**CONFIDENCE:** HIGH, based on strong support from multiple evidence types and significant associations with T2D pathways.
2026-02-10 20:36:59,732 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:36:59,732 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:36:59,732 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:36:59,735 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:36:59,735 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 20:36:59,735 - root - INFO - Crossover 4/18: parents '** Integrated Multi-Target Str...' x 'Alternative Multi-Target Strat...'
2026-02-10 20:36:59,785 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:37:44,073 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:37:44,078 - root - INFO - TOKEN_USAGE: input=40360, output=787, total=41147, cost=$0.006526
2026-02-10 20:37:44,078 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:37:44,078 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Approach for Improved Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G04436** | Score: **4.0/17** | This enzyme is central to metabolic regulation, demonstrating strong evidence across multiple datasets and significant correlation with T2D pathways.
2. **G22553** | Score: **4.0/17** | Functions as a primary driver in insulin signaling, supporting glucose metabolism and showing consistent results across analyses.
3. **G23245** | Score: **4.0/17** | A primary driver for glucose uptake and insulin sensitivity, contributing significantly to metabolic control in relevant tissues.
4. **G19943** | Score: **4.0/17** | Acts as a hub in insulin signaling, enhancing glucose homeostasis while complementing the primary targets without overshadowing them.
5. **G33764** | Score: **4.0/17** | Provides regulatory support within metabolic pathways, enhancing the efficacy of the primary targets identified.

**PRIMARY_TARGET:** **G04436**

**SUMMARY:** This hypothesis combines the strengths of both parent hypotheses by emphasizing G04436 as a pivotal enzyme for metabolic regulation while still leveraging the synergistic effects of G22553, G23245, G19943, and G33764. This multi-targeted approach addresses the complexities of Type 2 Diabetes by targeting both insulin signaling and metabolic regulation pathways.

**DATA_EVIDENCE:**
- Priority Score: **4.0/17 for primary target**
- Cross-dataset consistency: **Yes, 2 datasets**
- Key pathways involved: **Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.**
- WGCNA module role: **G04436 identified as a primary driver in the negatively correlated T2D module; G22553 is a primary driver in the positively correlated module.**
- Regulating TFs: **None reported.**

**MECHANISM_HYPOTHESIS:** The mechanism centers on G04436 enhancing metabolic regulation, which influences both lipid profiles and glucose metabolism. G22553 enhances insulin sensitivity through its role in insulin signaling, while G23245 supports glucose uptake critical for metabolic control. G19943 provides additional regulatory support within insulin signaling pathways, and G33764 enhances the overall efficacy of the multi-target approach by addressing metabolic imbalances associated with Type 2 Diabetes.

**TISSUE_RATIONALE:** The relevant tissues include the liver, skeletal muscle, and adipose tissue, as they play crucial roles in insulin action, glucose uptake, and lipid metabolism. Targeting these genes within these tissues is essential for reversing the metabolic disturbances linked to Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule activation of G04436 to enhance its metabolic regulation, alongside modulation of G22553 and G23245 to optimize insulin signaling and glucose uptake, respectively. G19943 and G33764 will be modulated to provide additional regulatory support within the overall therapeutic framework.

**PREDICTED_OUTCOME:** The integrated modulation of these targets is expected to significantly enhance metabolic regulation, improve insulin sensitivity, and promote better glucose metabolism, leading to improved patient outcomes in managing Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their established roles as primary drivers in T2D pathways, strength of evidence across multiple datasets, and potential synergistic interactions. G04436 was prioritized for its central role in metabolic regulation, with G22553 and G23245 following for their significant contributions to glucose metabolism and insulin sensitivity. G19943 and G33764 were included to ensure comprehensive coverage of insulin signaling and metabolic regulation without overshadowing the primary targets.

**CONFIDENCE:** **HIGH** based on robust data support across multiple evidence types and pathways relevant to Type 2 Diabetes management.
2026-02-10 20:37:44,079 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:37:44,079 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:37:44,079 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:37:44,081 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:37:44,081 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Approach f...'
2026-02-10 20:37:44,081 - root - INFO - Crossover 5/18: parents 'Targeting G04436 for Enhanced ...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 20:37:44,120 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:37:59,753 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:37:59,756 - root - INFO - TOKEN_USAGE: input=40349, output=805, total=41154, cost=$0.006535
2026-02-10 20:37:59,757 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:37:59,757 - root - INFO - 
### TITLE: Integrated Targeting of G22553, G04436, and G23245 for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | As a primary driver in insulin signaling pathways, G22553 is crucial for enhancing glucose metabolism and complements the effects of G23245.
2. **G04436** | Score: **4.0** | This enzyme's role in lipid metabolism is essential for improving insulin sensitivity, and it synergizes with G22553 to enhance metabolic control.
3. **G23245** | Score: **4.0** | Known for its pivotal role in glucose uptake, targeting G23245 will reinforce the actions of both G22553 and G04436, providing a comprehensive therapeutic strategy.
4. **G33764** | Score: **4.0** | This enzyme supports metabolic regulation and insulin signaling, adding robustness to the therapeutic approach by complementing the actions of the primary targets.
5. **G00484** | Score: **4.0** | As a transcription factor, it provides regulatory support to the insulin signaling pathways, enhancing the effectiveness of the primary targets.

#### PRIMARY_TARGET: G22553

### SUMMARY:
This hypothesis proposes a multi-target approach focusing on G22553, G04436, and G23245 to enhance insulin sensitivity and improve glucose metabolism in Type 2 Diabetes. By integrating the roles of these critical targets, the strategy aims to address the multifactorial nature of T2D, leveraging their synergistic interactions to optimize therapeutic outcomes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation.
- **WGCNA module role**: G22553 is identified as a primary driver in the module positively correlated with T2D.
- **Regulating TFs**: G00484 acts as a regulator in insulin signaling pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism involves targeting G22553 to enhance insulin signaling, thus improving glucose metabolism. Concurrent activation of G04436 will boost lipid metabolism, facilitating better insulin sensitivity. Additionally, G23245 will enhance glucose uptake, while G33764 will ensure robust metabolic regulation. The transcription factor G00484 will provide further regulatory support to these pathways, creating a comprehensive approach to managing T2D.

### TISSUE_RATIONALE:
The most relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are essential for insulin action and glucose homeostasis. Enhancing the function of these tissues can directly impact insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The therapeutic strategy will involve small molecule activation of G22553, alongside modulation of G04436, G23245, G33764, and G00484 to strengthen metabolic regulation and improve insulin sensitivity.

### PREDICTED_OUTCOME:
Effective modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhancements in glucose metabolism, and better management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
The targets were ranked based on their established roles as primary drivers in T2D pathways and strong data support across multiple evidence types. G22553 was prioritized for its critical role in insulin signaling, followed by G04436 for its lipid metabolism contribution, G23245 for glucose uptake, G33764 for metabolic regulation support, and G00484 for its essential transcriptional regulatory role.

### CONFIDENCE: HIGH
This hypothesis is grounded in robust data support across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 20:37:59,758 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:37:59,758 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:37:59,759 - root - INFO -   -> Created offspring: 'Integrated Targeting of G22553, G04436, ...'
2026-02-10 20:37:59,759 - root - INFO - Crossover 6/18: parents 'Enhanced Multi-Target Modulati...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 20:37:59,793 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:38:39,465 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:38:39,470 - root - INFO - TOKEN_USAGE: input=40312, output=821, total=41133, cost=$0.006539
2026-02-10 20:38:39,470 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:38:39,470 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity and Metabolic Homeostasis in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is critical for enhancing glucose metabolism, making it the focal point for intervention.
2. **G19943** | Score: 4.0 | Identified as a central hub in insulin signaling, G19943 complements G22553's action, enhancing metabolic regulation and insulin sensitivity.
3. **G23245** | Score: 4.0 | A pivotal player in glucose uptake and insulin sensitivity, targeting G23245 alongside G22553 and G19943 reinforces the therapeutic strategy.
4. **G00484** | Score: 4.0 | This transcription factor is crucial for regulating insulin signaling and glucose homeostasis, providing essential transcriptional support to the other targets.
5. **G33764** | Score: 4.0 | Enhancing metabolic regulation and supporting insulin signaling pathways, G33764 adds robustness to the multi-target approach, addressing potential metabolic dysregulation.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a robust multi-target approach to enhance insulin sensitivity in Type 2 Diabetes by leveraging the synergistic actions of G22553, G19943, G23245, G00484, and G33764. By focusing on G22553 as the primary target, we integrate key regulatory mechanisms that enhance insulin signaling and metabolic homeostasis, addressing the multifactorial nature of T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D, while G19943 is a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways, enhancing the regulatory framework.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that targeting G22553 will enhance insulin signaling pathways, significantly improving glucose metabolism. G19943's role as a central coordinator will complement this action, while G23245's involvement in glucose uptake will further enhance insulin sensitivity. G00484's transcriptional regulatory role will amplify these effects, ensuring robust metabolic responses. G33764 will provide additional support by contributing to metabolic regulation, thereby creating a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they play critical roles in insulin action, glucose uptake, and overall metabolic homeostasis. These tissues are optimal targets for therapeutic interventions aimed at improving insulin sensitivity.

**THERAPEUTIC_APPROACH:** The therapeutic strategy involves small molecule activation of G22553 to enhance its function, alongside modulation of G19943, G23245, G00484, and G33764 to strengthen insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is anticipated to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes, ultimately aiming for restored metabolic homeostasis.

**RANKING_RATIONALE:** Targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role in insulin signaling, followed by G19943, which complements its function. G23245, G00484, and G33764 are included for their essential support in glucose uptake and metabolic regulation.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:38:39,470 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:38:39,471 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:38:39,471 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:38:39,474 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:38:39,474 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy for Enh...'
2026-02-10 20:38:39,474 - root - INFO - Crossover 7/18: parents 'Alternative Multi-Target Strat...' x 'Synergistic Multi-Target Modul...'
2026-02-10 20:38:39,543 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:39:03,098 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:39:03,102 - root - INFO - TOKEN_USAGE: input=40352, output=768, total=41120, cost=$0.006514
2026-02-10 20:39:03,102 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:39:03,102 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhanced Metabolic Regulation in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Central hub in T2D pathways with strong evidence supporting its role in insulin signaling and metabolic regulation.
2. **G04436** | Score: 4.0 | A critical enzyme for metabolic regulation, enhancing both insulin sensitivity and glucose metabolism, supported by multiple datasets.
3. **G22553** | Score: 4.0 | Key driver in insulin signaling pathways that complement G19943, further promoting glucose metabolism.
4. **G23245** | Score: 4.0 | Essential for glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy alongside G19943 and G22553.
5. **G33764** | Score: 4.0 | Provides regulatory support within metabolic pathways, enhancing the overall efficacy of the proposed multi-target strategy.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis combines the strength of G19943 as a central regulator of insulin signaling with G04436's role in metabolic regulation, while also leveraging G22553 and G23245 for enhanced glucose metabolism. The inclusion of G33764 adds further regulatory support, creating a comprehensive strategy to address the complexities of Type 2 Diabetes management.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- **WGCNA module role**: G19943 identified as a hub component in modules negatively correlated with T2D.
- **Regulating TFs**: G00484 acts as a regulator in insulin signaling pathways.

### MECHANISM_HYPOTHESIS:
The mechanism proposed integrates G19943 as a pivotal regulator in insulin signaling and lipid metabolism, essential for restoring metabolic homeostasis in T2D. G04436 enhances metabolic pathways critical for lipid profiles and glucose metabolism. G22553 and G23245 synergistically support insulin signaling and glucose uptake, respectively. G33764 further reinforces metabolic regulation, ensuring a comprehensive approach to improving insulin sensitivity and glucose homeostasis.

### TISSUE_RATIONALE:
The targeted tissues include the liver, muscle, pancreatic -cells, and adipose tissue, which are vital for effective insulin action, glucose uptake, and overall metabolic regulation. Focusing on these tissues is crucial for developing therapies aimed at reversing metabolic disturbances associated with Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The proposed approach involves the small molecule activation of G19943 and G04436 to enhance their metabolic functions, along with the modulation of G22553, G23245, and G33764 to strengthen insulin signaling and glucose uptake. This multi-target strategy aims for comprehensive metabolic regulation.

### PREDICTED_OUTCOME:
The integrated modulation of these targets is anticipated to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
The targets were ranked based on their established roles as primary drivers in T2D pathways, strength of evidence across multiple datasets, and their potential for synergistic interactions. G19943 was prioritized for its central role in metabolic regulation, followed by G04436 for its critical enzymatic function. G22553 and G23245 were included for their complementary roles in promoting glucose metabolism, while G33764 provided necessary regulatory support.

### CONFIDENCE: HIGH
The hypothesis is supported by robust data across multiple evidence types and significant associations with pathways relevant to Type 2 Diabetes management.
2026-02-10 20:39:03,102 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:39:03,103 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:39:03,108 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 20:39:03,109 - root - INFO - Crossover 8/18: parents 'Enhanced Multi-Target Modulati...' x '** Combination Approach to Enh...'
2026-02-10 20:39:03,146 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:39:30,662 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:39:30,665 - root - INFO - TOKEN_USAGE: input=40354, output=762, total=41116, cost=$0.006510
2026-02-10 20:39:30,665 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:39:30,666 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Approach to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in insulin signaling pathways, crucial for coordinating metabolic regulation and enhancing insulin sensitivity in T2D.
2. **G22553** | Score: 4.0 | Primary driver in T2D-related pathways, its activation is expected to synergistically improve glucose uptake and metabolism alongside G19943.
3. **G04436** | Score: 4.0 | This enzyme's activation will enhance glucose metabolism efficiency, complementing the actions of G19943 and G22553.
4. **G33764** | Score: 4.0 | Modulating this enzyme to enhance lipid metabolism can counteract insulin resistance, providing a balanced metabolic response in conjunction with other activated targets.
5. **G19122** | Score: 3.0 | A major regulator of insulin signaling, its activation supports the metabolic balance and enhances the effects of the primary targets.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a synergistic multi-target strategy to enhance insulin sensitivity in Type 2 Diabetes by targeting G19943 as the central hub, complemented by G22553 and G04436 to improve glucose metabolism. Additionally, G33764 and G19122 will be modulated to enhance lipid metabolism and metabolic regulation, addressing insulin resistance comprehensively.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 (Hub Component), G22553 (Primary Driver), G33764 (Primary Driver), G19122 (Major Regulator)
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** G19943 serves as a central coordinator in insulin signaling and lipid metabolism, essential for restoring metabolic homeostasis in T2D. Its activation will enhance insulin signaling pathways and glucose uptake, while G22553 will facilitate improved glucose metabolism. Concurrent activation of G04436 will boost metabolic efficiency, and modulation of G33764 will help to regulate lipid metabolism, thereby alleviating insulin resistance. Additionally, G19122's role as a major regulator further enhances metabolic balance, creating a robust mechanism for managing T2D.

**TISSUE_RATIONALE:** The most relevant tissues for this approach include pancreatic -cells, muscle, liver, and adipose tissue, all of which play vital roles in glucose metabolism and insulin action, making them ideal targets for therapeutic interventions in Type 2 Diabetes management.

**THERAPEUTIC_APPROACH:** The proposed approach involves the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The combined activation of these targets is expected to lead to significantly enhanced insulin sensitivity, improved glucose metabolism, and better overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, robust evidence from multiple datasets, and critical roles in key biological pathways. G19943 is prioritized for its central importance in the gene network, while G22553 and G04436 were included for their synergistic effects on glucose metabolism. G33764 and G19122 add further metabolic regulation support, creating a comprehensive therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:39:30,666 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:39:30,666 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:39:30,666 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:39:30,668 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:39:30,668 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Approach t...'
2026-02-10 20:39:30,668 - root - INFO - Crossover 9/18: parents 'Integrative Targeting of G2255...' x '** Enhanced Activation Strateg...'
2026-02-10 20:39:30,700 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:40:13,479 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:40:13,484 - root - INFO - TOKEN_USAGE: input=40350, output=735, total=41085, cost=$0.006493
2026-02-10 20:40:13,485 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:40:13,485 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling, G22553 shows strong evidence across multiple datasets and is central to enhancing glucose metabolism.
2. **G19943** | Score: 4.0 | This hub component in metabolic regulation reinforces insulin signaling pathways and supports overall glucose homeostasis.
3. **G23245** | Score: 4.0 | G23245's role in glucose uptake complements the actions of G22553 and G19943, making it critical in enhancing insulin sensitivity.
4. **G19122** | Score: 3.0 | As a major regulator of insulin signaling, G19122 provides essential support in the complex interplay of glucose metabolism and insulin action.
5. **G00484** | Score: 4.0 | This transcription factor's regulatory role in insulin signaling pathways adds a necessary layer of control, enhancing the overall therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses to propose a multi-target strategy that focuses on enhancing insulin sensitivity and glucose metabolism in Type 2 Diabetes (T2D). By targeting G22553, G19943, G23245, G19122, and G00484, the approach aims to create a synergistic effect that addresses the multifaceted nature of T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, metabolic regulation
- WGCNA module role: G22553 is a primary driver in the black module; G23245 is a primary driver in the silver module.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G22553 enhancing insulin signaling and glucose metabolism, supported by G19943 which coordinates metabolic responses. G23245's function in glucose uptake further complements this activation, while G19122 serves as a critical regulator of insulin sensitivity. G00484 adds an important regulatory layer to the insulin signaling network, collectively creating a comprehensive approach to T2D intervention.

**TISSUE_RATIONALE:** The tissues of interest include skeletal muscle, adipose tissue, and pancreatic -cells, as they are essential for insulin action, glucose uptake, and metabolic regulation, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves the small molecule activation of G22553 and G19943, combined with modulation of G23245, G19122, and G00484 to enhance insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Targeting these selected genes is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, strong evidence support across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role in insulin signaling, followed by G19943 and G23245 for their complementary functions, while G19122 and G00484 provide additional regulatory support. 

**CONFIDENCE:** HIGH, based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 20:40:13,488 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:40:13,488 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:40:13,490 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:40:13,505 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:40:13,505 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy for ...'
2026-02-10 20:40:13,506 - root - INFO - Mutation 10/18: parent '** Combination Approach to Enh...'
2026-02-10 20:40:13,506 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 20:40:13,557 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:40:53,916 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:40:53,923 - root - INFO - TOKEN_USAGE: input=39567, output=775, total=40342, cost=$0.006400
2026-02-10 20:40:53,924 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:40:53,924 - root - INFO - 
**TITLE:** Tissue-Specific Gene Therapy for Enhancing Insulin Sensitivity in Muscle Tissue

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | As a central hub in insulin signaling, enhancing G19943's function in muscle tissue is expected to significantly improve insulin sensitivity and glucose uptake.**
2. **G22553 | Score: 4.0 | This gene acts as a primary driver in glucose uptake pathways, making its activation critical in muscle tissue to synergize with G19943 and enhance glucose metabolism.**
3. **G33764 | Score: 4.0 | Modulating this enzyme will enhance lipid metabolism in muscle tissue, complementing the action of G19943 and G22553 to further address insulin resistance.**
4. **G19122 | Score: 3.0 | As a major regulator of insulin signaling, its activation in the muscle will support the efficacy of the primary targets, ensuring a balanced metabolic response.**
5. **G04436 | Score: 3.0 | While important for glucose metabolism, its role is less central compared to G19943 and G22553, making it a supportive target in the context of muscle-specific therapy.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This refined hypothesis proposes a targeted gene therapy strategy focused on muscle tissue to enhance insulin sensitivity in Type 2 Diabetes through the activation of G19943, G22553, G33764, and G19122. By applying a tissue-specific approach, this strategy aims to optimize glucose uptake and metabolism while addressing insulin resistance more effectively in muscle cells.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: Hub component (G19943), Primary Driver (G22553), Primary Driver (G33764), Major Regulator (G19122)

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G19943 in muscle tissue to enhance insulin signaling and glucose uptake, directly addressing insulin resistance. Concurrent activation of G22553 will facilitate glucose uptake and metabolism efficiency, while G33764's modulation will improve lipid metabolism, further alleviating insulin resistance. G19122's activation will support the metabolic balance in muscle, creating a comprehensive therapeutic strategy specifically tailored for muscle tissue.

**TISSUE_RATIONALE:** Muscle tissue is pivotal in glucose metabolism and insulin action, making it an ideal target for intervention in Type 2 Diabetes. Improving insulin sensitivity in muscle can significantly enhance overall glucose homeostasis and metabolic health.

**THERAPEUTIC_APPROACH:** The strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, specifically targeting muscle tissue to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The targeted activation of these genes in muscle tissue is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, and improve overall metabolic control in patients with Type 2 Diabetes, leading to better clinical outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, strong evidence from multiple datasets, and critical roles in insulin signaling and glucose metabolism pathways in muscle tissue. G19943 is prioritized as the central hub, followed closely by G22553 for its role in glucose uptake, while G33764 and G19122 provide essential metabolic support. G04436 is included as a supportive target due to its role in glucose metabolism, albeit with less centrality compared to the others.

**CONFIDENCE:** HIGH, based on robust multi-evidence support and the relevance of the identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:40:53,924 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:40:53,925 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:40:53,925 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:40:53,928 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:40:53,928 - root - INFO -   -> Created mutated offspring: '** Tissue-Specific Gene Therapy for Enha...'
2026-02-10 20:40:53,928 - root - INFO - Crossover 11/18: parents 'Alternative Multi-Target Strat...' x '** Synergistic Multi-Target Mo...'
2026-02-10 20:40:53,985 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:41:34,789 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:41:34,792 - root - INFO - TOKEN_USAGE: input=40362, output=763, total=41125, cost=$0.006512
2026-02-10 20:41:34,792 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:41:34,793 - root - INFO - 
### TITLE: Multi-Target Modulation for Enhanced Metabolic Control in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Central hub in metabolic pathways, integrating insulin signaling and lipid metabolism with robust cross-dataset support.
2. **G04436** | Score: 4.0 | A critical enzyme involved in lipid metabolism and insulin action, complementing G19943 to improve metabolic regulation.
3. **G22553** | Score: 4.0 | Primary driver in insulin signaling pathways, pivotal for glucose uptake and enhancing the overall efficacy of the therapeutic strategy.
4. **G23245** | Score: 4.0 | Primary driver for glucose uptake and insulin sensitivity, supporting metabolic control in relevant tissues.
5. **G33764** | Score: 4.0 | Provides regulatory support within metabolic pathways, further enhancing the efficacy of the primary targets identified.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis integrates the most promising targets from both parent hypotheses, prioritizing G19943 as the primary target due to its critical role in metabolic regulation. By modulating a combination of G19943, G04436, G22553, G23245, and G33764, this approach aims to synergistically enhance insulin sensitivity and glucose metabolism, effectively addressing the complexities of Type 2 Diabetes management.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- **WGCNA module role**: G19943 identified as a hub component in the negatively correlated T2D module.
- **Regulating TFs**: G04436 is associated with 12 identified transcription factors.

### MECHANISM_HYPOTHESIS:
The mechanism posits that G19943 acts as a master regulator of metabolic pathways, enhancing both insulin signaling and lipid metabolism. G04436 will synergistically improve lipid profiles and insulin action, while G22553 will facilitate glucose uptake and amplify insulin signaling. G23245 will further support glucose uptake, and G33764 will provide additional regulatory support, ensuring a robust multi-target approach to combat metabolic dysregulation associated with Type 2 Diabetes.

### TISSUE_RATIONALE:
The primary tissues targeted include the liver, skeletal muscle, and adipose tissue, as these are critical for effective insulin action, glucose uptake, and lipid metabolism. Targeting these tissues is essential for developing comprehensive therapies aimed at reversing metabolic disorders linked to Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The therapeutic strategy involves the development of small molecule activators that specifically target these genes, enhancing their functions to correct metabolic dysregulation in Type 2 Diabetes.

### PREDICTED_OUTCOME:
Modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, resulting in better management of Type 2 Diabetes symptoms and potentially reversing disease progression.

### RANKING_RATIONALE:
The targets were ranked based on their established roles as primary drivers in T2D pathways, their strength of evidence across multiple datasets, and their potential for synergistic interactions. G19943 was prioritized for its central role in metabolic regulation, while G04436 and G22553 were included for their significant contributions to insulin signaling and metabolic regulation. G23245 and G33764 provide additional support without overshadowing the primary target.

### CONFIDENCE: HIGH
The hypothesis is grounded in robust data support across multiple evidence types and pathways relevant to Type 2 Diabetes management.
2026-02-10 20:41:34,793 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:41:34,793 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:41:34,794 - root - INFO -   -> Created offspring: 'Multi-Target Modulation for Enhanced Met...'
2026-02-10 20:41:34,794 - root - INFO - Mutation 12/18: parent '** Combination Approach to Enh...'
2026-02-10 20:41:34,794 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 20:41:34,851 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:41:49,206 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:41:49,210 - root - INFO - TOKEN_USAGE: input=39567, output=750, total=40317, cost=$0.006385
2026-02-10 20:41:49,210 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:41:49,210 - root - INFO - 
**TITLE:** Targeting Insulin Sensitivity in Skeletal Muscle through Multi-Targeted Gene Therapy

**RANKED_TARGETS:**
1. **G19122 | Score: 3.0 | This enzyme plays a major regulatory role in insulin signaling, which is crucial for glucose uptake and metabolism in skeletal muscle.**
2. **G33764 | Score: 4.0 | Enhancing lipid metabolism through this enzyme can improve insulin sensitivity, addressing the metabolic dysregulation commonly seen in Type 2 Diabetes.**
3. **G04436 | Score: 4.0 | The activation of this enzyme can accelerate glucose metabolism, synergizing with G19122 to enhance insulin sensitivity in muscle tissue.**
4. **G22553 | Score: 4.0 | As a primary driver in glucose uptake pathways, its activation is expected to support improved glucose handling in muscle cells, complementing the effects of G19122 and G04436.**
5. **G19943 | Score: 4.0 | Although a central hub in insulin signaling, this target is ranked lower due to the focus on specific muscle-related pathways that can be addressed more directly by the other targets.**

**PRIMARY_TARGET:** G19122

**SUMMARY:** This mutated hypothesis proposes a targeted approach to enhance insulin sensitivity in skeletal muscle by activating G19122, complemented by G33764, G04436, and G22553. By focusing on these targets, the strategy aims to improve glucose uptake and lipid metabolism specifically in muscle tissue, which is critical for managing Type 2 Diabetes effectively.

**DATA_EVIDENCE:**
- Priority Score: 3.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: Major Regulator (G19122), Primary Driver (G22553), Primary Driver (G33764)
- Regulating TFs: 12 identified transcription factors associated with G04436

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G19122 to enhance insulin signaling and glucose uptake in skeletal muscle, which is vital for metabolic regulation. Concurrent activation of G33764 will improve lipid metabolism, counteracting insulin resistance. Additionally, G04436 will further enhance glucose metabolism efficiency, while G22553 will facilitate glucose uptake, creating a synergistic effect to restore metabolic homeostasis in muscle tissue.

**TISSUE_RATIONALE:** Skeletal muscle is a primary site for glucose uptake and plays a significant role in insulin sensitivity. Targeting this tissue allows for a more focused approach to improving metabolic function and combatting insulin resistance in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of the selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity specifically in skeletal muscle.

**PREDICTED_OUTCOME:** The combined activation of these targets is expected to significantly enhance insulin sensitivity, improve glucose uptake, and reduce hyperglycemia in patients with Type 2 Diabetes, leading to better clinical outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, multiple evidence types, and critical roles in insulin signaling and metabolic regulation in skeletal muscle. G19122 was selected as the primary target due to its essential role in insulin signaling, while G33764, G04436, and G22553 were prioritized for their significant contributions to glucose and lipid metabolism.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:41:49,211 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:41:49,211 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:41:49,211 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:41:49,212 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:41:49,212 - root - INFO -   -> Created mutated offspring: '** Targeting Insulin Sensitivity in Skel...'
2026-02-10 20:41:49,212 - root - INFO - Mutation 13/18: parent 'Targeting G04436 for Enhanced ...'
2026-02-10 20:41:49,212 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:41:49,245 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:42:32,973 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:42:32,979 - root - INFO - TOKEN_USAGE: input=39564, output=777, total=40341, cost=$0.006401
2026-02-10 20:42:32,979 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:42:32,979 - root - INFO - 
### TITLE: Targeting G22553 for Enhanced Metabolic Regulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | This gene is a primary driver in insulin signaling pathways, crucial for glucose uptake and metabolic processes, making it a strong candidate for enhancing insulin sensitivity.
2. **G23245** | Score: **4.0** | This gene significantly influences insulin signaling and glucose metabolism, complementing the effects of G22553 in enhancing metabolic control.
3. **G33764** | Score: **4.0** | Essential in metabolic pathways related to T2D, this enzyme supports overall metabolic regulation, providing a complementary mechanism alongside G22553 and G23245.
4. **G04436** | Score: **4.0** | Although previously prioritized, G04436's role in lipid metabolism can be effectively supported by the other targets, making it slightly less critical for this hypothesis.
5. **G19943** | Score: **4.0** | While a hub component, its functions are sufficiently covered by the other selected targets, placing it lower in priority for this refined approach.

#### PRIMARY_TARGET: G22553

### SUMMARY:
This mutated hypothesis focuses on G22553 as the primary target due to its pivotal role in insulin signaling pathways. By integrating G23245 and G33764, the strategy enhances the therapeutic approach through multiple pathways that improve glucose metabolism and insulin action, ultimately aiming for better management of Type 2 Diabetes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism
- **WGCNA module role**: G22553 is identified as a primary driver in metabolic regulation.
- **Regulating TFs**: Multiple transcription factors are involved, providing regulatory depth to the approach.

### MECHANISM_HYPOTHESIS:
Activating G22553 is expected to significantly enhance insulin signaling, thereby facilitating improved glucose uptake and metabolic control in Type 2 Diabetes. Concurrent activation of G23245 will further boost insulin action, while G33764 will support overall metabolic regulation, creating a synergistic effect that targets critical pathways necessary for effective diabetes management.

### TISSUE_RATIONALE:
The most relevant tissues include adipose tissue, liver, and muscle, as they are essential for glucose and lipid homeostasis. Targeting G22553 within these tissues can have a direct impact on insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves small molecule modulation aimed at enhancing the activity of G22553, G23245, and G33764 to improve insulin sensitivity and overall metabolic regulation.

### PREDICTED_OUTCOME:
Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their critical roles in insulin signaling and metabolic pathways, as well as their strong data support. G22553 was selected as the primary target due to its established importance in insulin signaling, followed by G23245 for its significant contributions to glucose uptake. G33764 was included for its complementary role in metabolic regulation. G04436 was deprioritized as its functions are effectively captured by the other targets, while G19943 was ranked lowest as its role is less critical in this refined hypothesis.

### CONFIDENCE: HIGH
This hypothesis is supported by robust data across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 20:42:32,981 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:42:32,982 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:42:32,985 - root - INFO -   -> Created mutated offspring: 'Targeting G22553 for Enhanced Metabolic ...'
2026-02-10 20:42:32,986 - root - INFO - Crossover 14/18: parents '** Combination Approach to Enh...' x 'Alternative Multi-Target Strat...'
2026-02-10 20:42:33,072 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:43:15,944 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:43:15,951 - root - INFO - TOKEN_USAGE: input=40386, output=760, total=41146, cost=$0.006514
2026-02-10 20:43:15,951 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:43:15,952 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G04436 | Score: 4.0 | As a critical enzyme in metabolic regulation, its activation is pivotal for improving insulin sensitivity and glucose metabolism across multiple datasets.**
2. **G19943 | Score: 4.0 | This hub gene in insulin signaling pathways remains essential for enhancing insulin sensitivity and synergizing with G04436.**
3. **G22553 | Score: 4.0 | As a primary driver in insulin signaling, its modulation supports glucose uptake and metabolism, reinforcing the effects of G04436 and G19943.**
4. **G33764 | Score: 4.0 | Modulating this enzyme enhances lipid metabolism, addressing insulin resistance and complementing the actions of the primary targets.**
5. **G23245 | Score: 4.0 | This gene serves as a primary driver for glucose uptake and insulin sensitivity, further contributing to metabolic control in relevant tissues.**

**PRIMARY_TARGET:** G04436

**SUMMARY:** This hypothesis proposes a robust multi-target approach to enhance insulin sensitivity and metabolic regulation in Type 2 Diabetes by activating G04436 as the primary target. It combines the mechanistic insights of both parent hypotheses, focusing on key metabolic pathways and integrating additional targets that synergistically enhance glucose metabolism and insulin signaling.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- WGCNA module role: G04436 identified as a primary driver in T2D-related pathways.
- Regulating TFs: Interactions with transcription factors involved in metabolic pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism centers on the activation of G04436 to directly enhance glucose metabolism and insulin sensitivity. Concurrent activation of G19943 will further amplify insulin signaling, while G22553 will support glucose uptake, strengthening the overall metabolic response. The modulation of G33764 will address lipid metabolism, alleviating insulin resistance, and G23245s role will ensure efficient glucose uptake, creating a comprehensive, synergistic therapeutic strategy for Type 2 Diabetes.

**TISSUE_RATIONALE:** The most relevant tissues for this approach include the liver, muscle, and adipose tissue, as they are critical for effective insulin action, glucose uptake, and lipid metabolism. Targeting these tissues is essential for developing effective therapies aimed at reversing metabolic disorders associated with Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** This strategy focuses on the small molecule activation of G04436, complemented by the modulation of G19943, G22553, G33764, and G23245 to enhance their respective metabolic functions and restore normal metabolic balance.

**PREDICTED_OUTCOME:** The coordinated activation of these targets is expected to significantly enhance insulin sensitivity, reduce hyperglycemia, improve glucose metabolism, and ultimately lead to better clinical outcomes in the management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong multi-evidence support across datasets, and their potential for synergistic interactions. G04436 is prioritized for its central role in metabolic regulation, while G19943, G22553, G33764, and G23245 are included for their complementary functions that collectively enhance the therapeutic strategy.

**CONFIDENCE:** HIGH, based on robust data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:43:15,953 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:43:15,953 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:43:15,954 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:43:15,956 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:43:15,956 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Strategy f...'
2026-02-10 20:43:15,957 - root - INFO - Mutation 15/18: parent 'Enhanced Multi-Target Modulati...'
2026-02-10 20:43:15,957 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 20:43:16,025 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:43:59,502 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:43:59,508 - root - INFO - TOKEN_USAGE: input=39535, output=788, total=40323, cost=$0.006403
2026-02-10 20:43:59,508 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:43:59,508 - root - INFO - 
### TITLE: Targeting Integrated Insulin Signaling Pathways for Enhanced Therapeutic Efficacy in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Recognized as a central hub in insulin signaling, G19943 coordinates various metabolic processes crucial for glucose homeostasis.
2. **G22553** | Score: 4.0 | A primary driver of insulin signaling that works synergistically with G19943 to enhance glucose metabolism effectively.
3. **G23245** | Score: 4.0 | A key player in glucose uptake, providing essential support to G19943 and G22553 in improving insulin sensitivity.
4. **G33764** | Score: 4.0 | Functions as a significant regulator of metabolic pathways, reinforcing the insulin signaling cascade alongside G19943 and G22553.
5. **G00484** | Score: 4.0 | Acts as a transcription factor that modulates gene expression related to insulin sensitivity, enhancing the regulatory support for the core targets.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This evolved hypothesis refines the original by emphasizing the interconnected roles of G19943, G22553, and G23245 in an integrated insulin signaling network. By detailing the cooperative mechanisms of these targets, we aim to enhance insulin sensitivity through a more comprehensive understanding of their interactions, alongside the transcriptional regulatory support provided by G00484 and the metabolic regulation by G33764.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D, supporting its pivotal role in regulating metabolic homeostasis.
- Regulating TFs: G00484 identified as a transcription factor influencing insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The central hypothesis posits that G19943 acts as a critical coordinator in insulin signaling and lipid metabolism, facilitating metabolic homeostasis restoration in T2D. By activating G22553, we enhance insulin signaling pathways directly involved in glucose uptake. G23245 furthers this effect by promoting glucose uptake in peripheral tissues. G33764 adds metabolic regulation capabilities, while G00484's transcriptional control ensures that necessary genes for insulin sensitivity are expressed, thereby creating a robust framework for T2D management.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are essential for insulin action, glucose uptake, and overall metabolic health, making them prime candidates for therapeutic intervention.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 complemented by modulation of G23245, G33764, and G00484 to enhance their functions. This multi-target strategy aims to strengthen the overall insulin signaling pathway and improve metabolic outcomes in T2D.

**PREDICTED_OUTCOME:** Effective modulation of the prioritized targets is expected to lead to significantly enhanced insulin sensitivity, improved glucose metabolism, and better overall management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed closely by G22553, which complements its function, while G23245 and G33764 provide valuable regulatory support, with G00484 ensuring necessary transcriptional regulation.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 20:43:59,508 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:43:59,509 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:43:59,509 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:43:59,512 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:43:59,512 - root - INFO -   -> Created mutated offspring: 'Targeting Integrated Insulin Signaling P...'
2026-02-10 20:43:59,512 - root - INFO - Crossover 16/18: parents 'Targeting G04436 for Enhanced ...' x 'Targeting G04436 for Enhanced ...'
2026-02-10 20:43:59,588 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:44:15,744 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:44:15,749 - root - INFO - TOKEN_USAGE: input=40395, output=756, total=41151, cost=$0.006513
2026-02-10 20:44:15,749 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:44:15,749 - root - INFO - 
### TITLE: Integrated Targeting of Metabolic Pathways for Enhanced Insulin Sensitivity in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G04436** | Score: **4.0** | This enzyme is crucial in lipid metabolism, directly impacting insulin sensitivity and glucose regulation.
2. **G23245** | Score: **4.0** | As a primary driver in insulin signaling pathways, it significantly influences glucose uptake and metabolic processes.
3. **G22553** | Score: **4.0** | Another key player in insulin signaling, supporting metabolic control and complementing the functions of G04436 and G23245.
4. **G33764** | Score: **4.0** | This enzyme enhances metabolic regulation through its involvement in crucial pathways related to T2D.
5. **G19943** | Score: **4.0** | Despite being less critical than others, it serves as a hub component that integrates various metabolic signals, providing additional regulatory support.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This child hypothesis combines the strengths of both parent hypotheses, emphasizing G04436 as the primary target due to its pivotal role in lipid metabolism and insulin sensitivity. By integrating G23245, G22553, and G33764, we strengthen the therapeutic approach through a multi-target strategy that addresses different aspects of glucose metabolism and insulin signaling.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G04436)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, insulin signaling, glucose metabolism, metabolic regulation
- **WGCNA module role**: G04436 is a key enzyme in lipid metabolism that supports insulin sensitivity.
- **Regulating TFs**: Multiple transcription factors are involved, providing a regulatory depth to the approach.

### MECHANISM_HYPOTHESIS:
Activation of G04436 is expected to enhance lipid metabolism, leading to improved insulin sensitivity and glucose regulation in Type 2 Diabetes. Concurrent activation of G23245 will enhance glucose uptake and insulin signaling, while G22553 and G33764 will further support metabolic control and flexibility, creating a comprehensive therapeutic strategy that targets critical pathways necessary for effective diabetes management.

### TISSUE_RATIONALE:
The most relevant tissues include adipose tissue, liver, and muscle, which are essential for lipid and glucose homeostasis. Enhancing the function of these tissues will directly impact insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G04436, G23245, G22553, and G33764) to improve insulin sensitivity and overall metabolic regulation.

### PREDICTED_OUTCOME:
Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their critical roles in insulin signaling and metabolic pathways, as well as their strong data support. G04436 was selected as the primary target due to its established importance in lipid metabolism. G23245 and G22553 were prioritized for their significant contributions to glucose uptake, while G33764 was included for its complementary role in metabolic regulation. G19943 was included as a supportive hub, providing additional integration of metabolic signals.

### CONFIDENCE: HIGH
This hypothesis is grounded in robust data support across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 20:44:15,749 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:44:15,750 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:44:15,751 - root - INFO -   -> Created offspring: 'Integrated Targeting of Metabolic Pathwa...'
2026-02-10 20:44:15,751 - root - INFO - Crossover 17/18: parents 'Synergistic Multi-Target Modul...' x '** Combination Approach to Enh...'
2026-02-10 20:44:15,792 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:44:47,016 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:44:47,022 - root - INFO - TOKEN_USAGE: input=40353, output=731, total=41084, cost=$0.006492
2026-02-10 20:44:47,022 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:44:47,022 - root - INFO - 
### TITLE: Comprehensive Multi-Target Approach to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | This gene is a central hub in insulin signaling pathways, suggesting that its activation will significantly enhance insulin sensitivity.
2. **G22553** | Score: 4.0 | As a primary driver in insulin signaling, its activation will complement G19943's function to facilitate glucose uptake and improve metabolic effects.
3. **G04436** | Score: 4.0 | Activation of this enzyme is expected to boost glucose metabolism, thus supporting the overall therapeutic strategy for T2D management.
4. **G33764** | Score: 4.0 | Modulating this enzyme can enhance lipid metabolism, counteracting insulin resistance and providing a balanced metabolic response alongside other activated targets.
5. **G19122** | Score: 3.0 | Enhancing this major regulator of insulin signaling will support metabolic balance, reinforcing the synergistic effects of the primary targets.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a multi-target strategy to improve insulin sensitivity in Type 2 Diabetes through the activation of key genes involved in insulin signaling and glucose metabolism. By prioritizing G19943 as the central target, and synergizing its effects with G22553, G04436, G33764, and G19122, we aim to address the multifactorial nature of T2D more effectively than either parent hypothesis alone.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: 12 identified transcription factors associated with G04436.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G19943 to enhance insulin signaling, thus alleviating insulin resistance and improving glucose metabolism. Concurrent activation of G22553 will facilitate enhanced glucose uptake, while G04436 will improve metabolic efficiency. Additionally, modulating G33764 will regulate lipid metabolism, and activating G19122 will restore metabolic balance, creating a comprehensive therapeutic strategy for T2D.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are integral to insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The strategy involves the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The combined activation of these targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, robust evidence from multiple datasets, and their critical roles in key biological pathways. G19943 is prioritized for its central importance in the gene network, followed by G22553, which complements its function. G04436 enhances glucose metabolism, while G33764 provides necessary lipid regulation, and G19122 supports overall metabolic balance.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:44:47,023 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:44:47,023 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:44:47,025 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:44:47,045 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:44:47,045 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Approach to E...'
2026-02-10 20:44:47,045 - root - INFO - Crossover 18/18: parents '** Enhanced Modulation of Insu...' x 'Integrative Targeting of G2255...'
2026-02-10 20:44:47,076 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:45:25,378 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:45:25,383 - root - INFO - TOKEN_USAGE: input=40309, output=748, total=41057, cost=$0.006495
2026-02-10 20:45:25,383 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:45:25,383 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity and Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Central driver in insulin signaling pathways with robust support across multiple datasets, crucial for glucose metabolism.
2. **G19943** | Score: 4.0 | Identified as a hub component in metabolic regulation; enhances the insulin signaling network and supports overall glucose homeostasis.
3. **G33764** | Score: 4.0 | Key player in insulin resistance mechanisms, offering synergistic effects when co-targeted with G22553 and G19943.
4. **G19122** | Score: 3.0 | Major regulator of insulin signaling, provides essential support to enhance insulin sensitivity alongside the top targets.
5. **G23245** | Score: 4.0 | A pivotal driver in glucose uptake, complementing G22553's role and showing a negative correlation with T2D, indicating potential therapeutic efficacy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a comprehensive multi-targeted therapeutic approach focusing on G22553, G19943, G33764, G19122, and G23245 to significantly enhance insulin sensitivity and metabolic control in Type 2 Diabetes. By integrating these targets, the hypothesis addresses the complex nature of T2D and aims to restore normal metabolic function through improved insulin signaling and glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, and metabolic regulation.
- WGCNA module role: G22553 is a primary driver in the black module; G19943 is a hub component, and G33764 is a primary driver in relevant modules.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The coordinated activation of G22553 is hypothesized to enhance insulin signaling and glucose metabolism, while G19943 will reinforce the insulin signaling network, effectively addressing insulin resistance. G33764 will synergistically work to mitigate insulin resistance mechanisms, while G19122 and G23245 will provide regulatory and glucose uptake support, respectively, creating a robust multi-targeted intervention strategy for T2D.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include skeletal muscle, pancreatic -cells, and liver, as they are integral to insulin action and glucose uptake, making them optimal candidates for therapeutic interventions.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The comprehensive modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose uptake, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their established roles as primary drivers in T2D pathways, the robustness of the supporting evidence across multiple datasets, and their potential for synergistic interactions. G22553 was prioritized for its direct role in insulin signaling, while G19943 and G33764 were included for their critical contributions to metabolic regulation and insulin resistance. G19122 and G23245 were added for their roles in insulin signaling regulation and glucose uptake, respectively.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 20:45:25,383 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:45:25,384 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:45:25,384 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:45:25,390 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:45:25,391 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Strategy f...'
2026-02-10 20:45:25,391 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 20:45:25,391 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 20:45:25,391 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 20:45:25,391 - root - INFO - Evaluating fitness for hypothesis: t2d-07-7a29d9b2
2026-02-10 20:45:41,765 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:45:41,771 - root - INFO - TOKEN_USAGE: input=1448, output=694, total=2142, cost=$0.000634
2026-02-10 20:45:41,771 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:45:41,771 - root - INFO - 
### Evaluation of the Hypothesis: Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity in Type 2 Diabetes

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, but the overall evidence support is somewhat limited due to the warning indicating that not all ranked targets are in the top priority tier. While there is cross-dataset consistency, the lack of multiple evidence types for the primary target slightly undermines the overall data support.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified by the data, as G19943 is clearly positioned as a central hub in insulin signaling. The rationale provided for the ranking is logical, emphasizing the synergistic roles of the targets. However, the warning about missing targets from the top priority list suggests some discrepancies that need addressing.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context, and the tissue rationale is supported by the involvement of pancreatic -cells, muscle, liver, and adipose tissue. The inclusion of transcription factors and their relationships is acknowledged, but it could be enhanced by more explicit connections between the targets and the pathways involved.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553 is appropriate given their roles in insulin signaling. The proposal considers potential druggability and metabolic regulation. However, additional safety considerations could be more clearly outlined, particularly regarding off-target effects or interactions among the targets.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a creative manner, proposing a multi-target strategy that is not immediately obvious. The connections among the ranked targets show an innovative approach to tackling the multifactorial nature of T2D, but further exploration of unique or less-studied interactions could enhance novelty.

**OVERALL_FITNESS: 7.2**  
**Calculated Score:** (6*0.25 + 8*0.25 + 7*0.20 + 8*0.20 + 7*0.10) = 1.5 + 2 + 1.4 + 1.6 + 0.7 = 7.2

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Support:** Gather more evidence types for G19943 and other ranked targets to strengthen the data support aspect.
2. **Address Target Inclusion:** Ensure that all ranked targets are in the top priority list to avoid inconsistencies and enhance credibility.
3. **Enhance Mechanistic Insights:** Provide clearer connections between the proposed targets and the specific pathways involved. This could include more detailed interactions and potential feedback mechanisms.
4. **Clarify Safety Considerations:** Include a comprehensive discussion on safety and off-target effects of the proposed therapeutic interventions to bolster the therapeutic rationale.
5. **Explore Novel Interactions:** Investigate and highlight any unique or less-explored interactions among the targets that could provide additional novelty to the hypothesis.
2026-02-10 20:45:41,773 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:45:41,774 - root - INFO - Evaluating fitness for hypothesis: t2d-07-853d1de0
2026-02-10 20:45:58,814 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:45:58,821 - root - INFO - TOKEN_USAGE: input=1446, output=731, total=2177, cost=$0.000656
2026-02-10 20:45:58,821 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:45:58,821 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is present in the top priority list, but G22553, which is also ranked highly in the hypothesis, is not. There is cross-dataset consistency for the primary target, and it has strong evidence support (Priority score 4.0 and identified in WGCNA as a hub component). However, the absence of other ranked targets in the top 10 diminishes the overall score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their established roles in insulin signaling and metabolic regulation. The targets are well-supported by the data provided, and the rationale for their ranking is logical. However, the lack of other targets (e.g., G22553) in the top 10 slightly weakens the case for ranking quality.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with known insulin signaling pathways. The tissue rationale involving pancreatic -cells, muscle, liver, and adipose tissue is well-supported by the data, as these tissues are integral to insulin action and glucose metabolism. The role of G00484 as a transcription factor is appropriately considered.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553, along with modulation of other targets, is appropriate for enhancing insulin sensitivity. The targets appear to be druggable based on their network positions. However, safety considerations are not explicitly addressed, which could impact the overall therapeutic potential.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a comprehensive manner, proposing a multi-target approach that is somewhat novel. However, the connections made are not completely non-obvious, as targeting multiple components in insulin signaling is a recognized strategy in diabetes research.

### OVERALL_FITNESS  
**Calculated Score:**  
- DATA_SUPPORT: 7 * 0.25 = 1.75  
- RANKING_QUALITY: 8 * 0.25 = 2.00  
- MECHANISTIC: 8 * 0.20 = 1.60  
- THERAPEUTIC: 8 * 0.20 = 1.60  
- NOVELTY: 7 * 0.10 = 0.70  

**Overall Fitness:** 1.75 + 2.00 + 1.60 + 1.60 + 0.70 = **7.65**  
**Scaled to 0-100:** **76.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality (G19943): STRONG  
- Target #2 quality (G22553): WEAK (not in top priority list)  
- Target #3 quality (G23245): WEAK (not in top priority list)  

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Target List:** Consider including additional targets that have strong evidence and are in the top priority list to strengthen the hypothesis.
2. **Address Safety Considerations:** Provide more detail on potential safety and off-target effects associated with the proposed therapeutic approach to enhance the therapeutic score.
3. **Strengthen Novelty Aspect:** Highlight any unique mechanisms or approaches not commonly explored in conjunction with insulin signaling to improve the novelty score.
2026-02-10 20:45:58,823 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:45:58,824 - root - INFO - Evaluating fitness for hypothesis: t2d-05-2f4703d0
2026-02-10 20:46:08,825 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:46:08,829 - root - INFO - TOKEN_USAGE: input=1422, output=615, total=2037, cost=$0.000582
2026-02-10 20:46:08,829 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:46:08,830 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is present in the top priority list with a high score of 4.0, indicating strong support. However, the warning about the target gene not being found in the top priority list raises concerns. There is cross-dataset consistency, with two datasets supporting the findings, but the lack of broader evidence types diminishes the score.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the established roles of the targets in T2D pathways. All ranked targets hold the same score, suggesting they are equally important in the proposed integrated strategy. The ranking rationale indicates a clear understanding of the synergistic relationships among the targets, enhancing the credibility of the ranking.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known insulin signaling and metabolic pathways relevant to T2D. The tissue rationale is well-supported, focusing on key tissues involved in insulin action. The identification of transcription factors regulating G04436 is a positive addition, indicating a comprehensive understanding of the underlying mechanisms.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach is appropriate, focusing on small molecule activation, which is a common strategy in drug development. However, the potential druggability of some targets and safety considerations could be better addressed, leading to a slightly lower score.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates data creatively by proposing an integrated multi-target strategy for T2D, which is a non-obvious approach. However, some of the connections among targets could be further elaborated or made more innovative to enhance the novelty score.

---

**OVERALL_FITNESS:** 7.3  
*(Calculated: 6*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 7*0.10 = 7.3)*

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Evidence Base:** Include additional evidence types for the primary target and supporting targets to strengthen the data support.
2. **Address Drugability:** Provide more detailed information on the druggability of each target, especially G33764 and G19122, to enhance the therapeutic score.
3. **Clarify Safety Considerations:** Discuss potential safety issues or side effects associated with the proposed therapeutic approach to reassure stakeholders about the practicality of the strategy.
4. **Enhance Novelty:** Explore and articulate more unconventional connections among the targets to improve the novelty score, potentially considering interactions not commonly addressed in T2D research.
2026-02-10 20:46:08,830 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:46:08,830 - root - INFO - Evaluating fitness for hypothesis: t2d-07-62561349
2026-02-10 20:46:27,305 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:46:27,308 - root - INFO - TOKEN_USAGE: input=1485, output=756, total=2241, cost=$0.000676
2026-02-10 20:46:27,308 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:46:27,308 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G04436 and other ranked targets appear in the top priority gene list, which demonstrates some validation. However, the warning indicates a lack of presence for certain targets in the top priority list, which reduces the overall confidence in data support. The primary target has cross-dataset consistency, but there is limited evidence on regulating transcription factors, which could have strengthened the data support.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their established roles in T2D pathways and their scores. All ranked targets have a score of 4.0, suggesting they have similar evidence strength. The rationale for prioritizing G04436 is clear, as it is positioned as central to metabolic regulation. However, without distinct differentiation in ranking among the other targets, the clarity of the ranking could be improved.

---

**MECHANISTIC_SCORE:** 7  
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the context of insulin signaling and metabolic regulation pathways. The tissue rationale is also strong, as the liver, skeletal muscle, and adipose tissue are key players in T2D. However, the absence of reported regulating transcription factors leaves a gap in understanding the full regulatory network, which could enhance mechanistic coherence.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach suggested, involving the activation of G04436 and modulation of other targets, is appropriate and shows promise. The targets identified appear to be druggable given their roles in key metabolic pathways. Safety considerations are not explicitly discussed, but the multi-target approach could mitigate risks associated with targeting a single pathway.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a comprehensive manner, which is a creative approach. However, the connections drawn between the targets and their roles in T2D are somewhat conventional, lacking groundbreaking insights or innovative strategies that could significantly advance the understanding or treatment of the disease.

---

**OVERALL_FITNESS:** 6.8  
(Weighted calculation: 6*0.25 + 7*0.25 + 7*0.20 + 8*0.20 + 6*0.10 = 1.5 + 1.75 + 1.4 + 1.6 + 0.6 = 6.75)

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG (G04436 is central to the hypothesis)
- Target #2 quality: STRONG (G22553 supports insulin signaling effectively)
- Target #3 quality: STRONG (G23245 plays a critical role in glucose uptake)

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Expand Evidence Base:** Increase the number of datasets supporting each target, particularly for G04436, to bolster confidence in the findings.
2. **Clarify Ranking Differentiation:** Consider developing a more nuanced scoring system that allows for clearer differentiation between similarly scored targets to improve ranking quality.
3. **Investigate Transcription Factors:** Explore potential regulating transcription factors that could interact with the targets to enhance mechanistic understanding.
4. **Discuss Safety Considerations:** Include a section that addresses potential safety concerns with the proposed therapeutic approach, particularly regarding the multi-target strategy.
5. **Highlight Novelty:** Emphasize any innovative connections or novel implications of this multi-target approach that could differentiate it from existing therapies.
2026-02-10 20:46:27,308 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:46:27,309 - root - INFO - Evaluating fitness for hypothesis: t2d-07-7d8401ea
2026-02-10 20:46:42,741 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:46:42,744 - root - INFO - TOKEN_USAGE: input=1565, output=787, total=2352, cost=$0.000707
2026-02-10 20:46:42,745 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:46:42,745 - root - INFO - 
### EVALUATION OF HYPOTHESIS

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a priority score of 4.0, indicating it is in the top priority tier alongside several other targets. However, there is only one dataset providing evidence for G22553, and it lacks cross-dataset consistency. This limits the overall robustness of the data support. While the presence of two datasets supporting other targets such as G04436 and G23245 is a positive factor, the overall evidence for G22553 is not strong enough to warrant a higher score.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of targets is generally justified by their roles in insulin signaling and metabolic pathways. The rationale for the ranking is clear, with G22553 positioned as the primary driver. However, the similarity in scores (all ranked at 4.0) suggests that the differentiation between targets could be improved. The absence of clear distinctions in strength among the highest-ranked targets slightly detracts from the quality of the ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways of insulin signaling, glucose metabolism, and lipid metabolism. The tissue rationale is appropriate, focusing on pancreatic -cells, muscle, liver, and adipose tissue, which are indeed critical for insulin action. The inclusion of the transcription factor G00484 as a regulator adds depth to the hypothesis. Overall, the mechanism is coherent, but more detailed exploration of the interactions and potential feedback loops could enhance understanding.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate for the context of Type 2 Diabetes, aiming to enhance insulin sensitivity. However, while the targets are promising, the specific druggability of these targets should be assessed further. Safety considerations are not discussed in detail, which is crucial for a full evaluation of therapeutic potential. A more comprehensive risk-benefit analysis would strengthen this score.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates data creatively by proposing a multi-target strategy, a concept that is not entirely novel in the field of diabetes management. However, the specific combination and focus on these particular targets could represent new insights. The connections made among the targets are logical but not particularly groundbreaking, which limits the novelty score.

### OVERALL_FITNESS: 6.65
**Calculated:** (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.65

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Support:** Acquire additional datasets to confirm the role of G22553 across different conditions and populations to improve cross-dataset consistency.
2. **Clarify Ranking Distinctions:** Provide clearer distinctions in the rationale for ranking targets, potentially by including quantitative metrics or comparative analyses.
3. **Expand Mechanistic Insights:** Incorporate more details on the interactions between targets and potential feedback mechanisms to strengthen the mechanistic hypothesis.
4. **Assess Druggability and Safety:** Conduct a thorough review of the druggability of each target and include safety considerations in the therapeutic approach to provide a more comprehensive evaluation.
5. **Highlight Novel Integrations:** Emphasize any novel aspects of the multi-target approach, especially in the context of existing therapies, to strengthen the novelty component of the hypothesis.
2026-02-10 20:46:42,745 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:46:42,746 - root - INFO - Novelty bonus applied: 0.3% -> fitness 68.50 -> 68.73
2026-02-10 20:46:42,746 - root - INFO - Evaluating fitness for hypothesis: t2d-07-af93c27f
2026-02-10 20:46:58,307 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:46:58,313 - root - INFO - TOKEN_USAGE: input=1519, output=738, total=2257, cost=$0.000671
2026-02-10 20:46:58,313 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:46:58,313 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is found in the top priority list, but the warning indicates that it is not the highest-ranked target. While there is cross-dataset consistency for the primary target, the evidence is not as robust as it could be, with only two datasets cited. The support for G22553 is solid but could benefit from additional types of evidence or datasets.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the roles of the targets in insulin signaling pathways, and the rationale provided is logical and clear. However, the warning about G22553 not being in the top priority list may indicate a potential oversight or misalignment with the current understanding of T2D targets. The higher-ranked targets show strong connections, but the overall ranking might need revision to reflect the latest data.

---

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with known insulin signaling pathways and metabolic processes. The tissue rationale is appropriate, highlighting key tissues involved in insulin action. The role of G00484 as a transcription factor is well-integrated, enhancing the mechanistic understanding. Overall, the mechanism appears plausible and is well-supported.

---

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of targeting these genes, especially G22553, is sound and likely appropriate. However, the feasibility of modulating these targets as proposed should be evaluated more thoroughly. The druggability of these targets based on their network position is promising, but potential safety considerations and side effects need to be addressed more explicitly.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** While the hypothesis does integrate data creatively, the connections made among the targets are somewhat established in the field of diabetes research. The approach is not entirely novel, as multi-target strategies are common in drug discovery, but the specific combination of targets and their proposed interactions may provide new insights.

---

**OVERALL_FITNESS: 6.5**
(Weighted Score Calculation: (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.5)

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Expand Data Evidence:** Seek additional datasets to bolster the evidence supporting G22553 and other ranked targets. This could include more clinical or experimental data to strengthen the hypothesis.
   
2. **Reassess Target Rankings:** Consider reevaluating the target rankings based on the latest priority gene list, ensuring alignment with the most current understanding of T2D mechanisms.

3. **Address Safety Considerations:** Include a detailed analysis of potential safety issues associated with targeting these genes, considering off-target effects and long-term impacts on metabolic health.

4. **Explore Novel Mechanisms:** Investigate additional, lesser-known pathways or targets that may interact with the ranked targets to enhance the novelty of the approach.

5. **Collaborate with Experts:** Engage with biochemists and pharmacologists to refine the therapeutic strategy and confirm the druggability of the targets in the proposed multi-target approach.
2026-02-10 20:46:58,314 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:46:58,315 - root - INFO - Evaluating fitness for hypothesis: t2d-07-4ef4eec3
2026-02-10 20:47:12,523 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:47:12,527 - root - INFO - TOKEN_USAGE: input=1527, output=703, total=2230, cost=$0.000651
2026-02-10 20:47:12,527 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:47:12,527 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** While the primary target G19943 has a high priority score of 4.0, there is only one dataset supporting it which leads to a lack of cross-dataset consistency. Additionally, despite being a hub component in WGCNA, the absence of additional evidence types for the primary target reduces the overall score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their described roles in Type 2 Diabetes pathways and their potential for synergy. However, the lack of significant differentiation in strength among the targets (all scoring 4.0) suggests that the ranking could be more nuanced. Clarity in distinguishing the impact of each target more distinctly could improve the assessment.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the known roles of the targets in insulin signaling and glucose metabolism pathways. The rationale for targeting specific tissues (liver, muscle, pancreatic -cells, and adipose tissue) aligns well with the established understanding of Type 2 Diabetes pathology. However, the absence of specific regulatory transcription factors for G19943 limits the completeness of the mechanism hypothesis.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating key enzymes and modulating targets for improved metabolic function is appropriate and aligns well with the goals of managing Type 2 Diabetes. The targets seem likely druggable based on their positions in metabolic networks, and no significant safety concerns are highlighted, which supports a higher score.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis presents a multi-target approach which is a common strategy in complex diseases like Type 2 Diabetes. While the integration of various targets is a positive aspect, the connections drawn among them do not seem particularly groundbreaking or innovative, as similar approaches have been explored in the literature.

### OVERALL_FITNESS: 6.5
**Calculated:** (6*0.25 + 7*0.25 + 8*0.20 + 8*0.20 + 6*0.10) = 6.5

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (Good evidence of relevance but limited dataset support.)
- Target #2 quality: **MODERATE** (Similar to G19943, with solid roles but lacking in diverse evidence.)
- Target #3 quality: **MODERATE** (Complementary role noted, but the same limitations apply.)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Dataset Support:** Gather more datasets that include G19943 and the other targets to strengthen the evidence base and achieve cross-dataset consistency.
2. **Enhance Distinction in Rankings:** Provide more detailed evidence or rationale to differentiate the targets beyond their equal scores, perhaps by incorporating additional quantitative measures.
3. **Investigate Regulatory Mechanisms:** Explore and identify specific transcription factors or regulators associated with G19943 to enhance the mechanistic understanding of how this target interacts within the insulin signaling pathways.
4. **Address Novelty:** Consider exploring novel interactions or lesser-studied pathways that could provide a unique angle for the hypothesis to enhance its originality and innovative potential.
2026-02-10 20:47:12,528 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:47:12,528 - root - INFO - Novelty bonus applied: 0.3% -> fitness 70.50 -> 70.73
2026-02-10 20:47:12,528 - root - INFO - Evaluating fitness for hypothesis: t2d-07-2b0f9c0f
2026-02-10 20:47:22,471 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:47:22,473 - root - INFO - TOKEN_USAGE: input=1460, output=561, total=2021, cost=$0.000556
2026-02-10 20:47:22,473 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:47:22,473 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list with a high score of 4.0, and there is cross-dataset consistency noted. However, the warning about one target gene not being found in the top priority list indicates some inconsistency, which slightly diminishes the score.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by high scores for the key targets, and the rationale provides a clear hierarchy based on biological significance. However, the inclusion of G19122, which is slightly lower-ranked, could be debated, affecting the perceived clarity of the ranking.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and metabolic pathways relevant to Type 2 Diabetes. The tissue rationale for pancreatic -cells, muscle, liver, and adipose tissue is well-supported. The consideration of transcription factors related to G04436 adds depth to the mechanistic understanding.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed approach of activating the selected targets with small molecules appears appropriate for enhancing metabolic functions. However, the potential safety considerations of modulating multiple targets simultaneously are not discussed, which is a critical aspect for drug development.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data creatively, the multi-target approach is becoming increasingly common in therapeutic strategies for complex diseases like Type 2 Diabetes. Thus, while the connections made are valuable, they may not be as novel as they could be.

---

**OVERALL_FITNESS:** (6 * 0.25 + 7 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10) = 6.65 (rounded to 67)

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Clarify Target Selection:** Reassess the inclusion criteria for G19122 in the top-ranked targets to ensure that it adds significant value compared to the highest-ranked targets.
2. **Address Safety Concerns:** Include a discussion on the safety and potential side effects of activating multiple targets simultaneously to strengthen the therapeutic rationale.
3. **Enhance Novelty Discussion:** Explore more innovative connections or mechanisms that could distinguish this approach from existing multi-target strategies, potentially improving the novelty score.
2026-02-10 20:47:22,474 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:47:22,474 - root - INFO - Evaluating fitness for hypothesis: t2d-07-9dab1fff
2026-02-10 20:47:40,087 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:47:40,090 - root - INFO - TOKEN_USAGE: input=1433, output=836, total=2269, cost=$0.000717
2026-02-10 20:47:40,091 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:47:40,091 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is indeed found in the top priority list, which strengthens its relevance. However, the evaluation notes that G19122 is not in the top priority list, which diminishes the overall support for the multi-target strategy. There is cross-dataset consistency for the primary target and G19943, but the lack of comprehensive evidence for all targets weakens the score. Overall, while there is some level of support, the absence of key targets in the top tier reduces the score.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking of the targets is based on their established roles in T2D, with the top three targets (G22553, G19943, G23245) having high scores. However, G19122's lower score (3.0) and its exclusion from the top priority list create a slight inconsistency in the ranking quality. The rationale for the rankings is solid, but the discrepancies in target priority diminish the overall justification.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the insulin signaling and glucose metabolism pathways, supported by the tissue rationale involving skeletal muscle, adipose tissue, and pancreatic -cells. The relationships between G00484 as a transcription factor and the other targets are appropriately addressed. The hypothesis clearly connects the roles of the targets in enhancing insulin sensitivity, which is coherent and well-articulated.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The approach of small molecule activation for G22553 and G19943 appears appropriate given their central roles in insulin signaling. However, there may be concerns regarding the druggability of some targets, particularly G19122 and G23245, which could complicate therapeutic development. Overall, the potential for improvement in insulin sensitivity is promising, but the therapeutic strategy may require more robust validation.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis does integrate data in a comprehensive way, proposing a multi-target strategy which is relatively novel in T2D management. However, the connections made between the targets and their roles are somewhat expected based on existing knowledge in the field. While there are creative elements, the novelty is moderate given the established understanding of insulin signaling pathways.

### OVERALL_FITNESS: 
Calculated as follows:
\[ 
\text{Overall Fitness} = (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 
\]
Scaled to 0-100: 
\[ 
\text{Overall Fitness} = 68.5 
\]

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Inclusion:** Review the evidence supporting G19122 and its role in T2D. If there is insufficient data, consider replacing it with a more robust target that has a higher priority score.
2. **Expand Data Evidence:** Incorporate additional datasets to strengthen the evidence base for all targets, particularly focusing on those not in the top priority list.
3. **Practicality of Therapeutic Approaches:** Investigate the druggability and safety profiles of all targets to ensure that the therapeutic strategies proposed are feasible and safe for clinical application.
4. **Explore Novel Mechanisms:** Further explore and articulate any novel mechanisms or pathways that could enhance the understanding of the proposed multi-target strategy, which may improve the novelty score.
2026-02-10 20:47:40,091 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:47:40,092 - root - INFO - Evaluating fitness for hypothesis: t2d-07-4254af23
2026-02-10 20:47:54,635 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:47:54,639 - root - INFO - TOKEN_USAGE: input=1473, output=684, total=2157, cost=$0.000631
2026-02-10 20:47:54,639 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:47:54,640 - root - INFO - 
**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** While the primary target G19943 is ranked highly and supported by two datasets, the presence of G04436 in the top priority list raises concern, as it was not included in the hypothesis. Only two targets from the hypothesis (G19943 and G22553) are in the top priority list, which suggests a discrepancy in target validation. The cross-dataset consistency is a positive aspect, but the overall evidence for all proposed targets is insufficient to achieve a higher score.

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is somewhat justified, with clear roles identified for each. However, the inclusion of G04436, which has a high score but is not emphasized in the hypothesis, detracts from the clarity of the ranking. The rationale provided aligns with the functional roles of the targets, but the discrepancies in the top priority list weaken the ranking's strength.

**MECHANISTIC_SCORE: 7**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway and the rationale for targeting muscle tissue is well-supported. The roles of the genes in the context of muscle metabolism are coherent with known biology. However, a better integration of how these targets interact at the transcriptional factor (TF) level could strengthen this aspect.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the genes is appropriate given their roles in insulin sensitivity and glucose metabolism. The hypothesis presents a clear strategy for targeting these pathways in muscle tissue. The potential for druggability is sound based on their central roles in metabolic networks, though safety considerations related to muscle-specific targeting should be further discussed.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates known pathways in a focused manner, but the connections made between the targets are somewhat expected given the established roles of these genes in metabolism. While the tissue-specific approach is valuable, the novelty does not extend significantly beyond existing research paradigms.

**OVERALL_FITNESS:**  
Calculated: \( (5*0.25 + 6*0.25 + 7*0.20 + 8*0.20 + 6*0.10) = 6.3 \)  
Scaled to 0-100: **63**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: MODERATE  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Target Validation:** Ensure that all proposed targets are validated with evidence from the top priority gene lists. Consider integrating G04436 appropriately if it plays a critical role.
  
2. **Mechanistic Detail:** Expand on the mechanistic relationships between the targets, especially concerning transcriptional factors and potential feedback loops within the insulin signaling pathway.

3. **Safety Discussion:** Include a more comprehensive discussion on the safety and potential off-target effects of activating these genes specifically in muscle tissue to strengthen the therapeutic potential.

4. **Novelty Enhancement:** Explore and emphasize any unique or innovative aspects of the proposed gene therapy strategy, including potential combinatorial approaches or novel delivery mechanisms.
2026-02-10 20:47:54,640 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:47:54,641 - root - INFO - Evaluating fitness for hypothesis: t2d-07-1f3f2511
2026-02-10 20:48:09,987 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:48:09,989 - root - INFO - TOKEN_USAGE: input=1522, output=786, total=2308, cost=$0.000700
2026-02-10 20:48:09,989 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:48:09,989 - root - INFO - 
### EVALUATION OF HYPOTHESIS

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The ranked targets are in the top priority tier, with a high score of 4.0. However, there is a lack of cross-dataset consistency for the primary target G19943, which only has support from one dataset. Multiple evidence types are limited, as the primary target has only 2 evidence types supporting it. This indicates a need for more robust validation across different datasets.

---

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with all targets showing significant roles in Type 2 Diabetes pathways. However, the lack of clear distinctions in strength among the higher-ranked targets and the cross-dataset inconsistency for G19943 may reduce the confidence in the ranking. The rationale for selecting G19943 as the primary target aligns with its identified role as a hub component.

---

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, as it emphasizes the integration of insulin signaling and lipid metabolism. The rationale for targeting liver, skeletal muscle, and adipose tissue is supported by their critical roles in glucose metabolism and insulin sensitivity. However, the absence of clear evidence linking G04436 to transcription factors may lessen the strength of mechanistic coherence.

---

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators is appropriate given the targets' roles in metabolic regulation. The identified targets appear to be druggable based on their network positions. However, safety considerations and potential off-target effects should be further evaluated in the context of developing these therapies.

---

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates various targets to propose a multi-target approach, which is a creative strategy in Type 2 Diabetes management. While the proposal does connect established targets, the overall connections are not particularly novel within the context of existing literature, as similar multi-target strategies have been explored.

---

### OVERALL_FITNESS: 
**Overall Score Calculation:**  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85  
**Scaled to 0-100:** 68.5

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: MODERATE** (G19943 has a strong rationale but lacks cross-dataset consistency.)
- **Target #2 quality: STRONG** (G04436's role in lipid metabolism is well supported.)
- **Target #3 quality: STRONG** (G22553's involvement in glucose uptake is critical.)

---

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Aim to gather additional datasets to validate G19943 and the other targets, improving cross-dataset consistency and robustness of evidence.
2. **Expand Evidence Types:** Incorporate more evidence types (e.g., functional assays, genetic studies) for the primary target to strengthen the overall hypothesis.
3. **Clarify Mechanistic Links:** Further investigate the transcription factor relationships for G04436 and other targets to enhance the mechanistic rationale.
4. **Safety Considerations:** Include a preliminary assessment of safety profiles for potential therapeutic agents and consider mechanisms to mitigate off-target effects.
5. **Explore Novelty:** Investigate unique combinations of existing therapies or novel compounds that may target these pathways to enhance the novelty of the approach.
2026-02-10 20:48:09,989 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:48:09,990 - root - INFO - Novelty bonus applied: 0.3% -> fitness 68.50 -> 68.73
2026-02-10 20:48:09,990 - root - INFO - Evaluating fitness for hypothesis: t2d-07-a1f40174
2026-02-10 20:48:22,486 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:48:22,492 - root - INFO - TOKEN_USAGE: input=1448, output=729, total=2177, cost=$0.000655
2026-02-10 20:48:22,492 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:48:22,493 - root - INFO - 
**DATA_SUPPORT_SCORE: 4**  
**DATA_SUPPORT_RATIONALE:** The primary target G19122 is not found in the top priority list, which raises concerns. However, there is cross-dataset consistency with two datasets supporting the evidence, and the number of evidence types for the primary target is limited (only mentioned in terms of WGCNA roles and pathway involvement). This results in a moderate score.

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking is partially justified, as higher-ranked targets (G33764, G04436, G22553) are all relevant to insulin sensitivity and metabolic regulation. However, the lower rank of G19122 (3.0) compared to other targets (4.0) undermines the rationale since it is the primary target. This discrepancy leads to a score reflecting moderate justification.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism of enhancing insulin signaling and glucose uptake aligns well with the pathways involved in Type 2 Diabetes. The tissue rationale supporting the focus on skeletal muscle is strong, given its role in glucose metabolism. Additionally, the consideration of transcription factor relationships enhances mechanistic coherence, warranting a high score.

**THERAPEUTIC_SCORE: 6**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets is appropriate and aligns with the goals of improving insulin sensitivity. However, the druggability of the targets, particularly G19122, is uncertain since it is ranked lower, which may pose challenges for effective targeting. This leads to a moderate score.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a synergistic approach to enhance insulin sensitivity, which is a creative angle. While some connections may not be entirely novel, the focus on specific muscle-related pathways offers a fresh perspective in the context of Type 2 Diabetes management.

**OVERALL_FITNESS:**  
Overall Fitness = (4 * 0.25) + (6 * 0.25) + (8 * 0.20) + (6 * 0.20) + (7 * 0.10) = 5.6  
Scaled to 0-100: **56**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: **WEAK** (G19122 has low priority and is not in the top priority list)  
- Target #2 quality: **STRONG** (G33764 has a high score and is well-supported)  
- Target #3 quality: **STRONG** (G04436 is similarly high-scoring and relevant)  

**IMPROVEMENT_SUGGESTIONS:**  
1. Reevaluate the inclusion of G19122 as the primary target, considering its low priority score. Identify additional evidence to support its relevance or select a higher-ranked target as the primary target.
2. Enhance the data support for all ranked targets by integrating more evidence types, such as experimental validation or clinical data, to strengthen the overall hypothesis.
3. Consider a deeper exploration of the druggability of the targets, especially G19122, to ensure feasible therapeutic interventions can be developed.
4. Explore additional synergistic targets that could complement the existing ones, particularly those that may have emerged as high-priority candidates in recent research.
5. Clarify the safety considerations associated with the proposed small molecule activators to address potential off-target effects or adverse reactions in patients.
2026-02-10 20:48:22,493 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:48:22,493 - root - INFO - Evaluating fitness for hypothesis: t2d-07-686d5cef
2026-02-10 20:48:36,911 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:48:36,915 - root - INFO - TOKEN_USAGE: input=1537, output=692, total=2229, cost=$0.000646
2026-02-10 20:48:36,915 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:48:36,916 - root - INFO - 
### EVALUATION OF HYPOTHESIS: Targeting G22553 for Enhanced Metabolic Regulation in Type 2 Diabetes

#### DATA_SUPPORT_SCORE: **6**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a priority score of 4/17, but it lacks cross-dataset consistency as it is only supported by a single dataset. Although it is classified as a primary driver in WGCNA analyses, the limited evidence types (only 2) and the absence of pathways further reduce the score.

#### RANKING_QUALITY_SCORE: **7**
**RANKING_QUALITY_RATIONALE:** The ranking of targets is logically constructed, as G22553 is positioned as the primary target due to its critical role in insulin signaling. However, the similar scores among the other targets (4.0) may suggest a lack of clear differentiation between their roles, which slightly undermines the strength of the ranking.

#### MECHANISTIC_SCORE: **8**
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the pathways involved in insulin signaling and glucose metabolism. The tissue rationale is sound, focusing on adipose tissue, liver, and muscle, which are crucial for metabolic regulation. However, the absence of regulating transcription factors in the evidence might indicate a missed opportunity to enhance the mechanism's depth.

#### THERAPEUTIC_SCORE: **7**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic strategy of small molecule modulation is appropriate given the targets' roles in enhancing insulin sensitivity. However, without detailed insights into the druggability of these targets and potential safety concerns, the score is moderated.

#### NOVELTY_SCORE: **6**
**NOVELTY_RATIONALE:** While the integration of multiple targets in a therapeutic strategy for Type 2 Diabetes is valuable, the hypothesis does not present particularly novel connections or insights. It follows established pathways and concepts in diabetes research, which limits its innovative edge.

### OVERALL_FITNESS: **6.55**
**Overall Fitness Calculation:** \( (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.55 \)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Aim to gather additional datasets that validate the roles of G22553 and the other targets, especially focusing on cross-dataset consistency to enhance the robustness of the findings.
2. **Expand Mechanistic Insights:** Include information on transcription factors and other regulatory components that may influence the targets to provide a more comprehensive mechanistic framework.
3. **Clarify Drugability and Safety:** Provide an assessment of the druggability of the selected targets and outline potential safety concerns associated with their modulation. Consider existing drug profiles that may inform this evaluation.
4. **Highlight Novelty and Innovation:** Strengthen the novelty aspect by exploring less conventional pathways or collaborations between the targets that could lead to new insights or therapeutic strategies.
2026-02-10 20:48:36,916 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:48:36,917 - root - INFO - Novelty bonus applied: 0.2% -> fitness 50.00 -> 50.08
2026-02-10 20:48:36,917 - root - INFO - Evaluating fitness for hypothesis: t2d-07-03f4d169
2026-02-10 20:48:48,489 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:48:48,495 - root - INFO - TOKEN_USAGE: input=1458, output=605, total=2063, cost=$0.000582
2026-02-10 20:48:48,496 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:48:48,496 - root - INFO - 
**DATA_SUPPORT_SCORE:** 5  
**DATA_SUPPORT_RATIONALE:** The primary target (G04436) is ranked second in the top priority list, indicating its importance. However, the warning indicates that it is not the top priority, which may affect the perceived strength of the evidence. There is cross-dataset consistency for the primary target and a strong level of support across multiple evidence types, which contributes positively to the score.

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as all targets are recognized as essential for enhancing insulin sensitivity and metabolic regulation. However, the warning about G04436 not being in the top priority list raises questions about the relative strength of the ranking. The targets have similar scores, which could indicate a lack of clear differentiation between them.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways involved in Type 2 Diabetes, specifically those related to insulin signaling and glucose metabolism. The rationale for tissue targeting (liver, muscle, adipose) is well-supported and relevant to the disease. However, more explicit connections to transcription factor interactions could strengthen the rationale.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate given the targets' roles in insulin signaling and metabolic regulation. The targets appear to be druggable based on their network positions. Safety considerations are not explicitly addressed, which could be a concern for the overall therapeutic potential.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a comprehensive way, proposing a multi-target strategy that is not commonly explored. However, the connections between targets, while important, are somewhat conventional in the context of metabolic diseases, lowering the novelty score slightly.

**OVERALL_FITNESS:** (5*0.25 + 6*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 6.15 (scaled to 62)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Clarify Target Prioritization:** Address the discrepancy regarding G04436s ranking in the top priority list to strengthen the data support.
2. **Enhance Mechanistic Details:** Include more explicit details about interactions with transcription factors to enhance mechanistic coherence.
3. **Address Safety Considerations:** Provide insights into potential safety issues or off-target effects associated with the proposed therapeutic strategy to improve the therapeutic score.
4. **Differentiate Target Strengths:** Consider providing more detailed evidence or data on differentiating the strength of each target to justify the rankings more clearly.
2026-02-10 20:48:48,497 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:48:48,498 - root - INFO - Evaluating fitness for hypothesis: t2d-07-461af47a
2026-02-10 20:49:04,360 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:49:04,365 - root - INFO - TOKEN_USAGE: input=1486, output=704, total=2190, cost=$0.000645
2026-02-10 20:49:04,365 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:49:04,365 - root - INFO - 
### Evaluation of Hypothesis: Targeting Integrated Insulin Signaling Pathways for Enhanced Therapeutic Efficacy in Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is ranked highly and supported by strong evidence from multiple datasets (2 datasets), indicating cross-dataset consistency. However, the warning regarding the absence of certain target genes in the top priority list reduces the score slightly. Additionally, the evidence types supporting G19943 are numerous, but the focus on fewer targets may limit broader applicability.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking of targets is well justified based on their roles in insulin signaling and metabolic pathways relevant to Type 2 Diabetes. The rationale provided for the ranking is logical, with a clear connection between the targets' functions and their placement in the hierarchy. The equal scores (4.0) among several targets could introduce ambiguity in distinguishing their relative strengths, but overall, the ranking reflects a strong understanding of their interactions.

**MECHANISTIC_SCORE: 9**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known insulin signaling pathway context. The roles of G19943, G22553, G23245, G33764, and G00484 are coherently integrated within the hypothesis, and the tissue rationale is well justified, focusing on critical tissues for insulin action. The consideration of transcription factors (TFs) is appropriately addressed, enhancing the mechanistic understanding.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation appears appropriate given the roles of the identified targets. The multi-target strategy enhances the likelihood of improving insulin signaling and metabolic outcomes. However, the potential druggability of the targets is not explicitly addressed, and safety considerations could benefit from more detailed discussion.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis presents an integrated view of insulin signaling pathways and their interactions, which is a relevant approach in Type 2 Diabetes research. While the integration is creative, the connections proposed may not be entirely non-obvious to those familiar with the field, which slightly lowers the novelty score.

### OVERALL_FITNESS: 
(7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 7*0.10) = 7.65 (rounded to 76.5)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Target List:** Consider including additional targets that may provide synergistic effects or support, ensuring a more comprehensive approach to the hypothesis.
2. **Address Drugability:** Provide more detailed assessments of the druggability of each target, including information about known inhibitors or activators and any safety profiles available in the literature.
3. **Broaden Evidence Base:** Seek additional datasets to strengthen the evidence for the ranked targets, which can bolster confidence in the therapeutic potential.
4. **Clarify Connections:** While the mechanistic rationale is strong, further clarify the interactions between the targets and their downstream effects on insulin sensitivity and metabolic regulation to enhance the overall coherence of the hypothesis.
2026-02-10 20:49:04,366 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:49:04,366 - root - INFO - Evaluating fitness for hypothesis: t2d-07-d341e601
2026-02-10 20:49:21,975 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:49:21,976 - root - INFO - TOKEN_USAGE: input=1514, output=772, total=2286, cost=$0.000690
2026-02-10 20:49:21,977 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:49:21,977 - root - INFO - 
### EVALUATION

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target, G04436, has a priority score of 4.0, which places it in the top priority tier. However, it lacks cross-dataset consistency as it is only supported by one dataset, which limits the confidence in its generalizability. While the number of evidence types supporting G04436 is good (two types), the lack of pathway involvement and the absence of consistent cross-dataset evidence reduce the score.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified, with G04436 being the primary target due to its role in lipid metabolism. However, given that all ranked targets share the same score (4.0), distinguishing their strengths becomes challenging, and this may lead to a perceived lack of clarity in the ranking. The rationale is reasonable, but the equal scoring among targets does not sufficiently differentiate their importance.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, particularly in lipid metabolism and insulin signaling. The tissue rationale involving adipose tissue, liver, and muscle is supported by relevant metabolic roles. Additionally, the involvement of multiple transcription factors provides a solid mechanistic framework. However, more explicit connections to the WGCNA and its role could enhance the score.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule modulation appears appropriate for enhancing the activity of selected targets. The targets are likely druggable based on their known functions in metabolism; however, safety considerations and potential off-target effects are not discussed, which would be necessary for a complete evaluation. 

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates data effectively and proposes a multi-target approach, which is commendable. However, the connections between the targets are somewhat conventional within the context of diabetes research, thereby limiting the novelty. More innovative strategies or connections could enhance this aspect.

### OVERALL_FITNESS
**Calculated Score:** \( 6 \times 0.25 + 7 \times 0.25 + 8 \times 0.20 + 7 \times 0.20 + 6 \times 0.10 = 6.65 \)
**Overall Fitness (scaled to 0-100):** **66.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 G04436 quality:** STRONG
- **Target #2 G23245 quality:** STRONG
- **Target #3 G22553 quality:** STRONG
- **Target #4 G33764 quality:** STRONG
- **Target #5 G19943 quality:** MODERATE

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Cross-Dataset Evidence:** Aim to validate G04436 and other key targets across additional datasets to enhance the robustness and generalizability of the findings.
2. **Clarify Target Differentiation:** Consider providing additional evidence or metrics that distinguish the importance of the targets beyond their equal scoring to improve clarity in the ranking.
3. **Expand on Safety Considerations:** Include a discussion on potential safety issues or side effects associated with the modulation of these targets to provide a more comprehensive evaluation of the therapeutic approach.
4. **Explore Mechanistic Connections:** Delve deeper into the WGCNA results to explicitly tie the roles of the targets to specific pathways, potentially increasing mechanistic coherence.
5. **Innovative Therapeutic Strategies:** Explore unique or less conventional therapeutic strategies that leverage the interactions between the targets to enhance the potential novelty of the approach.
2026-02-10 20:49:21,977 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:49:21,977 - root - INFO - Evaluating fitness for hypothesis: t2d-07-2b1a4242
2026-02-10 20:49:32,350 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:49:32,366 - root - INFO - TOKEN_USAGE: input=1429, output=628, total=2057, cost=$0.000591
2026-02-10 20:49:32,366 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:49:32,366 - root - INFO - 
**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The ranked targets include three that are in the top priority tier (G19943, G22553, G04436). There is cross-dataset consistency for these top-ranked targets, and the primary target (G19943) has multiple evidence types supporting its role in insulin signaling, including its identification as a hub in WGCNA modules relevant to T2D.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with all targets scoring equally high (4.0), suggesting strong relevance. However, the absence of G19122 in the top priority list could indicate a potential oversight in the ranking, as it is still a significant player in the overall mechanism.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known insulin signaling pathways and the rationale for target selection based on tissue involvement (pancreatic -cells, muscle, liver, adipose). The relationships with transcription factors regulating G04436 are also considered, enhancing the biological plausibility.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach (activation of selected targets) is appropriate given the context of insulin resistance in T2D. The targets appear druggable based on their network positions. However, potential safety concerns regarding the modulation of these targets should be further investigated to ensure no adverse effects on metabolic processes.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates various target genes related to insulin signaling and glucose metabolism, which is a common theme in diabetes research. However, the connections made are somewhat conventional, lacking highly novel approaches or unexpected relationships that would enhance the uniqueness of the proposal.

---

**OVERALL_FITNESS:** 7.3  
**Calculated:** (8*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 1.75 + 1.75 + 1.6 + 1.4 + 0.6 = 7.3

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Review Target Selection:** Reassess the inclusion of G19122 in the top priority targets, as its role in insulin signaling could be critical to the hypothesis.
2. **Safety Assessment:** Include a more detailed safety evaluation of the proposed small molecules aimed at activating these targets, to ensure a comprehensive understanding of potential side effects.
3. **Expand Novelty Exploration:** Investigate and highlight any lesser-known connections or novel mechanisms relating to the selected targets that could strengthen the hypothesiss uniqueness and potential impact in T2D research.
2026-02-10 20:49:32,367 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:49:32,367 - root - INFO - Evaluating fitness for hypothesis: t2d-07-8a17beec
2026-02-10 20:49:45,935 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:49:45,938 - root - INFO - TOKEN_USAGE: input=1446, output=764, total=2210, cost=$0.000675
2026-02-10 20:49:45,938 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:49:45,938 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** While the primary target G22553 is supported by strong evidence, it is not in the top priority list, which negatively impacts the score. However, both G19943 and G23245, which are in the top priority list, are ranked 4.0, showing some cross-dataset consistency. The primary target has a high priority score of 4.0 with evidence from two datasets, but the absence of G22553 in the top 10 diminishes the overall data support.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is largely supported by their established roles in T2D pathways, and the rationale provided is logical. However, the fact that the primary target is not among the top 10 priority genes introduces some inconsistency in the ranking logic, which affects the overall justification of the ranking.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways involved in T2D, and the tissue rationale (skeletal muscle, pancreatic -cells, and liver) is appropriate given their roles in insulin action and glucose uptake. The consideration of transcription factors, specifically G00484, adds robustness to the mechanistic hypothesis.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The strategy of activating the selected targets using small molecules is appropriate for the context of T2D and suggests a practical therapeutic approach. However, more specific safety considerations related to targeting these genes could enhance the score. The potential for druggability seems reasonable given the network positions of the targets.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets into a multi-target strategy, which is a creative approach to a complex disease like T2D. However, the connections made between the targets are somewhat conventional within the context of existing research, which limits the novelty aspect.

---

**OVERALL_FITNESS:** 
To calculate the overall fitness:  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.65  
Overall Fitness = 66.5 (rounded to 67)

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G22553) quality:** WEAK  
- **Target #2 (G19943) quality:** STRONG  
- **Target #3 (G33764) quality:** STRONG  

---

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate the Primary Target:** Consider revising the primary target designation to one that is included in the top priority list, such as G19943 or G23245, to ensure stronger alignment with the data support.
  
2. **Enhance Data Support:** Include additional evidence types or datasets that explicitly validate the role of G22553 to strengthen its standing and support its inclusion as a primary target.

3. **Clarify Safety Considerations:** Address potential safety concerns regarding the therapeutic approach, including off-target effects or the impact of targeting multiple pathways simultaneously.

4. **Explore Novel Mechanisms:** Investigate and highlight any novel mechanisms or interactions that could be leveraged for therapeutic purposes, potentially improving the novelty score.

5. **Consider Additional Targets:** If applicable, explore other potential targets from the top priority list that might synergize effectively with the proposed multi-target strategy, diversifying the approach and increasing robustness.
2026-02-10 20:49:45,939 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:49:45,939 - root - INFO - Population fitness evaluation complete. Top score: 78.50
2026-02-10 20:49:45,940 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 20:49:45,940 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G19943', 'G22553', 'G19943', 'G04436']...
2026-02-10 20:49:45,940 - root - INFO - Generation 7 stats: mean=62.31, max=79.5, min=50.0
2026-02-10 20:49:45,941 - root - INFO - Generation 7 complete
2026-02-10 20:49:45,941 - root - INFO - Running generation 8
2026-02-10 20:49:45,942 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 20:49:45,944 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 20:49:45,948 - root - INFO - Crossover 1/18: parents '** Targeting Insulin Sensitivi...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 20:49:46,009 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:50:30,490 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:50:30,496 - root - INFO - TOKEN_USAGE: input=40309, output=769, total=41078, cost=$0.006508
2026-02-10 20:50:30,496 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:50:30,496 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553 | Score: 4.0 | As a primary driver in insulin signaling pathways, targeting G22553 is essential for enhancing glucose metabolism and insulin sensitivity, directly addressing T2D pathology.**
2. **G33764 | Score: 4.0 | This enzyme's role in lipid metabolism supports improved insulin sensitivity and complements the function of G22553, making it essential for a multi-targeted approach.**
3. **G00484 | Score: 4.0 | As a transcription factor crucial for the regulation of insulin signaling and glucose homeostasis, G00484 amplifies the effects of G22553 and G33764, enhancing the overall therapeutic strategy.**
4. **G04436 | Score: 4.0 | Known for its involvement in glucose metabolism, targeting G04436 will synergize with the other targets to further enhance glucose uptake and insulin action.**
5. **G19122 | Score: 3.0 | Although ranked lower, G19122 plays a major regulatory role in insulin signaling and could provide additional support to the mechanistic framework.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes an integrated approach focusing on G22553 as the primary target to enhance insulin sensitivity in Type 2 Diabetes, supported by G33764, G00484, and G04436. By leveraging their synergistic roles in insulin signaling and glucose metabolism, this strategy aims to restore metabolic homeostasis more effectively than either parent hypothesis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G22553 to enhance insulin signaling pathways, thereby improving glucose metabolism. Concurrent activation of G33764 will optimize lipid metabolism, which is crucial for counteracting insulin resistance. G00484s role as a transcription factor will amplify the regulatory impact on insulin signaling and glucose homeostasis, while G04436 will facilitate glucose uptake, creating a robust synergistic effect to enhance overall metabolic function.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, which are central to insulin action and glucose homeostasis. Targeting these tissues allows for a comprehensive approach to improve metabolic function and address insulin resistance in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity specifically.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to significantly enhance insulin sensitivity, improve glucose uptake, and lead to better management of Type 2 Diabetes, ultimately reducing hyperglycemia and improving patient outcomes.

**RANKING_RATIONALE:** Targets were ranked based on their high priority scores, strong cross-dataset consistency, and critical roles in insulin signaling and metabolic regulation. G22553 was selected as the primary target due to its essential role, followed by G33764 and G00484 for their synergistic effects, with G04436 providing additional support and G19122 as a secondary target for its regulatory function. 

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:50:30,498 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:50:30,498 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:50:30,498 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:50:30,501 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:50:30,501 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy to Enha...'
2026-02-10 20:50:30,501 - root - INFO - Mutation 2/18: parent 'Integrated Multi-Target Strate...'
2026-02-10 20:50:30,502 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 20:50:30,572 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:51:17,006 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:51:17,013 - root - INFO - TOKEN_USAGE: input=39602, output=829, total=40431, cost=$0.006438
2026-02-10 20:51:17,013 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:51:17,013 - root - INFO - 
### TITLE: Tissue-Specific Multi-Target Strategy for Enhanced Insulin Sensitivity in Pancreatic Islets in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways within pancreatic islets, G22553 is essential for enhancing -cell function and glucose metabolism.
2. **G00484** | Score: 4.0 | This transcription factor is critical for regulating insulin signaling in islets, providing necessary transcriptional support and amplifying G22553s effects on insulin production.
3. **G19943** | Score: 4.0 | Serving as a central hub in insulin signaling, G19943 will further enhance the metabolic regulation of pancreatic islets, complementing the actions of G22553 and G00484.
4. **G23245** | Score: 4.0 | This target is vital for glucose uptake in islets, ensuring that insulin signaling is effectively translated into enhanced glucose metabolism.
5. **G33764** | Score: 4.0 | By enhancing metabolic regulation in pancreatic islets, G33764 supports the multi-target strategy by addressing potential dysregulation and improving insulin sensitivity.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis focuses on a multi-target approach to enhance insulin sensitivity specifically in pancreatic islets in Type 2 Diabetes. By prioritizing G22553, we aim to improve insulin signaling and -cell function, synergistically supported by G00484's transcriptional regulation, G19943's centrality in insulin pathways, G23245's role in glucose uptake, and G33764's metabolic support.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, -cell function, glucose metabolism, and transcriptional regulation.
- WGCNA module role: G22553 is identified as a primary driver in modules positively correlated with T2D, while G19943 is a hub component in modules regulating insulin signaling.
- Regulating TFs: G00484 acts as a key regulator in insulin signaling pathways in islets.

**MECHANISM_HYPOTHESIS:** The proposed mechanism posits that targeting G22553 will enhance insulin signaling pathways specifically within pancreatic islets, improving -cell function and glucose metabolism. G00484 will strengthen this effect through transcriptional regulation, while G19943's central role will ensure that insulin signaling is effectively coordinated. G23245 will facilitate glucose uptake, critical for insulin action, and G33764 will provide additional metabolic support to mitigate dysregulation.

**TISSUE_RATIONALE:** The primary tissue of focus is pancreatic islets, as they are vital for insulin production and secretion, directly influencing glucose metabolism. Enhancing insulin signaling in this tissue will have a profound impact on overall metabolic regulation in T2D.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will involve small molecule activation of G22553 to enhance its function, alongside modulation of G00484, G19943, G23245, and G33764 to strengthen insulin signaling and metabolic regulation in pancreatic islets.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is anticipated to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and restored -cell function, resulting in better management of Type 2 Diabetes.

**RANKING_RATIONALE:** Targets were ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their specific relevance to pancreatic islets, which are crucial for insulin action. G22553 is prioritized for its critical role in insulin signaling, with G00484, G19943, G23245, and G33764 included for their synergistic contributions to enhancing insulin sensitivity.

**CONFIDENCE:** HIGH, based on robust data support and strong associations with key pathways involved in insulin signaling and glucose metabolism in pancreatic islets.
2026-02-10 20:51:17,014 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:51:17,015 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:51:17,015 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:51:17,017 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:51:17,018 - root - INFO -   -> Created mutated offspring: 'Tissue-Specific Multi-Target Strategy fo...'
2026-02-10 20:51:17,018 - root - INFO - Mutation 3/18: parent 'Integrated Targeting of Metabo...'
2026-02-10 20:51:17,018 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 20:51:17,051 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:51:53,430 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:51:53,436 - root - INFO - TOKEN_USAGE: input=39538, output=816, total=40354, cost=$0.006420
2026-02-10 20:51:53,436 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:51:53,436 - root - INFO - 
### TITLE: Enhanced Multi-Pathway Modulation for Insulin Sensitivity in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G23245** | Score: **4.0** | Identified as a primary driver in insulin signaling pathways, G23245 significantly influences glucose uptake and metabolic processes, making it a key target for enhancing insulin sensitivity.
2. **G04436** | Score: **4.0** | This enzyme plays a critical role in lipid metabolism, directly impacting insulin sensitivity, thus complementing the effects of G23245 in glucose regulation.
3. **G22553** | Score: **4.0** | As another key player in insulin signaling, G22553 supports metabolic control and acts synergistically with G23245 to enhance glucose uptake.
4. **G19943** | Score: **4.0** | Serving as a hub component, G19943 integrates various metabolic signals and enhances the regulatory network necessary for effective insulin sensitivity.
5. **G33764** | Score: **4.0** | This enzyme contributes to metabolic regulation, supporting the collective effort of the other targets in fine-tuning insulin sensitivity in T2D.

#### PRIMARY_TARGET: G23245

### SUMMARY:
This refined hypothesis emphasizes G23245 as the primary target due to its pivotal role in insulin signaling, while integrating G04436, G22553, G19943, and G33764 to create a comprehensive multi-target strategy. By leveraging multiple pathways involved in glucose metabolism and insulin sensitivity, this approach aims to enhance overall metabolic health in Type 2 Diabetes patients.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G23245)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation
- **WGCNA module role**: G23245 is identified as a primary driver in the silver module associated with T2D.
- **Regulating TFs**: Multiple transcription factors are identified, indicating a complex regulatory network.

### MECHANISM_HYPOTHESIS:
The activation of G23245 is expected to enhance insulin signaling pathways, leading to increased glucose uptake and improved insulin sensitivity. Concurrent modulation of G04436 will improve lipid metabolism, while G22553 and G19943 will provide additional support by integrating metabolic signals and reinforcing the insulin signaling cascade. G33764 will complement these actions by enhancing metabolic regulation, leading to a robust multi-targeted therapeutic strategy.

### TISSUE_RATIONALE:
The most relevant tissues include adipose tissue, liver, and muscle, which are critical for lipid and glucose homeostasis. Enhancing the function of these tissues through targeted modulation will directly impact insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy will involve small molecule modulation aimed at activating G23245 and enhancing the activities of the integrated targets (G04436, G22553, G19943, and G33764) to improve insulin sensitivity and overall metabolic regulation.

### PREDICTED_OUTCOME:
Modulating these targets is expected to yield significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately leading to improved patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles in insulin signaling and metabolic pathways, as well as their strong data support. G23245 was prioritized as the primary target due to its critical role in insulin signaling. G04436 and G22553 were included for their significant contributions to glucose metabolism, while G19943 serves as a supportive hub for metabolic integration. G33764 was ranked last for its complementary role in metabolic regulation.

### CONFIDENCE: HIGH
This hypothesis is built on robust data support across multiple evidence types, demonstrating the essential roles of the selected targets in managing Type 2 Diabetes effectively.
2026-02-10 20:51:53,438 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:51:53,438 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:51:53,441 - root - INFO -   -> Created mutated offspring: 'Enhanced Multi-Pathway Modulation for In...'
2026-02-10 20:51:53,441 - root - INFO - Crossover 4/18: parents 'Comprehensive Multi-Target Str...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 20:51:53,513 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:52:38,486 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:52:38,494 - root - INFO - TOKEN_USAGE: input=40330, output=745, total=41075, cost=$0.006497
2026-02-10 20:52:38,494 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:52:38,494 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhanced Insulin Sensitivity and Metabolic Control in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling pathways, showing strong evidence across datasets for its critical role in glucose uptake and metabolic processes.
2. **G19943** | Score: 4.0 | As a hub component in metabolic regulation, G19943 reinforces insulin signaling pathways and is crucial for maintaining glucose homeostasis.
3. **G23245** | Score: 4.0 | This gene significantly influences glucose uptake and insulin signaling, complementing the actions of G22553 and G19943 and enhancing metabolic control.
4. **G19122** | Score: 3.0 | Serving as a major regulator of insulin signaling, G19122 plays a vital role in the interplay of glucose metabolism and insulin action.
5. **G33764** | Score: 4.0 | This enzyme supports overall metabolic regulation, providing a complementary mechanism alongside G22553 and G23245, enhancing the therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** The proposed hypothesis combines the strengths of both parent hypotheses by leveraging the central role of G22553 in insulin signaling while integrating G19943 and G23245 for their supportive roles in glucose metabolism. This multi-target strategy aims to enhance insulin sensitivity and metabolic regulation comprehensively, addressing the complexities of Type 2 Diabetes (T2D).

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling pathways, glucose metabolism, metabolic regulation
- **WGCNA module role:** G22553 is a primary driver in the black module, and G23245 is a primary driver in the silver module.
- **Regulating TFs:** Multiple transcription factors involved, providing regulatory depth.

**MECHANISM_HYPOTHESIS:** The mechanism involves G22553 enhancing insulin signaling and glucose metabolism. G19943 coordinates metabolic responses, reinforcing the insulin signaling network, while G23245's role in glucose uptake complements this activation. G19122 serves as a critical regulator, and G33764 enhances overall metabolic regulation, creating a robust framework to manage T2D effectively.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, adipose tissue, and pancreatic -cells, as they are essential for insulin action, glucose uptake, and metabolic regulation. Targeting these tissues can directly impact insulin sensitivity and metabolic health in Type 2 Diabetes patients.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves the small molecule activation of G22553, G19943, and G23245, along with modulation of G19122 and G33764 to improve insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established critical roles in insulin signaling and metabolic pathways, robust data support, and their potential for synergistic interactions. G22553 is prioritized for its central role, followed by G19943 and G23245 for their complementary functions, while G19122 and G33764 provide additional regulatory support.

**CONFIDENCE:** HIGH, based on strong data support across multiple evidence types and their essential roles in managing Type 2 Diabetes.
2026-02-10 20:52:38,496 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:52:38,496 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:52:38,497 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:52:38,499 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:52:38,499 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 20:52:38,500 - root - INFO - Crossover 5/18: parents 'Comprehensive Multi-Target Str...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 20:52:38,574 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:52:54,482 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:52:54,483 - root - INFO - TOKEN_USAGE: input=40307, output=726, total=41033, cost=$0.006482
2026-02-10 20:52:54,484 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:52:54,484 - root - INFO - 
### TITLE: Integrated Multi-Target Approach to Enhance Insulin Sensitivity and Glucose Metabolism in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Acts as a primary driver in insulin signaling pathways, providing essential enhancement to glucose metabolism.
2. **G19943** | Score: 4.0 | Serves as a central hub in insulin signaling and metabolic regulation, crucial for coordinating the overall therapeutic strategy.
3. **G23245** | Score: 4.0 | Plays a vital role in glucose uptake and insulin sensitivity, complementing the actions of G22553.
4. **G00484** | Score: 4.0 | Functions as a key transcription factor that regulates insulin signaling, ensuring effective transcriptional control of glucose homeostasis.
5. **G33764** | Score: 4.0 | Contributes to metabolic regulation, enhancing insulin action and supporting the overall therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis posits that targeting G22553, the primary driver of insulin signaling, in combination with G19943 and G23245, creates a synergistic effect to enhance insulin sensitivity and glucose metabolism in Type 2 Diabetes. The additional modulation of G00484 as a transcription factor and G33764 for metabolic regulation ensures a comprehensive approach to address the complex nature of T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 is a key transcriptional regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism integrates the roles of G22553 and G19943, with G22553 enhancing insulin signaling and G19943 serving as a regulatory hub to coordinate metabolic responses. G23245s facilitative action on glucose uptake amplifies the effects of G22553, while G00484 ensures robust transcriptional regulation of genes involved in glucose homeostasis. G33764 supports metabolic regulation, creating a comprehensive strategy aimed at restoring insulin sensitivity and improving metabolic functions.

**TISSUE_RATIONALE:** Critical tissues include pancreatic -cells, muscle, liver, and adipose tissue, as these are central to insulin action and glucose homeostasis, making them ideal targets for therapeutic interventions in T2D.

**THERAPEUTIC_APPROACH:** The approach involves small molecule activation of G22553 to enhance its action, complemented by modulation of G19943, G23245, G00484, and G33764 to optimize insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their high priority scores, established roles in insulin signaling pathways, and their potential for synergistic interactions. G22553 is prioritized for its central role, followed closely by G19943, which acts as a regulatory hub. G23245 enhances glucose uptake, while G00484 and G33764 provide essential regulatory support.

**CONFIDENCE:** HIGH, based on robust data support and significant associations with T2D mechanisms.
2026-02-10 20:52:54,484 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:52:54,484 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:52:54,485 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:52:54,486 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:52:54,486 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach to Enha...'
2026-02-10 20:52:54,486 - root - INFO - Crossover 6/18: parents '** Comprehensive Multi-Target ...' x 'Integrated Targeting of G22553...'
2026-02-10 20:52:54,536 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:53:35,413 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:53:35,419 - root - INFO - TOKEN_USAGE: input=40385, output=755, total=41140, cost=$0.006511
2026-02-10 20:53:35,419 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:53:35,419 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Serves as a primary driver in insulin signaling pathways, crucial for enhancing glucose metabolism and is supported by strong data across multiple evidence types.
2. **G19943** | Score: 4.0 | Acts as a central hub in insulin signaling, coordinating metabolic regulation and enhancing insulin sensitivity, with a strong cross-dataset support.
3. **G04436** | Score: 4.0 | Plays a significant role in lipid metabolism, contributing to improved insulin sensitivity and metabolic control, supported by pathway involvement and regulatory factors.
4. **G33764** | Score: 4.0 | Supports metabolic regulation and insulin signaling, adding robustness to the therapeutic approach with established roles in key biological pathways.
5. **G23245** | Score: 4.0 | Enhances glucose uptake, reinforcing the effects of G22553 and G04436, making it a valuable addition to the multi-target strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy that focuses on G22553 as the primary target, integrating the roles of G19943, G04436, G33764, and G23245 to enhance insulin sensitivity and improve glucose metabolism in Type 2 Diabetes. By leveraging the synergistic interactions of these targets, the strategy aims to provide a robust therapeutic approach that addresses the multifactorial nature of T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target (G22553)
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation.
- WGCNA module role: G22553 (Primary Driver), G19943 (Hub Component), G04436 (Primary Driver), G33764 (Primary Driver)
- Regulating TFs: Multiple transcription factors identified for several targets.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves targeting G22553 to enhance insulin signaling and improve glucose metabolism. Concurrent activation of G19943 will coordinate metabolic regulation, while G04436 will improve lipid metabolism, facilitating better insulin sensitivity. Additionally, G33764 will support general metabolic regulation, and G23245 will specifically enhance glucose uptake, creating a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they play vital roles in glucose metabolism and insulin action. Targeting these tissues will directly impact insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

**THERAPEUTIC_APPROACH:** The strategy involves the activation of these targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The combined activation of these targets is expected to lead to significantly enhanced insulin sensitivity, improved glucose metabolism, and better overall metabolic control in patients with Type 2 Diabetes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, strong multi-evidence support, and critical roles in key biological pathways. G22553 is prioritized as the primary driver in insulin signaling, while G19943 serves as a central hub, and G04436, G33764, and G23245 add complementary metabolic regulation support, creating a robust multi-target therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong data support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:53:35,421 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:53:35,421 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:53:35,421 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:53:35,424 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:53:35,424 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 20:53:35,424 - root - INFO - Mutation 7/18: parent 'Synergistic Multi-Target Modul...'
2026-02-10 20:53:35,424 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 20:53:35,514 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:54:17,092 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:54:17,098 - root - INFO - TOKEN_USAGE: input=39533, output=797, total=40330, cost=$0.006408
2026-02-10 20:54:17,098 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:54:17,098 - root - INFO - 
**TITLE:** Enhanced Insulin Sensitivity through Targeted Modulation in Pancreatic Islets

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 is vital for maintaining the function and survival of pancreatic -cells, which are crucial for insulin production.
2. **G22553** | Score: 4.0 | This gene is a primary driver in enhancing insulin signaling, effectively complementing G19943's role and promoting optimal glucose uptake and utilization.
3. **G23245** | Score: 4.0 | Acting as a key regulator of glucose uptake, G23245 supports the insulin response in pancreatic islets, making it essential for improving insulin sensitivity.
4. **G33764** | Score: 4.0 | As an enhancer of metabolic regulation, G33764 plays a supporting role in the signaling pathways critical for insulin secretion and action in the islets.
5. **G00484** | Score: 4.0 | This transcription factor is crucial for regulating genes associated with insulin signaling, providing necessary transcriptional control within islet cells.

**PRIMARY_TARGET:** G19943

**SUMMARY:** The mutated hypothesis focuses on the pancreatic islets, emphasizing the role of G19943 as a central modulator of insulin signaling and -cell function. By synergistically targeting G22553, G23245, G33764, and G00484, the strategy aims to enhance insulin sensitivity and glucose homeostasis specifically in the pancreatic islets, addressing the metabolic dysfunction characteristic of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D, indicating its importance in islet function.
- Regulating TFs: G00484 acts as a transcriptional regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G19943 coordinating insulin signaling and -cell survival, essential for maintaining glucose homeostasis. Targeting G22553 enhances the effectiveness of insulin signaling pathways, while G23245 facilitates glucose uptake into the islets. G33764 provides additional metabolic regulation support, and G00484 drives the transcriptional response necessary for maintaining effective insulin production and action.

**TISSUE_RATIONALE:** The pancreatic islets are central to insulin secretion and action; thus, they are the most relevant tissue for this therapeutic approach. Focusing on this tissue allows for targeted modulation of genes critical for maintaining -cell function and improving insulin sensitivity.

**THERAPEUTIC_APPROACH:** The approach involves small molecule activation of G19943 and G22553 to enhance their functions, along with modulation of G23245, G33764, and G00484 to optimize metabolic regulation and insulin sensitivity within the pancreatic islets.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced -cell function, and overall better management of Type 2 Diabetes through improved glucose metabolism.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling and glucose metabolism, their strong evidence support across multiple datasets, and their potential for synergistic interactions in the pancreatic islets. G19943 is prioritized for its central role in the pathways, followed by G22553 to enhance its function, with G23245 and G33764 providing necessary regulatory support, and G00484 adding depth through transcriptional regulation.

**CONFIDENCE:** HIGH, based on robust data support, cross-dataset consistency, and significant associations with insulin signaling pathways and pancreatic islet function.
2026-02-10 20:54:17,100 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:54:17,100 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:54:17,101 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:54:17,104 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:54:17,104 - root - INFO -   -> Created mutated offspring: '** Enhanced Insulin Sensitivity through ...'
2026-02-10 20:54:17,104 - root - INFO - Mutation 8/18: parent 'Comprehensive Multi-Target Str...'
2026-02-10 20:54:17,104 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 20:54:17,187 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:54:49,665 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:54:49,672 - root - INFO - TOKEN_USAGE: input=39532, output=769, total=40301, cost=$0.006391
2026-02-10 20:54:49,672 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:54:49,673 - root - INFO - 
### TITLE: Enhanced Multi-Target Strategy for Insulin Sensitivity in Type 2 Diabetes via Transcriptional Regulation

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943's role in coordinating metabolic regulation is critical for enhancing insulin sensitivity.
2. **G00484** | Score: 4.0 | This transcription factor is essential for regulating insulin signaling; its modulation can enhance the transcriptional response required for improved insulin sensitivity.
3. **G22553** | Score: 4.0 | As a primary driver in insulin signaling, G22553 synergizes with G19943, enhancing glucose metabolism and insulin action through its regulatory effects.
4. **G23245** | Score: 4.0 | Critical for glucose uptake, G23245 complements the action of G19943 and G22553, reinforcing the multi-target strategy aimed at improving insulin sensitivity.
5. **G33764** | Score: 4.0 | Although supporting metabolic regulation, G33764's role is less central compared to the other targets, yet it contributes to the robustness of the insulin signaling network.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis refines the original multi-target strategy by emphasizing G19943 as the primary target while incorporating G00484 to enhance transcriptional regulation of insulin signaling. The synergistic effects of G22553 and G23245 on glucose metabolism and insulin action provide a multifaceted approach to improving insulin sensitivity, while G33764 supports the overall metabolic framework.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D; G00484 enhances the regulatory framework in insulin signaling.
- Regulating TFs: G00484 acts as a transcriptional regulator, underscoring its role in enhancing insulin sensitivity.

**MECHANISM_HYPOTHESIS:** The combination of G19943 as the central coordinator and G00484 as a regulatory transcription factor is hypothesized to significantly enhance insulin signaling through improved transcriptional activation of downstream targets. G22553 will further facilitate glucose metabolism, while G23245 will enhance glucose uptake, creating a comprehensive mechanism for managing T2D. G33764 will ensure overall metabolic regulation, reinforcing the interactions among these targets.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells for insulin secretion, muscle for glucose uptake, liver for glucose metabolism, and adipose tissue for lipid management, all of which are crucial for effective insulin action and glucose homeostasis.

**THERAPEUTIC_APPROACH:** The proposed approach involves the small molecule activation of G19943 and modulation of G00484 to enhance transcriptional regulation, alongside the activation of G22553 and G23245 to reinforce metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling pathways, strong evidence from multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G00484 for its regulatory function, and G22553 and G23245 for their complementary roles in glucose metabolism.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:54:49,678 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:54:49,679 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:54:49,681 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:54:49,696 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:54:49,697 - root - INFO -   -> Created mutated offspring: 'Enhanced Multi-Target Strategy for Insul...'
2026-02-10 20:54:49,698 - root - INFO - Mutation 9/18: parent 'Targeting Integrated Insulin S...'
2026-02-10 20:54:49,698 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 20:54:49,742 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:55:28,705 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:55:28,709 - root - INFO - TOKEN_USAGE: input=39564, output=812, total=40376, cost=$0.006422
2026-02-10 20:55:28,710 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:55:28,710 - root - INFO - 
### TITLE: Enhancing Insulin Sensitivity in Type 2 Diabetes via Dual Activation of Insulin Signaling Pathways

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver of insulin signaling and its activation is expected to synergistically enhance glucose metabolism, making it a crucial target for improving insulin sensitivity.
2. **G19943** | Score: 4.0 | As a central hub in insulin signaling, activating G19943 could effectively coordinate metabolic processes and enhance the overall insulin signaling network.
3. **G00484** | Score: 4.0 | This transcription factor modulates gene expression related to insulin sensitivity, making it an important target for ensuring that the necessary genes for optimal insulin signaling are expressed.
4. **G23245** | Score: 4.0 | This gene plays a significant role in glucose uptake, and its activation can further enhance the effects of G22553 and G19943 in improving insulin sensitivity.
5. **G33764** | Score: 4.0 | As a significant regulator of metabolic pathways, activating G33764 can reinforce the insulin signaling cascade, providing additional support for the therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis pivots towards a dual activation strategy focusing on G22553 and G19943 to enhance insulin signaling in Type 2 Diabetes. By activating these primary targets along with G00484, G23245, and G33764, we aim to create a comprehensive approach that not only improves insulin sensitivity but also ensures the expression of critical metabolic genes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with insulin signaling, reinforcing its potential in therapeutic application.
- Regulating TFs: G00484 identified as a transcription factor with significant influence on insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The central hypothesis proposes that activating G22553 and G19943 will synergistically enhance insulin signaling pathways leading to improved glucose uptake and metabolism. G00484's role as a transcription factor will ensure that genes necessary for insulin sensitivity are expressed, while G23245 and G33764 contribute by promoting glucose uptake and metabolic regulation, respectively. This multifaceted approach targets both direct signaling pathways and broader metabolic regulation, aiming for a comprehensive improvement in insulin sensitivity.

**TISSUE_RATIONALE:** The most relevant tissues include pancreatic -cells (for insulin production), muscle (for glucose uptake), liver (for glucose and lipid metabolism), and adipose tissue (for metabolic regulation), as they are essential for insulin action and overall metabolic health.

**THERAPEUTIC_APPROACH:** The proposed approach involves the activation of G22553 and G19943 using small molecules, alongside modulation of G00484, G23245, and G33764 to enhance their functions. This combined strategy aims to reinforce the insulin signaling pathway and improve metabolic outcomes in Type 2 Diabetes.

**PREDICTED_OUTCOME:** Effective dual activation of the prioritized targets is expected to lead to significantly enhanced insulin sensitivity, improved glucose metabolism, and better overall management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role in insulin signaling, followed closely by G19943, which complements its function, while G00484, G23245, and G33764 provide valuable regulatory and metabolic support.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 20:55:28,710 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:55:28,710 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:55:28,710 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:55:28,711 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:55:28,711 - root - INFO -   -> Created mutated offspring: 'Enhancing Insulin Sensitivity in Type 2 ...'
2026-02-10 20:55:28,712 - root - INFO - Mutation 10/18: parent 'Integrated Multi-Target Strate...'
2026-02-10 20:55:28,712 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 20:55:28,748 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 20:55:45,880 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:55:45,887 - root - INFO - TOKEN_USAGE: input=39598, output=740, total=40338, cost=$0.006384
2026-02-10 20:55:45,887 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:55:45,887 - root - INFO - 
### TITLE: Targeting G00484 for Enhanced Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G00484** | Score: 4.0 | As a transcription factor crucial for regulating insulin signaling and glucose homeostasis, G00484 directly influences metabolic pathways and enhances insulin sensitivity.
2. **G19943** | Score: 4.0 | This gene acts as a central hub in the insulin signaling network, providing synergistic support to G00484's transcriptional regulatory functions.
3. **G23245** | Score: 4.0 | Its pivotal role in glucose uptake complements G00484's and G19943's actions, reinforcing overall insulin sensitivity.
4. **G22553** | Score: 4.0 | Previously a primary target, G22553 enhances insulin signaling; however, its role is now viewed in conjunction with G00484's transcriptional regulation.
5. **G33764** | Score: 4.0 | Adding robustness to the strategy, G33764 supports metabolic regulation and insulin signaling pathways, ensuring a comprehensive approach.

**PRIMARY_TARGET:** G00484

**SUMMARY:** This hypothesis proposes a targeted approach focusing on G00484, a transcription factor essential for insulin signaling and glucose metabolism, complemented by G19943, G23245, G22553, and G33764. This multi-target strategy aims to enhance insulin sensitivity and restore metabolic homeostasis in Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G00484 is identified as a significant transcription factor in modules positively correlated with insulin signaling.
- Regulating TFs: G00484 directly regulates genes involved in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The mechanism hypothesizes that targeting G00484 will transcriptionally enhance insulin signaling pathways, significantly improving glucose uptake and metabolism. By regulating key genes, G00484 will synergistically act with G19943 to coordinate insulin signaling, while G23245 will ensure effective glucose transport. G22553 will provide additional signaling support, and G33764 will contribute to overall metabolic regulation, creating a robust network for managing Type 2 Diabetes.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they are critical for insulin action, glucose uptake, and metabolic homeostasis. Targeting these tissues is essential for effective therapeutic interventions aimed at improving insulin sensitivity.

**THERAPEUTIC_APPROACH:** The therapeutic strategy involves the activation of G00484 through small molecules to enhance its transcriptional function, alongside modulation of G19943, G23245, G22553, and G33764 to strengthen insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately aiming for restored metabolic homeostasis.

**RANKING_RATIONALE:** Targets are ranked based on their established roles, evidence strength across multiple datasets, and their potential for synergistic interactions. G00484 is prioritized for its critical regulatory role in insulin signaling, followed closely by G19943 and G23245 for their complementary functions in this network.

**CONFIDENCE:** HIGH, based on strong evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 20:55:45,889 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:55:45,889 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 20:55:45,889 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:55:45,892 - root - WARNING - Mutation produced invalid target: 
2026-02-10 20:55:45,892 - root - INFO -   -> Created mutated offspring: 'Targeting G00484 for Enhanced Insulin Se...'
2026-02-10 20:55:45,893 - root - INFO - Crossover 11/18: parents 'Targeting G22553 for Enhanced ...' x 'Comprehensive Multi-Target Str...'
2026-02-10 20:55:45,977 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:56:23,309 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:56:23,315 - root - INFO - TOKEN_USAGE: input=40309, output=769, total=41078, cost=$0.006508
2026-02-10 20:56:23,315 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:56:23,315 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 coordinates metabolic regulation, making it essential for improving insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling, G22553s modulation complements G19943, enhancing glucose metabolism and insulin action.
3. **G23245** | Score: 4.0 | Critical for glucose uptake and insulin sensitivity, G23245 reinforces the therapeutic strategy by working synergistically with G19943 and G22553.
4. **G00484** | Score: 4.0 | This transcription factor is a key regulator of insulin signaling, providing necessary regulatory support to the actions of G19943 and G22553.
5. **G33764** | Score: 4.0 | Supporting metabolic regulation, G33764 adds depth to the multi-target approach, ensuring robust interaction within insulin signaling pathways.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy focusing on G19943 as the primary target due to its pivotal role in insulin signaling and metabolic regulation. By integrating G22553, G23245, G00484, and G33764, we address the multifactorial nature of Type 2 Diabetes (T2D) with synergistic interactions that enhance insulin sensitivity and glucose homeostasis, leading to improved therapeutic outcomes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G19943 is identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways, enhancing the regulatory framework.

**MECHANISM_HYPOTHESIS:** The combination of G19943 as the central coordinator and G22553 as a primary driver is hypothesized to significantly enhance insulin signaling and glucose metabolism in T2D. G23245 will facilitate glucose uptake, while G00484 will regulate transcriptional responses critical for insulin sensitivity. G33764 will ensure overall metabolic regulation, creating a comprehensive mechanism for managing T2D through synergistic interactions among the targets.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are integral to insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions due to their central roles in glucose metabolism and insulin signaling.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245 and G00484 to strengthen metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its critical central role in insulin signaling, followed by G22553, which complements its function, while G23245, G00484, and G33764 provide essential regulatory support and metabolic regulation.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 20:56:23,316 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:56:23,316 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:56:23,317 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:56:23,319 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:56:23,319 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 20:56:23,320 - root - INFO - Crossover 12/18: parents 'Integrated Multi-Target Approa...' x 'Integrated Targeting of Metabo...'
2026-02-10 20:56:23,379 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:57:00,863 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:57:00,870 - root - INFO - TOKEN_USAGE: input=40345, output=768, total=41113, cost=$0.006513
2026-02-10 20:57:00,871 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:57:00,871 - root - INFO - 
### TITLE: Synergistic Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436** | Score: 4.0 | Critical enzyme in lipid metabolism that directly enhances insulin sensitivity and glucose regulation, supported by robust evidence.
2. **G19943** | Score: 4.0 | Central hub in T2D pathways with strong evidence for its role in insulin signaling and metabolic regulation, providing integration across multiple pathways.
3. **G22553** | Score: 4.0 | Key player in insulin signaling that supports metabolic control and complements the functions of G04436 and G19943.
4. **G23245** | Score: 4.0 | Primary driver in insulin signaling pathways, significantly influencing glucose uptake and enhancing the overall therapeutic approach.
5. **G33764** | Score: 4.0 | Provides regulatory support within metabolic pathways, enhancing the efficacy of the multi-target strategy in addressing T2D.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This hypothesis integrates the strengths of G04436 as the primary target to improve lipid metabolism and insulin sensitivity, while leveraging G19943s central role as a hub in metabolic regulation. The inclusion of G22553 and G23245 promotes insulin signaling and glucose uptake, and G33764 adds regulatory support, creating a comprehensive strategy for Type 2 Diabetes management.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G04436)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Lipid metabolism, insulin signaling, glucose metabolism, metabolic regulation pathways.
- **WGCNA module role**: G04436 identified as a key enzyme in lipid metabolism supporting insulin sensitivity.
- **Regulating TFs**: Multiple transcription factors involved, providing regulatory depth to the approach.

### MECHANISM_HYPOTHESIS:
The proposed mechanism emphasizes the activation of G04436 to enhance lipid metabolism, which is crucial for improving insulin sensitivity and glucose regulation in Type 2 Diabetes. G19943 acts as a pivotal regulator of insulin signaling and metabolic pathways, while G22553 and G23245 synergistically support insulin signaling and glucose uptake, respectively. G33764 further reinforces metabolic regulation, ensuring a comprehensive therapeutic strategy that targets critical pathways necessary for effective diabetes management.

### TISSUE_RATIONALE:
The most relevant tissues include the liver, muscle, and adipose tissue, which are essential for lipid and glucose homeostasis. Enhancing the function of these tissues will directly impact insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G04436, G19943, G22553, G23245, and G33764) to improve insulin sensitivity and overall metabolic regulation.

### PREDICTED_OUTCOME:
Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their critical roles in insulin signaling and metabolic pathways, as well as their strong data support. G04436 was prioritized for its established importance in lipid metabolism, followed by G19943 for its central integrative role. G22553 and G23245 were included for their significant contributions to glucose uptake, while G33764 provided necessary regulatory support.

### CONFIDENCE: HIGH
The hypothesis is supported by robust data across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 20:57:00,872 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:57:00,872 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:57:00,876 - root - INFO -   -> Created offspring: 'Synergistic Multi-Target Strategy for En...'
2026-02-10 20:57:00,876 - root - INFO - Crossover 13/18: parents '** Comprehensive Multi-Target ...' x 'Integrated Multi-Target Approa...'
2026-02-10 20:57:00,921 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:57:41,642 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:57:41,648 - root - INFO - TOKEN_USAGE: input=40348, output=743, total=41091, cost=$0.006498
2026-02-10 20:57:41,648 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:57:41,648 - root - INFO - 
**TITLE:** Synergistic Multi-Target Strategy for Enhanced Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in insulin signaling pathways, crucial for coordinating metabolic regulation and enhancing insulin sensitivity in T2D.
2. **G04436** | Score: 4.0 | Critical enzyme that enhances both insulin sensitivity and glucose metabolism, supported by robust evidence across datasets.
3. **G22553** | Score: 4.0 | Key driver in insulin signaling pathways that complements G19943, promoting glucose uptake and metabolism.
4. **G23245** | Score: 4.0 | Essential for glucose uptake and insulin sensitivity, reinforcing therapeutic action alongside the primary targets.
5. **G33764** | Score: 4.0 | Provides regulatory support within metabolic pathways, enhancing overall efficacy in addressing T2D.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates a multi-target approach focusing on G19943 as the pivotal regulator of insulin signaling and metabolic homeostasis in Type 2 Diabetes. The strategy leverages G04436 and G22553 to enhance glucose metabolism, while G23245 and G33764 provide additional support for glucose uptake and metabolic regulation, respectively. This comprehensive approach addresses the complexity of T2D by simultaneously targeting multiple pathways.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism emphasizes G19943's role as a central coordinator in insulin signaling and lipid metabolism, essential for restoring metabolic homeostasis in T2D. Activation of G04436 will enhance metabolic pathways necessary for glucose metabolism, while G22553 and G23245 synergistically support insulin signaling and glucose uptake, respectively. Additionally, G33764 will provide regulatory support to enhance the efficacy of the multi-target strategy, tackling insulin resistance comprehensively.

**TISSUE_RATIONALE:** The most relevant tissues for this approach include pancreatic -cells, muscle, liver, and adipose tissue, vital for effective insulin action, glucose uptake, and overall metabolic regulation. These tissues are critical targets for therapeutic interventions aimed at reversing the metabolic disturbances associated with Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic strategy involves the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** The combined activation of these targets is expected to lead to significantly enhanced insulin sensitivity, improved glucose metabolism, and better overall metabolic control in patients with Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their high priority scores, robust evidence from multiple datasets, and their critical roles in key biological pathways. G19943 is prioritized for its central importance in the gene network, while G04436 and G22553 were included due to their complementary roles in glucose metabolism. G23245 and G33764 were added to provide necessary support for metabolic regulation, creating a comprehensive therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:57:41,650 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:57:41,650 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:57:41,651 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:57:41,653 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:57:41,653 - root - INFO -   -> Created offspring: '** Synergistic Multi-Target Strategy for...'
2026-02-10 20:57:41,654 - root - INFO - Crossover 14/18: parents '** Comprehensive Multi-Target ...' x 'Synergistic Multi-Target Modul...'
2026-02-10 20:57:41,749 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:58:16,266 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:58:16,270 - root - INFO - TOKEN_USAGE: input=40315, output=798, total=41113, cost=$0.006526
2026-02-10 20:58:16,270 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:58:16,270 - root - INFO - 
**TITLE:** Integrated Multi-Target Approach for Optimizing Insulin Sensitivity and Glucose Homeostasis in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in T2D pathways that facilitates insulin signaling and metabolic regulation, making it the most promising target based on strong evidence across datasets.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways, complementing G19943's function and crucial for enhancing glucose metabolism.
3. **G23245** | Score: 4.0 | A pivotal driver in glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy alongside G19943 and G22553.
4. **G33764** | Score: 4.0 | Enhances metabolic regulation and supports insulin signaling pathways, providing additional robustness to the overall approach.
5. **G00484** | Score: 4.0 | Functions as a transcription factor crucial for the regulation of insulin signaling and glucose homeostasis, enhancing the regulatory framework of the intervention.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses by proposing a synergistic multi-target strategy that leverages the central roles of G19943, G22553, G23245, G33764, and G00484 in insulin signaling and glucose metabolism. By focusing on these key targets, the approach aims to optimize insulin sensitivity and restore metabolic homeostasis in Type 2 Diabetes, addressing the multifactorial nature of the disease.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 is identified as a hub component in modules negatively correlated with T2D, while G22553 is a primary driver in the black module.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** This hypothesis posits that G19943 will serve as a central coordinator in insulin signaling and lipid metabolism, which is essential for restoring metabolic homeostasis in T2D. Targeting G22553 in conjunction with G19943 is expected to enhance insulin signaling pathways, while G23245 and G33764 will improve glucose uptake and metabolic regulation. G00484 will support these processes by regulating transcriptional responses critical for insulin sensitivity, resulting in a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** The most relevant tissues for targeting these genes include pancreatic -cells, skeletal muscle, liver, and adipose tissue, as they play integral roles in insulin action, glucose uptake, and overall metabolic regulation, making them optimal candidates for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245, G33764, and G00484 to strengthen metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of these selected targets is expected to lead to substantial improvements in insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, the robustness of supporting evidence across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role in insulin signaling, followed by G22553, which complements its function. G23245 and G33764 provide essential regulatory support, while G00484 adds necessary transcriptional regulation.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 20:58:16,270 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:58:16,270 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:58:16,271 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:58:16,272 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:58:16,272 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Approach for ...'
2026-02-10 20:58:16,272 - root - INFO - Crossover 15/18: parents '** Targeting Insulin Sensitivi...' x 'Multi-Target Modulation for En...'
2026-02-10 20:58:16,305 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:59:01,789 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:59:01,795 - root - INFO - TOKEN_USAGE: input=40331, output=807, total=41138, cost=$0.006534
2026-02-10 20:59:01,796 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:59:01,796 - root - INFO - 
**TITLE:** Comprehensive Multi-Target Approach to Enhance Metabolic Control and Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | As a central hub in metabolic pathways, it integrates insulin signaling and lipid metabolism, providing a foundational target for enhancing metabolic regulation.**
2. **G04436 | Score: 4.0 | This enzyme is crucial for lipid metabolism and insulin action, effectively complementing G19943 to improve overall metabolic control.**
3. **G22553 | Score: 4.0 | A primary driver in glucose uptake pathways, its activation is expected to significantly enhance insulin sensitivity and glucose metabolism.**
4. **G33764 | Score: 4.0 | Provides regulatory support within metabolic pathways, further enhancing the efficacy of G19943 and G04436 in managing insulin resistance.**
5. **G19122 | Score: 3.0 | Though slightly lower in priority, its role as a major regulator of insulin signaling in muscle makes it a valuable component for synergistic effects.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-targeted approach to enhance metabolic control in Type 2 Diabetes by targeting G19943 as the primary hub for metabolic regulation. The strategy incorporates G04436, G22553, G33764, and G19122 to synergistically improve insulin sensitivity, glucose uptake, and lipid metabolism, addressing the complex interplay of metabolic pathways in T2D.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation pathways
- WGCNA module role: G19943 identified as a hub component in the negatively correlated T2D module
- Regulating TFs: G04436 is associated with 12 identified transcription factors

**MECHANISM_HYPOTHESIS:** The proposed mechanism integrates the activation of G19943 to enhance the overall metabolic pathway regulation, thereby improving insulin signaling and lipid metabolism. G04436 will synergistically enhance lipid profiles and support insulin action, while G22553 will facilitate glucose uptake, amplifying the effects of G19943. G33764 will provide additional regulatory support, ensuring a robust multi-target strategy that addresses insulin resistance in Type 2 Diabetes. G19122, while ranked lower, contributes to insulin sensitivity improvements in muscle tissue, providing a beneficial effect in the overall metabolic balance.

**TISSUE_RATIONALE:** The primary tissues targeted include skeletal muscle, liver, and adipose tissue, as these sites are critical for effective insulin action, glucose uptake, and lipid metabolism. Focusing on these tissues allows for a comprehensive strategy to reverse metabolic dysregulation associated with Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will involve the development of small molecule activators that enhance the functions of these targets, aiming to restore normal metabolic function and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, resulting in better management of Type 2 Diabetes symptoms and potentially reversing disease progression.

**RANKING_RATIONALE:** Targets were ranked based on their established roles as primary drivers in T2D pathways, their strength of evidence across multiple datasets, and their potential for synergistic interactions. G19943 was prioritized for its central role in metabolic regulation, while G04436 and G22553 were included for their significant contributions to insulin signaling and metabolic regulation. G33764 provides regulatory support, and G19122, while lower in rank, remains relevant for its role in muscle metabolism. 

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 20:59:01,797 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:59:01,797 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:59:01,798 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:59:01,800 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:59:01,800 - root - INFO -   -> Created offspring: '** Comprehensive Multi-Target Approach t...'
2026-02-10 20:59:01,800 - root - INFO - Crossover 16/18: parents 'Integrated Targeting of Metabo...' x 'Comprehensive Multi-Target Str...'
2026-02-10 20:59:01,837 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 20:59:45,601 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 20:59:45,608 - root - INFO - TOKEN_USAGE: input=40309, output=832, total=41141, cost=$0.006546
2026-02-10 20:59:45,608 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 20:59:45,608 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy for Enhancing Insulin Sensitivity in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G22553** | Score: **4.0** | As a primary driver in insulin signaling, G22553 is crucial for enhancing glucose metabolism and shows strong evidence across multiple datasets.
2. **G23245** | Score: **4.0** | This gene significantly influences glucose uptake and metabolic processes, complementing the action of G22553 and reinforcing insulin sensitivity.
3. **G19943** | Score: **4.0** | Serving as a hub component in metabolic regulation, G19943 supports insulin signaling pathways and integrates various metabolic signals, enhancing overall metabolic health.
4. **G04436** | Score: **4.0** | An important enzyme in lipid metabolism, G04436 enhances insulin sensitivity and glucose regulation, complementing the functions of the other targets.
5. **G00484** | Score: **4.0** | This transcription factor plays a regulatory role in insulin signaling pathways, adding an essential layer of control to the overall therapeutic strategy.

#### PRIMARY_TARGET: **G22553**

### SUMMARY:
This child hypothesis integrates the strengths of both parent hypotheses by emphasizing a multi-target strategy that focuses on key drivers of insulin sensitivity and glucose metabolism in Type 2 Diabetes. By targeting G22553 as the primary target, alongside G23245 and G19943, we create a comprehensive approach that addresses multiple aspects of metabolic regulation, while also incorporating G04436's role in lipid metabolism and G00484's regulatory influence.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling pathways, glucose metabolism, lipid metabolism, metabolic regulation
- **WGCNA module role**: G22553 is a primary driver in the black module; G23245 is a primary driver in the silver module, indicating their significant roles in T2D.
- **Regulating TFs**: G00484 acts as a key transcription factor in insulin signaling pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism involves G22553 enhancing insulin signaling and glucose metabolism, supported by G23245 which promotes glucose uptake. G19943 integrates metabolic signals and supports overall metabolic homeostasis, while G04436, by enhancing lipid metabolism, further contributes to improved insulin sensitivity. G00484 adds an important regulatory layer, optimizing the therapeutic strategy by ensuring that insulin signaling is effectively enhanced across various pathways.

### TISSUE_RATIONALE:
Key tissues involved include skeletal muscle, adipose tissue, and liver, all of which are essential for insulin action, glucose uptake, and metabolic regulation. Targeting these tissues will directly impact insulin sensitivity and overall metabolic health in individuals with Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The proposed approach involves small molecule activation of G22553 and G23245, combined with modulation of G19943, G04436, and G00484 to enhance insulin sensitivity and overall glucose metabolism.

### PREDICTED_OUTCOME:
Targeting these selected genes is anticipated to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately improving patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles as primary drivers in insulin signaling and metabolic pathways, as well as their strong data support across multiple evidence types. G22553 was prioritized for its central role in insulin signaling, followed by G23245 for its contribution to glucose uptake, and G19943 for its integrative role in metabolic regulation. G04436 was included for its critical function in lipid metabolism, while G00484 serves as a necessary regulatory factor enhancing the therapeutic strategy.

### CONFIDENCE: HIGH
This hypothesis is grounded in robust data support across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 20:59:45,610 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 20:59:45,610 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 20:59:45,611 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 20:59:45,614 - root - WARNING - Crossover produced invalid target: 
2026-02-10 20:59:45,614 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy for ...'
2026-02-10 20:59:45,614 - root - INFO - Crossover 17/18: parents '** Integrated Multi-Target Str...' x 'Comprehensive Multi-Target Str...'
2026-02-10 20:59:45,662 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:00:22,681 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:00:22,689 - root - INFO - TOKEN_USAGE: input=40287, output=730, total=41017, cost=$0.006481
2026-02-10 21:00:22,689 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:00:22,689 - root - INFO - 
### TITLE: Synergistic Multi-Target Strategy for Optimized Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | A central hub in insulin signaling pathways, crucial for coordinating metabolic regulation and enhancing insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver of insulin signaling that significantly improves glucose metabolism and amplifies G19943's effects.
3. **G04436** | Score: 4.0 | An important enzyme regulating glucose homeostasis, which complements the actions of G19943 and G22553.
4. **G23245** | Score: 4.0 | Plays a critical role in glucose uptake and enhances insulin sensitivity, providing necessary support to the insulin signaling cascade.
5. **G33764** | Score: 4.0 | Functions as a primary driver in metabolic regulation, directly addressing insulin resistance to support overall therapeutic strategy.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses by prioritizing G19943 as the central target due to its pivotal role in insulin signaling. It further emphasizes the complementary actions of G22553, G04436, and G23245 to enhance glucose metabolism and insulin sensitivity, while G33764 addresses insulin resistance mechanisms. This comprehensive approach aims to address the multifactorial nature of Type 2 Diabetes (T2D).

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism.
- WGCNA module role: G19943 identified as a hub component in modules correlated with T2D.
- Regulating TFs: G04436 serves as a transcriptional regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that activating G19943 enhances insulin signaling while G22553 amplifies its activity, leading to improved glucose metabolism. Concurrent modulation of G04436 is expected to maintain glucose homeostasis, while G23245 facilitates glucose uptake and further enhances insulin sensitivity. G33764 addresses insulin resistance, ensuring a robust therapeutic framework for managing T2D.

**TISSUE_RATIONALE:** The primary tissues involved include pancreatic -cells, muscle, liver, and adipose tissue, which are crucial for insulin action, glucose uptake, and overall metabolic regulation, making them prime targets for therapeutic intervention in T2D.

**THERAPEUTIC_APPROACH:** The proposed strategy involves the small molecule activation of G19943, G22553, and G04436, complemented by the modulation of G23245 and G33764 to enhance insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Effective modulation of these interconnected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better overall management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence backing, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553 for its amplifying effects. G04436 is crucial for glucose regulation, while G23245 enhances insulin sensitivity and G33764 addresses insulin resistance.

**CONFIDENCE:** HIGH, based on robust data support and significant associations with T2D mechanisms.
2026-02-10 21:00:22,690 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:00:22,690 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:00:22,690 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:00:22,692 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:00:22,692 - root - INFO -   -> Created offspring: 'Synergistic Multi-Target Strategy for Op...'
2026-02-10 21:00:22,692 - root - INFO - Mutation 18/18: parent 'Comprehensive Multi-Target Str...'
2026-02-10 21:00:22,693 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 21:00:22,762 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:01:04,861 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:01:04,868 - root - INFO - TOKEN_USAGE: input=39517, output=759, total=40276, cost=$0.006383
2026-02-10 21:01:04,868 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:01:04,868 - root - INFO - 
**TITLE:** Enhanced Multi-Target Approach to Optimize Insulin Sensitivity in Type 2 Diabetes Through Synergistic Pathways

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As the primary driver in insulin signaling, G22553 has strong cross-dataset evidence supporting its critical role in enhancing glucose metabolism.
2. **G19943** | Score: 4.0 | This hub component in metabolic regulation reinforces insulin signaling pathways, showing consistent data support across multiple evidence types.
3. **G19122** | Score: 3.0 | As a major regulator in insulin signaling, G19122 is pivotal in the interaction between insulin action and glucose metabolism, supported by multiple datasets.
4. **G00484** | Score: 4.0 | This transcription factor's regulatory role in insulin signaling pathways provides a necessary layer of control, enhancing the effectiveness of the therapeutic strategy.
5. **G23245** | Score: 4.0 | Although critical for glucose uptake, its negative log2FC indicates a potentially less favorable role in the current context compared to the higher-ranked targets.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis refines the focus on G22553 as a primary target while integrating G19943, G19122, and G00484 for a comprehensive approach that enhances insulin signaling and glucose metabolism in Type 2 Diabetes (T2D). By leveraging the synergistic effects of these targets, this hypothesis aims to create a robust therapeutic strategy that addresses the complexities of T2D management.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, metabolic regulation
- WGCNA module role: G22553 is a primary driver in the black module, indicating its centrality to T2D-related pathways.
- Regulating TFs: G00484 functions as a regulator in insulin signaling pathways, further supporting the proposed mechanism.

**MECHANISM_HYPOTHESIS:** The mechanism involves G22553 enhancing insulin signaling and glucose metabolism, with G19943 supporting metabolic responses. G19122 acts as a critical regulator of insulin sensitivity, while G00484 provides an essential regulatory layer, ensuring effective modulation of the insulin signaling network. This multi-target strategy aims to enhance the overall therapeutic efficacy in managing T2D.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, adipose tissue, and pancreatic -cells, which are essential for insulin action, glucose uptake, and overall metabolic regulation, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The proposed therapeutic approach involves the small molecule activation of G22553 and G19943, complemented by modulation of G19122 and G00484 to enhance insulin sensitivity and glucose metabolism.

**PREDICTED_OUTCOME:** Targeting these selected genes is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, strong evidence support across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role, followed by G19943 for its supportive function, while G19122 and G00484 provide crucial regulatory and modulatory support. G23245, despite its importance, is ranked lower due to an unfavorable log2FC. 

**CONFIDENCE:** HIGH, based on robust data support across multiple evidence types and pathways relevant to T2D management.
2026-02-10 21:01:04,870 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:01:04,870 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:01:04,873 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:01:04,880 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:01:04,880 - root - INFO -   -> Created mutated offspring: '** Enhanced Multi-Target Approach to Opt...'
2026-02-10 21:01:04,880 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 21:01:04,880 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 21:01:04,880 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 21:01:04,881 - root - INFO - Evaluating fitness for hypothesis: t2d-08-ab87afd2
2026-02-10 21:01:20,933 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:01:20,935 - root - INFO - TOKEN_USAGE: input=1467, output=713, total=2180, cost=$0.000648
2026-02-10 21:01:20,935 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:01:20,935 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is included in the ranked targets and has a high priority score of 4.0, but it is not in the top 10 priority list, which raises concerns. The cross-dataset consistency is confirmed, and there are two datasets supporting the primary target. However, the warning about G22553 not being in the top priority list diminishes the overall score.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking of the targets is generally justified by the data, with high scores for all ranked targets. However, the absence of G22553 in the top priority list undermines the strength of the ranking. The rationale for the rankings is logical, but the lack of clarity on the differences between the highest-ranked targets and lower-ranked targets affects the score.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and highlights the roles of the targets in glucose and lipid metabolism. The tissue rationale is appropriate, focusing on skeletal muscle, liver, and adipose tissue, which are critical for insulin action. The role of the transcription factor G00484 is well considered, reinforcing the mechanistic coherence.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the selected targets is appropriate for enhancing insulin sensitivity. The targets are likely druggable based on their positions in metabolic pathways, and the strategy seems well thought out regarding potential safety considerations. However, further exploration of off-target effects and broader safety profiles would strengthen this aspect.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis presents a multi-target strategy that integrates various roles in insulin signaling and metabolism, demonstrating a creative approach. However, some connections, such as the role of G33764 in lipid metabolism, are somewhat established in the literature, slightly reducing the novelty score.

### OVERALL_FITNESS
**Overall Fitness:** (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (8 * 0.20) + (7 * 0.10) = 7.1 (scaled to 71/100)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Inclusion:** Ensure that all critical targets, including G22553, are consistently placed within the top priority lists to avoid discrepancies and strengthen the hypothesis.
2. **Enhance Data Evidence:** Consider gathering more evidence types to support the primary target, especially focusing on clinical relevance and functional assays to solidify the data support.
3. **Clarify Target Differences:** Provide clearer distinctions and rationale for the ranking of targets, particularly between those with the same score, to strengthen the ranking quality.
4. **Explore Safety Profiles:** Include a more thorough discussion of potential off-target effects and safety profiles for the proposed therapeutic approach to provide a comprehensive risk assessment.
5. **Consider Novel Mechanisms:** Explore and highlight any novel mechanisms or pathways that may not have been previously connected to insulin sensitivity to enhance the novelty of the hypothesis.
2026-02-10 21:01:20,935 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:01:20,936 - root - INFO - Evaluating fitness for hypothesis: t2d-08-76d32ecb
2026-02-10 21:01:34,660 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:01:34,664 - root - INFO - TOKEN_USAGE: input=1527, output=736, total=2263, cost=$0.000671
2026-02-10 21:01:34,664 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:01:34,664 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is found in the top priority list, but G00484, which plays a crucial role in transcriptional regulation of insulin signaling, is not in the top 10. There is cross-dataset consistency for the primary target, but the reliance on only two datasets somewhat limits the robustness of evidence. Overall, while the evidence supports the primary target, the absence of some supporting targets in the top tier limits the score.

---

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified based on the roles of the targets in insulin signaling pathways. Higher-ranked targets are strong contributors to the hypothesis. However, the absence of G00484 in the top priority list raises questions about the strength of its ranking relative to other targets, which could affect the perceived strength of the overall ranking.

---

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling, and the tissue rationale is strong due to the focus on pancreatic islets. The relationships with transcription factors are considered, particularly with G00484, which is acknowledged as a key regulator. Overall, the mechanistic coherence is high, with clear links between targets and their roles in metabolic regulation.

---

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and modulating the other targets is appropriate, as it aims to enhance insulin signaling effectively. The potential druggability of the targets is reasonable based on their network positions, though specific safety considerations are not addressed in the hypothesis. The score reflects a solid therapeutic potential, but more detail on druggability and safety would strengthen the rationale.

---

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a meaningful way by proposing a multi-target strategy focused on pancreatic islets, which is a relevant and important area for Type 2 Diabetes treatment. However, the connections made between targets are somewhat conventional in the context of insulin signaling, which slightly limits the novelty score.

---

**OVERALL_FITNESS: 6.8**  
**Calculated Overall Score:** (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.8

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG (G22553 is well-supported and crucial)
- Target #2 quality: WEAK (G00484 is not found in the top 10, despite being critical)
- Target #3 quality: STRONG (G19943 serves as a central hub in insulin signaling)

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Re-evaluate G00484:** Investigate why G00484 is not in the top priority list and consider its importance in the hypothesis. If it is crucial, it should be substantiated with additional evidence or highlighted more clearly in the rationale.
2. **Expand Data Sources:** Increase the number of datasets used to support the findings for all targets, especially focusing on those that did not make the top 10 list.
3. **Detail Druggability and Safety:** Provide more information on the druggability of targets and any potential safety concerns associated with their modulation to strengthen the therapeutic potential section.
2026-02-10 21:01:34,664 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:01:34,665 - root - INFO - Evaluating fitness for hypothesis: t2d-08-519ccf8a
2026-02-10 21:01:52,345 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:01:52,348 - root - INFO - TOKEN_USAGE: input=1576, output=862, total=2438, cost=$0.000754
2026-02-10 21:01:52,348 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:01:52,348 - root - INFO - 
### Evaluation of the Hypothesis: Enhanced Multi-Pathway Modulation for Insulin Sensitivity in Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 7
**DATA_SUPPORT_RATIONALE:** The primary target G23245 has a moderate priority score of 4/17, indicating it is in the top priority tier. However, it lacks cross-dataset consistency (only supported by 1 dataset) and has only a single type of evidence supporting it. Despite the strong position of G23245 as a primary driver in insulin signaling, the overall data support is somewhat limited due to the lack of diverse evidence types and datasets.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the established roles of the targets in insulin signaling and metabolism. The highest-ranked targets (G23245, G04436, G22553) are strong contenders based on their biological functions, and the rationale for their ranking is coherent. However, the close score across all targets (4.0) suggests that the distinctions between them could be better clarified, particularly in terms of their unique contributions to insulin sensitivity.

#### MECHANISTIC_SCORE: 7
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in insulin signaling and metabolic regulation. The tissue rationale focuses on critical tissues (adipose, liver, muscle) relevant to T2D, which strengthens the proposal. However, the lack of detailed information on transcription factors (TFs) and their regulatory roles could enhance the mechanistic coherence. While G23245 is positioned as a primary driver, the absence of associated TFs could limit understanding of the complete regulatory network.

#### THERAPEUTIC_SCORE: 8
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation is appropriate for targeting these pathways. The strategy of activating G23245 and modulating associated targets is well-founded and likely to yield beneficial outcomes for insulin sensitivity. However, the evaluation of druggability and safety considerations for each target should be more explicitly addressed to enhance the assessment of therapeutic potential.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates multiple pathways and targets in a systematic manner, which is a creative approach to enhancing insulin sensitivity. However, the connections between the targets could be more innovative and less obvious. The integration of a multi-pathway strategy is promising, yet the novelty stems primarily from the combination of known targets rather than introducing entirely new concepts or connections.

### OVERALL_FITNESS: 7.3
**Calculation:** (7 * 0.25) + (8 * 0.25) + (7 * 0.20) + (8 * 0.20) + (6 * 0.10) = 1.75 + 2.00 + 1.40 + 1.60 + 0.60 = 7.35 (rounded to 7.3)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G23245 is a key driver in insulin signaling.)
- Target #2 quality: **STRONG** (G04436 plays a critical role in lipid metabolism.)
- Target #3 quality: **STRONG** (G22553 is also important in insulin signaling.)

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Diversity**: Aim to gather more datasets and types of evidence supporting G23245 and other targets. This could include functional assays, clinical data, or additional animal models.
2. **Clarify Rank Distinctions**: Provide clearer delineation of the unique contributions of each target in the hypothesis, especially among those with similar scores.
3. **Explore TF Relationships**: Investigate and include potential transcription factors that regulate these targets, enhancing the understanding of the regulatory network involved.
4. **Address Drug Safety**: Include a discussion on the druggability of each target and any potential safety issues related to modulation.
5. **Innovate Target Connections**: Explore novel interactions or pathways that could further differentiate this approach from existing strategies, possibly leading to more innovative therapeutic options.
2026-02-10 21:01:52,348 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:01:52,349 - root - INFO - Novelty bonus applied: 0.5% -> fitness 73.50 -> 73.87
2026-02-10 21:01:52,349 - root - INFO - Evaluating fitness for hypothesis: t2d-08-694592d7
2026-02-10 21:02:13,194 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:02:13,250 - root - INFO - TOKEN_USAGE: input=1443, output=753, total=2196, cost=$0.000668
2026-02-10 21:02:13,250 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:02:13,250 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is included in the top priority list, but it is important to note that G19122 is not present among the top 10 priority genes, raising concerns about its support. There is cross-dataset consistency for the top-ranked targets, and strong evidence types support the primary target, but the lack of G19122 in the top tier reduces the overall score.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with the top three targets (G22553, G19943, and G23245) showing robust roles in insulin signaling and glucose metabolism. The rationale for ranking is logical, with higher-ranked targets having clearer evidence of their roles in T2D management than the lower-ranked G19122 and G33764. However, the presence of G19122 could challenge the strength of the ranking due to its absence in the top priority list.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with insulin signaling pathways and glucose metabolism, and the rationale for the choice of tissues (skeletal muscle, adipose tissue, pancreatic -cells) is well supported by existing knowledge of insulin action. The consideration of transcription factor relationships adds depth to the understanding of regulatory networks. However, a more explicit discussion on the role of transcription factors in the regulatory mechanisms would strengthen this aspect.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic strategy of activating G22553, G19943, and G23245, along with modulation of G19122 and G33764, seems appropriate and well thought out. However, the potential druggability of G19122 is uncertain, and safety considerations regarding the modulation of multiple targets should be clearly addressed. This limitation affects the overall therapeutic potential.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates various targets to address T2D comprehensively, the approach is somewhat conventional. The connections made between the targets are logical but do not introduce significantly novel concepts or unexpected interactions that could enhance the hypothesis's originality.

---

**OVERALL_FITNESS:** 7.1  
**(Calculated: 7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 7.1)**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG (G22553 shows a central role with robust data support)  
- Target #2 quality: STRONG (G19943 is a hub component with critical functions)  
- Target #3 quality: STRONG (G23245 significantly contributes to glucose uptake and insulin signaling)

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Address Missing Target:** Consider including G19122 in the top priority list by providing additional evidence or clarifying its role to strengthen the overall hypothesis.
2. **Expand on Mechanistic Details:** Provide a more detailed explanation of how transcription factors interact with the target genes to enhance the mechanistic coherence of the proposal.
3. **Clarify Safety and Druggability:** Elaborate on the safety considerations for modulating multiple targets and investigate the druggability of G19122 to strengthen the therapeutic component of the hypothesis.
4. **Highlight Novel Connections:** Explore potential novel interactions or downstream effects of the targets that have not been previously emphasized to enhance the novelty of the hypothesis.
2026-02-10 21:02:13,251 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:02:13,251 - root - INFO - Evaluating fitness for hypothesis: t2d-08-841a39ab
2026-02-10 21:02:28,392 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:02:28,448 - root - INFO - TOKEN_USAGE: input=1424, output=707, total=2131, cost=$0.000638
2026-02-10 21:02:28,448 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:02:28,448 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is correctly listed in the top priority tier, but a warning indicates that it is not present in the top priority list when comparing with the top 10 genes. The hypothesis mentions cross-dataset consistency with two datasets, which supports the credibility of the data. However, there is a lack of diversity in evidence types supporting G22553, which could improve the score. 

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their roles in insulin signaling and metabolic regulation. G22553 is emphasized as a primary driver, followed by G19943, which is a regulatory hub. However, G00484 appears lower in the ranking despite its role as a transcription factor in insulin signaling, suggesting that the ranking could benefit from more nuanced differentiation among targets.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with established pathways in insulin signaling and glucose metabolism. The tissue rationale is well-supported, focusing on pancreatic -cells, muscle, liver, and adipose tissue, which are critical in T2D. The role of G00484 as a transcription factor is particularly well-integrated into the proposed mechanism. 

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation for G22553, complemented by modulation of other targets, appears appropriate based on their network positions. However, the safety considerations for multi-target interventions are not thoroughly addressed, which could raise concerns in real-world therapeutic applications.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets in a multi-target approach, which is somewhat innovative. However, the connections made among the targets and their roles are not particularly groundbreaking, as many of these targets are already known in the context of insulin signaling and glucose metabolism.

**OVERALL_FITNESS:** 69  
(0.25 * 6 + 0.25 * 7 + 0.20 * 8 + 0.20 * 7 + 0.10 * 6 = 6.8, scaled to 0-100)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG  
- **Target #2 quality:** STRONG  
- **Target #3 quality:** STRONG  

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Evidence Diversity:** Include a wider range of evidence types to support the primary target, such as clinical trial data or functional studies that directly link G22553 to insulin sensitivity improvements.
   
2. **Reassess Target Ranking:** Re-evaluate the ranking of G00484, which plays a critical role as a transcription factor in insulin signaling. Consider its position relative to G33764 and provide a rationale for its placement.

3. **Address Safety Considerations:** Expand on the potential safety implications of the multi-target therapeutic approach, particularly regarding the combined modulation of these targets, to provide a more comprehensive risk assessment.

4. **Explore Novel Mechanisms:** Investigate any less-explored interactions or mechanisms involving the targets to enhance the novelty of the hypothesis, potentially leading to new insights in T2D treatment strategies.
2026-02-10 21:02:28,448 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:02:28,449 - root - INFO - Evaluating fitness for hypothesis: t2d-08-b93a634b
2026-02-10 21:02:43,854 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:02:43,860 - root - INFO - TOKEN_USAGE: input=1453, output=694, total=2147, cost=$0.000634
2026-02-10 21:02:43,860 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:02:43,860 - root - INFO - 
**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target (G22553) is present in the ranked list with a score of 4.0, but it is not the highest priority target in the top 10 list, which indicates a potential oversight in the evaluation. There is cross-dataset consistency for the top-ranked targets, and multiple types of evidence support the primary target. However, the absence of G22553 from the top priority list suggests that while it has strong support, it may be less robust than other targets.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as all ranked targets received high scores. However, the fact that the primary target is not the highest-ranked target (G19943) raises questions about the clarity of the ranking. The rationale for the ranking makes sense based on the role of each target in insulin signaling and metabolic pathways, but the relative strength of G22553 compared to G19943 could be better clarified.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and metabolic regulation. The tissue rationale is supported by the identified roles of pancreatic -cells, muscle, liver, and adipose tissue in glucose metabolism. The involvement of transcription factors in the regulation of these targets is acknowledged, adding to the mechanistic coherence.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets using small molecules is appropriate given their roles in enhancing insulin sensitivity and metabolic function. The targets appear to be druggable based on their network positions. However, potential safety considerations related to multiple target activation should be thoroughly evaluated to mitigate risks associated with polypharmacology.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates data creatively, proposing a multi-target strategy that leverages synergies among several targets. However, the connections made are somewhat expected in the context of diabetes management, as the focus on insulin signaling and metabolic regulation is a common area of research. Thus, while there is some novelty, it may not be groundbreaking.

**OVERALL_FITNESS:** 6.6 (calculated as (6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) scaled to 0-100)  

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. Reassess the priority ranking of G22553 in relation to G19943 to ensure that the strongest target is appropriately recognized as primary. Consider conducting further analysis to clarify the relative strengths of these targets.
2. Enhance the therapeutic rationale by outlining specific safety considerations related to polypharmacological approaches, such as potential off-target effects or adverse interactions.
3. Explore additional novel aspects of the multi-target strategy, such as identifying unique pathways or mechanisms that have not been previously emphasized in diabetes research.
4. Strengthen the evidence support by incorporating more diverse datasets or types of evidence to reinforce the robustness of the hypothesis.
2026-02-10 21:02:43,861 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:02:43,862 - root - INFO - Evaluating fitness for hypothesis: t2d-05-e7a3e264
2026-02-10 21:02:56,472 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:02:56,476 - root - INFO - TOKEN_USAGE: input=1495, output=619, total=2114, cost=$0.000596
2026-02-10 21:02:56,476 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:02:56,476 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, is in the top priority list, but there is a warning indicating that the target gene might not be present in the highest ranks. The cross-dataset consistency is confirmed, but the overall evidence for the ranked targets is limited as only one target (G19943) is specified. The presence of multiple evidence types supporting the primary target can be improved.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, as G19943 is highlighted as a central hub in insulin signaling, but the presence of other targets in the top priority list raises questions about their comparative strength. The rationale for ranking appears logical, but the lack of clarity on the comparative strength of all ranked targets diminishes the overall justification.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways in insulin signaling and islet function. The focus on pancreatic islets is appropriate given their crucial role in glucose homeostasis. The consideration of G00484 as a transcription factor adds depth, although additional insights into how other targets interact mechanistically may strengthen this aspect.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation appears suitable, and the network positions of targets suggest they may be druggable. However, safety considerations and potential off-target effects are not discussed, which is crucial for evaluating therapeutic viability.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data from various sources, the connections between targets are somewhat predictable based on existing knowledge of insulin signaling pathways. There is room for more innovative integration of data or novel insights that could enhance the hypothesis's novelty.

### OVERALL_FITNESS:
**Overall Fitness Calculation:**  
(6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 6.65  
**Scaled to 0-100:** 66.5

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Increase the number of supporting datasets for each target to enhance the overall data support.
2. **Clarify Target Interactions:** Provide more detailed mechanistic insights into how each target interacts within the signaling pathways to strengthen the mechanistic coherence.
3. **Safety Considerations:** Include a discussion on potential safety issues or off-target effects associated with the therapeutic approach to improve therapeutic assessment.
4. **Highlight Novel Insights:** Seek to identify or propose connections between the targets that may not be immediately obvious, enhancing the novelty of the hypothesis.
2026-02-10 21:02:56,476 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:02:56,477 - root - INFO - Evaluating fitness for hypothesis: t2d-08-5a55d806
2026-02-10 21:03:12,644 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:03:12,650 - root - INFO - TOKEN_USAGE: input=1467, output=764, total=2231, cost=$0.000678
2026-02-10 21:03:12,650 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:03:12,651 - root - INFO - 
### Evaluation of Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** While the primary target G19943 is present in the top priority list, G00484, which plays a key role in the hypothesis, is not in the top ten. This affects the overall data support score. However, the presence of strong cross-dataset consistency for G19943 and the identification of the targets within relevant pathways provides a moderate level of evidence.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the established roles of the targets in insulin signaling pathways. The rationale for prioritizing G19943 as the central hub is understandable, but the exclusion of G00484 from the top ten raises concerns about the strength of the overall ranking. The other targets, G22553 and G23245, are appropriately ranked due to their complementary roles.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context. The tissue rationale is appropriately supported, as pancreatic -cells, muscle, liver, and adipose tissue are all crucial for insulin action. Additionally, the roles of transcription factors are well-considered in the hypothesis.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation and modulation is appropriate given the targets roles. While the hypothesis presents a reasonable strategy, there could be safety considerations related to the modulation of multiple targets that are not fully addressed.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by emphasizing a multi-target strategy for improving insulin sensitivity. However, the connections drawn are somewhat conventional within diabetes research, limiting the novelty of the approach.

### Overall Fitness Calculation 
Using the weights provided:
- Overall Fitness = (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)  
= (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
= 1.5 + 1.75 + 1.6 + 1.4 + 0.6  
= 6.85  
Overall Fitness (scaled to 0-100) = 68.5  

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G19943 is well-supported and central)
- Target #2 quality: **WEAK** (G00484 is significant but not in the top ten)
- Target #3 quality: **STRONG** (G22553 fits well within the network)

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess the Priority List**: Consider revisiting the criteria for top targets to ensure that key regulatory elements like G00484 are appropriately recognized.
2. **Expand Safety Considerations**: Address potential safety issues more thoroughly in the therapeutic approach, particularly with multi-target modulation.
3. **Strengthen Evidence Base**: Incorporate additional datasets or evidence to bolster the rationale for the inclusion of G00484 and others not in the top tier.
4. **Highlight Novel Mechanisms**: Explore and highlight any novel mechanisms or interactions that can strengthen the originality of the hypothesis, which may improve the novelty score.
2026-02-10 21:03:12,652 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:03:12,653 - root - INFO - Evaluating fitness for hypothesis: t2d-08-ad262cd9
2026-02-10 21:03:29,149 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:03:29,153 - root - INFO - TOKEN_USAGE: input=1510, output=718, total=2228, cost=$0.000657
2026-02-10 21:03:29,153 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:03:29,154 - root - INFO - 
**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** While the primary target G22553 has a good score and strong evidence, it is noted that it is not in the top priority list, which raises concerns about its overall support. The presence of cross-dataset consistency is a positive aspect, but the warning about the target not being found in the top priority list indicates a potential gap in data validation.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is reasonably justified by the data provided, with higher-ranked targets aligning well with their expected impact on insulin signaling. However, the concern regarding G22553 not being in the top priority list detracts from the robustness of the ranking. The rationale for ranking is sound, but the implications of missing a top priority target could affect overall strength.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known insulin signaling pathways, and the tissue rationale is well-supported by the data. The involvement of G00484 as a transcription factor adds depth to the mechanism, indicating a thoughtful consideration of regulatory relationships. Overall, the mechanistic coherence is strong, with clear connections made to relevant pathways.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating key targets seems appropriate, and the potential for druggability is supported by the network position of the targets. However, without specific data on safety considerations or potential off-target effects, there is a slight uncertainty regarding the overall therapeutic viability.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** While the hypothesis does integrate data creatively, the connections made are somewhat expected in the context of diabetes treatment. The dual activation strategy is interesting, but the components involved (insulin signaling pathways) are relatively well-studied, which may limit the novelty factor.

**OVERALL_FITNESS: 69.5**  
**Calculated:** (6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 6.75 + 7.25 + 1.6 + 1.4 + 0.6 = 17.0 / 25 = 0.68 scaled to 100 = 68.0 (rounded to 69.5).

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Re-evaluate Target Selection:** Consider conducting a more thorough literature review to ensure that G22553 is indeed a valid target based on the latest research and its absence from the top priority list is addressed.
2. **Enhance Safety Data:** Include preliminary safety data or considerations for the proposed therapeutic approach, such as known side effects or off-target effects related to the activation of these genes.
3. **Expand on Novelty:** To further strengthen the hypothesis, consider integrating additional novel mechanisms or targets that have not been widely explored in the context of Type 2 Diabetes, enhancing the creativity of the approach.
4. **Clarify Evidence Types:** Provide more details on the types of evidence supporting the primary target and other ranked targets, which can help solidify the rationale for their inclusion in the hypothesis.
2026-02-10 21:03:29,154 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:03:29,154 - root - INFO - Evaluating fitness for hypothesis: t2d-08-0c50b6c5
2026-02-10 21:03:43,477 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:03:43,484 - root - INFO - TOKEN_USAGE: input=1438, output=633, total=2071, cost=$0.000596
2026-02-10 21:03:43,484 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:03:43,484 - root - INFO - 
**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G00484 is included in the list of top priority genes, but it is positioned lower than G19943, which could indicate a lack of clarity in its established importance relative to others. There is cross-dataset consistency supporting G00484's role, and it is backed by two datasets, which is good, but the warning indicates it is not in the top priority list, which detracts from the score.

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking of targets appears justified based on their roles, but the warning regarding G00484 not being found in the top priority list raises concerns about the validity of the ranking. The rationale provided does support the selection of targets, but the absence of G00484 in the top tier creates ambiguity in the strength of the lower-ranked targets.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways related to insulin signaling and glucose metabolism. The tissue rationale includes relevant organs involved in insulin action, and the relationships among transcription factors (TFs) are considered effectively. The strong mechanistic link to G00484s function as a transcription factor enhances the score.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G00484 through small molecules is appropriate, and the multi-target strategy indicates a comprehensive understanding of the network. However, more information on druggability and potential safety concerns related to the combined modulation of targets would strengthen the rationale.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** While the hypothesis integrates various targets in a novel multi-target approach, it does not present significantly non-obvious connections. The idea of targeting multiple genes in a network is common in diabetes research, which may detract from the novelty aspect.

**OVERALL_FITNESS: 6.6 (rounded to 67)**  
(Score calculation: 7*0.25 + 6*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 6.6)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Clarify the Ranking:** Ensure G00484s position is justified based on more robust data or evidence to avoid confusion regarding its importance.
2. **Expand Data Evidence:** Include additional evidence types that support the primary target and the roles of the ranked targets to enhance credibility.
3. **Detail Drug Development:** Provide more information on the druggability of each target and outline potential safety considerations for the proposed therapeutic approach.
4. **Explore Novel Mechanisms:** Consider integrating less obvious connections or pathways to enhance the novelty of the hypothesis and distinguish it from existing research.
2026-02-10 21:03:43,486 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:03:43,486 - root - INFO - Evaluating fitness for hypothesis: t2d-08-75ac07ab
2026-02-10 21:03:57,815 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:03:57,822 - root - INFO - TOKEN_USAGE: input=1467, output=648, total=2115, cost=$0.000609
2026-02-10 21:03:57,822 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:03:57,822 - root - INFO - 
**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, which is positive for data support. However, the warning about other ranked targets not being in the top priority list indicates some gaps in support for those targets. There is cross-dataset consistency for the primary target, and it is supported by multiple evidence types, emphasizing its relevance in T2D pathways.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data, with G19943 clearly being the strongest target due to its central role in insulin signaling. However, the equal scores of the other targets (4.0) may indicate a lack of clear differentiation in their strength, which slightly detracts from the clarity of the ranking rationale.

**MECHANISTIC_SCORE: 9**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in insulin signaling, and the tissue rationale is strong, focusing on key tissues relevant for T2D. The relationships with transcription factors are considered and integrated into the hypothesis, reinforcing its coherence.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation appears appropriate for the targets selected, which have significant roles in metabolic regulation. The potential for druggability is supported by their central positions in the network. However, safety considerations could be further elaborated to strengthen this aspect.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** While the hypothesis proposes a multi-target approach, which is not entirely novel in the field, the integration of specific targets and their synergistic interactions is creative. However, the connections made may not be fully non-obvious, as they align with existing literature on insulin signaling.

**OVERALL_FITNESS: 7.8**  
\[Overall Fitness = (7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 7*0.10) = 7.8\]

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: MODERATE  
- Target #3 quality: MODERATE  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Enhance clarity in target differentiation:** Provide more detailed evidence or rationale that distinguishes the roles and importance of G22553, G23245, G00484, and G33764 to strengthen their ranking relative to each other.
2. **Expand on safety considerations:** Include a discussion on potential adverse effects or safety profiles of modulating these targets in the context of T2D therapy.
3. **Consider additional datasets:** Incorporate more datasets to strengthen the evidence for the ranked targets, particularly for those that are not in the top priority list.
4. **Focus on mechanism exploration:** Further explore the mechanistic details of how the proposed interactions between the targets will translate to improved insulin sensitivitythis will bolster the mechanistic coherence of the hypothesis.
2026-02-10 21:03:57,823 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:03:57,824 - root - INFO - Evaluating fitness for hypothesis: t2d-08-ee08c891
2026-02-10 21:04:16,244 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:04:16,247 - root - INFO - TOKEN_USAGE: input=1526, output=618, total=2144, cost=$0.000600
2026-02-10 21:04:16,248 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:04:16,248 - root - INFO - 
### EVALUATION

#### DATA_SUPPORT_SCORE: 7
**DATA_SUPPORT_RATIONALE:** The primary target, G04436, has a Priority Score of 4.0/17, indicating a strong position. However, there is a lack of cross-dataset consistency for G04436, which lowers the score slightly. Two different evidence types support it, but the overall dataset evidence is limited.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their critical roles in insulin signaling and metabolic pathways. Each target has a score of 4.0, indicating equal strength, with a clear rationale provided for their selection. The relationship between targets is logical, and the prioritization of G04436 aligns with its key role in lipid metabolism.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, focusing on lipid metabolism and insulin sensitivity. The tissue rationale is also relevant, as liver, muscle, and adipose tissues are crucial for metabolic regulation. The inclusion of transcription factors adds depth to the mechanistic understanding.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The proposed therapeutic strategy of small molecule modulation is appropriate for the targets identified. However, the evaluation of druggability and potential safety concerns is somewhat limited as specific compounds or mechanisms are not discussed. Still, the targets appear to be well-positioned within metabolic networks.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** While the hypothesis integrates multiple targets creatively, the connections made between them are somewhat conventional within the field of diabetes research. The approach appears systematic rather than offering groundbreaking insights or pathways that are not already well-established in the literature.

### OVERALL_FITNESS: 7.3
**Calculated:** (7 * 0.25 + 8 * 0.25 + 8 * 0.20 + 7 * 0.20 + 6 * 0.10) = 7.3

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Evidence:** Increase the number of datasets that support G04436 to improve cross-dataset consistency. This could involve integrating more experimental data or clinical trial outcomes.
2. **Expand Mechanistic Understanding:** Include specific examples of how transcription factors regulate the primary and secondary targets to provide a deeper mechanistic insight.
3. **Therapeutic Validation:** Identify specific small molecules or compounds that could modulate the targets effectively, including potential safety profiles and pharmacokinetic considerations to enhance the therapeutic approach.
4. **Novelty Enhancement:** Explore less traditional connections or emerging pathways that could provide a unique angle to the hypothesis, potentially increasing the novelty score.
2026-02-10 21:04:16,248 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:04:16,249 - root - INFO - Evaluating fitness for hypothesis: t2d-08-5a504c8f
2026-02-10 21:04:34,072 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:04:34,077 - root - INFO - TOKEN_USAGE: input=1441, output=787, total=2228, cost=$0.000688
2026-02-10 21:04:34,078 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:04:34,078 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 7
**DATA_SUPPORT_RATIONALE:** The ranked targets are indeed in the top priority tier, with all five being assigned a score of 4.0. There is cross-dataset consistency for these top-ranked targets, as indicated by evidence from two datasets. However, the warning regarding the target gene not being found in the top priority list suggests a potential oversight or an area requiring further validation. The primary target also has a good number of evidence types supporting its role, contributing positively to the data support score.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking appears to be justified by the data, with all targets showing a high score and significant roles in insulin signaling and metabolic regulation. The clear distinction in the roles of the targets enhances the justification for their ranking. However, the rationale could be strengthened by explicitly stating how each target complements the others in the multi-target strategy.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, highlighting G19943 as a central coordinator in insulin signaling and lipid metabolism. The tissue rationale for pancreatic -cells, muscle, liver, and adipose tissue is appropriate, as these are critical for insulin action and metabolic regulation. The mention of regulating transcription factors (TFs) like G00484 adds depth to the mechanistic understanding, though a more detailed exploration of how these TFs interact with the targets would enhance clarity.

#### THERAPEUTIC_SCORE: 8
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating selected targets with small molecules is appropriate for enhancing insulin sensitivity and metabolic function. The targets network positions suggest they are likely druggable, but safety considerations should be explicitly addressed, especially concerning potential off-target effects or interactions.

#### NOVELTY_SCORE: 7
**NOVELTY_RATIONALE:** The hypothesis integrates data creatively by proposing a multi-target strategy that addresses the complexity of T2D. However, the connections between the targets could be made more explicit, particularly regarding novel pathways or interactions not previously explored in T2D treatment.

### OVERALL_FITNESS: 7.5
(Scaled to 0-100) = (7 * 0.25 + 8 * 0.25 + 8 * 0.20 + 8 * 0.20 + 7 * 0.10) * 10 = 75

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Validation of Target Gene:** Ensure that all relevant target genes are included in the priority list and clarify the status of any "missing" genes. This may require a review of the underlying datasets to confirm their relevance.
   
2. **Elaborate on Interconnectivity:** Clearly articulate how the targets interact with one another within the proposed framework. This could involve detailing their roles in shared pathways or regulatory networks to strengthen claims of synergy.

3. **Expand on Safety Considerations:** Include a discussion of potential safety concerns or side effects associated with activating these targets. This could involve reviewing existing literature on drug interactions or adverse effects related to similar therapeutic strategies.

4. **Enhance Transcription Factor Analysis:** Provide more detailed insights into the roles of regulating transcription factors, including how they might influence the activity and regulation of the primary and secondary targets.

5. **Consider Broader Patient Populations:** Discuss how the multi-target approach could be tailored or adapted for different patient populations with Type 2 Diabetes, which may improve the therapeutic potential and applicability of the proposed strategy.
2026-02-10 21:04:34,080 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:04:34,082 - root - INFO - Evaluating fitness for hypothesis: t2d-08-1e87d33f
2026-02-10 21:04:51,980 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:04:51,987 - root - INFO - TOKEN_USAGE: input=1496, output=740, total=2236, cost=$0.000668
2026-02-10 21:04:51,987 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:04:51,987 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed in the top priority list, scoring 4.0, which indicates strong support for its relevance. However, while G22553, G23245, G33764, and G00484 also scored 4.0, they are not in the top 10 priority genes. There is cross-dataset consistency for the primary target and two datasets support the overall hypothesis. The evidence is robust for the primary target, but the lower-ranked targets' exclusion from the top tier diminishes the score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the established roles of the targets in T2D pathways. Each target's function builds upon the others, creating a coherent strategy. The rationale for the ranking is solid, with higher-ranked targets showing stronger evidence and more critical roles in the mechanisms of T2D. The integration of these targets in a multi-target approach is logical and well-supported by the data.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the identified pathways, particularly insulin signaling and glucose metabolism. The tissue rationale is appropriate, targeting pancreatic -cells, skeletal muscle, liver, and adipose tissue, which are critical for insulin action. The role of the transcription factor G00484 is well integrated into the mechanism, supporting the overall hypothesis. However, further elucidation of the exact interactions between these targets could strengthen the mechanistic coherence.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation for G19943 and G22553 appears appropriate given their roles in insulin signaling. The targets are positioned well within the network for potential druggability. However, safety considerations and off-target effects are not discussed, which could be critical in a multi-target therapy for T2D. This lack of detail prevents a higher score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis demonstrates creativity by integrating multiple targets into a single therapeutic approach, which is an innovative strategy in T2D management. However, while the connections made between the targets are reasonable, they may not be entirely non-obvious given the existing literature on T2D pathways. More novel or less explored connections could improve this score.

**OVERALL_FITNESS:** 7.4 (rounded to 74)  
**Calculation:** (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.4

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. Incorporate additional evidence or literature to support the roles of G22553, G23245, G33764, and G00484, potentially elevating their priority or identifying their relevance in the context of T2D.
2. Expand on the safety considerations of the therapeutic approach, discussing potential side effects or off-target impacts for a more comprehensive evaluation.
3. Elaborate further on the mechanistic interactions among the targets to clarify how they synergistically contribute to the desired outcomes in glucose homeostasis and insulin sensitivity.
4. Highlight any novel compounds or mechanisms that could provide unique therapeutic insights or strategies to enhance the proposal's originality.
2026-02-10 21:04:51,988 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:04:51,988 - root - INFO - Evaluating fitness for hypothesis: t2d-08-2cb38cef
2026-02-10 21:05:08,113 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:05:08,120 - root - INFO - TOKEN_USAGE: input=1505, output=716, total=2221, cost=$0.000655
2026-02-10 21:05:08,120 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:05:08,120 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is well-supported with a high priority score and cross-dataset consistency. However, the warning regarding the target gene not being in the top priority list raises concerns. There are only two datasets supporting the hypothesis, which is relatively low for a comprehensive multi-target approach.

---

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the established roles of the targets in metabolic pathways related to Type 2 Diabetes. However, the presence of additional high-scoring targets (e.g., G23245, G01138, etc.) in the top priority list that are not considered in the hypothesis could indicate a potential oversight. The rationale provided makes sense, but the absence of relevant competing targets could affect the robustness of the ranking.

---

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in insulin signaling and metabolism. The tissue rationale is strong, focusing on skeletal muscle, liver, and adipose tissue, which are critical for insulin action and glucose metabolism. Additionally, the involvement of transcription factors (TFs) enhances the mechanistic coherence of the hypothesis.

---

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators is appropriate and aligns with the proposed mechanism. The targets appear to be druggable based on their network positions. However, safety considerations related to the potential off-target effects of multi-target approaches should be addressed more explicitly to bolster confidence in the therapeutic strategy.

---

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a creative manner, which is a positive aspect. However, the connections between the targets could be considered somewhat conventional in the context of Type 2 Diabetes research. More innovative links or novel mechanisms of action could enhance the novelty score.

---

### OVERALL_FITNESS: 
Calculated as follows: 
\[ \text{Overall Fitness} = (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 6.65 \]
Scaled to 0-100: 
\[ \text{Overall Fitness} = 66.5 \]

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

---

### IMPROVEMENT_SUGGESTIONS:
1. **Broaden Data Sources:** Consider including additional datasets to strengthen the evidence for the primary target and provide a more robust basis for the multi-target approach.
2. **Address Overlooked Targets:** Evaluate the potential roles of other high-scoring targets in the top priority list that were not included in the hypothesis to ensure a comprehensive assessment of all relevant targets.
3. **Expand on Safety Considerations:** Clearly outline potential safety concerns related to the therapeutic approach, particularly regarding off-target effects, to increase confidence in the proposed drug development strategy.
4. **Innovate Mechanistic Insights:** Explore novel mechanisms or pathways that may involve the targets to enhance the novelty of the hypothesis and provide a more compelling justification for the multi-target approach.
2026-02-10 21:05:08,123 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:05:08,126 - root - INFO - Evaluating fitness for hypothesis: t2d-08-b3cd3d99
2026-02-10 21:05:29,563 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:05:29,566 - root - INFO - TOKEN_USAGE: input=1530, output=880, total=2410, cost=$0.000758
2026-02-10 21:05:29,566 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:05:29,566 - root - INFO - 
### Evaluation of the RANKED Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** While the primary target G22553 is supported by a priority score of 4.0 and shows cross-dataset consistency, it is noted that G23245 is not found in the top priority list, which reduces confidence in the overall data support. Moreover, while there is consistency across datasets, the evidence types supporting G22553 could be more robust, as highlighted by the warning regarding the target gene not being in the top priority list. Thus, a score of 6 reflects moderate support due to the strength of G22553 but acknowledges limitations with G23245.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is based on their established roles in insulin signaling and metabolic pathways, which is justified by the data presented. However, the absence of G23245 in the top tier raises questions about the strength of the ranking for the multi-target approach. The rationale for ranking is logical, but the ranking quality is somewhat diminished due to the inconsistency in target prioritization. This leads to a score of 7.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways involved in insulin signaling and glucose metabolism. The tissue rationale is well-supported, as skeletal muscle, adipose tissue, and liver are critical for insulin action. Additionally, the consideration of G00484 as a transcription factor adds depth to the mechanism proposed. This coherence within the mechanistic framework earns a score of 8.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and G23245, along with modulating the other targets, is appropriate given their roles in insulin sensitivity and glucose metabolism. However, the absence of G23245 in the top priority list raises concerns about its druggability and the potential safety of targeting multiple pathways simultaneously. While the approach is well-founded, these concerns warrant a score of 7.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets involved in insulin sensitivity and metabolic regulation, which is a creative approach. However, the connections between targets and the proposed multi-target strategy are not particularly novel within the existing body of research on Type 2 Diabetes, limiting the perceived novelty. Thus, a score of 6 reflects this moderate level of creativity.

### Calculated OVERALL_FITNESS: 
Overall Fitness = (Data Support * 0.25) + (Ranking Quality * 0.25) + (Mechanistic * 0.20) + (Therapeutic * 0.20) + (Novelty * 0.10)  
Overall Fitness = (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.5 + 1.75 + 1.6 + 1.4 + 0.6  
Overall Fitness = 6.85 (scaled to 0-100) = **68.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **MODERATE**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify the Role of G23245:** Provide additional evidence or rationale for including G23245 in the therapeutic strategy, especially given its absence from the top priority list. Consider exploring alternative targets that may have stronger support.
2. **Enhance Data Evidence:** Increase the number of evidence types supporting G22553 and other targets. Incorporate additional datasets or experimental validation to strengthen the claims made in the hypothesis.
3. **Address Safety Concerns:** Include a discussion of potential off-target effects or safety profiles for the proposed therapeutic approach, particularly when modulating multiple targets simultaneously.
4. **Explore Novel Connections:** Investigate more unique interactions or lesser-known pathways that could be targeted to enhance novelty and potential therapeutic impact.
2026-02-10 21:05:29,567 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:05:29,567 - root - INFO - Evaluating fitness for hypothesis: t2d-08-cb8e701d
2026-02-10 21:05:41,360 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:05:41,369 - root - INFO - TOKEN_USAGE: input=1428, output=677, total=2105, cost=$0.000620
2026-02-10 21:05:41,369 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:05:41,369 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed ranked highly (4.0) and is supported by cross-dataset consistency. However, the warning indicates that some targets are not found in the top priority list, which diminishes the overall strength of support. While there are multiple evidence types for G19943, the absence of certain targets in the top 10 limits the support score.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the central role of G19943 in insulin signaling. Each subsequent target has a clear rational basis for its rank, with synergistic effects on metabolic regulation. However, the similarity in scores (4.0) among the top targets may suggest a lack of distinctiveness in their ranking, which slightly lowers the score.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the biological pathways involved in T2D. The tissue rationale is sound, as pancreatic -cells, muscle, liver, and adipose tissues are crucial for insulin action and glucose metabolism. The inclusion of G04436 as a transcriptional regulator adds depth to the mechanistic understanding.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation is appropriate, given the roles of the targets in insulin signaling and metabolic regulation. However, the druggability of G22553 and G33764 is less clear, which could pose safety and efficacy issues. More information on potential off-target effects and safety profiles would strengthen this score.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets in a synergistic fashion, highlighting non-obvious connections between them. This multi-target approach to insulin sensitivity and metabolic regulation is innovative, but the overall concept of targeting insulin signaling pathways is well-established in T2D research.

### OVERALL_FITNESS:
Overall Fitness = (7 * 0.25 + 8 * 0.25 + 8 * 0.20 + 7 * 0.20 + 7 * 0.10) = 7.5  
Scaled to 0-100: **75**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Address Target Gene Concerns:** Ensure all targets are included in the priority list and provide a robust rationale for their ranking.
2. **Enhance Distinctiveness of Rankings:** Consider additional data or analyses that could help differentiate between targets with similar scores.
3. **Clarify Druggability and Safety Profiles:** Provide more detailed information regarding the druggability of G22553 and G33764, including potential side effects and safety considerations to enhance therapeutic potential.
4. **Expand Novelty Aspects:** Explore additional novel mechanisms or connections that may not have been previously considered to further strengthen the innovative angle of the hypothesis.
2026-02-10 21:05:41,370 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:05:41,370 - root - INFO - Evaluating fitness for hypothesis: t2d-08-111ec9b0
2026-02-10 21:06:01,826 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:06:01,833 - root - INFO - TOKEN_USAGE: input=1457, output=789, total=2246, cost=$0.000692
2026-02-10 21:06:01,833 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:06:01,833 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is not found in the top priority list, which affects its data support score negatively. However, G19943, which is also a primary target in the hypothesis, has a score of 4.0 and high cross-dataset consistency. The analysis indicates there is robust data for G22553 but lacking direct inclusion in higher priority rankings.

---

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking is somewhat justified by the evidence provided, but the inclusion of G22553 as the primary target, while not listed in the top priority genes, weakens the overall justification for this ranking. The higher-ranked targets in the hypothesis do show strong roles in T2D pathways, but the rationale for G23245 being ranked lower due to unfavorable log2FC could be better articulated.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and glucose metabolism. The tissue rationale is clearly supported, addressing skeletal muscle, adipose tissue, and pancreatic -cells explicitly. The role of G00484 as a transcription factor is appropriately acknowledged, enhancing the mechanistic coherence.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation for G22553 and G19943 is appropriate and shows promise for improving insulin sensitivity. However, the consideration of safety and potential side effects is not adequately discussed, which could impact the feasibility of the therapeutic strategy.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets with a focus on synergistic effects, which is a creative approach in T2D research. However, the connections made, while plausible, do not significantly deviate from established therapeutic strategies and could benefit from more innovative insights regarding novel interactions among the targets.

---

### OVERALL_FITNESS: 
Calculated as follows:  
\[
\text{Overall Fitness} = (7 \times 0.25) + (6 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (7 \times 0.10) = 1.75 + 1.5 + 1.6 + 1.4 + 0.7 = 7.95 \approx 80
\]  
**Overall Fitness:** 80

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G22553):** WEAK - Despite its central role in the hypothesis, it does not appear in the top priority list, impacting its credibility.
- **Target #2 quality (G19943):** STRONG - Consistent evidence across datasets and high relevance to insulin signaling pathways.
- **Target #3 quality (G19122):** MODERATE - Important role in insulin sensitivity but less emphasized compared to higher-ranked targets.

---

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate Target Inclusion:** Investigate the reasons for G22553's absence from the top priority list and consider adjusting the hypothesis to include only those targets with strong evidence backing.
2. **Enhance Safety Considerations:** Expand the discussion on safety profiles and potential adverse effects related to the therapeutic approach to strengthen the proposal's feasibility.
3. **Clarify Ranking Justifications:** Provide more detailed reasoning for the rank placements, particularly for G23245 and its relationship with other targets to add context to the proposed strategy.
4. **Innovate the Therapeutic Strategy:** Explore novel compounds or mechanisms that could enhance the multi-target approach, potentially increasing the novelty score and therapeutic potential.
2026-02-10 21:06:01,834 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:06:01,835 - root - INFO - Population fitness evaluation complete. Top score: 78.50
2026-02-10 21:06:01,836 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 21:06:01,836 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G23245', 'G04436']...
2026-02-10 21:06:01,836 - root - INFO - Generation 8 stats: mean=64.04, max=79.5, min=50.0
2026-02-10 21:06:01,837 - root - INFO - Generation 8 complete
2026-02-10 21:06:01,837 - root - INFO - Running generation 9
2026-02-10 21:06:01,837 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 21:06:01,837 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 21:06:01,837 - root - INFO - Crossover 1/18: parents 'Synergistic Multi-Target Strat...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 21:06:01,936 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:06:43,197 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:06:43,204 - root - INFO - TOKEN_USAGE: input=40289, output=753, total=41042, cost=$0.006495
2026-02-10 21:06:43,204 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:06:43,204 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhanced Insulin Sensitivity and Glucose Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Serves as a primary driver in insulin signaling pathways, pivotal for enhancing glucose metabolism and insulin sensitivity.
2. **G19943** | Score: 4.0 | Functions as a central hub in insulin signaling, coordinating metabolic regulation and further amplifying the effects of G22553.
3. **G23245** | Score: 4.0 | Plays a critical role in glucose uptake, complementing G22553 by enhancing insulin sensitivity and glucose homeostasis.
4. **G33764** | Score: 4.0 | Addresses insulin resistance directly and supports metabolic regulation, reinforcing the therapeutic strategy.
5. **G00484** | Score: 4.0 | Acts as a significant transcription factor in insulin signaling, providing essential regulatory support to enhance the overall therapeutic efficacy of the approach.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a robust multi-target strategy focusing on G22553 as the primary target to enhance insulin sensitivity and glucose metabolism in Type 2 Diabetes (T2D). By integrating the synergistic roles of G19943, G23245, G33764, and G00484, the hypothesis aims to comprehensively address the multifactorial aspects of T2D, ensuring a strong therapeutic impact.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 serves as a transcriptional regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that targeting G22553 will enhance insulin signaling pathways, leading to improved glucose metabolism. G19943, as a hub component, will further amplify these effects, while G23245 facilitates glucose uptake and enhances insulin sensitivity. Additionally, G33764 addresses insulin resistance directly, and G00484 serves to regulate the transcriptional aspects of these pathways, collectively providing a comprehensive framework for managing T2D.

**TISSUE_RATIONALE:** The tissues involved include pancreatic -cells, muscle, liver, and adipose tissue, which are critical for insulin action, glucose uptake, and overall metabolic regulation. These tissues are prime targets for therapeutic intervention, as they are directly involved in the pathophysiology of T2D.

**THERAPEUTIC_APPROACH:** The strategy involves activating G22553 and leveraging small molecules to modulate the functions of G19943, G23245, G33764, and G00484, enhancing insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Effective modulation of these interconnected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and provide better management of Type 2 Diabetes, ultimately reducing the risk of complications associated with the disease.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, the strength of evidence supporting their involvement, and their potential for synergistic interactions. G22553 is prioritized for its critical role in insulin signaling, followed by G19943 for its amplification effects, and so forth to provide a comprehensive multi-target approach.

**CONFIDENCE:** HIGH, based on robust data support and significant associations with T2D mechanisms.
2026-02-10 21:06:43,205 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:06:43,205 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:06:43,206 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:06:43,209 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:06:43,209 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 21:06:43,209 - root - INFO - Crossover 2/18: parents 'Enhanced Multi-Pathway Modulat...' x '** Comprehensive Multi-Target ...'
2026-02-10 21:06:43,308 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:07:33,374 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:07:33,381 - root - INFO - TOKEN_USAGE: input=40441, output=809, total=41250, cost=$0.006552
2026-02-10 21:07:33,382 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:07:33,382 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity and Metabolic Control in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Identified as a central hub in metabolic pathways, G19943 integrates insulin signaling and lipid metabolism, making it essential for enhancing overall metabolic regulation.
2. **G23245** | Score: **4.0** | A primary driver in insulin signaling pathways, G23245 directly influences glucose uptake, reinforcing its critical role in improving insulin sensitivity.
3. **G04436** | Score: **4.0** | This enzyme is pivotal for lipid metabolism and insulin action, complementing G19943 and G23245 to enhance metabolic control and support insulin signaling.
4. **G22553** | Score: **4.0** | As a primary driver in glucose uptake pathways, G22553 will significantly contribute to improving insulin sensitivity when activated alongside the other targets.
5. **G33764** | Score: **4.0** | This enzyme provides regulatory support within metabolic pathways, enhancing the efficacy of the primary targets in addressing insulin resistance.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis integrates the strengths of both parent hypotheses by prioritizing G19943 as the primary target due to its role as a metabolic hub. The inclusion of G23245, G04436, G22553, and G33764 creates a comprehensive strategy for improving insulin sensitivity and metabolic control through synergistic actions across multiple pathways.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation
- **WGCNA module role**: G19943 identified as a hub component in the negatively correlated T2D module, indicating its critical role in T2D pathology.
- **Regulating TFs**: G04436 is associated with multiple transcription factors, enhancing the robustness of the regulatory network.

### MECHANISM_HYPOTHESIS:
The proposed mechanism suggests that activation of G19943 will enhance overall metabolic regulation through improved insulin signaling and lipid metabolism. Concurrent modulation of G23245 will support glucose uptake, while G04436 will optimize lipid profiles, reinforcing insulin action. G22553 will amplify glucose metabolism, and G33764 will provide additional regulatory support, ensuring a robust multi-target strategy that addresses insulin resistance in Type 2 Diabetes.

### TISSUE_RATIONALE:
The primary tissues targeted include adipose tissue, liver, and skeletal muscle, as these are critical for effective insulin action, glucose uptake, and lipid metabolism. Targeting these tissues will facilitate a comprehensive strategy to reverse metabolic dysregulation associated with Type 2 Diabetes, ultimately improving patient outcomes.

### THERAPEUTIC_APPROACH:
The therapeutic strategy will involve small molecule activators that enhance the functions of these targets, aiming to restore normal metabolic function and improve insulin sensitivity.

### PREDICTED_OUTCOME:
Modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, resulting in better management of Type 2 Diabetes symptoms and potentially reversing disease progression.

### RANKING_RATIONALE:
Targets were ranked based on their established roles as primary drivers in T2D pathways, their strength of evidence across multiple datasets, and their potential for synergistic interactions. G19943 was prioritized for its central role in metabolic regulation. G23245 and G04436 were included for their significant contributions to insulin signaling and metabolic regulation, while G22553 and G33764 were included for their supporting roles in glucose uptake and metabolic regulation.

### CONFIDENCE: HIGH
This hypothesis is built on robust data support across multiple evidence types, demonstrating the essential roles of the selected targets in managing Type 2 Diabetes effectively.
2026-02-10 21:07:33,383 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:07:33,384 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:07:33,388 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy for Enh...'
2026-02-10 21:07:33,388 - root - INFO - Crossover 3/18: parents 'Tissue-Specific Multi-Target S...' x 'Tissue-Specific Multi-Target S...'
2026-02-10 21:07:33,501 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:08:05,728 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:08:05,735 - root - INFO - TOKEN_USAGE: input=40473, output=837, total=41310, cost=$0.006573
2026-02-10 21:08:05,736 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:08:05,736 - root - INFO - 
### TITLE: Enhanced Multi-Target Strategy for Optimizing Insulin Sensitivity in Pancreatic Islets in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is essential for enhancing -cell function and glucose metabolism, supported by multiple lines of evidence across datasets.
2. **G19943** | Score: 4.0 | Serving as a central hub in insulin signaling, G19943 will ensure effective coordination of insulin pathways, crucial for metabolic regulation in pancreatic islets.
3. **G00484** | Score: 4.0 | This transcription factor is vital for regulating insulin signaling in islets, amplifying the effects of G22553 and enhancing insulin production through transcriptional support.
4. **G23245** | Score: 4.0 | This target plays a crucial role in glucose uptake in islets, ensuring that insulin signaling translates effectively into improved glucose metabolism.
5. **G33764** | Score: 4.0 | By enhancing metabolic regulation in pancreatic islets, G33764 supports the multi-target strategy, addressing potential dysregulation and improving insulin sensitivity.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis integrates a robust multi-target strategy that emphasizes the role of G22553 as a primary driver of insulin signaling in pancreatic islets, complemented by G19943's central role in pathway coordination and G00484's transcriptional regulation. G23245's importance in glucose uptake and G33764's metabolic support together provide a comprehensive approach to restoring insulin sensitivity in Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, -cell function, glucose metabolism, and transcriptional regulation.
- WGCNA module role: G22553 is identified as a primary driver in modules positively correlated with T2D, while G19943 is a hub component in modules regulating insulin signaling.
- Regulating TFs: G00484 acts as a key regulator in insulin signaling pathways in islets.

**MECHANISM_HYPOTHESIS:** The proposed mechanism posits that targeting G22553 will enhance insulin signaling pathways within pancreatic islets, leading to improved -cell function and glucose metabolism. G19943's hub role will ensure that insulin signaling is effectively coordinated throughout the islets. G00484 will amplify this effect through transcriptional regulation, while G23245 will facilitate glucose uptake, critical for insulin action. G33764 will provide additional metabolic support to mitigate dysregulation, thereby enhancing overall insulin sensitivity.

**TISSUE_RATIONALE:** The primary tissue of focus is pancreatic islets, as they are vital for insulin production and secretion, directly influencing glucose metabolism. Enhancing insulin signaling and glucose uptake in this tissue will have a profound impact on overall metabolic regulation in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will involve small molecule activation of G22553 to enhance its function, alongside modulation of G19943, G00484, G23245, and G33764 to strengthen insulin signaling and metabolic regulation in pancreatic islets.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is anticipated to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and restored -cell function, resulting in better management of Type 2 Diabetes.

**RANKING_RATIONALE:** Targets were ranked based on their established roles as primary drivers in T2D pathways, their strong evidence support across multiple datasets, and their specific relevance to pancreatic islets. G22553 is prioritized due to its critical role in insulin signaling, while G19943, G00484, G23245, and G33764 are included for their synergistic contributions to enhancing insulin sensitivity and metabolic regulation.

**CONFIDENCE:** HIGH, based on robust data support and strong associations with key pathways involved in insulin signaling and glucose metabolism in pancreatic islets.
2026-02-10 21:08:05,738 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:08:05,738 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:08:05,738 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:08:05,741 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:08:05,742 - root - INFO -   -> Created offspring: 'Enhanced Multi-Target Strategy for Optim...'
2026-02-10 21:08:05,742 - root - INFO - Mutation 4/18: parent 'Integrated Multi-Target Approa...'
2026-02-10 21:08:05,742 - root - INFO - T2D mutation using strategy: mechanism_refinement
2026-02-10 21:08:05,818 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:08:45,540 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:08:45,544 - root - INFO - TOKEN_USAGE: input=39551, output=771, total=40322, cost=$0.006395
2026-02-10 21:08:45,544 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:08:45,544 - root - INFO - 
### TITLE: Enhanced Insulin Sensitivity Through Multi-Target Modulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 is critical for coordinating metabolic regulation, making it essential for improving insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling, G22553's modulation complements G19943, enhancing glucose metabolism and insulin action, particularly in muscle and adipose tissues.
3. **G23245** | Score: 4.0 | This target is vital for glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy by synergistically working with G19943 and G22553.
4. **G00484** | Score: 4.0 | The transcription factor G00484 plays a crucial role in regulating insulin signaling, providing necessary transcriptional support for the actions of G19943 and G22553.
5. **G33764** | Score: 4.0 | As an enzyme that supports metabolic regulation, G33764 integrates with insulin signaling, ensuring robust interactions with the other targets.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This refined hypothesis proposes a detailed multi-target strategy focusing on G19943 as the primary target due to its pivotal role in insulin signaling and metabolic regulation. Integrating G22553, G23245, G00484, and G33764 addresses the multifactorial nature of Type 2 Diabetes (T2D) through enhanced interactions that promote insulin sensitivity and glucose homeostasis, leading to improved therapeutic outcomes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G19943 is identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 enhances transcriptional regulation in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The mechanism proposed involves G19943 acting as a central coordinator in the insulin signaling network, while G22553 enhances insulin receptor signaling and glucose uptake. G23245 will facilitate glucose transport into cells, and G00484 will regulate the expression of genes necessary for maintaining insulin sensitivity. G33764 ensures metabolic homeostasis, creating a comprehensive mechanism for managing T2D through synergistic interactions of these targets.

**TISSUE_RATIONALE:** Key tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are integral for insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions due to their roles in glucose metabolism and insulin signaling.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G19943 and G22553 to enhance their functions, while modulating G23245 and G00484 to strengthen metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role in insulin signaling, followed by G22553, which complements its function, while G23245, G00484, and G33764 provide essential regulatory support and metabolic regulation.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:08:45,547 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:08:45,547 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:08:45,548 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:08:45,550 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:08:45,550 - root - INFO -   -> Created mutated offspring: 'Enhanced Insulin Sensitivity Through Mul...'
2026-02-10 21:08:45,551 - root - INFO - Crossover 5/18: parents 'Enhancing Insulin Sensitivity ...' x 'Integrated Multi-Target Strate...'
2026-02-10 21:08:45,591 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:09:31,335 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:09:31,338 - root - INFO - TOKEN_USAGE: input=40396, output=806, total=41202, cost=$0.006543
2026-02-10 21:09:31,338 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:09:31,338 - root - INFO - 
### TITLE: Comprehensive Multi-Target Approach to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling pathways, essential for enhancing glucose metabolism and directly addressing Type 2 Diabetes pathology.
2. **G00484** | Score: 4.0 | As a transcription factor critical for regulating insulin signaling and glucose homeostasis, its activation is expected to amplify the effects of G22553 and enhance overall metabolic function.
3. **G33764** | Score: 4.0 | This enzyme plays a significant role in lipid metabolism, supporting improved insulin sensitivity, and complements the function of G22553, making it essential for a multi-targeted approach.
4. **G04436** | Score: 4.0 | This gene is involved in glucose metabolism, and its modulation can synergize with G22553 and G33764 to further enhance glucose uptake and insulin action.
5. **G19943** | Score: 4.0 | As a hub component in insulin signaling, its coordination of metabolic processes can effectively enhance the overall insulin signaling network when combined with other targets.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy that focuses on G22553 as the primary target, supported by G00484, G33764, G04436, and G19943. By leveraging their synergistic roles in insulin signaling and glucose metabolism, this approach aims to restore metabolic homeostasis more effectively than either parent hypothesis. This combination addresses potential weaknesses by ensuring robust regulatory mechanisms through transcription factors and metabolic pathways.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a significant regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves activating G22553 to enhance insulin signaling pathways and improve glucose metabolism. Concurrent activation of G00484 will ensure the transcription of genes necessary for efficient insulin signaling, while G33764 optimizes lipid metabolism to counteract insulin resistance. G04436 will facilitate glucose uptake, creating a robust synergistic effect to enhance overall metabolic function. Additionally, G19943's role as a hub component will coordinate and amplify these interactions across the insulin signaling network, ensuring a comprehensive improvement in insulin sensitivity.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells (for insulin production), muscle (for glucose uptake), liver (for glucose and lipid metabolism), and adipose tissue (for metabolic regulation), as they are central to insulin action and overall metabolic health.

**THERAPEUTIC_APPROACH:** The strategy focuses on the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity specifically.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to significantly enhance insulin sensitivity, improve glucose uptake, and lead to better management of Type 2 Diabetes, ultimately reducing hyperglycemia and improving patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role in insulin signaling, followed by G00484 for its regulatory influence, G33764 for its lipid metabolism role, G04436 for its glucose uptake facilitation, and G19943 for its coordination of metabolic processes. 

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:09:31,339 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:09:31,339 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:09:31,339 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:09:31,341 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:09:31,341 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Approach to E...'
2026-02-10 21:09:31,341 - root - INFO - Crossover 6/18: parents 'Targeting G22553 for Enhanced ...' x '** Comprehensive Multi-Target ...'
2026-02-10 21:09:31,376 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:10:16,483 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:10:16,490 - root - INFO - TOKEN_USAGE: input=40366, output=824, total=41190, cost=$0.006549
2026-02-10 21:10:16,491 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:10:16,491 - root - INFO - 
**TITLE:** Synergistic Targeting of Metabolic Pathways for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943 | Score: 4.0 | As a central hub in metabolic pathways, targeting G19943 is critical for integrating insulin signaling with lipid metabolism, directly addressing insulin resistance.**
2. **G22553 | Score: 4.0 | This gene is a primary driver of glucose uptake and insulin signaling, making it essential for improving insulin sensitivity and glucose metabolism.**
3. **G00484 | Score: 4.0 | Serving as a transcription factor, G00484 enhances the regulation of insulin signaling pathways, providing complementary support to both G19943 and G22553.**
4. **G33764 | Score: 4.0 | This enzyme plays a significant role in metabolic regulation, reinforcing the actions of G19943 and G22553 to ensure effective insulin action and glucose homeostasis.**
5. **G19122 | Score: 3.0 | While lower in rank, G19122's role as a major regulator of insulin signaling in muscle tissue offers additional support for the overall strategy aimed at enhancing insulin sensitivity.**

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a comprehensive multi-targeted strategy that centers on G19943 as the primary target for enhancing insulin sensitivity through its role as a metabolic hub. By integrating the actions of G22553, G00484, G33764, and G19122, the hypothesis aims to synergistically address the complex interplay of metabolic pathways involved in Type 2 Diabetes, thereby improving glucose metabolism and insulin signaling.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- WGCNA module role: G19943 identified as a hub component in T2D negatively correlated modules; G22553 is a primary driver in positively correlated modules.
- Regulating TFs: G00484 is associated with multiple transcription factors, enhancing regulatory mechanisms in insulin signaling.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves activating G19943 to enhance metabolic regulation, which will improve insulin signaling and lipid metabolism. G22553 will facilitate glucose uptake, while G00484 will amplify insulin signaling pathways through transcriptional regulation. G33764 will support metabolic regulation, ensuring a robust multi-target strategy that effectively addresses insulin resistance. G19122, although lower in rank, provides important regulatory support in muscle tissue, contributing to the overall enhancement of insulin sensitivity.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, as these are critical sites for insulin action, glucose uptake, and lipid metabolism. Targeting these tissues is essential for reversing metabolic dysregulation associated with Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will involve the development of small molecule activators for these targets, aiming to restore normal metabolic functions and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, resulting in better management of Type 2 Diabetes symptoms and potentially reversing disease progression.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role in metabolic regulation, followed by G22553 for its role in glucose uptake and insulin signaling. G00484 enhances transcriptional regulation, while G33764 provides metabolic support, and G19122, though lower in rank, reinforces the focus on muscle metabolism.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 21:10:16,493 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:10:16,495 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:10:16,500 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:10:16,506 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:10:16,506 - root - INFO -   -> Created offspring: '** Synergistic Targeting of Metabolic Pa...'
2026-02-10 21:10:16,507 - root - INFO - Mutation 7/18: parent 'Integrated Multi-Target Approa...'
2026-02-10 21:10:16,507 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 21:10:16,596 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:10:52,751 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:10:52,758 - root - INFO - TOKEN_USAGE: input=39526, output=743, total=40269, cost=$0.006375
2026-02-10 21:10:52,758 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:10:52,758 - root - INFO - 
### TITLE: Targeting Muscle-Specific Pathways for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling pathways within muscle tissues, showing robust evidence for its critical role in glucose uptake and metabolic regulation.
2. **G19943** | Score: 4.0 | As a hub component in metabolic regulation specifically within skeletal muscle, G19943 enhances insulin signaling pathways and is essential for maintaining glucose homeostasis.
3. **G33764** | Score: 4.0 | This enzyme supports overall metabolic regulation in muscle tissue, providing a complementary mechanism alongside G22553 to enhance insulin sensitivity.
4. **G19122** | Score: 3.0 | Serving as a major regulator of insulin signaling in muscle, G19122 plays a vital role in glucose metabolism and insulin action, supporting the primary targets.
5. **G23245** | Score: 4.0 | This gene significantly influences glucose uptake in muscle tissue and complements the actions of G22553 and G19943, enhancing metabolic control.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis focuses on leveraging the critical role of G22553 in insulin signaling specifically within muscle tissue, supported by G19943 and G33764 for their roles in glucose metabolism and regulation. By refining the multi-target approach to muscle tissue, this strategy aims to enhance insulin sensitivity specifically in skeletal muscle, addressing Type 2 Diabetes more effectively.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, muscle metabolism
- WGCNA module role: G22553 is a primary driver in the black module, indicating its central role in muscle-related metabolic pathways.
- Regulating TFs: Multiple transcription factors involved, providing regulatory depth specific to muscle tissue.

**MECHANISM_HYPOTHESIS:** The mechanism involves G22553 enhancing insulin signaling and glucose metabolism specifically in skeletal muscle tissue. G19943 coordinates metabolic responses within muscle, reinforcing the insulin signaling network, while G33764's role in metabolic regulation complements this activation. G19122 serves as a critical regulator, promoting insulin action and glucose uptake in muscle.

**TISSUE_RATIONALE:** Skeletal muscle is the primary site for insulin-mediated glucose uptake and metabolism, making it critical for improving insulin sensitivity and overall metabolic health in Type 2 Diabetes patients. Targeting this tissue specifically can lead to more pronounced therapeutic benefits.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves the small molecule activation of G22553, G19943, and G33764 to improve insulin sensitivity and metabolic regulation in skeletal muscle.

**PREDICTED_OUTCOME:** Modulating these targets is expected to significantly enhance insulin sensitivity in skeletal muscle, leading to reduced blood glucose levels and improved metabolic control in Type 2 Diabetes patients, thereby enhancing overall patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established critical roles in muscle insulin signaling and metabolic pathways, robust data support, and their potential for synergistic interactions specific to muscle physiology. G22553 is prioritized for its central role, followed by G19943 and G33764 for their complementary functions in muscle metabolism, while G19122 and G23245 provide additional regulatory support.

**CONFIDENCE:** HIGH, based on strong data support across multiple evidence types and their essential roles in managing Type 2 Diabetes in skeletal muscle context.
2026-02-10 21:10:52,760 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:10:52,760 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:10:52,761 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:10:52,763 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:10:52,764 - root - INFO -   -> Created mutated offspring: 'Targeting Muscle-Specific Pathways for E...'
2026-02-10 21:10:52,764 - root - INFO - Crossover 8/18: parents 'Integrated Multi-Target Approa...' x 'Enhancing Insulin Sensitivity ...'
2026-02-10 21:10:52,801 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:11:36,167 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:11:36,171 - root - INFO - TOKEN_USAGE: input=40396, output=774, total=41170, cost=$0.006524
2026-02-10 21:11:36,172 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:11:36,172 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver of insulin signaling, G22553s activation is crucial for enhancing glucose metabolism and synergistically improves insulin sensitivity.
2. **G19943** | Score: 4.0 | Serving as a central hub in insulin signaling pathways, G19943 coordinates metabolic processes and provides a robust regulatory framework for insulin action.
3. **G00484** | Score: 4.0 | As a key transcription factor, G00484 enhances the expression of genes necessary for optimal insulin signaling, making it essential in the therapeutic strategy.
4. **G23245** | Score: 4.0 | This target plays a significant role in glucose uptake, further enhancing the effects of G22553 and G19943 to improve insulin sensitivity.
5. **G33764** | Score: 4.0 | As a regulator of metabolic pathways, G33764 supports the overall insulin signaling cascade, providing additional metabolic regulation.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy that prioritizes G22553 as the primary target due to its critical role in insulin signaling. By activating G22553 alongside G19943 and G00484, and incorporating G23245 and G33764, this approach aims to address the multifactorial nature of Type 2 Diabetes (T2D) with synergistic interactions that enhance insulin sensitivity and glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with insulin signaling.
- Regulating TFs: G00484 is a significant transcription factor influencing insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism combines the activation of G22553 and G19943, which are both central to insulin signaling pathways, significantly enhancing insulin action and glucose uptake. G00484 ensures that key metabolic genes are expressed, while G23245 facilitates glucose uptake, and G33764 reinforces metabolic regulation. This comprehensive approach targets direct signaling pathways and broader metabolic regulation, aiming for a robust improvement in insulin sensitivity in T2D.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells (for insulin production), muscle (for glucose uptake), liver (for glucose and lipid metabolism), and adipose tissue (for metabolic regulation), all of which are integral to insulin action and glucose homeostasis.

**THERAPEUTIC_APPROACH:** The therapeutic approach involves the activation of G22553 and G19943 using small molecules, alongside modulation of G00484, G23245, and G33764 to enhance their functions and improve metabolic outcomes in Type 2 Diabetes.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their strong evidence across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role in insulin signaling, followed by G19943, which complements its function, while G00484, G23245, and G33764 provide valuable regulatory and metabolic support.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:11:36,172 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:11:36,173 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:11:36,173 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:11:36,174 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:11:36,174 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy to E...'
2026-02-10 21:11:36,175 - root - INFO - Crossover 9/18: parents 'Integrated Multi-Target Strate...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 21:11:36,216 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:11:54,801 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:11:54,806 - root - INFO - TOKEN_USAGE: input=40328, output=742, total=41070, cost=$0.006494
2026-02-10 21:11:54,806 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:11:54,806 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553 | Score: 4.0 | As a primary driver in insulin signaling pathways, targeting G22553 is essential for enhancing glucose metabolism and insulin sensitivity, forming the backbone of this integrated approach.**
2. **G00484 | Score: 4.0 | This transcription factor plays a crucial role in regulating insulin signaling and glucose homeostasis, amplifying the effects of G22553 and enhancing overall therapeutic efficacy.**
3. **G33764 | Score: 4.0 | Targeting this enzyme supports metabolic regulation and insulin signaling pathways, complementing the functions of G22553 and G00484 for a synergistic effect.**
4. **G23245 | Score: 4.0 | As a key driver in glucose uptake, G23245 strengthens the therapeutic strategy by directly enhancing insulin sensitivity alongside G22553.**
5. **G19122 | Score: 3.0 | Although ranked lower, G19122's regulatory role in insulin signaling provides additional support, ensuring a robust multi-target approach.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a comprehensive multi-target approach focusing on G22553, leveraging its central role in insulin signaling. The inclusion of G00484, G33764, and G23245 aims to synergistically enhance insulin sensitivity and metabolic regulation, addressing the multifactorial nature of Type 2 Diabetes more effectively than either parent hypothesis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, metabolic regulation
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G22553 to enhance insulin signaling pathways, thereby improving glucose metabolism. Concurrently, G00484 as a transcription factor amplifies insulin signaling regulation, while G33764 optimizes lipid metabolism crucial for overcoming insulin resistance. G23245 enhances glucose uptake, creating a comprehensive and synergistic effect that improves overall metabolic function.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, which are central to insulin action and glucose homeostasis. Targeting these tissues allows for a holistic approach to improve metabolic function and address insulin resistance in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** This strategy focuses on the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity specifically.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to significantly enhance insulin sensitivity, improve glucose uptake, and lead to better management of Type 2 Diabetes, ultimately reducing hyperglycemia and improving patient outcomes.

**RANKING_RATIONALE:** Targets were ranked based on their high priority scores, robust evidence across multiple datasets, and critical roles in insulin signaling and metabolic regulation. G22553 is prioritized for its essential role, followed by G00484 for its regulatory impact, and G33764 and G23245 for their complementary effects on metabolism. G19122 provides additional regulatory support, ensuring a comprehensive approach.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 21:11:54,806 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:11:54,807 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:11:54,807 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:11:54,817 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:11:54,818 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy for ...'
2026-02-10 21:11:54,819 - root - INFO - Mutation 10/18: parent 'Tissue-Specific Multi-Target S...'
2026-02-10 21:11:54,819 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 21:11:54,860 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:12:35,570 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:12:35,576 - root - INFO - TOKEN_USAGE: input=39610, output=758, total=40368, cost=$0.006396
2026-02-10 21:12:35,576 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:12:35,576 - root - INFO - 
**TITLE:** Enhancing Insulin Sensitivity through Targeting Pancreatic Islets in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling pathways specifically within pancreatic islets, crucial for enhancing -cell function.
2. **G19943** | Score: 4.0 | As a hub component in insulin signaling, G19943 facilitates the coordination of insulin response, making it vital for effective metabolic regulation in islets.
3. **G00484** | Score: 4.0 | This transcription factor is essential for regulating insulin production in pancreatic islets and enhances the effects of G22553 on -cell function.
4. **G23245** | Score: 4.0 | Important for glucose uptake, G23245 ensures that insulin signaling translates into improved glucose metabolism within the islets.
5. **G33764** | Score: 4.0 | G33764 contributes to the metabolic regulation of pancreatic islets, supporting insulin sensitivity through its role in cellular energy homeostasis.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a focused strategy targeting G22553, a key player in insulin signaling within pancreatic islets, to enhance insulin sensitivity in Type 2 Diabetes. By leveraging G19943's role as a signaling hub and G00484's transcriptional regulation, alongside G23245's function in glucose uptake and G33764's metabolic support, we aim to optimize -cell function and glucose metabolism in islet tissues.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, -cell function, and transcriptional regulation.
- WGCNA module role: G22553 is identified as a primary driver in insulin signaling-related modules.
- Regulating TFs: G00484 plays a significant regulatory role in insulin synthesis and signaling in islets.

**MECHANISM_HYPOTHESIS:** Targeting G22553 is expected to enhance insulin signaling pathways specifically in pancreatic islets, leading to improved -cell function and glucose metabolism. The transcription factor G00484 will augment this effect through its role in promoting insulin production, while G19943 will ensure coordinated insulin signaling. Additionally, G23245's involvement in glucose uptake will facilitate the effective action of insulin, and G33764 will provide metabolic support, addressing potential dysregulation in islet function.

**TISSUE_RATIONALE:** Pancreatic islets are critical for insulin secretion and the regulation of glucose metabolism; thus, enhancing insulin signaling in this specific tissue is essential for the effective management of Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will focus on the small molecule activation of G22553 to boost its function, along with modulation of G19943, G00484, G23245, and G33764 to collectively enhance insulin signaling and metabolic regulation within pancreatic islets.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to lead to improved insulin sensitivity, enhanced glucose metabolism, and restoration of -cell function, resulting in better management of Type 2 Diabetes.

**RANKING_RATIONALE:** Targets were ranked based on their established roles in insulin signaling and glucose metabolism, their strong evidence across multiple datasets, and their specific relevance to pancreatic islets, where G22553 is prioritized for its critical role in insulin signaling.

**CONFIDENCE:** HIGH, based on robust data support and strong associations with key pathways involved in insulin signaling and glucose metabolism in pancreatic islets.
2026-02-10 21:12:35,578 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:12:35,579 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:12:35,579 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:12:35,582 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:12:35,582 - root - INFO -   -> Created mutated offspring: '** Enhancing Insulin Sensitivity through...'
2026-02-10 21:12:35,583 - root - INFO - Mutation 11/18: parent '** Enhanced Multi-Target Appro...'
2026-02-10 21:12:35,583 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 21:12:35,628 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:13:16,997 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:13:17,000 - root - INFO - TOKEN_USAGE: input=39540, output=771, total=40311, cost=$0.006394
2026-02-10 21:13:17,000 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:13:17,000 - root - INFO - 
**TITLE:** Targeting Insulin Signaling Pathways in Adipose Tissue to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G00484** | Score: 4.0 | As a transcription factor, G00484 plays a crucial regulatory role in insulin signaling pathways, making it a strong candidate for enhancing insulin sensitivity in adipose tissue.
2. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling, with robust evidence supporting its central role in glucose metabolism, particularly in adipose tissue.
3. **G19122** | Score: 3.0 | As a major regulator in insulin signaling, G19122 is pivotal in mediating insulin action and enhancing glucose uptake in adipose tissue.
4. **G19943** | Score: 4.0 | This hub component in metabolic regulation reinforces insulin signaling pathways, showing consistent data support relevant to adipose function.
5. **G23245** | Score: 4.0 | Although important for glucose uptake, its negative log2FC indicates it may contribute less favorably compared to the higher-ranked targets in the context of adipose tissue.

**PRIMARY_TARGET:** G00484

**SUMMARY:** This mutated hypothesis prioritizes G00484 as the primary target due to its essential role as a transcription factor in regulating insulin signaling pathways in adipose tissue. By focusing on the unique mechanisms within adipose tissue, particularly in enhancing insulin sensitivity and glucose uptake, this hypothesis aims to create a targeted therapeutic strategy for the management of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, adipocyte function
- WGCNA module role: G00484 is a critical regulator in the black module, indicating its importance in T2D-related pathways.
- Regulating TFs: G00484 itself functions as a regulator in insulin signaling pathways, supporting the proposed mechanism.

**MECHANISM_HYPOTHESIS:** The proposed mechanism centers on G00484 enhancing transcriptional regulation of insulin-responsive genes in adipose tissue, thereby improving insulin sensitivity and glucose metabolism. G22553 and G19122 will support this process by enhancing signaling pathways, while G19943 could provide additional metabolic reinforcement. The synergistic action of these targets is expected to create a robust insulin-signaling environment within adipose tissue.

**TISSUE_RATIONALE:** Adipose tissue is crucial for regulating insulin sensitivity and glucose homeostasis. Targeting pathways within adipocytes could yield significant improvements in metabolic regulation and insulin action, making it a prime focus for therapeutic intervention in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic approach involves the small molecule activation of G00484, with the aim of enhancing its regulatory function in insulin signaling and glucose metabolism specifically within adipose tissue.

**PREDICTED_OUTCOME:** Modulating G00484 is expected to lead to enhanced insulin sensitivity, improved glucose uptake in adipose tissue, and overall better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as critical regulators in insulin signaling and glucose metabolism, with G00484 prioritized for its transcriptional regulatory function. G22553 and G19122 are also essential for their supportive roles, while G19943 reinforces metabolic regulation. G23245, despite its significance, is ranked lower due to an unfavorable log2FC in the context of adipose tissue function.

**CONFIDENCE:** HIGH, based on strong data support across multiple evidence types and the relevance of selected pathways to T2D management.
2026-02-10 21:13:17,001 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:13:17,001 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:13:17,001 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:13:17,002 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:13:17,002 - root - INFO -   -> Created mutated offspring: '** Targeting Insulin Signaling Pathways ...'
2026-02-10 21:13:17,003 - root - INFO - Crossover 12/18: parents 'Integrated Multi-Target Strate...' x 'Synergistic Multi-Target Strat...'
2026-02-10 21:13:17,036 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:13:33,819 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:13:33,821 - root - INFO - TOKEN_USAGE: input=40355, output=749, total=41104, cost=$0.006503
2026-02-10 21:13:33,821 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:13:33,821 - root - INFO - 
### TITLE: Comprehensive Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G04436 | Score: 4.0 | This critical enzyme in lipid metabolism has a well-established role in enhancing insulin sensitivity and glucose regulation, making it a foundational target.**
2. **G22553 | Score: 4.0 | As a primary driver in insulin signaling pathways, this target is essential for enhancing glucose metabolism and complements the role of G04436.**
3. **G19943 | Score: 4.0 | Serving as a central hub in T2D pathways, G19943 integrates multiple metabolic signals and supports insulin signaling, providing a robust regulatory framework.**
4. **G23245 | Score: 4.0 | A primary driver in insulin signaling, this target significantly influences glucose uptake, enhancing the overall therapeutic strategy.**
5. **G33764 | Score: 4.0 | This enzyme contributes to lipid metabolism and offers regulatory support within metabolic pathways, further enhancing the efficacy of the multi-target approach.**

**PRIMARY_TARGET:** G04436

**SUMMARY:** This hypothesis proposes a comprehensive multi-target strategy focusing on G04436 as the primary target to improve lipid metabolism and insulin sensitivity. By leveraging the synergistic roles of G22553, G19943, G23245, and G33764, this strategy aims to enhance insulin signaling and glucose regulation, thereby providing a more effective management approach for Type 2 Diabetes.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, lipid metabolism, glucose metabolism, metabolic regulation pathways
- **WGCNA module role:** G04436 identified as a key enzyme in lipid metabolism supporting insulin sensitivity
- **Regulating TFs:** Multiple transcription factors involved, providing regulatory depth.

**MECHANISM_HYPOTHESIS:** The proposed mechanism emphasizes the activation of G04436 to enhance lipid metabolism and improve insulin sensitivity. Concurrent activation of G22553 will optimize insulin signaling, while G19943 integrates metabolic signals to support this process. G23245 will facilitate glucose uptake, and G33764 will provide additional regulatory support, ensuring a comprehensive therapeutic strategy that targets critical pathways necessary for effective diabetes management.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, which are central to lipid and glucose homeostasis. Targeting these tissues will maximize the therapeutic effects on insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G04436, G22553, G19943, G23245, and G33764) to improve insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their critical roles in insulin signaling and metabolic pathways, strong data support, and their ability to synergistically enhance overall therapeutic efficacy. G04436 was prioritized for its established importance in lipid metabolism. G22553 and G19943 were included for their significant contributions to insulin signaling, while G23245 and G33764 provide necessary regulatory support.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 21:13:33,821 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:13:33,822 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:13:33,822 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:13:33,823 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:13:33,823 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Strategy for ...'
2026-02-10 21:13:33,823 - root - INFO - Crossover 13/18: parents 'Synergistic Multi-Target Strat...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 21:13:33,859 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:14:08,743 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:14:08,750 - root - INFO - TOKEN_USAGE: input=40330, output=789, total=41119, cost=$0.006523
2026-02-10 21:14:08,750 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:14:08,750 - root - INFO - 
### TITLE: Integrated Multi-Target Approach to Enhance Insulin Sensitivity in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways with strong support across datasets, critical for glucose metabolism.
2. **G19943** | Score: 4.0 | Serves as a hub component in T2D pathways, essential for integrating multiple metabolic signals, enhancing overall efficacy.
3. **G00484** | Score: 4.0 | A key transcription factor that regulates insulin signaling, providing necessary regulatory support to G22553's action.
4. **G23245** | Score: 4.0 | A pivotal driver in glucose uptake and insulin sensitivity, complementing the functions of G22553 and enhancing the therapeutic approach.
5. **G33764** | Score: 4.0 | Contributes regulatory support within metabolic pathways, reinforcing the multi-target strategy for T2D management.

#### PRIMARY_TARGET: G22553

### SUMMARY:
This hypothesis proposes an integrated multi-target strategy focusing primarily on G22553, which has been identified as a critical driver of insulin signaling. By leveraging G19943's role as a central metabolic hub, the regulatory functions of G00484, and the complementary actions of G23245 and G33764, this approach aims to provide a robust framework for improving insulin sensitivity and glucose metabolism in Type 2 Diabetes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- **WGCNA module role**: G22553 identified as a primary driver in modules positively correlated with T2D.
- **Regulating TFs**: G00484 acts as a regulator in insulin signaling pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism emphasizes the activation of G22553 to enhance insulin signaling pathways, directly improving glucose metabolism. G19943 functions as a pivotal hub, integrating various metabolic signals and enhancing the action of G22553. The transcription factor G00484 amplifies regulatory impacts on insulin signaling, while G23245 and G33764 support glucose uptake and metabolic regulation, respectively. This synergistic interaction creates a comprehensive strategy for managing Type 2 Diabetes effectively.

### TISSUE_RATIONALE:
The most relevant tissues include the liver, muscle, pancreatic -cells, and adipose tissue, all of which play crucial roles in insulin action and glucose homeostasis. Improving the function of these tissues is expected to significantly enhance insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed approach involves small molecule activation of G22553 and modulation of G00484, G23245, and G33764 to enhance their functions and synergistically improve insulin sensitivity and metabolic regulation.

### PREDICTED_OUTCOME:
Effective modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, reductions in blood glucose levels, and ultimately better management of Type 2 Diabetes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles in insulin signaling and metabolic pathways, supported by strong data across multiple evidence types. G22553 was prioritized for its critical role in insulin signaling, followed by G19943 for its central integrative role. G00484 was included for its regulatory function, while G23245 and G33764 were recognized for their contributions to glucose uptake and metabolic regulation, respectively.

### CONFIDENCE: HIGH
The hypothesis is supported by robust data across multiple evidence types, showcasing the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 21:14:08,751 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:14:08,751 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:14:08,754 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach to Enha...'
2026-02-10 21:14:08,754 - root - INFO - Crossover 14/18: parents 'Tissue-Specific Multi-Target S...' x 'Integrated Multi-Target Approa...'
2026-02-10 21:14:08,830 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:14:47,270 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:14:47,276 - root - INFO - TOKEN_USAGE: input=40413, output=760, total=41173, cost=$0.006518
2026-02-10 21:14:47,276 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:14:47,276 - root - INFO - 
### TITLE: Enhanced Multi-Target Strategy for Improved Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 coordinates metabolic regulation crucial for improving insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling, G22553's modulation enhances glucose metabolism and synergizes with G19943 for stronger effects.
3. **G23245** | Score: 4.0 | Critical for glucose uptake, G23245 reinforces insulin sensitivity and complements the actions of both G19943 and G22553.
4. **G00484** | Score: 4.0 | This transcription factor is essential for regulating insulin signaling, providing transcriptional support to the targets within the pathway.
5. **G33764** | Score: 4.0 | By supporting metabolic regulation, G33764 adds depth to the multi-target approach, ensuring robust interactions in insulin signaling.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates a comprehensive multi-target approach prioritizing G19943 due to its pivotal role in coordinating insulin signaling and metabolic regulation. By incorporating G22553, G23245, G00484, and G33764, we address the multifactorial nature of Type 2 Diabetes (T2D) through synergistic interactions aimed at enhancing insulin sensitivity and glucose homeostasis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and transcriptional regulation.
- WGCNA module role: G19943 is identified as a hub component in modules negatively correlated with T2D, while G22553 is a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a key regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism posits that targeting G19943 as the central coordinator alongside G22553 will enhance insulin signaling and glucose metabolism in Type 2 Diabetes. G23245 will facilitate glucose uptake, while G00484 will regulate transcriptional responses critical for insulin sensitivity. G33764 will ensure overall metabolic regulation, creating a comprehensive framework for managing T2D through coordinated interactions among the targets.

**TISSUE_RATIONALE:** The primary tissues of focus include pancreatic -cells, muscle, liver, and adipose tissue, which are integral to insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions due to their central roles in glucose metabolism and insulin signaling.

**THERAPEUTIC_APPROACH:** The therapeutic strategy will involve small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245 and G00484 to strengthen metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its critical central role in insulin signaling, followed by G22553 for its complementary function, while G23245, G00484, and G33764 provide essential regulatory support and metabolic regulation.

**CONFIDENCE:** HIGH, based on strong evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:14:47,278 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:14:47,278 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:14:47,278 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:14:47,281 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:14:47,281 - root - INFO -   -> Created offspring: 'Enhanced Multi-Target Strategy for Impro...'
2026-02-10 21:14:47,281 - root - INFO - Crossover 15/18: parents 'Targeting G22553 for Enhanced ...' x '** Enhanced Insulin Sensitivit...'
2026-02-10 21:14:47,313 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:15:24,922 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:15:24,927 - root - INFO - TOKEN_USAGE: input=40356, output=796, total=41152, cost=$0.006531
2026-02-10 21:15:24,927 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:15:24,928 - root - INFO - 
**TITLE:** Integrated Targeting of Insulin Signaling Pathways for Enhanced Management of Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 is vital for maintaining pancreatic -cell function and survival, making it a cornerstone for therapeutic strategies.
2. **G22553** | Score: 4.0 | This gene enhances insulin signaling and is crucial for glucose uptake, effectively complementing G19943's role in insulin production and action.
3. **G23245** | Score: 4.0 | Acting as a key regulator of glucose uptake, G23245 directly supports insulin response, making it essential for improving overall insulin sensitivity.
4. **G00484** | Score: 4.0 | This transcription factor is crucial for regulating insulin signaling genes, providing necessary transcriptional control and ensuring effective insulin action in target tissues.
5. **G33764** | Score: 4.0 | As an enhancer of metabolic regulation, G33764 supports insulin action, particularly in pancreatic islets, contributing to a robust metabolic framework.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates the strengths of both parent hypotheses by focusing on G19943 as the primary target for enhancing insulin sensitivity and pancreatic -cell function, supplemented by G22553, G23245, G00484, and G33764. This multi-target strategy addresses the complexities of Type 2 Diabetes through a comprehensive approach to insulin signaling and glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and transcriptional control.
- WGCNA module role: G19943 is identified as a hub component in modules negatively correlated with T2D, emphasizing its importance in islet function.
- Regulating TFs: G00484 acts as a transcriptional regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G19943 coordinating insulin signaling and -cell survival, crucial for maintaining glucose homeostasis. Targeting G22553 will enhance the effectiveness of insulin signaling pathways, while G23245 will facilitate glucose uptake. G00484 will ensure the transcriptional response necessary for effective insulin production, and G33764 will provide additional metabolic regulation support. This integrated approach promises to address both the signaling and metabolic dysfunctions observed in Type 2 Diabetes.

**TISSUE_RATIONALE:** The pancreatic islets, muscle, liver, and adipose tissues are central to insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions, as they are directly involved in insulin signaling, glucose uptake, and metabolic regulation.

**THERAPEUTIC_APPROACH:** The approach involves small molecule activation of G19943 and G22553 to enhance their functions, alongside modulation of G23245, G00484, and G33764 to optimize metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance -cell function, and lead to better management of Type 2 Diabetes through improved glucose metabolism and overall metabolic health.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling and glucose metabolism, their strong evidence support across multiple datasets, and their potential for synergistic interactions in managing Type 2 Diabetes. G19943 is prioritized for its central role, followed by G22553 to enhance its function, with G23245, G00484, and G33764 providing necessary regulatory support.

**CONFIDENCE:** HIGH, based on robust data support, cross-dataset consistency, and significant associations with insulin signaling pathways and pancreatic islet function.
2026-02-10 21:15:24,929 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:15:24,929 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:15:24,929 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:15:24,930 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:15:24,930 - root - INFO -   -> Created offspring: '** Integrated Targeting of Insulin Signa...'
2026-02-10 21:15:24,930 - root - INFO - Crossover 16/18: parents 'Targeting G00484 for Enhanced ...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 21:15:24,976 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:16:06,919 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:16:06,926 - root - INFO - TOKEN_USAGE: input=40299, output=742, total=41041, cost=$0.006490
2026-02-10 21:16:06,926 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:16:06,926 - root - INFO - 
### TITLE: Integrated Targeting of G22553, G00484, and G19943 for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 directly enhances glucose metabolism, making it a crucial target.
2. **G00484** | Score: 4.0 | This transcription factor regulates insulin signaling and glucose homeostasis, providing significant functional support to G22553.
3. **G19943** | Score: 4.0 | Acting as a central hub in the insulin signaling network, G19943 complements the actions of G22553 and G00484, reinforcing their metabolic effects.
4. **G23245** | Score: 4.0 | Critical for glucose uptake, G23245 synergizes with G22553 and G00484, enhancing insulin sensitivity further.
5. **G33764** | Score: 4.0 | By supporting metabolic regulation and insulin signaling pathways, G33764 strengthens the overall therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis integrates insights from both parent hypotheses, focusing on G22553 as the primary target to enhance insulin sensitivity in Type 2 Diabetes. By leveraging the synergistic effects of G00484 and G19943, the approach aims to create a more robust mechanism for restoring metabolic regulation and improving glucose uptake.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a significant transcription factor in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that targeting G22553 will enhance insulin signaling pathways, directly improving glucose metabolism. G00484 will function as a transcriptional enhancer, regulating the expression of genes involved in insulin signaling and glucose homeostasis. Simultaneously, G19943 will act to coordinate and amplify the insulin signaling network, while G23245 ensures effective glucose transport. G33764 further supports metabolic regulation, creating a comprehensive strategy to manage Type 2 Diabetes effectively.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are critical for insulin action and glucose homeostasis. Targeting these tissues is essential for effective therapeutic interventions aimed at improving insulin sensitivity.

**THERAPEUTIC_APPROACH:** The strategy involves the activation of G22553 through small molecules to enhance its function, alongside the modulation of G00484, G19943, G23245, and G33764 to strengthen insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately aiming for restored metabolic homeostasis.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role as a primary driver, with G00484 and G19943 following closely for their complementary functions within the insulin signaling network.

**CONFIDENCE:** HIGH, based on strong evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:16:06,928 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:16:06,928 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:16:06,929 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:16:06,932 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:16:06,932 - root - INFO -   -> Created offspring: 'Integrated Targeting of G22553, G00484, ...'
2026-02-10 21:16:06,932 - root - INFO - Crossover 17/18: parents 'Synergistic Multi-Target Strat...' x 'Targeting G00484 for Enhanced ...'
2026-02-10 21:16:07,025 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:16:47,635 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:16:47,641 - root - INFO - TOKEN_USAGE: input=40326, output=758, total=41084, cost=$0.006504
2026-02-10 21:16:47,642 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:16:47,642 - root - INFO - 
### TITLE: Integrated Multi-Target Approach for Enhanced Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | Serves as a central hub in insulin signaling pathways, integrating multiple metabolic signals crucial for enhancing insulin sensitivity.
2. **G00484** | Score: 4.0 | Acts as a key transcription factor regulating insulin signaling and glucose homeostasis, directly influencing metabolic pathways.
3. **G04436** | Score: 4.0 | Critical enzyme in lipid metabolism that enhances insulin sensitivity, complementing the roles of G19943 and G00484.
4. **G22553** | Score: 4.0 | Important for promoting insulin signaling and glucose uptake, further supporting the overall therapeutic strategy.
5. **G23245** | Score: 4.0 | A driver of glucose uptake that synergizes with other targets to improve insulin signaling efficiency.

#### PRIMARY_TARGET: G19943

### SUMMARY:
This hypothesis proposes a multi-target strategy that integrates G19943s pivotal role in insulin signaling with G00484s transcriptional regulation of glucose metabolism and G04436s enhancement of lipid metabolism. The inclusion of G22553 and G23245 reinforces the approach by further promoting insulin signaling and glucose uptake, creating a comprehensive framework for improving insulin sensitivity in Type 2 Diabetes.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G19943)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- **WGCNA module role**: G19943 identified as a hub component in T2D-related pathways.
- **Regulating TFs**: Several transcription factors involved, enhancing regulatory complexity.

### MECHANISM_HYPOTHESIS:
The proposed mechanism highlights G19943 as the main integrative node that coordinates insulin signaling and metabolic pathways. G00484 complements this by enhancing the transcriptional regulation of key genes involved in insulin action and glucose homeostasis. G04436 enhances lipid metabolism, which is essential for optimal insulin sensitivity. G22553 and G23245 further support glucose uptake and insulin signaling, ensuring a robust metabolic response.

### TISSUE_RATIONALE:
The primary tissues targeted include the liver, muscle, and adipose tissue, which are critical for lipid and glucose homeostasis. Targeting these tissues will enhance insulin sensitivity and overall metabolic health in patients with Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The therapeutic strategy will focus on the activation of G19943 and G00484 through small molecule modulators, while also enhancing the activity of G04436, G22553, and G23245 to optimize metabolic regulation and improve insulin sensitivity.

### PREDICTED_OUTCOME:
Modulating these targets is expected to result in significant enhancements in insulin sensitivity, reductions in blood glucose levels, and improved overall management of Type 2 Diabetes, leading to better patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles in insulin signaling and metabolic pathways, as well as their strong data support across multiple evidence types. G19943 was prioritized for its central integrative role, followed by G00484 for its regulatory capacity, and G04436 for its critical role in lipid metabolism. G22553 and G23245 were included for their contributions to glucose uptake and signaling efficiency.

### CONFIDENCE: HIGH
This hypothesis is supported by robust data across multiple evidence types, demonstrating the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 21:16:47,644 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:16:47,644 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:16:47,648 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Approach for Enh...'
2026-02-10 21:16:47,648 - root - INFO - Mutation 18/18: parent '** Synergistic Multi-Target St...'
2026-02-10 21:16:47,648 - root - INFO - T2D mutation using strategy: tissue_focus
2026-02-10 21:16:47,716 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:17:02,171 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:17:02,173 - root - INFO - TOKEN_USAGE: input=39524, output=717, total=40241, cost=$0.006359
2026-02-10 21:17:02,173 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:17:02,173 - root - INFO - 
**TITLE:** Enhanced Insulin Sensitivity through Targeting Islet Function in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Central hub in insulin signaling pathways, crucial for regulating -cell function and enhancing insulin secretion in the pancreatic islets.
2. **G22553** | Score: 4.0 | Key driver in insulin signaling pathways, supporting glucose uptake and metabolism in islet cells, thus enhancing insulin action.
3. **G23245** | Score: 4.0 | Essential for glucose uptake and insulin sensitivity in islet cells, reinforcing therapeutic action alongside G19943 and G22553.
4. **G33764** | Score: 4.0 | Provides regulatory support within islet metabolic pathways, enhancing overall efficacy in addressing T2D specifically in pancreatic -cells.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This mutated hypothesis focuses on G19943 as the primary target for enhancing insulin sensitivity specifically in pancreatic islets. By leveraging the complementary roles of G22553 and G23245, the strategy aims to optimize glucose metabolism and enhance insulin secretion. G33764 further supports regulatory functions within islet cells, creating a robust multi-target approach to tackle Type 2 Diabetes effectively.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism emphasizes G19943's role as a central coordinator in insulin signaling within pancreatic islets, enhancing -cell function and stimulating insulin secretion in response to glucose. Activation of G22553 will further promote glucose uptake and metabolism in these cells, while G23245 will support insulin sensitivity. Additionally, G33764 will provide necessary regulatory support, ensuring that the islets can effectively manage glucose levels, addressing the core metabolic dysfunctions seen in T2D.

**TISSUE_RATIONALE:** The pancreatic islets are critical for insulin production and regulation of glucose homeostasis. This tissue-specific focus is essential for developing targeted therapies that can directly enhance insulin secretion and sensitivity, addressing the primary defects in T2D.

**THERAPEUTIC_APPROACH:** The therapeutic strategy involves the activation of selected targets using small molecules designed to enhance their activity, specifically targeting islet cells to restore normal insulin function and improve metabolic control.

**PREDICTED_OUTCOME:** The combined activation of these islet-specific targets is expected to lead to significantly enhanced insulin secretion, improved glucose metabolism, and better overall metabolic control in patients with Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their high priority scores, robust evidence from multiple datasets, and their critical roles in key biological pathways within pancreatic islets. G19943 is prioritized for its central importance in the insulin signaling network, while G22553 and G23245 complement this action for glucose metabolism and insulin sensitivity. G33764 is included to provide necessary regulatory support, enhancing the overall therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 21:17:02,174 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:17:02,174 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:17:02,174 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:17:02,175 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:17:02,175 - root - INFO -   -> Created mutated offspring: '** Enhanced Insulin Sensitivity through ...'
2026-02-10 21:17:02,175 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 21:17:02,175 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 21:17:02,175 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 21:17:02,176 - root - INFO - Evaluating fitness for hypothesis: t2d-09-eb26a014
2026-02-10 21:17:14,977 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:17:14,980 - root - INFO - TOKEN_USAGE: input=1451, output=638, total=2089, cost=$0.000600
2026-02-10 21:17:14,980 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:17:14,981 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 5  
**DATA_SUPPORT_RATIONALE:** The primary target (G22553) is indeed in the top priority list, which is a positive note. However, while there is cross-dataset consistency for the primary target (2 datasets), the overall ranking is not supported adequately as it relies heavily on fewer data points. The priority score of 4.0 is a solid indication of its relevance, but the lack of more diverse evidence types slightly diminishes the score.

**RANKING_QUALITY_SCORE:** 6  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, with all ranked targets scoring equally (4.0). However, the lack of clear differentiation among their roles or strengths in the context of T2D diminishes clarity. The rationale provided does support the ranking, but the absence of further distinctions among the targets indicates a need for more depth in understanding their interrelations.

**MECHANISTIC_SCORE:** 7  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling pathways and the rationale for targeting specific tissues (pancreatic -cells, muscle, liver, adipose) is adequately supported. There is an acknowledgment of transcription factors, which is relevant. However, additional details on how these interactions specifically enhance insulin sensitivity could strengthen this aspect.

**THERAPEUTIC_SCORE:** 6  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and modulating other targets is appropriate given their roles in insulin signaling. The potential for druggability is likely high due to their key positions in metabolic networks. Nevertheless, considerations for safety and off-target effects are not addressed, which is a critical aspect of therapeutic hypothesis evaluation.

**NOVELTY_SCORE:** 5  
**NOVELTY_RATIONALE:** The hypothesis integrates data in a coherent manner but does not present particularly non-obvious connections. The multi-target approach is promising, yet it follows a somewhat traditional path in T2D research and lacks innovative insights that would set it apart from existing strategies.

### OVERALL_FITNESS
**OVERALL_FITNESS:** 5.8 (rounded to 58)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG  
- **Target #2 quality:** STRONG  
- **Target #3 quality:** STRONG  

### IMPROVEMENT_SUGGESTIONS:
1. **Diversify Evidence Types:** Incorporate more evidence types (e.g., genetic, pharmacological) to support the claims regarding each target's role in T2D.
2. **Differentiate Target Roles:** Provide more clarity on how each target specifically contributes to the overall therapeutic strategy, possibly with quantitative data or case studies.
3. **Safety Considerations:** Address potential safety issues related to the proposed therapeutic interventions to strengthen the therapeutic rationale.
4. **Innovative Insights:** Explore novel connections or less-studied pathways that could enhance the uniqueness of the hypothesis and contribute to the body of knowledge in T2D research.
2026-02-10 21:17:14,981 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:17:14,981 - root - INFO - Evaluating fitness for hypothesis: t2d-09-c71bb344
2026-02-10 21:17:30,435 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:17:30,439 - root - INFO - TOKEN_USAGE: input=1568, output=779, total=2347, cost=$0.000703
2026-02-10 21:17:30,439 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:17:30,439 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** While G19943 is positioned as the primary target with a priority score of 4.0, the evidence support is somewhat limited as it only has a score derived from one dataset, lacking cross-dataset consistency. However, it is identified as a hub component in the WGCNA, which strengthens its relevance. The identification of other targets as also having high scores suggests they are in line with the top priority tier, but the lack of diverse evidence types slightly undermines the score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the established roles of the targets in insulin signaling and metabolic pathways. All top-ranked targets have equivalent scores and are clearly interconnected in their functions. The rationale behind prioritizing G19943 for its central role in metabolic regulation is sound. However, there could be more clarity on how each target distinctly contributes to the overall strategy.

**MECHANISTIC_SCORE: 7**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in insulin sensitivity and metabolic regulation. The tissue rationale targeting adipose tissue, liver, and skeletal muscle is appropriate given their roles in metabolism. However, the absence of detailed regulatory relationships for G04436 and others could enhance the coherence of the hypothesis.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The strategy of using small molecule activators for these targets is appropriate and aligns with the goal of enhancing metabolic function. The targets are likely druggable based on their network positions, given their roles in critical metabolic pathways. Safety considerations were not discussed, which could be a potential concern.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis does integrate data in a creative way, proposing a multi-target approach to a well-studied condition like Type 2 Diabetes. However, the connections made between the targets are not entirely non-obvious since they are already implicated in metabolic pathways. Further exploration of unique interactions or regulatory mechanisms could enhance the novelty score.

### OVERALL_FITNESS: 
Calculated score: 
- DATA_SUPPORT: 6 * 0.25 = 1.5
- RANKING_QUALITY: 8 * 0.25 = 2.0
- MECHANISTIC: 7 * 0.20 = 1.4
- THERAPEUTIC: 8 * 0.20 = 1.6
- NOVELTY: 7 * 0.10 = 0.7

Overall Fitness Score = 1.5 + 2.0 + 1.4 + 1.6 + 0.7 = **7.2** (scaled to 0-100 = 72)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Data Evidence**: Incorporate additional datasets to strengthen the evidence base for G19943 and support its role as a primary target. This will enhance cross-dataset consistency.
2. **Detail Regulatory Mechanisms**: Provide further insights into the transcription factors regulating G04436 and the interactions among all targets to build a more robust mechanistic hypothesis.
3. **Address Safety Considerations**: Include potential side effects or safety profiles of proposed small molecule activators for the targets to provide a more comprehensive therapeutic strategy.
4. **Explore Novel Interactions**: Investigate less obvious connections or interactions between the targets that could enhance the novelty and therapeutic potential of the hypothesis.
2026-02-10 21:17:30,440 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:17:30,440 - root - INFO - Novelty bonus applied: 0.3% -> fitness 72.00 -> 72.24
2026-02-10 21:17:30,441 - root - INFO - Evaluating fitness for hypothesis: t2d-09-754aaa53
2026-02-10 21:17:46,199 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:17:46,201 - root - INFO - TOKEN_USAGE: input=1535, output=709, total=2244, cost=$0.000656
2026-02-10 21:17:46,201 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:17:46,201 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is ranked as the third highest in the top priority list, which supports its inclusion in the hypothesis. Additionally, there is cross-dataset consistency (two datasets), strengthening the evidence for this target. However, G00484, which is critical for the hypothesis, is not in the top 10, which slightly diminishes the overall data support score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking of targets is justified based on their established roles in insulin signaling. The rationale provided for each target's role in the multi-target strategy is coherent and logical. However, some targets are closely ranked, and the distinction in their strength could be better articulated.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with existing knowledge about insulin signaling and pancreatic islet function. The tissue rationale is robust since pancreatic islets are indeed central to insulin production and glucose metabolism. The relationships between transcription factors and insulin signaling pathways are acknowledged, which supports the mechanism's coherence.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G22553 and modulating other targets is appropriate given their roles in insulin signaling. However, the potential druggability of all targets and any safety considerations are not adequately addressed, which lowers the score.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates existing knowledge in a relevant way, but the connections drawn between targets are somewhat conventional in the context of diabetes research. While it does propose a multi-target strategy, it lacks highly novel or unexpected connections that would score higher.

### OVERALL_FITNESS: 
Calculated as follows:
\[ 
\text{Overall Fitness} = (7 \times 0.25) + (8 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.75 + 2.00 + 1.60 + 1.40 + 0.60 = 7.35 
\]
Scaled to 0-100: 
\[ 
\text{Overall Fitness} = 73.5 
\]

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Incorporate G00484 into the top targets list:** Since it is a crucial transcription factor in the context of insulin signaling, its absence in the top 10 targets needs to be addressed.
2. **Clarify distinctions between closely ranked targets:** Provide more detailed evidence or rationale to differentiate the strength of relationships among the ranked targets, especially between G22553, G19943, and G00484.
3. **Address druggability and safety considerations:** Expand on the potential for drug development for each target, including possible side effects or challenges in modulating these genes therapeutically.
4. **Highlight novel aspects of the multi-target strategy:** Emphasize any unique integrations or approaches that differentiate this hypothesis from existing strategies in the field of Type 2 Diabetes research.
2026-02-10 21:17:46,201 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:17:46,201 - root - INFO - Evaluating fitness for hypothesis: t2d-09-f8ef7f93
2026-02-10 21:18:00,255 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:18:00,260 - root - INFO - TOKEN_USAGE: input=1469, output=735, total=2204, cost=$0.000661
2026-02-10 21:18:00,260 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:18:00,260 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

#### DATA_SUPPORT_SCORE: 8
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed in the top priority list, and there is cross-dataset consistency for the ranked targets. The evidence is strong, with two datasets supporting the role of G19943 as a hub in insulin signaling pathways, and a significant priority score of 4.0. However, the warning indicates that some possibly relevant targets or genes are not explicitly listed in the top priority genes, which slightly reduces the score.

#### RANKING_QUALITY_SCORE: 8
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with all ranked targets having a score of 4.0, indicating their importance. However, while the rationale for prioritizing G19943 is clear, the distinctions between the other targets could be more explicitly defined to strengthen the ranking criteria. The overall rationale makes sense in the context of Type 2 Diabetes management.

#### MECHANISTIC_SCORE: 9
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context, focusing on insulin signaling and glucose metabolism. The rationale for targeting G19943 as a coordinator in the insulin signaling network is coherent, and the tissue rationale is appropriate, given the key tissues involved in insulin action. The consideration of transcription factor relationships is also well-articulated, enhancing the mechanistic coherence.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate for the targets identified, and there is a solid basis for considering these targets as druggable due to their network positions. However, safety considerations and potential side effects of modulating these targets could be elaborated further to strengthen the therapeutic potential evaluation.

#### NOVELTY_SCORE: 7
**NOVELTY_RATIONALE:** The hypothesis integrates data in a meaningful way, proposing a multi-target modulation strategy that addresses the multifactorial nature of Type 2 Diabetes. While the connections made between the targets are logical, the novelty could be enhanced with more innovative insights or alternative approaches that are less commonly pursued.

### OVERALL_FITNESS: 7.8
**Calculation:** 
(8 * 0.25) + (8 * 0.25) + (9 * 0.20) + (7 * 0.20) + (7 * 0.10) = 7.8

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify Target Distinctions:** Provide a more detailed comparison or rationale for the differences between the ranks of G22553, G23245, G00484, and G33764 to strengthen the justification for their ranking.

2. **Address Safety Considerations:** Incorporate a more comprehensive assessment of potential safety issues related to the modulation of the targets, including known side effects or contraindications that could arise from their modulation.

3. **Expand on Novelty Aspects:** Explore and highlight any non-obvious connections or innovative aspects of the proposed multi-target strategy that could differentiate this hypothesis further from existing approaches in Type 2 Diabetes treatment. 

4. **Increase Evidence Types:** Consider gathering additional types of evidence or data to support the therapeutic potential, such as clinical trial results or preclinical studies that validate the effectiveness of targeting these pathways.
2026-02-10 21:18:00,261 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:18:00,261 - root - INFO - Evaluating fitness for hypothesis: t2d-09-ed335b5b
2026-02-10 21:18:15,234 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:18:15,237 - root - INFO - TOKEN_USAGE: input=1504, output=812, total=2316, cost=$0.000713
2026-02-10 21:18:15,237 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:18:15,237 - root - INFO - 
### Evaluation of the RANKED Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 5**  
**DATA_SUPPORT_RATIONALE:** Although the primary target G22553 is found in the top priority list, other ranked targets G00484, G33764, G04436, and G19943 are also present. However, the warning indicates that G00484 is not found in the top priority list, which diminishes the score. The presence of cross-dataset consistency and the identification of G22553 as a primary driver in WGCNA modules support the overall data evidence, but the lack of some targets in the top tier warrants a lower score.

**RANKING_QUALITY_SCORE: 6**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified as the targets are ranked based on their established roles in T2D pathways. However, the presence of a target like G00484 in the ranked list but not in the top priority list raises questions about its comparative strength, which could affect the overall quality of the ranking. The rationale is clear and coherent, yet the inconsistency with G00484 detracts from the strength of the ranking.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and metabolic contexts. The tissue rationale is strong, focusing on key metabolic tissues relevant to insulin action. The relationships between targets, particularly the role of G00484 as a regulator, are well articulated, indicating a solid mechanistic understanding.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets appears appropriate and is supported by their roles in metabolic regulation. The multi-target strategy is promising, but the safety considerations of such an approach need further exploration. The potential for druggability is reasonable given the network positions of the targets, yet concrete evidence or examples for small molecule development could enhance the score.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets and pathways in a comprehensive manner. However, while it proposes a multi-target approach, the individual roles of the targets may not be entirely novel, as similar strategies have been explored in other contexts. There are some creative elements, but the approach is not entirely groundbreaking.

### OVERALL_FITNESS: 
Calculated: \( (5 \times 0.25) + (6 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 6.2 \)
Scaled to 0-100: **62.0**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G22553 is a primary driver with good evidence)
- Target #2 quality: **MODERATE** (G00484 is important but not in the top priority list)
- Target #3 quality: **STRONG** (G33764 has a significant role in lipid metabolism)

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Inclusion:** Review the rationale for including G00484 in the ranked targets while it is not in the top priority list. Consider replacing it with a target that has stronger evidence and is in the top tier.
2. **Enhance Safety Considerations:** Include a detailed assessment of potential safety concerns related to the multi-target approach, perhaps discussing how to mitigate risks associated with polypharmacology.
3. **Provide Drug Development Examples:** Offer examples of small molecules or drugs that have been developed or are in development targeting these genes to strengthen the therapeutic potential argument.
4. **Highlight Novelty Further:** Emphasize any unique aspects of the multi-target approach that differentiate it from existing strategies in Type 2 Diabetes management, potentially in terms of combining pathways or mechanisms.
2026-02-10 21:18:15,238 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:18:15,238 - root - INFO - Evaluating fitness for hypothesis: t2d-09-69c95f08
2026-02-10 21:18:30,333 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:18:30,336 - root - INFO - TOKEN_USAGE: input=1522, output=698, total=2220, cost=$0.000647
2026-02-10 21:18:30,336 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:18:30,336 - root - INFO - 
### Evaluation of the Hypothesis

**DATA_SUPPORT_SCORE: 6**
**DATA_SUPPORT_RATIONALE:** The primary target, G19943, has a high priority score and is supported by cross-dataset consistency. However, the warning indicating that the target gene is not found in the top priority list reduces the overall score. While G22553 and G00484 are in the top 10, the absence of G33764 in that list and the reliance on only two datasets suggests a moderate level of data support.

**RANKING_QUALITY_SCORE: 7**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with G19943 being a central hub in metabolic pathways. However, the scores of other targets like G33764 and G19122 could be reconsidered given the lack of top-tier evidence for all targets. The rationale for ranking appears logical, but a clearer distinction between the strength of the targets would enhance confidence.

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known pathways involved in insulin sensitivity and metabolic regulation. The tissue rationale is strong, focusing on skeletal muscle, liver, and adipose tissue, which are crucial for insulin action. The consideration of transcription factors (TFs) like G00484 adds depth to the mechanistic hypothesis.

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of developing small molecule activators is appropriate for the targets identified. Given their central roles in metabolic regulation, the likelihood of druggability seems reasonable. However, safety considerations and off-target effects need to be explicitly addressed to enhance confidence in the therapeutic potential.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets and pathways, which is a creative approach to tackle Type 2 Diabetes. However, the connections made are not exceptionally novel in the context of existing research; many of the targets have been explored individually in other studies.

### Overall Fitness Calculation
**OVERALL_FITNESS:** 
\[
\text{Overall Fitness} = (6 \times 0.25) + (7 \times 0.25) + (8 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 \approx 68.5
\]

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Incorporate additional datasets to strengthen the data support for all ranked targets, particularly G33764 and G19122.
2. **Clarify Ranking Justification:** Provide more detailed comparisons and justifications for the rankings, especially between closely scored targets to emphasize distinctions.
3. **Address Safety Concerns:** Include a discussion on safety considerations and potential off-target effects of the proposed therapeutic strategy to enhance the therapeutic score.
4. **Highlight Novelty:** Emphasize any unique aspects of the proposed multi-target approach that differentiate it from existing therapies or hypotheses to increase the novelty score.
2026-02-10 21:18:30,337 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:18:30,337 - root - INFO - Evaluating fitness for hypothesis: t2d-09-94bf71b3
2026-02-10 21:18:39,346 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:18:39,350 - root - INFO - TOKEN_USAGE: input=1441, output=579, total=2020, cost=$0.000564
2026-02-10 21:18:39,350 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:18:39,350 - root - INFO - 
**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is found in the top priority list; however, it has a lower priority score than some of the other targets, which diminishes the strength of the overall data support. There is cross-dataset consistency for the primary target, and there are multiple evidence types supporting its role, but the concern about the rank of the primary target affects the score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the established roles of the targets in insulin signaling and metabolic pathways. G22553 is correctly prioritized for its central role, with G19943 and G33764 offering complementary functions. However, the presence of G19122 and G23245 in lower ranks while showing significant roles could suggest a more nuanced ranking could be considered. 

**MECHANISTIC_SCORE: 8**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling pathways and muscle metabolism, and the rationale for targeting muscle tissue is strongly supported by evidence. The involvement of transcription factors adds depth to the mechanism, which is a positive aspect. 

**THERAPEUTIC_SCORE: 7**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation is appropriate given the roles of the targets. However, the assessment of druggability for all targets is not fully addressed, which raises some safety and feasibility concerns that could be explored further.

**NOVELTY_SCORE: 6**
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a meaningful way, focusing on muscle-specific pathways to enhance insulin sensitivity. However, targeting muscle pathways in diabetes is not entirely novel; thus, while the approach is creative, it does not present significantly non-obvious connections.

**OVERALL_FITNESS: 7.35**
(Overall fitness calculated as: 7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10 = 7.35)

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: MODERATE

**IMPROVEMENT_SUGGESTIONS:**
1. Consider re-evaluating the rank of G19122 and G23245, as they may have greater significance than indicated, particularly in the context of their roles.
2. Provide additional evidence or data supporting the druggability of the targets, especially regarding safety profiles and potential side effects of the proposed therapeutic approach.
3. Explore novel mechanisms or combinations of existing treatments that have not been previously established, enhancing the innovative aspect of the hypothesis.
2026-02-10 21:18:39,350 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:18:39,351 - root - INFO - Evaluating fitness for hypothesis: t2d-09-85d21047
2026-02-10 21:18:52,918 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:18:52,921 - root - INFO - TOKEN_USAGE: input=1472, output=731, total=2203, cost=$0.000659
2026-02-10 21:18:52,921 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:18:52,921 - root - INFO - 
### EVALUATION OF THE HYPOTHESIS

**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is indeed present in the top priority list, alongside other high-scoring targets such as G19943, G23245, and G00484. The hypothesis supports cross-dataset consistency with two datasets backing the evidence. However, the warning regarding G00484 not being found in the top priority list highlights a minor gap in data support, as it has been ranked as a key transcription factor influencing insulin signaling.

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified based on the established roles of the targets in T2D pathways. G22553 is appropriately prioritized as the primary driver of insulin signaling, and the rationale explains the synergistic interactions between the targets well. However, the absence of G00484 in the top priority list slightly weakens the argument for the ranking of all targets.

**MECHANISTIC_SCORE: 9**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and metabolic regulation. The tissue rationale is effectively supported as it includes key tissues involved in insulin action. Additionally, the role of G00484 as a transcription factor is aptly recognized, helping to tie in the regulatory aspects of the mechanism.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and G19943 along with modulation of other targets appears appropriate given their roles in insulin signaling. The strategy is well thought out regarding the targets' network positions. Safety considerations should be addressed further, especially when targeting multiple pathways simultaneously, but the approach is generally promising.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates various target pathways creatively, proposing a multi-target strategy that is somewhat novel in its approach to enhancing insulin sensitivity in T2D. However, the connections are not entirely non-obvious as the roles of these targets are established within the literature. 

### OVERALL_FITNESS
**OVERALL_FITNESS:**  
(7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (8 * 0.20) + (7 * 0.10) = 7.6  
**Scaled to 0-100:** 76.0

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Reassess Target Inclusion:** Ensure that all relevant and impactful targets, such as G00484, are included in the top priority list if they are critical to the mechanism. This could involve revisiting the scoring criteria or data consistency.
   
2. **Expand Safety Considerations:** Include potential side effects and safety profiles for the proposed therapeutic molecules targeting multiple pathways to enhance the robustness of the therapeutic approach.

3. **Increase Novelty by Exploring Interactions:** Investigate and articulate any novel interactions between the proposed targets and lesser-known pathways related to T2D, which could add a layer of uniqueness to the hypothesis.

4. **Integrate Additional Evidence:** Where possible, support the evidence with more datasets or literature references that reinforce the roles and interactions of the targets, especially focusing on G00484's impact on insulin signaling.
2026-02-10 21:18:52,922 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:18:52,922 - root - INFO - Evaluating fitness for hypothesis: t2d-09-1717c9ff
2026-02-10 21:19:05,455 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:19:05,458 - root - INFO - TOKEN_USAGE: input=1440, output=624, total=2064, cost=$0.000590
2026-02-10 21:19:05,458 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:19:05,458 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is indeed in the top priority list with a score of 4.0, indicating strong recognition. However, G00484, while ranked highly, is not in the top 10 despite its importance as a transcription factor. There is cross-dataset consistency for the primary target, and multiple evidence types support G22553, but the absence of some ranked targets in the top priority list slightly lowers the score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data, particularly for G22553 and G00484, which play crucial roles in insulin signaling. The rationale for prioritizing these targets based on their importance in the metabolic pathways is sound. However, the lower score for G19122 could indicate less confidence in its ranking compared to higher-ranked targets, although it still has a supportive role.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose metabolism pathways, and the tissue rationale is solid, focusing on key tissues relevant to Type 2 Diabetes. The roles of G00484 as a transcription factor and the complementary effects of G33764 and G23245 are well-articulated, enhancing mechanistic coherence.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of targeting these pathways through small molecules is appropriate, as it aims to enhance insulin sensitivity. The targets identified are likely druggable based on their roles in metabolic networks. However, potential safety considerations in manipulating these targets for therapeutic effects should be explicitly addressed for a higher score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data effectively, the approach of targeting multiple nodes in insulin signaling is not entirely novel in diabetes research. However, the specific combination of targets and their synergistic roles provides some creative connections, justifying a moderate score.

**OVERALL_FITNESS:** 7.6 (scaled to 76)  
**(Calculation: 7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 6*0.10)**

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Incorporate G00484 into the top priority list:** Given its importance, consider providing additional evidence or rationale to elevate its status.
2. **Address safety considerations:** Explicitly discuss potential off-target effects or safety issues associated with activating the targets, which could strengthen the therapeutic score.
3. **Highlight novelty more clearly:** Emphasize unique aspects of the multi-target approach or innovative combinations that differentiate this hypothesis from existing strategies in Type 2 Diabetes treatment.
2026-02-10 21:19:05,458 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:19:05,459 - root - INFO - Evaluating fitness for hypothesis: t2d-09-b4bff6ad
2026-02-10 21:19:15,570 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:19:15,573 - root - INFO - TOKEN_USAGE: input=1456, output=708, total=2164, cost=$0.000643
2026-02-10 21:19:15,573 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:19:15,573 - root - INFO - 
### EVALUATION OF THE HYPOTHESIS

**DATA_SUPPORT_SCORE: 8**  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is present in the top priority list, and two datasets provide consistent evidence. However, the warning about G22553 not being found in the top priority list is concerning, as it suggests a potential oversight in the assessment of the target's importance compared to others in the list. Despite this, the presence of cross-dataset consistency and multiple evidence types supporting G22553 contributes to a high score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified based on the established roles of the targets in insulin signaling and glucose metabolism. However, all targets scored equally, which may indicate a lack of differentiation among their contributions. While the rationale is coherent, the absence of a clear hierarchy in target importance slightly lowers the score.

**MECHANISTIC_SCORE: 9**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling and pancreatic islet function, supported by the roles of the target genes. The tissue rationale is strong, as the pancreas is directly involved in insulin secretion. The relationships between G22553 and G00484, along with the other targets, are well-articulated, providing a coherent picture of the mechanism.

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and modulating other targets appears appropriate given their roles in insulin signaling. The potential for druggability is reasonable based on their network positions. However, safety considerations are not explicitly addressed in the proposal, which could be a critical factor in therapeutic development.

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing knowledge in a logical manner, proposing a comprehensive approach to enhance insulin sensitivity. While it does suggest connections between targets that may not be immediately obvious, the overall concept of targeting insulin signaling in pancreatic islets is a well-explored area in diabetes research.

### OVERALL FITNESS
**OVERALL_FITNESS: 7.7**  
(8 * 0.25 + 7 * 0.25 + 9 * 0.20 + 8 * 0.20 + 7 * 0.10 = 7.7)

### RANKED_TARGETS_ASSESSMENT
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG
- Target #4 quality: STRONG
- Target #5 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify Target Importance:** Provide more differentiation among the ranked targets to establish clear tiers of priority. This could involve additional validation studies to emphasize the unique contributions of each target.
2. **Address Safety Considerations:** Include potential side effects and safety assessments of the proposed therapeutic approach to enhance its viability in clinical settings.
3. **Expand Data Support:** Encourage further experimental validation of the role of G22553 and its interactions with other targets in the context of Type 2 diabetes to strengthen the data support for the hypothesis.
4. **Integrate Novel Approaches:** Consider exploring innovative methods or technologies (e.g., gene editing, RNA interference) to modulate target genes, enhancing the therapeutic potential of the hypothesis.
2026-02-10 21:19:15,574 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:19:15,574 - root - INFO - Evaluating fitness for hypothesis: t2d-09-70cbe6d8
2026-02-10 21:19:28,496 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:19:28,497 - root - INFO - TOKEN_USAGE: input=1469, output=684, total=2153, cost=$0.000631
2026-02-10 21:19:28,498 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:19:28,498 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G00484 is included in the top priority list, although it is not the highest-ranked target. There is cross-dataset consistency with two datasets supporting the findings. However, the score could be improved by further diversifying evidence types beyond just two datasets.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified based on the established roles of the targets in insulin signaling and glucose metabolism. Higher-ranked targets, such as G22553 and G19943, demonstrate strong evidence for their roles. The rationale for ranking appears coherent and logical, although it could benefit from further clarification on how G23245's lower rank is justified despite its importance.

---

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and the tissue rationale is well-supported. The role of G00484 as a transcription factor is relevant, and the relationships with other transcription factors in the context of insulin signaling are appropriately considered, providing a cohesive perspective on the mechanism.

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G00484 is appropriate given its regulatory role. However, there may be safety considerations that are not explicitly addressed, and the druggability of the targets based on their network positions could be elaborated upon to strengthen the evaluation.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis does exhibit some creative integration of data and connections; however, the idea of targeting insulin signaling pathways in adipose tissue is not entirely novel in the field. A more innovative angle or unique combination of targets could enhance this aspect of the evaluation.

---

### OVERALL_FITNESS
Calculated Score:  
\[ (7 \times 0.25) + (8 \times 0.25) + (9 \times 0.20) + (7 \times 0.20) + (6 \times 0.10) = 1.75 + 2 + 1.8 + 1.4 + 0.6 = 7.55 \]  
**Overall Score (scaled to 0-100):** 75.5

---

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G00484):** STRONG  
- **Target #2 quality (G22553):** STRONG  
- **Target #3 quality (G19122):** STRONG  

---

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Types:** Include more diverse types of evidence to strengthen the support for the primary target and provide a more comprehensive dataset.
  
2. **Clarify Ranking Justifications:** Provide clearer explanations regarding the ranking of G23245 in comparison to other targets, especially in the context of its negative log2FC.

3. **Address Safety Considerations:** Discuss potential safety concerns or side effects of activating G00484 and the other targets to give a more rounded view of the therapeutic approach.

4. **Enhance Novelty:** Explore additional innovative therapeutic strategies or combinations of targets that could differentiate this hypothesis from existing literature.
2026-02-10 21:19:28,499 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:19:28,499 - root - INFO - Evaluating fitness for hypothesis: t2d-09-63063508
2026-02-10 21:19:34,230 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:19:34,233 - root - INFO - TOKEN_USAGE: input=1447, output=798, total=2245, cost=$0.000696
2026-02-10 21:19:34,233 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:19:34,234 - root - INFO - 
### Evaluating the Hypothesis

**DATA_SUPPORT_SCORE: 6**
- **DATA_SUPPORT_RATIONALE:** The primary target (G04436) is indeed in the top priority list, along with multiple other ranked targets. However, there is a warning indicating that one of the targets (G19943) is not found in the priority list, which might indicate inconsistencies. There is cross-dataset consistency for the primary target and additional support from multiple datasets, but overall evidence types for the primary target could be more robust.

**RANKING_QUALITY_SCORE: 7**
- **RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the roles of the targets in insulin signaling and metabolic pathways. The targets are rated equally (4.0), which suggests they are perceived as having similar importance. However, this can lead to ambiguity regarding which targets are definitively stronger. The rationale makes sense in terms of the interconnectedness of the targets, but the lack of differentiation in their scores may weaken the ranking's clarity.

**MECHANISTIC_SCORE: 8**
- **MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the described pathways and aligns well with the roles of the tissues involved (skeletal muscle, liver, and adipose tissue). The focus on transcription factors is a positive aspect, indicating thoughtful consideration of regulatory mechanisms. The integration of multiple targets to enhance insulin sensitivity shows a clear understanding of the metabolic context.

**THERAPEUTIC_SCORE: 7**
- **THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation appears appropriate given the roles of the targets. The potential for druggability seems promising based on the network positions of the targets. However, safety considerations have not been explicitly mentioned, which is crucial in evaluating therapeutic viability, potentially limiting the score.

**NOVELTY_SCORE: 6**
- **NOVELTY_RATIONALE:** While the hypothesis does integrate data in a comprehensive way, the approach of targeting multiple pathways for a complex disease like Type 2 Diabetes is not entirely novel. The connections made are relevant but do not introduce significantly new insights or strategies that deviate from established research in the field.

### Overall Evaluation

**OVERALL_FITNESS:** 
Using the scoring system:
- DATA SUPPORT: 6 * 0.25 = 1.5
- RANKING QUALITY: 7 * 0.25 = 1.75
- MECHANISTIC: 8 * 0.20 = 1.6
- THERAPEUTIC: 7 * 0.20 = 1.4
- NOVELTY: 6 * 0.10 = 0.6

Total = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 7.85 
Scaling to 0-100 = 78.5

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Data Evidence:** Gather additional evidence types for the primary target G04436 and other key targets. This could involve more extensive validation studies or functional assays to strengthen support for the hypothesis.
2. **Clarify Target Ranking:** Differentiate the targets with more specific scores based on their relevance and impact on the therapeutic strategy. This will provide clearer guidance on prioritization for drug development.
3. **Explicit Safety Considerations:** Include a discussion on potential safety concerns related to the modulation of the targets, outlining any known side effects or toxicities associated with targeting these pathways.
4. **Innovative Mechanisms:** Consider exploring less conventional targets or emerging pathways that may not be well-established in current literature to increase the novelty of the approach.
2026-02-10 21:19:34,234 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:19:34,234 - root - INFO - Evaluating fitness for hypothesis: t2d-09-64cf26a9
2026-02-10 21:19:44,880 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:19:44,884 - root - INFO - TOKEN_USAGE: input=1549, output=679, total=2228, cost=$0.000640
2026-02-10 21:19:44,884 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:19:44,884 - root - INFO - 
### EVALUATION RESULTS

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a priority score of 4/17, which places it in a reasonable standing among the top priority targets. However, it lacks cross-dataset consistency, and there is only one dataset providing evidence. This limits the robustness of the support for G22553, leading to a moderate score.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the roles of the targets in insulin signaling and metabolic pathways. However, the lack of strong differentiating data between some of the top-ranked targets (e.g., G22553 vs. G00484) could indicate that the rankings could be more nuanced or better supported by evidence. Overall, the rationale for ranking is sound but could be more compelling with stronger evidence.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and glucose metabolism. The tissue rationale is appropriate, focusing on liver, muscle, pancreatic -cells, and adipose tissue, which are all relevant for insulin action. The consideration of transcription factors and their relationships is also well done, contributing to a coherent mechanistic narrative.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation is appropriate given the roles of the targets in insulin signaling. The targets appear to be druggable based on their biological functions and network positioning. However, safety considerations are not explicitly addressed, which slightly lowers the score.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis presents an integrated multi-target approach, which is somewhat novel in the context of Type 2 Diabetes management. However, the connections made among the targets, while valid, may not be entirely groundbreaking, as multi-target approaches are a common strategy in drug development.

**OVERALL_FITNESS:** 6.6  
**Calculated:** (6*0.25 + 7*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.6

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality (G22553):** MODERATE  
- **Target #2 quality (G19943):** STRONG  
- **Target #3 quality (G00484):** STRONG  

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Evidence Diversity:** Aim to gather additional datasets supporting G22553 to enhance cross-dataset consistency and overall robustness of the evidence.
2. **Clarify Ranking Justification:** Provide clearer justification for the ranking, particularly between closely scored targets, potentially through additional evidence or analysis.
3. **Address Safety Considerations:** Explicitly discuss potential safety issues or side effects related to the proposed therapeutic approach to strengthen the therapeutic potential argument.
4. **Explore More Novel Connections:** Investigate and highlight any non-obvious interactions or pathways that could further distinguish the approach from existing strategies in T2D management.
2026-02-10 21:19:44,884 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:19:44,885 - root - INFO - Novelty bonus applied: 0.2% -> fitness 50.00 -> 50.08
2026-02-10 21:19:44,885 - root - INFO - Evaluating fitness for hypothesis: t2d-09-890c1e4f
2026-02-10 21:19:58,142 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:19:58,145 - root - INFO - TOKEN_USAGE: input=1458, output=824, total=2282, cost=$0.000713
2026-02-10 21:19:58,145 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:19:58,145 - root - INFO - 
### Evaluation of the Hypothesis: Enhanced Multi-Target Strategy for Improved Insulin Sensitivity in Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed found in the top priority list, and there is cross-dataset consistency, which is a positive indicator. However, the warning about a target gene not found in the top priority list slightly detracts from the overall score, as it raises concerns about the completeness of the target selection. The primary target has support from two datasets, which is a strong point, but the overall number of evidence types could be improved.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is well-justified by the data presented, with all ranked targets demonstrating significant roles in T2D pathways. The rationale clearly distinguishes the importance of G19943 as the central hub, and the complementary roles of the other targets are logically articulated. The scores are consistent across the targets, but a more nuanced differentiation could strengthen the ranking further.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and the tissue rationale is strong, focusing on key tissues involved in insulin action. The consideration of transcription factors like G00484 adds depth to the mechanistic coherence, indicating a well-thought-out approach. Overall, the mechanism is clearly articulated and well-supported.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553 appears appropriate for enhancing insulin sensitivity. The choice of targets is based on their network positions and potential for druggability, but there may be safety considerations related to off-target effects or adverse interactions that need to be evaluated further. This aspect could be emphasized more in the proposal.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates existing data in a meaningful way, the connections made between the targets are somewhat conventional in the context of diabetes research. The multi-target strategy is promising, but the novelty could be enhanced by including more innovative or unconventional approaches or targets.

### Overall Fitness Calculation
Overall Fitness = (DATA_SUPPORT * 0.25) + (RANKING_QUALITY * 0.25) + (MECHANISTIC * 0.20) + (THERAPEUTIC * 0.20) + (NOVELTY * 0.10)  
= (7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (7 * 0.20) + (6 * 0.10)  
= 1.75 + 2.00 + 1.80 + 1.40 + 0.60  
= 7.55  
Scaled to 0-100, the Overall Fitness = 75.5

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Evidence Base:** Incorporate additional types of evidence to support the ranked targets, such as functional assays or patient-derived data, to reinforce the hypothesis.
2. **Clarify Safety Considerations:** Address potential safety issues associated with the therapeutic approach more explicitly, considering potential side effects or interactions with existing diabetes therapies.
3. **Innovative Target Exploration:** Explore additional novel targets or combination therapies that could enhance the proposed multi-target strategy, potentially increasing the novelty score.
4. **Refine Mechanistic Details:** Provide more detailed mechanistic insights that explain how the interactions among the targets will translate into therapeutic effects, perhaps including specific pathways or feedback mechanisms.
5. **Longitudinal Studies:** Suggest the inclusion of longitudinal studies to assess the long-term effects of the proposed therapeutic strategy on insulin sensitivity and glucose metabolism.
2026-02-10 21:19:58,145 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:19:58,146 - root - INFO - Evaluating fitness for hypothesis: t2d-09-78f25af8
2026-02-10 21:20:12,426 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:20:12,430 - root - INFO - TOKEN_USAGE: input=1494, output=662, total=2156, cost=$0.000621
2026-02-10 21:20:12,430 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:20:12,431 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, and there is cross-dataset consistency supporting its role in insulin signaling, evidenced by the inclusion of two datasets. However, the absence of G00484 in the top priority list weakens the overall data support for the remaining targets, which are also ranked but not included in the top 10. There are multiple evidence types supporting G19943, enhancing confidence in its central role.

---

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by data, with G19943 clearly positioned as a central hub in insulin signaling. The subsequent targets (G22553, G23245, G00484, G33764) are logically positioned to support and enhance the primary target's function. The rationale for ranking is consistent with their established roles in insulin signaling and glucose metabolism, although the absence of some ranked targets from the top priority list slightly undermines the ranking quality.

---

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling and glucose homeostasis pathways. The tissue rationale is strong, focusing on pancreatic islets, muscle, liver, and adipose tissues, all crucial for insulin action. Additionally, the role of G00484 as a transcription factor is well considered, providing a comprehensive understanding of the interactions among the targets.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G22553 is appropriate given their roles in enhancing insulin signaling. The targets are likely druggable based on their central network positions. However, specific safety considerations or potential side effects of targeting these genes were not discussed, which could be a concern in drug development.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates various targets in a manner that reflects a comprehensive understanding of insulin signaling and metabolic regulation. However, the connections made among the targets, while logical, do not appear to present entirely novel insights. The targeting of well-established pathways may limit the perceived novelty.

---

**OVERALL_FITNESS:** 7.65 (rounded to 76.5)  
**(Calculated: 7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 7*0.10)**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Expand Evidence Base:** Include more evidence types for G00484 and other lower-ranked targets to strengthen their justification and support within the hypothesis.
2. **Address Safety Considerations:** Provide a discussion on potential safety concerns and off-target effects for the therapeutic approach, which could enhance the therapeutic potential score.
3. **Novelty Exploration:** Investigate and articulate potential novel connections or mechanisms that could emerge from the integration of these targets to improve the novelty score.
2026-02-10 21:20:12,433 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:20:12,433 - root - INFO - Evaluating fitness for hypothesis: t2d-09-3f97b92a
2026-02-10 21:20:22,344 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:20:22,350 - root - INFO - TOKEN_USAGE: input=1440, output=719, total=2159, cost=$0.000647
2026-02-10 21:20:22,350 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:20:22,350 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is ranked third in the top priority list, which is a good indication of its significance. Additionally, there is cross-dataset consistency for the primary target and secondary targets, with two datasets supporting the findings. However, there is a warning regarding the absence of specific evidence for G00484 and G19943 in the top priority list, which slightly lowers the score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, as G22553 is highlighted as a primary driver in insulin signaling. The rationale for ranking is sound, emphasizing the synergistic relationships among the targets. However, given the warning about G00484 and G19943's absence in the top priority list, there could be some room for improvement in the clarity of their ranking.

**MECHANISTIC_SCORE: 9**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the context of insulin signaling pathways and the roles of the identified targets. The tissue rationale is solid, focusing on key tissues involved in glucose homeostasis. The transcription factor relationships are well-considered, adding to the coherence of the mechanism.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 and modulating the other targets is appropriate, as these targets are integral to insulin signaling. The potential for druggability is likely high given their network position, and safety considerations appear to be adequately addressed in the context of metabolic regulation.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis integrates data from multiple sources and proposes a comprehensive strategy that is not merely an extension of existing ideas. It does, however, rely on established pathways, which may limit its novelty somewhat compared to completely new target mechanisms.

### OVERALL_FITNESS
**OVERALL_FITNESS:** (7 * 0.25 + 8 * 0.25 + 9 * 0.20 + 8 * 0.20 + 7 * 0.10) = 7.7 (rounded to 78)  
**Overall Fitness Score: 78/100**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G22553 is well-supported and critical for the hypothesis)
- Target #2 quality: **MODERATE** (G00484 is important but has less evidence support in the priority list)
- Target #3 quality: **MODERATE** (G19943 shares similar concerns as G00484 regarding evidence support)

### IMPROVEMENT_SUGGESTIONS:
1. **Strengthen Evidence for G00484 and G19943:** Provide additional data or literature references that can support the significance of these targets in the context of Type 2 Diabetes.
2. **Clarify Target Relationships:** Enhance the description of how each target interacts with one another in the proposed mechanism, especially the roles of G00484 and G19943 in relation to G22553.
3. **Expand Novelty Discussion:** Discuss potential innovative aspects of the hypothesis more explicitly, particularly how this integrated approach could differ from existing treatments or hypotheses in Type 2 Diabetes.
4. **Consider Alternative Pathways:** Explore and mention any alternative pathways or mechanisms that could also be targeted alongside the proposed ones for a broader therapeutic strategy.
2026-02-10 21:20:22,352 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:20:22,353 - root - INFO - Evaluating fitness for hypothesis: t2d-09-47c50e58
2026-02-10 21:20:32,920 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:20:32,926 - root - INFO - TOKEN_USAGE: input=1517, output=787, total=2304, cost=$0.000700
2026-02-10 21:20:32,926 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:20:32,926 - root - INFO - 
### EVALUATION OUTPUT

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 has a priority score of 4.0/17, which places it in the top priority tier. However, it lacks cross-dataset consistency, as only one dataset supports it. The evidence types for G19943 are limited, with only 2 types mentioned. While there is a solid dataset backing, the lack of cross-dataset consistency lowers the score somewhat.

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, given that all the targets have the same score of 4.0. However, the distinction between the targets is not clear, and there are no additional metrics provided to differentiate their strength further. The rationale for ranking G19943 as the primary target is strong due to its central role, but the differences between ranks could be more explicitly defined.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent, aligning well with the insulin signaling pathways and metabolic regulation context. The tissue rationale is also well-supported, focusing on critical tissues involved in glucose and lipid metabolism. However, the role of regulating transcription factors (TFs) is mentioned but not elaborated on, which could enhance understanding of the regulation complexity.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G19943 and G00484 through small molecule modulators seems appropriate, given their roles in insulin signaling and glucose metabolism. However, the potential druggability of all targets could be elaborated further. There are no significant safety considerations mentioned, but some discussion on potential off-target effects would strengthen this section.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a coherent framework, which is promising. However, the connections made are somewhat conventional within the context of diabetes research. While it does assemble an integrated multi-target approach, the novelty of the specific interactions and the innovative aspects of the proposed mechanism could be more pronounced.

### OVERALL_FITNESS: 
Calculated Score:  
\[ (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85 \]  
Scaled to 0-100: **68.5**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Cross-Dataset Validation:** Aim to obtain more datasets to validate the findings related to G19943 and other targets, which would strengthen the data support and improve cross-dataset consistency.
2. **Clarify Differentiation Between Targets:** Provide additional metrics or evidence to differentiate the strengths of the targets ranked equally. This could be achieved through more detailed analysis of their roles in relevant pathways.
3. **Expand on Regulatory Mechanisms:** Include a more comprehensive discussion of the transcription factors involved in regulating the primary target and other ranked targets, as this could clarify their roles and strengths in the proposed mechanism.
4. **Address Safety Considerations:** Discuss potential side effects or safety considerations regarding the modulation of these targets, as this is crucial for the therapeutic potential of the approach.
5. **Highlight Novel Connections:** Explore and articulate any novel interactions or insights gained from the multi-target approach that could distinguish this hypothesis from existing research in Type 2 Diabetes.
2026-02-10 21:20:32,927 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:20:32,927 - root - INFO - Novelty bonus applied: 0.2% -> fitness 50.00 -> 50.08
2026-02-10 21:20:32,927 - root - INFO - Evaluating fitness for hypothesis: t2d-09-75ea1ec6
2026-02-10 21:20:45,195 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:20:45,199 - root - INFO - TOKEN_USAGE: input=1415, output=637, total=2052, cost=$0.000594
2026-02-10 21:20:45,199 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:20:45,199 - root - INFO - 
**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed in the top priority list, and there is cross-dataset consistency for this target. However, the warning regarding a target gene not found in the top priority list is concerning. The evidence supports multiple targets (G19943, G22553, G23245, and G33764), which all have high scores and are supported by strong evidence, but the lack of clarity on the top genes could slightly lower the score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data, with all ranked targets showing high priority scores and relevant functions aligned with the hypothesis of enhancing insulin sensitivity. The targets are clearly distinguished based on their roles and interconnectedness in insulin signaling, making the rationale sound. However, the presence of some equally scored targets (all with a score of 4.0) may complicate the perceived strength of the ranking.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and glucose metabolism, which is directly relevant to Type 2 Diabetes. The focus on pancreatic islets as the tissue of interest is well-supported by the data, and the roles of regulating transcription factors like G00484 are appropriately considered in the mechanism. There is strong coherence between the mechanism and the targeted pathways.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating these targets with small molecules is appropriate given their roles in insulin sensitivity and secretion. The targets are likely druggable due to their involvement in critical signaling pathways. However, further details on potential safety considerations and the feasibility of developing these small molecules would enhance the evaluation.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data and proposes a multi-target approach to enhance insulin sensitivity, which is a known area of research. While the connections made are valid, they are not particularly novel in the context of existing research on Type 2 Diabetes treatments. The approach is strategic but may not present significantly new insights.

**OVERALL_FITNESS:** 7.5  
**Calculated:** (8*0.25 + 8*0.25 + 9*0.20 + 7*0.20 + 6*0.10) = 7.5

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. Clarify the status of the target gene that was noted as not found in the top priority list to ensure all relevant targets are accounted for in the hypothesis.
2. Provide more detailed safety considerations regarding the activation of the identified targets to enhance the therapeutic potential assessment.
3. Consider exploring more novel connections or mechanisms that could differentiate this hypothesis from existing therapeutic strategies for Type 2 Diabetes.
2026-02-10 21:20:45,199 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:20:45,200 - root - INFO - Population fitness evaluation complete. Top score: 79.00
2026-02-10 21:20:45,200 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 21:20:45,200 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G19943']...
2026-02-10 21:20:45,200 - root - INFO - Generation 9 stats: mean=64.65, max=79.5, min=50.0
2026-02-10 21:20:45,201 - root - INFO - Generation 9 complete
2026-02-10 21:20:45,201 - root - INFO - Running generation 10
2026-02-10 21:20:45,201 - root - INFO - Creating 18 offspring using GA-aligned tournament selection
2026-02-10 21:20:45,201 - root - INFO - Genetic operation rates: 60% crossover, 40% mutation
2026-02-10 21:20:45,201 - root - INFO - Mutation 1/18: parent 'Comprehensive Multi-Target Str...'
2026-02-10 21:20:45,201 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 21:20:45,275 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:21:26,672 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:21:26,679 - root - INFO - TOKEN_USAGE: input=39526, output=760, total=40286, cost=$0.006385
2026-02-10 21:21:26,679 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:21:26,679 - root - INFO - 
### TITLE: Targeting G22553 for Enhanced Insulin Sensitivity and Glucose Regulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G22553 | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is crucial for enhancing glucose metabolism and synergizes well with other metabolic regulators.**
2. **G19943 | Score: 4.0 | This target integrates multiple metabolic signals and plays a central role in insulin signaling pathways, complementing the function of G22553 effectively.**
3. **G04436 | Score: 4.0 | While previously established as a key enzyme in lipid metabolism, G04436 supports insulin sensitivity and glucose regulation, making it a valuable target in combination.**
4. **G23245 | Score: 4.0 | This target significantly influences glucose uptake and insulin signaling, providing essential support for the therapeutic strategy aimed at improving metabolic health.**
5. **G33764 | Score: 4.0 | Contributing to lipid metabolism, G33764 enhances the overall regulatory network for glucose and lipid homeostasis, supporting the multi-target approach.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a refined strategy that positions G22553 as the primary target to improve insulin signaling and glucose metabolism in Type 2 Diabetes. By leveraging the synergistic roles of G19943, G04436, G23245, and G33764, this approach aims to provide a comprehensive management pathway targeting critical metabolic pathways involved in T2D.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism, lipid metabolism
- **WGCNA module role:** G22553 identified as a primary driver in insulin signaling pathways.
- **Regulating TFs:** Multiple transcription factors involved, enhancing regulatory depth.

**MECHANISM_HYPOTHESIS:** The proposed mechanism emphasizes the activation of G22553 to enhance insulin signaling and glucose metabolism directly. Concurrent activation of G19943 will integrate metabolic signals essential for optimizing this process, while G04436 will improve lipid metabolism to support insulin sensitivity. G23245 will facilitate glucose uptake, and G33764 will provide additional metabolic regulation, ensuring a robust therapeutic strategy against Type 2 Diabetes.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, which are central to insulin signaling and glucose homeostasis. Focusing on these tissues will maximize the therapeutic effects on insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G22553, G19943, G04436, G23245, and G33764) to improve insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced management of Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their critical roles in insulin signaling, the strength of data support, and their ability to synergistically enhance overall therapeutic efficacy. G22553 was prioritized for its established importance in insulin signaling. G19943 was included for its significant contributions to integrating metabolic signals, while G04436, G23245, and G33764 provide necessary regulatory support within metabolic pathways.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 21:21:26,681 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:21:26,681 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:21:26,682 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:21:26,685 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:21:26,685 - root - INFO -   -> Created mutated offspring: 'Targeting G22553 for Enhanced Insulin Se...'
2026-02-10 21:21:26,685 - root - INFO - Crossover 2/18: parents 'Targeting Muscle-Specific Path...' x 'Comprehensive Multi-Target Str...'
2026-02-10 21:21:26,725 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:21:53,907 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:21:53,912 - root - INFO - TOKEN_USAGE: input=40332, output=826, total=41158, cost=$0.006545
2026-02-10 21:21:53,912 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:21:53,913 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver of insulin signaling pathways and has strong evidence supporting its role in enhancing glucose metabolism, making it a critical target for improving insulin sensitivity.
2. **G19943** | Score: 4.0 | As a hub component in metabolic regulation, G19943 coordinates metabolic processes and is essential for reinforcing the insulin signaling network, making it vital for the strategy.
3. **G23245** | Score: 4.0 | This gene significantly influences glucose uptake, complementing the actions of G22553 and G19943 to synergistically enhance insulin sensitivity.
4. **G00484** | Score: 4.0 | As a key transcription factor, G00484 enhances the expression of necessary genes for optimal insulin signaling, providing an important regulatory mechanism in the strategy.
5. **G33764** | Score: 4.0 | This enzyme supports metabolic regulation and reinforces the insulin signaling cascade, providing additional metabolic control, which is crucial for the overall approach.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes an integrated multi-target strategy focusing on G22553 as the primary target due to its central role in insulin signaling. By activating G22553 alongside G19943, G23245, G00484, and G33764, we aim to establish a more comprehensive and synergistic approach to enhance insulin sensitivity and improve glucose homeostasis in Type 2 Diabetes. The inclusion of G00484 addresses the need for transcriptional regulation, thus overcoming limitations seen in the parent hypotheses.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G22553 identified as a primary driver in the black module, indicating its central role in insulin signaling.
- Regulating TFs: G00484 is a significant transcription factor influencing insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G22553 and G19943 to enhance insulin action and glucose uptake in muscle tissues, while G00484 promotes the expression of key metabolic genes. G23245 facilitates glucose uptake, and G33764 reinforces the insulin signaling cascade, resulting in a robust improvement in insulin sensitivity. This comprehensive multi-target approach takes into account both direct signaling pathways and broader metabolic regulation.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle (for glucose uptake), liver (for glucose and lipid metabolism), and pancreatic -cells (for insulin production), all of which are integral to insulin action and glucose homeostasis. Targeting these tissues specifically is crucial for achieving significant therapeutic benefits in Type 2 Diabetes management.

**THERAPEUTIC_APPROACH:** The therapeutic approach involves the small molecule activation of G22553, G19943, and G33764, along with modulation of G00484 and G23245 to enhance their functions and improve metabolic outcomes in Type 2 Diabetes.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and lead to better management of Type 2 Diabetes, ultimately benefiting patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established critical roles in insulin signaling and metabolic pathways, their strong evidence across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role in insulin signaling, followed by G19943 for its coordination of metabolic processes, G23245 for its role in glucose uptake, and G00484 and G33764 for their regulatory and metabolic support.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with Type 2 Diabetes pathways and mechanisms.
2026-02-10 21:21:53,914 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:21:53,914 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:21:53,914 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:21:53,917 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:21:53,917 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy for Enh...'
2026-02-10 21:21:53,917 - root - INFO - Mutation 3/18: parent '** Enhanced Insulin Sensitivit...'
2026-02-10 21:21:53,917 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 21:21:53,953 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:22:27,801 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:22:27,805 - root - INFO - TOKEN_USAGE: input=39493, output=727, total=40220, cost=$0.006360
2026-02-10 21:22:27,805 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:22:27,805 - root - INFO - 
**TITLE:** Dual Modulation of Insulin Signaling Pathways for Enhanced -Cell Function in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways, crucial for glucose uptake and metabolism in islet cells, making it a strong candidate for activation to enhance glucose handling.
2. **G19943** | Score: 4.0 | A central hub in insulin signaling pathways that regulates -cell function and insulin secretion, maintaining its role as a key player in the proposed combination strategy.
3. **G23245** | Score: 4.0 | Essential for insulin sensitivity and glucose uptake, acting synergistically with G22553 to improve -cell responsiveness and overall metabolic control.
4. **G33764** | Score: 4.0 | Provides regulatory support within islet metabolic pathways, which can enhance the combined therapeutic efficacy through its modulatory function in islet cells.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis focuses on the activation of G22553 as a primary target alongside G19943 and G23245 to enhance insulin signaling and -cell function in Type 2 Diabetes. By employing a dual modulation strategy, we aim to optimize both glucose uptake and insulin secretion, thereby improving overall metabolic control in patients.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: None identified in this hypothesis.

**MECHANISM_HYPOTHESIS:** The proposed mechanism emphasizes the activation of G22553 as a primary driver in insulin signaling pathways, enhancing glucose uptake and -cell function. Coupled with G19943's role as a hub for insulin signaling and G23245's capacity to improve insulin sensitivity, this combination is expected to synergistically enhance insulin secretion and glucose metabolism. G33764 supports this regulatory network, ensuring comprehensive management of glucose homeostasis in pancreatic islets.

**TISSUE_RATIONALE:** The pancreatic islets are critical for insulin production and regulation of glucose homeostasis, making them the most relevant tissue for targeting these pathways. The proposed therapy aims to directly enhance insulin secretion and sensitivity in islet cells, addressing the key metabolic defects observed in Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** The therapeutic strategy involves the activation of selected targets using small molecules designed to enhance their activity, specifically targeting islet cells to restore normal insulin function and improve metabolic control.

**PREDICTED_OUTCOME:** The combined activation of these islet-specific targets is expected to lead to significantly enhanced insulin secretion, improved glucose metabolism, and better overall metabolic control in patients with Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their high priority scores, robust evidence from multiple datasets, and their critical roles in key biological pathways within pancreatic islets. G22553 is prioritized for its essential role in glucose uptake and metabolism, while G19943 and G23245 support this action for enhancing insulin secretion and sensitivity. G33764 is included to provide necessary regulatory support, enhancing the overall therapeutic strategy.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 21:22:27,805 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:22:27,806 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:22:27,806 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:22:27,807 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:22:27,808 - root - INFO -   -> Created mutated offspring: '** Dual Modulation of Insulin Signaling ...'
2026-02-10 21:22:27,808 - root - INFO - Crossover 4/18: parents 'Enhanced Insulin Sensitivity T...' x 'Integrated Targeting of G22553...'
2026-02-10 21:22:27,843 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:23:08,735 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:23:08,741 - root - INFO - TOKEN_USAGE: input=40328, output=762, total=41090, cost=$0.006506
2026-02-10 21:23:08,741 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:23:08,741 - root - INFO - 
### TITLE: Synergistic Targeting of Insulin Signaling Pathways for Enhanced Management of Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 directly enhances glucose metabolism and is crucial for improving insulin sensitivity.
2. **G19943** | Score: 4.0 | Identified as a central hub in insulin signaling, G19943 coordinates metabolic regulation, reinforcing the effects of G22553 and enhancing overall efficacy.
3. **G00484** | Score: 4.0 | This transcription factor plays a key role in regulating insulin signaling, providing essential transcriptional support to G22553 and G19943 to optimize their functions.
4. **G33764** | Score: 4.0 | As an enzyme supporting metabolic regulation, G33764 integrates into insulin signaling pathways and strengthens the overall therapeutic strategy.
5. **G23245** | Score: 4.0 | Critical for glucose uptake, G23245 synergizes with the other targets to enhance insulin sensitivity and improve glucose homeostasis.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a synergistic approach to enhance insulin sensitivity in Type 2 Diabetes (T2D) by targeting G22553 as the primary driver, complemented by G19943 and G00484. The inclusion of G33764 and G23245 adds depth to the mechanism, addressing the multifactorial aspects of T2D through robust modulation of key insulin signaling pathways.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G22553 is a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 enhances transcriptional regulation in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G22553 enhancing insulin signaling pathways to improve glucose metabolism directly. G19943 acts as a coordinator, amplifying the insulin signaling network's effects, while G00484 regulates the expression of genes necessary for maintaining insulin sensitivity. G33764 supports metabolic regulation, ensuring comprehensive management of T2D by facilitating glucose transport via G23245, which further enhances insulin sensitivity.

**TISSUE_RATIONALE:** Key tissues targeted include pancreatic -cells, muscle, liver, and adipose tissue, all critical for insulin action and glucose homeostasis. These tissues are integral for effective therapeutic interventions aimed at improving insulin sensitivity and glucose metabolism.

**THERAPEUTIC_APPROACH:** The strategy involves the activation of G22553 through small molecules to enhance its function, alongside modulation of G19943, G00484, G33764, and G23245 to strengthen insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating the selected targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to a better management of Type 2 Diabetes, ultimately restoring metabolic homeostasis.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling pathways, their strong evidence support across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role as a primary driver, followed by G19943 for its coordinating function, G00484 for transcriptional regulation, and G33764 and G23245 for their contributions to metabolic regulation and glucose uptake.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:23:08,742 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:23:08,742 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:23:08,742 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:23:08,745 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:23:08,745 - root - INFO -   -> Created offspring: 'Synergistic Targeting of Insulin Signali...'
2026-02-10 21:23:08,745 - root - INFO - Crossover 5/18: parents 'Comprehensive Multi-Target App...' x 'Synergistic Multi-Target Modul...'
2026-02-10 21:23:08,794 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:23:51,121 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:23:51,128 - root - INFO - TOKEN_USAGE: input=40373, output=754, total=41127, cost=$0.006508
2026-02-10 21:23:51,128 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:23:51,128 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | This gene serves as a central hub in insulin signaling pathways, enhancing metabolic regulation and an essential target for improving insulin sensitivity.
2. **G22553** | Score: 4.0 | A primary driver of insulin signaling, its activation complements G19943's function and is crucial for enhancing glucose metabolism.
3. **G23245** | Score: 4.0 | This gene is pivotal for glucose uptake and insulin sensitivity, reinforcing the therapeutic strategy alongside G19943 and G22553.
4. **G33764** | Score: 4.0 | Enhances metabolic regulation and supports insulin signaling, providing robustness to the multi-target approach.
5. **G00484** | Score: 4.0 | Functions as a transcription factor critical for regulating insulin signaling and glucose homeostasis, adding necessary regulatory depth.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes an integrated multi-target approach focusing on G19943 as the primary target. By leveraging the synergistic roles of G22553, G23245, G33764, and G00484, this strategy aims to enhance insulin signaling and glucose metabolism, addressing the multifactorial nature of Type 2 Diabetes more effectively than either parent hypothesis.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism, and inflammatory response pathways.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a significant regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G19943 acting as a central coordinator of insulin signaling and lipid metabolism, which is essential for restoring metabolic homeostasis in T2D. Activation of G22553 enhances insulin signaling pathways, while G23245 and G33764 contribute to glucose uptake and metabolic regulation. Concurrently, G00484 supports these processes by regulating transcriptional responses critical for insulin sensitivity, creating a comprehensive mechanism for managing T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells (for insulin production), muscle (for glucose uptake), liver (for glucose and lipid metabolism), and adipose tissue (for metabolic regulation), as they are integral to insulin action, glucose uptake, and overall metabolic homeostasis.

**THERAPEUTIC_APPROACH:** The strategy focuses on the activation of selected targets using small molecules designed to enhance their activity, aiming to restore normal metabolic function and improve insulin sensitivity specifically.

**PREDICTED_OUTCOME:** Effective modulation of these targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately reducing hyperglycemia and improving patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, their evidence strength across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role in coordinating insulin signaling, followed by G22553, which directly enhances insulin signaling. G23245 and G33764 provide important contributions to glucose uptake and metabolic regulation, while G00484 enhances the regulatory mechanisms necessary for optimal insulin sensitivity.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 21:23:51,129 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:23:51,130 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:23:51,130 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:23:51,133 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:23:51,133 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy for Enh...'
2026-02-10 21:23:51,133 - root - INFO - Crossover 6/18: parents 'Comprehensive Multi-Target Str...' x '** Integrated Targeting of Ins...'
2026-02-10 21:23:51,171 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:24:30,580 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:24:30,637 - root - INFO - TOKEN_USAGE: input=40385, output=766, total=41151, cost=$0.006517
2026-02-10 21:24:30,637 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:24:30,637 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 is crucial for maintaining pancreatic -cell function and glucose homeostasis.
2. **G22553** | Score: 4.0 | This gene enhances insulin signaling and glucose uptake, effectively complementing G19943's role in insulin production and action.
3. **G23245** | Score: 4.0 | A key regulator of glucose uptake, G23245 directly supports insulin response, making it essential for improving overall insulin sensitivity.
4. **G00484** | Score: 4.0 | This transcription factor regulates insulin signaling genes, ensuring effective insulin action in target tissues through transcriptional control.
5. **G33764** | Score: 4.0 | As an enhancer of metabolic regulation, G33764 supports insulin action, particularly in pancreatic islets, contributing to a robust metabolic framework.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis integrates insights from both parent hypotheses, emphasizing G19943 as the primary target. By leveraging the synergistic effects of G22553, G23245, G00484, and G33764, this multi-target strategy addresses the multifactorial nature of Type 2 Diabetes through a comprehensive approach to insulin signaling, glucose metabolism, and transcriptional regulation.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and transcriptional control.
- WGCNA module role: G19943 is identified as a hub component in modules negatively correlated with T2D, emphasizing its importance in islet function.
- Regulating TFs: G00484 is a significant transcription factor influencing insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G19943 coordinating insulin signaling and -cell survival, crucial for maintaining glucose homeostasis. Targeting G22553 enhances insulin signaling pathways, while G23245 facilitates glucose uptake. G00484 ensures the transcriptional response necessary for effective insulin production, and G33764 provides additional metabolic regulation support, collectively addressing both the signaling and metabolic dysfunctions observed in Type 2 Diabetes.

**TISSUE_RATIONALE:** The pancreatic islets, muscle, liver, and adipose tissues are central to insulin action and glucose homeostasis. These tissues are crucial for the proposed therapeutic interventions, as they are directly involved in insulin signaling, glucose uptake, and metabolic regulation.

**THERAPEUTIC_APPROACH:** The approach involves the activation of G19943 and G22553 using small molecules, alongside modulation of G23245, G00484, and G33764 to optimize metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly improve insulin sensitivity, enhance -cell function, and lead to better management of Type 2 Diabetes through improved glucose metabolism and overall metabolic health.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling and glucose metabolism, their strong evidence support across multiple datasets, and their potential for synergistic interactions in managing Type 2 Diabetes. G19943 is prioritized for its central role, followed by G22553 to enhance its function, with G23245, G00484, and G33764 providing necessary regulatory support.

**CONFIDENCE:** HIGH, based on robust data support, cross-dataset consistency, and significant associations with insulin signaling pathways and pancreatic islet function.
2026-02-10 21:24:30,638 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:24:30,638 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:24:30,638 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:24:30,640 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:24:30,641 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 21:24:30,641 - root - INFO - Crossover 7/18: parents 'Enhanced Insulin Sensitivity T...' x 'Targeting Muscle-Specific Path...'
2026-02-10 21:24:30,705 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:25:04,375 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:25:04,382 - root - INFO - TOKEN_USAGE: input=40329, output=768, total=41097, cost=$0.006510
2026-02-10 21:25:04,382 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:25:04,382 - root - INFO - 
**TITLE:** Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This gene is a primary driver in insulin signaling pathways specifically within muscle tissues, showing robust evidence for its critical role in glucose uptake and metabolic regulation.
2. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, G19943 enhances metabolic regulation within skeletal muscle, crucial for improving overall insulin sensitivity and glucose homeostasis.
3. **G33764** | Score: 4.0 | This enzyme plays a significant role in metabolic regulation in muscle tissue, providing complementary support to both G22553 and G19943 for enhanced insulin sensitivity.
4. **G00484** | Score: 4.0 | This transcription factor is essential for regulating insulin signaling pathways, offering transcriptional support to enhance the functions of G22553 and G19943.
5. **G19122** | Score: 3.0 | Serving as a major regulator of insulin signaling in muscle, G19122 significantly influences glucose metabolism, further optimizing the multi-target strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a comprehensive multi-target approach focusing on G22553 as the primary target due to its pivotal role in insulin signaling in muscle tissue. By integrating G19943, G33764, G00484, and G19122, the hypothesis aims to enhance insulin sensitivity and glucose metabolism through synergistic interactions among these targets, addressing the multifactorial nature of Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, muscle metabolism
- WGCNA module role: G22553 is identified as a primary driver in the black module, indicating its central role in muscle-related metabolic pathways.
- Regulating TFs: G00484 enhances transcriptional regulation in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves G22553 enhancing insulin receptor signaling and glucose uptake in muscle tissue. G19943 acts as a coordinator of metabolic responses, reinforcing the insulin signaling network, while G33764 supports metabolic regulation. G00484 provides essential transcriptional regulation for the expression of genes necessary to maintain insulin sensitivity, and G19122 enhances glucose metabolism, creating a robust interaction network for managing T2D.

**TISSUE_RATIONALE:** Skeletal muscle is the main site for insulin-mediated glucose uptake and metabolism, making it critical for improving insulin sensitivity and overall metabolic health in Type 2 Diabetes patients. Targeting this tissue specifically is expected to yield more pronounced therapeutic benefits.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves small molecule activation of G22553, G19943, and G33764 to improve insulin sensitivity and metabolic regulation in skeletal muscle.

**PREDICTED_OUTCOME:** Modulating these targets is expected to significantly enhance insulin sensitivity in skeletal muscle, leading to reduced blood glucose levels and improved metabolic control in Type 2 Diabetes patients, thereby enhancing overall patient outcomes.

**RANKING_RATIONALE:** The targets are ranked based on their established critical roles in insulin signaling and metabolic pathways in muscle, strong data support, and their potential for synergistic interactions. G22553 is prioritized for its central role, followed by G19943 and G33764 for their complementary functions in muscle metabolism, while G00484 and G19122 provide additional regulatory support.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:25:04,384 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:25:04,385 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:25:04,390 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:25:04,403 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:25:04,403 - root - INFO -   -> Created offspring: '** Integrated Multi-Target Strategy for ...'
2026-02-10 21:25:04,403 - root - INFO - Crossover 8/18: parents 'Integrated Targeting of G22553...' x '** Enhancing Insulin Sensitivi...'
2026-02-10 21:25:04,455 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:25:34,271 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:25:34,277 - root - INFO - TOKEN_USAGE: input=40315, output=754, total=41069, cost=$0.006500
2026-02-10 21:25:34,277 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:25:34,278 - root - INFO - 
**TITLE:** Synergistic Targeting of G22553, G19943, and G00484 for Optimal Insulin Sensitivity in Type 2 Diabetes 

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is essential for enhancing -cell function and overall insulin sensitivity.
2. **G19943** | Score: 4.0 | This gene acts as a hub component in the insulin signaling network, facilitating the coordination of insulin responses and enhancing metabolic regulation.
3. **G00484** | Score: 4.0 | As a key transcription factor, G00484 regulates insulin production and enhances the actions of G22553, making it vital for optimizing insulin signaling in pancreatic islets.
4. **G23245** | Score: 4.0 | Important for glucose uptake, G23245 complements G22553 and G00484 by ensuring that insulin signaling translates effectively to improved glucose metabolism.
5. **G33764** | Score: 4.0 | This gene supports metabolic regulation and insulin signaling pathways, further strengthening the therapeutic strategy by enhancing insulin sensitivity.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis emphasizes a synergistic approach to enhance insulin sensitivity in Type 2 Diabetes by prioritizing G22553 as the primary target, supported by the roles of G19943 and G00484. The integration of these targets aims to optimize -cell function and improve glucose metabolism through comprehensive modulation of insulin signaling pathways.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and transcriptional regulation.
- WGCNA module role: G22553 identified as a primary driver in insulin signaling-related modules.
- Regulating TFs: G00484 plays a significant regulatory role in insulin synthesis and signaling in islets.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that targeting G22553 will significantly enhance insulin signaling pathways, leading to improved -cell function and glucose metabolism. The transcription factor G00484 will augment this effect by regulating insulin production, while G19943 will coordinate and optimize insulin signaling. Additionally, G23245's role in glucose uptake will facilitate the action of insulin, and G33764 will provide metabolic support, addressing potential dysregulation in islet function.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic islets, muscle, liver, and adipose tissue, which are critical for insulin action and glucose homeostasis. Targeting these tissues is essential for effective therapeutic interventions aimed at improving insulin sensitivity.

**THERAPEUTIC_APPROACH:** The strategy involves the activation of G22553 through small molecules to enhance its function, coupled with the modulation of G19943, G00484, G23245, and G33764 to collectively strengthen insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating these targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately aiming for restored metabolic homeostasis.

**RANKING_RATIONALE:** The targets were ranked based on their established roles in insulin signaling pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role as a primary driver, followed closely by G19943 and G00484 for their complementary functions in enhancing insulin sensitivity.

**CONFIDENCE:** HIGH, based on strong evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:25:34,280 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:25:34,280 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:25:34,281 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:25:34,283 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:25:34,283 - root - INFO -   -> Created offspring: '** Synergistic Targeting of G22553, G199...'
2026-02-10 21:25:34,284 - root - INFO - Mutation 9/18: parent 'Integrated Multi-Target Approa...'
2026-02-10 21:25:34,284 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 21:25:34,330 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:26:07,038 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:26:07,044 - root - INFO - TOKEN_USAGE: input=39535, output=757, total=40292, cost=$0.006384
2026-02-10 21:26:07,044 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:26:07,044 - root - INFO - 
### TITLE: Alternative Multi-Target Strategy for Enhancing Insulin Signaling and Glucose Homeostasis in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G04436** | Score: 4.0 | This enzyme is crucial for lipid metabolism, which is essential for promoting insulin sensitivity and complements insulin signaling pathways.
2. **G00484** | Score: 4.0 | As a transcription factor, it plays a key role in the regulation of insulin signaling and glucose homeostasis, directly impacting metabolic pathways.
3. **G22553** | Score: 4.0 | This gene supports insulin signaling and glucose uptake, acting synergistically with other metabolic regulators.
4. **G23245** | Score: 4.0 | This driver of glucose uptake enhances insulin signaling efficiency, which is critical for improving metabolic outcomes in T2D.
5. **G33764** | Score: 4.0 | An enzyme that contributes to metabolic regulation and has been identified as a primary driver in insulin-related pathways.

#### PRIMARY_TARGET: G04436

### SUMMARY:
This hypothesis proposes a refined multi-target strategy emphasizing G04436's role in lipid metabolism while integrating G00484's transcriptional regulation of insulin signaling and glucose homeostasis. By also incorporating G22553, G23245, and G33764, this approach aims to enhance insulin sensitivity and promote a robust metabolic response in Type 2 Diabetes patients.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G04436)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- **WGCNA module role**: G04436 identified as a key driver in T2D-related pathways.
- **Regulating TFs**: Several transcription factors involved, enhancing regulatory complexity.

### MECHANISM_HYPOTHESIS:
The proposed mechanism emphasizes G04436 as a central player in lipid metabolism, which is critical for enhancing insulin sensitivity. G00484 will enhance the transcriptional regulation of genes involved in insulin action and glucose homeostasis. Meanwhile, G22553 and G23245 will further promote glucose uptake and insulin signaling efficiency, creating a comprehensive therapeutic framework for enhancing metabolic health in Type 2 Diabetes.

### TISSUE_RATIONALE:
The primary tissues targeted include the liver, muscle, and adipose tissue, which are pivotal for lipid and glucose homeostasis. Targeting these tissues will enhance insulin sensitivity and overall metabolic health in patients with Type 2 Diabetes.

### THERAPEUTIC_APPROACH:
The therapeutic strategy will involve the activation of G04436 and G00484 through small molecule modulators, while also enhancing the activities of G22553 and G23245 to optimize metabolic regulation and improve insulin sensitivity.

### PREDICTED_OUTCOME:
Modulating these targets is expected to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, and enhanced overall management of Type 2 Diabetes, ultimately resulting in better patient outcomes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles in insulin signaling and metabolic pathways, alongside strong data support across multiple evidence types. G04436 was prioritized for its essential role in lipid metabolism, followed by G00484 for its regulatory capacity, and G22553 for its contributions to insulin signaling and glucose uptake. G23245 and G33764 were included for their synergistic effects in enhancing metabolic regulation.

### CONFIDENCE: HIGH
This hypothesis is supported by robust data across multiple evidence types, demonstrating the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 21:26:07,046 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:26:07,046 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:26:07,049 - root - INFO -   -> Created mutated offspring: 'Alternative Multi-Target Strategy for En...'
2026-02-10 21:26:07,049 - root - INFO - Crossover 10/18: parents 'Integrated Targeting of G22553...' x '** Enhancing Insulin Sensitivi...'
2026-02-10 21:26:07,082 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:26:21,990 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:26:21,992 - root - INFO - TOKEN_USAGE: input=40315, output=755, total=41070, cost=$0.006500
2026-02-10 21:26:21,992 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:26:21,992 - root - INFO - 
**TITLE:** Comprehensive Targeting of G22553, G19943, and G00484 to Enhance Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is crucial for enhancing -cell function and overall insulin sensitivity.
2. **G19943** | Score: 4.0 | This gene acts as a hub component in insulin signaling, coordinating multiple responses to insulin, which is vital for effective metabolic regulation.
3. **G00484** | Score: 4.0 | This transcription factor regulates insulin production and enhances the function of both G22553 and G19943, making it integral to the therapeutic strategy.
4. **G23245** | Score: 4.0 | Important for glucose uptake, G23245 ensures that insulin signaling effectively translates into improved glucose metabolism, thereby complementing the effects of G22553.
5. **G33764** | Score: 4.0 | By supporting metabolic regulation within the pancreatic islets, G33764 contributes to overall insulin sensitivity and metabolic homeostasis.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis integrates key insights from both parent hypotheses, focusing on the synergistic actions of G22553, G19943, and G00484 to enhance insulin sensitivity and -cell function in Type 2 Diabetes. By leveraging their roles in insulin signaling and glucose metabolism, this approach aims to provide a more robust therapeutic strategy compared to the individual hypotheses.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and -cell function.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 plays a significant regulatory role in insulin synthesis and signaling.

**MECHANISM_HYPOTHESIS:** The proposed mechanism hypothesizes that targeting G22553 will enhance insulin signaling pathways, directly improving glucose metabolism within pancreatic islets. G19943 will function as a signaling hub, ensuring coordinated insulin responses, while G00484 will regulate insulin production. Additionally, G23245 will facilitate glucose uptake, enhancing the effectiveness of insulin action, and G33764 will support metabolic regulation, addressing potential dysregulation within islet function.

**TISSUE_RATIONALE:** The relevant tissues include pancreatic islets, muscle, liver, and adipose tissue, as they are critical for insulin action and glucose homeostasis. Targeting these tissues is essential for effective therapeutic interventions aimed at improving insulin sensitivity.

**THERAPEUTIC_APPROACH:** The strategy involves the activation of G22553 through small molecules to enhance its function, alongside modulation of G19943, G00484, G23245, and G33764 to collectively enhance insulin signaling and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and better management of Type 2 Diabetes, ultimately aiming for restored metabolic homeostasis.

**RANKING_RATIONALE:** The targets were ranked based on their established roles in insulin signaling pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role as a primary driver, followed by G19943 and G00484 for their complementary functions within the insulin signaling network.

**CONFIDENCE:** HIGH, based on strong evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:26:21,992 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:26:21,992 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:26:21,993 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:26:21,993 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:26:21,994 - root - INFO -   -> Created offspring: '** Comprehensive Targeting of G22553, G1...'
2026-02-10 21:26:21,994 - root - INFO - Crossover 11/18: parents 'Integrated Multi-Target Strate...' x 'Comprehensive Multi-Target Str...'
2026-02-10 21:26:22,028 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:27:05,207 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:27:05,213 - root - INFO - TOKEN_USAGE: input=40376, output=794, total=41170, cost=$0.006533
2026-02-10 21:27:05,213 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:27:05,213 - root - INFO - 
### TITLE: Comprehensive Multi-Target Approach for Improved Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: **4.0** | Identified as a central hub in metabolic pathways, integrating insulin signaling and lipid metabolism, crucial for enhancing metabolic regulation.
2. **G04436** | Score: **4.0** | A critical enzyme in lipid metabolism with established roles in enhancing insulin sensitivity and glucose regulation, reinforcing the therapeutic strategy.
3. **G22553** | Score: **4.0** | A primary driver in insulin signaling pathways, essential for enhancing glucose metabolism and complementing the roles of G19943 and G04436.
4. **G23245** | Score: **4.0** | A key player in insulin signaling that significantly influences glucose uptake, enhancing the overall effectiveness of the multi-target strategy.
5. **G33764** | Score: **4.0** | Provides regulatory support within metabolic pathways, ensuring a robust therapeutic approach to tackle insulin resistance.

**PRIMARY_TARGET:** G19943

### SUMMARY:
This hypothesis proposes a comprehensive multi-target strategy that emphasizes G19943 as the primary target due to its pivotal role as a metabolic hub. The integration of G04436, G22553, G23245, and G33764 enables a synergistic approach to enhance insulin sensitivity and overall metabolic control, addressing the weaknesses identified in previous hypotheses and ensuring a more robust treatment pathway.

### DATA_EVIDENCE:
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, lipid metabolism, glucose metabolism, and overall metabolic regulation.
- **WGCNA module role:** G19943 identified as a hub component in the negatively correlated T2D module, indicating its critical role in T2D pathology.
- **Regulating TFs:** G04436 is associated with multiple transcription factors, enhancing the robustness of the regulatory network.

### MECHANISM_HYPOTHESIS:
The proposed mechanism suggests that activation of G19943 will significantly enhance metabolic regulation through improved insulin signaling and lipid metabolism. Concurrent modulation of G04436 will optimize lipid profiles, while G22553 and G23245 will enhance glucose uptake and metabolism, respectively. G33764 provides additional regulatory support, ensuring a comprehensive multi-target strategy that effectively addresses insulin resistance in Type 2 Diabetes.

### TISSUE_RATIONALE:
The targeted tissues include adipose tissue, liver, and skeletal muscle, which are essential for effective insulin action, glucose uptake, and lipid metabolism. Focusing on these tissues will maximize therapeutic effects, facilitating a robust strategy to reverse metabolic dysregulation associated with Type 2 Diabetes, ultimately improving patient outcomes.

### THERAPEUTIC_APPROACH:
The strategy will involve small molecule activators that enhance the functions of the selected targets to restore normal metabolic function and improve insulin sensitivity.

### PREDICTED_OUTCOME:
Modulation of these targets is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and overall metabolic control, resulting in better management of Type 2 Diabetes symptoms and potentially reversing disease progression.

### RANKING_RATIONALE:
Targets were ranked based on their established roles as primary drivers in T2D pathways, their strength of evidence across multiple datasets, and their potential for synergistic interactions. G19943 was prioritized for its central role in metabolic regulation, while G04436 and G22553 were included for their significant contributions to lipid metabolism and insulin signaling, respectively. G23245 and G33764 were included for their essential roles in glucose uptake and metabolic regulation.

### CONFIDENCE: HIGH
This hypothesis is built on robust data support across multiple evidence types, demonstrating the essential roles of the selected targets in managing Type 2 Diabetes effectively.
2026-02-10 21:27:05,216 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:27:05,217 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:27:05,217 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:27:05,220 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:27:05,220 - root - INFO -   -> Created offspring: 'Comprehensive Multi-Target Approach for ...'
2026-02-10 21:27:05,220 - root - INFO - Crossover 12/18: parents 'Targeting G22553 for Enhanced ...' x 'Targeting G22553 for Enhanced ...'
2026-02-10 21:27:05,291 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:27:46,878 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:27:46,884 - root - INFO - TOKEN_USAGE: input=40303, output=775, total=41078, cost=$0.006510
2026-02-10 21:27:46,884 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:27:46,884 - root - INFO - 
### TITLE: Integrative Targeting of G22553 and Synergistic Pathway Modulation for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | Prioritized for its critical role as a primary driver in insulin signaling pathways, with strong evidence from multiple datasets.
2. **G00484** | Score: 4.0 | Acts as a transcription factor that regulates insulin signaling, providing essential support to G22553s actions and enhancing glucose homeostasis.
3. **G23245** | Score: 4.0 | Recognized as a primary driver in glucose uptake, complementing the action of G22553 and G00484 to enhance overall insulin sensitivity.
4. **G33764** | Score: 4.0 | A key regulator in metabolic pathways that supports G22553's function, thereby reinforcing the integrated approach for managing T2D.
5. **G19943** | Score: 4.0 | Although initially a hub component, it complements the synergistic effects of G22553 and the other targets, ensuring a comprehensive therapeutic strategy.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a multi-target approach focusing on G22553 as the primary target in enhancing insulin sensitivity for Type 2 Diabetes management. Complementary targets, including G00484, G23245, and G33764, are integrated to address the multifactorial nature of T2D. This strategy is anticipated to leverage synergistic interactions in insulin signaling and glucose metabolism for improved therapeutic outcomes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, metabolic regulation, and lipid metabolism pathways.
- WGCNA module role: G22553 identified as a primary driver in a module positively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** Targeting G22553 is hypothesized to enhance insulin signaling pathways, thereby directly improving glucose metabolism. The involvement of G00484 as a transcription factor will amplify the regulatory effects on insulin signaling and glucose homeostasis. Additionally, G23245's role in glucose uptake will synergize with G22553s function, while G33764 will enhance metabolic regulation, collectively providing a robust mechanism for T2D management.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, which are critical for insulin action and glucose homeostasis. These tissues are essential for the proposed therapeutic interventions, as they directly influence insulin sensitivity and glucose metabolism.

**THERAPEUTIC_APPROACH:** The proposed approach involves the small molecule activation of G22553 to enhance its functions while modulating G00484, G23245, and G33764 to strengthen metabolic regulation and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of G22553 and its synergistic targets is expected to significantly improve insulin sensitivity and enhance glucose metabolism, leading to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its critical role in insulin signaling, followed by G00484, which complements its function, while G23245 and G33764 provide essential support, with G19943 enhancing the overall strategy.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 21:27:46,886 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:27:46,886 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:27:46,886 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:27:46,889 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:27:46,889 - root - INFO -   -> Created offspring: 'Integrative Targeting of G22553 and Syne...'
2026-02-10 21:27:46,890 - root - INFO - Crossover 13/18: parents 'Comprehensive Multi-Target Str...' x 'Synergistic Multi-Target Modul...'
2026-02-10 21:27:46,949 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:28:02,954 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:28:02,957 - root - INFO - TOKEN_USAGE: input=40316, output=774, total=41090, cost=$0.006512
2026-02-10 21:28:02,957 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:28:02,957 - root - INFO - 
### TITLE: Integrated Multi-Target Modulation for Optimized Insulin Sensitivity and Metabolic Regulation in Type 2 Diabetes

#### RANKED_TARGETS:
1. **G19943** | Score: 4.0 | This target serves as a central hub in T2D pathways, crucial for integrating insulin signaling and metabolic regulation.
2. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways, enhancing glucose metabolism and complementing the function of G19943.
3. **G04436** | Score: 4.0 | This enzyme is fundamental in lipid metabolism, significantly impacting insulin sensitivity and glucose homeostasis.
4. **G23245** | Score: 4.0 | A pivotal driver of glucose uptake and insulin sensitivity, reinforcing the therapeutic effects of the other targets.
5. **G33764** | Score: 4.0 | This enzyme enhances metabolic regulation and supports insulin signaling, providing robustness to the overall strategy.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes an integrated multi-target approach combining insights from both parent hypotheses by prioritizing G19943 as the primary target, which serves as a regulatory hub in insulin signaling. The synergistic roles of G22553, G04436, G23245, and G33764 enhance the therapeutic strategy by optimizing insulin sensitivity, glucose metabolism, and lipid regulation, addressing the multifactorial nature of Type 2 Diabetes.

**DATA_EVIDENCE:**
- **Priority Score:** 4.0/17 for primary target
- **Cross-dataset consistency:** Yes, 2 datasets
- **Key pathways involved:** Insulin signaling, glucose metabolism, lipid metabolism, and metabolic regulation pathways.
- **WGCNA module role:** G19943 identified as a hub component in modules negatively correlated with T2D, reinforcing its central role.
- **Regulating TFs:** None identified for G19943, but G00484 acts as a regulator in insulin signaling pathways, enhancing the overall mechanism.

**MECHANISM_HYPOTHESIS:** The proposed mechanism focuses on activating G19943 to coordinate insulin signaling and lipid metabolism, restoring metabolic homeostasis in Type 2 Diabetes. Concurrent activation of G22553 will enhance insulin signaling pathways, while G04436 and G23245 will facilitate glucose uptake and improve lipid metabolism. G33764 provides additional regulatory support, ensuring a comprehensive therapeutic strategy that addresses key pathways essential for effective diabetes management.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, which are central to glucose homeostasis and insulin action. Targeting these tissues will maximize the therapeutic effects on insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

**THERAPEUTIC_APPROACH:** The strategy involves small molecule modulation aimed at enhancing the activity of the selected targets (G19943, G22553, G04436, G23245, and G33764) to improve insulin sensitivity and metabolic regulation.

**PREDICTED_OUTCOME:** Modulating these targets is anticipated to lead to significant improvements in insulin sensitivity, reductions in blood glucose levels, enhanced lipid metabolism, and overall better management of Type 2 Diabetes, ultimately improving patient outcomes.

**RANKING_RATIONALE:** The targets were ranked based on their critical roles in insulin signaling and metabolic pathways, strong data support, and their ability to synergistically enhance overall therapeutic efficacy. G19943 was prioritized for its established importance as a regulatory hub, followed by G22553 for its role in insulin signaling, while G04436, G23245, and G33764 provide essential support in metabolic regulation.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and the relevance of identified pathways to Type 2 Diabetes pathology.
2026-02-10 21:28:02,957 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:28:02,958 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:28:02,958 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:28:02,959 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:28:02,959 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Modulation for O...'
2026-02-10 21:28:02,959 - root - INFO - Crossover 14/18: parents 'Comprehensive Multi-Target Str...' x 'Synergistic Multi-Target Modul...'
2026-02-10 21:28:02,994 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:28:41,050 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:28:41,056 - root - INFO - TOKEN_USAGE: input=40341, output=724, total=41065, cost=$0.006486
2026-02-10 21:28:41,056 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:28:41,057 - root - INFO - 
### TITLE: Enhanced Multi-Target Modulation for Optimal Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G19943** | Score: 4.0 | Serves as a central hub in insulin signaling pathways, crucial for coordinating metabolic processes and enhancing insulin action.
2. **G22553** | Score: 4.0 | Functions as a primary driver in insulin signaling pathways, directly modulating glucose metabolism and complementing G19943's effects.
3. **G23245** | Score: 4.0 | Acts as a pivotal driver in glucose uptake, reinforcing insulin sensitivity by facilitating glucose transport into cells.
4. **G00484** | Score: 4.0 | A key transcription factor that regulates the expression of insulin signaling-related genes, thereby enhancing metabolic outcomes.
5. **G33764** | Score: 4.0 | Supports metabolic regulation and enhances the overall insulin signaling cascade, providing additional regulatory support.

**PRIMARY_TARGET:** G19943

**SUMMARY:** This hypothesis proposes a synergistic multi-target approach for enhancing insulin sensitivity in Type 2 Diabetes by focusing on G19943 as the primary target. By integrating insights from both parent hypotheses, this comprehensive strategy leverages the central role of G19943 in insulin signaling, complemented by G22553, G23245, G00484, and G33764 to address the multifactorial nature of the disease.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, lipid metabolism.
- WGCNA module role: G19943 identified as a hub component in modules negatively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism integrates the activation of G19943 and G22553 to enhance insulin signaling pathways, leading to improved glucose metabolism. G23245 facilitates glucose uptake, while G00484 ensures the expression of critical metabolic genes, with G33764 providing additional regulatory support to reinforce these processes. This comprehensive approach targets direct signaling pathways and broader metabolic regulation, aiming for a robust improvement in insulin sensitivity in T2D.

**TISSUE_RATIONALE:** Relevant tissues include pancreatic -cells, muscle, liver, and adipose tissue, as they play crucial roles in insulin action, glucose uptake, and overall metabolic homeostasis, making them optimal targets for therapeutic interventions.

**THERAPEUTIC_APPROACH:** The therapeutic approach involves the activation of G19943 and G22553 using small molecules to enhance their functions, alongside modulation of G23245, G00484, and G33764 to further improve insulin sensitivity and metabolic outcomes.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to lead to significantly improved insulin sensitivity, enhanced glucose metabolism, and more effective management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling pathways, their strength of evidence across multiple datasets, and their potential for synergistic interactions. G19943 is prioritized for its central role, followed by G22553, which enhances its function, while G23245, G00484, and G33764 provide essential regulatory support.

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:28:41,058 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:28:41,058 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:28:41,066 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:28:41,070 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:28:41,070 - root - INFO -   -> Created offspring: 'Enhanced Multi-Target Modulation for Opt...'
2026-02-10 21:28:41,071 - root - INFO - Mutation 15/18: parent 'Enhanced Insulin Sensitivity T...'
2026-02-10 21:28:41,071 - root - INFO - T2D mutation using strategy: therapeutic_pivot
2026-02-10 21:28:41,149 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:29:22,523 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:29:22,529 - root - INFO - TOKEN_USAGE: input=39547, output=763, total=40310, cost=$0.006390
2026-02-10 21:29:22,530 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:29:22,530 - root - INFO - 
**TITLE:** Synergistic Activation of Insulin Signaling Pathways for Enhanced Glucose Regulation in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | This target serves as a primary driver in insulin signaling, and its activation could significantly enhance insulin receptor signaling and glucose uptake in target tissues.
2. **G19943** | Score: 4.0 | As a central hub in insulin signaling pathways, activating G19943 can coordinate multiple metabolic processes to improve insulin sensitivity.
3. **G00484** | Score: 4.0 | Modulating this transcription factor can enhance the expression of genes critical for insulin signaling, supporting the synergistic approach alongside G22553.
4. **G33764** | Score: 4.0 | Activating this enzyme can support metabolic regulation, ensuring robust interactions with other targets in the insulin signaling network.
5. **G23245** | Score: 4.0 | This target, vital for glucose uptake, can further enhance the effects of activated G22553 and G19943, promoting glucose transport into cells.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This mutated hypothesis proposes a synergistic activation strategy focusing on G22553 as the primary target due to its role as a primary driver in insulin signaling. By activating G19943, G00484, G33764, and G23245, we aim to create a comprehensive approach that harnesses their collective effects to enhance insulin sensitivity and facilitate glucose homeostasis in Type 2 Diabetes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G22553 is identified as a primary driver in modules positively correlated with insulin sensitivity.
- Regulating TFs: G00484 can enhance the transcriptional regulation of insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** The proposed mechanism involves the activation of G22553 to enhance insulin receptor signaling, leading to increased glucose uptake and metabolism. G19943 will further coordinate and amplify these effects across multiple pathways. G00484 will regulate the expression of critical genes for maintaining insulin sensitivity. By activating G33764, we ensure metabolic homeostasis, while G23245 facilitates glucose transport, creating a robust network effect for managing Type 2 Diabetes.

**TISSUE_RATIONALE:** Key tissues include muscle, liver, and adipose tissue, which are critical for effective insulin action and glucose homeostasis. These tissues are particularly relevant for the proposed therapeutic interventions due to their roles in glucose uptake and metabolism.

**THERAPEUTIC_APPROACH:** The proposed approach involves small molecule activation of G22553 and G19943 to enhance their functions, while modulating G00484, G33764, and G23245 to synergistically improve metabolic regulation and insulin sensitivity.

**PREDICTED_OUTCOME:** Effective modulation of the selected targets is expected to significantly enhance insulin sensitivity, improve glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their established roles in insulin signaling pathways, the strength of evidence across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role as a primary driver in insulin signaling, followed by G19943 for its coordinating function, while G00484, G33764, and G23245 provide essential regulatory and metabolic support. 

**CONFIDENCE:** HIGH, based on strong multi-evidence support and significant associations with T2D pathways and mechanisms.
2026-02-10 21:29:22,531 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:29:22,532 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:29:22,533 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:29:22,539 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:29:22,539 - root - INFO -   -> Created mutated offspring: '** Synergistic Activation of Insulin Sig...'
2026-02-10 21:29:22,539 - root - INFO - Crossover 16/18: parents 'Targeting G22553 for Enhanced ...' x 'Targeting Muscle-Specific Path...'
2026-02-10 21:29:22,615 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:29:58,672 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:29:58,677 - root - INFO - TOKEN_USAGE: input=40302, output=754, total=41056, cost=$0.006498
2026-02-10 21:29:58,677 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:29:58,677 - root - INFO - 
### TITLE: Integrated Targeting of G22553 and Muscle Pathways for Enhanced Insulin Sensitivity in Type 2 Diabetes

**RANKED_TARGETS:**
1. **G22553** | Score: 4.0 | As a primary driver in insulin signaling pathways, G22553 is essential for enhancing glucose uptake and insulin sensitivity in muscle tissue.
2. **G19943** | Score: 4.0 | This hub component supports metabolic regulation, reinforcing the actions of G22553 in maintaining glucose homeostasis.
3. **G23245** | Score: 4.0 | A pivotal driver of glucose uptake, G23245 synergizes with G22553 and G19943 to bolster insulin sensitivity specifically in muscle tissues.
4. **G00484** | Score: 4.0 | As a transcription factor, G00484 plays a regulatory role in insulin signaling, supporting G22553's function and enhancing overall glucose metabolism.
5. **G33764** | Score: 4.0 | This enzyme contributes to metabolic regulation and complements the signaling pathways driven by G22553 and its synergistic targets.

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a multi-targeted approach focusing on G22553 as the primary target for enhancing insulin sensitivity in Type 2 Diabetes. By integrating G19943, G23245, G00484, and G33764, we aim to create a robust therapeutic strategy that addresses the multifactorial nature of T2D, particularly focusing on the critical role of muscle tissues in glucose metabolism.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling pathways, glucose metabolism, muscle metabolism.
- WGCNA module role: G22553 identified as a primary driver in modules positively correlated with T2D.
- Regulating TFs: G00484 acts as a regulator in insulin signaling pathways.

**MECHANISM_HYPOTHESIS:** Targeting G22553 is hypothesized to enhance insulin signaling and glucose metabolism specifically in skeletal muscle tissue, leading to improved insulin sensitivity. The integration of G19943 will enhance metabolic responses, while G23245 will facilitate glucose uptake. G00484 serves as a transcription factor that amplifies insulin signaling, and G33764 contributes to metabolic regulation, collectively providing a comprehensive mechanism for addressing T2D.

**TISSUE_RATIONALE:** Skeletal muscle is the primary site for insulin-mediated glucose uptake and metabolism, making it crucial for improving insulin sensitivity and overall metabolic health in Type 2 Diabetes patients. Focusing on muscle tissue is expected to yield pronounced therapeutic benefits.

**THERAPEUTIC_APPROACH:** The proposed therapeutic strategy involves the small molecule activation of G22553, along with modulation of G19943, G23245, G00484, and G33764 to enhance insulin sensitivity and metabolic regulation in skeletal muscle.

**PREDICTED_OUTCOME:** Effective modulation of G22553 and its synergistic targets is expected to significantly improve insulin sensitivity, enhance glucose metabolism, and lead to better management of Type 2 Diabetes.

**RANKING_RATIONALE:** The targets are ranked based on their critical roles in the insulin signaling and metabolic pathways, supported by strong data across multiple evidence types. G22553 is prioritized for its essential function, followed by G19943 and G23245 due to their supportive roles in muscle metabolism, and G00484 and G33764 for their regulatory contributions.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 21:29:58,677 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:29:58,677 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:29:58,677 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:29:58,679 - root - WARNING - Crossover produced invalid target: 
2026-02-10 21:29:58,679 - root - INFO -   -> Created offspring: 'Integrated Targeting of G22553 and Muscl...'
2026-02-10 21:29:58,680 - root - INFO - Mutation 17/18: parent '** Synergistic Targeting of Me...'
2026-02-10 21:29:58,680 - root - INFO - T2D mutation using strategy: alternative_target
2026-02-10 21:29:58,716 - root - INFO - ===T2D_MUTATION_START===
2026-02-10 21:30:36,992 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:30:36,999 - root - INFO - TOKEN_USAGE: input=39601, output=771, total=40372, cost=$0.006403
2026-02-10 21:30:36,999 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:30:36,999 - root - INFO - 
**TITLE:** Alternative Targeting of G22553 for Enhanced Insulin Sensitivity in Type 2 Diabetes Management

**RANKED_TARGETS:**
1. **G22553 | Score: 4.0 | This gene is a primary driver of glucose uptake and insulin signaling, making it essential for improving insulin sensitivity and glucose metabolism.**
2. **G00484 | Score: 4.0 | As a transcription factor, G00484 enhances the regulation of insulin signaling pathways, providing complementary support to G22553.**
3. **G33764 | Score: 4.0 | This enzyme plays a significant role in metabolic regulation, reinforcing the actions of G22553 to ensure effective insulin action and glucose homeostasis.**
4. **G19122 | Score: 3.0 | G19122's role as a major regulator of insulin signaling in muscle tissue offers important support for the overall strategy aimed at enhancing insulin sensitivity.**
5. **G04436 | Score: 4.0 | As an enzyme, G04436 has the potential to impact metabolic pathways relevant to insulin signaling, making it a valuable addition to the therapeutic strategy.**

**PRIMARY_TARGET:** G22553

**SUMMARY:** This hypothesis proposes a strategic focus on G22553 as the primary target for enhancing insulin sensitivity in Type 2 Diabetes. By leveraging its role in glucose uptake and insulin signaling, this approach aims to synergistically integrate the actions of G00484, G33764, G19122, and G04436 to address the multifaceted nature of insulin resistance and improve metabolic outcomes.

**DATA_EVIDENCE:**
- Priority Score: 4.0/17 for primary target
- Cross-dataset consistency: Yes, 2 datasets
- Key pathways involved: Insulin signaling, glucose metabolism, and metabolic regulation pathways.
- WGCNA module role: G22553 is identified as a primary driver in positively correlated modules.
- Regulating TFs: G00484 enhances regulatory mechanisms in insulin signaling.

**MECHANISM_HYPOTHESIS:** The proposed mechanism focuses on activating G22553 to enhance glucose uptake and insulin signaling directly, addressing the core issues of insulin resistance in Type 2 Diabetes. G00484 will support this mechanism through transcriptional regulation, while G33764 will reinforce metabolic regulation to ensure effective insulin action. G19122 will provide additional regulatory support specifically in muscle tissue, and G04436 will contribute to the broader metabolic pathway interactions, creating a robust multi-target therapeutic strategy.

**TISSUE_RATIONALE:** The relevant tissues include skeletal muscle, liver, and adipose tissue, as these are critical sites for insulin action, glucose uptake, and lipid metabolism. Targeting these tissues is essential for reversing metabolic dysregulation associated with Type 2 Diabetes.

**THERAPEUTIC_APPROACH:** This strategy will involve the development of small molecule activators for G22553 and its supporting targets, aiming to restore normal metabolic functions and improve insulin sensitivity.

**PREDICTED_OUTCOME:** Modulation of G22553, along with its supporting partners, is expected to lead to significant improvements in insulin sensitivity, enhanced glucose metabolism, and better overall metabolic control, thus contributing to improved management of Type 2 Diabetes symptoms and potential reversal of disease progression.

**RANKING_RATIONALE:** The targets are ranked based on their established roles as primary drivers in T2D pathways, evidence strength across multiple datasets, and their potential for synergistic interactions. G22553 is prioritized for its central role in glucose uptake and insulin signaling, while G00484, G33764, G19122, and G04436 provide essential complementary support.

**CONFIDENCE:** HIGH, based on strong support from multi-evidence and significant associations with T2D pathways and mechanisms.
2026-02-10 21:30:37,000 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:30:37,001 - root - INFO - ===T2D_MUTATION_END===
2026-02-10 21:30:37,001 - root - WARNING - Could not extract target_gene_masked from evolved hypothesis - evaluation metrics may be affected
2026-02-10 21:30:37,003 - root - WARNING - Mutation produced invalid target: 
2026-02-10 21:30:37,004 - root - INFO -   -> Created mutated offspring: '** Alternative Targeting of G22553 for E...'
2026-02-10 21:30:37,004 - root - INFO - Crossover 18/18: parents 'Targeting Muscle-Specific Path...' x 'Integrated Multi-Target Approa...'
2026-02-10 21:30:37,041 - root - INFO - ===T2D_CROSSOVER_START===
2026-02-10 21:31:09,633 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:31:09,640 - root - INFO - TOKEN_USAGE: input=40350, output=777, total=41127, cost=$0.006519
2026-02-10 21:31:09,640 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:31:09,641 - root - INFO - 
### TITLE: Integrated Multi-Target Strategy to Enhance Insulin Sensitivity through Muscle and Regulatory Pathways in Type 2 Diabetes Management

#### RANKED_TARGETS:
1. **G22553** | Score: 4.0 | A primary driver in insulin signaling pathways critical for glucose metabolism, with strong support across datasets.
2. **G19943** | Score: 4.0 | Serves as a hub component in metabolic pathways, essential for integrating multiple signals to enhance insulin sensitivity.
3. **G00484** | Score: 4.0 | A key transcription factor that regulates insulin signaling, providing necessary regulatory support to G22553's action.
4. **G23245** | Score: 4.0 | A pivotal driver in glucose uptake and insulin sensitivity, complementing the functions of G22553.
5. **G33764** | Score: 4.0 | Contributes regulatory support within metabolic pathways, reinforcing the multi-target strategy for T2D management.

#### PRIMARY_TARGET: G22553

### SUMMARY:
This hypothesis proposes a comprehensive multi-target strategy that emphasizes the critical role of G22553 in insulin signaling, augmented by G19943's integrative functions and the regulatory role of G00484. The inclusion of G23245 and G33764 enhances the approach, focusing on both muscle-specific pathways and broader metabolic regulation, aiming for a synergistic improvement in insulin sensitivity and glucose metabolism.

### DATA_EVIDENCE:
- **Priority Score**: 4.0/17 for primary target (G22553)
- **Cross-dataset consistency**: Yes, 2 datasets
- **Key pathways involved**: Insulin signaling, glucose metabolism, metabolic regulation, muscle metabolism.
- **WGCNA module role**: G22553 is a primary driver in the black module, indicating its central role in muscle-related metabolic pathways.
- **Regulating TFs**: G00484 acts as a regulator in insulin signaling pathways.

### MECHANISM_HYPOTHESIS:
The proposed mechanism emphasizes the activation of G22553 to enhance insulin signaling pathways, directly improving glucose metabolism in muscle and other tissues. G19943 functions as a pivotal hub, integrating various metabolic signals to enhance the action of G22553. G00484 amplifies regulatory impacts on insulin signaling, while G23245 and G33764 support glucose uptake and metabolic regulation, creating a comprehensive strategy for managing Type 2 Diabetes effectively.

### TISSUE_RATIONALE:
The most relevant tissues include skeletal muscle, liver, pancreatic -cells, and adipose tissue, all of which play crucial roles in insulin action and glucose homeostasis. Targeting these tissues is expected to significantly enhance insulin sensitivity and overall metabolic health in Type 2 Diabetes patients.

### THERAPEUTIC_APPROACH:
The proposed therapeutic strategy involves the small molecule activation of G22553 and modulation of G00484, G23245, and G33764 to enhance their functions and synergistically improve insulin sensitivity and metabolic regulation.

### PREDICTED_OUTCOME:
Effective modulation of these targets is expected to lead to substantial improvements in insulin sensitivity, enhanced glucose metabolism, reduced blood glucose levels, and ultimately better management of Type 2 Diabetes.

### RANKING_RATIONALE:
Targets were ranked based on their established roles in insulin signaling and metabolic pathways, supported by strong data across multiple evidence types. G22553 was prioritized for its critical role in insulin signaling, followed by G19943 for its central integrative role and G00484 for its regulatory function. G23245 and G33764 were included for their contributions to glucose uptake and metabolic regulation, respectively.

### CONFIDENCE: HIGH
The hypothesis is supported by robust data across multiple evidence types, demonstrating the essential roles of the selected targets in managing Type 2 Diabetes.
2026-02-10 21:31:09,642 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:31:09,642 - root - INFO - ===T2D_CROSSOVER_END===
2026-02-10 21:31:09,646 - root - INFO -   -> Created offspring: 'Integrated Multi-Target Strategy to Enha...'
2026-02-10 21:31:09,646 - root - INFO - Successfully created 18 offspring using GA selection
2026-02-10 21:31:09,646 - root - INFO - Evaluating fitness for 18 offspring
2026-02-10 21:31:09,646 - root - INFO - Evaluating fitness for population of 18 hypotheses
2026-02-10 21:31:09,646 - root - INFO - Evaluating fitness for hypothesis: t2d-10-7c113a9d
2026-02-10 21:31:21,030 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:31:21,033 - root - INFO - TOKEN_USAGE: input=1458, output=680, total=2138, cost=$0.000627
2026-02-10 21:31:21,033 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:31:21,033 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is indeed mentioned in the ranked targets and is supported by cross-dataset consistency, but it is not among the top priority genes listed. This discrepancy affects the overall data support score. The presence of two datasets strengthens the evidence, but the absence from the top priority list slightly diminishes confidence.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is largely justified by the data, given that G22553 and other targets are assigned high scores based on their roles in insulin signaling. However, the rationale for ranking G22553 as the primary target is solid, and the synergy with other targets is well articulated, making the ranking quality strong but not perfect.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and glucose metabolism. The tissue rationale is clearly defined, focusing on relevant tissues (skeletal muscle, liver, and adipose tissue). The involvement of transcription factors provides a coherent understanding of regulatory depth, enhancing the score.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation appears appropriate for enhancing target activity. The potential druggability of the targets is reasonable given their roles in metabolic pathways. However, safety considerations could be more explicitly addressed to ensure comprehensive evaluation.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** While the hypothesis presents a well-integrated strategy, it does not significantly propose non-obvious connections or innovative approaches that would elevate its novelty score. The integration of existing knowledge is effective, but additional novel insights could strengthen the hypothesis.

**OVERALL_FITNESS:** 7.6 (calculated as: 7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 7*0.10 = 1.75 + 2 + 1.8 + 1.6 + 0.7 = 7.85, scaled to 0-100 gives 76)

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Address Top Priority Gene Discrepancy:** Ensure that G22553 is included in the top priority list to enhance data support and consistency.
  
2. **Expand on Safety Considerations:** Include a more detailed discussion of safety and potential adverse effects associated with the modulation of each target. This will improve the therapeutic score.

3. **Highlight Novelty:** Incorporate additional innovative aspects of the proposed approach, whether through unique combinations of targets or novel applications of existing drugs, to enhance the novelty score.

4. **Refine Mechanistic Details:** While the mechanism is well-articulated, consider providing more data or literature references that support the proposed interactions and regulatory networks, which could strengthen the mechanistic coherence.

5. **Clarify the Role of Transcription Factors:** Detail how the identified transcription factors specifically influence the regulation of the proposed targets to enhance mechanistic understanding.
2026-02-10 21:31:21,033 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:31:21,034 - root - INFO - Evaluating fitness for hypothesis: t2d-10-aa7156ca
2026-02-10 21:31:33,698 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:31:33,704 - root - INFO - TOKEN_USAGE: input=1524, output=647, total=2171, cost=$0.000617
2026-02-10 21:31:33,705 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:31:33,705 - root - INFO - 
### EVALUATION

**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The ranked targets include G22553, G19943, G23245, G00484, and G33764, all of which have strong scores and cross-dataset consistency. The primary target, G22553, has strong evidence and is supported by two datasets, indicating robustness in the data. However, because one target (G00484) is not in the top priority list, this slightly reduces the score.

**RANKING_QUALITY_SCORE:** 9  
**RANKING_QUALITY_RATIONALE:** The ranking is justified based on the critical roles of the targets in insulin signaling and metabolic pathways. Each targets score reflects its contribution, with G22553 appropriately placed as the primary target due to its central role. The rationale aligns well with the data supporting their interactions and importance.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanisms align well with the documented pathways, emphasizing the activation of G22553 and its coordination with the other targets. The tissue rationale is appropriate, focusing on skeletal muscle, liver, and pancreatic -cells. The role of G00484 as a transcription factor is also well-considered, enhancing the overall coherence of the mechanism.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule activation and modulation appears appropriate given the roles of the targets. However, more detail on specific safety considerations or potential side effects would strengthen this score, especially since targeting multiple pathways could lead to unforeseen interactions.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets in a novel way, focusing on a synergistic approach to enhance insulin sensitivity. While the connections made are significant, some of the relationships between targets are more established in the literature, which slightly reduces the novelty score.

### OVERALL_FITNESS: 
Calculated as follows:  
(8 * 0.25) + (9 * 0.25) + (8 * 0.20) + (7 * 0.20) + (7 * 0.10) = 2 + 2.25 + 1.6 + 1.4 + 0.7 = 8.95  
Overall Fitness = 89.5 (scaled to 0-100)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand on Safety Considerations:** Provide more comprehensive details regarding potential side effects, drug-drug interactions, and overall safety profiles when targeting multiple pathways.
   
2. **Enhance Novelty Elements:** Explore less-obvious connections or potential off-target effects of the proposed targets that may offer additional insights or innovative angles for the hypothesis.

3. **Further Validation:** Consider validating the proposed multi-target approach in preclinical models to assess the synergistic effects and optimize therapeutic strategies before proceeding to clinical trials.
2026-02-10 21:31:33,706 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:31:33,707 - root - INFO - Evaluating fitness for hypothesis: t2d-10-25c84d5c
2026-02-10 21:31:49,279 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:31:49,281 - root - INFO - TOKEN_USAGE: input=1425, output=644, total=2069, cost=$0.000600
2026-02-10 21:31:49,282 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:31:49,282 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The ranked targets include G22553, which is indeed a top priority gene (ranked 3rd) but is not the highest-ranked target (G19943 is first). The evidence of cross-dataset consistency is strong, with two datasets supporting the findings. However, there are no regulating transcription factors (TFs) identified, which could strengthen the data support.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the data presented, with all ranked targets having high scores and being part of the same pathway context. Targets G22553, G19943, and G23245 are clearly related and support the primary goal of enhancing -cell function. The rationale for the ranking is well-explained, although it could have benefited from a more explicit demonstration of how each target's unique contribution is quantitatively assessed.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathways and emphasizes the roles of the targets in glucose metabolism. The rationale for focusing on pancreatic islets is strong, as they are critical in Type 2 Diabetes management. While the mechanism is coherent, the lack of identified regulating TFs may limit the understanding of further regulatory aspects of the proposed therapy.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating the targets using small molecules is appropriate and aligns with the goal of improving insulin function. The targets appear to be druggable based on their central roles in the insulin signaling network. However, safety considerations are not discussed, which is critical in evaluating therapeutic potential.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates known data on insulin signaling pathways but does not introduce significantly novel connections or strategies beyond the dual modulation approach. However, the combination of targets is a relevant and creative strategy within existing frameworks.

**OVERALL_FITNESS:**  
Calculated: (7*0.25 + 8*0.25 + 8*0.20 + 8*0.20 + 7*0.10) = 7.65, scaled to 0-100 = 77  

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. **Incorporate Safety Data:** Include potential safety considerations for the therapeutic strategy to enhance the therapeutic potential score.
2. **Identify Regulating TFs:** Investigate potential regulatory transcription factors that might influence the activity of the chosen targets to improve mechanistic coherence.
3. **Quantitative Assessment of Contributions:** Provide quantitative assessments or mechanistic studies that illustrate how each target contributes to the overall strategy to enhance the ranking quality.
4. **Expand on Novelty:** Explore and discuss any novel connections or implications of dual modulation that have not been widely addressed in current literature, enhancing the novelty score.
2026-02-10 21:31:49,282 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:31:49,282 - root - INFO - Evaluating fitness for hypothesis: t2d-10-739e1cc4
2026-02-10 21:32:02,764 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:32:02,769 - root - INFO - TOKEN_USAGE: input=1460, output=735, total=2195, cost=$0.000660
2026-02-10 21:32:02,769 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:32:02,769 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 6**  
**DATA_SUPPORT_RATIONALE:** The ranked targets include some that are found in the top priority list, specifically G22553 and G19943, which are both critical in insulin signaling. However, G00484, which plays a key role in transcriptional regulation, is not in the top 10 priority genes, which is a significant concern. While there is cross-dataset consistency and strong support for the primary target, the absence of one target from the top priority list affects the overall score.

**RANKING_QUALITY_SCORE: 7**  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the roles of the targets in insulin signaling pathways. Targets such as G19943 and G22553 are correctly prioritized based on their critical functions, and the rationale for ranking is logical. However, the lack of distinction in strength among the top-ranked targets diminishes the scoring.

**MECHANISTIC_SCORE: 8**  
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent with the insulin signaling pathway context, and the tissue rationale is well-supported, particularly for pancreatic -cells, muscle, liver, and adipose tissue. The integration of transcription factors, such as G00484 in the mechanism, is an important consideration, although the lack of its presence in the top priority list does reduce confidence slightly.

**THERAPEUTIC_SCORE: 7**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 appears appropriate, and the other targets are likely druggable due to their central roles in metabolic pathways. However, the absence of comprehensive safety considerations in the proposal could be a potential weakness, hence the slightly lower score.

**NOVELTY_SCORE: 6**  
**NOVELTY_RATIONALE:** While the hypothesis integrates data in a meaningful way and proposes connections among the targets, the approach of targeting insulin signaling pathways has been previously explored, which limits the novelty. The connections made between the targets are logical but not particularly groundbreaking.

**OVERALL_FITNESS: 6.7**  
Calculated as:  
(6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10) = 6.7

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality: STRONG**  
  G22553 is well-supported by evidence and has a critical role in insulin signaling.
  
- **Target #2 quality: STRONG**  
  G19943 is also well-justified in its role as a central hub in insulin signaling.
  
- **Target #3 quality: MODERATE**  
  G00484 is important for transcriptional regulation, but its absence from the top priority list diminishes its perceived strength.

### IMPROVEMENT_SUGGESTIONS:
1. **Review Target Inclusion:** Re-evaluate the inclusion of G00484 and explore its data support further to justify its role in the therapeutic strategy.
2. **Enhance Safety Considerations:** Include a discussion of potential safety issues or side effects associated with modulation of the targets.
3. **Expand Novelty Aspects:** Consider integrating novel experimental approaches or new compounds that could enhance the uniqueness of the therapeutic strategy.
4. **Clarify Mechanistic Pathways:** Strengthen the mechanistic rationale by explicitly detailing how all ranked targets interact within the insulin signaling network.
2026-02-10 21:32:02,771 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:32:02,771 - root - INFO - Evaluating fitness for hypothesis: t2d-10-05c9dfc1
2026-02-10 21:32:18,544 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:32:18,547 - root - INFO - TOKEN_USAGE: input=1452, output=723, total=2175, cost=$0.000652
2026-02-10 21:32:18,548 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:32:18,548 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis for Type 2 Diabetes

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, but G22553, G23245, G33764, and G00484 are not individually recognized in the top 10. While there is cross-dataset consistency for the primary target and evidence from two datasets supports G19943, the lack of recognition for the other targets reduces the overall strength of data support. 

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, especially for the primary target G19943 and G22553. However, the absence of G22553 and other key targets in the top priority list suggests a potential oversight. The rationale for ranking appears coherent, but the consistency of lower-ranked targets with their expected roles needs to be clarified.

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism is well-aligned with the insulin signaling pathways and addresses the multifactorial nature of Type 2 Diabetes. The tissue rationale is clearly articulated, covering all relevant tissues involved in insulin action and metabolism. The role of G00484 as a transcription factor is appropriately considered, providing a solid mechanistic foundation.

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating these targets using small molecules is appropriate and aligns with current strategies in metabolic disease management. The targets identified are likely druggable given their roles in critical pathways, but safety considerations regarding polypharmacy and interactions among targets should be further evaluated.

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates multiple targets into a cohesive strategy, which is relatively novel compared to single-target approaches. However, the connections made among the targets could be more explicitly tied to unique mechanisms or insights to enhance the perception of novelty.

### OVERALL_FITNESS
Calculated as:  
(7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (8 * 0.20) + (7 * 0.10) = 7.75  
Scaled to 0-100: **78**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG (G19943 is well-supported and central to the hypothesis)
- Target #2 quality: MODERATE (G22553 is important but not in the top priority list)
- Target #3 quality: MODERATE (G23245 has a significant role but is not recognized in the top targets)

### IMPROVEMENT_SUGGESTIONS:
1. **Re-evaluate Target List:** Conduct a thorough review of the evidence supporting G22553, G23245, G33764, and G00484 to potentially reclassify them into the top priority tier if warranted.
2. **Clarify Mechanistic Pathways:** Enhance the explanation of how each target interacts with the others within the proposed mechanism, providing clearer connections that support the overall hypothesis.
3. **Address Safety Considerations:** Include a discussion on potential safety concerns with the multi-target strategy, including possible adverse effects of simultaneous modulation of multiple pathways.
4. **Expand Novelty Discussion:** Highlight specific novel aspects of the integrated approach that distinguish it from existing therapeutic strategies, potentially enhancing the appeal of the hypothesis to funding or collaboration opportunities.
2026-02-10 21:32:18,548 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:32:18,549 - root - INFO - Evaluating fitness for hypothesis: t2d-10-b649e710
2026-02-10 21:32:31,855 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:32:31,860 - root - INFO - TOKEN_USAGE: input=1464, output=730, total=2194, cost=$0.000658
2026-02-10 21:32:31,860 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:32:31,860 - root - INFO - 
### Evaluation of the Hypothesis: Integrated Multi-Target Strategy for Enhanced Insulin Sensitivity in Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is present in the top priority list, along with G22553, G23245, G00484, and G33764, which reinforces the support for the hypothesis. However, the warning indicates that not all ranked targets are in the very top priority tier, which slightly lowers the overall score. There is cross-dataset consistency for the primary target, and it has strong evidence across multiple types, contributing positively to the score.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking appears well justified based on the established roles of each target in insulin signaling and glucose metabolism. The rationale for prioritizing G19943 as the central hub is clear, and the supplementary roles of the other targets are logically positioned. However, the slight ambiguity regarding the relative strength of targets outside the top priority tier prevents a perfect score.

**MECHANISTIC_SCORE: 9**
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with known insulin signaling pathways. The tissue rationale is strong, focusing on pancreatic islets, muscle, liver, and adipose tissues, which are critical for insulin action. Additionally, the consideration of transcription factors (e.g., G00484) adds depth to the mechanistic understanding.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G19943 and G22553 while modulating the other targets is appropriate. The targets are likely druggable based on their network positions, although safety considerations and potential off-target effects should be carefully evaluated in the development process.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively and proposes connections between targets that are relevant to the treatment of Type 2 Diabetes. However, the concept of multi-target strategies is not entirely novel within the broader context of diabetes research, which slightly limits the score.

### OVERALL_FITNESS
Overall Fitness = (7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (8 * 0.20) + (7 * 0.10)  
Overall Fitness = 1.75 + 2.00 + 1.80 + 1.60 + 0.70 = 7.85  
**Scaled to 0-100:** **78.5**

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 quality:** STRONG
- **Target #2 quality:** STRONG
- **Target #3 quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Incorporate Additional Evidence:** Strengthen the hypothesis by including more data types, such as in vivo models or clinical data, to support the efficacy of the multi-target strategy.
2. **Clarify Safety Profiles:** Conduct thorough evaluations of the safety profiles for each target, especially the effects of modulation on off-target interactions, to enhance therapeutic viability.
3. **Expand the Novelty Aspect:** Explore and highlight any unique combinations or novel approaches in targeting these genes that may not have been previously reported in the literature.
4. **Consider Alternative Pathways:** Investigate additional regulatory pathways or feedback mechanisms that may affect insulin sensitivity and glucose metabolism to provide a more comprehensive framework for the proposed strategy.
2026-02-10 21:32:31,860 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:32:31,861 - root - INFO - Evaluating fitness for hypothesis: t2d-10-18567c31
2026-02-10 21:32:44,453 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:32:44,456 - root - INFO - TOKEN_USAGE: input=1466, output=560, total=2026, cost=$0.000556
2026-02-10 21:32:44,456 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:32:44,456 - root - INFO - 
DATA_SUPPORT_SCORE: 7  
DATA_SUPPORT_RATIONALE: The primary target G22553 is indeed in the top priority list, but it is noteworthy that while other ranked targets (G19943, G33764, G00484) are also in the top tier, the evidence for the primary target does not indicate it is the highest priority in the overall analysis. However, there is cross-dataset consistency for the primary target and a good number of evidence types supporting it.

RANKING_QUALITY_SCORE: 8  
RANKING_QUALITY_RATIONALE: The ranking is mostly justified by the data, as the primary target (G22553) and other targets (G19943, G33764) have strong evidence backing their roles in insulin sensitivity and glucose metabolism. The rationale is coherent and clearly delineates the importance of each target, but some targets have equal scores which might necessitate a more nuanced differentiation.

MECHANISTIC_SCORE: 8  
MECHANISTIC_RATIONALE: The proposed mechanism aligns well with the insulin signaling pathways and muscle tissue context, which is critical for glucose metabolism. The inclusion of transcription factors like G00484 in the mechanism demonstrates a solid understanding of regulatory relationships, enhancing the coherence of the hypothesis.

THERAPEUTIC_SCORE: 7  
THERAPEUTIC_RATIONALE: The proposed therapeutic strategy of small molecule activation appears appropriate based on the targets roles. However, more information on the druggability of these targets and any potential safety concerns would improve the assessment. The position in the network suggests good therapeutic potential, but this could be elaborated further.

NOVELTY_SCORE: 6  
NOVELTY_RATIONALE: The hypothesis integrates existing data in a meaningful way, suggesting a multi-target approach, which is not completely novel in the field but is a creative application to enhance insulin sensitivity. The connections made are logical but may not be particularly groundbreaking.

OVERALL_FITNESS: 7.3 (calculated as 7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10)

RANKED_TARGETS_ASSESSMENT:  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

IMPROVEMENT_SUGGESTIONS: 
1. Consider providing additional evidence regarding the druggability of G22553 and the safety considerations associated with modulating its activity.
2. Differentiate the targets more clearly in the ranking to avoid ties and provide a more definitive ranking that could guide future research.
3. Expand on the interactions among the targets and potential adverse effects of targeting multiple pathways simultaneously to enhance therapeutic potential assessment.
2026-02-10 21:32:44,457 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:32:44,457 - root - INFO - Evaluating fitness for hypothesis: t2d-10-ec608613
2026-02-10 21:33:02,078 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:33:02,086 - root - INFO - TOKEN_USAGE: input=1452, output=767, total=2219, cost=$0.000678
2026-02-10 21:33:02,086 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:33:02,086 - root - INFO - 
### Evaluation of the Hypothesis

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** While the primary target G22553 is ranked as a top priority in the hypothesis, it is important to note that it is not included in the top 10 priority genes list provided. However, cross-dataset consistency is confirmed with two datasets supporting the findings. The evidence types supporting G22553 are strong, particularly in relation to its role within insulin signaling pathways. The overall data support is somewhat limited by the absence of G22553 in the top priority list, hence the score of 6.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking of targets is logically justified by their roles in insulin signaling and their established synergistic interactions. However, the absence of G22553 from the top 10 list raises questions about its prioritization, which slightly undermines the strength of the ranking. While the rationale is sound and the targets share a strong connection, the inconsistency with the top priority genes could affect the perceived strength of the ranking.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the known pathways involved in insulin signaling and glucose metabolism. The tissue rationale is appropriate, as pancreatic islets, muscle, liver, and adipose tissue are indeed crucial for insulin action. The consideration of transcription factors and their relationships adds depth to the mechanistic hypothesis. Overall, the coherence with established biological pathways and the integration of tissue-specific contexts supports a high score.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 to enhance its function, along with the modulation of other targets, appears to be appropriate for improving insulin sensitivity. However, the druggability of these targets is not explicitly discussed, which may raise concerns about the feasibility of the proposed interventions. Safety considerations are also not mentioned, which is important when evaluating any therapeutic strategy. Thus, while the approach has potential, the lack of detail on druggability and safety slightly lowers the score.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis does integrate various targets in a synergistic approach, which is a creative angle. However, the connections drawn between the targets may not be entirely novel as they are established within the context of insulin signaling research. While the integration of data is well done, the lack of truly novel insights or unexpected connections limits the novelty score.

### OVERALL_FITNESS: 6.75
**Calculated:** \(6 \times 0.25 + 7 \times 0.25 + 8 \times 0.20 + 7 \times 0.20 + 6 \times 0.10 = 6.75\)

### RANKED_TARGETS_ASSESSMENT:
- **Target #1 (G22553) quality:** MODERATE
- **Target #2 (G19943) quality:** STRONG
- **Target #3 (G00484) quality:** STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify Target Prioritization:** Provide additional justification for the prioritization of G22553 over other top-ranked targets. Including data or evidence supporting its critical role would strengthen the hypothesis.
2. **Expand on Drugability and Safety:** Include a discussion on the druggability of the targets and potential safety concerns related to their modulation, which is crucial for assessing therapeutic feasibility.
3. **Highlight Novel Insights:** Emphasize any unique or novel aspects of the proposed interactions between the targets that may not be well-documented in existing literature to enhance the novelty score.
2026-02-10 21:33:02,088 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:33:02,091 - root - INFO - Evaluating fitness for hypothesis: t2d-10-ccaeed34
2026-02-10 21:33:17,314 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:33:17,317 - root - INFO - TOKEN_USAGE: input=1515, output=783, total=2298, cost=$0.000697
2026-02-10 21:33:17,317 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:33:17,317 - root - INFO - 
### EVALUATION SCORES

**DATA_SUPPORT_SCORE:** 6  
**DATA_SUPPORT_RATIONALE:** The primary target (G04436) has a priority score of 4/17, indicating it is in the top priority tier. However, it lacks cross-dataset consistency and has only one dataset supporting it. There are two evidence types supporting the primary target, which is moderate but not robust.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking of targets is overall justified based on their biological roles in insulin signaling and metabolic pathways. All ranked targets have the same score of 4.0, suggesting they have similar importance. However, the rationale for prioritizing G04436 could be strengthened by more evidence supporting its unique contributions relative to other targets.

---

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with existing knowledge of insulin signaling and glucose metabolism. The tissue rationale is appropriate, focusing on liver, muscle, and adipose tissues, which are critical for T2D management. The role of transcription factors is acknowledged, adding depth to the regulatory framework. 

---

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The therapeutic approach suggests activation of G04436 and G00484, with the goal of enhancing insulin sensitivity and metabolic regulation. This is a reasonable approach, considering the roles of these targets. However, the druggability of these targets should be more clearly established, and potential safety considerations need to be addressed, particularly with multi-target strategies.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis presents a multi-target strategy that integrates various aspects of insulin signaling and glucose homeostasis, which is somewhat creative. However, the connections made among the targets are not highly innovative, as the roles of these genes in T2D are relatively well-established.

---

### OVERALL_FITNESS:
Overall Fitness = (DATA_SUPPORT_SCORE * 0.25) + (RANKING_QUALITY_SCORE * 0.25) + (MECHANISTIC_SCORE * 0.20) + (THERAPEUTIC_SCORE * 0.20) + (NOVELTY_SCORE * 0.10)  
Overall Fitness = (6 * 0.25) + (7 * 0.25) + (8 * 0.20) + (7 * 0.20) + (6 * 0.10)  
Overall Fitness = 1.5 + 1.75 + 1.6 + 1.4 + 0.6 = 6.85  
Scaled to 0-100: Overall Fitness = 68.5

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **MODERATE** (G04436 has some evidence but lacks cross-dataset support)
- Target #2 quality: **STRONG** (G00484 has a significant role in regulation)
- Target #3 quality: **STRONG** (G22553 plays a critical supporting role in insulin signaling)

---

### IMPROVEMENT_SUGGESTIONS:
1. **Enhance Evidence Base:** Seek additional datasets that provide cross-validation for G04436 and other targets to strengthen the data support aspect.
2. **Clarify Druggability:** Conduct a thorough investigation into the druggability of the primary target and related genes, including potential side effects of multi-target approaches.
3. **Expand Novelty:** Explore less conventional connections or potential novel pathways associated with these targets to elevate the novelty of the hypothesis.
4. **Consider Safety Profiles:** Address safety considerations in the therapeutic approach, particularly regarding the potential for off-target effects or adverse reactions from multi-target modulation.
2026-02-10 21:33:17,318 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:33:17,318 - root - INFO - Novelty bonus applied: 0.2% -> fitness 50.00 -> 50.08
2026-02-10 21:33:17,318 - root - INFO - Evaluating fitness for hypothesis: t2d-10-dfa3bef1
2026-02-10 21:33:31,046 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:33:31,049 - root - INFO - TOKEN_USAGE: input=1453, output=646, total=2099, cost=$0.000606
2026-02-10 21:33:31,049 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:33:31,049 - root - INFO - 
**DATA_SUPPORT_SCORE: 7**  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is ranked third in the top priority genes, which indicates it has strong support. However, while G22553, G19943, and G00484 are all present in the top 10 priority list, there is a warning about the target gene not being found in the top priority list. The presence of cross-dataset consistency across two datasets supports the reliability of the data, but the lack of higher priority scores for all top-ranked targets somewhat limits confidence.

---

**RANKING_QUALITY_SCORE: 8**  
**RANKING_QUALITY_RATIONALE:** The ranking of G22553, G19943, and G00484 as primary targets is well justified by their established roles in insulin signaling pathways. The rationale for ranking is logical, with targets showing complementary functions within the insulin signaling network. However, further differentiation among the targets could improve the clarity of their relative strength.

---

**MECHANISTIC_SCORE: 9**  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and glucose metabolism. The rationale for targeting specific tissues (pancreatic islets, muscle, liver, and adipose) is well supported, and the relationships with transcription factors are appropriately considered. The mechanism is coherent and well-articulated.

---

**THERAPEUTIC_SCORE: 8**  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of activating G22553 through small molecules and modulating the other targets is appropriate and could lead to enhanced insulin sensitivity. The targets have favorable network positions, suggesting they are likely druggable. Safety considerations were not explicitly mentioned and could be addressed further.

---

**NOVELTY_SCORE: 7**  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data in a creative manner, particularly in how it connects the roles of different targets in insulin signaling. However, some connections might be considered more conventional, and further novel insights could strengthen the hypothesis.

---

**OVERALL_FITNESS:**  
Calculated: (7*0.25 + 8*0.25 + 9*0.20 + 8*0.20 + 7*0.10) = 7.75  
Scaled to 0-100: **78**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Clarify Target Gene Status:** Address the warning regarding the absence of the target gene in the priority list. Ensure that all key targets are appropriately ranked and justified.
2. **Expand Safety Considerations:** Include potential safety concerns and side effects of modulating these targets to enhance the therapeutic profile.
3. **Differentiate Target Strengths:** Provide more detailed comparisons of the strengths and weaknesses of each target to clarify their ranking further.
4. **Explore Novel Mechanisms:** Investigate and incorporate any novel mechanisms or interactions that could enhance the innovative aspect of the hypothesis.
2026-02-10 21:33:31,049 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:33:31,050 - root - INFO - Evaluating fitness for hypothesis: t2d-10-39d76207
2026-02-10 21:33:43,124 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:33:43,128 - root - INFO - TOKEN_USAGE: input=1492, output=688, total=2180, cost=$0.000637
2026-02-10 21:33:43,129 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:33:43,129 - root - INFO - 
### EVALUATION

#### DATA_SUPPORT_SCORE: **8**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is in the top priority list, and there is cross-dataset consistency for this target as indicated by its presence in two datasets. However, while the primary target has strong evidence support, the overall support for the other ranked targets is not as strong due to their absence in the top 10 priority genes list.

#### RANKING_QUALITY_SCORE: **7**
**RANKING_QUALITY_RATIONALE:** The ranking is mostly justified by the data, as the selected targets have established roles in T2D pathways. However, the lack of distinction in scores among the targets means it is challenging to ascertain clear differences in strength or importance. All targets receive the same score, which does not reflect nuanced differences in their contributions.

#### MECHANISTIC_SCORE: **9**
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathway context of insulin signaling and lipid metabolism. The tissue rationale is supported, emphasizing critical tissues involved in insulin action. Furthermore, the relationships with transcription factors are well articulated, enhancing the understanding of regulatory networks involved in T2D.

#### THERAPEUTIC_SCORE: **8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach involving small molecule activators is appropriate for the targets identified. Given their roles in metabolic pathways, the likelihood of druggability is high. However, safety considerations for multi-target modulation need to be explicitly addressed, as activating multiple targets simultaneously could lead to unforeseen side effects.

#### NOVELTY_SCORE: **6**
**NOVELTY_RATIONALE:** The hypothesis does integrate data creatively, particularly in proposing a comprehensive multi-target strategy. However, the connections among the targets are somewhat expected based on their known functions, and no groundbreaking or non-obvious insights are presented.

### OVERALL_FITNESS: 
Calculated as follows: 
\[ \text{Overall Fitness} = 8 \times 0.25 + 7 \times 0.25 + 9 \times 0.20 + 8 \times 0.20 + 6 \times 0.10 = 8.0 \]

Overall Fitness = **80**

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG** (G19943 is well-supported and central to the metabolic pathways)
- Target #2 quality: **MODERATE** (G04436 has established roles but is not in the top priority list)
- Target #3 quality: **MODERATE** (G22553 is important for insulin signaling but similarly lacks top priority validation)

### IMPROVEMENT_SUGGESTIONS:
1. **Strengthen Evidence Base:** Enhance the data support for all ranked targets, especially those not present in the top priority list, by gathering additional datasets or experimental validation.
2. **Refine Ranking Distinctions:** Consider providing more granular scoring or differentiation among the targets to better reflect their relative importance and unique contributions to T2D management.
3. **Address Safety Concerns:** Include a dedicated section discussing potential safety concerns and strategies to mitigate adverse effects when using multi-target therapies.
4. **Explore Novel Mechanisms:** Investigate and integrate any novel interactions or mechanisms that could enhance the therapeutic approach, potentially discovering new angles for treatment or drug development.
2026-02-10 21:33:43,131 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:33:43,131 - root - INFO - Evaluating fitness for hypothesis: t2d-07-cef4cea1
2026-02-10 21:33:55,214 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:33:55,221 - root - INFO - TOKEN_USAGE: input=1473, output=687, total=2160, cost=$0.000633
2026-02-10 21:33:55,221 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:33:55,221 - root - INFO - 
### EVALUATION OF HYPOTHESIS

**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is included in the top priority list and has a solid cross-dataset consistency with evidence from two datasets. However, while the primary target and several complementary targets (G00484, G23245, G33764) align with the top priority genes, the lack of additional unique evidence types specifically supporting the primary target limits a perfect score.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified by the data, with G22553 having strong evidence as a primary driver in insulin signaling. The complementary targets are also well-supported and clearly enhance the overall strategy. The rationale provided for the ranking aligns with their established roles in Type 2 Diabetes pathways, thus making it a sound ranking.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism of action aligns well with the insulin signaling pathways and the roles of the identified targets. The tissue rationale is appropriate given the physiological relevance of pancreatic -cells, liver, muscle, and adipose tissue in insulin action. The inclusion of transcription factor relationships (like G00484) is a strong point, though more detail on specific interactions could enhance coherence.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation of G22553 and modulation of complementary targets is appropriate given their roles in insulin sensitivity. However, the assessment of druggability and safety considerations is somewhat vague and could benefit from more specific data on potential drug interactions or side effects.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis demonstrates some creativity in integrating multiple targets for enhanced insulin sensitivity, which is a well-explored area in Type 2 Diabetes research. However, the connections made between the targets and their roles, while valid, are somewhat conventional. More innovative or less explored connections could enhance the novelty score.

### OVERALL FITNESS
**OVERALL_FITNESS:** (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 7.4, scaled to 74

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG
- Target #4 quality: STRONG
- Target #5 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Expand Data Evidence:** Provide more diverse types of evidence (e.g., in vivo studies or specific functional assays) that support the roles of the primary and complementary targets in the context of T2D.
2. **Clarify Druggability and Safety:** Include specific data on the druggability of each target, potential drug interactions, and safety considerations to strengthen the therapeutic rationale.
3. **Enhance Mechanistic Details:** Elaborate on the specific interactions between targets and their roles in the proposed pathways to improve mechanistic coherence.
4. **Explore Novel Mechanisms:** Investigate and propose less conventional pathways or interactions among the targets that could provide additional therapeutic insights or strategies.
2026-02-10 21:33:55,222 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:33:55,222 - root - INFO - Evaluating fitness for hypothesis: t2d-10-fbd74584
2026-02-10 21:34:09,341 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:34:09,344 - root - INFO - TOKEN_USAGE: input=1472, output=772, total=2244, cost=$0.000684
2026-02-10 21:34:09,345 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:34:09,345 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target (G19943) is indeed within the top priority list, and there is cross-dataset consistency supporting its role in Type 2 Diabetes. However, the warning indicates that one of the other targets (G00484) is not found in the top priority list, which slightly reduces the score. The primary target has strong multi-evidence support, but the presence of targets outside the top tier affects the overall data support.

---

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking appears justified based on the data provided, with all ranked targets scoring equally and being relevant to insulin signaling and metabolic pathways. However, the lack of differentiation among the scores may suggest that not all targets are equally critical, which could lead to ambiguity in the ranking. Still, the rationale provided aligns well with the data, warranting a high score.

---

**MECHANISTIC_SCORE: 9**
**MECHANISTIC_RATIONALE:** The proposed mechanism is coherent and aligns well with the pathways relevant to Type 2 Diabetes. The tissue rationale is solid, focusing on skeletal muscle, liver, and adipose tissue, which are crucial for glucose homeostasis. However, while there is a mention of a regulating transcription factor (TF), the absence of identified TFs for G19943 might present a slight gap in mechanistic understanding.

---

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The therapeutic approach of small molecule modulation targeting critical pathways is appropriate, and the targets seem druggable based on their roles in insulin signaling and metabolic regulation. The potential safety considerations are not explicitly mentioned, which could be a concern in evaluation but does not significantly detract from the overall therapeutic potential.

---

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis integrates data in a relatively creative manner by proposing a multi-target approach, which is not always the standard in Type 2 Diabetes research. However, the connections between the targets, while relevant, do not seem particularly non-obvious, leading to a moderate score in this dimension.

---

### OVERALL_FITNESS: 
Calculated as follows: 
- (7 * 0.25) + (8 * 0.25) + (9 * 0.20) + (8 * 0.20) + (7 * 0.10) = 1.75 + 2.00 + 1.80 + 1.60 + 0.70 = 7.85, scaled to 0-100 = **78.5**

---

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: **STRONG**
- Target #2 quality: **STRONG**
- Target #3 quality: **STRONG**

---

### IMPROVEMENT_SUGGESTIONS:
1. **Clarify Target Roles:** Further delineate the specific roles and unique contributions of the ranked targets, especially since they are tightly clustered in scoring. This could help strengthen the rationale for their prioritization.
   
2. **Address Regulatory Factors:** Identify and discuss potential regulating transcription factors for the primary target (G19943) to enhance the mechanistic understanding and provide a more comprehensive overview of the regulatory network.

3. **Safety Considerations:** Include a section discussing potential safety concerns or adverse effects related to the proposed therapeutic approach, which could strengthen the therapeutic score further.

4. **Novelty Enhancement:** Explore and highlight any less obvious connections or novel pathways that could be integrated into the hypothesis, potentially through literature review or emerging research that may not be widely recognized yet.
2026-02-10 21:34:09,345 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:34:09,345 - root - INFO - Evaluating fitness for hypothesis: t2d-10-34956c4f
2026-02-10 21:34:25,827 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:34:25,831 - root - INFO - TOKEN_USAGE: input=1422, output=825, total=2247, cost=$0.000708
2026-02-10 21:34:25,831 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:34:25,832 - root - INFO - 
### Evaluation of the Drug Target Hypothesis Set for Type 2 Diabetes

**DATA_SUPPORT_SCORE: 7**
**DATA_SUPPORT_RATIONALE:** The primary target G19943 is indeed found in the top priority list, alongside G22553, G23245, G00484, and G33764, which also exhibit strong relevance to insulin signaling. However, there is a warning indicating that one of the target genes is not found in the top priority list, which slightly reduces confidence in the dataset's completeness. There is cross-dataset consistency for the primary target and supporting targets, and the evidence types supporting G19943 are strong, resulting in a score of 7.

**RANKING_QUALITY_SCORE: 8**
**RANKING_QUALITY_RATIONALE:** The ranking of the targets seems justified by their established roles in insulin signaling pathways. The rationale for prioritizing G19943 as the central hub and the complementary roles of the other targets is logical. All higher-ranked targets are indeed strong in terms of their relevance to the therapeutic objective, which supports the overall ranking quality.

**MECHANISTIC_SCORE: 9**
**MECHANISTIC_RATIONALE:** The proposed mechanism effectively aligns with the insulin signaling pathway context. The tissue rationale is well-supported, targeting key metabolic tissues (pancreatic -cells, muscle, liver, adipose tissue) that are integral to insulin action and glucose uptake. Additionally, the role of G00484 as a transcription factor regulating insulin signaling genes is appropriately considered, enhancing the mechanistic coherence.

**THERAPEUTIC_SCORE: 8**
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of activating G19943 and G22553 using small molecules appears appropriate and aligns well with enhancing insulin sensitivity. The targets' positions within the insulin signaling network suggest they are likely druggable. There are safety considerations to consider with any modulation of these targets, especially in a complex disease like T2D, but the overall therapeutic potential remains strong.

**NOVELTY_SCORE: 7**
**NOVELTY_RATIONALE:** The hypothesis presents a multi-target approach that creatively integrates various pathways involved in insulin sensitivity. While the targets themselves are established in the literature, the specific combination and emphasis on synergistic interactions highlight a novel angle. However, the overall concept of multi-target modulation in T2D is not entirely new, hence a score of 7.

**OVERALL_FITNESS: 7.65 (scaled to 76.5)**
Calculating: 
- DATA_SUPPORT: 7 * 0.25 = 1.75
- RANKING_QUALITY: 8 * 0.25 = 2.00
- MECHANISTIC: 9 * 0.20 = 1.80
- THERAPEUTIC: 8 * 0.20 = 1.60
- NOVELTY: 7 * 0.10 = 0.70
Total = 1.75 + 2.00 + 1.80 + 1.60 + 0.70 = 7.85
Scaled to 100 = 76.5

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

**IMPROVEMENT_SUGGESTIONS:**
1. **Enhance Data Completeness:** Address the warning regarding the missing target by verifying the inclusion criteria and ensuring all relevant genes are represented in the priority list.
2. **Expand Mechanistic Insights:** Further elucidate the interactions between targets to clarify the synergistic effects and potential feedback mechanisms.
3. **Safety Profile Assessment:** Conduct a thorough literature review of safety profiles for the targeted modulation of these genes to preemptively address any safety concerns.
4. **Broaden Therapeutic Strategy:** Consider investigating alternative therapeutic modalities (e.g., gene therapy or CRISPR-based approaches) that might provide additional avenues for modulation of these targets.
2026-02-10 21:34:25,832 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:34:25,832 - root - INFO - Evaluating fitness for hypothesis: t2d-10-90b67b29
2026-02-10 21:34:36,788 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:34:36,795 - root - INFO - TOKEN_USAGE: input=1461, output=667, total=2128, cost=$0.000619
2026-02-10 21:34:36,795 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:34:36,795 - root - INFO - 
**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is ranked 3rd in the top priority list, which shows some alignment. However, it is concerning that G00484, which plays a significant role in the mechanism and is listed in the hypothesis, is not in the top priority list. Cross-dataset consistency is affirmed, and there are multiple evidence types supporting the primary target, including pathway involvement and WGCNA analysis.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the role of G22553 as a primary driver in insulin signaling. However, the absence of G00484 in the top priority list diminishes the alignment with the rationale. The rationale provided does make sense, but the lack of top-tier evidence for all targets slightly weakens the overall ranking clarity.

---

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the pathways involved in insulin signaling, and the rationale for focusing on muscle, liver, and adipose tissue is well-supported. The relationship of G00484 as a transcription factor enhancing insulin signaling is also clearly articulated, indicating a coherent mechanistic approach.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach of small molecule activation is appropriate, and the targets identified are likely to be druggable given their network positions. However, safety considerations need further elaboration, particularly regarding off-target effects or unwanted metabolic consequences.

---

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** While the hypothesis integrates data in a creative way, the connections among the targets and their roles in enhancing insulin sensitivity are somewhat established in the literature. The proposal of synergistic activation is valuable but doesnt present a radically new concept.

---

**OVERALL_FITNESS:** (8*0.25 + 7*0.25 + 9*0.20 + 8*0.20 + 6*0.10) = 7.65, which scales to approximately **76.5 out of 100**.

---

**RANKED_TARGETS_ASSESSMENT:**
- Target #1 quality: **STRONG** (G22553 is a primary driver with significant data support)
- Target #2 quality: **STRONG** (G19943 is well-justified as a coordinating hub in insulin signaling)
- Target #3 quality: **WEAK** (G00484 is crucial but not in the top priority list, leading to a weaker assessment)

---

**IMPROVEMENT_SUGGESTIONS:**
1. **Re-evaluate G00484:** Investigate why G00484 is not in the top priority list despite its important role in the proposed mechanism. If data supports its significance, consider advocating for its inclusion.
2. **Expand Safety Considerations:** Provide a more detailed assessment of potential side effects or safety issues related to the therapeutic approach.
3. **Strengthen Novelty Aspect:** Consider identifying any unique aspects of the synergistic activation strategy that could differentiate this hypothesis from existing literature, perhaps by exploring novel interactions or pathways not previously considered.
2026-02-10 21:34:36,796 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:34:36,797 - root - INFO - Evaluating fitness for hypothesis: t2d-10-48006825
2026-02-10 21:34:48,748 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:34:48,750 - root - INFO - TOKEN_USAGE: input=1452, output=660, total=2112, cost=$0.000614
2026-02-10 21:34:48,751 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:34:48,751 - root - INFO - 
**DATA_SUPPORT_SCORE:** 8  
**DATA_SUPPORT_RATIONALE:** While the primary target G22553 is not listed in the top priority genes, it is still ranked highly (score of 4.0). The data support is strong due to cross-dataset consistency (2 datasets supporting the findings) and multiple evidence types backing the primary target. However, the lack of inclusion in the top priority list slightly lowers the score.

---

**RANKING_QUALITY_SCORE:** 7  
**RANKING_QUALITY_RATIONALE:** The ranking is generally justified based on the roles of the targets in insulin signaling and metabolic regulation. However, the absence of G22553 in the top priority list raises questions about the reliability of its ranking compared to the others. This inconsistency affects the overall clarity of the ranking.

---

**MECHANISTIC_SCORE:** 9  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with existing knowledge of insulin signaling and glucose metabolism, particularly in skeletal muscle. The tissue rationale is strong, and the role of G00484 as a transcription factor is duly acknowledged. The integration of multiple targets enhances the mechanistic coherence.

---

**THERAPEUTIC_SCORE:** 8  
**THERAPEUTIC_RATIONALE:** The therapeutic approach of targeting G22553 while modulating its synergistic targets is appropriate for improving insulin sensitivity. The targets appear druggable, but further investigation into potential safety considerations (such as off-target effects) is necessary to fully validate the therapeutic potential.

---

**NOVELTY_SCORE:** 7  
**NOVELTY_RATIONALE:** The hypothesis integrates a multi-target approach that is somewhat novel; however, targeting insulin signaling pathways is a well-trodden area in Type 2 Diabetes research. The connections made among the targets are reasonable, but they may not be entirely unexpected given the context.

---

**OVERALL_FITNESS:** 7.6  
**(Calculated: 8*0.25 + 7*0.25 + 9*0.20 + 8*0.20 + 7*0.10 = 1.9 + 1.75 + 1.8 + 1.6 + 0.7 = 7.75, scaled to 0-100 = 7.6)**

---

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

---

**IMPROVEMENT_SUGGESTIONS:**  
1. **Re-evaluate G22553's Position:** Investigate why G22553 is not in the top priority list and consider additional evidence or data that may further support its role in Type 2 Diabetes.
2. **Enhance Mechanistic Clarity:** Provide more detailed mechanistic studies or data to clarify how each target specifically contributes to enhancing insulin sensitivity, especially in muscle tissue.
3. **Safety Profile Assessment:** Conduct preliminary assessments on the safety and potential side effects of targeting these pathways to ensure the therapeutic strategy is viable.
4. **Explore Novel Targets:** Consider integrating lower-ranked targets or novel compounds that might have synergistic effects with the proposed targets to enhance therapeutic potential.
2026-02-10 21:34:48,751 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:34:48,751 - root - INFO - Evaluating fitness for hypothesis: t2d-10-f7eb1b15
2026-02-10 21:35:00,952 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:35:00,958 - root - INFO - TOKEN_USAGE: input=1469, output=599, total=2068, cost=$0.000580
2026-02-10 21:35:00,958 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:35:00,958 - root - INFO - 
**DATA_SUPPORT_SCORE:** 7  
**DATA_SUPPORT_RATIONALE:** The primary target G22553 is identified within the top priority list, with a high priority score of 4.0. There is cross-dataset consistency with two datasets confirming its role. However, the warning indicates that while G22553 itself is included, there is confusion regarding its absence from the "top priority list" in the evaluation context, suggesting a need for clarity. The evidence type supporting G22553 is strong, with multiple pathways highlighted.

**RANKING_QUALITY_SCORE:** 8  
**RANKING_QUALITY_RATIONALE:** The ranking is justified by the established roles of the targets in Type 2 Diabetes pathways. The primary target G22553 is appropriately prioritized for its central role, while the supporting targets provide complementary functions. The rationale for ranking seems logical, with targets ranked based on their roles in insulin signaling and metabolic regulation.

**MECHANISTIC_SCORE:** 8  
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with the insulin signaling pathway context and appropriately identifies the relevant tissues involved in glucose metabolism. The role of G00484 as a transcription factor enhancing regulatory mechanisms is well-justified, and the relationships among the targets are considered effectively.

**THERAPEUTIC_SCORE:** 7  
**THERAPEUTIC_RATIONALE:** The proposed therapeutic approach aims to activate G22553, which is appropriate for enhancing insulin sensitivity. The targets appear to be druggable based on their roles in metabolic pathways. However, safety considerations regarding the activation of these targets in a therapeutic context should be more explicitly addressed.

**NOVELTY_SCORE:** 6  
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively to propose a multi-target strategy, which is a non-obvious approach in the context of Type 2 Diabetes. However, while the connections are insightful, they are not entirely groundbreaking within the broader context of diabetes research.

**OVERALL_FITNESS:** 7.3  
**Calculated:** (7*0.25 + 8*0.25 + 8*0.20 + 7*0.20 + 6*0.10) = 1.75 + 2.00 + 1.60 + 1.40 + 0.60 = 7.3

**RANKED_TARGETS_ASSESSMENT:**  
- Target #1 quality: STRONG  
- Target #2 quality: STRONG  
- Target #3 quality: STRONG  

**IMPROVEMENT_SUGGESTIONS:**  
1. Clarify the evaluation context regarding the target gene's presence in the top priority list to avoid confusion.
2. Explicitly address potential safety concerns regarding the therapeutic activation of the targets, including potential off-target effects or adverse reactions.
3. Consider further validation of the proposed multi-target strategy in preclinical models to strengthen the hypothesis and support its clinical relevance.
2026-02-10 21:35:00,959 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:35:00,959 - root - INFO - Evaluating fitness for hypothesis: t2d-10-cbf3a590
2026-02-10 21:35:14,226 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:35:14,228 - root - INFO - TOKEN_USAGE: input=1537, output=786, total=2323, cost=$0.000702
2026-02-10 21:35:14,229 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:35:14,229 - root - INFO - 
### Evaluation of the Ranked Drug Target Hypothesis

#### DATA_SUPPORT_SCORE: 6
**DATA_SUPPORT_RATIONALE:** The primary target G22553 has a priority score of 4/17, which places it in the mid-high range among the evaluated targets. However, it lacks cross-dataset consistency, with only one dataset supporting it. The evidence type count is low for G22553, which suggests that while there is some support, it may not be robust enough to draw definitive conclusions about its efficacy. The other ranked targets, such as G19943 and G00484, have similar scores, but the lack of strong multi-dataset validation limits the overall data support.

#### RANKING_QUALITY_SCORE: 7
**RANKING_QUALITY_RATIONALE:** The ranking appears justified as each target is associated with significant roles in insulin signaling and metabolic pathways. Higher-ranked targets like G22553 and G19943 have specific functions that make them stronger candidates based on their roles. The rationale provided aligns well with their biological significance, although the clarity of differentiation between the ranks could be improved since many targets share similar scores and functions.

#### MECHANISTIC_SCORE: 8
**MECHANISTIC_RATIONALE:** The proposed mechanism aligns well with known insulin signaling pathways and the targets' roles. The tissue rationale is articulated effectively, with emphasis on key tissues relevant to diabetes management. The inclusion of regulatory transcription factors (TFs) like G00484 is appropriate, suggesting a well-thought-out approach to enhancing insulin sensitivity through modulation of these pathways.

#### THERAPEUTIC_SCORE: 7
**THERAPEUTIC_RATIONALE:** The therapeutic approachactivation of G22553 and modulation of supporting targetsis appropriate for achieving the desired outcomes in insulin sensitivity. The network positions of the targets suggest they could be druggable. However, the hypothesis could benefit from a more detailed discussion of potential safety considerations and off-target effects, which is crucial in drug development for chronic conditions like diabetes.

#### NOVELTY_SCORE: 6
**NOVELTY_RATIONALE:** The hypothesis integrates existing data creatively by proposing a multi-target strategy for enhancing insulin sensitivity, which is somewhat novel. However, the connections drawn between the targets are not entirely non-obvious, as many researchers are exploring similar multi-target approaches in diabetes. More emphasis on unique aspects of the proposed mechanisms or unexpected relationships could enhance the novelty score.

### OVERALL_FITNESS: 
Calculated as: (6*0.25) + (7*0.25) + (8*0.20) + (7*0.20) + (6*0.10) = 6.65 (scaled to 0-100 = 67)

### RANKED_TARGETS_ASSESSMENT:
- Target #1 quality: STRONG
- Target #2 quality: STRONG
- Target #3 quality: STRONG

### IMPROVEMENT_SUGGESTIONS:
1. **Increase Data Support:** Expand the number of datasets used to validate the findings for G22553 and other targets. Cross-validation with additional datasets could strengthen the argument for their roles in diabetes management.
   
2. **Detailed Mechanistic Insights:** Provide more in-depth mechanistic insights into how the targeted pathways interact and the specific expected outcomes of their modulation.

3. **Safety Considerations:** Include a thorough discussion on potential safety issues and off-target effects for the proposed therapeutic approach, as well as any known drug interactions.

4. **Highlight Novelty:** Emphasize unique aspects of the multi-targeted approach to insulin sensitivity that differentiate it from other existing strategies in the literature. This could involve discussing novel interactions or mechanisms not previously explored.

5. **Visual Representations:** Incorporate diagrams or models illustrating the interactions between the targets and their pathways. This can enhance understanding and support the proposed mechanisms visually.
2026-02-10 21:35:14,229 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:35:14,230 - root - INFO - Novelty bonus applied: 0.3% -> fitness 68.50 -> 68.73
2026-02-10 21:35:14,230 - root - INFO - Population fitness evaluation complete. Top score: 78.50
2026-02-10 21:35:14,230 - root - INFO - Population replaced: 20 hypotheses in new generation
2026-02-10 21:35:14,230 - root - INFO - Updated previous_generation_genes for novelty scoring: ['G22553']...
2026-02-10 21:35:14,230 - root - INFO - Generation 10 stats: mean=62.59, max=79.5, min=50.0
2026-02-10 21:35:14,231 - root - INFO - Generation 10 complete
2026-02-10 21:35:14,231 - root - INFO - --- CAPTURING CHECKPOINT GEN 10 ---
2026-02-10 21:35:14,231 - root - INFO - GENETIC GA GENETIC ALGORITHM COMPLETED in 9508.1 seconds
2026-02-10 21:35:14,234 - root - INFO - Processing Generation 1 results...
2026-02-10 21:35:14,296 - root - INFO - Starting comprehensive T2D evaluation...
2026-02-10 21:35:14,297 - root - INFO - Gene mapping built: 0 genes
2026-02-10 21:35:14,335 - utils.ground_truth_loader - INFO - TSV file not found, falling back to OpenTargets API...
2026-02-10 21:35:14,335 - utils.ground_truth_loader - INFO - Loading Tier 1 targets (approved drugs) for MONDO_0005148...
2026-02-10 21:35:15,196 - utils.ground_truth_loader - INFO - Found 77 Tier 1 targets with approved drugs
2026-02-10 21:35:15,197 - utils.ground_truth_loader - INFO - Loading Tier 2 targets (GWAS) for MONDO_0005148...
2026-02-10 21:35:16,742 - utils.ground_truth_loader - INFO - Found 500 Tier 2 targets with GWAS evidence
2026-02-10 21:35:16,743 - utils.ground_truth_loader - INFO - Loading Tier 3 targets (clinical trials) for MONDO_0005148...
2026-02-10 21:35:17,166 - utils.ground_truth_loader - INFO - Found 1 Tier 3 targets in clinical trials
2026-02-10 21:35:17,166 - utils.ground_truth_loader - INFO - Total ground truth: 77 Tier 1, 500 Tier 2, 1 Tier 3
2026-02-10 21:35:17,167 - root - INFO - Loaded ground truth: 77 Tier 1, 500 Tier 2, 1 Tier 3
2026-02-10 21:35:17,205 - root - INFO - Expanded 1 hypotheses to 1 ranked predictions
2026-02-10 21:35:17,205 - root - INFO - Running full T2D evaluation pipeline...
2026-02-10 21:35:17,205 - root - INFO - Set ground truth: 570 total targets
2026-02-10 21:35:17,205 - root - INFO -   tier1: 77 genes
2026-02-10 21:35:17,205 - root - INFO -   tier2: 500 genes
2026-02-10 21:35:17,206 - root - INFO -   tier3: 1 genes
2026-02-10 21:35:17,206 - root - INFO -   all: 570 genes
2026-02-10 21:35:17,206 - root - INFO - Computing OpenTargets correlation...
2026-02-10 21:35:17,206 - root - WARNING - No OpenTargets scores loaded. Call load_opentargets_association_scores first.
2026-02-10 21:35:17,206 - root - INFO - Running baseline LLM comparison...
2026-02-10 21:35:17,206 - root - INFO - Running baseline LLM prediction for 5 genes (DATA ONLY, no literature)...
2026-02-10 21:35:21,942 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:35:21,945 - root - INFO - TOKEN_USAGE: input=1995, output=249, total=2244, cost=$0.000449
2026-02-10 21:35:21,945 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:35:21,945 - root - INFO - 
RANKED_PREDICTIONS:
1. G19943 - Highest priority score (4.0) as a Hub Component with a DE rank of 42 and a positive log2FC (0.85), indicating potential activation in T2D.
2. G04436 - Also a top priority score (4.0) as an Enzyme, with a DE rank of 69 and a positive log2FC (0.80), suggesting its involvement in T2D-related metabolic pathways.
3. G22553 - Priority score of 4.0 as a Primary Driver, despite a higher DE rank (1803) and a lower log2FC (0.60), indicating a potential role in T2D.
4. G23245 - Priority score of 4.0 as a Primary Driver with a DE rank of 35007 and a negative log2FC (-0.42), suggesting a complex role in T2D pathophysiology.
5. G33764 - Priority score of 4.0 as an Enzyme with a DE rank of 33864 and a negative log2FC (-0.26), indicating a possible regulatory role in T2D.

CONFIDENCE: HIGH
2026-02-10 21:35:21,945 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:35:21,948 - root - INFO - Baseline LLM predicted 5 genes
2026-02-10 21:35:21,949 - root - INFO - Computing @K metrics...
2026-02-10 21:35:21,949 - root - INFO - Full evaluation complete
2026-02-10 21:35:21,949 - root - INFO - 
======================================================================
T2D DRUG TARGET PREDICTION - COMPREHENSIVE EVALUATION REPORT
======================================================================

----------------------------------------------------------------------
1. OPENTARGETS ASSOCIATION SCORE CORRELATION
----------------------------------------------------------------------
  Error: No OpenTargets scores available

----------------------------------------------------------------------
2. BASELINE LLM COMPARISON
----------------------------------------------------------------------
  Framework total hits: 0
  Baseline total hits: 0
  Hit improvement: 0
  Framework outperforms: False

  Detailed Rank Comparison (Validated Targets):
    Gene       Tier       FwRank   BaseRank Diff   Status
    ------------------------------------------------------------

    Win Rate: 0.0% (0 wins, 0 losses)

  Performance at different K:
    @3: Framework=0 hits, Baseline=0 hits, Advantage=0
    @5: Framework=0 hits, Baseline=0 hits, Advantage=0
    @10: Framework=0 hits, Baseline=0 hits, Advantage=0

----------------------------------------------------------------------
3. @K METRICS (RECALL, PRECISION, MRR, MAP)
----------------------------------------------------------------------
  Error: No predictions could be mapped to real genes

======================================================================
END OF EVALUATION REPORT
======================================================================
2026-02-10 21:35:21,950 - root - INFO - Processing Generation 3 results...
2026-02-10 21:35:21,950 - root - INFO - Starting comprehensive T2D evaluation...
2026-02-10 21:35:21,950 - root - INFO - Gene mapping built: 0 genes
2026-02-10 21:35:21,982 - root - INFO - Expanded 1 hypotheses to 1 ranked predictions
2026-02-10 21:35:21,983 - root - INFO - Running full T2D evaluation pipeline...
2026-02-10 21:35:21,983 - root - INFO - Set ground truth: 570 total targets
2026-02-10 21:35:21,983 - root - INFO -   tier1: 77 genes
2026-02-10 21:35:21,983 - root - INFO -   tier2: 500 genes
2026-02-10 21:35:21,983 - root - INFO -   tier3: 1 genes
2026-02-10 21:35:21,983 - root - INFO -   all: 570 genes
2026-02-10 21:35:21,983 - root - INFO - Computing OpenTargets correlation...
2026-02-10 21:35:21,983 - root - WARNING - No OpenTargets scores loaded. Call load_opentargets_association_scores first.
2026-02-10 21:35:21,983 - root - INFO - Running baseline LLM comparison...
2026-02-10 21:35:21,983 - root - INFO - Running baseline LLM prediction for 5 genes (DATA ONLY, no literature)...
2026-02-10 21:35:27,164 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:35:27,167 - root - INFO - TOKEN_USAGE: input=1995, output=292, total=2287, cost=$0.000474
2026-02-10 21:35:27,167 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:35:27,167 - root - INFO - 
RANKED_PREDICTIONS:
1. G19943 - High priority score (4.0) with evidence from 2 types of datasets, DE rank of 42, and it is a hub component in the silver module, which has a significant negative correlation to T2D (p=9.06e-03).
2. G23245 - High priority score (4.0) with evidence from 2 types of datasets, DE rank of 35007, and identified as a primary driver in the silver module, indicating potential causal involvement in T2D.
3. G27976 - High priority score (3.0) with evidence from 2 types of datasets, DE rank of 35431, and serves as a major regulator in the silver module, contributing to the significant negative correlation to T2D (p=9.06e-03).
4. G19122 - High priority score (3.0) with evidence from 2 types of datasets, DE rank of 36406, and identified as a major regulator in the silver module, suggesting a role in the disease phenotype.
5. G22553 - High priority score (4.0) with evidence from 2 types of datasets, DE rank of 1803, and serves as a primary driver in the black module, which correlates positively with T2D (p=4.29e-02).

CONFIDENCE: HIGH
2026-02-10 21:35:27,167 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:35:27,168 - root - INFO - Baseline LLM predicted 5 genes
2026-02-10 21:35:27,168 - root - INFO - Computing @K metrics...
2026-02-10 21:35:27,168 - root - INFO - Full evaluation complete
2026-02-10 21:35:27,168 - root - INFO - 
======================================================================
T2D DRUG TARGET PREDICTION - COMPREHENSIVE EVALUATION REPORT
======================================================================

----------------------------------------------------------------------
1. OPENTARGETS ASSOCIATION SCORE CORRELATION
----------------------------------------------------------------------
  Error: No OpenTargets scores available

----------------------------------------------------------------------
2. BASELINE LLM COMPARISON
----------------------------------------------------------------------
  Framework total hits: 0
  Baseline total hits: 0
  Hit improvement: 0
  Framework outperforms: False

  Detailed Rank Comparison (Validated Targets):
    Gene       Tier       FwRank   BaseRank Diff   Status
    ------------------------------------------------------------

    Win Rate: 0.0% (0 wins, 0 losses)

  Performance at different K:
    @3: Framework=0 hits, Baseline=0 hits, Advantage=0
    @5: Framework=0 hits, Baseline=0 hits, Advantage=0
    @10: Framework=0 hits, Baseline=0 hits, Advantage=0

----------------------------------------------------------------------
3. @K METRICS (RECALL, PRECISION, MRR, MAP)
----------------------------------------------------------------------
  Error: No predictions could be mapped to real genes

======================================================================
END OF EVALUATION REPORT
======================================================================
2026-02-10 21:35:27,168 - root - INFO - Processing Generation 5 results...
2026-02-10 21:35:27,169 - root - INFO - Starting comprehensive T2D evaluation...
2026-02-10 21:35:27,169 - root - INFO - Gene mapping built: 0 genes
2026-02-10 21:35:27,202 - root - INFO - Expanded 1 hypotheses to 1 ranked predictions
2026-02-10 21:35:27,202 - root - INFO - Running full T2D evaluation pipeline...
2026-02-10 21:35:27,203 - root - INFO - Set ground truth: 570 total targets
2026-02-10 21:35:27,203 - root - INFO -   tier1: 77 genes
2026-02-10 21:35:27,203 - root - INFO -   tier2: 500 genes
2026-02-10 21:35:27,203 - root - INFO -   tier3: 1 genes
2026-02-10 21:35:27,203 - root - INFO -   all: 570 genes
2026-02-10 21:35:27,203 - root - INFO - Computing OpenTargets correlation...
2026-02-10 21:35:27,203 - root - WARNING - No OpenTargets scores loaded. Call load_opentargets_association_scores first.
2026-02-10 21:35:27,203 - root - INFO - Running baseline LLM comparison...
2026-02-10 21:35:27,203 - root - INFO - Running baseline LLM prediction for 5 genes (DATA ONLY, no literature)...
2026-02-10 21:35:33,616 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:35:33,619 - root - INFO - TOKEN_USAGE: input=1995, output=357, total=2352, cost=$0.000513
2026-02-10 21:35:33,620 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:35:33,620 - root - INFO - 
RANKED_PREDICTIONS:
1. G19943 - This gene has a high priority score of 4.0, is a hub component in the co-expression network, and shows a significant DE rank of 42 with a positive log2FC of 0.85, suggesting a potential role in T2D.
2. G23245 - Also scoring 4.0, it acts as a primary driver in the silver module with a correlation of -0.461 to T2D, indicating a potential negative impact on the disease phenotype, despite a DE rank of 35007 and a negative log2FC of -0.42.
3. G19122 - This gene has a priority score of 3.0 and serves as a major regulator within the silver module, correlating negatively with T2D (correlation of -0.461). It has a DE rank of 36406 and a negative log2FC of -0.60, suggesting involvement in T2D pathology.
4. G22553 - With a priority score of 4.0, it is identified as a primary driver in the black module, which correlates positively with T2D (correlation of 0.366). Its DE rank is 1803, and it has a log2FC of 0.60, indicating a plausible role in T2D.
5. G33764 - This gene ranks 4.0 and is a primary driver in the darkgrey module, which has a minimal correlation to T2D (correlation of -0.007). However, its DE rank of 33864 and a negative log2FC of -0.26 suggest a complex role in T2D.

CONFIDENCE: HIGH
2026-02-10 21:35:33,620 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:35:33,620 - root - INFO - Baseline LLM predicted 5 genes
2026-02-10 21:35:33,620 - root - INFO - Computing @K metrics...
2026-02-10 21:35:33,620 - root - INFO - Full evaluation complete
2026-02-10 21:35:33,620 - root - INFO - 
======================================================================
T2D DRUG TARGET PREDICTION - COMPREHENSIVE EVALUATION REPORT
======================================================================

----------------------------------------------------------------------
1. OPENTARGETS ASSOCIATION SCORE CORRELATION
----------------------------------------------------------------------
  Error: No OpenTargets scores available

----------------------------------------------------------------------
2. BASELINE LLM COMPARISON
----------------------------------------------------------------------
  Framework total hits: 0
  Baseline total hits: 0
  Hit improvement: 0
  Framework outperforms: False

  Detailed Rank Comparison (Validated Targets):
    Gene       Tier       FwRank   BaseRank Diff   Status
    ------------------------------------------------------------

    Win Rate: 0.0% (0 wins, 0 losses)

  Performance at different K:
    @3: Framework=0 hits, Baseline=0 hits, Advantage=0
    @5: Framework=0 hits, Baseline=0 hits, Advantage=0
    @10: Framework=0 hits, Baseline=0 hits, Advantage=0

----------------------------------------------------------------------
3. @K METRICS (RECALL, PRECISION, MRR, MAP)
----------------------------------------------------------------------
  Error: No predictions could be mapped to real genes

======================================================================
END OF EVALUATION REPORT
======================================================================
2026-02-10 21:35:33,621 - root - INFO - Processing Generation 10 results...
2026-02-10 21:35:33,621 - root - INFO - Starting comprehensive T2D evaluation...
2026-02-10 21:35:33,621 - root - INFO - Gene mapping built: 0 genes
2026-02-10 21:35:33,655 - root - INFO - Expanded 1 hypotheses to 1 ranked predictions
2026-02-10 21:35:33,655 - root - INFO - Running full T2D evaluation pipeline...
2026-02-10 21:35:33,656 - root - INFO - Set ground truth: 570 total targets
2026-02-10 21:35:33,656 - root - INFO -   tier1: 77 genes
2026-02-10 21:35:33,656 - root - INFO -   tier2: 500 genes
2026-02-10 21:35:33,656 - root - INFO -   tier3: 1 genes
2026-02-10 21:35:33,656 - root - INFO -   all: 570 genes
2026-02-10 21:35:33,656 - root - INFO - Computing OpenTargets correlation...
2026-02-10 21:35:33,656 - root - WARNING - No OpenTargets scores loaded. Call load_opentargets_association_scores first.
2026-02-10 21:35:33,656 - root - INFO - Running baseline LLM comparison...
2026-02-10 21:35:33,656 - root - INFO - Running baseline LLM prediction for 5 genes (DATA ONLY, no literature)...
2026-02-10 21:35:38,019 - httpx - INFO - HTTP Request: POST https://api.openai.com/v1/chat/completions "HTTP/1.1 200 OK"
2026-02-10 21:35:38,020 - root - INFO - TOKEN_USAGE: input=1995, output=275, total=2270, cost=$0.000464
2026-02-10 21:35:38,020 - root - INFO - GPT-4O-MINI RESPONSE START==================================================
2026-02-10 21:35:38,021 - root - INFO - 
RANKED_PREDICTIONS:
1. G19943 - Highest priority score (4.0) with evidence from 2 types, a notable DE rank (42), and a positive log2FC (0.85), indicating a potential role as a hub component in the disease phenotype.
2. G04436 - High priority score (4.0) supported by 2 types of evidence, a DE rank of 69, and a positive log2FC (0.80), suggesting its involvement as an enzyme in T2D.
3. G22553 - High priority score (4.0) from 2 types of evidence, a DE rank of 1803, and a positive log2FC (0.60), serving as a primary driver in the co-expression network.
4. G23245 - High priority score (4.0) from 2 types of evidence, with a DE rank of 35007 and a negative log2FC (-0.42), indicating a complex role as a primary driver despite downregulation.
5. G33764 - High priority score (4.0) from 2 types of evidence, DE rank of 33864, and a negative log2FC (-0.26), serving as a primary driver, suggesting a potentially regulatory role in T2D.

CONFIDENCE: HIGH
2026-02-10 21:35:38,021 - root - INFO - GPT-4O-MINI RESPONSE END==================================================
2026-02-10 21:35:38,021 - root - INFO - Baseline LLM predicted 5 genes
2026-02-10 21:35:38,021 - root - INFO - Computing @K metrics...
2026-02-10 21:35:38,021 - root - INFO - Full evaluation complete
2026-02-10 21:35:38,021 - root - INFO - 
======================================================================
T2D DRUG TARGET PREDICTION - COMPREHENSIVE EVALUATION REPORT
======================================================================

----------------------------------------------------------------------
1. OPENTARGETS ASSOCIATION SCORE CORRELATION
----------------------------------------------------------------------
  Error: No OpenTargets scores available

----------------------------------------------------------------------
2. BASELINE LLM COMPARISON
----------------------------------------------------------------------
  Framework total hits: 0
  Baseline total hits: 0
  Hit improvement: 0
  Framework outperforms: False

  Detailed Rank Comparison (Validated Targets):
    Gene       Tier       FwRank   BaseRank Diff   Status
    ------------------------------------------------------------

    Win Rate: 0.0% (0 wins, 0 losses)

  Performance at different K:
    @3: Framework=0 hits, Baseline=0 hits, Advantage=0
    @5: Framework=0 hits, Baseline=0 hits, Advantage=0
    @10: Framework=0 hits, Baseline=0 hits, Advantage=0

----------------------------------------------------------------------
3. @K METRICS (RECALL, PRECISION, MRR, MAP)
----------------------------------------------------------------------
  Error: No predictions could be mapped to real genes

======================================================================
END OF EVALUATION REPORT
======================================================================
